CANCER COUNTY PROFILES 2017–2021 Incidence Years

June 2024

A Publication of the Cancer Data Registry of Idaho



Editors:

Christopher J. Johnson, MPH, Epidemiologist Bożena M. Morawski, PhD, MPH, Epidemiologist

Contributors:

Randi K. Rycroft, MSPH, CTR, Registry Manager Denise Jozwik, RHIT, CTR, Director of Data Quality Teresa Chapple, CTR, Data Quality & Collection Coordinator Shannon Makinen, RHIT, CTR, Data Quality & Collection Coordinator Tessa Morrison, CTR, Data Quality & Collection Coordinator Patti Rose, RHIT, CTR, Data Quality & Collection Coordinator Regina Eck, Database Administrator

> CANCER DATA REGISTRY OF IDAHO P.O. Box 1278 Boise, Idaho 83701-1278 Phone: 208-489-1380 https://www.idcancer.org





ADA COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 12,448 cases of invasive cancer were diagnosed among Ada County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in Ada Countyand the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Ada County	State of Idaho
All Sites/Types	12,448	47,333
Female Breast	2,053	6,943
Prostate	1,908	6,766
Lung & Bronchus	1,183	4,959
Colorectal	814	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Ada County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Ada County. The table also shows the number of observed cases, person-years, and

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 3,684 Ada County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Ada County and the State of Idaho, 2018–2022

Mortality 2018–2022	Ada County	State of Idaho
All Deaths	18,272	80,538
Cancer Deaths	3,684	15,233
% of All Deaths	20.2%	18.9%
Lung & Bronchus	679	2,937
Colorectal	281	1,332
Pancreas	308	1,190
Female Breast	295	1,111
Prostate	207	997

crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Ada County was 515.4 cases per 100,000 personyears per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (530.4) gives an estimate of the relative burden of disease in Ada County.

The age- and sex-adjusted incidence rate of invasive cancer in Ada County, all sites combined, was 540.9 cases per 100,000 persons per year during 2017–2021. There were statistically significantly more cases of cancer in Ada County (12,448) than expected (12,208.0) based upon rates in the remainder of the state (p=.031).

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Ada County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Ada County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Ada County, all sites combined, was 158.7 deaths per 100,000 persons per year during 2018–2022, compared with 171.5 for the remainder of the state. There were statistically significantly fewer cancer deaths in Ada County (3,684) than expected (3,980.8) based upon rates in the remainder of the state (p<.001).

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN ADA COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			A	da County				Ren	nainder of Ida	aho
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)		P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	12,448	2,415,348	515.4	540.9	12,208.0	0.031 >>	34,885	6,576,758	530.4
All Sites Combined	Male	6,535	1,211,536	539.4	589.1	6,297.0	0.003 >>	18,735	3,300,737	567.6
All Sites Combined	Female	5,913	1,203,812	491.2	498.9	5,843.3	0.365	16,150	3,276,021	493.0
Bladder	Total	554	2,415,348	22.9	25.1	559.5	0.839	1,666	6,576,758	25.3
Bladder	Male	427	1,211,536	35.2	40.1	434.2	0.752	1,346	3,300,737	40.8
Bladder	Female		1,203,812	10.5	11.1	111.9	0.171	320	3,276,021	9.8
Brain - malignant Brain - malignant	Total Male	181 99	2,415,348 1,211,536	7.5 8.2	7.6 8.3	171.7 101.7	0.497 0.842	476 283	6,576,758 3,300,737	7.2 8.6
Brain - malignant	Female	82	1,203,812	6.8	6.9	69.6	0.159	193	3,276,021	5.9
Brain and other CNS - non-malignant	Total	390	2,415,348	16.1	16.6	413.1	0.266	1,157	6,576,758	17.6
	Male	123	1,211,536	10.2	10.6	132.3	0.448	377	3,300,737	11.4
	Female	267	1,203,812	22.2	22.4	283.3	0.349	780	3,276,021	23.8
Breast	Total	2,073	2,415,348	85.8	87.4	1,779.5	0.000 >>	4,935	6,576,758	75.0
Breast	Male	20	1,211,536	1.7	1.8	14.9	0.243	45	3,300,737	1.4
Breast Breast - in situ	Female Total	2,053 468	1,203,812 2,415,348	170.5 19.4	170.9 19.5	1,793.5 329.5	0.000 >>	4,890 901	3,276,021 6,576,758	149.3 13.7
Breast - in situ	Male	400	1,211,536	0.1	0.1	1.1	1.000	301	3,300,737	0.1
Breast - in situ	Female	467	1,203,812	38.8	38.4	333.0	0.000 >>	898	3,276,021	27.4
Cervix	Female	64	1,203,812	5.3	4.9	91.5	0.003 <<	230	3,276,021	7.0
Colorectal	Total	814	2,415,348	33.7	35.0	996.5	>> 000.0	2,818	6,576,758	42.8
Colorectal	Male	420	1,211,536	34.7	36.7	539.4	0.000 <<	1,557	3,300,737	47.2
Colorectal	Female	394	1,203,812	32.7	33.4	454.2	0.004 <<	1,261	3,276,021	38.5
Corpus Uteri	Female	310	1,203,812	25.8	25.9	380.9	0.000 <<	1,044	3,276,021	31.9
Esophagus	Total	127	2,415,348	5.3	5.6	130.2	0.821 1.000	380	6,576,758	5.8
Esophagus Esophagus	Male Female	107 20	1,211,536 1,203,812	8.8 1.7	9.7 1.7	107.3 20.3	1.000	322 58	3,300,737 3,276,021	9.8 1.8
Hodgkin Lymphoma	Total	74	2,415,348	3.1	3.1	54.2	0.012 >>	148	6,576,758	2.3
Hodgkin Lymphoma	Male	40	1.211.536	3.3	3.3	32.6	0.229	89	3,300,737	2.7
Hodgkin Lymphoma	Female	34	1,203,812	2.8	2.8	21.5	0.015 >>	59	3,276,021	1.8
Kidney and Renal Pelvis	Total	461	2,415,348	19.1	19.9	526.1	0.004 <<	1,490	6,576,758	22.7
Kidney and Renal Pelvis	Male	312	1,211,536	25.8	27.3	345.3	0.075	998	3,300,737	30.2
Kidney and Renal Pelvis	Female	149	1,203,812	12.4	12.7	176.6	0.037 <<	492	3,276,021	15.0
Larynx	Total	47	2,415,348	1.9	2.1	59.5	0.111	173	6,576,758	2.6
Larynx	Male	38	1,211,536	3.1	3.5	43.0	0.500	129	3,300,737	3.9
Larynx Leukemia	Female Total	9 441	1,203,812 2,415,348	0.7 18.3	0.8 19.4	15.6 444.6	0.107 0.890	44 1,286	3,276,021 6,576,758	1.3 19.6
Leukemia	Male	262	1,211,536	21.6	23.6	259.9	0.915	774	3,300,737	23.4
Leukemia	Female	179	1,203,812	14.9	15.4	181.5	0.892	512	3,276,021	15.6
Liver and Bile Duct	Total	212	2,415,348	8.8	9.3	218.8	0.677	631	6,576,758	9.6
Liver and Bile Duct	Male	139	1,211,536	11.5	12.5	153.6	0.252	455	3,300,737	13.8
Liver and Bile Duct	Female		1,203,812	6.1	6.3	62.5	0.211	176	3,276,021	5.4
Lung and Bronchus	Total	1,183	2,415,348	49.0	53.4	1,272.9	0.011 <<	3,776	6,576,758	57.4
Lung and Bronchus	Male	569	1,211,536	47.0	53.1	625.2	0.024 <<	1,926	3,300,737	58.4
Lung and Bronchus	Female	614	1,203,812	51.0	53.8 41.2	644.1	0.243	1,850	3,276,021	56.5 33.1
Melanoma of the Skin Melanoma of the Skin	Total Male	964 585	2,415,348 1,211,536	39.9 48.3	41.2 52.1	776.3 446.0	0.000 >>	2,180 1,310	6,576,758 3,300,737	39.7
Melanoma of the Skin	Female	379	1,203,812	40.3	31.2	322.9	0.003 >>	870	3,276,021	26.6
Myeloma	Total	191	2,415,348	7.9	8.5	184.5	0.651	537	6,576,758	8.2
Myeloma	Male	116	1,211,536	9.6	10.5	110.4	0.617	331	3,300,737	10.0
Myeloma	Female	75	1,203,812	6.2	6.5	72.7	0.819	206	3,276,021	6.3
Non-Hodgkin Lymphoma	Total	500	2,415,348	20.7	21.8	519.5	0.405	1,492	6,576,758	22.7
Non-Hodgkin Lymphoma	Male	306	1,211,536	25.3	27.2	285.9	0.248	840	3,300,737	25.4
Non-Hodgkin Lymphoma	Female	194	1,203,812	16.1	16.7	231.6	0.012 <<	652	3,276,021	19.9
Oral Cavity and Pharynx Oral Cavity and Pharynx	Total Male	349 249	2,415,348 1,211,536	14.4 20.6	15.0 21.8	340.8 238.6	0.671 0.517	966 691	6,576,758 3,300,737	14.7 20.9
Oral Cavity and Pharynx Oral Cavity and Pharynx	iviale Female		1,211,536	20.6	21.8 8.5	238.6 98.9	0.517 0.938	275	3,300,737	20.9
Ovary	Female	138	1,203,812	11.5	11.5	152.1	0.938	415	3,276,021	12.7
Pancreas	Total	377	2,415,348	15.6	16.8	380.0	0.906	1,111	6,576,758	16.9
Pancreas	Male	202	1,211,536	16.7	18.5	206.8	0.774	624	3,300,737	18.9
Pancreas	Female		1,203,812	14.5	15.2	171.1	0.785	487	3,276,021	14.9
Prostate	Male	1,908	1,211,536	157.5	174.5	1,608.9	0.000 >>	4,858	3,300,737	147.2
Stomach	Total	109	2,415,348	4.5	4.8	126.7	0.120	365	6,576,758	5.5
Stomach	Male	69 40	1,211,536	5.7	6.3	79.3	0.269	238	3,300,737	7.2
Stomach	Female	40	1,203,812	3.3	3.4	46.0	0.424	127	3,276,021	3.9
Testis	Male	85	1,211,536	7.0	6.4	75.6	0.308	189	3,300,737	5.7
Thyroid	Total	311	2,415,348	12.9	12.4	333.3	0.230	874	6,576,758	13.3
Thyroid	Male	90	1,211,536	7.4	7.4	103.6	0.193	282	3,300,737	8.5
Thyroid Pediatric Age 0 to 19	Female	221	1,203,812	18.4	17.5	228.6	0.646	592	3,276,021	18.1
Peoplattic Ade U to 19	Total	106	620,640	17.1	17.1	105.2	0.965	319	1,878,684	17.0
	Mala	4-7	247 070	44.0	440	EF 0	0.005	407	056 040	475
Pediatric Age 0 to 19 Pediatric Age 0 to 19	Male Female	47 59	317,672 302,968	14.8 19.5	14.8 19.5	55.3 49.8	0.295 0.222	167 152	956,649 922,035	17.5 16.5

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018–2022 COMPARISON BETWEEN ADA COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			A	da County				Re	mainder of Idah	10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	18,272	2,477,261	737.6	784.3	21,539.7	0.000 <<	62,263	6,734,133	924.6
All Causes of Death	Male	9,440	1,245,093	758.2	826.6	11,257.5	0.000 <<	33,346	3,382,604	985.8
All Causes of Death	Female	8,832	1,232,168	716.8	746.2	10,211.5	0.000 <<	28,917	3,351,529	862.8
All Malignant Cancers	Total	3,684	2,477,261	148.7	158.7	3,980.8	0.000 <<	11,549	6,734,133	171.5
All Malignant Cancers	Male	1,905	1,245,093	153.0	169.4	2,104.4	0.000 <<	6,330	3,382,604	187.1
All Malignant Cancers	Female	1,779	1,232,168	144.4	149.4	1,854.0	0.082	5,219	3,351,529	155.7
Bladder	Total	117	2,477,261	4.7	5.1	124.2	0.557	368	6,734,133	5.5
Bladder	Male	82	1,245,093	6.6	7.5	95.1	0.191	293	3,382,604	8.7
Bladder	Female	35	1,232,168	2.8	3.0	26.0	0.106	75	3,351,529	2.2
Brain and Other Nervous System	Total	150	2,477,261	6.1	6.2	131.5	0.121	368	6,734,133	5.5
Brain and Other Nervous System	Male	81	1,245,093	6.5	6.8	72.9	0.370	208	3,382,604	6.1
	Female	69	1,232,168	5.6	5.7	58.2	0.183	160	3,351,529	4.8
Breast	Total	298	2,477,261	12.0	12.6	290.9	0.692	826	6,734,133	12.3
Breast	Male	3	1,245,093	0.2	0.3	3.2	1.000	10	3,382,604	0.3
Breast	Female	295	1,232,168	23.9	24.4	294.0	0.969	816	3,351,529	24.3
Cervix	Female	21	1,232,168	1.7	1.6	25.8	0.397	67	3,351,529	2.0
Colorectal	Total	281	2,477,261	11.3	11.9	369.0	0.000 <<	1,051	6,734,133	15.6
Colorectal	Male	152 129	1,245,093 1,232,168	12.2 10.5	13.1 10.8	199.7 168.2	0.001 << 0.002 <<	580 471	3,382,604 3,351,529	17.1 14.1
Colorectal	Female	49	1,232,168	4.0		42.6	0.360			3.6
Corpus Uteri Esophagus	Female Total	49 125	2,477,261	4.0	4.1 5.4	42.6	0.360	120 336	3,351,529 6,734,133	3.0 5.0
Esophagus	Male	125	1,245,093	8.4	9.2	96.0	0.385	286	3,382,604	8.5
Esophagus	Female	20	1,232,168	1.6	9.2 1.7	17.6	0.631	200 50	3,351,529	1.5
Hodgkin Lymphoma	Total	8	2,477,261	0.3	0.3	5.8	0.454	17	6,734,133	0.3
Hodgkin Lymphoma	Male	6	1,245,093	0.5	0.6	2.6	0.091	8	3,382,604	0.2
Hodgkin Lymphoma	Female	2	1,232,168	0.0	0.0	3.2	0.765	9	3,351,529	0.2
Kidney	Total	99	2,477,261	4.0	4.3	97.8	0.930	287	6,734,133	4.3
Kidney	Male	64	1,245,093	5.1	5.7	60.3	0.668	182	3,382,604	5.4
Kidney	Female	35	1,232,168	2.8	3.0	36.6	0.876	105	3,351,529	3.1
Larynx	Total	22	2,477,261	0.9	0.9	18.6	0.493	54	6,734,133	0.8
Larynx	Male	18	1,245,093	1.4	1.6	15.6	0.615	47	3,382,604	1.4
Larynx	Female	4	1,232,168	0.3	0.3	2.5	0.500	7	3,351,529	0.2
Leukemia	Total	173	2,477,261	7.0	7.5	168.4	0.743	492	6,734,133	7.3
Leukemia	Male	96	1,245,093	7.7	8.6	99.7	0.759	301	3,382,604	8.9
Leukemia	Female	77	1,232,168	6.2	6.5	67.1	0.256	191	3,351,529	5.7
Liver and Bile Duct	Total	156	2,477,261	6.3	6.7	165.9	0.470	479	6,734,133	7.1
Liver and Bile Duct	Male	103	1,245,093	8.3	9.1	107.6	0.703	320	3,382,604	9.5
Liver and Bile Duct	Female	53	1,232,168	4.3	4.4	56.5	0.703	159	3,351,529	4.7
Lung and Bronchus	Total	679	2,477,261	27.4	29.6	768.9	0.001 <<	2,258	6,734,133	33.5
Lung and Bronchus	Male Female	341	1,245,093	27.4	30.6	394.7	0.006 <<	1,200	3,382,604	35.5
Lung and Bronchus Melanoma of the Skin	Female Total	338 78	1,232,168 2,477,261	27.4 3.1	28.7 3.3	371.2 77.7	0.087 1.000	1,058 223	3,351,529 6,734,133	31.6 3.3
Melanoma of the Skin	Male	7 o 54	1,245,093	4.3	3.3 4.7	49.2	0.531	223 146	3,382,604	3.3 4.3
Melanoma of the Skin	Female	24	1,232,168	4.3	2.0	27.6	0.567	77	3,351,529	2.3
Myeloma	Total	76	2,477,261	3.1	3.3	84.3	0.307	249	6,734,133	3.7
Myeloma	Male	39	1,245,093	3.1	3.5	48.9	0.172	149	3,382,604	4.4
Myeloma	Female	37	1,232,168	3.0	3.2	34.8	0.749	100	3,351,529	3.0
Non-Hodgkin Lymphoma	Total	119	2,477,261	4.8	5.2	152.9	0.005 <<	449	6,734,133	6.7
Non-Hodgkin Lymphoma	Male	67	1,245,093	5.4	6.0	80.3	0.146	243	3,382,604	7.2
Non-Hodgkin Lymphoma	Female	52	1,232,168	4.2	4.4	72.0	0.017 <<	206	3,351,529	6.1
Oral Cavity and Pharynx	Total	70	2,477,261	2.8	3.0	71.0	0.968	205	6,734,133	3.0
Oral Cavity and Pharynx	Male	53	1,245,093	4.3	4.7	46.4	0.371	139	3,382,604	4.1
Oral Cavity and Pharynx	Female	17	1,232,168	1.4	1.4	23.7	0.197	66	3,351,529	2.0
Ovary	Female	96	1,232,168	7.8	8.0	94.7	0.918	265	3,351,529	7.9
Pancreas	Total	308	2,477,261	12.4	13.3	302.9	0.785	882	6,734,133	13.1
Pancreas	Male	166	1,245,093	13.3	14.8	160.7	0.696	484	3,382,604	14.3
Pancreas	Female	142	1,232,168	11.5	12.0	140.7	0.935	398	3,351,529	11.9
Prostate	Male	207	1,245,093	16.6	19.0	255.0	0.002 <<	790	3,382,604	23.4
Stomach	Total	48	2,477,261	1.9	2.0	51.9	0.655	146	6,734,133	2.2
Stomach	Male	26	1,245,093	2.1	2.3	31.5	0.375	93	3,382,604	2.7
Stomach	Female	22	1,232,168	1.8	1.8	19.7	0.668	53	3,351,529	1.6

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Ada County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	93.1% 10.2%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	66.2% 73.8% 67.2%
Current Tobacco User (2020–2022) Other Cancer-Related	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	20.5%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	34.0% 83.5% 25.5% 25.8%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





ADAMS COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 162 cases of invasive cancer were diagnosed among Adams County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in AdamsCounty and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021						
All Sites/Types	162	47,333				
Female Breast	19	6,943				
Prostate	32	6,766				
Lung & Bronchus	21	4,959				
Colorectal	4	3,632				

Table 3 (*Cancer Incidence 2017–2021, Comparison between Adams County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Adams County. The table also shows the number of observed cases, person-

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 68 Adams County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Adams County and the State of Idaho, 2018–2022

Mortality 2018–2022	Adams County	State of Idaho
All Deaths	243	80,538
Cancer Deaths	68	15,233
% of All Deaths	28.0%	18.9%
Lung & Bronchus	15	2,937
Colorectal	2	1,332
Pancreas	3	1,190
Female Breast	7	1,111
Prostate	5	997

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Adams County was 747.0 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (525.9) gives an estimate of the relative burden of disease in Adams County.

The age- and sex-adjusted incidence rate of invasive cancer in Adams County, all sites combined, was 462.8 cases per 100,000 persons per year during 2017–2021. There were fewer cases of cancer in Adams County (162) than expected (184.1) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Adams County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Adams County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Adams County, all sites combined, was 184.3 deaths per 100,000 persons per year during 2018–2022, compared with 165.0 for the remainder of the state. There were more cancer deaths in Adams County (68) than expected (60.9) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN ADAMS COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Ada	ams County	/			Ren	nainder of Ida	aho
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)		P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	162	21,687	747.0	462.8	184.1	0.108	47,171	8,970,419	525.9
All Sites Combined	Male	96	11,238	854.2	486.4	110.4	0.182	25,174	4,501,035	559.3
All Sites Combined	Female	66	10,449	631.6	423.3	76.7	0.239	21,997	4,469,384	492.2
Bladder	Total	8	21,687	36.9	21.4	9.2	0.859	2,212	8,970,419	24.7
Bladder	Male	7	11,238	62.3	33.5	8.2	0.853	1,766	4,501,035	39.2
Bladder Broin molignant	Female	1	10,449 21,687	9.6 9.2	6.0 6.5	1.7 2.2	1.000 1.000	446 655	4,469,384 8,970,419	10.0 7.3
Brain - malignant Brain - malignant	Total Male	2 2	11,238	9.2 17.8	12.2	2.2 1.4	0.806	380	4,501,035	8.4
Brain - malignant	Female		10,449	-	-	0.9	0.824	275	4,469,384	6.2
Brain and other CNS - non-malignant	Total	1	21,687	4.6	3.1	5.6	0.051	1,546	8,970,419	17.2
	Male	-	11,238	-	-	1.9	0.300	500	4,501,035	11.1
Brain and other CNS - non-malignant	Female	1	10,449	9.6	6.7	3.5	0.270	1,046	4,469,384	23.4
Breast	Total	20	21,687	92.2	59.6	26.2	0.265	6,988	8,970,419	77.9
Breast Breast	Male Female	1 19	11,238 10,449	8.9 181.8	5.3 121.9	0.3 24.1	0.473 0.346	64 6,924	4,501,035 4,469,384	1.4 154.9
Breast - in situ	Total	3	21,687	13.8	9.0	5.1	0.508	1,366	8,970,419	154.9
Breast - in situ	Male	-	11,238	-	-	0.0	1.000	1,000	4,501,035	0.1
Breast - in situ	Female	3	10,449	28.7	19.2	4.8	0.599	1,362	4,469,384	30.5
Cervix	Female	-	10,449	-	-	0.8	0.928	294	4,469,384	6.6
Colorectal	Total	4	21,687	18.4	11.8	13.7	0.004 <<	3,628	8,970,419	40.4
Colorectal	Male	4	11,238	35.6	21.6	8.1	0.185	1,973	4,501,035	43.8
Colorectal	Female	-	10,449	-	-	5.7	0.007 <<	1,655	4,469,384	37.0
Corpus Uteri	Female	2	10,449	19.1	12.3	4.9	0.261	1,352	4,469,384	30.3
Esophagus Esophagus	Total Male	1	21,687 11,238	4.6 8.9	2.7 4.9	2.1 1.9	0.774 0.856	506 428	8,970,419 4,501,035	5.6 9.5
Esophagus Esophagus	iviale Female	_ '	10,449	0.9	4.9	1.9 0.3	1.000	428 78	4,501,035 4,469,384	9.5 1.7
Hodgkin Lymphoma	Total	2	21,687	9.2	8.2	0.5	0.240	220	8,970,419	2.5
Hodgkin Lymphoma	Male	2	11,238	17.8	14.7	0.4	0.114	127	4,501,035	2.8
Hodgkin Lymphoma	Female	-	10,449	-	-	0.2	1.000	93	4,469,384	2.1
Kidney and Renal Pelvis	Total	6	21,687	27.7	17.4	7.5	0.767	1,945	8,970,419	21.7
Kidney and Renal Pelvis	Male	4	11,238	35.6	21.3	5.4	0.735	1,306	4,501,035	29.0
Kidney and Renal Pelvis	Female	2	10,449	19.1	12.8	2.2	1.000	639	4,469,384	14.3
Larynx	Total	1	21,687	4.6	2.7	0.9	1.000	219	8,970,419	2.4
Larynx Larynx	Male Female	- 1	11,238 10,449	- 9.6	- 5.9	0.7 0.2	0.947 0.358	167 52	4,501,035 4,469,384	3.7 1.2
Leukemia	Total	2	21,687	9.2	5.9	6.5	0.085	1,725	8,970,419	19.2
Leukemia	Male	1	11,238	8.9	5.3	4.3	0.143	1,035	4,501,035	23.0
Leukemia	Female	1	10,449	9.6	6.5	2.4	0.628	690	4,469,384	15.4
Liver and Bile Duct	Total	2	21,687	9.2	5.4	3.5	0.643	841	8,970,419	9.4
Liver and Bile Duct	Male	2	11,238	17.8	9.8	2.7	0.996	592	4,501,035	13.2
Liver and Bile Duct	Female	-	10,449	-	-	0.9	0.787	249	4,469,384	5.6
Lung and Bronchus Lung and Bronchus	Total Male	21 8	21,687 11,238	96.8 71.2	55.5 37.8	20.8 11.7	1.000 0.354	4,938 2,487	8,970,419 4,501,035	55.0 55.3
Lung and Bronchus	Female	13	10,449	124.4	76.5	9.3	0.298	2,407	4,469,384	54.8
Melanoma of the Skin	Total	10	21,687	46.1	30.2	11.6	0.200	3,134	8,970,419	34.9
Melanoma of the Skin	Male	6	11,238	53.4	31.9	7.9	0.651	1,889	4,501,035	42.0
Melanoma of the Skin	Female	4	10,449	38.3	27.6	4.0	1.000	1,245	4,469,384	27.9
Myeloma	Total	1	21,687	4.6	2.7	3.0	0.408	727	8,970,419	8.1
Myeloma	Male	1	11,238	8.9	5.0	2.0	0.816	446	4,501,035	9.9
Nyeloma	Female		10,449	-	-	1.1	0.699	281	4,469,384	6.3
Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma	Total Male	7 5	21,687 11,238	32.3	20.2 26.4	7.7	0.996 1.000	1,985	8,970,419	22.1 25.3
Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma	iviale Female	5	10,449	44.5 19.1	20.4 12.5	4.8 3.0	0.839	1,141 844	4,501,035 4,469,384	25.3 18.9
Oral Cavity and Pharynx	Total	7	21.687	32.3	12.5	5.2	0.541	1,308	8,970,419	14.6
Oral Cavity and Pharynx	Male	4	11,238	35.6	20.7	4.0	1.000	936	4,501,035	20.8
Oral Cavity and Pharynx	Female	3	10,449	28.7	18.5	1.3	0.308	372	4,469,384	8.3
Ovary	Female	3	10,449	28.7	19.4	1.9	0.592	550	4,469,384	12.3
Pancreas	Total	6	21,687	27.7	16.4	6.0	1.000	1,482	8,970,419	16.5
Pancreas	Male	4	11,238	35.6	19.8	3.7	1.000	822	4,501,035	18.3
Pancreas Prostate	Female Male	2 32	10,449 11,238	19.1	12.1 152.2	2.4 31.4	1.000 0.969	660 6 734	4,469,384	14.8 149.6
Prostate Stomach	Total	32	21,687	284.7 9.2	152.2	31.4 1.8	1.000	6,734 472	4,501,035 8,970,419	5.3
Stomach	Male	2 1	11,238	9.2 8.9	5.0	1.0	1.000	306	4,501,035	6.8
Stomach	Female	1	10,449	9.6	6.6	0.6	0.860	166	4,469,384	3.7
Testis	Male		11,238	-	-	0.0	1.000	274	4,501,035	6.1
Thyroid	Total	5	21,687	23.1	19.3	3.4	0.517	1,180	8,970,419	13.2
		2	11,238	17.8	12.7	1.3	0.740	370	4,501,035	8.2
Thyroid	iviale							0.0		
Thyroid Thyroid	Male Female		10,449	28.7	25.6	2.1	0.711	810	4,469.384	18.1
Thyroid	Female	3	10,449	28.7 48.8	25.6 49.4	2.1 0.7	0.711 0.302	810 423	4,469,384 2,495,226	18.1 17.0
							0.711 0.302 0.607		4,469,384 2,495,226 1,272,140	

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN ADAMS COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Ada	ams County	,			Re	mainder of Idah	10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	243	22,376	1,086.0	702.0	302.5	0.000 <<	80,292	9,189,018	873.8
All Causes of Death	Male	144	11,607	1,240.6	747.5	178.0	0.010 <<	42,642	4,616,090	923.8
All Causes of Death	Female	99	10,769	919.3	635.5	128.3	0.009 <<	37,650	4,572,928	823.3
All Malignant Cancers	Total	68	22,376	303.9	184.3	60.9	0.393	15,165	9,189,018	165.0
All Malignant Cancers	Male	39	11,607	336.0	188.8	36.7	0.744	8,196	4,616,090	177.6
All Malignant Cancers	Female	29	10,769	269.3	174.9	25.3	0.508	6,969	4,572,928	152.4
Bladder	Total	1	22,376	4.5	2.7	1.9	0.852	484	9,189,018	5.3
Bladder	Male	1	11,607	8.6	4.8	1.7	0.998	374	4,616,090	8.1
Bladder	Female	-	10,769	-	-	0.4	1.000	110	4,572,928	2.4
Brain and Other Nervous System	Total	2	22,376	8.9	5.8	2.0	1.000	516	9,189,018	5.6
Brain and Other Nervous System	Male	2	11,607	17.2	10.7	1.2	0.650	287	4,616,090	6.2
Brain and Other Nervous System Breast	Female		10,769	- 31.3	- 19.8	0.8	0.891	229	4,572,928	5.0
Breast	Total Male	- 7	22,376 11,607	31.3	19.0	4.3 0.1	0.287 1.000	1,117 13	9,189,018 4,616,090	12.2 0.3
Breast	Female	- 7	10,769	- 65.0	43.3	3.9	0.202	1,104	4,572,928	24.1
Cervix	Female	-	10,769	-	-	0.3	1.000	88	4,572,928	1.9
Colorectal	Total	- 2	22,376	- 8.9	5.6	5.2	0.223	1,330	9,189,018	14.5
Colorectal	Male	1	11,607	8.6	5.1	3.1	0.368	731	4,616,090	15.8
Colorectal	Female	1	10,769	9.3	6.2	2.1	0.752	599	4,572,928	13.1
Corpus Uteri	Female	1	10,769	9.3	5.7	0.6	0.949	168	4,572,928	3.7
Esophagus	Total	2	22,376	8.9	5.3	1.9	1.000	459	9,189,018	5.0
Esophagus	Male	2	11,607	17.2	9.5	1.8	1.000	389	4,616,090	8.4
Esophagus	Female	-	10,769	-	-	0.3	1.000	70	4,572,928	1.5
Hodgkin Lymphoma	Total	-	22,376	-	-	0.1	1.000	25	9,189,018	0.3
Hodgkin Lymphoma	Male	-	11,607	-	-	0.1	1.000	14	4,616,090	0.3
Hodgkin Lymphoma	Female	-	10,769	-	-	0.0	1.000	11	4,572,928	0.2
Kidney	Total	-	22,376	-	-	1.6	0.409	386	9,189,018	4.2
Kidney	Male	-	11,607	-	-	1.1	0.658	246	4,616,090 4,572,928	5.3 3.1
Kidney Larynx	Female Total	- 1	10,769 22,376	- 4.5	- 2.7	0.5	1.000 0.530	140 75	4,572,928 9,189,018	0.8
Larynx	Male	-	11,607	4.5	2.1	0.3	1.000	65	4,616,090	1.4
Larynx	Female	- 1	10,769	9.3	5.7	0.0	0.075	10	4,572,928	0.2
Leukemia	Total	1	22,376	4.5	2.8	2.6	0.533	664	9,189,018	7.2
Leukemia	Male	1	11,607	8.6	4.9	1.7	0.959	396	4,616,090	8.6
Leukemia	Female	-	10,769	-	-	0.9	0.784	268	4,572,928	5.9
Liver and Bile Duct	Total	2	22,376	8.9	5.2	2.6	1.000	633	9,189,018	6.9
Liver and Bile Duct	Male	2	11,607	17.2	9.5	1.9	1.000	421	4,616,090	9.1
Liver and Bile Duct	Female	-	10,769	-	-	0.8	0.906	212	4,572,928	4.6
Lung and Bronchus	Total	15	22,376	67.0	39.1	12.2	0.494	2,922	9,189,018	31.8
Lung and Bronchus	Male	8	11,607	68.9	37.3	7.1	0.839	1,533	4,616,090	33.2
Lung and Bronchus	Female	7	10,769	65.0	40.7	5.2	0.544	1,389	4,572,928	30.4
Melanoma of the Skin Melanoma of the Skin	Total Malo	3	22,376 11,607	13.4 25.8	8.4 15.1	1.2 0.8	0.221 0.108	298 197	9,189,018 4,616,090	3.2 4.3
Melanoma of the Skin	Male Female	- 3	10,769	23.6	15.1	0.8	1.000	197	4,616,090 4,572,928	4.3
Myeloma	Total	- 1	22,376	- 4.5	- 2.6	1.3	1.000	324	9,189,018	3.5
Myeloma	Male	1	11,607	4.5	2.0 4.7	0.9	1.000	187	4,616,090	4.1
Myeloma	Female	- '	10,769	-	-	0.5	1.000	137	4,572,928	3.0
Non-Hodgkin Lymphoma	Total	4	22,376	17.9	10.9	2.3	0.381	564	9,189,018	6.1
Non-Hodgkin Lymphoma	Male	2	11,607	17.2	9.8	1.4	0.791	308	4,616,090	6.7
Non-Hodgkin Lymphoma	Female	2	10,769	18.6	12.2	0.9	0.470	256	4,572,928	5.6
Oral Cavity and Pharynx	Total	4	22,376	17.9	10.6	1.1	0.053	271	9,189,018	2.9
Oral Cavity and Pharynx	Male	3	11,607	25.8	14.4	0.9	0.111	189	4,616,090	4.1
Oral Cavity and Pharynx	Female	1	10,769	9.3	5.9	0.3	0.522	82	4,572,928	1.8
Ovary	Female	1	10,769	9.3	5.9	1.3	1.000	360	4,572,928	7.9
Pancreas	Total	3	22,376	13.4	7.9	4.9	0.557	1,187	9,189,018	12.9
Pancreas	Male	2	11,607	17.2	9.5	3.0	0.863	648	4,616,090	14.0
Pancreas Prostato	Female	1	10,769	9.3	5.9	2.0	0.804	539	4,572,928	11.8
Prostate Stomach	Male Total	5	11,607	43.1	23.9	4.5 0.7	0.936 0.966	992 194	4,616,090	21.5
Stomach	Male	-	22,376 11,607	-	-	0.7	1.000	194	9,189,018 4,616,090	2.1 2.6
		-	10,769	-	-					
Stomach	Female	-	10,769	-	-	0.2	1.000	75	4,572,928	1.6

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Adams County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	10.2%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	
Current Tobacco User (2020–2022) Other Cancer-Related	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	29.3%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	26.7% 71.7% 12.3% 20.8%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





BANNOCK COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 1,964 cases of invasive cancer were diagnosed among Bannock County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in BannockCounty and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021						
All Sites/Types	1,964	47,333				
Female Breast	295	6,943				
Prostate	238	6,766				
Lung & Bronchus	199	4,959				
Colorectal	153	3,632				

Table 3 (*Cancer Incidence 2017–2021, Comparison between Bannock County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Bannock County. The table also shows the number of observed cases, person-

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 694 Bannock County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Bannock County and the State of Idaho, 2018–2022

Mortality 2018–2022	Bannock County	State of Idaho
All Deaths	4,204	80,538
Cancer Deaths	694	15,233
% of All Deaths	16.5%	18.9%
Lung & Bronchus	130	2,937
Colorectal	61	1,332
Pancreas	60	1,190
Female Breast	51	1,111
Prostate	50	997

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Bannock County was 449.1 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (530.3) gives an estimate of the relative burden of disease in Bannock County.

The age- and sex-adjusted incidence rate of invasive cancer in Bannock County, all sites combined, was 492.0 cases per 100,000 persons per year during 2017–2021. There were statistically significantly fewer cases of cancer in Bannock County (1,964) than expected (2,116.8) based upon rates in the remainder of the state (p<.001).

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Bannock County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Bannock County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Bannock County, all sites combined, was 176.5 deaths per 100,000 persons per year during 2018–2022, compared with 165.8 for the remainder of the state. There were more cancer deaths in Bannock County (694) than expected (651.7) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN BANNOCK COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Ban	nock Coun	ty			Ren	nainder of Ida	aho
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	1,964	437,298	449.1	492.0	2,116.8	0.001 <<	45,369	8,554,808	530.3
All Sites Combined	Male	1,034	217,900	474.5	525.8	1,109.8	0.022 <<	,	4,294,373	564.4
All Sites Combined	Female	930	219,398	423.9	459.4	1,004.1	0.019 <<	21,133	4,260,435	496.0
Bladder	Total	85	437,298	19.4	21.7	97.6	0.216	2,135	8,554,808	25.0
Bladder	Male	71	217,900	32.6	36.9	76.2	0.597	1,702	4,294,373	39.6
Bladder	Female	14	219,398	6.4	7.1	20.2	0.196	433	4,260,435	10.2
Brain - malignant	Total	36	437,298	8.2	8.8	29.8	0.301	621	8,554,808	7.3
Brain - malignant	Male	20	217,900	9.2	9.8	17.2	0.555	362	4,294,373	8.4
	Female	16	219,398	7.3	7.7	12.6	0.402	259	4,260,435	6.1
	Total Male	42 10	437,298 217,900	9.6 4.6	10.4 5.0	70.9 22.8	0.000 << 0.004 <<	1,505 490	8,554,808	17.6
	Female	32	217,900	4.0	15.7	48.4	0.004 <<	1,015	4,294,373 4,260,435	11.4 23.8
Breast	Total	299	437,298	68.4	74.6	314.3	0.404	6,709	8,554,808	78.4
Breast	Male	4	217,900	1.8	2.1	2.8	0.600	61	4,294,373	1.4
Breast	Female	295	219,398	134.5	145.8	315.7	0.255	6,648	4,260,435	156.0
Breast - in situ	Total	63	437,298	14.4	15.7	61.2	0.855	1,306	8,554,808	15.3
Breast - in situ	Male	-	217,900	-	-	0.2	1.000	4	4,294,373	0.1
Breast - in situ	Female	63	219,398	28.7	31.2	61.8	0.909	1,302	4,260,435	30.6
Cervix	Female	23	219,398	10.5	10.7	13.6	0.025 >>	271	4,260,435	6.4
Colorectal	Total	153	437,298	35.0	38.5	161.7	0.522	3,479	8,554,808	40.7
Colorectal	Male	77	217,900	35.3	39.3	86.7	0.322	1,900	4,294,373	44.2
Colorectal	Female	76	219,398	34.6	37.7	74.7	0.913	1,579	4,260,435	37.1
Corpus Uteri	Female	55	219,398	25.1	27.2	61.6	0.439	1,299	4,260,435	30.5
Esophagus	Total	25	437,298	5.7	6.3	22.2	0.609	482	8,554,808	5.6
Esophagus	Male Female	22 3	217,900	10.1	11.3	18.4 3.5	0.465 1.000	407	4,294,373	9.5
Esophagus Hodakin Lymphomo		3 14	219,398 437,298	1.4 3.2	1.5 3.2	3.5 10.6	0.363	75 208	4,260,435 8,554,808	1.8 2.4
Hodgkin Lymphoma Hodgkin Lymphoma	Total Male	7	217,900	3.2	3.2 3.3	6.1	0.818	122	4,294,373	2.4
Hodgkin Lymphoma	Female	7	219,398	3.2	3.3	4.5	0.329	86	4,294,373	2.0
Kidney and Renal Pelvis	Total	, 91	437,298	20.8	22.8	86.7	0.674	1,860	8,554,808	21.7
Kidney and Renal Pelvis	Male	69	217,900	31.7	35.0	57.0	0.133	1,241	4,294,373	28.9
Kidney and Renal Pelvis	Female	22	219,398	10.0	10.9	29.2	0.205	619	4,260,435	14.5
Larynx	Total	13	437,298	3.0	3.3	9.6	0.341	207	8,554,808	2.4
Larynx	Male	12	217,900	5.5	6.2	7.0	0.108	155	4,294,373	3.6
Larynx	Female	1	219,398	0.5	0.5	2.5	0.595	52	4,260,435	1.2
Leukemia	Total	67	437,298	15.3	16.8	77.6	0.250	1,660	8,554,808	19.4
Leukemia	Male	38	217,900	17.4	19.3	45.8	0.276	998	4,294,373	23.2
Leukemia	Female	29	219,398	13.2	14.4	31.4	0.759	662	4,260,435	15.5
Liver and Bile Duct	Total	40	437,298	9.1	10.0	37.4	0.711	803	8,554,808	9.4
Liver and Bile Duct	Male	25	217,900	11.5	12.6	26.2	0.912	569	4,294,373	13.2
Liver and Bile Duct	Female	15	219,398	6.8	7.5	11.0	0.290	234	4,260,435	5.5
Lung and Bronchus Lung and Bronchus	Total Male	199 100	437,298 217,900	45.5 45.9	50.8 51.7	218.1 107.9	0.205 0.480	4,760 2,395	8,554,808 4,294,373	55.6 55.8
Lung and Bronchus	Female	99	217,900 219,398	45.9 45.1	49.9	107.9	0.460	2,395	4,294,373	55.5
Melanoma of the Skin	Total	145	437,298	33.2	36.0	141.2	0.770	2,999	8,554,808	35.1
Melanoma of the Skin	Male	86	217,900	39.5	43.7	82.9	0.760	1,809	4,294,373	42.1
Melanoma of the Skin	Female	59	219,398	26.9	28.6	57.6	0.886	1,190	4,260,435	27.9
Myeloma	Total	26	437,298	5.9	6.6	32.3	0.304	702	8,554,808	8.2
Myeloma	Male	15	217,900	6.9	7.7	19.5	0.371	432	4,294,373	10.1
Myeloma	Female		219,398	5.0	5.5	12.7	0.776	270	4,260,435	6.3
Non-Hodgkin Lymphoma	Total	83	437,298	19.0	20.8	89.2	0.552	1,909	8,554,808	22.3
Non-Hodgkin Lymphoma	Male	55	217,900	25.2	27.7	50.5	0.558	1,091	4,294,373	25.4
Non-Hodgkin Lymphoma	Female		219,398	12.8	13.9	38.7	0.092	818	4,260,435	19.2
Oral Cavity and Pharynx	Total	48	437,298	11.0	12.0	59.0	0.165	1,267	8,554,808	14.8
Oral Cavity and Pharynx	Male	29	217,900	13.3	14.7	41.9	0.046 <<		4,294,373	21.2
Oral Cavity and Pharynx	Female	19	219,398	8.7	9.5	16.8	0.654	356	4,260,435	8.4
Ovary Pancreas	Female	18 68	219,398	8.2	8.9 17.3	25.5	0.154 0.774	535 1,420	4,260,435 8,554,808	12.6
Pancreas Pancreas	Total Male	68 36	437,298 217,900	15.6 16.5	17.3 18.6	65.3 35.7	1.000	790	8,554,808 4,294,373	16.6 18.4
Pancreas	Female	30 32	217,900 219,398	16.5	16.0	35.7 29.4	0.680	790 630	4,294,373	10.4
Prostate	Male	238	217,900	109.2	120.7	299.6	0.000 <<		4,200,433	14.0
Stomach	Total	25	437,298	5.7	6.3	20.8	0.408	449	8,554,808	5.2
Stomach	Male	19	217,900	8.7	9.8	13.0	0.143	288	4,294,373	6.7
	Female	6	219,398	2.7	3.0	7.6	0.717	161	4,260,435	3.8
	Male	14	217,900	6.4	6.2	13.7	1.000	260	4,294,373	6.1
Thyroid	Total	48	437,298	11.0	11.3	56.4	0.288	1,137	8,554,808	13.3
Thyroid	Male	18	217,900	8.3	8.8	16.9	0.855	354	4,294,373	8.2
Thyroid	Female	30	219,398	13.7	13.9	39.8	0.132	783	4,260,435	18.4
		20	126,235	15.8	15.8	21.6	0.836	405	2,373,089	17.1
	10121									
Pediatric Age 0 to 19 Pediatric Age 0 to 19	Total Male	12	64,443	18.6	18.6	10.8	0.788	202	1,209,878	16.7

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN BANNOCK COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Ban	nock Count	у			Re	mainder of Idah	0
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	4,204	441,244	952.8	1,070.9	3,416.8	0.000 >>	76,331	8,770,150	870.3
All Causes of Death	Male	2,200	220,232	998.9	1,136.3	1.782.9	0.000 >>	40.586	4,407,465	920.8
All Causes of Death	Female	2,004	221,012	906.7	1,010.6	1,624.7	0.000 >>	35,745	4,362,685	819.3
All Malignant Cancers	Total	694	441,244	157.3	176.5	651.7	0.104	14,539	8,770,150	165.8
All Malignant Cancers	Male	366	220,232	166.2	189.6	344.6	0.262	7,869	4,407,465	178.5
All Malignant Cancers	Female	328	221,012	148.4	164.6	304.7	0.193	6,670	4,362,685	152.9
Bladder	Total	14	441,244	3.2	3.6	20.7	0.160	471	8,770,150	5.4
Bladder	Male	10	220,232	4.5	5.3	15.5	0.189	365	4,407,465	8.3
Bladder	Female	4	221,012	1.8	2.0	4.8	0.962	106	4,362,685	2.4
Brain and Other Nervous System	Total	28	441,244	6.3	6.9	22.6	0.305	490	8,770,150	5.6
Brain and Other Nervous System	Male	13	220,232	5.9	6.5	12.6	0.979	276	4,407,465	6.3
Brain and Other Nervous System	Female	15	221,012	6.8	7.4	10.0	0.166	214	4,362,685	4.9
Breast	Total	52	441,244	11.8	13.2	48.3	0.628	1,072	8,770,150	12.2
Breast	Male	1	220,232	0.5	0.5	0.5	0.832	12	4,407,465	0.3
Breast	Female	51	221,012	23.1	25.5	48.6	0.768	1,060	4,362,685	24.3
Cervix	Female	7	221,012	3.2	3.3	3.9	0.198	81	4,362,685	1.9
Colorectal	Total	61	441,244	13.8	15.5	57.2	0.649	1,271	8,770,150	14.5
Colorectal	Male	32	220,232	14.5	16.4	31.0	0.902	700	4,407,465	15.9
Colorectal	Female	29	221,012	13.1	14.6	26.1	0.618	571	4,362,685	13.1
Corpus Uteri	Female	7	221,012	3.2	3.5	7.4	1.000	162	4,362,685	3.7
Esophagus	Total	12	441,244 220,232	2.7	3.0	20.2	0.071	449	8,770,150	5.1
Esophagus Esophagus	Male Female	11 1	220,232	5.0 0.5	5.6 0.5	16.8 3.2	0.183 0.356	380 69	4,407,465 4,362,685	8.6 1.6
Hodgkin Lymphoma	Total	3	441,244	0.5	0.5	1.0	0.350	22	8,770,150	0.3
Hodgkin Lymphoma	Male	5 1	220,232	0.7	0.7	0.6	0.887	13	4,407,465	0.3
Hodgkin Lymphoma	Female	2	221,012	0.9	1.0	0.0	0.134	9	4,362,685	0.3
Kidney	Total	18	441,244	4.1	4.6	16.4	0.765	368	8,770,150	4.2
Kidney	Male	12	220,232	5.4	6.2	10.4	0.669	234	4,407,465	5.3
Kidney	Female	6	221,012	2.7	3.0	6.1	1.000	134	4,362,685	3.1
Larynx	Total	8	441,244	1.8	2.0	3.1	0.027 >>	68	8,770,150	0.8
Larynx	Male	8	220,232	3.6	4.2	2.5	0.008 >>	57	4,407,465	1.3
Larýnx	Female	-	221,012	-	-	0.5	1.000	11	4,362,685	0.3
Leukemia	Total	34	441,244	7.7	8.7	28.2	0.317	631	8,770,150	7.2
Leukemia	Male	20	220,232	9.1	10.4	16.5	0.442	377	4,407,465	8.6
Leukemia	Female	14	221,012	6.3	7.1	11.5	0.543	254	4,362,685	5.8
Liver and Bile Duct	Total	34	441,244	7.7	8.6	27.2	0.232	601	8,770,150	6.9
Liver and Bile Duct	Male	22	220,232	10.0	11.1	18.0	0.397	401	4,407,465	9.1
Liver and Bile Duct	Female	12	221,012	5.4	6.0	9.1	0.419	200	4,362,685	4.6
Lung and Bronchus	Total	130	441,244	29.5	33.2	125.4	0.701	2,807	8,770,150	32.0
Lung and Bronchus	Male	69	220,232	31.3	35.7	64.6	0.613	1,472	4,407,465	33.4
Lung and Bronchus	Female	61	221,012	27.6	30.8	60.6	0.991	1,335	4,362,685	30.6
Melanoma of the Skin Melanoma of the Skin	Total Mala	11	441,244	2.5	2.8	13.1	0.685	290 105	8,770,150	3.3
Melanoma of the Skin Melanoma of the Skin	Male Female	5 6	220,232 221,012	2.3 2.7	2.6 3.0	8.6 4.4	0.287 0.561	195 95	4,407,465 4,362,685	4.4 2.2
Melanoma of the Skin	Total	о 18	441,244	4.1	3.0 4.6	4.4	0.561	95 307	, ,	2.2
Myeloma Myeloma	Male	10	220,232	4.1	4.0 5.2	7.7	0.297	307 178	8,770,150 4,407,465	3.5 4.0
Myeloma	Female	8	220,232	4.5	4.0	5.8	0.301	129	4,362,685	4.0
Non-Hodgkin Lymphoma	Total	22	441,244	5.0	4.0 5.6	24.3	0.736	546	8,770,150	6.2
Non-Hodgkin Lymphoma	Male	13	220,232	5.9	6.7	13.0	1.000	297	4,407,465	6.7
Non-Hodgkin Lymphoma	Female	9	221.012	4.1	4.6	11.3	0.622	249	4,362,685	5.7
Oral Cavity and Pharynx	Total	10	441,244	2.3	2.5	12.0	0.703	265	8,770,150	3.0
Oral Cavity and Pharynx	Male	7	220,232	3.2	3.6	8.2	0.844	185	4,407,465	4.2
Oral Cavity and Pharynx	Female	3	221,012	1.4	1.5	3.7	1.000	80	4,362,685	1.8
Ovary	Female	15	221,012	6.8	7.5	15.9	0.962	346	4,362,685	7.9
Pancreas	Total	60	441,244	13.6	15.2	50.8	0.224	1,130	8,770,150	12.9
Pancreas	Male	29	220,232	13.2	14.9	27.4	0.815	621	4,407,465	14.1
Pancreas	Female	31	221,012	14.0	15.6	23.2	0.139	509	4,362,685	11.7
Prostate	Male	50	220,232	22.7	26.7	40.2	0.151	947	4,407,465	21.5
Stomach	Total	9	441,244	2.0	2.3	8.4	0.916	185	8,770,150	2.1
Stomach	Male	7	220,232	3.2	3.6	4.9	0.440	112	4,407,465	2.5
Stomach	Female	2	221,012	0.9	1.0	3.4	0.674	73	4,362,685	1.7

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Bannock County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	91.6% 11.6%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	64.3% 78.9% 62.8%
Current Tobacco User (2020–2022) <u>Other Cancer-Related</u>	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	23.9%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	30.0% 78.5% 24.1% 24.2%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





BEAR LAKE COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 171 cases of invasive cancer were diagnosed among Bear Lake County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in Bear LakeCounty and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Bear Lake County	State of Idaho
All Sites/Types	171	47,333
Female Breast	16	6,943
Prostate	24	6,766
Lung & Bronchus	15	4,959
Colorectal	14	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Bear Lake County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Bear Lake County. The table also shows the number of observed cases,

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 61 Bear Lake County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Bear Lake County and the State of Idaho, 2018–2022

Mortality 2018–2022	Bear Lake County	State of Idaho
All Deaths	342	80,538
Cancer Deaths	61	15,233
% of All Deaths	17.8%	18.9%
Lung & Bronchus	12	2,937
Colorectal	9	1,332
Pancreas	3	1,190
Female Breast	5	1,111
Prostate	4	997

person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, nonmalignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Bear Lake County was 553.6 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (526.3) gives an estimate of the relative burden of disease in Bear Lake County.

The age- and sex-adjusted incidence rate of invasive cancer in Bear Lake County, all sites combined, was 467.1 cases per 100,000 persons per year during 2017–2021. There were fewer cases of cancer in Bear Lake County (171) than expected (192.7) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Bear Lake County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Bear Lake County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Bear Lake County, all sites combined, was 156.1 deaths per 100,000 persons per year during 2018–2022, compared with 165.3 for the remainder of the state. There were fewer cancer deaths in Bear Lake County (61) than expected (64.6) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN BEAR LAKE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Bear	Lake Cour	itv			Ren	nainder of Ida	aho
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)		P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	171	30,888	553.6	467.1	192.7	0.123	47,162	8,961,218	526.3
All Sites Combined	Male	106	15,416	687.6	562.8	105.4	0.979	25,164	4,496,857	559.6
All Sites Combined	Female	65	15,472	420.1	365.0	87.7	0.014 <<		4,464,361	492.7
Bladder	Total	13	30,888	42.1	33.3	9.6	0.346	2,207	8,961,218	24.6
Bladder	Male	12	15,416	77.8	60.4	7.8	0.194	1,761	4,496,857	39.2
Bladder	Female	1	15,472	6.5	5.3	1.9	0.869	446	4,464,361	10.0
Brain - malignant Brain - malignant	Total Male	4 1	30,888 15.416	13.0 6.5	11.5 5.8	2.5 1.5	0.495 1.000	653 381	8,961,218 4,496,857	7.3 8.5
Brain - malignant Brain - malignant	Female	3	15,470	19.4	17.2	1.5	0.183	272	4,490,857	6.1
Brain and other CNS - non-malignant	Total	12	30,888	38.9	33.8	6.1	0.044 >>	1,535	8,961,218	17.1
Brain and other CNS - non-malignant	Male	3	15,416	19.5	16.9	2.0	0.626	497	4,496,857	11.1
Brain and other CNS - non-malignant	Female	9	15,472	58.2	51.0	4.1	0.049 >>	1,038	4,464,361	23.3
Breast	Total	17	30,888	55.0	48.2	27.5	0.044 <<	6,991	8,961,218	78.0
Breast	Male	1	15,416	6.5	5.3	0.3	0.474	64	4,496,857	1.4
Breast Breast - in situ	Female Total	16 4	15,472 30,888	103.4 13.0	91.5 11.6	27.1 5.2	0.030 << 0.797	6,927 1,365	4,464,361 8,961,218	155.2 15.2
Breast - in situ	Male	- 4	15,416	-	-	0.0	1.000	1,303	4,496,857	0.1
Breast - in situ	Female	4	15,472	25.9	23.4	5.2	0.808	1,361	4,464,361	30.5
Cervix	Female	2	15,472	12.9	13.3	1.0	0.518	292	4,464,361	6.5
Colorectal	Total	14	30,888	45.3	38.5	14.7	0.999	3,618	8,961,218	40.4
Colorectal	Male	10	15,416	64.9	54.8	8.0	0.563	1,967	4,496,857	43.7
Colorectal	Female	4	15,472	25.9	22.1	6.7	0.404	1,651	4,464,361	37.0
Corpus Uteri	Female	3	15,472 30,888	19.4 6.5	17.2	5.3 2.1	0.459 1.000	1,351	4,464,361 8.961.218	30.3
Esophagus Esophagus	Total Male	2 2	30,888 15,416	6.5 13.0	5.3 10.5	2.1 1.8	1.000	505 427	8,961,218 4,496,857	5.6 9.5
Esophagus	Female	- 2	15,472	-	-	0.3	1.000	427 78	4,464,361	9.3 1.7
Hodgkin Lymphoma	Total	1	30,888	3.2	3.2	0.8	1.000	221	8,961,218	2.5
Hodgkin Lýmphoma	Male	-	15,416	-	-	0.5	1.000	129	4,496,857	2.9
Hodgkin Lymphoma	Female	1	15,472	6.5	6.6	0.3	0.536	92	4,464,361	2.1
Kidney and Renal Pelvis	Total	4	30,888	13.0	11.0	7.9	0.215	1,947	8,961,218	21.7
Kidney and Renal Pelvis	Male Female	4	15,416	25.9	21.9	5.3	0.777	1,306	4,496,857	29.0
Kidney and Renal Pelvis Larynx	Total	- 1	15,472 30,888	- 3.2	- 2.7	2.6 0.9	0.151 1.000	641 219	4,464,361 8,961,218	14.4 2.4
Larynx	Male	1	15,416	6.5	5.2	0.5	1.000	166	4,496,857	3.7
Larynx	Female	- '	15,472	-	-	0.2	1.000	53	4,464,361	1.2
Leukemia	Total	9	30,888	29.1	24.3	7.1	0.567	1,718	8,961,218	19.2
Leukemia	Male	7	15,416	45.4	37.3	4.3	0.287	1,029	4,496,857	22.9
Leukemia	Female	2	15,472	12.9	11.0	2.8	0.930	689	4,464,361	15.4
Liver and Bile Duct Liver and Bile Duct	Total Male	4 2	30,888 15,416	13.0 13.0	10.8 10.6	3.5 2.5	0.913 1.000	839 592	8,961,218 4,496,857	9.4 13.2
Liver and Bile Duct	Female	2	15,470	12.9	10.0	2.5	0.539	247	4,490,857 4,464,361	5.5
Lung and Bronchus	Total	15	30,888	48.6	38.7	21.4	0.194	4,944	8,961,218	55.2
Lung and Bronchus	Male	10	15,416	64.9	50.8	10.9	0.948	2,485	4,496,857	55.3
Lung and Bronchus	Female	5	15,472	32.3	26.2	10.5	0.099	2,459	4,464,361	55.1
Melanoma of the Skin	Total	14	30,888	45.3	39.1	12.5	0.744	3,130	8,961,218	34.9
Melanoma of the Skin	Male	9	15,416	58.4	48.5	7.8	0.755	1,886	4,496,857	41.9
Melanoma of the Skin	Female	5	15,472	32.3	29.3	4.8	1.000	1,244	4,464,361	27.9
Myeloma Myeloma	Total Male	2	30,888 15,416	6.5 13.0	5.3 10.4	3.1 1.9	0.815 1.000	726 445	8,961,218 4,496,857	8.1 9.9
Myeloma	Female	2	15,470	-	-	1.9	0.613	281	4,490,857 4,464,361	9.9 6.3
Non-Hodgkin Lymphoma	Total	9	30,888	29.1	24.6	8.1	0.845	1,983	8,961,218	22.1
Non-Hodgkin Lymphoma	Male	6	15,416	38.9	32.5	4.7	0.656	1,140	4,496,857	25.4
Non-Hodgkin Lymphoma	Female	3	15,472	19.4	16.4	3.4	1.000	843	4,464,361	18.9
Oral Cavity and Pharynx	Total	3	30,888	9.7	8.3	5.3	0.452	1,312	8,961,218	14.6
Oral Cavity and Pharynx Oral Cavity and Pharynx	Male Female	2 1	15,416 15,472	13.0 6.5	10.9 5.6	3.8 1.5	0.533 1.000	938 374	4,496,857 4,464,361	20.9 8.4
Ovary	Female	1	15,472	6.5	5.0 5.7	2.2	0.732	552	4,464,361	0.4 12.4
Pancreas	Total	4	30,888	13.0	10.5	6.3	0.732	1,484	8,961,218	12.4
Pancreas	Male	3	15,416	19.5	15.5	3.5	1.000	823	4,496,857	18.3
Pancreas	Female	1	15,472	6.5	5.3	2.8	0.470	661	4,464,361	14.8
Prostate	Male	24	15,416	155.7	125.8	28.6	0.450	6,742	4,496,857	149.9
Stomach	Total	1	30,888	3.2	2.7	2.0	0.832	473	8,961,218	5.3
Stomach	Male	1	15,416	6.5	5.3	1.3	1.000	306	4,496,857	6.8
Stomach	Female Male	- 1	15,472 15,416	- 6.5	- 7.4	0.7 0.8	1.000 1.000	167 273	4,464,361	3.7
Testis Thyroid	Total	1 5	15,416 30,888	6.5 16.2	7.4 16.0	0.8 4.1	0.784		4,496,857 8,961,218	6.1 13.2
Thyroid Thyroid	Male	5	30,888 15,416	16.2	16.0 17.9	4.1 1.4	0.784 0.320	1,180 369	8,961,218 4,496,857	8.2
			,	19.5	17.9	1.4 2.7	0.320 0.971	369 811	4,496,857 4,464,361	8.2 18.2
	Female	, ,								
Thyroid	Female Total	2	15,472							
	Female Total Male	2	9,005 4,561	22.2	22.3 21.8	1.5 0.8	0.899	423 213	2,490,319	17.0 16.8

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN BEAR LAKE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Bear	Lake Coun	ty			Re	emainder of Idah	10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	342	31,581	1,082.9	876.0	341.1	0.974	80,193	9,179,813	873.6
All Causes of Death	Male	182	15,820	1,150.4	915.6	183.6	0.944	42,604	4,611,877	923.8
All Causes of Death	Female	160	15,761	1,015.2	834.3	157.8	0.883	37,589	4,567,936	822.9
All Malignant Cancers	Total	61	31,581	193.2	156.1	64.6	0.714	15,172	9,179,813	165.3
All Malignant Cancers	Male	35	15,820	221.2	174.2	35.7	0.993	8,200	4,611,877	177.8
All Malignant Cancers	Female	26	15,761	165.0	136.2	29.1	0.643	6,972	4,567,936	152.6
Bladder	Total	1	31,581	3.2	2.5	2.1	0.736	484	9,179,813	5.3
Bladder	Male	1	15,820	6.3	4.7	1.7	0.978	374	4,611,877	8.1
Bladder	Female	-	15,761	-	-	0.5	1.000	110	4,567,936	2.4
Brain and Other Nervous System	Total	3	31,581	9.5	8.2	2.1	0.676	515	9,179,813	5.6
Brain and Other Nervous System	Male	1	15,820	6.3	5.4	1.2	1.000 0.452	288 227	4,611,877	6.2
Brain and Other Nervous System Breast	Female Total	2 5	15,761 31,581	12.7 15.8	11.1 13.1	0.9 4.6	0.452	1,119	4,567,936 9,179,813	5.0 12.2
Breast	Male	5	15,820	15.0	13.1	0.1	1.000	13	4,611,877	0.3
Breast	Female	- 5	15,761	- 31.7	26.9	4.5	0.935	1,106	4,567,936	24.2
Cervix	Female	-	15,761	-	-	0.3	1.000	88	4,567,936	1.9
Colorectal	Total	9	31,581	28.5	23.6	5.5	0.212	1,323	9,179,813	14.4
Colorectal	Male	5	15,820	31.6	25.9	3.0	0.383	727	4,611,877	15.8
Colorectal	Female	4	15,761	25.4	21.1	2.5	0.471	596	4,567,936	13.0
Corpus Uteri	Female	-	15,761	-	-	0.7	0.994	169	4,567,936	3.7
Esophagus	Total	2	31,581	6.3	5.2	1.9	1.000	459	9,179,813	5.0
Esophagus	Male	2	15,820	12.6	10.1	1.7	0.990	389	4,611,877	8.4
Esophagus	Female	-	15,761	-	-	0.3	1.000	70	4,567,936	1.5
Hodgkin Lymphoma	Total	-	31,581	-	-	0.1	1.000	25	9,179,813	0.3
Hodgkin Lymphoma Hodgkin Lymphoma	Male Female	-	15,820 15,761	-	-	0.1 0.0	1.000 1.000	14 11	4,611,877 4,567,936	0.3 0.2
Kidney	Total	- 1	31,581	- 3.2	- 2.5	1.7	1.000	385	9,179,813	4.2
Kidney	Male	1	15,820	6.3	5.0	1.1	1.000	245	4,611,877	5.3
Kidney	Female	- '	15,761	-	-	0.6	1.000	140	4,567,936	3.1
Larynx	Total	-	31,581	-	-	0.3	1.000	76	9,179,813	0.8
Larynx	Male	-	15,820	-	-	0.3	1.000	65	4,611,877	1.4
Larýnx	Female	-	15,761	-	-	0.0	1.000	11	4,567,936	0.2
Leukemia	Total	5	31,581	15.8	12.6	2.8	0.319	660	9,179,813	7.2
Leukemia	Male	3	15,820	19.0	14.8	1.7	0.501	394	4,611,877	8.5
Leukemia	Female	2	15,761	12.7	10.3	1.1	0.626	266	4,567,936	5.8
Liver and Bile Duct	Total	4	31,581	12.7	10.4 5.1	2.6	0.546	631	9,179,813	6.9
Liver and Bile Duct Liver and Bile Duct	Male Female	1 3	15,820 15,761	6.3 19.0	5.1 15.7	1.8 0.9	0.931 0.117	422 209	4,611,877 4,567,936	9.2 4.6
Lung and Bronchus	Total	12	31,581	38.0	30.2	12.6	1.000	2,925	9,179,813	31.9
Lung and Bronchus	Male	8	15,820	50.6	39.6	6.7	0.720	1,533	4,611,877	33.2
Lung and Bronchus	Female	4	15,761	25.4	20.4	6.0	0.578	1,392	4,567,936	30.5
Melanoma of the Skin	Total	1	31,581	3.2	2.6	1.3	1.000	300	9,179,813	3.3
Melanoma of the Skin	Male	1	15,820	6.3	5.1	0.8	1.000	199	4,611,877	4.3
Melanoma of the Skin	Female	-	15,761	-	-	0.4	1.000	101	4,567,936	2.2
Myeloma	Total	1	31,581	3.2	2.5	1.4	1.000	324	9,179,813	3.5
Myeloma	Male	1	15,820	6.3	4.9	0.8	1.000	187	4,611,877	4.1
Myeloma	Female	-	15,761	-	-	0.6	1.000	137	4,567,936	3.0
Non-Hodgkin Lymphoma	Total Malo	3	31,581	9.5 10.0	7.5	2.4	0.885	565	9,179,813	6.2 6.7
Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma	Male Female	3	15,820 15,761	19.0 -	15.0 -	1.3 1.1	0.299 0.651	307 258	4,611,877 4,567,936	6.7 5.6
Oral Cavity and Pharvnx	Total	-	31,581	-	-	1.1	0.633	230	9,179,813	3.0
Oral Cavity and Pharynx	Male	_	15,820	_	_	0.8	0.880	192	4,611,877	4.2
Oral Cavity and Pharynx	Female	-	15,761	-	-	0.3	1.000	83	4,567,936	1.8
Ovary	Female	1	15,761	6.3	5.3	1.5	1.000	360	4,567,936	7.9
Pancreas	Total	3	31,581	9.5	7.7	5.1	0.516	1,187	9,179,813	12.9
Pancreas	Male	2	15,820	12.6	10.1	2.8	0.941	648	4,611,877	14.1
Pancreas	Female	1	15,761	6.3	5.2	2.3	0.679	539	4,567,936	11.8
Prostate	Male	4	15,820	25.3	18.9	4.6	1.000	993	4,611,877	21.5
Stomach	Total	-	31,581	-	-	0.8	0.902	194	9,179,813	2.1
Stomach	Male	-	15,820	-	-	0.5	1.000	119	4,611,877	2.6
Stomach	Female	-	15,761	-	-	0.3	1.000	75	4,567,936	1.6

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Bear Lake County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	19.0%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	
Current Tobacco User (2020–2022) Other Cancer-Related	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	16.4%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	23.7% 74.3% 19.2% 33.8%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





BENEWAH COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 310 cases of invasive cancer were diagnosed among Benewah County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in BenewahCounty and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Benewah County	State of Idaho
All Sites/Types	310	47,333
Female Breast	43	6,943
Prostate	38	6,766
Lung & Bronchus	41	4,959
Colorectal	24	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Benewah County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Benewah County. The table also shows the number of observed cases,

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 121 Benewah County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Benewah County and the State of Idaho, 2018–2022

Mortality 2018–2022	Benewah County	State of Idaho
All Deaths	667	80,538
Cancer Deaths	121	15,233
% of All Deaths	18.1%	18.9%
Lung & Bronchus	33	2,937
Colorectal	5	1,332
Pancreas	11	1,190
Female Breast	8	1,111
Prostate	8	997

person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, nonmalignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Benewah County was 658.7 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (525.7) gives an estimate of the relative burden of disease in Benewah County.

The age- and sex-adjusted incidence rate of invasive cancer in Benewah County, all sites combined, was 498.9 cases per 100,000 persons per year during 2017–2021. There were fewer cases of cancer in Benewah County (310) than expected (326.7) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Benewah County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Benewah County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Benewah County, all sites combined, was 189.8 deaths per 100,000 persons per year during 2018–2022, compared with 164.9 for the remainder of the state. There were more cancer deaths in Benewah County (121) than expected (105.1) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN BENEWAH COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Ben	ewah Coun	ty			Rem	nainder of Ida	aho
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)		P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	310	47,063	658.7	498.9	326.7	0.372	47,023	8,945,043	525.7
All Sites Combined	Male	176	24,082	730.8	522.6	188.3	0.392	25,094	4.488.191	559.1
All Sites Combined	Female	134	22,981	583.1	464.2	142.0	0.533	21,929	4,456,852	492.0
Bladder	Total	20	47,063	42.5	30.9	15.9	0.361	2,200	8,945,043	24.6
Bladder	Male	15	24,082	62.3	42.6	13.8	0.815	1,758	4,488,191	39.2
Bladder	Female	5	22,981	21.8	16.7	3.0	0.359	442	4,456,852	9.9
Brain - malignant	Total	5	47,063	10.6	8.7	4.2	0.813	652	8,945,043	7.3
Brain - malignant Brain - malignant	Male Female	1 4	24,082 22,981	4.2 17.4	3.3 14.5	2.5 1.7	0.561 0.179	381 271	4,488,191 4,456,852	8.5 6.1
Brain and other CNS - non-malignant	Total	9	47,063	17.4	14.5	10.1	0.882	1,538	8,945,043	17.2
	Male	4	24,082	16.6	13.0	3.4	0.886	496	4,488,191	11.1
	Female	5	22,981	21.8	17.8	6.6	0.720	1,042	4,456,852	23.4
Breast	Total	44	47,063	93.5	72.4	47.3	0.694	6,964	8,945,043	77.9
Breast	Male	1	24,082	4.2	3.0	0.5	0.761	64	4,488,191	1.4
Breast	Female	43	22,981	187.1	147.6	45.1	0.828	6,900	4,456,852	154.8
Breast - in situ	Total	13	47,063	27.6	21.4	9.2	0.283	1,356	8,945,043	15.2
Breast - in situ	Male	1	24,082	4.2	3.6	0.0	0.037 >>	3	4,488,191	0.1
Breast - in situ	Female	12	22,981 22,981	52.2	40.7	9.0	0.385	1,353	4,456,852 4,456,852	30.4
Cervix Colorectal	Female Total	1 24	47,063	4.4 51.0	4.1 39.3	1.6 24.6	1.000	293 3,608	4,456,852 8,945,043	6.6 40.3
Colorectal	Male	24 12	24,082	49.8	39.3	14.3	0.653	3,008 1,965	6,945,045 4,488,191	40.3
Colorectal	Female	12	22,981	52.2	42.2	14.5	0.716	1,643	4,456,852	36.9
Corpus Uteri	Female	5	22,981	21.8	16.8	9.0	0.229	1,349	4,456,852	30.3
Esophagus	Total	6	47,063	12.7	9.3	3.6	0.311	501	8,945,043	5.6
Esophagus	Male	6	24,082	24.9	17.4	3.2	0.222	423	4,488,191	9.4
Esophagus	Female	-	22,981	-	-	0.5	1.000	78	4,456,852	1.8
Hodgkin Lymphoma	Total	-	47,063	-	-	1.2	0.588	222	8,945,043	2.5
Hodgkin Lymphoma	Male	-	24,082	-	-	0.8	0.941	129	4,488,191	2.9
Hodgkin Lymphoma Kidney and Renal Pelvis	Female	- 22	22,981	- 46.7	- 35.6	0.5	1.000	93	4,456,852	2.1 21.6
Kidney and Renal Pelvis	Total Male	22 17	47,063 24,082	40.7 70.6	52.0	13.3 9.4	0.036 >> 0.033 >>	1,929 1,293	8,945,043 4,488,191	21.0
Kidney and Renal Pelvis	Female	5	22,981	21.8	17.2	4.2	0.802	636	4,456,852	14.3
Larynx	Total	2	47,063	4.2	3.1	1.6	0.927	218	8,945,043	2.4
Larynx	Male	2	24,082	8.3	5.8	1.3	0.720	165	4,488,191	3.7
Larynx	Female	-	22,981	-	-	0.4	1.000	53	4,456,852	1.2
Leukemia	Total	5	47,063	10.6	8.2	11.7	0.048 <<	1,722	8,945,043	19.3
Leukemia	Male	5	24,082	20.8	15.2	7.5	0.475	1,031	4,488,191	23.0
Leukemia	Female	-	22,981	-	-	4.4	0.024 <<	691	4,456,852	15.5
Liver and Bile Duct	Total Male	9 7	47,063	19.1	14.0	6.0	0.308 0.328	834	8,945,043	9.3
Liver and Bile Duct Liver and Bile Duct	Female	2	24,082 22,981	29.1 8.7	20.5 6.7	4.5 1.7	0.328	587 247	4,488,191 4,456,852	13.1 5.5
Lung and Bronchus	Total	41	47,063	87.1	62.7	36.0	0.333	4,918	8,945,043	55.0
Lung and Bronchus	Male	22	24,082	91.4	62.3	19.4	0.621	2,473	4,488,191	55.1
Lung and Bronchus	Female	19	22,981	82.7	62.3	16.7	0.643	2,445	4,456,852	54.9
Melanoma of the Skin	Total	7	47,063	14.9	11.7	21.0	0.001 <<	3,137	8,945,043	35.1
Melanoma of the Skin	Male	5	24,082	20.8	15.2	13.8	0.013 <<	1,890	4,488,191	42.1
Melanoma of the Skin	Female	2	22,981	8.7	7.3	7.7	0.034 <<	1,247	4,456,852	28.0
Myeloma	Total	9	47,063	19.1	14.0	5.2	0.158	719	8,945,043	8.0
Myeloma	Male Female	4 5	24,082	16.6	11.6 16.5	3.4	0.885	443	4,488,191	9.9 6.2
Myeloma Non-Hodgkin Lymphoma	Total	5 16	22,981 47,063	21.8 34.0	16.5 25.9	1.9 13.7	0.084 0.594	276 1,976	4,456,852 8,945,043	22.1
Non-Hodgkin Lymphoma	Male	9	24.082	37.4	27.5	8.3	0.898	1,137	4.488.191	25.3
Non-Hodgkin Lymphoma	Female	5 7	22,981	30.5	24.1	5.5	0.620	839	4,456,852	18.8
Oral Cavity and Pharynx	Total	10	47,063	21.2	15.8	9.2	0.881	1,305	8,945,043	14.6
Oral Cavity and Pharynx	Male	10	24,082	41.5	30.0	6.9	0.322	930	4,488,191	20.7
Oral Cavity and Pharynx	Female	-	22,981	-	-	2.5	0.168	375	4,456,852	8.4
Ovary	Female	5	22,981	21.8	17.4	3.5	0.559	548	4,456,852	12.3
Pancreas	Total	13	47,063	27.6	20.4	10.5	0.518	1,475	8,945,043	16.5
Pancreas Pancreas	Male Female	7 6	24,082 22,981	29.1 26.1	20.4 20.3	6.3 4.4	0.876 0.547	819 656	4,488,191 4,456,852	18.2 14.7
Prostate	Male	38	22,961	157.8	20.3	4.4 52.1	0.047	6,728	4,450,652	14.7
Stomach	Total	6	47,062	12.7	9.7	3.2	0.032	468	8,945,043	5.2
Stomach	Male	6	24,082	24.9	17.7	2.3	0.057	301	4,488,191	6.7
			22,981		-	1.0	0.706	167	4,456,852	3.7
Stomach	Female	-	22,901							
Stomach Testis	Female Male	- 2	22,981	8.3	9.8	1.2	0.699	272	4,488,191	6.1
				8.3 8.5	9.8 7.7	1.2 6.8	0.699 0.380	272 1,181	4,488,191 8,945,043	6.1 13.2
Testis	Male	2	24,082							13.2
Testis Thyroid	Male Total	2 4	24,082 47,063	8.5	7.7	6.8	0.380	1,181	8,945,043	
Testis Thyroid Thyroid	Male Total Male	2 4 1	24,082 47,063 24,082	8.5 4.2	7.7 3.5	6.8 2.4	0.380 0.621	1,181 371	8,945,043 4,488,191	13.2 8.3
Testis Thyroid Thyroid Thyroid	Male Total Male Female	2 4 1 3	24,082 47,063 24,082 22,981	8.5 4.2 13.1	7.7 3.5 12.3	6.8 2.4 4.4	0.380 0.621 0.709	1,181 371 810	8,945,043 4,488,191 4,456,852	13.2 8.3 18.2

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN BENEWAH COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Ben	ewah Count	y			Re	mainder of Idah	10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years		Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	667	48,266	1,381.9	1,109.6	524.0	0.000 >>	79,868	9,163,128	871.6
All Causes of Death	Male	370	24,787	1.492.7	1,094.5	311.5	0.001 >>	42,416	4,602,910	921.5
All Causes of Death	Female	297	23,479	1,265.0	1,120.2	217.7	0.000 >>	37,452	4,560,218	821.3
All Malignant Cancers	Total	121	48.266	250.7	189.8	105.1	0.139	15,112	9,163,128	164.9
All Malignant Cancers	Male	69	24,787	278.4	195.9	62.5	0.442	8,166	4,602,910	177.4
All Malignant Cancers	Female	52	23,479	221.5	178.5	44.4	0.286	6,946	4,560,218	152.3
Bladder	Total	6	48,266	12.4	9.7	3.2	0.221	479	9,163,128	5.2
Bladder	Male	6	24,787	24.2	16.8	2.9	0.140	369	4,602,910	8.0
Bladder	Female	-	23,479	-	-	0.7	1.000	110	4,560,218	2.4
Brain and Other Nervous System	Total	1	48,266	2.1	1.6	3.5	0.270	517	9,163,128	5.6
Brain and Other Nervous System	Male	-	24,787	-	-	2.1	0.253	289	4,602,910	6.3
Brain and Other Nervous System	Female	1	23,479	4.3	3.4	1.5	1.000	228	4,560,218	5.0
Breast	Total	9	48,266	18.6	14.6	7.5	0.683	1,115	9,163,128	12.2
Breast	Male	1	24,787	4.0	2.8	0.1	0.177	12	4,602,910	0.3
Breast	Female	8	23,479	34.1	28.0	6.9	0.776	1,103	4,560,218	24.2
Cervix	Female	-	23,479	-	-	0.5	1.000	88	4,560,218	1.9
Colorectal	Total	5	48,266	10.4	8.0	9.1	0.225	1,327	9,163,128	14.5
Colorectal	Male	4	24,787	16.1	11.7	5.4	0.743	728	4,602,910	15.8
Colorectal	Female	1	23,479	4.3	3.5	3.7	0.231	599	4,560,218	13.1
Corpus Uteri	Female	1	23,479	4.3	3.3	1.1	1.000	168	4,560,218	3.7
Esophagus	Total	4	48,266	8.3	6.1	3.3	0.822 0.694	457	9,163,128	5.0 8.4
Esophagus	Male Female	•	24,787 23,479	16.1	11.3	3.0 0.4	0.694	387 70	4,602,910 4,560,218	8.4 1.5
Esophagus Hodgkin Lymphoma	Total	-	48,266	-	-	0.4	1.000	25	9,163,128	0.3
Hodgkin Lymphoma	Male	-	24,787	-	-	0.2	1.000	14	4,602,910	0.3
Hodgkin Lymphoma	Female	_	23,479	-		0.1	1.000	14	4,560,218	0.3
Kidney	Total	- 3	48,266	6.2	4.7	2.7	1.000	383	9,163,128	4.2
Kidney	Male	2	24,787	8.1	5.7	1.9	1.000	244	4,602,910	5.3
Kidney	Female	1	23,479	4.3	3.4	0.9	1.000	139	4.560.218	3.0
Larynx	Total	1	48,266	2.1	1.5	0.5	0.826	75	9,163,128	0.8
Larynx	Male	1	24,787	4.0	2.8	0.5	0.781	64	4,602,910	1.4
Larýnx	Female	-	23,479	-	-	0.1	1.000	11	4,560,218	0.2
Leukemia	Total	6	48,266	12.4	9.6	4.5	0.596	659	9,163,128	7.2
Leukemia	Male	4	24,787	16.1	11.5	3.0	0.697	393	4,602,910	8.5
Leukemia	Female	2	23,479	8.5	7.1	1.6	0.981	266	4,560,218	5.8
Liver and Bile Duct	Total	6	48,266	12.4	9.2	4.5	0.593	629	9,163,128	6.9
Liver and Bile Duct	Male	4	24,787	16.1	11.4	3.2	0.794	419	4,602,910	9.1
Liver and Bile Duct	Female	2	23,479	8.5	6.6	1.4	0.811	210	4,560,218	4.6
Lung and Bronchus	Total	33	48,266	68.4	50.2	20.8	0.017 >>	2,904	9,163,128	31.7
Lung and Bronchus	Male	15	24,787	60.5	41.7	11.9	0.440	1,526	4,602,910	33.2
Lung and Bronchus	Female	18	23,479	76.7	59.7	9.1	0.012 >>	1,378	4,560,218	30.2
Melanoma of the Skin	Total	-	48,266	-	-	2.1	0.256	301	9,163,128	3.3
Melanoma of the Skin	Male Female	-	24,787 23,479	-	-	1.5 0.6	0.446 1.000	200 101	4,602,910 4,560,218	4.3 2.2
Melanoma of the Skin	Total	-	48,266	- 10.4	- 7.7		0.159	320		3.5
Myeloma Myeloma	Male	5 3	48,266 24,787	10.4	7.7 8.4	2.3 1.4	0.159	320 185	9,163,128 4,602,910	3.5 4.0
Myeloma	Female	2	23,479	8.5	6.4 6.7	0.9	0.352	135	4,560,218	4.0
Non-Hodgkin Lymphoma	Total	3	48,266	6.2	4.7	3.9	0.439	565	9,163,128	6.2
Non-Hodgkin Lymphoma	Male	1	24,787	4.0	2.8	2.4	0.631	309	4,602,910	6.7
Non-Hodgkin Lymphoma	Female	2	23,479	8.5	7.0	1.6	0.949	256	4,560,218	5.6
Oral Cavity and Pharynx	Total	1	48,266	2.1	1.5	1.0	0.841	274	9,163,128	3.0
Oral Cavity and Pharynx	Male	1	24,787	4.0	2.8	1.5	1.000	191	4,602,910	4.1
Oral Cavity and Pharynx	Female	-	23,479	-	-	0.5	1.000	83	4,560,218	1.8
Ovary	Female	-	23,479	-	-	2.4	0.185	361	4,560,218	7.9
Pancreas	Total	11	48,266	22.8	16.9	8.4	0.449	1,179	9,163,128	12.9
Pancreas	Male	4	24,787	16.1	11.3	5.0	0.891	646	4,602,910	14.0
Pancreas	Female	7	23,479	29.8	23.4	3.5	0.131	533	4,560,218	11.7
Prostate	Male	8	24,787	32.3	22.3	7.7	1.000	989	4,602,910	21.5
Stomach	Total	2	48,266	4.1	3.3	1.3	0.737	192	9,163,128	2.1
Stomach	Male	2	24,787	8.1	5.8	0.9	0.440	117	4,602,910	2.5
Stomach	Female	-	23,479	-	-	0.5	1.000	75	4,560,218	1.6

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Benewah County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	92.9% 9.2%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	59.1%
Current Tobacco User (2020–2022) Other Cancer-Related	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	24.4%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	31.7% 72.9% 22.7% 15.3%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





BINGHAM COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 1,094 cases of invasive cancer were diagnosed among Bingham County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in BinghamCounty and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Bingham County	State of Idaho
All Sites/Types	1,094	47,333
Female Breast	136	6,943
Prostate	135	6,766
Lung & Bronchus	100	4,959
Colorectal	103	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Bingham County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Bingham County. The table also shows the number of observed cases, person-

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 362 Bingham County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Bingham County and the State of Idaho, 2018–2022

Mortality 2018–2022	Bingham County	State of Idaho
All Deaths	2,238	80,538
Cancer Deaths	362	15,233
% of All Deaths	16.2%	18.9%
Lung & Bronchus	65	2,937
Colorectal	39	1,332
Pancreas	20	1,190
Female Breast	30	1,111
Prostate	28	997

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Bingham County was 465.9 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (528.0) gives an estimate of the relative burden of disease in Bingham County.

The age- and sex-adjusted incidence rate of invasive cancer in Bingham County, all sites combined, was 511.1 cases per 100,000 persons per year during 2017–2021. There were fewer cases of cancer in Bingham County (1,094) than expected (1,130.3) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Bingham County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Bingham County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Bingham County, all sites combined, was 168.0 deaths per 100,000 persons per year during 2018–2022, compared with 165.7 for the remainder of the state. There were more cancer deaths in Bingham County (362) than expected (357.1) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN BINGHAM COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

				Bing	ham Coun	ty			Ren	nainder of Ida	aho
Site/Type Sac Cases Years Rate (1) Rate (1) Rate (1) Cases (3) P-Jaur (4) Cases Years R.7 All Sites Combined Male 501 117,163 502.3 542.5 6.11.8 0.413 24,679 4.394,610 Bindder Forala 42 237,763 207 52.5 0.408 21,500 4.362,662 Bindder Forala 42 237,763 207 52.7 0.508 2.41.4 4.394,610 Brain -malignant Forala 117,151 6.0 6.7 10.5 0.380 14.40 4.382,682 Brain -malignant Male 117,151 6.0 6.4 6.8 10.072 537 6.438,4610 Brain -malignant Male 117,151 2.4 6.24 0.428 4.411 4.382,682 Brain and other CNS -non-malignant Forala 117,663 7.4 7.44 0.408 6.57 6.394,610 Breast Male -	Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
All Sites Combined Total 1094 234 814 465.5 511.1 1103.3 237 46.237 44.238 87.7328 All Sites Combined Female 503 117.151 429.4 47.58 52.25 0.408 21.679 43.84.610 All Sites Combined Female 47 117.151 6.0 6.7 40.5 0.380 1.4.04 4382.682 Biadder Female 47 117.151 6.0 6.7 40.5 0.223 6.464 8.77.7292 Brain - malignant Female 7 117.151 6.0 6.4 6.8 1.000 228.44 4.822.682 Brain and other CNS - non-malignant Female 20 17.151 7.5 7.7 8 37.3 0.3900 7.57.729 Breast Female 20 117.151 16.0 4.8 1.000 228.27 7.77.28 8.77.228 8.77.728 8.77.292 8.77.728 8.77.292 8.77.728 8.77.292 8.77.728 8.77.292 8.77.729 8.34.410 1.16 1.28 7.48 8.48.100 <t< td=""><td></td><td>Sex</td><td>-</td><td></td><td></td><td></td><td></td><td>P-Value (4)</td><td></td><td></td><td>Rate (1)</td></t<>		Sex	-					P-Value (4)			Rate (1)
All Sites Combined Male Sent 117,663 502.3 542.5 611.8 0.413 24,679 4.394,610 Male All Sites Combined Female 503 117.151 429.4 77.6 822.5 0.408 21.600 4.302,682 Biadder Total 49 234,814 20.9 23.2 52.5 0.896 2.171 8.757,292 Biadder Male 4 117,663 3.0 7.7 5 0.896 2.171 8.757,292 Brain malignant Female 7 117,151 6.0 6.4 6.8 1.000 288 4.362,682 Brain malignant Male 4 117,663 3.4 3.6 0.96 0.076 378 4.394,610 Brain malignant Male 7 117,156 5.0 6.4 6.8 1.000 288 4.362,682 Brain and other CNS non-malignant Total 38 234,814 162 17.6 3.7 3.0 980 1.010 1.000 288 4.362,682 Brain and other CNS non-malignant Female 28 127,14 2.5 6 2.1 12.4 0.0428 4.41 1.000 288 4.362,682 Brain and other CNS non-malignant Female 28 127,14 2.5 6 2.1 12.4 0.0428 4.41 1.139,7292 Brain and other CNS non-malignant Female 28 127,14 2.5 6 2.1 12.4 0.023 4.6 6.87 1.000 2.88 6.627 7.392 Brain and other CNS non-malignant Female 29 117,663 1.6 1.2 12.8.7 14.4 9.0 0.033 4.6 6.807 1.439,4010 Breast in situ Total 2.3 234,814 9.8 10.7 3.3 0.0097 1.346 8.757,292 Breast in situ Total 2.3 234,814 9.8 10.7 3.3 0.0097 1.346 8.757,292 Colorectal Male - 117,663 5.2.7 5.6 7 47.6 0.0087 1.344,610 Breast in situ Female 20 117,151 16. 12.8.7 14.4 9.0023 4.6 8.07 1.330,4610 Breast in situ Female 20 117,151 13.6 1.2 12.7 12.2 0.1 0.1 1.444 4.362,082 Breast in situ Female 20 117,151 13.6 1.2 12.7 12.2 0.1 0.1 1.444 4.362,082 Colorectal Male 2 117,663 5.2.7 5.6 7 47.6 0.052 1.977,272 Colorectal Male 12 117,663 5.2.7 5.6 7 47.6 0.052 1.977,272 Colorectal Male 12 117,663 5.2.7 5.6 7 47.6 0.052 1.977,727 1.977,727 Colorectal Male 12 117,663 5.2.7 5.6 7 47.6 0.052 1.977,727 1.977,727 Colorectal Male 2 117,663 5.2.7 5.6 7 47.6 0.052 1.977,727 1.977,727 Colorectal Male 2 117,663 5.2.7 5.6 7 47.6 0.052 1.977,727 2.2 7 Colorectal Male 2 117,663 5.2.7 5.6 7 4.7 6 0.052 1.977,727 2.2 7 0.0000 4.4 4.334,610 1.000 4.4 4.344,610 1.000 4.4 4.344,610 1.000 4.4 4.344,610 1.000 4.4 4.344,610 1.000 4.4 4.344,610 1.000 4.4 4.344,610 1.000 4.4 4.344,610 1.000 4.4 4.344,610 1.000 4.4 4.344,6						. ,	,	,			528.0
All Sites Combined Female 503 117, 151 429.4 475.8 522 5 0.408 21, 500 4, 362, 682 Bladder Total 49 234 814 203 232 525 0.408 21, 761 4, 394, 610 810 420 117, 65 7, 729 81 4, 404 42 117, 66 3, 75 38.7 42.2 0.996 1, 771 4, 394, 610 810 420 4, 262 62 100 100 100 100 100 100 100 100 100 10											561.6
Bladder Total 49 234,814 20.9 23.2 52.5 0.666 2,171 8,757,292 Bladder All 42 117,663 35.7 38.7 42.7 0.995 1,731 4,334,610 4,362,682 Bladder Female 7 117,151 6.0 6.7 10.5 0.360 440 4,362,682 Brain-malignant Total 7 117,151 6.0 6.4 6.8 10.00 268 4,362,682 Brain-malignant Total 7 117,151 6.0 6.4 6.8 10.00 268 4,362,682 Brain and other CNS - non-malignant Total 7 117,151 6.0 6.4 6.8 10.00 268 4,362,682 Brain and other CNS - non-malignant Total 7 117,151 6.0 6.4 6.8 10.00 268 4,362,682 Brain and other CNS - non-malignant Female 7 117,151 7.5 2.4 7.7 2.4 0.0442 4,011 4,362,682 Brain and other CNS - non-malignant Female 29 117,65 7.6 8.1 12.4 0.442 4,011 4,362,682 Breast Total 7.5 2.2 3,243,14 57.9 6.3 108.3 10.22 \ll 6.876 8,757,292 Brain and other CNS - non-malignant Female 29 117,151 16.1 28.7 7 144 9 0.023 \ll 6.877 8,757,292 Breast in situ Female 23 117,151 16.1 28.7 144 9 0.023 \ll 6.877 4,326,882 Breast in situ Female 23 117,151 16.6 2.1 7 3 33.0 10.037 1,346 8,757,292 Breast in situ Female 10 117,151 16.6 2.1 7 2.0 378 124 4,362,682 Colvectal Total 102 23,43.61 4.5 \times 1.0 1 1.000 4 4,34.610 Breast in situ Female 10 117,151 16.5 \times 1.7 2.0 378 124 4,362,682 Colvectal Total 102 23,43.61 4.5 \times 4.5 \times 1.0 1 1.002 4.4 4,34.610 Breast in situ Female 23 117,151 16.6 2.1 7 3.2 6 0.101 1,342 4,362,682 Colvectal Total 102 23,43.61 4.5 \times 4.5 \times 1.0 10 1.4 4,34.610 Breast in situ Female 24 117,151 3.2.4 3.5 9 3.1 0.032 \times 3.5 \times 5.7 57,292 Esophagus Total 11 23,461 4.7 5.1 12.0 0.899 468 8,77,292 Esophagus Male 9 117,663 6,6 3 8.8 0.0 0.7 9.3 1.346 13,2682 Colvectal Female 24 117,151 3.2.4 3.5 0.3 1.0 0.323 3.1 3.61 4,362,682 Colvectal Female 24 117,151 3.2.4 3.5 0.3 3.0 1.0 7.9 4.342,682 Colvectal Female 24 117,151 3.2.4 3.5 0.3 3.0 1.0 7.9 4.342,682 Colvectal Female 24 117,151 3.2.4 3.5 0.3 3.0 1.0 7.9 4.342,682 Colvectal Female 24 117,151 \times 4.34 10.0 0.7 4.342,682 Colvectal Female 24 117,151 \times 4.34 10.0 0.7 7 4.342,682 Colvectal Female 24 117,151 \times 4.35 0.0 0.3 3.0 1.0 1.33 1.336 1.77 4.342,682 Colvect											494.2
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $											24.8
Brain - mailgnant Total 11 224,814 4.7 5.0 16.3 0.0223 646 6,757,292 Brain - mailgnant Male 4 117,665 3.4 3.6 0.00 2268 4,394,610 Brain and Other CNS - non-mailgnant Male 9 117,663 7.6 8.1 12.4 0.420 4.91 4,394,610 Brain and Other CNS - non-mailgnant Female 23 21,117 5.5 - - 1643 0.023 4.394,610 Breast Male - - - 164,9 0.023 - 6,807 4.394,610 Breast - In situ Male - - - 1 1.000 4 4.394,610 Breast - In situ Female 23 117,151 19.6 2.17 32.6 0.000 4 4.394,610 Correctal Female 23 117,151 19.6 5 0.100 4 4.394,610 Correctal Female <	Bladder	Male	42	117,663	35.7			0.995	1,731	4,394,610	39.4
	Bladder	Female	7	117,151	6.0	6.7	10.5	0.360	440		10.1
											7.4
Brain and offser CNS - non-malignant Total 38 234.814 16.2 17.66 37.7 0.950 1.509 8.777.922 Brain and other CNS - non-malignant Female 29 117.663 7.6 8.1 12.4 0.4426 4.91 4.394.610 Breast Male - 117.663 - 1.6 0.398 667 4.394.610 Breast In altit Female 123 124.814 57.9 63.4 188.3 0.012 <	5										8.6
Brain and other CNS - non-malignant Female 29 117,163 7.6 8.1 12.4 0.426 4.91 4.384,610 Breast Male - 117,165 24.8 27.3 24.8 0.426 6.872 8.757,292 Breast Male - 117,165 - - 16 0.398 66.807 4.362,682 Breast in situ Male 23 23.8314 9.8 10.77 33.0 0.0077 1.346 6.757,292 Breast in situ Male 23 117,661 9.8 2.7 7.0.1 1.000 1.4 4.394,610 Gerorical Female 101 117,165 9.8 2.7 7.6.7 4.7.6 0.022 3.223 4.362,682 Colorectal Male 62 117,165 3.5 7.6 7.4 6.6 0.022 3.323 1.316 4.362,682 Colorectal Male 62 117,155 3.24 3.55 3.1 1.21 1.382 4.357,292 Colorectal Male 9 117,663 3.6 <td></td> <td>6.1</td>											6.1
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $											17.2
Breast Total 136 234,814 57.9 63.4 188.3 0.012 65 4,394.610 Breast Female 117,663 - 16.6 0.023 65 4,394.610 Breast - in situ Total 23 234,814 9.8 10.7 33.0 0.028 6,807 4,362.682 Breast - in situ Fermatie 23 177,151 19.6 2.7 2.20 0.101 1.424 4,362.682 Calorscala Total 10 117,151 8.9 9.1 7.7 0.378 2.244 4,362.682 Colorscala Total 10 117,151 8.9 9.1 7.8 0.523 1.516 4,362.682 Corpus Uleri Fermale 2117,151 1.7 1.9 0.323 1.316 4,362.682 Esophagus Male 9 117,663 7.6 6.2 10.5 0.805 4,204,4,44.610 Esophagus Male 2 117,151 1.7			-	,							11.2
Breast Male - 117,165 - - 16 0.398 665 4,394,610 Breast - in situ Total 23 234,814 9.8 10.7 163.00 0.023 <											23.3 78.5
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$					57.9	03.4					1.5
					116 1	128.7					156.0
$ \begin{array}{l c c c c c c c c c c c c c c c c c c c$											15.4
Breast-in situ Female 23 117,151 19,6 21.7 32.6 0.101 1,342 4,362,682 Cervix Female 103 224,814 43.9 48.0 85.5 0.092 3.529 8,757,292 Colorectal Male 62 117,663 52.7 56.7 47.6 0.052 3.941 4.362,682 Corpus Uleri Female 31 17,151 32.4 35.9 31.9 0.323 1.316 4.362,682 Esophagus Total 11 223,814 4.7 5.1 0.899 496 8.757,292 Esophagus Female 2 117,151 1.7 1.9 1.8 1.000 76 4.362,682 Hodgkin Lymphoma Total 3 234,814 1.3 1.5 5.6 0.387 218 4.394,610 Hodgkin Lymphoma Male 1 17,663 0.8 0.2 31.7 0.483 1.894 8.757,292 Larynx			-		-	-					0.1
$ \begin{array}{c} \mbox{Colorectal} & \mbox{Total} & To$			23		19.6	21.7			1,342		30.8
Colorectal Male 62 117,663 52.7 56.7 47.6 0.052 1,915 4,384,610 Corpus Uter Female 38 117,151 32.4 35.9 31.9 0.799 1,614 4,382,682 Esophagus Total 117,151 32.4 35.9 31.9 0.323 1,316 4,382,682 Esophagus Female 2 117,151 1.7 1.9 1.8 10.00 76 4,362,682 Hodgkin Lymphoma Total 3 234,814 1.3 1.3 5.6 0.387 219 8,757,292 Hodgkin Lymphoma Female 2 117,151 1.7 1.8 2.3 1.000 76 4,394,610 Hodgkin Lymphoma Female 2 117,663 28.0 30.2 3.30 128 8,757,292 Kidney and Renal Pelvis Male 31 1.7663 1.7 1.8 4.1 0.44 1.64 4,394,610 1.377 4.382,682			10	117,151	8.5			0.378		4,362,682	6.5
$ \begin{array}{c} \mbox{Cohron} Cohron Cohrom Permale $$ 41$ 117,151 $$ 35.0 $$ 38.8 $$ 39.1 $$ 0.799 $$ 1.614 $$ 4.362.682 $$ 1.500 hagus $$ 10a1 $$ 11$ 234,814 $$ 4.7 $$ 5.1 $$ 12.1 $$ 0.899 $$ 496 $$ 8.757.292 $$ 1.500 hagus $$ Male $$ 117,163 $$ 7.6 $$ 8.2 $$ 10.5 $$ 0.805 $$ 420 $$ 4.394.610 $$ 1.500 $$ 7.897 $$ 1.51 $$ 1.7 $$ 1.9 $$ 1.8 $$ 1.000 $$ 76 $$ 4.362.682 $$ 1.500 hagus $$ 10a1 $$ 117,163 $$ 0.8 $$ 0.9 $$ 3.2 $$ 0.330 $$ 128 $$ 4.394.610 $$ 1.600 $$ 1.600 $$ 128 $$ 4.394.610 $$ 1.600 $$ 1.600 $$ 1.200 $$$ 1.200 $$ 1.200 $$ 1.200 $$ 1.200 $$$ 1.200 $$$											40.3
Corpus Uteri Female 38 117.151 32.4 35.9 31.9 0.32.3 1.316 4.382.682 Esophagus Total 9 117.663 7.6 8.2 10.5 0.895 496 8.757.292 Esophagus Female 2 117.151 1.7 1.9 1.8 1.000 7.6 4.382.682 Hodgkin Lymphoma Male 1 17.663 0.8 0.9 3.2 0.300 128 4.394.610 Hodgkin Lymphoma Female 2 117.161 1.7 1 8 2.3 1.000 91 4.362.682 Kidney and Renal Pelvis Total 57 234.814 2.43 266 46.3 0.143 1.894 8.757.292 Kidney and Renal Pelvis Female 2 117.663 2.80 30.2 31.7 0.85 1.77 4.384.610 Larynx Kemale 2 117.663 1.7 1.8 4.1 0.444 165 4.362.682				,						4,394,610	43.6
Esophagus Total 11 234,814 4.7. 5.1 12.1 0.899 496 8,757,292 Esophagus Female 2 117,151 1.7. 19 18. 1.000 76 4.362,682 Hodgkin Lymphoma Total 3 234,814 1.3 1.3 56 0.387 219 8,757,292 Hodgkin Lymphoma Female 2 117,151 1.7 1.8 2.3 1.000 91 4,362,682 Kidney and Renal Pelvis Total 57 234,814 24.3 28.6 46.3 0.143 1.894 8,757,292 Kidney and Renal Pelvis Female 2 117,663 28.0 30.2 31.7 0.865 1,277 4,384,610 Larynx Male 2 134,814 0.9 0.9 5.3 0.199 218 8,757,292 Larynx Female - 117,151 - - 1.3 0.560 5.3 4,34,304,610 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td>39.1</td><td></td><td></td><td></td><td>37.0</td></t<>							39.1				37.0
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$											30.2
Esophağus Female 2 117, 151 1.7 1.9 1.8 1.000 76 4.362,682 Hodgkin Lymphoma Male 1 117,663 0.8 0.9 3.2 0.330 128 4.377,7292 Hodgkin Lymphoma Female 2 117,151 1.7 1.8 2.3 1.000 91 4.382,682 Kidney and Renal Pelvis Total 57 234,814 24.3 26.6 46.3 0.143 1.894 8.757,292 Kidney and Renal Pelvis Female 24 117,151 20.5 22.8 14.9 0.037 > 617 4.394,610 Kidney and Renal Pelvis Female 117,151 - - 1.3 0.560 53 4.394,610 Larynx Male 28 117,663 1.7 1.8 4.1 0.068 4.394,610 Leukemia Male 28 117,663 2.3. 0.247 1.008 4.394,610 Leukemia Male 15	1 5										5.7
Hodgkin Lymphoma fotal 3 224,814 1.3 1.3 5.6 0.387 219 8,757,292 Hodgkin Lymphoma Female 2 117,161 1.7 1.8 2.3 1.000 91 4,382,682 Kidney and Renal Pelvis Male 33 123,4814 2.3 2.030 30.7 8,434,610 Kidney and Renal Pelvis Male 2 117,663 2.80 30.2 31.7 0.865 1.277 4.394,610 Kidney and Renal Pelvis Female 24 117,151 20.5 22.8 14.9 0.037 >> 617 4.362,682 Larynx Female - 117,151 - - 1.3 0.560 53 4.362,682 Larynx Female - 117,151 - - 1.3 0.560 53 4.362,682 Leukemia Total 54 234,814 23.0 24.9 41.4 0.068 1.673 8.757,292 Leukemia Female 26 117,151 2.2 24.4 4.34 4.32,682											9.6
$\begin{array}{c c} \begin Lymphoma & Male & 1 & 117,663 & 0.8 & 0.9 & 3.2 & 0.330 & 128 & 4,394,610 \\ \begin Lymphoma & Female & 2 & 117,151 & 1.7 & 1.8 & 2.3 & 1.000 & 91 & 4,382,682 \\ \begin Lymphoma & Female & 2 & 117,151 & 2.43 & 26.6 & 46.3 & 0.143 & 1,894 & 8,757,292 \\ \begin Larynx & Male & 33 & 117,663 & 28.0 & 30.2 & 31.7 & 0.865 & 1.277 & 4,394,610 \\ \begin Larynx & Total & 2 & 234,814 & 0.9 & 0.9 & 5.3 & 0.199 & 218 & 8,757,292 \\ \begin Larynx & Total & 2 & 234,814 & 0.9 & 0.9 & 5.3 & 0.199 & 218 & 8,757,292 \\ \begin Larynx & Female & - & 117,151 & - & - & 1.3 & 0.560 & 5.3 & 4,362,682 \\ \begin Larynx & Female & - & 117,151 & - & - & 1.3 & 0.560 & 5.3 & 4,362,682 \\ \begin Leukemia & Total & 54 & 234,814 & 23.0 & 24.9 & 41.4 & 0.068 & 1.673 & 8,757,292 \\ \begin Leukemia & Total & 54 & 234,814 & 23.0 & 24.9 & 41.4 & 0.068 & 1.673 & 8,757,292 \\ \begin Leukemia & Female & 26 & 117,151 & 2.2 & 24.4 & 16.2 & 0.030 >> & 665 & 4,362,682 \\ \begin Liver and Bile Duct & Total & 21 & 234,814 & 8.9 & 9.8 & 20.0 & 0.890 & 822 & 8,757,292 \\ \begin Liver and Bile Duct & Female & 6 & 117,151 & 5.1 & 5.7 & 5.9 & 1.000 & 24.3 & 4,362,682 \\ \begin Lung and Bronchus & Total & 100 & 234,814 & 42.6 & 47.3 & 117.3 & 0.115 & 4,889 & 8,757,292 \\ \begin Lung and Bronchus & Total & 100 & 234,814 & 42.6 & 47.3 & 117.3 & 0.115 & 4,889 & 8,757,292 \\ \begin Lung and Bronchus & Total & 100 & 234,814 & 42.8 & 37.6 & 40.0 & 0.19 < 2,424 & 4,362,682 \\ \begin Lung and Bronchus & Female & 40 & 117,151 & 34.1 & 38.6 & 57.6 & 0.019 < 2,424 & 4,362,682 \\ \begin Lung and Bronchus & Female & 15 & 117,151 & 12.8 & 14.0 & 0.33 < < 1,234 & 4,362,682 \\ \begin Melanoma & Othe Skin & Female & 15 & 117,151 & 12.8 & 14.0 & 0.302 & 0.003 < < 1,234 & 4,362,682 \\ \end Helanoma & Othe Skin & Female & 16 & 117,151 & 34.8 & 37.6 & 46.0 & 0.517 & 1.854 & 4,394,610 \\ \end Helanoma & Othe Skin & Female & 17 & 117,151 & 12.8 & 14.0 & 0.517 & 1.854 & 4,394,610 \\ \end Helanoma & Othe Skin & Female & 17 & 117,151 & 12.8 & 14.0 & 0.518 & 0.716 & 438 & 4,394,610 \\ \end Carad$	1 5										1.7
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$											2.5 2.9
$ \begin{array}{llllllllllllllllllllllllllllllllllll$	3 7 1										2.9
Kidney and Renal PelvisMale33117,66322.030.231.70.8651.2774.394,610Kidney and Renal PelvisFemale24117,15120.522.814.90.0376174.362,682LarynxMale2234,8140.90.95.30.1992188.757,292LarynxMale2117,6631.71.84.10.4441654.394,610LarynxFemale-117,1511.30.560534.362,682LeukemiaTotal54234,81423.024.941.40.0681.6738.757,292LeukemiaMale26117,15122.224.416.20.0306654.362,682Liver and Bile DuctTotal21234,8148.99.820.00.8908228.757,292Liver and Bile DuctFemale6117,1515.15.75.91.0002.4334.362,682Lung and BronchusTotal100234,81442.66.75.75.91.0002.4354.394,610Lung and BronchusMale60117,66351.055.559.91.0002.4354.394,610Lung and BronchusFemale6117,1513.138.657.60.019<											2.1
Kidney and Renal PelvisFemale24117,15120.522.814.90.037 >>6174,362,682LarynxTotal2234,8140.90.95.30.1992188,757,292LarynxFemale-117,1511.30.560534,392,682LeukemiaTotal54234,81423.024.941.40.0681.6738,757,292LeukemiaMale28117,66323.825.425.30.6471,0084,394,610LeukemiaFemale26117,15122.224.416.20.030 >>6654,362,682Liver and Bile DuctTotal21234,8148.99.820.00.8808228,757,292Liver and Bile DuctMale15117,66312.713.814.40.9345794,394,610Liver and Bile DuctMale6117,1515.15.75.91.0002.4354,384,610Lung and BronchusTotal100234,81442.647.3117.30.1154,8598,757,292Lung and BronchusFemale40117,16334.1836.66.00.5171.8544,394,610Lung and BronchusFemale41117,66334.825.675.70.022 <											21.0
$\begin{array}{c c c c c c c c c c c c c c c c c c c $,							14.1
$\begin{array}{c c c c c c c c c c c c c c c c c c c $											2.5
Larýnx Female - 117,151 - - 1.3 0.560 53 4.362,682 Leukemia Total 54 234,814 23.0 24.9 41.4 0.068 1,673 8,757,292 Leukemia Female 26 117,151 22.2 24.4 16.2 0.030 665 4,362,682 Liver and Bile Duct Total 21 234,814 8.9 9.8 20.0 0.890 822 8,757,292 Liver and Bile Duct Female 6 117,151 5.7 5.9 1.000 243 4,362,682 Lung and Bronchus Total 100 234,814 42.6 47.3 117.3 0.115 4,859 8,757,292 Lung and Bronchus Male 60 117,151 34.1 38.6 57.6 0.019 2,424 4,362,682 Lung and Bronchus Female 40 117,151 34.8 37.6 46.0 0.517 1,854 4,394,610 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>3.8</td></td<>											3.8
Leukemia Total 54 234,814 23.0 24.9 41.4 0.068 1,673 8,757,292 Leukemia Male 28 117,663 23.8 25.4 25.3 0.647 1,008 4,394,610 Leukemia Female 26 117,151 22.2 24.4 16.2 0.030 >> 665 4,362,682 Liver and Bile Duct Male 15 117,663 12.7 13.8 14.4 0.930 822 8,757,292 Lung and Bronchus Total 100 233,814 42.6 47.3 117.3 0.115 4,859 8,757,292 Lung and Bronchus Male 60 117,151 5.1 5.7 5.9 1.000 24.34 4,362,682 Lung and Bronchus Female 40 117,161 34.1 38.6 57.6 0.019 <<	,				-	-					1.2
LeukemiaFemale26117,15122.224.416.20.030 >>6654,362,682Liver and Bile DuctMale15117,66312.713.814.40.9345794,394,610Liver and Bile DuctFemale6117,1515.15.75.91.0002434,362,682Lung and BronchusTotal100234,81442.647.3117.30.1154,8598,757,292Lung and BronchusMale60117,66351.055.559.91.0002,4354,394,610Lung and BronchusFemale40117,15134.138.657.60.019 <	Leukemia	Total	54	234,814	23.0			0.068	1,673		19.1
Liver and Bile Duct Total 21 234,814 8.9 9.8 20.0 0.890 822 8,757,292 Liver and Bile Duct Female 6 117,151 5.1 5.7 5.9 1.000 243 4,362,682 Lung and Bronchus Total 100 234,814 42.6 47.3 117.3 0.115 4,859 8,757,292 Lung and Bronchus Male 60 117,663 51.0 55.5 59.9 1.000 2,435 4,392,610 Lung and Bronchus Female 40 117,151 34.1 38.6 57.6 0.019 2,424 4,362,682 Melanoma of the Skin Total 56 234,814 23.8 26.1 75.7 0.022 <<											22.9
Liver and Bile DuctMale15117,66312.713.814.40.9345794,394,610Liver and Bile DuctFemale6117,1515.15.75.91.0002434,362,682Lung and BronchusTotal100234,81442.647.3117.30.1154.8598,757,292Lung and BronchusMale60117,16351.055.559.91.0002,4354,394,610Lung and BronchusFemale40117,15134.138.657.60.019 <<											15.2
Liver and Bile DuctFemale6117,1515.15.75.91.0002434,362,682Lung and BronchusTotal100234,81442.647.3117.30.1154,8598,757,292Lung and BronchusMale60117,66351.055.559.91.0002,4354,394,610Lung and BronchusFemale40117,15134.138.657.60.019 <											9.4
Lung and BronchusTotal100234,81442.647.3117.30.1154,8598,757,292Lung and BronchusFemale40117,15134.138.657.60.0192,4354,394,610Lung and BronchusFemale40117,15134.138.657.60.0192,4244,362,682Melanoma of the SkinTotal56234,81423.826.175.70.0223,0888,757,292Melanoma of the SkinMale41117,66334.837.646.00.5171,8544,394,610Melanoma of the SkinFemale15117,15112.814.030.20.0031,2344,362,682MyelomaTotal15234,8146.47.117.30.6907138,757,292MyelomaMale9117,6637.68.310.80.7164384,394,610MyelomaMale9117,6637.68.310.80.7164384,394,610Mon-Hodgkin LymphomaFemale6117,1515.15.86.61.0002754,362,682Non-Hodgkin LymphomaMale28117,66323.825.627.91.0001,1184,394,610Non-Hodgkin LymphomaFemale27117,15123.025.619.80.1408194,362,682Oral Cavity and PharynxTotal2423,81410.211.231.60.1971,29											13.2
Lung and BronchusMale60117,66351.055.559.91.0002,4354,394,610Lung and BronchusFemale40117,15134.138.657.60.019 <			-			-					5.6
Lung and BronchusFemale40117,15134.138.657.60.019 <2,4244,362,682Melanoma of the SkinMale4117,66334.826.175.70.022 <											55.5
Melanoma of the Skin Total 56 234,814 23.8 26.1 75.7 0.022 < 3,088 8,757,292 Melanoma of the Skin Male 41 117,663 34.8 37.6 46.0 0.517 1,854 4,394,610 Melanoma of the Skin Female 15 117,151 12.8 14.0 30.2 0.003 <											55.4 55.6
Melanoma of the SkinMale41117,66334.837.646.00.5171,8544,394,610Melanoma of the SkinFemale15117,15112.814.030.20.003 <<											35.3
Melanoma of the SkinFemale15117,15112.814.030.20.003 <1,2344,362,682MyelomaTotal15234,8146.47.117.30.6907138,757,292MyelomaMale9117,6637.68.310.80.7164384,394,610MyelomaFemale6117,1515.15.86.61.0002754,362,682Non-Hodgkin LymphomaTotal55234,81423.425.647.50.3101,9378,757,292Non-Hodgkin LymphomaMale28117,66323.825.627.91.0001,1184,394,610Non-Hodgkin LymphomaFemale27117,15123.025.619.80.1408194,362,682Oral Cavity and PharynxTotal24234,81410.211.231.60.1971,2918,757,292Oral Cavity and PharynxMale17117,66314.415.523.00.2459234,394,610Oral Cavity and PharynxFemale7117,15113.715.113.10.4885374,362,682OvaryFemale16117,15113.715.113.10.4885374,362,682PancreasTotal28234,81411.913.235.40.2391,4608,757,292PancreasMale18117,66315.316.620.00.7688084,394,610 <td></td> <td></td> <td></td> <td>- , -</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>42.2</td>				- , -							42.2
Myeloma Total 15 234,814 6.4 7.1 17.3 0.690 713 8,757,292 Myeloma Male 9 117,663 7.6 8.3 10.8 0.716 438 4,394,610 Myeloma Female 6 117,151 5.1 5.8 6.6 1.000 275 4,362,682 Non-Hodgkin Lymphoma Total 55 234,814 23.4 25.6 47.5 0.310 1,937 8,757,292 Non-Hodgkin Lymphoma Male 28 117,663 23.8 25.6 27.9 1.000 1,118 4,394,610 Non-Hodgkin Lymphoma Female 27 117,151 23.0 25.6 19.8 0.140 819 4,362,682 Oral Cavity and Pharynx Total 24 234,814 10.2 11.2 31.6 0.197 1,291 8,757,292 Oral Cavity and Pharynx Male 17 117,663 14.4 15.5 23.0 0.245 923 4,394,610<											28.3
MyelomaMale9117,6637.68.310.80.7164384,394,610MyelomaFemale6117,1515.15.86.61.0002754,362,682Non-Hodgkin LymphomaTotal55234,81423.425.647.50.3101,9378,757,292Non-Hodgkin LymphomaMale28117,66323.825.627.91.0001,1184,394,610Non-Hodgkin LymphomaFemale27117,15123.025.619.80.1408194,362,682Oral Cavity and PharynxTotal24234,81410.211.231.60.1971,2918,757,292Oral Cavity and PharynxMale17117,66314.415.523.00.2459234,394,610Oral Cavity and PharynxFemale7117,1516.06.78.90.6783684,362,682OvaryFemale16117,15113.715.113.10.4885374,362,682PancreasTotal28234,81411.913.235.40.2391,4608,757,292PancreasMale18117,66315.316.620.00.7688084,394,610PancreasFemale10117,1518.59.615.60.1866524,362,682PancreasFemale10117,1518.59.615.60.1866524,362,682Prostate<											8.1
MyelomaFemale6117,1515.15.86.61.0002754,362,682Non-Hodgkin LymphomaTotal55234,81423.425.647.50.3101,9378,757,292Non-Hodgkin LymphomaMale28117,66323.825.627.91.0001,1184,394,610Non-Hodgkin LymphomaFemale27117,15123.025.619.80.1408194,362,682Oral Cavity and PharynxTotal24234,81410.211.231.60.1971,2918,757,292Oral Cavity and PharynxMale17117,66314.415.523.00.2459234,394,610Oral Cavity and PharynxFemale7117,1516.06.78.90.6783684,362,682OvaryFemale16117,15113.715.113.10.4885374,362,682PancreasTotal28234,81411.913.235.40.2391,4608,757,292PancreasMale18117,66315.316.620.00.7688084,394,610PancreasFemale10117,1518.59.615.60.1866524,362,682ProstateMale13117,663114.7124.6163.50.025 <<	Myeloma	Male						0 740		, ,	10.0
Non-Hodgkin LymphomaTotal55234,81423.425.647.50.3101,9378,757,292Non-Hodgkin LymphomaMale28117,66323.825.627.91.0001,1184,394,610Non-Hodgkin LymphomaFemale27117,15123.025.619.80.1408194,362,682Oral Cavity and PharynxTotal24234,81410.211.231.60.1971,2918,757,292Oral Cavity and PharynxMale17117,66314.415.523.00.2459234,394,610Oral Cavity and PharynxFemale7117,1516.06.78.90.6783684,362,682OvaryFemale16117,15113.715.113.10.4885374,362,682PancreasTotal28234,81411.913.235.40.2391,4608,757,292PancreasMale18117,66315.316.620.00.7688084,394,610PancreasFemale10117,1518.59.615.60.1866524,362,682PancreasFemale10117,1518.59.615.60.1866524,362,682PancreasFemale10117,1518.59.615.60.1866524,362,682ProstateMale135117,663114.7124.6163.50.025 <<	Myeloma	Female								4,362,682	6.3
Non-Hodğkin LýmphomaFemale27117,15123.025.619.80.1408194,362,682Oral Cavity and PharynxTotal24234,81410.211.231.60.1971,2918,757,292Oral Cavity and PharynxMale17117,66314.415.523.00.2459234,394,610Oral Cavity and PharynxFemale7117,1516.06.78.90.6783684,362,682OvaryFemale16117,15113.715.113.10.4885374,362,682PancreasTotal28234,81411.913.235.40.2391,4608,757,292PancreasMale18117,66315.316.620.00.7688084,394,610PancreasFemale10117,1518.59.615.60.1866524,362,682ProstateMale135117,663114.7124.6163.50.025 <	Non-Hodgkin Lymphoma	Total				25.6		0.310			22.1
Oral Cavity and PharynxTotal24234,81410.211.231.60.1971,2918,757,292Oral Cavity and PharynxMale17117,66314.415.523.00.2459234,394,610Oral Cavity and PharynxFemale7117,1516.06.78.90.6783684,362,682OvaryFemale16117,15113.715.113.10.4885374,362,682PancreasTotal28234,81411.913.235.40.2391,4608,757,292PancreasMale18117,66315.316.620.00.7688084,394,610PancreasFemale10117,1518.59.615.60.1866524,362,682ProstateMale135117,663114.7124.6163.50.025 <										4,394,610	25.4
Oral Cavity and Pharynx Male 17 117,663 14.4 15.5 23.0 0.245 923 4,394,610 Oral Cavity and Pharynx Female 7 117,151 6.0 6.7 8.9 0.678 368 4,362,682 Ovary Female 16 117,151 13.7 15.1 13.1 0.488 537 4,362,682 Pancreas Total 28 234,814 11.9 13.2 35.4 0.239 1,460 8,757,292 Pancreas Male 18 117,663 15.3 16.6 20.0 0.768 808 4,394,610 Pancreas Male 18 117,663 15.3 16.6 20.0 0.768 808 4,394,610 Pancreas Female 10 117,151 8.5 9.6 15.6 0.186 652 4,362,682 Prostate Male 135 117,663 114.7 124.6 163.5 0.025 <											18.8
Oral Cavity and PharynxFemale7117,1516.06.78.90.6783684,362,682OvaryFemale16117,15113.715.113.10.4885374,362,682PancreasTotal28234,81411.913.235.40.2391,4608,757,292PancreasMale18117,66315.316.620.00.7688084,394,610PancreasFemale10117,1518.59.615.60.1866524,362,682ProstateMale135117,663114.7124.6163.50.025 <											14.7
Ovary Female 16 117,151 13.7 15.1 13.1 0.488 537 4,362,682 Pancreas Total 28 234,814 11.9 13.2 35.4 0.239 1,460 8,757,292 Pancreas Male 18 117,663 15.3 16.6 20.0 0.768 808 4,394,610 Pancreas Female 10 117,151 8.5 9.6 15.6 0.186 652 4,362,682 Prostate Male 135 117,663 114.7 124.6 163.5 0.025 <											21.0
PancreasTotal28234,81411.913.235.40.2391,4608,757,292PancreasMale18117,66315.316.620.00.7688084,394,610PancreasFemale10117,1518.59.615.60.1866524,362,682ProstateMale135117,663114.7124.6163.50.025 <											8.4
PancreasMale18117,66315.316.620.00.7688084,394,610PancreasFemale10117,1518.59.615.60.1866524,362,682ProstateMale135117,663114.7124.6163.50.025 <											12.3
Pancreas Female 10 117,151 8.5 9.6 15.6 0.186 652 4,362,682 Prostate Male 135 117,663 114.7 124.6 163.5 0.025 <											16.7
Prostate Male 135 117,663 114.7 124.6 163.5 0.025 < 6,631 4,394,610 Stomach Total 13 234,814 5.5 6.1 11.2 0.676 461 8,757,292	Pancreas	Female									18.4 14.9
Stomach Total 13 234,814 5.5 6.1 11.2 0.676 461 8,757,292											14.9
											5.3
Stomach IMale 8 117.663 6.8 7.3 7.4 0.924 299 4.394.610		Male	8	117,663	6.8	7.3	7.4	0.924	299	4,394,610	6.8
Stomach Female 5 117,151 4.3 4.7 3.9 0.713 162 4,362,682											3.7
Testis Male 6 117,663 5.1 5.5 6.7 1.000 268 4,394,610											6.1
Thyroid Total 58 234,814 24.7 26.5 28.1 0.000 > 1,127 8,757,292											12.9
Thyroid Male 19 117,663 16.1 17.4 8.8 0.004 >> 353 4,394,610											8.0
Thyroid Female 39 117,151 33.3 35.6 19.4 0.000 >> 774 4,362,682											17.7
Pediatric Age 0 to 19 Total 15 77,578 19.3 19.6 13.0 0.644 410 2,421,746											16.9
Pediatric Age 0 to 19 Male 7 39,475 17.7 17.8 6.6 0.972 207 1,234,846											16.8
Pediatric Age 0 to 19 Male 7 39,475 17.7 17.6 0.6 0.972 207 1,234,646 Pediatric Age 0 to 19 Female 8 38,103 21.0 21.5 6.4 0.617 203 1,186,900						21.0					10.0

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN BINGHAM COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Bing	ham Count	у			Re	mainder of Idah	0
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years		Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	2,238	238,849	937.0	1,030.6	1.894.9	0.000 >>	78,297	8,972,545	872.6
All Causes of Death	Male	1,208	119,875	1,007.7	1,086.9	1,025.1	0.000 >>	41,578	4.507.822	922.4
All Causes of Death	Female	1,030	118,974	865.7	969.5	873.7	0.000 >>	36,719	4,464,723	822.4
All Malignant Cancers	Total	362	238,849	151.6	168.0	357.1	0.808	14,871	8,972,545	165.7
All Malignant Cancers	Male	194	119,875	161.8	175.8	196.8	0.879	8,041	4,507,822	178.4
All Malignant Cancers	Female	168	118,974	141.2	159.2	161.5	0.628	6,830	4,464,723	153.0
Bladder	Total	15	238,849	6.3	7.0	11.3	0.330	470	8,972,545	5.2
Bladder	Male	11	119,875	9.2	9.9	8.9	0.574	364	4,507,822	8.1
Bladder	Female	4	118,974	3.4	3.8	2.5	0.477	106	4,464,723	2.4
Brain and Other Nervous System	Total	8	238,849	3.3	3.6	12.5	0.251	510	8,972,545	5.7
Brain and Other Nervous System	Male	4	119,875	3.3	3.6	7.1	0.331	285	4,507,822	6.3
Brain and Other Nervous System	Female	4	118,974	3.4	3.7	5.4	0.733	225	4,464,723	5.0
Breast	Total	30	238,849	12.6	13.8	26.4	0.535	1,094	8,972,545	12.2
Breast	Male	-	119,875	-	-	0.3	1.000	13	4,507,822	0.3
Breast	Female	30	118,974	25.2	28.2	25.7	0.448	1,081	4,464,723	24.2
Cervix	Female	5 39	118,974	4.2	4.5	2.0 31.3	0.114	83	4,464,723	1.9
Colorectal Colorectal	Total Male	39 23	238,849 119,875	16.3 19.2	18.0 20.7	17.5	0.202 0.236	1,293 709	8,972,545 4,507,822	14.4 15.7
Colorectal	Female	23 16	118,974	19.2	20.7 15.1	17.5	0.236	709 584	4,507,622	13.1
Colorectal Corpus Uteri	Female	5	118,974	4.2	4.8	3.9	0.636	564 164	4,464,723	3.7
Esophagus	Total	10	238,849	4.2	4.6	10.8	0.963	451	8,972,545	5.0
Esophagus	Male	9	119,875	7.5	8.2	9.4	1.000	382	4,507,822	8.5
Esophagus	Female	1	118,974	0.8	1.0	1.6	1.000	69	4,464,723	1.5
Hodgkin Lymphoma	Total	-	238.849	-	-	0.6	1.000	25	8,972,545	0.3
Hodgkin Lymphoma	Male	-	119,875	-	-	0.3	1.000	14	4,507,822	0.3
Hodgkin Lymphoma	Female	-	118,974	-	-	0.3	1.000	11	4,464,723	0.2
Kidney	Total	12	238,849	5.0	5.6	9.0	0.385	374	8,972,545	4.2
Kidney	Male	9	119,875	7.5	8.2	5.8	0.264	237	4,507,822	5.3
Kidney	Female	3	118,974	2.5	2.9	3.2	1.000	137	4,464,723	3.1
Larynx	Total	-	238,849	-	-	1.8	0.319	76	8,972,545	0.8
Larynx	Male	-	119,875	-	-	1.6	0.402	65	4,507,822	1.4
Larynx	Female	-	118,974	-	-	0.3	1.000	11	4,464,723	0.2
Leukemia	Total	18	238,849	7.5	8.4	15.5	0.597	647	8,972,545	7.2
Leukemia	Male	8	119,875	6.7	7.2	9.5	0.774	389	4,507,822	8.6
Leukemia	Female	10	118,974	8.4	9.5	6.1	0.180	258	4,464,723	5.8
Liver and Bile Duct Liver and Bile Duct	Total Male	13 8	238,849 119,875	5.4 6.7	6.0 7.3	14.9 10.1	0.740 0.633	622 415	8,972,545	6.9 9.2
Liver and Bile Duct	Female	о 5	118,974	4.2	4.7	4.9	1.000	207	4,507,822 4,464,723	9.2 4.6
Lung and Bronchus	Total	65	238,849	27.2	30.4	4.9 68.5	0.734	2.872	8,972,545	32.0
Lung and Bronchus	Male	42	238,849	35.0	30.4	36.5	0.734	1,499	4,507,822	33.3
Lung and Bronchus	Female	23	118,974	19.3	22.0	32.1	0.117	1,373	4,464,723	30.8
Melanoma of the Skin	Total	1	238,849	0.4	0.5	7.3	0.012 <<	300	8,972,545	3.3
Melanoma of the Skin	Male	- '	119,875	-	-	4.9	0.015 <<	200	4,507,822	4.4
Melanoma of the Skin	Female	1	118,974	0.8	0.9	2.4	0.618	100	4,464,723	2.2
Myeloma	Total	9	238,849	3.8	4.2	7.5	0.682	316	8,972,545	3.5
Myeloma	Male	6	119,875	5.0	5.5	4.4	0.569	182	4,507,822	4.0
Myeloma	Female	3	118,974	2.5	2.9	3.1	1.000	134	4,464,723	3.0
Non-Hodgkin Lymphoma	Total	13	238,849	5.4	6.0	13.3	1.000	555	8,972,545	6.2
Non-Hodgkin Lymphoma	Male	4	119,875	3.3	3.6	7.5	0.264	306	4,507,822	6.8
Non-Hodgkin Lymphoma	Female	9	118,974	7.6	8.6	5.8	0.273	249	4,464,723	5.6
Oral Cavity and Pharynx	Total	6	238,849	2.5	2.8	6.4	1.000	269	8,972,545	3.0
Oral Cavity and Pharynx	Male	4	119,875	3.3	3.6	4.6	1.000	188	4,507,822	4.2
Oral Cavity and Pharynx	Female	2	118,974	1.7	1.9	1.9	1.000	81	4,464,723	1.8
Ovary	Female	16	118,974	13.4	15.2	8.1	0.019 >>	345	4,464,723	7.7
Pancreas	Total	20	238,849	8.4	9.3	27.9	0.148	1,170	8,972,545	13.0
Pancreas	Male	13	119,875	10.8	11.9	15.5	0.637	637	4,507,822	14.1
Pancreas Prostato	Female	7	118,974	5.9	6.7	12.5	0.137	533	4,464,723	11.9
Prostate	Male	28	119,875	23.4	25.4 2.3	23.7	0.429	969 189	4,507,822	21.5
Stomach Stomach	Total Male	5 4	238,849 119,875	2.1 3.3	2.3 3.6	4.6 2.8	0.967 0.628	109	8,972,545 4,507,822	2.1 2.6
Stomach	Female	1	118,974	0.8	0.9	1.8	0.932	74	4,464,723	1.7

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Bingham County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	89.7% 8.2%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	57.6% 50.6% 60.5%
Current Tobacco User (2020–2022) Other Cancer-Related	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	21.6%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	20.2% 76.2% 18.9% 24.1%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





BLAINE COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 711 cases of invasive cancer were diagnosed among Blaine County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in BlaineCounty and the State of Idaho. 2017–2021

Cancer Incidence 2017–2021	Blaine County	State of Idaho
All Sites/Types	711	47,333
Female Breast	114	6,943
Prostate	110	6,766
Lung & Bronchus	38	4,959
Colorectal	44	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Blaine County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Blaine County. The table also shows the number of observed cases, person-

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 155 Blaine County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Blaine County and the State of Idaho, 2018–2022

Mortality 2018–2022	Blaine County	State of Idaho
All Deaths	676	80,538
Cancer Deaths	155	15,233
% of All Deaths	22.9%	18.9%
Lung & Bronchus	15	2,937
Colorectal	17	1,332
Pancreas	11	1,190
Female Breast	10	1,111
Prostate	14	997

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Blaine County was 611.1 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (525.3) gives an estimate of the relative burden of disease in Blaine County.

The age- and sex-adjusted incidence rate of invasive cancer in Blaine County, all sites combined, was 503.9 cases per 100,000 persons per year during 2017–2021. There were fewer cases of cancer in Blaine County (711) than expected (741.1) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Blaine County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Blaine County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Blaine County, all sites combined, was 106.4 deaths per 100,000 persons per year during 2018–2022, compared with 165.8 for the remainder of the state. There were statistically significantly fewer cancer deaths in Blaine County (155) than expected (241.7) based upon rates in the remainder of the state (p<.001).

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN BLAINE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Bla	ine County	,			Rem	nainder of Ida	aho
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)		P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	711	116,342	611.1	503.9	741.1	0.276	46,622	8,875,764	525.3
All Sites Combined	Male	375	58,283	643.4	513.0	408.6	0.099	24,895	4,453,990	558.9
All Sites Combined	Female	336	58,059	578.7	489.5	337.3	0.973	21,727	4,421,774	491.4
Bladder	Total	30	116,342	25.8	21.1	35.1	0.446	2,190	8,875,764	24.7
Bladder	Male	21	58,283	36.0	28.2	29.3	0.139	1,752	4,453,990	39.3
Bladder	Female	9	58,059	15.5	13.1	6.8	0.492	438	4,421,774	9.9
Brain - malignant	Total	15	116,342 58,283	12.9	11.2	9.7	0.134	642	8,875,764	7.2
Brain - malignant Brain - malignant	Male Female	8 7	58,265 58,059	13.7 12.1	11.8 10.7	5.7 4.0	0.436 0.213	374 268	4,453,990 4,421,774	8.4 6.1
Brain and other CNS - non-malignant	Total	26	116,342	22.3	10.7	23.5	0.654	1,521	8,875,764	17.1
	Male	9	58,283	15.4	13.0	7.6	0.712	491	4,453,990	11.0
Brain and other CNS - non-malignant	Female	17	58,059	29.3	25.2	15.7	0.808	1,030	4,421,774	23.3
Breast	Total	114	116,342	98.0	80.6	109.9	0.718	6,894	8,875,764	77.7
Breast	Male	-	58,283	-	-	1.1	0.695	65	4,453,990	1.5
Breast	Female	114	58,059	196.4	162.7	108.2	0.602	6,829	4,421,774	154.4
Breast - in situ	Total	25	116,342	21.5	17.4	21.7	0.533	1,344	8,875,764	15.1
Breast - in situ Breast - in situ	Male Female	- 25	58,283 58,059	- 43.1	- 34.9	0.1 21.7	1.000 0.532	4	4,453,990 4,421,774	0.1 30.3
Cervix	Female	25	58,059	43.1	4.6	4.3	0.532	1,340 291	4,421,774	30.3 6.6
Colorectal	Total	44	116,342	37.8	4.0 31.4	4.3 56.6	0.099	3,588	8,875,764	40.4
Colorectal	Male	24	58,283	41.2	33.2	31.7	0.195	1,953	4,453,990	43.8
Colorectal	Female	20	58,059	34.4	29.6	24.9	0.376	1,635	4,421,774	37.0
Corpus Uteri	Female	17	58,059	29.3	23.8	21.6	0.382	1,337	4,421,774	30.2
Esophagus	Total	8	116,342	6.9	5.6	8.1	1.000	499	8,875,764	5.6
Esophagus	Male	8	58,283	13.7	10.8	7.0	0.800	421	4,453,990	9.5
Esophagus	Female	-	58,059	-	-	1.2	0.596	78	4,421,774	1.8
Hodgkin Lymphoma	Total	2	116,342	1.7	1.7	3.0	0.849	220	8,875,764	2.5
Hodgkin Lymphoma	Male Female	- 2	58,283 58,059	- 3.4	- 3.5	1.8 1.2	0.326 0.661	129 91	4,453,990 4,421,774	2.9 2.1
Hodgkin Lymphoma Kidney and Renal Pelvis	Total	19	116,342	16.3	13.4	30.8	0.031 <<	1,932	8,875,764	2.1
Kidney and Renal Pelvis	Male	9	58,283	15.4	12.5	21.1	0.005 <<	1,301	4,453,990	29.2
Kidney and Renal Pelvis	Female	10	58,059	17.2	14.5	9.8	1.000	631	4,421,774	14.3
Larynx	Total	2	116,342	1.7	1.4	3.5	0.631	218	8,875,764	2.5
Larynx	Male	1	58,283	1.7	1.4	2.7	0.481	166	4,453,990	3.7
Larynx	Female	1	58,059	1.7	1.4	0.9	1.000	52	4,421,774	1.2
Leukemia	Total	29	116,342	24.9	21.1	26.3	0.654	1,698	8,875,764	19.1
Leukemia	Male	19	58,283	32.6	26.7	16.3	0.559	1,017	4,453,990	22.8
Leukemia	Female	10 9	58,059 116,342	17.2	14.9 6.2	10.3 13.6	1.000 0.263	681 834	4,421,774 8,875,764	15.4 9.4
Liver and Bile Duct Liver and Bile Duct	Total Male	9 7	58,283	7.7 12.0	0.2 9.5	9.7	0.263	634 587	6,675,764 4,453,990	9.4 13.2
Liver and Bile Duct	Female	2	58,059	3.4	2.9	3.9	0.509	247	4,421,774	5.6
Lung and Bronchus	Total	38	116,342	32.7	26.4	79.8	0.000 <<	4,921	8,875,764	55.4
Lung and Bronchus	Male	21	58,283	36.0	28.0	41.7	0.001 <<	2,474	4,453,990	55.5
Lung and Bronchus	Female	17	58,059	29.3	24.5	38.5	0.000 <<	2,447	4,421,774	55.3
Melanoma of the Skin	Total	93	116,342	79.9	67.3	47.5	0.000 >>	3,051	8,875,764	34.4
Melanoma of the Skin	Male	55	58,283	94.4	76.5	29.7	0.000 >>	1,840	4,453,990	41.3
Melanoma of the Skin	Female	38	58,059	65.5	56.8	18.3	0.000 >>	1,211	4,421,774	27.4
Myeloma Myeloma	Total Male	16 12	116,342 58,283	13.8 20.6	11.2 16.2	11.5 7.2	0.239 0.129	712 435	8,875,764 4,453,990	8.0 9.8
Myeloma Myeloma	Female	4	58,059	20.0	5.8	4.3	1.000	435 277	4,453,990	9.0 6.3
Non-Hodgkin Lymphoma	Total	32	116,342	27.5	22.8	31.0	0.901	1,960	8,875,764	22.1
Non-Hodgkin Lymphoma	Male	16	58,283	27.5	22.2	18.3	0.705	1,130	4,453,990	25.4
Non-Hodgkin Lymphoma	Female	16	58,059	27.6	23.4	12.8	0.441	830	4,421,774	18.8
Oral Cavity and Pharynx	Total	26	116,342	22.3	18.1	20.9	0.312	1,289	8,875,764	14.5
Oral Cavity and Pharynx	Male	19	58,283	32.6	26.0	15.1	0.378	921	4,453,990	20.7
Oral Cavity and Pharynx	Female	7	58,059	12.1	10.0	5.8	0.723	368	4,421,774	8.3
Ovary Pancreas	Female Total	16 13	58,059	27.6	23.2 9.2	8.4 23.6	0.024 >> 0.026 <<	537	4,421,774 8,875,764	12.1 16.6
Pancreas	Male	6	116,342 58,283	11.2 10.3	9.2 8.1	23.0 13.6	0.026 <<	1,475 820	6,675,764 4,453,990	18.4
Pancreas	Female	7	58,059	10.3	10.2	10.2	0.410	655	4,433,990	14.8
Prostate	Male	110	58,283	188.7	147.1	111.8	0.918	6,656	4,453,990	149.4
Stomach	Total	4	116,342	3.4	2.9	7.4	0.275	470	8,875,764	5.3
Stomach	Male	2	58,283	3.4	2.7	5.0	0.247	305	4,453,990	6.8
Stomach	Female	2	58,059	3.4	3.0	2.5	1.000	165	4,421,774	3.7
Testis	Male	4	58,283	6.9	7.3	3.3	0.851	270	4,453,990	6.1
Thyroid	Total	16	116,342	13.8	12.5	16.9	0.961	1,169	8,875,764	13.2
Thyroid	Male	8	58,283	13.7	11.8	5.5	0.386	364	4,453,990	8.2
Thyroid	Female	8	58,059	13.8	12.8	11.4	0.394	805	4,421,774	18.2
		7	27,069	25.9	26.0	4.6	0.352	418	2,472,255	16.9
Pediatric Age 0 to 19	Total									
Pediatric Age 0 to 19 Pediatric Age 0 to 19 Pediatric Age 0 to 19	Total Male Female	7 3 4	13,897 13,172	20.9 21.6 30.4	20.0 21.8 30.3	2.3 2.3	0.809 0.384	211 207	1,260,424 1,211,831	16.7 17.1

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN BLAINE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Bla	aine County				Re	mainder of Idah	0
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	676	118,807	569.0	484.3	1,226.0	0.000 <<	79,859	9,092,587	878.3
All Causes of Death	Male	394	59,425	663.0	533.4	685.4	0.000 <<	42,392	4,568,272	928.0
All Causes of Death	Female	282	59,382	474.9	427.7	546.0	0.000 <<	37,467	4,524,315	828.1
All Malignant Cancers	Total	155	118,807	130.5	106.4	241.7	0.000 <<	15,078	9,092,587	165.8
All Malignant Cancers	Male	91	59,425	153.1	118.9	136.4	>> 000.0	8,144	4,568,272	178.3
All Malignant Cancers	Female	64	59,382	107.8	91.4	107.3	>> 000.0	6,934	4,524,315	153.3
Bladder	Total	3	118,807	2.5	2.1	7.5	0.117	482	9,092,587	5.3
Bladder	Male	2	59,425	3.4	2.6	6.2	0.107	373	4,568,272	8.2
Bladder	Female	1	59,382	1.7	1.5	1.6	1.000	109	4,524,315	2.4
Brain and Other Nervous System	Total	8	118,807	6.7	5.6	8.1	1.000	510	9,092,587	5.6
Brain and Other Nervous System	Male Female	5 3	59,425 59,382	8.4 5.1	6.8 4.3	4.6 3.5	0.967 1.000	284 226	4,568,272 4,524,315	6.2 5.0
Brain and Other Nervous System Breast	Total	10	118,807	8.4	4.3 6.9	17.6	0.073	1,114	9,092,587	12.3
Breast	Male	10	59,425	- 0.4	0.5	0.2	1.000	13	4,568,272	0.3
Breast	Female	10	59,382	16.8	14.3	17.0	0.096	1,101	4,524,315	24.3
Cervix	Female	1	59,382	1.7	1.4	1.4	1.000	87	4,524,315	1.9
Colorectal	Total	17	118,807	14.3	11.7	21.0	0.459	1,315	9,092,587	14.5
Colorectal	Male	9	59,425	15.1	11.9	11.9	0.495	723	4,568,272	15.8
Colorectal	Female	8	59,382	13.5	11.6	9.0	0.899	592	4,524,315	13.1
Corpus Uteri	Female	3	59,382	5.1	4.2	2.6	0.986	166	4,524,315	3.7
Esophagus	Total	5	118,807	4.2	3.4	7.5	0.492	456	9,092,587	5.0
Esophagus	Male	5	59,425	8.4	6.5	6.5	0.735	386	4,568,272	8.4
Esophagus	Female	-	59,382	-	-	1.1	0.675	70	4,524,315	1.5
Hodgkin Lymphoma Hodgkin Lymphoma	Total Male	-	118,807 59,425	-	-	0.4 0.2	1.000 1.000	25 14	9,092,587 4,568,272	0.3 0.3
Hodgkin Lymphoma	Female	-	59,425	-	-	0.2	1.000	14	4,508,272	0.3
Kidney	Total	- 2	118,807	- 1.7	- 1.4	6.2	0.109	384	9,092,587	4.2
Kidney	Male	1	59,425	1.7	1.3	4.1	0.170	245	4,568,272	5.4
Kidney	Female	1	59,382	1.7	1.4	2.1	0.747	139	4,524,315	3.1
Larynx	Total	-	118,807	-	-	1.2	0.585	76	9,092,587	0.8
Larynx	Male	-	59,425	-	-	1.1	0.670	65	4,568,272	1.4
Larynx	Female	-	59,382	-	-	0.2	1.000	11	4,524,315	0.2
Leukemia	Total	9	118,807	7.6	6.3	10.4	0.827	656	9,092,587	7.2
Leukemia	Male	4	59,425	6.7	5.3	6.5	0.440	393	4,568,272	8.6
Leukemia	Female	5	59,382	8.4	7.3	4.0	0.732	263	4,524,315	5.8
Liver and Bile Duct	Total	6 4	118,807 59,425	5.1 6.7	4.0 5.2	10.3 7.0	0.227 0.341	629 419	9,092,587 4,568,272	6.9 9.2
Liver and Bile Duct Liver and Bile Duct	Male Female	4	59,382	3.4	2.8	3.3	0.341	210	4,508,272	9.2 4.6
Liver and Bronchus	Total	15	118,807	12.6	10.1	47.7	0.000 <<	2,922	9,092,587	32.1
Lung and Bronchus	Male	9	59,425	15.1	11.6	26.1	0.000 <<	1,532	4,568,272	33.5
Lung and Bronchus	Female	6	59,382	10.1	8.5	21.8	0.000 <<	1,390	4,524,315	30.7
Melanoma of the Skin	Total	4	118,807	3.4	2.8	4.7	0.978	297	9,092,587	3.3
Melanoma of the Skin	Male	4	59,425	6.7	5.3	3.3	0.820	196	4,568,272	4.3
Melanoma of the Skin	Female	-	59,382	-	-	1.5	0.429	101	4,524,315	2.2
Myeloma	Total	5	118,807	4.2	3.4	5.2	1.000	320	9,092,587	3.5
Myeloma	Male	4	59,425	6.7	5.2	3.1	0.762	184	4,568,272	4.0
Myeloma	Female	1	59,382	1.7	1.4	2.1	0.764	136	4,524,315	3.0
Non-Hodgkin Lymphoma	Total	5	118,807	4.2	3.4	9.0	0.235	563	9,092,587	6.2
Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma	Male Female	3 2	59,425 59,382	5.0 3.4	3.9 2.9	5.2 3.8	0.483 0.523	307 256	4,568,272 4,524,315	6.7 5.7
Oral Cavity and Pharynx	Total	2	59,382 118,807	3.4	2.9	3.8 4.5	0.523	256	4,524,315 9,092,587	5.7 3.0
Oral Cavity and Pharynx	Male	2	59,425	3.4	2.6	3.2	0.762	190	4,568,272	4.2
Oral Cavity and Pharynx	Female	- 2	59,382	-	-	1.3	0.539	83	4,524,315	1.8
Ovary	Female	6	59,382	10.1	8.4	5.6	0.968	355	4,524,315	7.8
Pancreas	Total	11	118,807	9.3	7.4	19.2	0.063	1,179	9,092,587	13.0
Pancreas	Male	6	59,425	10.1	7.8	10.9	0.165	644	4,568,272	14.1
Pancreas	Female	5	59,382	8.4	7.0	8.4	0.311	535	4,524,315	11.8
Prostate	Male	14	59,425	23.6	18.3	16.4	0.654	983	4,568,272	21.5
Stomach	Total	-	118,807	-	-	3.1	0.094	194	9,092,587	2.1
Stomach	Male	-	59,425	-	-	2.0	0.277	119	4,568,272	2.6
Stomach	Female	-	59,382	-	-	1.1	0.644	75	4,524,315	1.7

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Blaine County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	90.6% 7.5%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	71.9%
Current Tobacco User (2020–2022) Other Cancer-Related	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	17.5%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	44.3% 85.1% 30.7% 54.7%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





BOISE COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 279 cases of invasive cancer were diagnosed among Boise County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,

 Lung and Bronchus, and Colorectal Cancers in Boise County

 and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Boise County	State of Idaho
All Sites/Types	279	47,333
Female Breast	32	6,943
Prostate	57	6,766
Lung & Bronchus	33	4,959
Colorectal	9	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Boise County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Boise County. The table also shows the number of observed cases, person-

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 68 Boise County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Boise County and the State of Idaho, 2018–2022

Mortality 2018–2022	Boise County	State of Idaho
All Deaths	362	80,538
Cancer Deaths	68	15,233
% of All Deaths	18.8%	18.9%
Lung & Bronchus	15	2,937
Colorectal	5	1,332
Pancreas	10	1,190
Female Breast	6	1,111
Prostate	4	997

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Boise County was 712.7 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (525.6) gives an estimate of the relative burden of disease in Boise County.

The age- and sex-adjusted incidence rate of invasive cancer in Boise County, all sites combined, was 468.3 cases per 100,000 persons per year during 2017–2021. There were fewer cases of cancer in Boise County (279) than expected (313.1) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Boise County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Boise County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Boise County, all sites combined, was 112.9 deaths per 100,000 persons per year during 2018–2022, compared with 165.4 for the remainder of the state. There were statistically significantly fewer cancer deaths in Boise County (68) than expected (99.6) based upon rates in the remainder of the state (p=.001).

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN BOISE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Bc	ise County				Ren	nainder of Ida	aho
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	279	39,148	712.7	468.3	313.1	0.054	47,054	8,952,958	525.6
All Sites Combined	Male	169	20,174	837.7	494.7	190.9	0.117	25,101	4,492,099	558.8
All Sites Combined	Female	110	18,974	579.7	419.7	129.0	0.098	21,953	4,460,859	492.1
Bladder	Total	21	39,148	53.6	34.6	14.9	0.158	2,199	8,952,958	24.6
Bladder	Male	19	20,174	94.2	54.2	13.7	0.201	1,754	4,492,099	39.0
Bladder	Female	2	18,974	10.5	7.5	2.7	1.000	445	4,460,859	10.0
Brain - malignant	Total	1	39,148	2.6	1.9	3.9	0.201	656	8,952,958	7.3
Brain - malignant	Male Female	1	20,174 18,974	5.0	3.5	2.4 1.5	0.599 0.446	381 275	4,492,099 4,460,859	8.5 6.2
Brain - malignant Brain and other CNS - non-malignant	Total		39,148	- 17.9	- 12.7	9.5	0.446	1,540	4,460,659	17.2
	Male	3	20,174	14.9	10.0	3.3	1.000	497	4,492,099	11.1
Brain and other CNS - non-malignant	Female	4	18,974	21.1	15.9	5.9	0.600	1,043	4,460,859	23.4
Breast	Total	32	39,148	81.7	54.3	45.9	0.039 <<	6,976	8,952,958	77.9
Breast	Male	-	20,174	-	-	0.5	1.000	65	4,492,099	1.4
Breast	Female	32	18,974	168.7	118.9	41.7	0.146	6,911	4,460,859	154.9
Breast - in situ	Total	11	39,148	28.1	18.3	9.1	0.612	1,358	8,952,958	15.2
Breast - in situ	Male	-	20,174	-	-	0.0	1.000	4	4,492,099	0.1
Breast - in situ Cervix	Female Female	11	18,974 18,974	58.0 5.3	39.6 4.4	8.4 1.5	0.457	1,354 293	4,460,859 4,460,859	30.4 6.6
Colorectal	Total	9	39,148	23.0	4.4	23.4	0.001 <<	3,623	8,952,958	40.5
Colorectal	Male	9 4	20,174	19.8	12.3	14.3	0.003 <<	1,973	4,492,099	40.3
Colorectal	Female	5	18,974	26.4	12.3	9.4	0.186	1,650	4.460.859	37.0
Corpus Uteri	Female	7	18,974	36.9	24.7	8.5	0.759	1,347	4,460,859	30.2
Esophagus	Total	7	39,148	17.9	11.4	3.4	0.122	500	8,952,958	5.6
Esophagus	Male	7	20,174	34.7	20.1	3.3	0.098	422	4,492,099	9.4
Esophagus	Female	-	18,974	-	-	0.5	1.000	78	4,460,859	1.7
Hodgkin Lymphoma	Total	2	39,148	5.1	4.6	1.1	0.577	220	8,952,958	2.5
Hodgkin Lymphoma	Male		20,174 18,974	- 10.5	- 10.6	0.7	0.999	129	4,492,099 4,460.859	2.9 2.0
Hodgkin Lymphoma Kidney and Renal Pelvis	Female Total	2	39,148	23.0	10.6	0.4 12.9	0.116 0.351	91 1,942	4,460,859 8,952,958	2.0
Kidney and Renal Pelvis	Male	5 7	20,174	34.7	21.2	9.6	0.518	1,303	4,492,099	21.7
Kidney and Renal Pelvis	Female	2	18,974	10.5	7.6	3.8	0.553	639	4,460,859	14.3
Larynx	Total	-	39,148	-	-	1.5	0.433	220	8,952,958	2.5
Larynx	Male	-	20,174	-	-	1.3	0.551	167	4,492,099	3.7
Larynx	Female	-	18,974	-	-	0.3	1.000	53	4,460,859	1.2
Leukemia	Total	12	39,148	30.7	21.2	10.8	0.801	1,715	8,952,958	19.2
Leukemia	Male	7	20,174	34.7	21.9	7.3	1.000	1,029	4,492,099	22.9
Leukemia	Female	5	18,974	26.4	20.0	3.8	0.681	686	4,460,859	15.4
Liver and Bile Duct Liver and Bile Duct	Total Male	6 5	39,148 20,174	15.3 24.8	9.4 14.0	6.0 4.7	1.000 1.000	837 589	8,952,958 4,492,099	9.3 13.1
Liver and Bile Duct	Female	J 1	18,974	24.0 5.3	3.6	1.5	1.000	248	4,492,099	5.6
Lung and Bronchus	Total	33	39,148	84.3	53.1	34.2	0.924	4,926	8,952,958	55.0
Lung and Bronchus	Male	15	20,174	74.4	41.8	19.8	0.333	2,480	4,492,099	55.2
Lung and Bronchus	Female	18	18,974	94.9	66.8	14.8	0.464	2,446	4,460,859	54.8
Melanoma of the Skin	Total	19	39,148	48.5	33.5	19.8	0.973	3,125	8,952,958	34.9
Melanoma of the Skin	Male	10	20,174	49.6	30.7	13.7	0.397	1,885	4,492,099	42.0
Melanoma of the Skin	Female	9	18,974	47.4	35.8	7.0	0.541	1,240	4,460,859	27.8
Myeloma Myeloma	Total Malo	4	39,148	10.2	6.6 8 7	4.9	0.906	724	8,952,958	8.1
Myeloma Myeloma	Male Female	3 1	20,174 18,974	14.9 5.3	8.7 3.7	3.4 1.7	1.000 0.988	444 280	4,492,099 4,460,859	9.9 6.3
Non-Hodgkin Lymphoma	Total	13	39,148	33.2	22.1	13.0	1.000	1,979	8,952,958	22.1
Non-Hodgkin Lymphoma	Male	5	20,174	24.8	15.2	8.4	0.320	1,141	4,492,099	25.4
Non-Hodgkin Lýmphoma	Female	8	18,974	42.2	30.6	4.9	0.249	838	4,460,859	18.8
Oral Cavity and Pharynx	Total	15	39,148	38.3	24.1	9.0	0.085	1,300	8,952,958	14.5
Oral Cavity and Pharynx	Male	14	20,174	69.4	40.6	7.1	0.029 >>	926	4,492,099	20.6
Oral Cavity and Pharynx	Female	1	18,974	5.3	3.7	2.3	0.671	374	4,460,859	8.4
Ovary	Female	3	18,974	15.8	11.4	3.2	1.000	550	4,460,859	12.3
Pancreas Pancreas	Total Male	9 5	39,148 20,174	23.0 24.8	14.9 14.5	10.0 6.3	0.917 0.793	1,479 821	8,952,958 4,492,099	16.5 18.3
Pancreas	Female	5	20,174 18,974	24.0 21.1	14.5	0.3 3.9	1.000	658	4,492,099	10.3
Prostate	Male	57	20,174	282.5	155.4	54.8	0.800	6,709	4,400,839	14.0
Stomach	Total	5	39,148	12.8	8.6	3.1	0.389	469	8,952,958	5.2
Stomach	Male	3	20,174	14.9	8.9	2.3	0.805	304	4,492,099	6.8
Stomach	Female	2	18,974	10.5	8.1	0.9	0.468	165	4,460,859	3.7
Testis	Male	-	20,174	-	-	1.0	0.741	274	4,492,099	6.1
Thyroid	Total	8	39,148	20.4	16.8	6.3	0.587	1,177	8,952,958	13.1
Thyroid	Male	4	20,174	19.8	14.1	2.3	0.408	368	4,492,099	8.2
Thyroid	Female	4	18,974	21.1	18.2	4.0	1.000	809	4,460,859	18.1
Pediatric Age 0 to 19	Total	5	7,018	71.2	70.7	1.2	0.015 >>	420	2,492,306	16.9
Pediatric Age 0 to 19	Male	2 3	3,690	54.2	54.6	0.6	0.251	212	1,270,631	16.7
Pediatric Age 0 to 19	Female	3	3,328	90.1	88.3	0.6	0.042 >>	208	1,221,675	17.0

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN BOISE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Bo	ise County				Re	mainder of Idah	10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years		Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	362	40,111	902.5	655.4	482.8	0.000 <<	80,173	9,171,283	874.2
All Causes of Death	Male	230	20,632	1,114.8	712.3	298.3	0.000 <<	42,556	4.607.065	923.7
All Causes of Death	Female	132	19,479	677.7	563.2	193.2	0.000 <<	37,617	4,564,218	824.2
All Malignant Cancers	Total	68	40,111	169.5	112.9	99.6	0.001 <<	15,165	9,171,283	165.4
All Malignant Cancers	Male	36	20,632	174.5	103.0	62.2	0.000 <<	8,199	4,607,065	178.0
All Malignant Cancers	Female	32	19,479	164.3	122.9	39.7	0.247	6,966	4,564,218	152.6
Bladder	Total	3	40,111	7.5	5.3	3.0	1.000	482	9,171,283	5.3
Bladder	Male	2	20,632	9.7	5.9	2.7	0.970	373	4,607,065	8.1
Bladder	Female	1	19,479	5.1	4.2	0.6	0.868	109	4,564,218	2.4
Brain and Other Nervous System	Total	1	40,111	2.5	1.7	3.4	0.304	517	9,171,283	5.6
	Male	1	20,632	4.8	3.0	2.1	0.781	288	4,607,065	6.3
Brain and Other Nervous System	Female	-	19,479	-	-	1.3	0.520	229	4,564,218	5.0
Breast	Total	6	40,111	15.0	10.2	7.2	0.852	1,118	9,171,283	12.2
Breast	Male	-	20,632	-	-	0.1	1.000	13	4,607,065	0.3
Breast	Female	6	19,479	30.8	23.1	6.3	1.000	1,105	4,564,218	24.2
Cervix	Female	1	19,479	5.1	3.9	0.5	0.772	87	4,564,218	1.9
Colorectal	Total	5	40,111	12.5	8.5	8.6	0.291	1,327	9,171,283	14.5
Colorectal	Male	3	20,632	14.5	8.8	5.4	0.435	729	4,607,065	15.8
Colorectal	Female	2	19,479	10.3	7.9	3.3	0.711	598	4,564,218	13.1
Corpus Uteri	Female	-	19,479	-	-	1.0	0.704	169	4,564,218	3.7
Esophagus	Total	4	40,111	10.0	6.3	3.1	0.769	457	9,171,283	5.0
Esophagus	Male	3	20,632	14.5	8.3	3.0	1.000	388	4,607,065	8.4
Esophagus	Female	1	19,479	5.1	3.9	0.4	0.647	69	4,564,218	1.5
Hodgkin Lymphoma	Total	-	40,111	-	-	0.2	1.000	25	9,171,283	0.3
Hodgkin Lymphoma	Male	-	20,632	-	-	0.1	1.000	14	4,607,065	0.3
Hodgkin Lymphoma	Female	-	19,479	-	-	0.1	1.000	11	4,564,218	0.2
Kidney	Total	-	40,111	-	-	2.6	0.151	386	9,171,283	4.2
Kidney	Male	-	20,632	-	-	1.9	0.301	246	4,607,065	5.3
Kidney	Female	-	19,479	-	-	0.8	0.904	140	4,564,218	3.1
Larynx	Total	-	40,111	-	-	0.5	1.000	76	9,171,283	0.8
Larynx	Male	-	20,632	-	-	0.5	1.000 1.000	65	4,607,065	1.4 0.2
Larynx	Female Total	- 1	19,479	- 2.5	- 17	0.1	0.160	11 664	4,564,218	7.2
Leukemia Leukemia	Male	1	40,111 20,632	2.5	1.7	4.2 2.9	0.100	004 397	9,171,283 4,607,065	8.6
Leukemia	Female	- 1	19,479	- 5.1	- 4.1	1.4	1.000	267	4,564,218	5.8
Liver and Bile Duct	Total	4	40,111	10.0	6.3	4.4	1.000	631	9,171,283	6.9
Liver and Bile Duct	Male	3	20,632	14.5	8.3	3.3	1.000	420	4,607,065	9.1
Liver and Bile Duct	Female	1	19,479	5.1	3.7	1.3	1.000	211	4,564,218	4.6
Lung and Bronchus	Total	15	40,111	37.4	24.1	19.9	0.328	2,922	9,171,283	31.9
Lung and Bronchus	Male	6	20,632	29.1	16.5	12.1	0.086	1,535	4,607,065	33.3
Lung and Bronchus	Female	9	19,479	46.2	34.0	8.1	0.830	1,387	4,564,218	30.4
Melanoma of the Skin	Total	2	40,111	5.0	3.4	1.9	1.000	299	9,171,283	3.3
Melanoma of the Skin	Male	2	20,632	9.7	5.9	1.5	0.858	198	4,607,065	4.3
Melanoma of the Skin	Female	-	19,479	-	-	0.6	1.000	101	4,564,218	2.2
Myeloma	Total	2	40,111	5.0	3.3	2.1	1.000	323	9,171,283	3.5
Mýeloma	Male	1	20,632	4.8	2.8	1.4	1.000	187	4,607,065	4.1
Myeloma	Female	1	19,479	5.1	3.9	0.8	1.000	136	4,564,218	3.0
Non-Hodgkin Lymphoma	Total	3	40,111	7.5	5.1	3.6	1.000	565	9,171,283	6.2
Non-Hodgkin Lymphoma	Male	2	20,632	9.7	5.8	2.3	1.000	308	4,607,065	6.7
Non-Hodgkin Lymphoma	Female	1	19,479	5.1	4.1	1.4	1.000	257	4,564,218	5.6
Oral Cavity and Pharynx	Total	-	40,111	-	-	1.9	0.301	275	9,171,283	3.0
Oral Cavity and Pharynx	Male	-	20,632	-	-	1.5	0.443	192	4,607,065	4.2
	Female	-	19,479	-	-	0.5	1.000	83	4,564,218	1.8
Ovary	Female	2	19,479	10.3	7.3	2.1	1.000	359	4,564,218	7.9
Pancreas	Total	10	40,111	24.9	16.0	8.0	0.579	1,180	9,171,283	12.9
Pancreas	Male	6	20,632	29.1	16.6	5.1	0.788	644	4,607,065	14.0
Pancreas	Female	4	19,479	20.5	14.9	3.2	0.777	536	4,564,218	11.7
Prostate	Male	4	20,632	19.4	11.7	7.4	0.284	993	4,607,065	21.6
Stomach	Total	-	40,111	-	-	1.2	0.593	194	9,171,283	2.1
	Male	-	20,632	-	-	0.9	0.842	119	4,607,065	2.6
Stomach	Female	-	19,479	-	-	0.4	1.000	75	4,564,218	1.6

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Boise County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	83.2% 9.0%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	54.8%
Current Tobacco User (2020–2022) Other Cancer-Related	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	24.0%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	40.3% 74.7% 22.4% 28.6%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





BONNER COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 1,732 cases of invasive cancer were diagnosed among Bonner County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in BonnerCounty and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Bonner County	State of Idaho
All Sites/Types	1,732	47,333
Female Breast	238	6,943
Prostate	257	6,766
Lung & Bronchus	186	4,959
Colorectal	152	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Bonner County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Bonner County. The table also shows the number of observed cases, person-

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 546 Bonner County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Bonner County and the State of Idaho, 2018–2022

Mortality 2018–2022	Bonner County	State of Idaho
All Deaths	2,577	80,538
Cancer Deaths	546	15,233
% of All Deaths	21.2%	18.9%
Lung & Bronchus	109	2,937
Colorectal	45	1,332
Pancreas	49	1,190
Female Breast	43	1,111
Prostate	41	997

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Bonner County was 751.0 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (520.5) gives an estimate of the relative burden of disease in Bonner County.

The age- and sex-adjusted incidence rate of invasive cancer in Bonner County, all sites combined, was 528.0 cases per 100,000 persons per year during 2017–2021. There were more cases of cancer in Bonner County (1,732) than expected (1,707.5) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Bonner County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Bonner County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Bonner County, all sites combined, was 157.6 deaths per 100,000 persons per year during 2018–2022, compared with 163.7 for the remainder of the state. There were fewer cancer deaths in Bonner County (546) than expected (567.2) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN BONNER COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Bor	nner County	/			Ren	nainder of Ida	aho
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	1,732	230,632	751.0	528.0	1,707.5	0.559	45,601	8,761,474	520.5
All Sites Combined	Male	965	115,561	835.1	550.4	969.1	0.911	24,305	4,396,712	552.8
All Sites Combined	Female	767	115,071	666.5	497.1	752.8	0.613	21,296	4,364,762	487.9
Bladder	Total	77	230,632	33.4	22.4	84.1	0.475	2,143	8,761,474	24.5
Bladder Bladder	Male Female	68 9	115,561 115,071	58.8 7.8	37.3 5.5	70.7 16.3	0.810 0.073	1,705 438	4,396,712 4,364,762	38.8 10.0
Brain - malignant	Total	23	230,632	10.0	7.8	21.4	0.073	634	8,761,474	7.2
Brain - malignant	Male	16	115,561	13.8	10.6	12.6	0.408	366	4,396,712	8.3
Brain - malignant	Female	7	115,071	6.1	4.8	8.9	0.679	268	4,364,762	6.1
Brain and other CNS - non-malignant	Total	58	230,632	25.1	18.8	52.4	0.472	1,489	8,761,474	17.0
- 3	Male	27	115,561	23.4	17.3	16.8	0.027 >>	473	4,396,712	10.8
Brain and other CNS - non-malignant	Female	31	115,071	26.9	20.7	34.9	0.574	1,016	4,364,762	23.3
Breast Breast	Total Male	245 7	230,632 115,561	106.2 6.1	76.6 4.2	246.8 2.2	0.941 0.016 >>	6,763 58	8,761,474 4,396,712	77.2 1.3
Breast	Female	238	115,071	206.8	4.2 153.9	237.5	0.993	6,705	4,390,712	153.6
Breast - in situ	Total	42	230,632	18.2	13.1	48.4	0.398	1,327	8,761,474	15.1
Breast - in situ	Male	-	115,561	-	-	0.1	1.000	4	4,396,712	0.1
Breast - in situ	Female	42	115,071	36.5	27.0	47.1	0.513	1,323	4,364,762	30.3
Cervix	Female	12	115,071	10.4	9.4	8.2	0.255	282	4,364,762	6.5
Colorectal	Total	152	230,632	65.9	47.3	127.6	0.039 >>	3,480	8,761,474	39.7
Colorectal Colorectal	Male Female	78 74	115,561 115,071	67.5 64.3	46.5 48.2	72.5 55.7	0.546 0.021 >>	1,899 1,581	4,396,712 4,364,762	43.2 36.2
Colorectal Corpus Uteri	Female	40	115,071	64.3 34.8	48.2	55.7 47.7	0.021 >>	1,581	4,364,762	30.2
Esophagus	Total	18	230,632	7.8	5.3	18.9	0.294	489	8,761,474	5.6
Esophagus	Male	14	115,561	12.1	7.8	16.8	0.588	415	4,396,712	9.4
Esophagus	Female	4	115,071	3.5	2.5	2.7	0.573	74	4,364,762	1.7
Hodgkin Lymphoma	Total	3	230,632	1.3	1.2	6.2	0.273	219	8,761,474	2.5
Hodgkin Lymphoma	Male	2	115,561	1.7	1.5	3.8	0.542	127	4,396,712	2.9
Hodgkin Lymphoma	Female	1 81	115,071	0.9	0.9 25.0	2.4	0.609	92	4,364,762	2.1 21.3
Kidney and Renal Pelvis Kidney and Renal Pelvis	Total Male	51	230,632 115,561	35.1 44.1	25.0 30.2	69.2 48.4	0.181 0.747	1,870 1,259	8,761,474 4,396,712	21.3
Kidney and Renal Pelvis	Female	30	115,071	26.1	19.3	21.8	0.108	611	4,364,762	14.0
Larynx	Total	14	230,632	6.1	4.2	7.9	0.064	206	8,761,474	2.4
Larynx	Male	9	115,561	7.8	5.1	6.3	0.379	158	4,396,712	3.6
Larynx	Female	5	115,071	4.3	3.1	1.8	0.070	48	4,364,762	1.1
Leukemia	Total	64	230,632	27.7	20.0	60.7	0.704	1,663	8,761,474	19.0
Leukemia	Male	38	115,561	32.9	22.7	38.0	1.000	998	4,396,712	22.7
Leukemia Liver and Bile Duct	Female Total	26 37	115,071 230,632	22.6 16.0	17.0 10.8	23.3 31.6	0.631 0.376	665 806	4,364,762 8,761,474	15.2 9.2
Liver and Bile Duct	Male	37	230,032	28.6	10.8	23.0	0.057	561	4,396,712	12.8
Liver and Bile Duct	Female	4	115,071	3.5	2.5	9.1	0.103	245	4,364,762	5.6
Lung and Bronchus	Total	186	230,632	80.6	53.5	189.3	0.848	4,773	8,761,474	54.5
Lung and Bronchus	Male	95	115,561	82.2	51.5	100.7	0.610	2,400	4,396,712	54.6
Lung and Bronchus	Female	91	115,071	79.1	55.4	89.4	0.890	2,373	4,364,762	54.4
Melanoma of the Skin	Total	104	230,632	45.1	32.9	109.6	0.633	3,040	8,761,474	34.7
Melanoma of the Skin	Male	69 35	115,561	59.7 30.4	40.7 23.8	70.4	0.931	1,826	4,396,712	41.5
Melanoma of the Skin Myeloma	Female Total	35 26	115,071 230,632	30.4 11.3	23.8	40.8 27.2	0.407 0.917	1,214 702	4,364,762 8,761,474	27.8 8.0
Myeloma	Male	17	230,032	14.7	9.5	17.4	1.000	430	4,396,712	9.8
Myeloma	Female	9	115,071	7.8	5.5	10.1	0.885	272	4,364,762	6.2
Non-Hodgkin Lymphoma	Total	57	230,632	24.7	17.5	71.9	0.081	1,935	8,761,474	22.1
Non-Hodgkin Lymphoma	Male	26	115,561	22.5	15.3	43.3	0.006 <<	1,120	4,396,712	25.5
Non-Hodgkin Lymphoma	Female	31	115,071	26.9	19.8	29.3	0.800	815	4,364,762	18.7
Oral Cavity and Pharynx	Total	48	230,632	20.8	14.4	48.2	1.000	1,267	8,761,474	14.5
Oral Cavity and Pharynx Oral Cavity and Pharynx	Male Female	33 15	115,561 115,071	28.6 13.0	19.0 9.5	35.8 13.1	0.715 0.660	907 360	4,396,712 4,364,762	20.6 8.2
Oral Cavity and Pharynx Ovary	Female	22	115,071	13.0	9.5 14.4	13.1	0.660	531	4,364,762	0.2
Pancreas	Total	60	230,632	26.0	17.7	55.2	0.549	1,428	8,761,474	16.3
Pancreas	Male	34	115,561	29.4	19.0	32.2	0.791	792	4,396,712	18.0
Pancreas	Female	26	115,071	22.6	16.2	23.4	0.650	636	4,364,762	14.6
Prostate	Male	257	115,561	222.4	139.3	273.2	0.343	6,509	4,396,712	148.0
Stomach	Total	14	230,632	6.1	4.3	17.2	0.536	460	8,761,474	5.3
Stomach	Male Female	12	115,561	10.4	6.9	11.7	1.000	295 165	4,396,712	6.7
Stomach Testis	Female Male	2	115,071 115,561	1.7 3.5	1.3 4.0	5.7 6.1	0.149 0.537	165 270	4,364,762 4,396,712	3.8 6.1
Thyroid	Total	30	230,632	13.0	4.0	34.9	0.337	1,155	8,761,474	13.2
Thyroid	Male	30 11	230,032	9.5	7.4	12.2	0.405	361	4,396,712	8.2
Thyroid	Female	19	115,071	9.5 16.5	15.2	22.8	0.502	794	4,364,762	18.2
Pediatric Age 0 to 19	Total	6	49,277	12.2	12.2	8.4	0.532	419	2,450,047	17.1
Pediatric Age 0 to 19	Male	2	25,034	8.0	8.0	4.2	0.410	212	1,249,287	17.0
Pediatric Age 0 to 19	Female	4	24,243	16.5	16.6	4.2	1.000	207	1,200,760	17.2

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN BONNER COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Bor	nner County	/			Re	mainder of Idah	10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	2,577	238,331	1,081.3	780.1	2,870.2	0.000 <<	77,958	8,973,063	868.8
All Causes of Death	Male	1,425	119,791	1,189.6	821.0	1,592.5	0.000 <<	41,361	4,507,906	917.5
All Causes of Death	Female	1,152	118,540	971.8	729.1	1,294.9	0.000 <<	36.597	4,465,157	819.6
All Malignant Cancers	Total	546	238,331	229.1	157.6	567.2	0.386	14,687	8,973,063	163.7
All Malignant Cancers	Male	306	119,791	255.4	166.2	323.8	0.336	7,929	4,507,906	175.9
All Malignant Cancers	Female	240	118,540	202.5	146.5	248.0	0.639	6,758	4,465,157	151.3
Bladder	Total	22	238,331	9.2	6.4	17.9	0.382	463	8,973,063	5.2
Bladder	Male	21	119,791	17.5	11.4	14.4	0.121	354	4,507,906	7.9
Bladder	Female	1	118,540	0.8	0.6	4.0	0.187	109	4,465,157	2.4
Brain and Other Nervous System	Total	19	238,331	8.0	5.8	18.4	0.943	499	8,973,063	5.6
	Male	12	119,791	10.0	7.0	10.6	0.741	277	4,507,906	6.1
Brain and Other Nervous System	Female	7	118,540	5.9	4.4	7.9	0.938	222	4,465,157	5.0 12.0
Breast	Total Male	44	238,331	18.5	13.1	40.4	0.613	1,080	8,973,063	
Breast Breast	Female	1 43	119,791 118,540	0.8 36.3	0.5 26.7	0.5 38.5	0.779 0.509	12 1,068	4,507,906 4,465,157	0.3 23.9
Cervix	Female	43	118,540	2.5	20.7	2.8	1.000	85	4,465,157	1.9
Colorectal	Total	45	238,331	18.9	13.3	48.5	0.682	1,287	8,973,063	14.3
Colorectal	Male	24	119,791	20.0	13.5	27.8	0.541	708	4,507,906	15.7
Colorectal	Female	21	118,540	17.7	13.0	20.9	1.000	579	4,465,157	13.0
Corpus Uteri	Female	3	118,540	2.5	1.8	6.3	0.254	166	4,465,157	3.7
Esophagus	Total	24	238,331	10.1	6.8	17.2	0.139	437	8,973,063	4.9
Esophagus	Male	20	119,791	16.7	10.7	15.4	0.292	371	4,507,906	8.2
Esophagus	Female	4	118,540	3.4	2.4	2.4	0.449	66	4,465,157	1.5
Hodgkin Lymphoma	Total	2	238,331	0.8	0.6	0.9	0.424	23	8,973,063	0.3
Hodgkin Lymphoma	Male	1	119,791	0.8	0.6	0.5	0.809	13	4,507,906	0.3
Hodgkin Lymphoma	Female	1	118,540	0.8	0.6	0.4	0.593	10	4,465,157	0.2
Kidney	Total	17	238,331	7.1	4.8	14.5	0.581	369	8,973,063	4.1
Kidney	Male	9 8	119,791	7.5 6.7	4.8	9.8	0.977	237	4,507,906 4,465,157	5.3
Kidney Larynx	Female Total	° 2	118,540 238,331	0.7	4.8 0.6	5.0 2.9	0.262 0.897	132 74	8,973,063	3.0 0.8
Larynx	Male	2	119,791	1.7	1.1	2.6	1.000	63	4,507,906	1.4
Larynx	Female	-	118,540	-	-	0.4	1.000	11	4,465,157	0.2
Leukemia	Total	25	238,331	10.5	7.3	24.3	0.946	640	8,973,063	7.1
Leukemia	Male	14	119,791	11.7	7.7	15.4	0.847	383	4,507,906	8.5
Leukemia	Female	11	118,540	9.3	6.8	9.2	0.647	257	4,465,157	5.8
Liver and Bile Duct	Total	25	238,331	10.5	7.0	24.1	0.916	610	8,973,063	6.8
Liver and Bile Duct	Male	19	119,791	15.9	10.1	16.8	0.655	404	4,507,906	9.0
Liver and Bile Duct	Female	6	118,540	5.1	3.6	7.7	0.696	206	4,465,157	4.6
Lung and Bronchus	Total	109	238,331	45.7	30.5	112.5	0.791	2,828	8,973,063	31.5
Lung and Bronchus	Male	54	119,791	45.1	28.4	62.6	0.302	1,487	4,507,906	33.0
Lung and Bronchus	Female	55	118,540	46.4	32.7	50.5	0.564	1,341	4,465,157	30.0
Melanoma of the Skin Melanoma of the Skin	Total Male	10 8	238,331 119,791	4.2 6.7	3.0 4.5	10.9 7.6	0.933 0.991	291 192	8,973,063 4,507,906	3.2 4.3
Melanoma of the Skin	Female	o 2	118,540	0.7	4.5 1.3	7.6	0.633	99	4,507,908	4.3
Myeloma	Total	2	238,331	0.8	0.6	12.8	0.003	323	8,973,063	3.6
Myeloma	Male	2	119,791	1.7	1.1	7.8	0.033 <<	186	4,507,906	4.1
Myeloma	Female	-	118,540	-	-	5.1	0.012 <<	137	4,465,157	3.1
Non-Hodgkin Lymphoma	Total	15	238,331	6.3	4.3	21.3	0.198	553	8,973,063	6.2
Non-Hodgkin Lymphoma	Male	8	119,791	6.7	4.4	12.3		302	4,507,906	6.7
Non-Hodgkin Lymphoma	Female	7	118,540	5.9	4.3	9.2	0.596	251	4,465,157	5.6
Oral Cavity and Pharynx	Total	9	238,331	3.8	2.6	10.4	0.814	266	8,973,063	3.0
	Male	4	119,791	3.3	2.1	7.8	0.225	188	4,507,906	4.2
	Female	5	118,540	4.2	3.0	2.9	0.331	78	4,465,157	1.7
Ovary	Female	12	118,540	10.1	7.2	13.0	0.925	349	4,465,157	7.8
Pancreas	Total	49	238,331	20.6	13.8	45.1	0.598	1,141	8,973,063	12.7
	Male Female	24 25	119,791 118,540	20.0 21.1	12.7 14.9	26.2 19.3	0.768 0.241	626 515	4,507,906 4,465,157	13.9 11.5
	Male	25 41	118,540	34.2	22.2	39.1	0.241	956	4,465,157 4,507,906	21.2
Stomach	Total	41	238,331	34.2 2.1	1.5	7.0	0.603	956	4,507,906	21.2
	Male	3	119,791	2.1	1.5	4.5	0.670	116	4,507,906	2.1
	Female	2	118,540	2.5	1.7	2.5	1.000	73	4,465,157	1.6
	i cillale	Z	110,040	I./	1.3	2.0	1.000	13	4,400,107	1.0

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Bonner County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	87.9% 11.8%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	60.3% 68.8% 61.3%
Current Tobacco User (2020–2022) Other Cancer-Related	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	27.5%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	34.1% 79.2% 22.4% 24.2%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





BONNEVILLE COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 2,771 cases of invasive cancer were diagnosed among Bonneville County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in BonnevilleCounty and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Bonneville County	State of Idaho
All Sites/Types	2,771	47,333
Female Breast	398	6,943
Prostate	376	6,766
Lung & Bronchus	202	4,959
Colorectal	228	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Bonneville County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Bonneville County. The table also shows the number of observed cases,

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 826 Bonneville County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Bonneville County and the State of Idaho, 2018–2022

Mortality 2018–2022	Bonneville County	State of Idaho
All Deaths	5,101	80,538
Cancer Deaths	826	15,233
% of All Deaths	16.2%	18.9%
Lung & Bronchus	137	2,937
Colorectal	82	1,332
Pancreas	51	1,190
Female Breast	66	1,111
Prostate	49	997

person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, nonmalignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Bonneville County was 461.3 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (531.0) gives an estimate of the relative burden of disease in Bonneville County.

The age- and sex-adjusted incidence rate of invasive cancer in Bonneville County, all sites combined, was 541.7 cases per 100,000 persons per year during 2017–2021. There were more cases of cancer in Bonneville County (2,771) than expected (2,716.5) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Bonneville County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Bonneville County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Bonneville County, all sites combined, was 160.1 deaths per 100,000 persons per year during 2018–2022, compared with 167.6 for the remainder of the state. There were fewer cancer deaths in Bonneville County (826) than expected (864.5) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN BONNEVILLE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Bonr	eville Cour	ntv			Ren	nainder of Ida	aho
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)		P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	2,771	600,734	461.3	541.7	2,716.5	0.301	44,562	8,391,372	531.0
All Sites Combined	Male	1,440	300,211	479.7	574.3	1,418.5	0.575	23,830	4,212,062	565.8
All Sites Combined	Female	1,331	300,523	442.9	511.7	1,290.3	0.263	20,732	4,179,310	496.1
Bladder	Total	132	600,734	22.0	26.3	124.7	0.537	2,088	8,391,372	24.9
Bladder	Male	103	300,211	34.3	41.9	97.4	0.596	1,670	4,212,062	39.6
Bladder	Female	29	300,523	9.6	11.4	25.5	0.534	418	4,179,310	10.0
Brain - malignant Brain - malignant	Total Male	44 24	600,734 300.211	7.3 8.0	8.2 9.0	39.4 22.7	0.503 0.832	613 358	8,391,372 4,212,062	7.3 8.5
Brain - malignant	Female	24	300,523	6.7	7.3	16.6	0.467	255	4,179,310	6.1
Brain and other CNS - non-malignant	Total	113	600,734	18.8	21.5	89.7	0.020 >>	1,434	8,391,372	17.1
Brain and other CNS - non-malignant	Male	33	300,211	11.0	12.5	29.2	0.523	467	4,212,062	11.1
Brain and other CNS - non-malignant	Female	80	300,523	26.6	30.4	61.0	0.022 >>	967	4,179,310	23.1
Breast	Total	400	600,734	66.6	77.7	405.6	0.808	6,608	8,391,372	78.7
Breast	Male	2	300,211	0.7	0.8	3.8	0.538	63	4,212,062	1.5
Breast Breast - in situ	Female Total	398 81	300,523 600,734	132.4 13.5	153.7 15.8	405.5 78.9	0.735 0.844	6,545 1,288	4,179,310 8,391,372	156.6 15.3
Breast - in situ	Male		300,211	-	15.0	0.3	1.000	1,200	4,212,062	0.1
Breast - in situ	Female	- 81	300,523	- 27.0	31.4	79.2	0.867	1,284	4,212,002	30.7
Cervix	Female	15	300,523	5.0	5.4	18.7	0.474	279	4,179,310	6.7
Colorectal	Total	228	600,734	38.0	44.4	208.5	0.191	3,404	8,391,372	40.6
Colorectal	Male	118	300,211	39.3	46.4	112.1	0.605	1,859	4,212,062	44.1
Colorectal	Female	110	300,523	36.6	42.3	96.2	0.180	1,545	4,179,310	37.0
Corpus Uteri	Female	100	300,523	33.3	39.0	77.0	0.013 >>	1,254	4,179,310	30.0
Esophagus	Total	22	600,734	3.7	4.4	29.1	0.214 0.098	485	8,391,372	5.8
Esophagus Esophagus	Male Female	16 6	300,211 300,523	5.3 2.0	6.4 2.4	24.3 4.4	0.098	413 72	4,212,062 4,179,310	9.8 1.7
Hodgkin Lymphoma	Total	10	600.734	2.0	1.8	14.2	0.330	212	8,391,372	2.5
Hodgkin Lymphoma	Male	9	300.211	3.0	3.3	7.9	0.776	120	4,212,062	2.3
Hodgkin Lymphoma	Female	1	300,523	0.3	0.0	6.3	0.027 <<	92	4,179,310	2.2
Kidney and Renal Pelvis	Total	124	600,734	20.6	24.1	111.8	0.270	1,827	8,391,372	21.8
Kidney and Renal Pelvis	Male	74	300,211	24.6	29.1	74.6	1.000	1,236	4,212,062	29.3
Kidney and Renal Pelvis	Female	50	300,523	16.6	19.2	36.8	0.044 >>	591	4,179,310	14.1
Larynx	Total	5	600,734	0.8	1.0	12.9	0.023 <<	215	8,391,372	2.6
Larynx	Male	4	300,211	1.3	1.6	9.7	0.072	163	4,212,062	3.9
Larynx	Female Total	1 112	300,523 600,734	0.3 18.6	0.4 21.4	3.2 100.7	0.355 0.283	52	4,179,310	1.2 19.2
Leukemia Leukemia	Male	71	300,211	23.7	21.4	59.2	0.285	1,615 965	8,391,372 4,212,062	22.9
Leukemia	Female	41	300,523	13.6	15.5	41.1	1.000	650	4,179,310	15.6
Liver and Bile Duct	Total	37	600,734	6.2	7.3	48.4	0.108	806	8,391,372	9.6
Liver and Bile Duct	Male	28	300,211	9.3	11.2	33.5	0.393	566	4.212.062	13.4
Liver and Bile Duct	Female	9	300,523	3.0	3.5	14.7	0.159	240	4,179,310	5.7
Lung and Bronchus	Total	202	600,734	33.6	40.5	282.9	>> 000.0	4,757	8,391,372	56.7
Lung and Bronchus	Male	101	300,211	33.6	41.3	139.0	0.001 <<	2,394	4,212,062	56.8
Lung and Bronchus	Female	101	300,523	33.6	39.8	143.4	0.000 <<	2,363	4,179,310	56.5
Melanoma of the Skin Melanoma of the Skin	Total Male	202 122	600,734 300,211	33.6 40.6	38.9 48.1	182.0 106.8	0.152 0.160	2,942 1,773	8,391,372	35.1 42.1
Melanoma of the Skin	Female	80	300,211	26.6	40.1 30.1	74.3	0.100	1,773	4,212,062 4,179,310	42.1 28.0
Myeloma	Total	48	600,323	8.0	9.5	40.7	0.291	680	8,391,372	8.1
Myeloma	Male	29	300,211	9.7	11.7	24.6	0.419	418	4,212,062	9.9
Myeloma	Female	19	300,523	6.3	7.5	16.0	0.511	262	4,179,310	6.3
Non-Hodgkin Lymphoma	Total	134	600,734	22.3	26.1	113.8	0.070	1,858	8,391,372	22.1
Non-Hodgkin Lymphoma	Male	72	300,211	24.0	28.3	65.0	0.414	1,074	4,212,062	25.5
Non-Hodgkin Lymphoma	Female	62	300,523	20.6	24.0	48.5	0.069	784	4,179,310	18.8
Oral Cavity and Pharynx Oral Cavity and Pharynx	Total Malo	69 51	600,734	11.5	13.6	75.4	0.506	1,246	8,391,372	14.8
Oral Cavity and Pharynx Oral Cavity and Pharynx	Male Female	51 18	300,211 300,523	17.0 6.0	20.2 7.0	53.2 22.0	0.836 0.471	889 357	4,212,062 4,179,310	21.1 8.5
Ovary	Female	27	300,523	9.0	10.4	32.8	0.471	526	4,179,310	12.6
Pancreas	Total	78	600,734	13.0	15.5	84.7	0.504	1,410	8,391,372	12.0
Pancreas	Male	39	300,211	13.0	15.7	46.4	0.311	787	4,212,062	18.7
Pancreas	Female	39	300,523	13.0	15.2	38.1	0.932	623	4,179,310	14.9
Prostate	Male	376	300,211	125.2	152.9	373.0	0.891	6,390	4,212,062	151.7
Stomach	Total	31	600,734	5.2	6.1	27.0	0.489	443	8,391,372	5.3
Stomach	Male	24	300,211	8.0	9.6	16.8	0.114	283	4,212,062	6.7
Stomach	Female	7	300,523	2.3	2.7	10.0	0.437	160	4,179,310	3.8
Testis	Male	20	300,211	6.7	6.7	17.9	0.680	254	4,212,062	6.0
Thyroid	Total	123	600,734	20.5	22.3	69.8	0.000 >>	1,062	8,391,372	12.7
Thyroid	Male	33	300,211	11.0	12.4	21.4	0.024 >>	339	4,212,062	8.0
Thyroid	Female	90	300,523	29.9	32.1	48.5	0.000 >>	723	4,179,310	17.3
Pediatric Age 0 to 19	Total	32	197,909	16.2	16.3	33.5	0.879	393	2,301,415	17.1
Pediatric Age 0 to 19 Pediatric Age 0 to 19	Male Female	20 12	100,908 97,001	19.8 12.4	19.8 12.6	16.7 16.8	0.482 0.291	194 199	1,173,413 1,128,002	16.5 17.6
1 Guiatrio Ayo V IV 13	i emale	12	91,001	12.4	12.0	10.0	0.231	199	1,120,002	17.0

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN BONNEVILLE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Bonr	eville Coun	ty			Re	emainder of Idah	10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	5,101	615,622	828.6	969.1	4.619.1	0.000 >>	75,434	8,595,772	877.6
All Causes of Death		2,620	308,161	850.2	1.009.2	2,414.2	0.000 >>	40,166	4,319,536	929.9
All Causes of Death	Male	2,620	307,461	806.9	933.0	2,414.2	0.000 >>	40,166 35,268	4,319,536	929.9 824.7
	Female Total		615.622		160.1	2,193.0	0.000			167.6
All Malignant Cancers		826		134.2				14,407	8,595,772	
All Malignant Cancers	Male	436 390	308,161	141.5	172.2	457.1 404.4	0.335 0.492	7,799 6,608	4,319,536 4,276,236	180.6 154.5
All Malignant Cancers	Female	390	307,461 615,622	126.8 4.9	149.0 5.8	27.3	0.492	455	8,595,772	5.3
Bladder Bladder	Total Male	23	308,161		9.1	27.3	0.657	455 352		8.1
Bladder	Female	23	307,461	7.5 2.3	9.1 2.7	20.0	0.888	103	4,319,536 4,276,236	2.4
Brain and Other Nervous System		35	615,622	<u>2.3</u> 5.7		29.8		483	8,595,772	2.4
Brain and Other Nervous System	Total	20	308,161		6.6 7.6		0.383 0.424			6.2
Brain and Other Nervous System	Male	20 15	307,461	6.5 4.9	7.6 5.6	16.3 13.4	0.424	269 214	4,319,536 4,276,236	6.2 5.0
Breast	Female Total	68	615,622	4.9	13.0	64.0	0.654	1,056	8,595,772	12.3
Breast		2		0.6		04.0	0.034			
	Male	2 66	308,161		0.8 25.1	-		11	4,319,536	0.3
Breast	Female	4	307,461	21.5	25.1	64.2 5.4	0.854 0.749	1,045 84	4,276,236	24.4 2.0
Cervix	Female	82	307,461	1.3					4,276,236	
Colorectal	Total Malo		615,622	13.3	15.8	75.6	0.494	1,250	8,595,772	14.5
Colorectal Colorectal	Male Female	42 40	308,161 307,461	13.6 13.0	16.3 15.2	41.1 34.5	0.928 0.386	690 560	4,319,536 4,276,236	16.0
Corpus Uteri		40	307,461			34.5 9.7	0.366	161		13.1
	Female	o 25		2.6 4.1	3.1 4.9	9.7			4,276,236	3.8
Esophagus	Total		615,622				0.961 1.000	436	8,595,772	5.1
Esophagus Esophagus	Male	21 4	308,161 307,461	6.8 1.3	8.3 1.5	21.6 4.0	1.000	370 66	4,319,536 4,276,236	8.6 1.5
	Female Total	4	615,622				0.297			
Hodgkin Lymphoma				0.5	0.6	1.3		22	8,595,772	0.3
Hodgkin Lymphoma	Male	1	308,161	0.3 0.7	0.4 0.8	0.8	1.000	13 9	4,319,536	0.3 0.2
Hodgkin Lymphoma	Female	2	307,461			0.6 21.8	0.215	-	4,276,236	
Kidney	Total	20	615,622	3.2	3.9		0.801	366	8,595,772	4.3
Kidney	Male	13 7	308,161	4.2	5.1	13.7	1.000	233	4,319,536	5.4
Kidney	Female	3	307,461 615,622	2.3 0.5	2.7	8.1	0.883	133	4,276,236	3.1
Larynx	Total Male	3	308,161	1.0	0.6 1.2	4.4 3.7	0.731 1.000	73 62	8,595,772 4,319,536	0.8 1.4
Larynx	Female		307,461		1.2	0.7	1.000	11	4,276,236	0.3
Larynx	Total	- 35	615,622	- 5.7	- 6.7	38.2	0.681	630	8,595,772	7.3
Leukemia Leukemia	Male	22	308,161	7.1	8.6	22.2	1.000	375	4,319,536	8.7
Leukemia	Female	13	307,461	4.2	4.9	15.8	0.586	255	4,276,236	6.0
Liver and Bile Duct	Total	31	615,622	5.0	6.1	35.9	0.380	604	8,595,772	7.0
Liver and Bile Duct	Male	15	308,161	4.9	5.9	23.9	0.400	408	4,319,536	9.4
Liver and Bile Duct	Female	16	307,461	4.9 5.2	6.2	11.9	0.295	196	4,276,236	9.4 4.6
Lung and Bronchus	Total	137	615,622	22.3	26.9	165.9	0.293		8,595,772	32.6
Lung and Bronchus	Male	79	308,161	25.6	31.6	84.5	0.596	1,462	4,319,536	33.8
Lung and Bronchus	Female	58	307,461	18.9	22.4	81.0	0.009 <<		4,276,236	31.3
Melanoma of the Skin	Total	18	615,622	2.9	3.5	17.2	0.009 <<	283	8,595,772	3.3
Melanoma of the Skin	Male	10	308,161	2.9	3.5 4.7	17.2	0.882	188	4,319,536	3.3 4.4
Melanoma of the Skin	Female	6	307,461	2.0	2.3	5.9	1.000	95	4,276,236	4.4 2.2
Myeloma	Total	22	615,622	3.6	4.3	18.0	0.407	303	8,595,772	3.5
Myeloma	Male	12	308,161	3.9	4.3	10.2	0.656	176	4,319,536	4.1
Myeloma	Female	12	307,461	3.3	4.0 3.8	7.7	0.000	127	4,276,236	3.0
Non-Hodgkin Lymphoma	Total	38	615,622	6.2	7.4	31.9	0.304	530	8,595,772	6.2
Non-Hodgkin Lymphoma	Male	17	308,161	5.5	6.7	17.2	1.000	293	4,319,536	6.8
Non-Hodgkin Lymphoma	Female	21	307,461	6.8	8.0	14.5	0.129	233	4,276,236	5.5
Oral Cavity and Pharynx	Total	13	615,622	2.1	2.5	14.5	0.129	262	8,595,772	3.0
Oral Cavity and Pharynx	Male	8	308,161	2.6	3.2	10.7	0.513	184	4,319,536	4.3
Oral Cavity and Pharynx	Female	5	307,461	1.6	1.9	4.7	1.000	78	4,276,236	1.8
Ovary	Female	25	307,461	8.1	9.6	20.4	0.358	336	4,276,236	7.9
Pancreas	Total	51	615,622	8.3	10.0	67.8	0.041 <<	1,139	8,595,772	13.3
Pancreas	Male	25	308,161	8.1	10.0	36.4	0.041 <<	625	4,319,536	14.5
Pancreas	Female	25	307,461	8.5	10.0	31.2	0.401	514	4,276,236	14.5
Prostate	Male	49	308,161	15.9	10.0	55.3	0.401	948	4,319,536	21.9
Stomach	Total	49	615,622	1.3	19.4	11.4	0.437	186	8,595,772	21.9
Stomach	Male	8	308,161	2.6	3.1	6.6	0.401	100	4,319,536	2.2
Stomach	Female	0	307,461	2.0	5.1	4.7	0.072	75	4,276,236	1.8
Stomacil	remale	-	307,401	-	-	4.7	0.010	C 1	4,270,230	1.0

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Bonneville County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	93.9% 12.2%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	63.0% 68.4% 64.3%
Current Tobacco User (2020–2022) <u>Other Cancer-Related</u>	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	21.7%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	28.4% 79.0% 21.0% 21.9%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





BOUNDARY COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 436 cases of invasive cancer were diagnosed among Boundary County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in BoundaryCounty and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Boundary County	State of Idaho
All Sites/Types	436	47,333
Female Breast	57	6,943
Prostate	57	6,766
Lung & Bronchus	51	4,959
Colorectal	46	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Boundary County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Boundary County. The table also shows the number of observed cases,

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 154 Boundary County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Boundary County and the State of Idaho, 2018–2022

Mortality 2018–2022	Boundary County	State of Idaho
All Deaths	692	80,538
Cancer Deaths	154	15,233
% of All Deaths	22.3%	18.9%
Lung & Bronchus	34	2,937
Colorectal	16	1,332
Pancreas	4	1,190
Female Breast	10	1,111
Prostate	16	997

person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, nonmalignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Boundary County was 706.7 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (525.1) gives an estimate of the relative burden of disease in Boundary County.

The age- and sex-adjusted incidence rate of invasive cancer in Boundary County, all sites combined, was 545.8 cases per 100,000 persons per year during 2017–2021. There were more cases of cancer in Boundary County (436) than expected (419.5) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Boundary County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Boundary County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Boundary County, all sites combined, was 181.1 deaths per 100,000 persons per year during 2018–2022, compared with 164.8 for the remainder of the state. There were more cancer deaths in Boundary County (154) than expected (140.2) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN BOUNDARY COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Bour	ndary Coun	ty			Rem	nainder of Ida	aho
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)		P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	436	61,699	706.7	545.8	419.5	0.433	46,897	8,930,407	525.1
All Sites Combined	Male	238	31.115	764.9	565.8	235.0	0.860	25,032	4,481,158	558.6
All Sites Combined	Female	198	30,584	647.4	520.2	187.0	0.441	21,865	4,449,249	491.4
Bladder	Total	15	61,699	24.3	17.9	20.7	0.244	2,205	8,930,407	24.7
Bladder	Male	14	31,115	45.0	32.0	17.2	0.532	1,759	4,481,158	39.3
Bladder	Female	1	30,584	3.3	2.5	4.0	0.178	446	4,449,249	10.0
Brain - malignant	Total	7 3	61,699	11.3	9.5	5.4 3.2	0.583 1.000	650 270	8,930,407	7.3
Brain - malignant Brain - malignant	Male Female	3	31,115 30,584	9.6 13.1	8.0 11.0	3.2 2.2	0.370	379 271	4,481,158 4,449,249	8.5 6.1
Brain and other CNS - non-malignant	Total	13	61,699	21.1	17.0	13.1	1.000	1,534	8,930,407	17.2
	Male	4	31,115	12.9	10.4	4.3	1.000	496	4,481,158	11.1
Brain and other CNS - non-malignant	Female	9	30,584	29.4	24.1	8.7	1.000	1,038	4,449,249	23.3
Breast	Total	57	61,699	92.4	73.3	60.5	0.711	6,951	8,930,407	77.8
Breast	Male		31,115	-	-	0.6	1.000	65	4,481,158	1.5
Breast Breast - in situ	Female Total	57	30,584 61,699	186.4 11.3	150.9 9.1	58.5 11.8	0.916 0.200	6,886 1,362	4,449,249	154.8 15.3
Breast - in situ	Male	<i>'</i>	31,115	11.5	9.1	0.0	1.000	1,302	8,930,407 4,481,158	0.1
Breast - in situ	Female	- 7	30,584	22.9	18.7	11.5	0.233	1,358	4,449,249	30.5
Cervix	Female	2	30,584	6.5	6.3	2.1	1.000	292	4,449,249	6.6
Colorectal	Total	46	61,699	74.6	58.2	31.7	0.020 >>	3,586	8,930,407	40.2
Colorectal	Male	26	31,115	83.6	64.0	17.7	0.076	1,951	4,481,158	43.5
Colorectal	Female	20	30,584	65.4	52.1	14.1	0.162	1,635	4,449,249	36.7
Corpus Uteri	Female	12	30,584	39.2	31.2	11.6	0.984	1,342	4,449,249	30.2
Esophagus Esophagus	Total Male	4 3	61,699 31,115	6.5 9.6	4.9 7.0	4.6 4.1	1.000 0.844	503 426	8,930,407 4,481,158	5.6 9.5
Esophagus	Female	3 1	30,584	9.0 3.3	2.5	4.1 0.7	0.991	420	4,461,156	9.5
Hodgkin Lymphoma	Total	1	61,699	1.6	1.6	1.6	1.000	221	8.930.407	2.5
Hodgkin Lymphoma	Male	1	31,115	3.2	3.0	1.0	1.000	128	4,481,158	2.9
Hodgkin Lymphoma	Female	-	30,584	-	-	0.6	1.000	93	4,449,249	2.1
Kidney and Renal Pelvis	Total	13	61,699	21.1	16.4	17.2	0.382	1,938	8,930,407	21.7
Kidney and Renal Pelvis	Male	9	31,115	28.9	22.1	11.8	0.517	1,301	4,481,158	29.0
Kidney and Renal Pelvis	Female Total	4	30,584 61,699	13.1 6.5	10.4 4.9	5.5 2.0	0.721 0.276	637 216	4,449,249 8,930,407	14.3 2.4
Larynx Larynx	Male	2	31,115	6.4	4.9	1.5	0.916	165	4,481,158	3.7
Larynx	Female	2	30,584	6.5	5.1	0.5	0.153	51	4,449,249	1.1
Leukemia	Total	19	61,699	30.8	24.0	15.2	0.384	1,708	8,930,407	19.1
Leukemia	Male	12	31,115	38.6	29.3	9.4	0.469	1,024	4,481,158	22.9
Leukemia	Female	7	30,584	22.9	18.2	5.9	0.754	684	4,449,249	15.4
Liver and Bile Duct	Total	3	61,699	4.9	3.6	7.8	0.100	840	8,930,407	9.4
Liver and Bile Duct Liver and Bile Duct	Male Female	1 2	31,115 30,584	3.2 6.5	2.3 5.0	5.6 2.2	0.047 << 1.000	593 247	4,481,158 4,449,249	13.2 5.6
Lung and Bronchus	Total	51	61,699	82.7	60.7	46.2	0.514	4,908	8.930.407	55.0
Lung and Bronchus	Male	32	31,115	102.8	72.7	24.2	0.147	2,463	4,481,158	55.0
Lung and Bronchus	Female	19	30,584	62.1	47.3	22.1	0.599	2,445	4,449,249	55.0
Melanoma of the Skin	Total	31	61,699	50.2	40.1	27.0	0.485	3,113	8,930,407	34.9
Melanoma of the Skin	Male	14	31,115	45.0	34.3	17.2	0.537	1,881	4,481,158	42.0
Melanoma of the Skin	Female	17	30,584	55.6	46.7	10.1	0.057	1,232	4,449,249	27.7
Myeloma Myeloma	Total Male	10	61,699 31 115	16.2	12.1	6.6	0.266	718 /30	8,930,407 4 481 158	8.0 0.8
Myeloma Myeloma	Male Female	8 2	31,115 30,584	25.7 6.5	18.8 5.0	4.2 2.5	0.125 1.000	439 279	4,481,158 4,449,249	9.8 6.3
Non-Hodgkin Lymphoma	Total	22	61,699	35.7	27.7	17.5	0.342	1,970	8,930,407	22.1
Non-Hodgkin Lymphoma	Male	15	31,115	48.2	36.6	10.3	0.205	1,131	4,481,158	25.2
Non-Hodgkin Lýmphoma	Female	7	30,584	22.9	18.0	7.3	1.000	839	4,449,249	18.9
Oral Cavity and Pharynx	Total	11	61,699	17.8	13.7	11.8	0.980	1,304	8,930,407	14.6
Oral Cavity and Pharynx	Male	8	31,115	25.7	19.3	8.6	1.000	932	4,481,158	20.8
Oral Cavity and Pharynx	Female	3	30,584	9.8	7.7	3.3	1.000	372	4,449,249	8.4
Ovary Pancreas	Female Total	5 9	30,584 61,699	16.3 14.6	13.2 10.9	4.7 13.7	0.993 0.252	548 1,479	4,449,249 8,930,407	12.3 16.6
Pancreas	Male	7	31,115	22.5	16.4	7.8	0.958	819	4,481,158	18.3
Pancreas	Female	2	30,584	6.5	5.0	5.9	0.132	660	4,449,249	14.8
Prostate	Male	57	31,115	183.2	130.6	65.3	0.332	6,709	4,481,158	149.7
Stomach	Total	6	61,699	9.7	7.5	4.2	0.498	468	8,930,407	5.2
Stomach	Male	3	31,115	9.6	7.1	2.9	1.000	304	4,481,158	6.8
Stomach	Female	3	30,584	9.8	7.8	1.4	0.340	164	4,449,249	3.7
Testis	Male	2	31,115	6.4	7.6	1.6	0.944	272	4,481,158	6.1
Thyroid	Total	7	61,699	11.3	10.6	8.7	0.717	1,178	8,930,407	13.2
Thyroid	Male	3	31,115	9.6	8.3	3.0	1.000	369	4,481,158	8.2
Thyroid	Female	4	30,584 15,725	13.1	12.7 31.7	5.7 2.7	0.643	809	4,449,249	18.2 16.9
Pediatric Age 0 to 19 Pediatric Age 0 to 19	Total Male	5	8,242	31.8 36.4	31.7		0.266 0.324	420 211	2,483,599 1,266,079	16.9
Pediatric Age 0 to 19 Pediatric Age 0 to 19	Female	3 2	8,242 7,483	36.4 26.7	36.2 26.6	1.4 1.3	0.324 0.741	211 209	1,266,079	16.7
I COLORING AGE VIO 18	i ciliale	Z	7,403	20.7	20.0	1.3	0.741	209	1,217,320	17.2

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN BOUNDARY COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Bour	ndary Count	ty			Re	mainder of Idah	10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	692	63,049	1,097.6	821.6	735.1	0.114	79,843	9,148,345	872.8
All Causes of Death	Male	378	31,845	1,187.0	898.4	388.2	0.625	42,408	4,595,852	922.7
All Causes of Death	Female	314	31,204	1,006.3	739.1	349.3	0.059	37,435	4,552,493	822.3
All Malignant Cancers	Total	154	63,049	244.3	181.1	140.2	0.261	15,079	9,148,345	164.8
All Malignant Cancers	Male	84	31,845	263.8	191.8	77.7	0.501	8,151	4,595,852	177.4
All Malignant Cancers	Female	70	31,204	224.3	169.4	62.9	0.400	6,928	4,552,493	152.2
Bladder	Total	3	63,049	4.8	3.4	4.6	0.642	482	9,148,345	5.3
Bladder	Male	3	31,845	9.4	6.8	3.6	1.000	372	4,595,852	8.1
Bladder	Female	-	31,204	-	-	1.0	0.706	110	4,552,493	2.4
Brain and Other Nervous System	Total	5	63,049	7.9	6.3	4.5	0.929	513	9,148,345	5.6
Brain and Other Nervous System	Male	2	31,845	6.3	4.9	2.6	1.000	287	4,595,852	6.2
Brain and Other Nervous System Breast	Female Total	3 10	31,204 63,049	9.6 15.9	7.6 12.0	2.0 10.1	0.622	226 1,114	4,552,493 9,148,345	5.0 12.2
Breast	Male	10	63,049 31,845	15.9	12.0	0.1	1.000	1,114	9,148,345 4,595,852	0.3
Breast	Female	- 10	31,204	- 32.0	- 24.4	9.9	1.000	1,101	4,595,852	24.2
Cervix	Female	10	31,204	3.2	24.4	0.7	0.993	87	4,552,493	1.9
Colorectal	Total	16	63,049	25.4	19.2	12.0	0.310	1,316	9,148,345	14.4
Colorectal	Male	6	31,845	18.8	14.2	6.7	0.999	726	4,595,852	15.8
Colorectal	Female	10	31,204	32.0	24.1	5.4	0.094	590	4,552,493	13.0
Corpus Uteri	Female	1	31,204	3.2	2.4	1.5	1.000	168	4,552,493	3.7
Esophagus	Total	3	63,049	4.8	3.5	4.3	0.771	458	9,148,345	5.0
Esophagus	Male	2	31,845	6.3	4.6	3.7	0.565	389	4,595,852	8.5
Esophagus	Female	1	31,204	3.2	2.4	0.6	0.925	69	4,552,493	1.5
Hodgkin Lymphoma	Total	1	63,049	1.6	1.2	0.2	0.392	24	9,148,345	0.3
Hodgkin Lymphoma Hodgkin Lymphoma	Male	1	31,845 31,204	3.1	2.3	0.1	0.230 1.000	13	4,595,852	0.3 0.2
Kidney	Female Total	- 5	63,049	- 7.9	- 5.8	0.1 3.6	0.589	11 381	4,552,493 9,148,345	4.2
Kidney	Male	5 4	31,845	7.9 12.6	9.1	2.3	0.389	242	4,595,852	4.2 5.3
Kidney	Female	4	31,204	3.2	2.3	1.3	1.000	139	4,552,493	3.1
Larynx	Total	-	63,049	-	-	0.7	0.990	76	9,148,345	0.8
Larynx	Male	-	31,845	-	-	0.6	1.000	65	4,595,852	1.4
Larynx	Female	-	31,204	-	-	0.1	1.000	11	4,552,493	0.2
Leukemia	Total	6	63,049	9.5	7.1	6.1	1.000	659	9,148,345	7.2
Leukemia	Male	4	31,845	12.6	9.2	3.7	1.000	393	4,595,852	8.6
Leukemia	Female	2	31,204	6.4	4.9	2.4	1.000	266	4,552,493	5.8
Liver and Bile Duct	Total	3	63,049	4.8	3.5	5.9	0.324	632	9,148,345	6.9
Liver and Bile Duct	Male		31,845	-	- 70	4.1	0.035 <<		4,595,852	9.2
Liver and Bile Duct	Female Total	3 34	31,204 63,049	9.6 53.9	7.3 39.4	1.9 27.4	0.585 0.248	209 2,903	4,552,493 9,148,345	4.6 31.7
Lung and Bronchus Lung and Bronchus	Male	34 23	31,845	72.2	59.4 51.4	14.8	0.248	2,903	4,595,852	33.0
Lung and Bronchus	Female	11	31,204	35.3	26.3	14.0	0.769	1,385	4,552,493	30.4
Melanoma of the Skin	Total	1	63,049	1.6	1.2	2.7	0.494	300	9,148,345	3.3
Melanoma of the Skin	Male	1	31,845	3.1	2.4	1.8	0.902	199	4,595,852	4.3
Melanoma of the Skin	Female	-	31,204	-	-	0.9	0.822	101	4,552,493	2.2
Myeloma	Total	2	63,049	3.2	2.3	3.1	0.819	323	9,148,345	3.5
Myeloma	Male	1	31,845	3.1	2.2	1.8	0.912	187	4,595,852	4.1
Myeloma	Female	1	31,204	3.2	2.4	1.2	1.000	136	4,552,493	3.0
Non-Hodgkin Lymphoma	Total	11	63,049	17.4	12.9	5.2	0.035 >>	557	9,148,345	6.1
Non-Hodgkin Lymphoma	Male	7	31,845	22.0	16.0	2.9		303	4,595,852	6.6
Non-Hodgkin Lymphoma Oral Cavity and Pharynx	Female Total	4	31,204 63,049	12.8 3.2	9.5 2.4	2.4 2.5	0.422	254 273	4,552,493 9,148,345	5.6 3.0
Oral Cavity and Pharynx	Male	2 1	31,845	3.2 3.1	2.4	2.5	0.913	191	4,595,852	4.2
Oral Cavity and Pharynx	Female	1	31,204	3.1	2.3	0.7	1.000	82	4,595,852	4.2
Ovary	Female	7	31,204	22.4	17.0	3.2	0.090	354	4,552,493	7.8
Pancreas	Total	4	63,049	6.3	4.7	11.1	0.028 <<	1,186	9,148,345	13.0
Pancreas	Male	4	31,845	12.6	9.0	6.2	0.514	646	4,595,852	14.1
Pancreas	Female	-	31,204	-	-	4.9	0.015 <<	540	4,552,493	11.9
Prostate	Male	16	31,845	50.2	35.9	9.5	0.068	981	4,595,852	21.3
Stomach	Total	3	63,049	4.8	3.7	1.7	0.487	191	9,148,345	2.1
Stomach	Male	1	31,845	3.1	2.4	1.1	1.000	118	4,595,852	2.6
Stomach	Female	2	31,204	6.4	5.1	0.6	0.259	73	4,552,493	1.6

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Boundary County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	3.3%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	45.8%
Current Tobacco User (2020–2022) <u>Other Cancer-Related</u>	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	19.1%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	27.5% 79.4% 21.0% 17.1%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





BUTTE COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 91 cases of invasive cancer were diagnosed among Butte County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,

 Lung and Bronchus, and Colorectal Cancers in Butte County

 and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Butte County	State of Idaho
All Sites/Types	91	47,333
Female Breast	10	6,943
Prostate	7	6,766
Lung & Bronchus	17	4,959
Colorectal	8	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Butte County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Butte County. The table also shows the number of observed cases, person-

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 36 Butte County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Butte County and the State of Idaho, 2018–2022

Mortality 2018–2022	Butte County	State of Idaho
All Deaths	188	80,538
Cancer Deaths	36	15,233
% of All Deaths	19.1%	18.9%
Lung & Bronchus	11	2,937
Colorectal	3	1,332
Pancreas	0	1,190
Female Breast	3	1,111
Prostate	0	997

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Butte County was 695.2 cases per 100,000 personyears per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (526.1) gives an estimate of the relative burden of disease in Butte County.

The age- and sex-adjusted incidence rate of invasive cancer in Butte County, all sites combined, was 511.2 cases per 100,000 persons per year during 2017–2021. There were fewer cases of cancer in Butte County (91) than expected (93.7) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Butte County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Butte County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Butte County, all sites combined, was 186.7 deaths per 100,000 persons per year during 2018–2022, compared with 165.2 for the remainder of the state. There were more cancer deaths in Butte County (36) than expected (31.9) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021 COMPARISON BETWEEN BUTTE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Butte County							Remainder of Idaho				
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude			
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)			
All Sites Combined	Total	91	13,090	695.2	511.2	93.7	0.837	47,242	8,979,016	526.1			
All Sites Combined	Male	50	6,657	751.1	515.9	54.2	0.623	25,220	4,505,616	559.7			
All Sites Combined	Female	41	6,433	637.3	500.1	40.4	0.961	22,022	4,473,400	492.3			
Bladder	Total	4	13,090	30.6	20.7	4.8	0.960	2,216	8,979,016	24.7			
Bladder Bladder	Male Female	4	6,657 6,433	60.1	38.3	4.1 0.9	1.000 0.820	1,769 447	4,505,616 4,473,400	39.3 10.0			
Brain - malignant	Total	- 3	13,090	- 22.9	- 18.5	1.2	0.820	654	8,979,016	7.3			
Brain - malignant	Male	1	6,657	15.0	11.9	0.7	1.000	381	4,505,616	8.5			
Brain - malignant	Female	2	6,433	31.1	25.3	0.5	0.170	273	4,473,400	6.1			
Brain and other CNS - non-malignant	Total	3	13,090	22.9	17.7	2.9	1.000	1,544	8,979,016	17.2			
	Male	1	6,657	15.0	11.3	1.0	1.000	499	4,505,616	11.1			
Brain and other CNS - non-malignant Breast	Female Total	2 10	6,433	31.1 76.4	24.7	1.9	1.000	1,045	4,473,400	23.4 77.9			
Breast	Male	10	13,090 6,657	76.4	58.9	13.2 0.1	0.466 1.000	6,998 65	8,979,016 4,505,616	1.4			
Breast	Female	10	6,433	155.4	125.2	12.4	0.617	6,933	4,473,400	155.0			
Breast - in situ	Total	3	13,090	22.9	18.2	2.5	0.915	1,366	8,979,016	15.2			
Breast - in situ	Male	-	6,657	-	-	0.0	1.000	4	4,505,616	0.1			
Breast - in situ	Female	3	6,433	46.6	38.7	2.4	0.840	1,362	4,473,400	30.4			
Cervix	Female	1	6,433	15.5	15.4	0.4	0.693	293	4,473,400	6.5			
Colorectal Colorectal	Total Male	8 4	13,090 6,657	61.1 60.1	45.4 43.3	7.1 4.0	0.834 1.000	3,624 1,973	8,979,016 4,505,616	40.4 43.8			
Colorectal	Female	4	6,433	62.2	43.3	4.0	0.753	1,973	4,473,400	43.8 36.9			
Corpus Uteri	Female	2	6,433	31.1	24.6	2.5	1.000	1,352	4.473.400	30.2			
Esophagus	Total	1	13,090	7.6	5.4	1.0	1.000	506	8,979,016	5.6			
Esophagus	Male	1	6,657	15.0	10.2	0.9	1.000	428	4,505,616	9.5			
Esophagus	Female	-	6,433	-	-	0.2	1.000	78	4,473,400	1.7			
Hodgkin Lymphoma	Total Male	-	13,090 6,657	-	-	0.3 0.2	1.000 1.000	222 129	8,979,016 4,505,616	2.5 2.9			
Hodgkin Lymphoma Hodgkin Lymphoma	Female	-	6,433	-	-	0.2	1.000	93	4,505,616	2.9			
Kidney and Renal Pelvis	Total	- 3	13,090	22.9	17.1	3.8	0.946	1,948	8,979,016	21.7			
Kidney and Renal Pelvis	Male	2	6,657	30.0	21.5	2.7	0.985	1,308	4,505,616	29.0			
Kidney and Renal Pelvis	Female	1	6,433	15.5	12.1	1.2	1.000	640	4,473,400	14.3			
Larynx	Total	-	13,090	-	-	0.5	1.000	220	8,979,016	2.5			
Larynx	Male	-	6,657	-	-	0.4	1.000	167	4,505,616	3.7			
Larynx	Female	-	6,433 13,090	- 38.2	- 28.0	0.1 3.4	1.000 0.521	53	4,473,400	1.2 19.2			
Leukemia Leukemia	Total Male	5 2	6,657	30.2	20.0	2.2	1.000	1,722 1,034	8,979,016 4,505,616	22.9			
Leukemia	Female	3	6,433	46.6	35.8	1.3	0.281	688	4,473,400	15.4			
Liver and Bile Duct	Total	1	13,090	7.6	5.5	1.7	0.981	842	8,979,016	9.4			
Liver and Bile Duct	Male	1	6,657	15.0	10.3	1.3	1.000	593	4,505,616	13.2			
Liver and Bile Duct	Female	-	6,433	-	-	0.5	1.000	249	4,473,400	5.6			
Lung and Bronchus	Total	17	13,090	129.9	88.5	10.6	0.083	4,942	8,979,016	55.0			
Lung and Bronchus Lung and Bronchus	Male Female	10 7	6,657 6,433	150.2 108.8	96.1 78.7	5.7 4.9	0.134 0.443	2,485 2,457	4,505,616 4,473,400	55.2 54.9			
Melanoma of the Skin	Total	9	13,090	68.8	52.4	6.0	0.445	3,135	8,979,016	34.9			
Melanoma of the Skin	Male	5	6,657	75.1	52.9	4.0	0.728	1,890	4,505,616	41.9			
Melanoma of the Skin	Female	4	6,433	62.2	51.7	2.2	0.343	1,245	4,473,400	27.8			
Myeloma	Total	5	13,090	38.2	26.8	1.5	0.037 >>	723	8,979,016	8.1			
Myeloma	Male	4	6,657	60.1	40.1	1.0	0.036 >>	443	4,505,616	9.8			
Myeloma Non-Hodgkin Lymphoma	Female Total	1	6,433 13,090	15.5 22.9	11.5 16.9	0.5 3.9	0.840 0.890	280 1,989	4,473,400 8,979,016	6.3 22.2			
Non-Hodgkin Lymphoma	Male	3 1	6,657	22.9 15.0	10.9	3.9 2.4	0.690	1,969	4,505,616	22.2			
Non-Hodgkin Lymphoma	Female	2	6,433	31.1	23.5	1.6	0.953	844	4,473,400	18.9			
Oral Cavity and Pharynx	Total	3	13,090	22.9	17.0	2.6	0.952	1,312	8,979,016	14.6			
Oral Cavity and Pharynx	Male	3	6,657	45.1	32.4	1.9	0.606	937	4,505,616	20.8			
Oral Cavity and Pharynx	Female		6,433	-	-	0.7	0.988	375	4,473,400	8.4			
Ovary	Female	2	6,433	31.1	24.9	1.0	0.522	551	4,473,400	12.3			
Pancreas Pancreas	Total Male	-	13,090 6,657	-	-	3.1 1.8	0.088 0.315	1,488 826	8,979,016 4.505.616	16.6 18.3			
Pancreas	Female	-	6,433	-	_	1.0	0.543	662	4,473,400	14.8			
Prostate	Male	7	6,657	105.2	70.5	14.9	0.038 <<	6,759	4,505,616	150.0			
Stomach	Total	1	13,090	7.6	5.5	1.0	1.000	473	8,979,016	5.3			
Stomach	Male	-	6,657	-	-	0.7	1.000	307	4,505,616	6.8			
Stomach	Female	1	6,433	15.5	11.8	0.3	0.539	166	4,473,400	3.7			
Testis	Male	-	6,657	-	-	0.3	1.000	274	4,505,616	6.1			
Thyroid	Total	1	13,090	7.6	7.2	1.8	0.900	1,184	8,979,016	13.2			
Thyroid	Male	1	6,657	15.0	12.3	0.7	0.976	371	4,505,616	8.2			
Thyroid Rediatric Age 0 to 10	Female	- 1	6,433	- 29.6	- 30.0	1.2	0.619	813	4,473,400 2,495,941	18.2			
Pediatric Age 0 to 19 Pediatric Age 0 to 19	Total Male	1	3,383 1,727	29.0	30.0	0.6 0.3	0.865 1.000	424 214	2,495,941 1,272,594	17.0 16.8			
Pediatric Age 0 to 19 Pediatric Age 0 to 19	iviale Female	- 1	1,727	- 60.4	- 61.9	0.3	0.485	214 210	1,272,594 1,223,347	10.8			
		e expressed as th					000	2.0	.,0,017				

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN BUTTE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Βι	Re	Remainder of Idaho					
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years		Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	188	13,192	1,425.1	977.8	168.0	0.135	80.347	9,198,202	873.5
All Causes of Death	Male	115	6,696	1,717.4	1,169.4	90.8	0.016 >>	42,671	4,621,001	923.4
All Causes of Death	Female	73	6,496	1,123.8	766.8	78.4	0.592	37,676	4,577,201	823.1
All Malignant Cancers	Total	36	13,192	272.9	186.7	31.9	0.507	15,197	9.198.202	165.2
All Malignant Cancers	Male	22	6,696	328.6	214.3	18.2	0.436	8,213	4,621,001	177.7
All Malignant Cancers	Female	14	6,496	215.5	154.3	13.8	1.000	6,984	4,577,201	152.6
Bladder	Total	3	13,192	22.7	14.7	1.1	0.187	482	9,198,202	5.2
Bladder	Male	3	6,696	44.8	28.4	0.9	0.110	372	4,621,001	8.1
Bladder	Female	-	6,496	-	-	0.2	1.000	110	4,577,201	2.4
Brain and Other Nervous System	Total	1	13,192	7.6	5.7	1.0	1.000	517	9,198,202	5.6
Brain and Other Nervous System	Male	1	6,696	14.9	10.9	0.6	0.873	288	4,621,001	6.2
Brain and Other Nervous System	Female	-	6,496	-	-	0.4	1.000	229	4,577,201	5.0
Breast	Total	3	13,192	22.7	16.1	2.3	0.792	1,121	9,198,202	12.2
Breast	Male	-	6,696	-	-	0.0	1.000	13	4,621,001	0.3
Breast	Female	3	6,496	46.2	33.8	2.1	0.727	1,108	4,577,201	24.2
Cervix	Female	-	6,496	-	-	0.1	1.000	88	4,577,201	1.9
Colorectal	Total	3	13,192	22.7	16.1	2.7	1.000	1,329	9,198,202	14.4
Colorectal	Male	2	6,696	29.9	20.7	1.5	0.903	730	4,621,001	15.8
Colorectal	Female	1	6,496	15.4	11.0	1.2	1.000	599	4,577,201	13.1
Corpus Uteri	Female Total	-	6,496	-	-	0.3	1.000 0.767	169 461	4,577,201	3.7 5.0
Esophagus	Male	-	13,192 6,696	-	-	0.9	0.767	-	9,198,202	5.0 8.5
Esophagus Esophagus	Female	-	6,496	-	-	0.9	1.000	391 70	4,621,001 4,577,201	0.5 1.5
Hodgkin Lymphoma	Total	-	13,192	-	-	0.1	1.000	25	9,198,202	0.3
Hodgkin Lymphoma	Male	-	6,696	-	-	0.0	1.000	14	4,621,001	0.3
Hodgkin Lymphoma	Female	_	6,496		_	0.0	1.000	11	4,577,201	0.2
Kidney	Total	- 1	13,192	7.6	5.1	0.0	1.000	385	9,198,202	4.2
Kidney	Male	1	6,696	14.9	9.7	0.5	0.842	245	4,621,001	5.3
Kidney	Female	- '	6,496	-	-	0.3	1.000	140	4,577,201	3.1
Larynx	Total	-	13,192	-	-	0.2	1.000	76	9,198,202	0.8
Larynx	Male	-	6,696	-	-	0.1	1.000	65	4,621,001	1.4
Larynx	Female	-	6,496	-	-	0.0	1.000	11	4,577,201	0.2
Leukemia	Total	2	13,192	15.2	10.2	1.4	0.822	663	9,198,202	7.2
Leukemia	Male	-	6,696	-	-	0.9	0.822	397	4,621,001	8.6
Leukemia	Female	2	6,496	30.8	21.8	0.5	0.201	266	4,577,201	5.8
Liver and Bile Duct	Total	3	13,192	22.7	15.8	1.3	0.286	632	9,198,202	6.9
Liver and Bile Duct	Male	3	6,696	44.8	29.9	0.9	0.130	420	4,621,001	9.1
Liver and Bile Duct	Female	-	6,496	-	-	0.4	1.000	212	4,577,201	4.6
Lung and Bronchus	Total	11	13,192	83.4	55.9	6.3	0.108	2,926	9,198,202	31.8
Lung and Bronchus	Male	7	6,696	104.5	66.5	3.5	0.130	1,534	4,621,001	33.2
Lung and Bronchus	Female	4	6,496	61.6	43.4	2.8	0.618	1,392	4,577,201	30.4
Melanoma of the Skin	Total	1	13,192	7.6	5.3	0.6	0.915	300	9,198,202	3.3
Melanoma of the Skin Melanoma of the Skin	Male Female	- 1	6,696 6,496	- 15.4	- 11.3	0.4 0.2	1.000 0.351	200 100	4,621,001 4,577,201	4.3 2.2
	Total	1	13,192	7.6	5.0	0.2	1.000	324		3.5
Myeloma Myeloma	Male	1	6,696	7.0 14.9	5.0 9.4	0.7	0.698	324 187	9,198,202 4,621,001	3.5 4.0
Myeloma	Female	- '	6,496	-	9.4	0.4	1.000	137	4,577,201	4.0
Non-Hodgkin Lymphoma	Total	- 2	13,192	- 15.2	10.2	1.2	0.682	566	9,198,202	6.2
Non-Hodgkin Lymphoma	Male	1	6,696	14.9	9.7	0.7	0.995	309	4,621,001	6.7
Non-Hodgkin Lymphoma	Female	1	6,496	15.4	10.4	0.5	0.832	257	4,577,201	5.6
Oral Cavity and Pharynx	Total	-	13,192	-	-	0.6	1.000	275	9,198,202	3.0
Oral Cavity and Pharynx	Male	-	6,696	-	-	0.0	1.000	192	4,621,001	4.2
Oral Cavity and Pharynx	Female	-	6,496	-	-	0.2	1.000	83	4,577,201	1.8
Ovary	Female	1	6,496	15.4	11.1	0.7	1.000	360	4,577,201	7.9
Pancreas	Total	-	13,192	-	-	2.5	0.164	1,190	9,198,202	12.9
Pancreas	Male	-	6,696	-	-	1.5	0.466	650	4,621,001	14.1
Pancreas	Female	-	6,496	-	-	1.1	0.685	540	4,577,201	11.8
Prostate	Male	-	6,696	-	-	2.3	0.198	997	4,621,001	21.6
Stomach	Total	-	13,192	-	-	0.4	1.000	194	9,198,202	2.1
Stomach	Male	-	6,696	-	-	0.3	1.000	119	4,621,001	2.6
Stomach	Female	-	6,496	-	-	0.1	1.000	75	4,577,201	1.6

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Butte County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	10.8%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	
Current Tobacco User (2020–2022) <u>Other Cancer-Related</u>	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	19.9%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	31.9% 76.2% 17.3% 40.2%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





CAMAS COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 28 cases of invasive cancer were diagnosed among Camas County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in CamasCounty and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Camas County	State of Idaho
All Sites/Types	28	47,333
Female Breast	1	6,943
Prostate	7	6,766
Lung & Bronchus	5	4,959
Colorectal	2	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Camas County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Camas County. The table also shows the number of observed cases, person-

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 13 Camas County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Camas County and the State of Idaho, 2018–2022

Mortality 2018–2022	Camas County	State of Idaho
All Deaths	51	80,538
Cancer Deaths	13	15,233
% of All Deaths	25.5%	18.9%
Lung & Bronchus	3	2,937
Colorectal	1	1,332
Pancreas	0	1,190
Female Breast	0	1,111
Prostate	3	997

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Camas County was 505.4 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (526.4) gives an estimate of the relative burden of disease in Camas County.

The age- and sex-adjusted incidence rate of invasive cancer in Camas County, all sites combined, was 383.1 cases per 100,000 persons per year during 2017–2021. There were fewer cases of cancer in Camas County (28) than expected (38.5) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Camas County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Camas County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Camas County, all sites combined, was 177.6 deaths per 100,000 persons per year during 2018–2022, compared with 165.3 for the remainder of the state. There were more cancer deaths in Camas County (13) than expected (12.1) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN CAMAS COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Ca	mas County	/			Rem	nainder of Ida	aho
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)		P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	28	5,540	505.4	383.1	38.5	0.097	47,305	8,986,566	526.4
All Sites Combined	Male	16	2,864	558.7	379.3	23.6	0.130	25,254	4,509,409	560.0
All Sites Combined	Female	12	2,676	448.4	376.6	15.7	0.428	22,051	4,477,157	492.5
Bladder	Total	1	5,540	18.1	13.4	1.8	0.897	2,219	8,986,566	24.7
Bladder	Male	1	2,864	34.9	23.2	1.7	0.991	1,772	4,509,409	39.3
Bladder	Female	-	2,676	-	-	0.3	1.000	447	4,477,157	10.0
Brain - malignant	Total	-	5,540	-	-	0.5	1.000	657	8,986,566	7.3
Brain - malignant	Male	-	2,864	-	-	0.3	1.000	382	4,509,409	8.5
Brain - malignant	Female	-	2,676	-	-	0.2	1.000	275	4,477,157	6.1
Brain and other CNS - non-malignant	Total	2	5,540	36.1	28.7	1.2	0.673	1,545	8,986,566	17.2
- 3	Male	1	2,864	34.9	26.2	0.4	0.688	499	4,509,409	11.1
Brain and other CNS - non-malignant	Female	1	2,676	37.4	32.0 13.8	0.7	1.000 0.046 <<	1,046	4,477,157	23.4 78.0
Breast Breast	Total Male	1	5,540 2,864	18.1	13.0	5.7 0.1	1.000	7,007 65	8,986,566 4,509,409	1.4
Breast	Female	- 1	2,604	- 37.4	30.9	5.0	0.080	6,942	4,309,409	155.1
Breast - in situ	Total		5,540		50.5	1.1	0.654	1,369	8,986,566	15.2
Breast - in situ	Male	-	2,864	-	-	0.0	1.000	1,000	4,509,409	0.1
Breast - in situ	Female	-	2,676	-	-	1.0	0.737	1,365	4,477,157	30.5
Cervix	Female	-	2,676	-	-	0.2	1.000	294	4,477,157	6.6
Colorectal	Total	2	5,540	36.1	27.9	2.9	0.895	3,630	8,986,566	40.4
Colorectal	Male	2	2,864	69.8	49.6	1.8	1.000	1,975	4,509,409	43.8
Colorectal	Female	-	2,676	-	-	1.2	0.621	1,655	4,477,157	37.0
Corpus Uteri	Female	-	2,676	-	-	1.0	0.739	1,354	4,477,157	30.2
Esophagus	Total	-	5,540	-	-	0.4	1.000	507	8,986,566	5.6
Esophagus	Male	-	2,864	-	-	0.4	1.000	429	4,509,409	9.5
Esophagus	Female	-	2,676	-	-	0.1	1.000	78	4,477,157	1.7
Hodgkin Lymphoma	Total	-	5,540	-	-	0.1	1.000	222	8,986,566	2.5
Hodgkin Lymphoma	Male	-	2,864	-	-	0.1	1.000	129	4,509,409	2.9
Hodgkin Lymphoma	Female	-	2,676	-	- 13.8	0.1	1.000	93	4,477,157	2.1 21.7
Kidney and Renal Pelvis Kidney and Renal Pelvis	Total Male	-	5,540 2,864	18.1	13.0	1.6 1.2	1.000 0.607	1,950 1,310	8,986,566 4,509,409	21.7
Kidney and Renal Pelvis	Female	- 1	2,604	- 37.4	- 31.4	0.5	0.007	640	4,309,409	14.3
Larynx	Total	'	5,540	- 57.4		0.3	1.000	220	8,986,566	2.4
Larynx	Male	-	2,864	-	_	0.2	1.000	167	4,509,409	3.7
Larynx	Female	-	2,676	-	-	0.0	1.000	53	4,477,157	1.2
Leukemia	Total	1	5,540	18.1	14.1	1.4	1.000	1,726	8,986,566	19.2
Leukemia	Male	-	2,864	-	-	0.9	0.795	1,036	4,509,409	23.0
Leukemia	Female	1	2,676	37.4	32.0	0.5	0.764	690	4,477,157	15.4
Liver and Bile Duct	Total	2	5,540	36.1	26.2	0.7	0.323	841	8,986,566	9.4
Liver and Bile Duct	Male	1	2,864	34.9	22.7	0.6	0.879	593	4,509,409	13.2
Liver and Bile Duct	Female	1	2,676	37.4	30.5	0.2	0.332	248	4,477,157	5.5
Lung and Bronchus	Total	5	5,540	90.3	66.0	4.2	0.810	4,954	8,986,566	55.1
Lung and Bronchus	Male	1	2,864	34.9	22.7	2.4	0.600	2,494	4,509,409	55.3
Lung and Bronchus	Female	4	2,676	149.5	123.9	1.8	0.209	2,460	4,477,157	54.9
Melanoma of the Skin	Total	1	5,540	18.1	14.1	2.5	0.582	3,143	8,986,566	35.0
Melanoma of the Skin	Male	1	2,864	34.9	24.5	1.7	0.979	1,894	4,509,409	42.0
Melanoma of the Skin	Female Total	-	2,676 5,540	-	-	0.9 0.6	0.839	1,249 728	4,477,157 8,986,566	27.9 8.1
Myeloma Myeloma	Male	-	5,540 2,864	-	-	0.6	1.000	720 447	6,960,566 4,509,409	0.1 9.9
Myeloma Myeloma	Female	-	2,604	-	-	0.4	1.000	281	4,309,409	9.9 6.3
Non-Hodgkin Lymphoma	Total	- 1	5,540	- 18.1	13.8	1.6	1.000	1,991	8,986,566	22.2
Non-Hodgkin Lymphoma	Male	- '	2,864	-	-	1.0	0.701	1,146	4,509,409	25.4
Non-Hodgkin Lymphoma	Female	1	2,676	37.4	31.5	0.6	0.901	845	4,477,157	18.9
Oral Cavity and Pharynx	Total	1	5,540	18.1	13.4	1.1	1.000	1,314	8,986,566	14.6
Oral Cavity and Pharynx	Male	1	2,864	34.9	23.7	0.9	1.000	939	4,509,409	20.8
Oral Cavity and Pharynx	Female	-	2,676	-	-	0.3	1.000	375	4,477,157	8.4
Ovary	Female	-	2,676	-	-	0.4	1.000	553	4,477,157	12.4
Pancreas	Total	-	5,540	-	-	1.2	0.583	1,488	8,986,566	16.6
Pancreas	Male	-	2,864	-	-	0.8	0.920	826	4,509,409	18.3
Pancreas	Female		2,676	-	-	0.5	1.000	662	4,477,157	14.8
Prostate	Male	/	2,864	244.4	156.5	6.7	1.000	6,759	4,509,409	149.9
Stomach	Total Malo	-	5,540	-	-	0.4	1.000	474	8,986,566	5.3
Stomach	Male Female	-	2,864	-	-	0.3	1.000 1.000	307 167	4,509,409	6.8 3 7
Stomach	Female Male	-	2,676	-	-	0.1	1.000	167	4,477,157	3.7
Testis		- 2	2,864	-	- 32.4	0.1		274	4,509,409	6.1
Thyroid	Total	2	5,540	36.1	32.4	0.8	0.391	1,183	8,986,566	13.2
Thyroid	Male	-	2,864	-	-	0.3	1.000	372	4,509,409	8.2
Thyroid	Female	2	2,676	74.7	72.1	0.5	0.182	811	4,477,157	18.1
Pediatric Age 0 to 19	Total	-	1,349	-	-	0.2	1.000	425	2,497,975	17.0
Pediatric Age 0 to 19	Male Female	-	640 709	-	-	0.1 0.1	1.000 1.000	214 211	1,273,681 1,224,294	16.8 17.2
Pediatric Age 0 to 19		-		-	-					

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN CAMAS COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Ca	mas County	,			Re	mainder of Idah	0
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years		Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	51	5,601	910.6	732.9	60.8	0.227	80.484	9,205,793	874.3
All Causes of Death	Male	34	2,911	1,168.0	878.3	35.8	0.851	42,752	4,624,786	924.4
All Causes of Death	Female	17	2,690	632.0	536.5	26.1	0.079	37,732	4,581,007	823.7
All Malignant Cancers	Total	13	5,601	232.1	177.6	12.1	0.871	15,220	9.205.793	165.3
All Malignant Cancers	Male	8	2,911	274.8	192.2	7.4	0.922	8,227	4,624,786	177.9
All Malignant Cancers	Female	5	2,690	185.9	155.4	4.9	1.000	6,993	4,581,007	152.7
Bladder	Total	-	5,601	-	-	0.4	1.000	485	9,205,793	5.3
Bladder	Male	-	2,911	-	-	0.3	1.000	375	4,624,786	8.1
Bladder	Female	-	2,690	-	-	0.1	1.000	110	4,581,007	2.4
Brain and Other Nervous System	Total	-	5,601	-	-	0.4	1.000	518	9,205,793	5.6
Brain and Other Nervous System	Male	-	2,911	-	-	0.3	1.000	289	4,624,786	6.2
Brain and Other Nervous System	Female	-	2,690	-	-	0.2	1.000	229	4,581,007	5.0
Breast	Total	-	5,601	-	-	0.9	0.828	1,124	9,205,793	12.2
Breast	Male	-	2,911	-	-	0.0	1.000	13	4,624,786	0.3
Breast	Female	-	2,690	-	-	0.8	0.912	1,111	4,581,007	24.3
Cervix	Female	-	2,690	-	-	0.1	1.000	88	4,581,007	1.9
Colorectal	Total	1	5,601	17.9	13.9	1.0	1.000	1,331	9,205,793	14.5
Colorectal	Male	1	2,911	34.4	24.5	0.6	0.952	731	4,624,786	15.8
Colorectal	Female	-	2,690	-	-	0.4	1.000	600	4,581,007	13.1
Corpus Uteri	Female	-	2,690	-	-	0.1	1.000	169	4,581,007	3.7
Esophagus	Total	-	5,601	-	-	0.4	1.000	461	9,205,793	5.0
Esophagus	Male	-	2,911	-	-	0.4	1.000	391	4,624,786	8.5
Esophagus	Female	-	2,690	-	-	0.0	1.000	70	4,581,007	1.5
Hodgkin Lymphoma	Total	-	5,601 2,911	-	-	0.0 0.0	1.000 1.000	25	9,205,793	0.3 0.3
Hodgkin Lymphoma Hodgkin Lymphoma	Male Female	-	2,911	-	-	0.0	1.000	14 11	4,624,786 4,581,007	0.3
Kidney	Total	-	5,601	-		0.0	1.000	386	9,205,793	4.2
Kidney	Male	-	2,911	-	-	0.3	1.000	246	4,624,786	5.3
Kidney	Female	_	2,690	-	-	0.2	1.000	140	4,581,007	3.1
Larynx	Total	1	5,601	17.9	13.7	0.1	0.115	75	9,205,793	0.8
Larynx	Male	1	2,911	34.4	24.7	0.1	0.109	64	4,624,786	1.4
Larynx	Female	- '	2,690	-	-	0.0	1.000	11	4,581,007	0.2
Leukemia	Total	1	5,601	17.9	14.0	0.5	0.804	664	9,205,793	7.2
Leukemia	Male	-	2,911	-	-	0.3	1.000	397	4,624,786	8.6
Leukemia	Female	1	2,690	37.2	31.8	0.2	0.335	267	4,581,007	5.8
Liver and Bile Duct	Total	-	5,601	-	-	0.5	1.000	635	9,205,793	6.9
Liver and Bile Duct	Male	-	2,911	-	-	0.4	1.000	423	4,624,786	9.1
Liver and Bile Duct	Female	-	2,690	-	-	0.2	1.000	212	4,581,007	4.6
Lung and Bronchus	Total	3	5,601	53.6	40.1	2.4	0.851	2,934	9,205,793	31.9
Lung and Bronchus	Male	1	2,911	34.4	23.1	1.4	1.000	1,540	4,624,786	33.3
Lung and Bronchus	Female	2	2,690	74.3	62.3	1.0	0.512	1,394	4,581,007	30.4
Melanoma of the Skin	Total	-	5,601	-	-	0.2	1.000	301	9,205,793	3.3
Melanoma of the Skin	Male	-	2,911	-	-	0.2	1.000	200	4,624,786	4.3
Melanoma of the Skin	Female	-	2,690	-	-	0.1	1.000	101	4,581,007	2.2
Myeloma Myeloma	Total Male	-	5,601 2,911	-	-	0.3 0.2	1.000 1.000	325 188	9,205,793 4,624,786	3.5 4.1
Myeloma	Female	-	2,911	-	-	0.2	1.000	100	4,624,786 4,581,007	4.1
Non-Hodgkin Lymphoma	Total	- 1	5,601	- 17.9	- 14.1	0.1	0.709	567	9,205,793	6.2
Non-Hodgkin Lymphoma	Male	_ '	2,911	-	- 14.1	0.4	1.000	310	4,624,786	6.7
Non-Hodgkin Lymphoma	Female	- 1	2,690	37.2	31.8	0.3	0.324	257	4,581,007	5.6
Oral Cavity and Pharynx	Total	-	5,601	-	-	0.2	1.000	275	9,205,793	3.0
Oral Cavity and Pharynx	Male	_	2,911	_	_	0.2	1.000	192	4,624,786	4.2
Oral Cavity and Pharynx	Female	-	2,690	-	-	0.1	1.000	83	4,581,007	1.8
Ovary	Female	1	2,690	37.2	30.5	0.3	0.454	360	4,581,007	7.9
Pancreas	Total	-	5,601	-	-	1.0	0.756	1,190	9,205,793	12.9
Pancreas	Male	-	2,911	-	-	0.6	1.000	650	4,624,786	14.1
Pancreas	Female	-	2,690	-	-	0.4	1.000	540	4,581,007	11.8
Prostate	Male	3	2,911	103.1	75.1	0.9	0.112	994	4,624,786	21.5
Stomach	Total	-	5,601	-	-	0.1	1.000	194	9,205,793	2.1
Stomach	Male	-	2,911	-	-	0.1	1.000	119	4,624,786	2.6
Stomach	Female	-	2,690	-	-	0.1	1.000	75	4,581,007	1.6

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Camas County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	
Current Tobacco User (2020–2022) <u>Other Cancer-Related</u>	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	·
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





CANYON COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 5,568 cases of invasive cancer were diagnosed among Canyon County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in CanyonCounty and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Canyon County	State of Idaho
All Sites/Types	5,568	47,333
Female Breast	867	6,943
Prostate	770	6,766
Lung & Bronchus	602	4,959
Colorectal	420	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Canyon County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Canyon County. The table also shows the number of observed cases, person-

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 1,802 Canyon County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Canyon County and the State of Idaho, 2018–2022

Mortality 2018–2022	Canyon County	State of Idaho
All Deaths	9,406	80,538
Cancer Deaths	1,802	15,233
% of All Deaths	19.2%	18.9%
Lung & Bronchus	358	2,937
Colorectal	167	1,332
Pancreas	134	1,190
Female Breast	145	1,111
Prostate	96	997

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Canyon County was 483.5 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (532.7) gives an estimate of the relative burden of disease in Canyon County.

The age- and sex-adjusted incidence rate of invasive cancer in Canyon County, all sites combined, was 549.2 cases per 100,000 persons per year during 2017–2021. There were statistically significantly more cases of cancer in Canyon County (5,568) than expected (5,400.3) based upon rates in the remainder of the state (p=.023).

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Canyon County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Canyon County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Canyon County, all sites combined, was 177.6 deaths per 100,000 persons per year during 2018–2022, compared with 167.3 for the remainder of the state. There were statistically significantly more cancer deaths in Canyon County (1,802) than expected (1,698.2) based upon rates in the remainder of the state (p=.013).

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN CANYON COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

All Sites Combined Male 2:015 572:328 590.3 690.5 2:805.5 0.040 92:355 939.8466 657.473 Bidder Fernale 2:551 753.24 477.9 511.5 2:560.5 0.049 783.445 2:501 390.550 497.6 497.6 Bidder Fernale 2:53 573.324 9.1 0.106 507.7 554 390.450 100.1 Brain - maignant Total 73 1:51.652 7.53 6.8 47.8 0.874 2:30 390.456 6.6 100.7 390.456 6.6 100.7 390.456 6.6 100.7 390.456 6.6 100.7 390.456 6.6 100.7 390.456 6.6 100.7 390.456 6.6 100.7 390.456 6.6 100.7 </th <th></th> <th></th> <th></th> <th>Car</th> <th>nyon Count</th> <th>y</th> <th></th> <th></th> <th>Ren</th> <th>nainder of Ida</th> <th>aho</th>				Car	nyon Count	y			Ren	nainder of Ida	aho	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude	
All Siles Combined Male 2,915 577,328 690.3 580.5 0.040 2,355 9,39,406 667.4 Bidder Formal 2,21 573,324 457.9 571.8 2,800.5 0.0153 11,91.0 3,900,500 497.6 3900,500 199.1 3900,500 199.1 3900,500 199.1 3900,500 199.1 3900,500 199.1 3900,500 199.1 3900,500 199.1 3900,500 199.1 3900,450 199.1 3900,450 199.1 3900,450 199.1 3900,450 199.1 3900,450 199.1 3900,450 199.1 3900,450 199.1 3900,450 199.1 199.1 199.1 199.1 3900,450 199.1	Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)	
All Siles Combined Formale 2.663 779.324 47.9 511.5 2.680.8 0.159 114,110 3.900.050 947.3 Bidder Franz 1151.55 2.280 22.63 22.64 10.56 1.90 1.93.9 3.909.050 3.909.050 3.909.050 3.909.050 3.909.050 3.909.050 6.93 3.93 9.93.945 6.6 3.93 3.939.945 6.6 3.93 3.939.945 6.6 3.93 3.93.945 6.6 3.93 3.93.945 6.6 3.93 3.93.945 6.6 3.93 6.224 > 2.45 3.93.945 6.6 3.93.945 6.6 3.93.945 6.6 3.93.945 6.6 3.93.945 6.6 3.93.945 6.6 3.93.945 6.6 3.93.945 6.6 3.93.945 6.6 3.93.945 6.6 3.93.945 6.1 8.93.945 6.1 8.93.945 6.1 1.93.93.945 6.1 8.93.945 6.1 1.93.93.945 6.1 7.73.228 7.7 7.80.0 6.36.93.945	All Sites Combined	Total	5,568	1,151,652	483.5	549.2	5,400.3	0.023 >>	41,765	7,840,454	532.7	
Binder total 224 1.151.652 22.9 26.8 245.9 0.264 1.956 7.840.459 245 0.264 1.956 7.840.459 245 0.864 4.9 245 0.775 1.562 3.980.456 3.86 0.475 1.956 7.950.450 3.980.456 3.86 0.475 1.956 7.950.450 3.980.456 3	All Sites Combined				509.3	589.5	2,805.5	0.040 >>	22,355	3,939,945	567.4	
Blader Male 211 572,328 36.9 43.7 191.6 0.775 1,562 3,933,445 366 367 349 300,500 10.1 190.6 50.7 0.774 394 390,500 10.1 190.6 50.7 0.774 394 390,500 10.1 190.6 50.7 0.774 394 390,500 10.1 190.6 50.7 0.774 394 390,500 10.1 190.6 50.7 0.774 394 394 390,500 10.1 190.6 50.7 0.774 394 394 390,500 10.1 190.6 50.7 0.774 394 394 390,500 10.1 190.6 50.7 190.7	All Sites Combined			, -							497.6	
Bladeer Fanis Algebra (1973) 113 (15) (55) 113 (15) (15) (15) (15) (15) (15) (15) (15)												
Brain - mailgnant Male 43 57.3 87.3 44.7 0.875 339 399.945 86.8 Brain and Other CNS - nor-mailgnant Tata 220 1.157.852 75.6 33.5 0.624 3.90.0450 63.3 Brain and Other CNS - nor-mailgnant Fenale 67.3 220 7.157.852 77.7 20 0.038 > 0.038 > 0.038 > 0.038 > 0.038 > 0.038 > 0.038 > 0.038 > 0.038 > 0.038 > 0.038 > 0.0048 1.5 5 0.0328 0.9 1.0 7.5 0.445 6.036 3.339.0450 1.5 5 1.007 7.5 0.445 6.036 3.445 1.0 7.5 0.445 6.036 3.445 1.5 0.877 1.41 2.448 3.900.690 6.0 1.5 0.000 7.40 3.445 4.00 0.000 7.40 4.44 4.50 0.000 6.00					-					, ,	-	
Brain and other CNS - non-malgnant Total 220 + 157 (582 + 14 + 162 + 172 + 175 3 + 0.01 >> 1.212 + 1.212 + 1.2												
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Brain - malignant											
	Brain and other CNS - non-malignant										16.9	
Breast Total B72 1151.652 75.7 84.7 805.5 0.022 $>>$ 6.138 7.480.454 78.3 Breast n altu Formale 607 1.322 2.22 0.042 0.042 0.044 0.072 1.300.600 155.6 Breast n altu Formale 607 1.325 1.44 1.00 1.00 7.22 7.930.45 1.00 1.22 7.930.45 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.12 2.00 0.00 1.12 2.00 0.00 1.12 2.00 0.	Brain and other CNS - non-malignant		75							- , ,	10.8	
Breast Male 6 572,328 0.9 1.0 7.5 0.485 6.078 3.309,945 15.5 Breast - In situ Total 166 175,182 142 160.1 152.5 6.078 3.309,945 15.3 Breast - In situ Permale 165 572,328 -7 3.5 1.6 1777 1.728 3.930,505 16.0 1.233,505 16.0 1.233,505 1.233,505,50 1.233,505,50 1.233,505,50 1.233,505,50 1.233,505,50 1.233,505,50 1.633,505,50 1.233,505,50												
Breast Female 867 579.324 149.7 166.1 813.3 0.064 6.076 3.900,509 155.8 Breast - in situ Male - 572.328 - - 0.5 1000 4.8 3.339.455 0.1 Disati - in situ Fermale 06 573.242 - - 0.5 1000 4.8 3.939.45 0.1 Disati - in situ Fermale 06 573.242 3.6 12.2 50.681 1.748 3.339.45 4.41 Colorectal Male 195.732 30.0 37.1 195.0 0.627 1.648 3.390.509 37.5 Colorectal Fermale 191 579.324 3.0 37.1 195.0 0.57 0.51 1.648 3.390.509 5.7 7.7 1.000 450 7.340.454 5.7 5.7 7.2 1.000 450 7.340.454 2.8 5.8 3.0 1.000 4.3 3.900,509 1.0 1.000 5.												
Breast - in situ Total 166 1,151,652 14.4 16.0 159.5 0.627 1,203 7,840,454 16.3 Breast - in situ Fernale 166 577,324 2.8 7 3.5 162.0 0.772 1,199 3,800,309 6.1 Colorectal Fernale 2.8 7 3.5 162.0 0.772 1,199 3,800,309 6.1 Colorectal Fernale 2.9 1.97,324 4.0 4.5,7 222.5 0.081 1.74 3,309,345 4.4 Colorectal Fernale 181 5.79,324 3.0 3.7 193.0 0.922 1.464 3,309,345 9.4 Colorectal Fernale 181 5.79,324 3.10 15.7 1.000 4.0 3.800,509 30.1 5.8 5.0 5.7 2 1.000 4.0 3.89,945 9.7 5.7 2.0 1.000 6.0 3.89,945 9.7 5.0 5.7 2.0 1.000 6.0 3.89,945 9.7 5.000,90 3.0 1.0 7.800,344 2.16 <td></td>												
Breast - in situ Male - 572,328 - - 0.5 10.00 4 3,939,945 0.01 Cervix Fernale 46 579,324 27.7 31.5 612.0 0.771 1.199 3,900,509 63.7 Cervix Fernale 46 579,324 27.7 31.5 62.0 0.771 1.199 3,900,509 64.4 41.0 Colorectal Male 20 1,716 32.12 7.800,809 64.4 41.0 65.7 22.25 0.002 1,743 3,939,945 96.7 57.5 1.000 450 7,840,454 57.7 57.0 0.001 7.800,454 57.7 57.0 0.001 810 579,324 1.6 1.8 8.4 1.000 69 3,900,509 1.8 1.000 1.000 80.3 3,939,945 2.9 1.000 1.000 1.000 80.4 3,94.2 2.4 1.000 1.000 1.000 1.000 1.0000 90.900 1.000 <td></td>												
Breast Female 166 579 324 7.9 8.2 35.7 0.117 1.199 3.900.509 300.709 Colorectal Total 420 1.151.652 36.5 41.3 416.5 0.876 3.212 7.840.454 41.0 Colorectal Male 229 57.228 40.0 40.7 122.5 0.681 1.748 3.989.945 44.4 Colorectal Female 181 577.324 33.0 37.1 193.0 0.922 1.464 3.900.509 36.7 Ecophagus Male 97 1.722.22 1.6 1.8 8.9 1.000 98.3 3.900.509 30.0 3.900.509 1.8 Hodgkin Lymphoma Total 22 1.151.652 2.8 2.0 1.0380 43.29.945 2.1 1.151.652 2.8 1.0 0.00 5.4 3.900.509 2.0 1.170 3.800.454 2.4 1.0 1.174 3.800.509 2.0 1.151.652 2.8 2.0<					-	-						
Cervix Female 46 579.324 7.9 8.2 357. 0111 248 3.900.509 6.4 Colorectal Male 220 571.232 40.0 45.7 222.6 0.681 1.7.48 3.939.945 44.0 Colorectal Female 191 577.9.224 33.0 37.7 193.0 0.922 1.464 3.900.509 3.01 Esophagus Total 57 155.7 0.001 450 7.484.954 5.7 Esophagus Male 6 573.32 8.6 9 5.7 7.000 450 7.484.954 5.7 Hodgkin Lymphoma Male 16 572.328 2.8 2.9 7.0 0.380.950 9.0 7.0 3.900.509 2.0 Kidney and Renal Pelvis Total 220 1.157.522 2.2.6 2.5.5 220.1 0.010 > 1.847 3.939.945 2.9 1.0 1.0 1.0 1.0 1.0 1.0 1.0	Breast - in situ				28.7	31.5						
Colorectal Total 420 1,161,652 36.5 41.3 41.65 0.876 3,212 7,840,454 44.4 Colorectal Fermale 191 572,328 40.0 45.7 222.5 0.081 1,748 3,939,945 44.4 Colorectal Fermale 191 579,324 33.0 37.1 193.0 0.922 1,464 3,900,059 30.1 Esophagus Total 57 1,573,224 43.0 45.7 1,572 0.050 1,450 7,804,454 5.7 5,77 0,700 450 7,804,454 2.9 7,70 0,300,450 1.8 1,804,454 2.9 1,000 3,000,509 2.0 1,001 5,017 1,303,944 2.9 1,001 9,018 1,804,454 2.9 1,000 3,000,509 2.0 1,017 1,141 3,939,945 2.9 2,70 0,300 1,80 1,840,454 2.5 1,804 1,840,454 2.5 1,840,454 1,840,454 2.1 1,840,4	Cervix							0.111			6.4	
Colorectal Female 191 579.324 33.0 37.1 193.0 0.922 1.464 3.900.509 37.5 Esophagus Total 57 157.7 0.051 1.73 3.900.509 30.1 Esophagus Female 9 579.324 1.6 1.8 8.9 47.3 0.900 381.3.939.945 9.7 Esophagus Female 9 579.324 1.6 1.8 8.9 1.000 69 3.900.509 1.8 Hodgkin Lymphoma Male 16 572.328 2.8 2.8 1.13 0.229 7.7 3.900.509 2.0 Kidney and Renal Pelvis Fotal 2.83 1.151.552 2.5 2.20 0.77 1.010 7.847.43 3.900.509 1.5 Larynx Female 6 579.324 2.8 2.8 1.81 0.100 > 1.447 3.900.509 1.5 Larynx Female 5 579.324 0.9 1.0 6.3<	Colorectal	Total		1,151,652	36.5	41.3	416.5		3,212	7,840,454	41.0	
Corpus Uleri Female 181 579,224 31.2 35.7 10.57 10.71 1,713 3900,509 30.1 Esophagus Male 48 572,328 8.4 9.8 47.3 0.960 381 3,939,945 9.7 Esophagus Female 9 579,324 1.6 1.8 8.9 1.000 683 3,900,509 1.8 Hodgkin Lymphoma Male 16 572,322 2.8 2.9 2.70 0.380 190 7,840,454 2.4 Hodgkin Lymphoma Female 16 572,324 2.8 2.0 1.5 0.006 > 544 3.900,509 2.0 Kidney and Renal Pelvis Male 163 572,324 2.8 2.5 2.20 1.906 3.44 3.900,509 3.2 1.417 3.939,445 2.9 2.0 1.417 3.939,445 3.900,509 3.2 1.141 3.939,445 1.2 1.7 7.23 0.0650 1.217 1.417	Colorectal										44.4	
EsophagusTotal571,151,6524.95.75.75.72.10.004507,840,4545.7EsophagusFernale9572,3241.61.88.49.10.006813.999,9459.7Bodgkin LymphomaMale16672,3282.82.92.700.3801907,840,4542.4Hodgkin LymphomaFernale16672,3282.82.82.100.0107.87.73.900,5092.0Kitney and Kenal PelvisTotal2601.151,6522.82.82.11.00.00>1.6817.840,4542.4LarynxMale10al2601.151,6522.62.52.010.010>1.6817.840,4542.7LarynxFernale77.23,340.91.06.50.8277.840,4542.72.7LarynxFernale75.73,3240.91.01.000.6531.5227.840,4541.2LeukerniaTotal1091.151,6521.77.07.99.0260.309,05091.2LeukerniaMale11572,3282.042.321.174.0009.193.939,9453.2.3Liver and Bile DuctTotal1091.151,6529.510.99.380.6531.329,9453.2.3Liver and Bile DuctMale797.73,2282.245.92.860.3442.163.	Colorectal											
Esophagus Male 48 572.328 8.4 9.8 47.3 0.960 381 3.939.945 9.7 Hodgkin Lymphoma Total 32 1,151.852 2.8 2.9 2.70 0.380 190 7,840.454 2.4 Hodgkin Lymphoma Female 16 579.324 2.8 2.9 2.70 0.380 190 7,840.454 2.4 Kidney and Renal Pelvis Male 163 572.328 2.26 2.55 220.1 0.010 >> 1.691 7.840.454 21.6 Kidney and Renal Pelvis Male 163 572.328 2.8 3.7 4.8 1.000 >> 44 3.009.509 1.29 Larynx Male 21 572.328 3.7 4.3 18.0 0.654 1.48 3.390.456 1.7 1.22 1.99 1.0 6.3 0.807 1.48 3.390.504 1.22 1.97 1.99 0.392 603 3.900.505 1.6 1.20 1.20			-							- , ,		
EsophagusFemale9579,3241.61.88.91.0006693.900,5091.8Hodgkin LymphomaMale16572,3282.83.01.550.9761.133.339,9452.9Hodgkin LymphomaFemale16572,3282.82.83.00.1550.9761.133.339,9452.9Kichey and Renal PelvisTotal2601.515,65222.62.52.5146.10.1791.1473.399,94522.1Kichey and Renal PelvisFemale97579,32416.718.77.2.30.006 >>5.443.900,5091.2.2LarynxTotal2.61.515,6522.32.62.4.50.8221.944,4544.32.5.5LarynxFemale5579,3240.91.06.30.8074.83.900,5091.2LeukemiaTotal2051.515,85217.820.11.98.30.8531.5227.840,4541.9.4LeukemiaHenale17572,3242.0.42.31.1741.0009.103.39,9452.3.3LeukemiaFemale86579,3241.5217.79.00.3926033.300,5001.5.5LeukemiaFemale1.51,85217.82.01.000.840.1337.947.840,4541.9.4LeukemiaFemale1.57,8221.521.709.98.80.1337.947.840,4541.9.												
Hodgkin Lymphoma Total 32 1,15,1652 2.8 2.9 27.0 0.3800 190 7,480,454 2.4 2.8 2.8 3.0 15.5 0.976 113 339,945 2.9 100 100 7 3,309,845 2.9 100 113 339,945 2.9 100 113 339,945 2.9 100 100 175 100 100 1691 7,840,454 2.4 100 179 1,417 3,339,945 22.1 100 114 3,339,945 22.1 130 22.3 166.1 171 173,339,945 23.1 130 22.2 147 7,840,454 25.5 130 130 130 130 12.3 130 130 130 130 130 130 130 130 130 130 130 130 130 130 130 131 130 131 130 131 130 131 130 131 130 130 131 <												
Hodgkin Lýmphoma Female 16 573,328 2.8 3.0 15.5 0.976 113 3,339,45 2.9 (2.0) Kidney and Renal Pelvis Total 260 1,151,652 22.6 25.5 220.1 0.010 >> 1.691 7,840,454 216 (2.0) Kidney and Renal Pelvis Male 163 572,328 28.5 32.5 146.1 0.179 >> 1.691 7,840,454 216 (2.0) Kidney and Renal Pelvis Female 97 579,324 16.7 18.7 72.3 0.006 >> 544 3,300,509 13.9 Larynx Total 226 1,151,652 2.3 2.6 24.5 0.822 1194 7,840,454 21.6 (2.0) Larynx Male 21 572,328 3.7 4.3 18.0 0.541 146 3,339,945 32.5 (2.0) Larynx Female 5 579,324 0.9 1.0 6.3 0.807 >> 544 3,300,509 13.9 Larynx Female 5 579,324 0.9 1.0 6.3 0.807 +48 3,300,509 12.2 Larynx Female 88 579,324 0.9 1.0 6.3 0.807 +48 3,300,509 12.2 Larynx Female 88 579,324 15.2 17.7 0.83 0.8553 1.522 7,840,454 19.4 Leukemia Male 117 572,328 13.8 16.1 0.803 1553 3,392,45 23.3 Leukemia Female 88 579,324 15.2 17.0 19.8 3 0.653 3,522 7,840,454 19.4 Liver and Bile Duct Total 109 1,151,852 9.5 10.9 9.38 0.133 734 7,340,454 19.4 Liver and Bile Duct Kernale 88 579,324 15.2 5.9 2.8 0.0 84 3 515 3,339,945 35.3 Liver and Bile Duct Female 30 578,322 45.2 5.9 2.8 0.0 844 219 3,300,500 15.5 Lung and Bronchus Total 109 1,151,852 25.3 00.9 248.2 0.027 >> 4,357 7,840,454 55.3 Lung and Bronchus Male 315 572,328 45.0 5.0 2.08 0.0 10 <2.4 (3.77 3,300,500 5.6 Lung and Bronchus Female 247 573.2 45.3 57 7 2.0 10 4.0 (10 <2.177 3,300,300 56 5.0 Lung and Bronchus Female 124 579,324 42.5 7 30 1.0 (10 <2.177 3,300,300 56 55.3 Lung and Bronchus Female 124 579,324 47.9 4.9 Mele 331 5,72,328 7.7 9.0 50.1 0.430 403 3,339,445 53.3 Lung and Bronchus Female 124 579,324 47.9 4 9.4 81.7 (10 <10 <2.177 3,300,300 56 56 Lung and Bronchus Female 124 579,324 47.9 9.0 $350.1 0.101 <2.177 3,300,500 45.8 Melenoma of the Skin Female 124 579,324 47.9 4 81.7 (2.15 0.011 <2.4 777 3,300,500 45.8 Melenoma female 44 572,328 7.7 9.0 50.1 0.430 4030 3,339,345 45.3 $					-					, ,		
Hodgkin Lýmphoma Female 16 579.324 2.8 2.8 11.3 0.223 77 3.900.509 2.0 Kidney and Renal Pelvis Male 163 577.328 28.5 25.5 22.01 0.010 >> 1.617.652 22.6 25.5 22.01 0.010 >> 1.47 3.390.945 29.1 Larynx Total 26 1.571.652 2.2 2.6 24.5 0.822 194 7.840.454 2.5 Larynx Total 26 1.151.652 2.3 2.6 24.5 0.822 194 7.840.454 2.5 Larynx Female 5 579.324 0.9 1.0 6.3 0.807 4.8 3.900.509 1.2 Leukemia Total 109 1.151.652 1.70 7.99 0.332 6.03 3.900.509 5.6 1.39 3.900.509 5.6 1.39 3.900.509 5.6 1.39 3.930.450 5.3 3.930.450 5.33.930.45 5.33.930.45												
Kidney and Renal Pelvis Male 163 572,328 28.5 32.5 146.1 0.179 1,147 3,390,945 28.2 Larynx Total 26 1,151,652 2.3 2.6 24.5 0.005 544 3,900,509 13.9 Larynx Female 5 579,324 0.9 1.0 6.3 0.687 48 3,930,945 23.5 Larynx Female 5 579,324 0.9 1.0 6.3 0.6807 48 3,930,9509 12.5 Laukemia Total 1751 552 17.8 20.1 198 0.603 1.653 3,900,509 15.5 Liver and Bile Duct Total 109 1,151<552	Hodgkin Lymphoma										2.0	
Kidney and Renal PelvisFemale97579,32416.717.872.30.006 >>5443,900,50913.9LarynxMale21572,3283.74.318.00.5411463,939,9453.7LarynxFemale579,3240.91.06.30.8674483,900,5091.2LeukemiaTotal2051,151,65217.820.1198.30.6531,5227,840,45419.4LeukemiaMale17572,32820.42.3.2117.41,000913,939,9453.33LeukemiaFemale88579,32415.217.079.90.3926033,900,50915.5Liver and Bile DuctTotal6021,151,6529.510.95.80.1337.347.840,4549.4Liver and Bile DuctFemale30579,3245.25.92.860.8442193,900,5095.6Ling and BronchusTotal6021,151,6522.5.360.9549.20.027>4.3577.840,45455.6Lung and BronchusFemale287579,3244.9.557.1280.40.1083.939,94553.3Lung and BronchusFemale171,151,6527.89.01.06.1281.7773.900,5095.8Melanoma of the SkinFemale193572,32833.733.734.721.60.1281.7723.939,94543.2 <td>Kidney and Renal Pelvis</td> <td>Total</td> <td>260</td> <td></td> <td>22.6</td> <td></td> <td></td> <td>0.010 >></td> <td></td> <td></td> <td>21.6</td>	Kidney and Renal Pelvis	Total	260		22.6			0.010 >>			21.6	
	Kidney and Renal Pelvis				28.5		146.1					
Larýnx Male 21 572,328 3.7 4.3 18.0 0.541 146 3,939,945 3.7 Leukemia Total 205 1,151,652 17.8 20.1 198.3 0.683 1,522 7,840,454 194.3 Leukemia Male 117 572,328 20.4 23.2 117.4 1.000 919 3,939,945 32.3 Leukemia Female 88 579,324 15.2 17.0 7.99 0.382 60.3 3,900,509 15.5 Liver and Bile Duct Male 75 572,328 13.8 16.1 64.3 0.032 60.3 3,900,509 5.5 Lung and Bronchus Total 579,324 5.2 5.9 2.86 0.844 2.19 3,900,509 5.5 Lung and Bronchus Female 131 1,151,652 27.5 30.9 37.01 0.005 <	Kidney and Renal Pelvis										13.9	
$ \begin{array}{c} Laryxm \\ Leukemia \\ Total \\ Leukemia \\ Leukemia \\ Leukemia \\ Leukemia \\ Leukemia \\ Leukemia \\ Hale \\ 117 \\ 572, 328 \\ 579, 324 \\ 152 \\ 170 \\ 79.9 \\ 0.392 \\ 0.392 \\ 0.392 \\ 0.392 \\ 0.392 \\ 0.398, 945 \\ 0.39$									-			
Leukemia Male 117 572,328 20.4 23.2 117.4 1.000 1919 3,339,945 23.33 Leukemia Female 88 579,324 15.2 17.0 93.9 0.392 603 3,900,509 15.5 Liver and Bile Duct Male 79 97.82 13.8 10.9 93.8 0.133 734 7,840,454 9.4 Liver and Bile Duct Female 30 579,324 5.2 5.9 28.6 0.844 219 3.900,509 55.3 Lung and Bronchus Total 602 1,151.652 27.5 30.9 370.1 0.005 <2.827			-									
LeukemiaFemale88579,32415.217.079.90.3926033.900,50915.5Liver and Bile DuctTotal1091,151,6529.510.993.80.1337347.840,4549.4Liver and Bile DuctFemale30579,3245.25.928.60.0835153,339,94513.1Liver and Bile DuctFemale30579,3245.260.9549.20.027 $>$ 4,3577,840,45455.6Lung and BronchusMale315572,32855.065.0268.00.006 >>2,1803,939,94555.3Lung and BronchusFemale287579,32449.557.1280.40.7102,1773,900,50955.8Melanoma of the SkinTotal1711,151,65227.530.9370.10.005 <<												
Liver and Bile Duct Total 109 1,151,652 9.5 10.9 93.8 0.133 734 7,840,454 9.4 Liver and Bile Duct Male 79 572,328 13.8 16.1 64.3 0.083 515 3,393,945 13.1 Liver and Bile Duct Fernale 30 579,324 5.2 5.9 28.6 0.844 219 3,900,509 5.6 Lung and Bronchus Total 602 1,151,652 52.3 60.9 549.2 0.027 \gg 4,357 7,840,454 55.5 Lung and Bronchus Male 135 572,328 55.0 65.0 268.0 0.006 \gg 2,180 3,939,945 55.3 Lung and Bronchus Fernale 287 579,324 49.5 57.1 280.4 0.710 2,177 3,900,509 55.8 Melanoma of the Skin Total 1317 1,151,652 27.5 300 9 370.1 0.005 $<$ 2,827 7,840,454 36.1 Melanoma of the Skin Total 1317 1,151,652 7.8 9.0 81.2 0.019 $<$ 1,125 3,900,509 28.8 Melanoma of the Skin Male 193 572,328 7.7 9.0 81.2 0.354 638 1,800,599 28.8 Myeloma Total 201 1,51,652 7.8 9.0 81.2 0.354 638 1,800,599 28.8 Myeloma Male 44 572,328 7.7 9.0 81.2 0.354 638 1,800,454 8.1 Myeloma Male 44 572,328 7.7 9.0 81.2 0.354 638 1,800,599 60.0 Non-Hodgkin Lymphoma Total 231 1,151,652 20.1 22.8 228.0 0.860 1.761 7,840,454 22.5 Non-Hodgkin Lymphoma Male 139 572,328 24.3 27.7 128.1 0.358 1,007 3,399,945 22.6 Non-Hodgkin Lymphoma Male 139 572,328 18.7 21.5 10.5.1 0.877 833 0,905,90 9.0 0.1 Crai 201 1,151,652 77, 3.24 1.5 0.591 7.54 3,900,509 19.3 Orai 201 Male 170 7,572,328 18.7 21.5 10.5.1 0.877 833 0,905,90 49.3 Non-Hodgkin Lymphoma Male 139 572,328 18.7 21.5 10.5.1 0.877 833 0,905,90 49.3 Crai 201 Male 139 572,328 18.7 21.5 10.5.1 0.877 833 0,935,945 22.6 Non-Hodgkin Lymphoma Female 92 579,324 11.4 12.7 65.1 0.941 487 3,900,509 19.3 Crai 201 Male 139 572,328 18.7 21.5 10.5.1 0.877 833 0,935,945 22.6 Non-Hodgkin Lymphoma Female 92 579,324 11.4 12.2 1.5 10.5.1 0.877 833 0,939,945 22.6 Non-Hodgkin Lymphoma Female 92 579,324 11.4 12.5 10.5.1 0.877 833 0,939,945 22.6 Non-Hodgkin Lymphoma Female 92 579,324 1.4 1.4 150.6 0.685 1,170 7,840,454 14.9 Orai 201 Male 39 572,328 18.7 21.5 10.5.1 0.877 833 0,939,945 24.1 1.4 12.5 10.5.1 0.877 833 0,939,945 24.1 1.4 12.5 10.5.1 0.877 833 0,939,945 24.1 1.4 12.5 10.5.1 0.877 833 0,939,945 24.1 1.4 12.5 10.5.1 0.847 8												
Liver and Bile DuctMale79572,32813.816.164.30.0835153.939,94513.1Liver and Bile DuctFemale30579,3245.25.92.8.60.8.442193.900,5095.6Lung and BronchusMale315572,32855.065.0268.00.0062.1803.933,94555.3Lung and BronchusFemale287579,32449.557.128.00.0162.1803.933,94555.3Melanoma of the SkinTotal3171,151,65227.530.9370.10.0052.8277.840,45436.1Melanoma of the SkinFemale124579,32421.423.4152.70.0191.1253.900,50928.8MyelomaTotal90151,6527.89.081.20.3546.387.840,45488.1MyelomaMale44572,3287.79.080.10.011>23.53.900,5096.0Non-Hodgkin LymphomaFemale46579,3247.99.130.50.011>23.53.900,5096.0Non-Hodgkin LymphomaFemale92579,3242.0.122.822.800.86001.7617.840,45442.5Non-Hodgkin LymphomaFemale92579,3241.5918.09.00.5217543.900,50919.3Oral Cavity and PharynxTotal1451.151,65212.81.80.99											9.4	
Lung and BronchusTotalG021,151,65252.360.9549.20.027 \rightarrow 4,3577,840,45455.3Lung and BronchusMale315572,32855.065.0268.00.006 \rightarrow 2,1803,939,94555.3Lung and BronchusFemale287579,32449.557.1280.40.7102,1773,900,50955.8Melanoma of the SkinMale133572,32833.738.7215.60.1281,7023,939,94543.2Melanoma of the SkinFemale124579,32421.423.4152.70.019 <	Liver and Bile Duct							0.083				
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Liver and Bile Duct	Female	30		5.2				219		5.6	
Lung and Bronchus Female 287 579,324 49.5 57.1 280.4 0.710 2.177 3.900,509 55.8 Melanoma of the Skin Male 1317 1,151,652 27.5 30.9 370.1 0.005 <											55.6	
Melanoma of the Skin Total 317 1,151,652 27.5 30.9 370.1 0.005 << 2,827 7,840,454 36.1 Melanoma of the Skin Male 193 572,328 33.7 38.7 215.6 0.128 1,702 3,939,945 43.2 43.2 Melanoma of the Skin Female 124 579,324 21.4 23.4 152.7 0.019 < <td>1,125 3,900,509 28.8 Myeloma Male 44 572,328 7.7 9.0 50.1 0.430 403 3,939,945 10.2 Non-Hodgkin Lymphoma Female 46 579,324 7.9 9.1 30.5 0.011 > 23.3,900,509 6.0 Non-Hodgkin Lymphoma Male 139 572,328 24.3 27.7 128.1 0.358 1.007 3,939,945 25.6 Non-Hodgkin Lymphoma Male 139 572,328 18.7 21.5 105.1 0.877 83.3 3.939,945 21.1 0.121 0.323</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>3,939,945</td> <td></td>	1,125 3,900,509 28.8 Myeloma Male 44 572,328 7.7 9.0 50.1 0.430 403 3,939,945 10.2 Non-Hodgkin Lymphoma Female 46 579,324 7.9 9.1 30.5 0.011 > 23.3,900,509 6.0 Non-Hodgkin Lymphoma Male 139 572,328 24.3 27.7 128.1 0.358 1.007 3,939,945 25.6 Non-Hodgkin Lymphoma Male 139 572,328 18.7 21.5 105.1 0.877 83.3 3.939,945 21.1 0.121 0.323										3,939,945	
Melanoma of the SkinMale193 $572,328$ 33.7 38.7 215.6 0.128 $1,702$ $3,939,945$ 43.2 Melanoma of the SkinFemale124 $579,324$ 21.4 23.4 152.7 $0.019 <1,1253,900,50928.8MyelomaTotal901,151,6527.89.081.20.3546387,840,4548.1MyelomaFemale46579,3247.99.130.50.011 >>2353,900,5096.0Non-Hodgkin LymphomaTotal2311,151,65220.122.822.800.8601,7617,840,45422.5Non-Hodgkin LymphomaFemale92579,32415.918.099.00.5217543,900,50919.3Non-Hodgkin LymphomaFemale92579,32415.918.099.00.5217543,900,50919.3Oral Cavity and PharynxTotal1451,151,65212.614.4150.60.8851,1707,840,45414.9Oral Cavity and PharynxFemale36579,32411.412.5105.10.8778333,939,94521.1Oral Cavity and PharynxFemale66579,32411.412.510.9414873,900,5098.6PancreasMale82572,32813.315.4169.30.2223$	$1,125$ $3,900,509$ 28.8 MyelomaTotal90 $1,151,652$ 7.8 9.0 81.2 0.354 638 $7,840,454$ 8.1 MyelomaFemale46 $579,324$ 7.9 9.1 30.5 $0.011 >>$ 235 $3,900,509$ 6.0 Non-Hodgkin LymphomaTotal231 $1,151,652$ 20.1 22.8 22.80 0.860 $1,761$ $7,840,454$ 22.5 Non-Hodgkin LymphomaFemale 92 $579,324$ 15.9 18.0 99.0 0.521 754 $3,900,509$ 19.3 Non-Hodgkin LymphomaFemale 92 $579,324$ 15.9 18.0 99.0 0.521 754 $3,900,509$ 19.3 Oral Cavity and PharynxTotal 145 $1,151,652$ 12.6 14.4 150.6 0.885 $1,170$ $7,840,454$ 14.9 Oral Cavity and PharynxFemale 36 $579,324$ 11.4 12.5 105.1 0.877 833 $3,939,945$ 21.1 Oral Cavity and PharynxFemale 66 $579,324$ 11.4 12.5 10.941 487 $3,900,509$ 8.6 PancreasMale 82 $572,328$ 13.3 15.4 169.3 0.2223											
Melanoma of the SkinFemale124579,32421.423.4152.7 $0.019 <<$ 1,1253,900,50928.8MyelomaMale44572,3287.79.050.10.4304033,939,94510.2MyelomaFemale46579,3247.99.130.50.011 >>2353,900,5096.0Non-Hodgkin LymphomaTotal2311,151,65220.122.8228.00.8601.7617,840,45422.5Non-Hodgkin LymphomaMale139572,32824.327.7128.10.3581,0073,939,94525.6Non-Hodgkin LymphomaFemale92579,32415.918.099.00.5217.543,900,50919.3Oral Cavity and PharynxTotal1451,151,65212.614.4150.60.6851,1707,840,45414.9Oral Cavity and PharynxMale107572,32818.721.5105.10.8778333,900,5098.6OvaryFemale66579,32411.412.765.10.9414873,900,50912.5PancreasMale82572,32814.316.892.20.3117,840,45417.0PancreasMale82572,32813.315.4169.30.2231,3357,840,45417.0PancreasMale70572,32813.5157.9742.20.3165.9963,939,945152.												
Myeloma Total 90 1,151,652 7.8 9.0 81.2 0.354 638 7,840,454 8.1 Myeloma Male 44 572,328 7.7 9.0 50.1 0.430 403 3,939,945 10.2 Non-Hodgkin Lymphoma Total 231 1,151,652 20.1 22.8 228.0 0.860 1,761 7,840,454 22.5 Non-Hodgkin Lymphoma Female 92 579,324 15.9 18.0 99.0 0.521 754 3,900,509 19.3 Non-Hodgkin Lymphoma Female 92 579,324 15.9 18.0 99.0 0.521 754 3,900,509 19.3 Oral Cavity and Pharynx Total 145 1,151,652 12.6 14.4 150.6 0.685 1,170 7,840,454 14.9 Oral Cavity and Pharynx Male 107 572,328 18.7 21.5 105.1 0.877 833 3,939,945 18.7 Pancreas Female												
Myeloma Male 44 572,328 7.7 9.0 50.1 0.430 403 3,939,945 10.2 Myeloma Total 231 1,151,652 20.1 22.8 228.0 0.860 1.761 7.840,454 22.5 3,900,509 6.0 Non-Hodgkin Lymphoma Male 139 572,328 24.3 27.7 128.1 0.358 1,007 3,939,945 22.5 Non-Hodgkin Lymphoma Female 92 579,324 15.9 18.0 99.0 0.521 754 3,900,509 19.3 Oral Cavity and Pharynx Total 145 1,151,652 12.6 14.4 150.6 0.685 1,170 7,840,454 14.9 Oral Cavity and Pharynx Male 107 572,328 18.7 21.5 10.51 0.877 833 3,939,945 11.1 Oral Cavity and Pharynx Female 66 579,324 11.4 12.7 65.1 0.941 487 3,900,509 8.6	Myeloma						81.2					
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Myeloma	Male									10.2	
Non-Hodgkin Lymphoma Total 231 1,151,652 20.1 22.8 228.0 0.860 1,761 7,840,454 22.5 Non-Hodgkin Lymphoma Female 92 579,324 15.9 18.0 99.0 0.521 754 3,900,945 25.6 Non-Hodgkin Lymphoma Female 92 577,328 15.9 18.0 99.0 0.521 754 3,900,909 19.3 Oral Cavity and Pharynx Total 145 1,151,652 12.6 14.4 150.6 0.685 1,170 7,840,454 14.9 Oral Cavity and Pharynx Male 107 572,328 18.7 21.5 105.1 0.877 833 3,939,945 21.1 Oral Cavity and Pharynx Female 66 579,324 11.4 12.7 65.1 0.941 487 3,900,509 18.6 Ovary Female 71 573,324 12.3 14.1 76.5 0.576 591 3,900,509 15.2 Pancreas <t< td=""><td>Myeloma</td><td>Female</td><td>46</td><td>579,324</td><td>7.9</td><td>9.1</td><td>30.5</td><td>0.011 >></td><td>235</td><td>3,900,509</td><td>6.0</td></t<>	Myeloma	Female	46	579,324	7.9	9.1	30.5	0.011 >>	235	3,900,509	6.0	
Non-Hodğkin LýmphomaFemale92579,32415.918.099.00.5217543,900,50919.3Oral Cavity and PharynxTotal1451,151,65212.614.4150.60.6851,1707,840,45414.9Oral Cavity and PharynxMale107572,32818.721.5105.10.8778333,939,94521.1Oral Cavity and PharynxFemale38579,3246.67.444.20.3933373,900,5098.6OvaryFemale66579,32411.412.765.10.9414873,900,50912.5PancreasTotal1531,5165213.315.4169.30.2231,3357,840,45417.0PancreasMale82572,32814.316.892.20.3117443,939,94518.9PancreasFemale71579,32412.314.176.50.5765913,939,945152.2ProstateMale770572,328134.5157.9742.20.3165,9963,939,945152.2StomachTotal631,151,6525.56.352.60.1804117,840,4545.2StomachMale39572,3286.87.933.60.3892683,939,9456.2ThyroidTotal631,151,6529.19.6150.70.000 <	Non-Hodgkin Lymphoma	Total									22.5	
Oral Cavity and Pharynx Total 145 1,151,652 12.6 14.4 150.6 0.685 1,170 7,840,454 14.9 Oral Cavity and Pharynx Male 107 572,328 18.7 21.5 105.1 0.877 833 3,939,945 21.1 Oral Cavity and Pharynx Female 38 579,324 6.6 7.4 44.2 0.393 37 3,900,509 8.6 Ovary Female 66 579,324 11.4 12.7 65.1 0.941 487 3,900,509 12.5 Pancreas Total 153 1,151,652 13.3 15.4 169.3 0.223 1,335 7,840,454 17.0 Pancreas Male 82 572,328 14.3 16.8 92.2 0.311 744 3,939,945 18.9 Pancreas Female 71 579,324 12.3 14.1 76.5 0.576 591 3,900,509 15.2 Stomach Male 39 <td< td=""><td>Non-Hodgkin Lymphoma</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>25.6</td></td<>	Non-Hodgkin Lymphoma										25.6	
Oral Cavity and Pharynx Male 107 572,328 18.7 21.5 105.1 0.877 833 3,939,945 21.1 Oral Cavity and Pharynx Female 38 579,324 6.6 7.4 44.2 0.393 337 3,900,509 8.6 Ovary Female 66 579,324 11.4 12.7 65.1 0.941 487 3,900,509 8.6 Pancreas Total 153 1,151,652 13.3 15.4 169.3 0.223 1,335 7,840,454 17.0 Pancreas Male 82 572,328 14.3 16.8 92.2 0.311 744 3,939,945 18.9 Pancreas Female 71 579,324 12.3 14.1 76.5 0.576 591 3,939,945 152.2 Stomach Male 700 572,328 134.5 157.9 742.2 0.316 5,996 3,939,945 6.8 Stomach Male 39 572,328			-									
Oral Cavity and Pharynx Female 38 579,324 6.6 7.4 44.2 0.393 337 3,900,509 8.6 Ovary Female 66 579,324 11.4 12.7 65.1 0.941 487 3,900,509 12.5 Pancreas Total 153 1,151,652 13.3 15.4 169.3 0.223 1,335 7,840,454 17.0 Pancreas Male 82 572,328 14.3 16.8 92.2 0.311 744 3,939,945 18.9 Pancreas Male 82 572,328 134.5 157.9 742.2 0.316 5,996 3,939,945 152.2 Prostate Male 70 572,328 134.5 157.9 742.2 0.316 5,996 3,939,945 152.2 Stomach Male 39 572,328 6.8 7.9 33.6 0.389 268 3,939,945 6.8 Stomach Male 39 572,328 5.2 <td></td>												
Ovary Female 66 579,324 11.4 12.7 65.1 0.941 487 3,900,509 12.5 Pancreas Total 153 1,151,652 13.3 15.4 169.3 0.223 1,335 7,840,454 17.0 Pancreas Male 82 572,328 14.3 16.8 92.2 0.311 744 3,399,945 18.9 Pancreas Female 71 579,324 12.3 14.1 765 0.576 591 3,900,509 15.2 Prostate Male 770 572,328 134.5 157.9 742.2 0.316 5,996 3,939,945 15.2 Stomach Total 63 1,151,652 5.5 6.3 52.6 0.180 411 7,840,454 5.2 Stomach Male 39 572,328 6.8 7.9 33.6 0.389 268 3,939,945 6.8 Stomach Female 24 579,324 4.1 4.7												
Pancreas Total 153 1,151,652 13.3 15.4 169.3 0.223 1,335 7,840,454 17.0 Pancreas Male 82 572,328 14.3 16.8 92.2 0.311 744 3,939,945 18.9 Pancreas Female 71 579,324 12.3 14.1 76.5 0.576 591 3,900,509 15.2 Prostate Male 770 572,328 134.5 157.9 742.2 0.316 5,996 3,939,945 152.2 Stomach Total 63 1,151,652 5.5 6.3 52.6 0.180 411 7,840,454 52.2 Stomach Male 39 572,328 6.8 7.9 33.6 0.389 268 3,939,945 6.8 Stomach Female 24 579,324 4.1 4.7 18.7 0.269 143 3,900,509 3.7 Testis Male 30 572,328 5.2 5.3<												
PancreasMale82572,32814.316.892.20.3117443,939,94518.9PancreasFemale71579,32412.314.176.50.5765913,900,50915.2ProstateMale770572,328134.5157.9742.20.3165,9963,939,945152.2StomachTotal631,151,6525.56.352.60.1804117,840,4545.2StomachMale39572,3286.87.933.60.3892683,939,9456.8StomachFemale24579,3244.14.718.70.2691433,900,5093.7TestisMale30572,3285.25.335.30.4292443,939,9456.2ThyroidTotal1051,151,6529.19.6150.70.000 <						15.4					17.0	
PancreasFemale71579,32412.314.176.50.5765913,900,50915.2ProstateMale770572,328134.5157.9742.20.3165,9963,939,945152.2StomachTotal631,151,6525.56.352.60.1804117,840,4545.2StomachMale39572,3286.87.933.60.3892683,939,9456.8StomachFemale24579,3244.14.718.70.2691433,900,5093.7TestisMale30572,3285.25.335.30.4292443,939,9456.2ThyroidTotal1051,151,6529.19.6150.70.000 <	Pancreas	Male		572,328	14.3					3,939,945	18.9	
ProstateMale770572,328134.5157.9742.20.3165,9963,939,945152.2StomachTotal631,151,6525.56.352.60.1804117,840,4545.2StomachMale39572,3286.87.933.60.3892683,939,9456.8StomachFemale24579,3244.14.718.70.2691433,900,5093.7TestisMale30572,3285.25.335.30.4292443,939,9456.2ThyroidTotal1051,151,6529.19.6150.70.000 <	Pancreas	Female		579,324	12.3	14.1	76.5	0.576	591	3,900,509	15.2	
Stomach Male 39 572,328 6.8 7.9 33.6 0.389 268 3,939,945 6.8 Stomach Female 24 579,324 4.1 4.7 18.7 0.269 143 3,900,509 3.7 Testis Male 30 572,328 5.2 5.3 35.3 0.429 244 3,939,945 6.2 Thyroid Total 105 1,151,652 9.1 9.6 150.7 0.000 << 1,080 7,840,454 13.8 Thyroid Male 28 572,328 4.9 5.3 45.9 0.006 < 344 3,939,945 6.2 Thyroid Male 28 572,328 4.9 5.3 45.9 0.006 < 344 3,939,945 8.7 Thyroid Female 77 579,324 13.3 13.7 105.9 0.004 < 73 3,900,509 18.9 Pediatric Age 0 to 19 Total 56 352,913 15.9 60	Prostate										152.2	
StomachFemale24579,3244.14.718.70.2691433,900,5093.7TestisMale30572,3285.25.335.30.4292443,939,9456.2ThyroidTotal1051,151,6529.19.6150.70.000 <<1,0807,840,45413.8ThyroidMale28572,3284.95.345.90.006 <3443,939,9458.7ThyroidFemale77579,32413.313.7105.90.004 <7363,900,50918.9Pediatric Age 0 to 19Total56352,91315.915.960.40.6263692,146,41117.2Pediatric Age 0 to 19Male29180,49016.116.130.50.8821851,093,83116.9	Stomach										5.2	
TestisMale30572,3285.25.335.30.4292443,939,9456.2ThyroidTotal1051,151,6529.19.6150.70.000 <<										3,939,945		
ThyroidTotal1051,151,6529.19.6150.70.000 <<1,0807,840,45413.8ThyroidMale28572,3284.95.345.90.006 <<				,								
Male 28 572,328 4.9 5.3 45.9 0.006 < 344 3,939,945 8.7 Thyroid Female 77 579,324 13.3 13.7 105.9 0.004 <												
Thyroid Female 77 579,324 13.3 13.7 105.9 0.004 < 736 3,900,509 18.9 Pediatric Age 0 to 19 Total 56 352,913 15.9 15.9 60.4 0.626 369 2,146,411 17.2 Pediatric Age 0 to 19 Male 29 180,490 16.1 16.1 30.5 0.882 185 1,093,831 16.9												
Pediatric Age 0 to 19 Total 56 352,913 15.9 15.9 60.4 0.626 369 2,146,411 17.2 Pediatric Age 0 to 19 Male 29 180,490 16.1 16.1 30.5 0.882 185 1,093,831 16.9												
Pediatric Age 0 to 19 Male 29 180,490 16.1 16.1 30.5 0.882 185 1,093,831 16.9												
	Pediatric Age 0 to 19 Pediatric Age 0 to 19	Male Female	29 27	180,490 172,423	16.1 15.7	16.1 15.8	30.5 29.9	0.882 0.682	185 184	1,093,831 1,052,580	16.9 17.5	

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN CANYON COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Car	yon County	/			Re	mainder of Idah	10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	9,406	1,185,680	793.3	927.5	8,988.2	0.000 >>	71,129	8,025,714	886.3
All Causes of Death	Male	5,007	590,340	848.2	993.8	4,714.4	0.000 >>	37,779	4,037,357	935.7
All Causes of Death	Female	4,399	595,340	738.9	866.6	4,244.8	0.019 >>	33,350	3,988,357	836.2
All Malignant Cancers	Total	1,802	1,185,680	152.0	177.6	1,698.2	0.013 >>	13,431	8.025.714	167.3
All Malignant Cancers	Male	974	590,340	165.0	195.6	895.6	0.010 >>	7,261	4,037,357	179.8
All Malignant Cancers	Female	828	595,340	139.1	160.7	797.1	0.282	6,170	3,988,357	154.7
Bladder	Total	46	1,185,680	3.9	4.6	54.1	0.299	439	8,025,714	5.5
Bladder	Male	37	590,340	6.3	7.6	40.7	0.635	338	4,037,357	8.4
Bladder	Female	9	595,340	1.5	1.8	12.7	0.370	101	3,988,357	2.5
Brain and Other Nervous System	Total	57	1,185,680	4.8	5.4	60.5	0.712	461	8,025,714	5.7
Brain and Other Nervous System	Male	28	590,340	4.7	5.4	33.6	0.379	261	4,037,357	6.5
Brain and Other Nervous System	Female Total	29 145	595,340 1,185,680	4.9 12.2	5.5 14.2	26.7 124.9	0.701 0.084	200 979	3,988,357 8,025,714	5.0 12.2
Breast Breast	Male	145	590,340	12.2	14.2	124.9	0.084	13	4,037,357	0.3
Breast	Female	- 145	595,340	- 24.4	27.9	125.7	0.098	966	3,988,357	24.2
Cervix	Female	20	595,340	3.4	3.6	9.5	0.004 >>	68	3,988,357	1.7
Colorectal	Total	167	1,185,680	14.1	16.3	148.7	0.149	1,165	8,025,714	14.5
Colorectal	Male	98	590,340	16.6	19.3	79.7	0.052	634	4,037,357	15.7
Colorectal	Female	69	595,340	11.6	13.4	68.6	0.992	531	3,988,357	13.3
Corpus Uteri	Female	23	595,340	3.9	4.4	18.9	0.406	146	3,988,357	3.7
Esophagus	Total	56	1,185,680	4.7	5.5	51.4	0.555	405	8,025,714	5.0
Esophagus	Male	46	590,340	7.8	9.2	42.8	0.661	345	4,037,357	8.5
Esophagus	Female	10	595,340	1.7	1.9	7.7	0.500	60	3,988,357	1.5
Hodgkin Lymphoma	Total	5	1,185,680	0.4	0.5	2.6	0.240	20	8,025,714	0.2
Hodgkin Lymphoma	Male	3	590,340	0.5	0.6	1.4	0.323	11	4,037,357	0.3
Hodgkin Lymphoma	Female	2	595,340	0.3	0.4	1.2	0.664	9	3,988,357	0.2
Kidney Kidney	Total Male	50 29	1,185,680 590,340	4.2 4.9	5.0 5.8	42.2 26.8	0.260 0.715	336 217	8,025,714 4,037,357	4.2 5.4
Kidney	Female	29	595,340	3.5	4.2	15.1	0.171	119	3,988,357	3.0
Larynx	Total	13	1,185,680	1.1	1.3	7.9	0.121	63	8,025,714	0.8
Larynx	Male	11	590,340	1.9	2.2	6.6	0.144	54	4,037,357	1.3
Larynx	Female	2	595,340	0.3	0.4	1.2	0.676	9	3,988,357	0.2
Leukemia	Total	88	1,185,680	7.4	8.7	73.0	0.096	577	8,025,714	7.2
Leukemia	Male	57	590,340	9.7	11.4	42.1	0.032 >>	340	4,037,357	8.4
Leukemia	Female	31	595,340	5.2	6.0	30.5	0.978	237	3,988,357	5.9
Liver and Bile Duct	Total	80	1,185,680	6.7	7.8	70.7	0.296	555	8,025,714	6.9
Liver and Bile Duct	Male	51	590,340	8.6	10.2	46.3	0.525	372	4,037,357	9.2
Liver and Bile Duct	Female	29 358	595,340	4.9	5.6	23.8	0.332	183	3,988,357	4.6
Lung and Bronchus Lung and Bronchus	Total Male	202	1,185,680 590,340	30.2 34.2	35.5 40.7	324.3 164.5	0.068 0.005 >>	2,579 1,339	8,025,714 4,037,357	32.1 33.2
Lung and Bronchus	Female	156	595,340	26.2	30.5	159.0	0.852	1,339	3,988,357	31.1
Melanoma of the Skin	Total	32	1,185,680	20.2	3.1	34.3	0.032	269	8,025,714	3.4
Melanoma of the Skin	Male	24	590,340	4.1	4.8	21.9	0.703	176	4,037,357	4.4
Melanoma of the Skin	Female	8	595,340	1.3	1.5	12.2	0.284	93	3,988,357	2.3
Myeloma	Total	36	1,185,680	3.0	3.6	36.1	1.000	289	8,025,714	3.6
Myeloma	Male	19	590,340	3.2	3.9	20.6	0.834	169	4,037,357	4.2
Myeloma	Female	17	595,340	2.9	3.3	15.3	0.731	120	3,988,357	3.0
Non-Hodgkin Lymphoma	Total	71	1,185,680	6.0	7.0	62.4	0.304	497	8,025,714	6.2
Non-Hodgkin Lymphoma	Male	35	590,340	5.9	7.0	34.0	0.908	275	4,037,357	6.8
Non-Hodgkin Lymphoma	Female	36	595,340	6.0	7.1	28.1	0.172	222	3,988,357	5.6
Oral Cavity and Pharynx Oral Cavity and Pharynx	Total Male	30 17	1,185,680 590,340	2.5 2.9	2.9	31.1	0.936 0.365	245 175	8,025,714 4,037,357	3.1
Oral Cavity and Pharynx Oral Cavity and Pharynx	Male Female	17	590,340 595,340	2.9	3.4 2.5	21.7 9.0	0.365	175 70	4,037,357 3,988,357	4.3 1.8
Orar Cavity and Filaryitx Ovary	Female	32	595,340	5.4	6.2	42.6	0.255	329	3,988,357	8.2
Pancreas	Total	134	1,185,680	11.3	13.2	133.6	0.998	1,056	8,025,714	13.2
Pancreas	Male	73	590,340	12.4	14.6	71.4	0.880	577	4,037,357	14.3
Pancreas	Female	61	595,340	10.2	11.9	61.8	0.987	479	3,988,357	12.0
Prostate	Male	96	590,340	16.3	19.8	108.2	0.260	901	4,037,357	22.3
Stomach	Total	38	1,185,680	3.2	3.7	20.0	0.000 >>	156	8,025,714	1.9
Stomach	Male	22	590,340	3.7	4.3	12.2	0.014 >>	97	4,037,357	2.4
Stomach	Female	16	595,340	2.7	3.1	7.8	0.013 >>	59	3,988,357	1.5

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Canyon County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	86.2% 10.4%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	61.5% 72.3% 58.7%
Current Tobacco User (2020–2022) Other Cancer-Related	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	23.8%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	26.6% 75.7% 20.7% 17.0%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





CARIBOU COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 201 cases of invasive cancer were diagnosed among Caribou County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in CaribouCounty and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Caribou County	State of Idaho
All Sites/Types	201	47,333
Female Breast	26	6,943
Prostate	33	6,766
Lung & Bronchus	18	4,959
Colorectal	14	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Caribou County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Caribou County. The table also shows the number of observed cases, person-

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 55 Caribou County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Caribou County and the State of Idaho, 2018–2022

Mortality 2018–2022	Caribou County	State of Idaho
All Deaths	365	80,538
Cancer Deaths	55	15,233
% of All Deaths	15.1%	18.9%
Lung & Bronchus	11	2,937
Colorectal	3	1,332
Pancreas	2	1,190
Female Breast	3	1,111
Prostate	1	997

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Caribou County was 568.1 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (526.2) gives an estimate of the relative burden of disease in Caribou County.

The age- and sex-adjusted incidence rate of invasive cancer in Caribou County, all sites combined, was 540.8 cases per 100,000 persons per year during 2017–2021. There were more cases of cancer in Caribou County (201) than expected (195.6) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Caribou County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Caribou County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Caribou County, all sites combined, was 143.9 deaths per 100,000 persons per year during 2018–2022, compared with 165.4 for the remainder of the state. There were fewer cancer deaths in Caribou County (55) than expected (63.2) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN CARIBOU COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Car	ibou Count	v			Ren	nainder of Ida	aho
Cancer		Observed	Person	Crude	, A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)		P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	201	35,381	568.1	540.8	195.6	0.717	47,132	8,956,725	526.2
All Sites Combined	Male	121	17,960	673.7	644.6	105.0	0.137	25,149	4,494,313	559.6
All Sites Combined	Female	80	17,421	459.2	436.9	90.2	0.306	21,983	4,462,412	492.6
Bladder	Total	8	35,381	22.6	20.8	9.5	0.786	2,212	8,956,725	24.7
Bladder	Male	8	17,960	44.5	42.0	7.5	0.947	1,765	4,494,313	39.3
Bladder	Female	-	17,421	-	-	1.9	0.295	447	4,462,412	10.0
Brain - malignant	Total	2	35,381	5.7	5.5	2.7	0.999	655	8,956,725	7.3
Brain - malignant	Male	1	17,960	5.6	5.4	1.6	1.000	381	4,494,313	8.5
Brain - malignant	Female	1	17,421	5.7	5.5	1.1	1.000	274	4,462,412	6.1
Brain and other CNS - non-malignant	Total	13	35,381	36.7	35.3	6.3	0.026 >>	1,534	8,956,725	17.1
Brain and other CNS - non-malignant	Male	3	17,960	16.7	16.3	2.0	0.665	497	4,494,313	11.1
Brain and other CNS - non-malignant Breast	Female	10 26	17,421 35,381	57.4 73.5	54.4 71.2	4.3 28.5	0.025 >>	1,037	4,462,412	23.2 78.0
Breast	Total Male	- 20	17,960	73.5	11.2	20.5	0.731 1.000	6,982 65	8,956,725 4,494,313	1.4
Breast	Female	- 26	17,900	- 149.2	144.3	27.9	0.810	6,917	4,462,412	155.0
Breast - in situ	Total	20	35,381	5.7	5.6	5.5	0.010	1,367	8,956,725	15.3
Breast - in situ	Male		17,960	-	-	0.0	1.000	4	4,494,313	0.1
Breast - in situ	Female	2	17,421	11.5	11.3	5.4	0.190	1,363	4,462,412	30.5
Cervix	Female	1	17,421	5.7	5.9	1.1	1.000	293	4,462,412	6.6
Colorectal	Total	14	35,381	39.6	37.7	15.0	0.927	3,618	8,956,725	40.4
Colorectal	Male	7	17,960	39.0	37.7	8.1	0.869	1,970	4,494,313	43.8
Colorectal	Female	7	17,421	40.2	37.5	6.9	1.000	1,648	4,462,412	36.9
Corpus Uteri	Female	8	17,421	45.9	44.8	5.4	0.354	1,346	4,462,412	30.2
Esophagus	Total	1	35,381	2.8	2.7	2.1	0.746	506	8,956,725	5.6
Esophagus	Male	1	17,960	5.6	5.3	1.8	0.925	428	4,494,313	9.5
Esophagus	Female	-	17,421	-	-	0.3	1.000	78	4,462,412	1.7
Hodgkin Lymphoma	Total	3	35,381	8.5	8.8	0.8	0.105	219	8,956,725	2.4
Hodgkin Lymphoma	Male Female	1	17,960	5.6	5.7 12.2	0.5	0.791 0.090	128	4,494,313	2.8 2.0
Hodgkin Lymphoma Kidney and Renal Pelvis	Total	2	17,421 35,381	11.5 22.6	21.6	0.3 8.0	1.000	91 1,943	4,462,412 8,956,725	2.0
Kidney and Renal Pelvis	Male	0 7	17,960	39.0	37.7	6.0 5.4	0.591	1,943	4,494,313	21.7
Kidney and Renal Pelvis	Female	1	17,300	5.7	5.4	2.7	0.514	640	4,462,412	14.3
Larynx	Total	2	35,381	5.7	5.4	0.9	0.460	218	8,956,725	2.4
Larynx	Male	2	17,960	11.1	10.7	0.7	0.303	165	4,494,313	3.7
Larynx	Female		17,421	-	-	0.2	1.000	53	4,462,412	1.2
Leukemia	Total	10	35,381	28.3	26.5	7.2	0.385	1,717	8,956,725	19.2
Leukemia	Male	5	17,960	27.8	26.6	4.3	0.865	1,031	4,494,313	22.9
Leukemia	Female	5	17,421	28.7	26.6	2.9	0.333	686	4,462,412	15.4
Liver and Bile Duct	Total	3	35,381	8.5	8.1	3.5	1.000	840	8,956,725	9.4
Liver and Bile Duct	Male	2	17,960	11.1	10.6	2.5	1.000	592	4,494,313	13.2
Liver and Bile Duct	Female	1	17,421	5.7	5.4	1.0	1.000	248	4,462,412	5.6
Lung and Bronchus	Total	18	35,381	50.9	47.2	21.0	0.597	4,941	8,956,725	55.2
Lung and Bronchus	Male	12	17,960	66.8	63.0	10.5	0.728	2,483	4,494,313	55.2
Lung and Bronchus Melanoma of the Skin	Female Total	6 16	17,421 35,381	34.4 45.2	31.5 43.4	10.5 12.9	0.205 0.452	2,458	4,462,412 8.956.725	55.1 34.9
Melanoma of the Skin	Male	10	17,960	45.2 55.7	43.4 53.5	7.8	0.452 0.527	3,128 1,885	4,494,313	34.9 41.9
Melanoma of the Skin	Female	6	17,900	34.4	33.5	7.8 5.0	0.527	1,005	4,494,313	27.9
Myeloma	Total	7	35,381	19.8	18.5	3.0	0.071	721	8,956,725	8.0
Myeloma	Male	5	17,960	27.8	26.5	1.9	0.081	442	4,494,313	9.8
Myeloma	Female	2	17,421	11.5	10.7	1.2	0.654	279	4,462,412	6.3
Non-Hodgkin Lymphoma	Total	9	35,381	25.4	24.2	8.2	0.882	1,983	8,956,725	22.1
Non-Hodgkin Lýmphoma	Male	6	17,960	33.4	32.1	4.7	0.679	1,140	4,494,313	25.4
Non-Hodgkin Lymphoma	Female	3	17,421	17.2	16.1	3.5	1.000	843	4,462,412	18.9
Oral Cavity and Pharynx	Total	6	35,381	17.0	16.3	5.4	0.902	1,309	8,956,725	14.6
Oral Cavity and Pharynx	Male	4	17,960	22.3	21.4	3.9	1.000	936	4,494,313	20.8
Oral Cavity and Pharynx	Female	2	17,421	11.5	10.9	1.5	0.910	373	4,462,412	8.4
Ovary	Female	-	17,421	-	-	2.2	0.214	553	4,462,412	12.4
Pancreas	Total	4	35,381	11.3	10.5	6.3	0.497	1,484	8,956,725	16.6
Pancreas	Male	3	17,960	16.7	15.9	3.5	1.000	823	4,494,313	18.3
Pancreas Prostate	Female Male	1 33	17,421 17,960	5.7 183.7	5.3 174.9	2.8 28.3	0.457 0.419	661 6,733	4,462,412 4,494,313	14.8 149.8
Stomach	Total	33	35,381	2.8	2.7	20.3	0.419	473	8,956,725	5.3
Stomach	Male	1	17,960	2.0 5.6	2.7 5.3	2.0	1.000	473 306	6,956,725 4,494,313	5.3 6.8
Stomach	Female	_ '	17,900	-	- 5.5	0.7	0.988	300 167	4,494,313	3.7
Testis	Male	2	17,960		- 12.2	1.0	0.526	272	4,494,313	6.1
Thyroid	Total	3	35,381	8.5	8.7	4.6	0.665	1,182	8,956,725	13.2
Thyroid	Male	3	17,960	16.7	16.6	4.0	0.005	369	4,494,313	8.2
Thyroid	Female	-	17,900	10.7	10.0	3.0	0.375	813	4,494,313	0.2 18.2
Pediatric Age 0 to 19	Total	- 1	10,941	- 9.1	- 9.2	1.8	0.090	424	2,488,383	17.0
Pediatric Age 0 to 19	Male	'	,	9.1	9.2	0.9	0.898	424 214	2,400,303	16.9
Pediatric Age 0 to 19 Pediatric Age 0 to 19	Female	- 1	5,621 5,320	- 18.8	- 19.2	0.9	1.000	214 210	1,200,700	10.9
1 Galatilo Ayo 0 to 13	- cmaie	1	5,520		19.2			210	1,213,003	17.2

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN CARIBOU COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Car	ibou Count	/			Re	mainder of Idah	0
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	365	35,591	1,025.5	939.5	339.4	0.176	80,170	9,175,803	873.7
All Causes of Death	Male	184	18,057	1,025.5	939.5 975.5	174.3	0.170	42,602	4,609,640	924.2
All Causes of Death	Female	181	17,534	1,019.0	902.7	165.0	0.483	37,568	4,566,163	822.7
All Malignant Cancers	Total	55	35,591	154.5	143.9	63.2	0.332	15,178	9,175,803	165.4
All Malignant Cancers	Male	31	18,057	171.7	163.7	33.7	0.723	8,204	4,609,640	178.0
All Malignant Cancers	Female	24	17,534	136.9	125.2	29.3	0.381	6,974	4,566,163	152.7
Bladder	Total	2	35,591	5.6	5.1	2.1	1.000	483	9,175,803	5.3
Bladder	Male	2	18,057	11.1	10.4	1.6	0.918	373	4,609,640	8.1
Bladder	Female	-	17,534	-	-	0.5	1.000	110	4,566,163	2.4
Brain and Other Nervous System	Total	1	35,591	2.8	2.7	2.1	0.771	517	9,175,803	5.6
Brain and Other Nervous System	Male	-	18,057	-	-	1.2	0.625	289	4,609,640	6.3
Brain and Other Nervous System	Female	1	17,534	5.7	5.5	0.9	1.000	228	4,566,163	5.0
Breast	Total	3	35,591	8.4	7.9	4.6	0.638	1,121	9,175,803	12.2
Breast	Male	-	18,057	-	-	0.1	1.000	13	4,609,640	0.3
Breast	Female	3	17,534	17.1	15.8	4.6	0.649	1,108	4,566,163	24.3
Cervix Colorectal	Female Total	- 3	17,534 35,591	- 8.4	- 7.9	0.3 5.5	1.000 0.407	88 1,329	4,566,163 9,175,803	1.9 14.5
Colorectal	Male	3 1	35,591 18,057	8.4 5.5	7.9 5.3	5.5 3.0	0.407	731	4,609,640	14.5 15.9
Colorectal	Female	2	17,534	11.4	5.3 10.4	2.5	1.000	598	4,566,163	13.9
Corpus Uteri	Female	1	17,534	5.7	5.4	0.7	0.993	168	4,566,163	3.7
Esophagus	Total	3	35,591	8.4	8.0	1.9	0.581	458	9,175,803	5.0
Esophagus	Male	3	18,057	16.6	15.9	1.6	0.426	388	4,609,640	8.4
Esophagus	Female	-	17,534	-	-	0.3	1.000	70	4,566,163	1.5
Hodgkin Lymphoma	Total	-	35,591	-	-	0.1	1.000	25	9,175,803	0.3
Hodgkin Lymphoma	Male	-	18,057	-	-	0.1	1.000	14	4,609,640	0.3
Hodgkin Lymphoma	Female	-	17,534	-	-	0.0	1.000	11	4,566,163	0.2
Kidney	Total	-	35,591	-	-	1.6	0.396	386	9,175,803	4.2
Kidney	Male	-	18,057	-	-	1.0	0.725	246	4,609,640	5.3
Kidney	Female	-	17,534	-	-	0.6	1.000	140	4,566,163	3.1
Larynx	Total	-	35,591	-	-	0.3	1.000	76	9,175,803	0.8
Larynx	Male Female	-	18,057 17,534	-	-	0.3 0.0	1.000 1.000	65 11	4,609,640 4,566,163	1.4 0.2
Larynx Leukemia	Total	- 4	35,591	- 11.2	- 10.3	2.8	0.610	661	9,175,803	7.2
Leukemia	Male	4 3	18,057	16.6	15.9	1.6	0.010	394	4,609,640	8.5
Leukemia	Female	1	17,534	5.7	5.1	1.0	1.000	267	4,566,163	5.8
Liver and Bile Duct	Total	2	35,591	5.6	5.3	2.6	1.000	633	9,175,803	6.9
Liver and Bile Duct	Male	1	18,057	5.5	5.3	1.7	0.970	422	4,609,640	9.2
Liver and Bile Duct	Female	1	17,534	5.7	5.3	0.9	1.000	211	4,566,163	4.6
Lung and Bronchus	Total	11	35,591	30.9	28.8	12.2	0.878	2,926	9,175,803	31.9
Lung and Bronchus	Male	6	18,057	33.2	31.6	6.3	1.000	1,535	4,609,640	33.3
Lung and Bronchus	Female	5	17,534	28.5	26.0	5.9	0.935	1,391	4,566,163	30.5
Melanoma of the Skin	Total	-	35,591	-	-	1.2	0.577	301	9,175,803	3.3
Melanoma of the Skin	Male	-	18,057	-	-	0.8	0.883	200	4,609,640	4.3
Melanoma of the Skin	Female	-	17,534	-	-	0.4	1.000	101	4,566,163	2.2
Myeloma	Total	4	35,591	11.2	10.4	1.4	0.097	321	9,175,803	3.5
Myeloma	Male	4	18,057	22.2	21.1	0.8	0.015 >>	184	4,609,640	4.0
Myeloma	Female Total	- 2	17,534 35,591	- 5.6	- 5.2	0.6 2.4	1.000 1.000	137 566	4,566,163 9,175,803	3.0 6.2
Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma	Male	2	18,057	11.1	10.7	1.3	0.714	308	4,609,640	6.7
Non-Hodgkin Lymphoma	Female	-	17,534			1.3	0.655	258	4,566,163	5.7
Oral Cavity and Pharynx	Total	1	35,591	- 2.8	- 2.7	1.1	1.000	230	9,175,803	3.0
Oral Cavity and Pharynx	Male	1	18,057	5.5	5.3	0.8	1.000	191	4,609,640	4.1
Oral Cavity and Pharynx	Female		17,534	-	-	0.3	1.000	83	4,566,163	1.8
Ovary	Female	1	17,534	5.7	5.3	1.5	1.000	360	4,566,163	7.9
Pancreas	Total	2	35,591	5.6	5.3	4.9	0.264	1,188	9,175,803	12.9
Pancreas	Male	1	18,057	5.5	5.3	2.7	0.513	649	4,609,640	14.1
Pancreas	Female	1	17,534	5.7	5.2	2.3	0.684	539	4,566,163	11.8
Prostate	Male	1	18,057	5.5	5.2	4.1	0.162	996	4,609,640	21.6
Stomach	Total	-	35,591	-	-	0.8	0.904	194	9,175,803	2.1
Stomach	Male	-	18,057	-	-	0.5	1.000	119	4,609,640	2.6
Stomach	Female	-	17,534	-	-	0.3	1.000	75	4,566,163	1.6

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Caribou County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	80.2% 13.1%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	43.1%
Current Tobacco User (2020–2022) Other Cancer-Related	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	20.1%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	19.9% 76.7% 17.7% 16.6%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





CASSIA COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 527 cases of invasive cancer were diagnosed among Cassia County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in CassiaCounty and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Cassia County	State of Idaho
All Sites/Types	527	47,333
Female Breast	84	6,943
Prostate	59	6,766
Lung & Bronchus	39	4,959
Colorectal	48	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Cassia County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Cassia County. The table also shows the number of observed cases, person-

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 171 Cassia County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Cassia County and the State of Idaho, 2018–2022

Mortality 2018–2022	Cassia County	State of Idaho
All Deaths	1,127	80,538
Cancer Deaths	171	15,233
% of All Deaths	15.2%	18.9%
Lung & Bronchus	17	2,937
Colorectal	16	1,332
Pancreas	13	1,190
Female Breast	11	1,111
Prostate	15	997

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Cassia County was 435.5 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (527.6) gives an estimate of the relative burden of disease in Cassia County.

The age- and sex-adjusted incidence rate of invasive cancer in Cassia County, all sites combined, was 484.6 cases per 100,000 persons per year during 2017–2021. There were fewer cases of cancer in Cassia County (527) than expected (573.8) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Cassia County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Cassia County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Cassia County, all sites combined, was 153.1 deaths per 100,000 persons per year during 2018–2022, compared with 165.7 for the remainder of the state. There were fewer cancer deaths in Cassia County (171) than expected (185.1) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN CASSIA COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Ca	ssia County	/			Ren	nainder of Ida	aho
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)		P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	527	121,008	435.5	484.6	573.8	0.051	46,806	8,871,098	527.6
All Sites Combined	Male	257	61,911	415.1	468.9	308.0	0.003 <<	25,013	4,450,362	562.0
All Sites Combined	Female	270	59,097	456.9	501.7	265.3	0.789	21,793	4,420,736	493.0
Bladder	Total	31	121,008	25.6	28.2	27.1	0.500	2,189	8,871,098	24.7
Bladder	Male	22	61,911	35.5	40.1	21.6	0.983	1,751	4,450,362	39.3
Bladder Brain - malignant	Female Total	9 8	59,097 121,008	15.2 6.6	16.5 7.1	5.4 8.2	0.194	438 649	4,420,736 8,871,098	9.9 7.3
Brain - malignant	Male	5	61,911	8.1	8.8	4.8	1.000	377	4,450,362	8.5
Brain - malignant	Female	3	59,097	5.1	5.4	3.4	1.000	272	4,420,736	6.2
Brain and other CNS - non-malignant	Total	35	121,008	28.9	31.7	18.8	0.001 >>	1,512	8,871,098	17.0
	Male	9	61,911	14.5	16.0	6.2	0.349	491	4,450,362	11.0
Brain and other CNS - non-malignant	Female	26	59,097	44.0	47.8	12.6	0.001 >>	1,021	4,420,736	23.1
Breast	Total	86	121,008	71.1	79.8	84.1	0.863	6,922	8,871,098	78.0
Breast	Male Female	2 84	61,911	3.2	3.6 158.6	0.8 82.2	0.368 0.869	63 6 950	4,450,362 4,420,736	1.4
Breast Breast - in situ	Total	04 11	59,097 121,008	142.1 9.1	10.3	62.2 16.3	0.869	6,859 1,358	4,420,736 8,871,098	155.2 15.3
Breast - in situ	Male	- ''	61,911	-	-	0.1	1.000	1,550	4,450,362	0.1
Breast - in situ	Female	11	59,097	18.6	21.1	15.9	0.259	1,354	4,420,736	30.6
Cervix	Female	3	59,097	5.1	5.6	3.5	1.000	291	4,420,736	6.6
Colorectal	Total	48	121,008	39.7	43.9	44.2	0.605	3,584	8,871,098	40.4
Colorectal	Male	22	61,911	35.5	40.0	24.1	0.761	1,955	4,450,362	43.9
Colorectal	Female	26	59,097	44.0	47.6	20.1	0.235	1,629	4,420,736	36.8
Corpus Uteri	Female	14	59,097	23.7	26.7	15.9	0.753	1,340	4,420,736	30.3
Esophagus	Total	3	121,008	2.5	2.8	6.2	0.271	504	8,871,098	5.7
Esophagus Esophagus	Male Female	3	61,911 59,097	4.8	5.5	5.2 1.0	0.466 0.766	426 78	4,450,362 4,420,736	9.6 1.8
Hodgkin Lymphoma	Total	- 4	121,008	- 3.3	- 3.5	2.8	0.616	218	8,871,098	2.5
Hodgkin Lymphoma	Male	3	61,911	4.8	5.2	1.6	0.449	126	4,450,362	2.3
Hodgkin Lymphoma	Female	1	59,097	1.7	1.8	1.0	1.000	92	4,420,736	2.1
Kidney and Renal Pelvis	Total	21	121,008	17.4	19.3	23.6	0.683	1,930	8,871,098	21.8
Kidney and Renal Pelvis	Male	13	61,911	21.0	23.7	16.0	0.549	1,297	4,450,362	29.1
Kidney and Renal Pelvis	Female	8	59,097	13.5	14.8	7.7	1.000	633	4,420,736	14.3
Larynx	Total	1	121,008	0.8	0.9	2.7	0.504	219	8,871,098	2.5
Larynx	Male	- ,	61,911		-	2.1	0.253	167	4,450,362	3.8
Larynx	Female	1	59,097	1.7	1.9	0.6	0.923	52	4,420,736	1.2
Leukemia Leukemia	Total Male	17 10	121,008 61,911	14.0 16.2	15.2 17.8	21.5 12.9	0.391 0.513	1,710 1,026	8,871,098 4,450,362	19.3 23.1
Leukemia	Female	7	59,097	11.8	12.6	8.6	0.753	684	4,420,736	15.5
Liver and Bile Duct	Total	8	121,008	6.6	7.4	10.1	0.640	835	8,871,098	9.4
Liver and Bile Duct	Male	ĕ	61,911	9.7	11.0	7.2	0.845	588	4,450,362	13.2
Liver and Bile Duct	Female	2	59,097	3.4	3.7	3.0	0.846	247	4,420,736	5.6
Lung and Bronchus	Total	39	121,008	32.2	35.9	60.3	0.005 <<	4,920	8,871,098	55.5
Lung and Bronchus	Male	22	61,911	35.5	40.4	30.3	0.147	2,473	4,450,362	55.6
Lung and Bronchus	Female	17	59,097	28.8	31.4	30.0	0.015 <<	2,447	4,420,736	55.4
Melanoma of the Skin	Total	43	121,008	35.5	39.4	38.2	0.474	3,101	8,871,098	35.0
Melanoma of the Skin Melanoma of the Skin	Male Female	24 19	61,911 59,097	38.8 32.2	43.6 35.3	23.1 15.0	0.910 0.357	1,871 1,230	4,450,362	42.0 27.8
Myeloma	Total	9	121,008	7.4	8.3	8.8	1.000	719	4,420,736 8,871,098	8.1
Myeloma	Male	5 7	61,911	11.3	12.8	5.4	0.602	440	4,450,362	9.9
Myeloma	Female		59,097	3.4	3.7	3.4	0.683	279	4,420,736	6.3
Non-Hodgkin Lymphoma	Total	20	121,008	16.5	18.3	24.3	0.444	1,972	8,871,098	22.2
Non-Hodgkin Lymphoma	Male	13	61,911	21.0	23.5	14.1	0.909	1,133	4,450,362	25.5
Non-Hodgkin Lymphoma	Female		59,097	11.8	12.9	10.3	0.389	839	4,420,736	19.0
Oral Cavity and Pharynx	Total	17	121,008	14.0	15.8	15.7	0.815	1,298	8,871,098	14.6
Oral Cavity and Pharynx	Male	10	61,911	16.2	18.3	11.4	0.826	930	4,450,362	20.9
Oral Cavity and Pharynx Ovary	Female Female	7	59,097 59,097	11.8 6.8	13.1	4.5 6.7	0.326 0.411	368 549	4,420,736 4,420,736	8.3 12.4
Pancreas	Total	16	121,008	13.2	7.5 14.6	18.1	0.411	549 1,472	4,420,736 8,871,098	12.4
Pancreas	Male	6	61.911	9.7	10.9	10.1	0.248	820	4.450.362	18.4
Pancreas	Female	10	59,097	16.9	18.4	8.0	0.576	652	4,420,736	14.7
Prostate	Male	59	61,911	95.3	109.3	81.4	0.011 <<	6,707	4,450,362	150.7
Stomach	Total	5	121,008	4.1	4.6	5.8	0.961	469	8,871,098	5.3
Stomach	Male	1	61,911	1.6	1.8	3.8	0.220	306	4,450,362	6.9
Stomach	Female	4	59,097	6.8	7.3	2.0	0.296	163	4,420,736	3.7
Testis	Male	4	61,911	6.5	6.9	3.5	0.930	270	4,450,362	6.1
Thyroid	Total	17	121,008	14.0	15.5	14.5	0.574	1,168	8,871,098	13.2
Thyroid	Male	5	61,911	8.1	9.0	4.6	0.971	367	4,450,362	8.2
Thyroid	Female	12	59,097	20.3	22.3	9.8	0.551	801	4,420,736	18.1
Pediatric Age 0 to 19	Total	10	41,420	24.1	24.2	7.0	0.332	415	2,457,904	16.9
Pediatric Age 0 to 19	Male	6	21,500	27.9	27.9	3.6	0.302	208	1,252,821	16.6
Pediatric Age 0 to 19	Female	4	19,920	20.1	20.3	3.4	0.878	207	1,205,083	17.2

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN CASSIA COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Ca	ssia County	,			Re	mainder of Idah	0
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	1,127	123,002	916.2	981.2	1,003.6	0.000 >>	79,408	9,088,392	873.7
All Causes of Death	Male	582	63,020	923.5	1,030.5	522.2	0.011 >>	42,204	4,564,677	924.6
All Causes of Death	Female	545	59,982	908.6	929.8	482.1	0.005 >>	37,204	4,523,715	822.4
All Malignant Cancers	Total	171	123,002	139.0	153.1	185.1	0.318	15,062	9,088,392	165.7
All Malignant Cancers	Male	96	63,020	152.3	172.6	99.2	0.802	8,139	4,564,677	178.3
All Malignant Cancers	Female	75	59,982	125.0	134.3	85.4	0.281	6,923	4,523,715	153.0
Bladder	Total	8	123,002	6.5	7.0	6.0	0.520	477	9,088,392	5.2
Bladder	Male	5	63,020	7.9	8.9	4.5	0.954	370	4,564,677	8.1
Bladder	Female	3	59,982	5.0	5.1	1.4	0.323	107	4,523,715	2.4
Brain and Other Nervous System	Total	7	123,002	5.7	6.3	6.2	0.866	511	9,088,392	5.6
Brain and Other Nervous System	Male	5 2	63,020	7.9 3.3	8.9	3.5 2.8	0.548	284 227	4,564,677 4,523,715	6.2 5.0
Brain and Other Nervous System Breast	Female Total		59,982 123,002	3.3 8.9	3.6 9.8	2.8	0.960 0.573	1,113	4,523,715	5.0
Breast	Male		63,020	0.9	9.0	0.2	1.000	13	4,564,677	0.3
Breast	Female	- 11	59,982	18.3	19.7	13.5	0.601	1,100	4,523,715	24.3
Cervix	Female	-	59,982	-	-	1.1	0.698	88	4,523,715	1.9
Colorectal	Total	16	123,002	13.0	14.3	16.2	1.000	1,316	9,088,392	14.5
Colorectal	Male	3	63,020	4.8	5.4	8.9	0.046 <<	729	4,564,677	16.0
Colorectal	Female	13	59,982	21.7	23.0	7.3	0.073	587	4,523,715	13.0
Corpus Uteri	Female	-	59,982	I	-	2.0	0.264	169	4,523,715	3.7
Esophagus	Total	2	123,002	1.6	1.8	5.5	0.171	459	9,088,392	5.1
Esophagus	Male	2	63,020	3.2	3.6	4.7	0.304	389	4,564,677	8.5
Esophagus	Female	-	59,982	-	-	0.9	0.844	70	4,523,715	1.5
Hodgkin Lymphoma	Total	-	123,002	-	-	0.3	1.000	25	9,088,392	0.3
Hodgkin Lymphoma	Male Female	-	63,020 59,982	-	-	0.2 0.1	1.000 1.000	14	4,564,677 4.523,715	0.3 0.2
Hodgkin Lymphoma Kidney	Total	- 4	123,002	- 3.3	- 3.6	4.7	0.993	11 382	9,088,392	4.2
Kidney	Male	2	63,020	3.3	3.6	3.0	0.862	244	4,564,677	4.2 5.3
Kidney	Female	2	59,982	3.3	3.5	1.7	1.000	138	4,523,715	3.1
Larynx	Total	1	123,002	0.8	0.9	0.9	1.000	75	9,088,392	0.8
Larynx	Male	-	63,020	-	-	0.8	0.904	65	4,564,677	1.4
Larynx	Female	1	59,982	1.7	1.9	0.1	0.219	10	4,523,715	0.2
Leukemia	Total	4	123,002	3.3	3.5	8.2	0.172	661	9,088,392	7.3
Leukemia	Male	3	63,020	4.8	5.3	4.9	0.573	394	4,564,677	8.6
Leukemia	Female	1	59,982	1.7	1.8	3.4	0.300	267	4,523,715	5.9
Liver and Bile Duct	Total	9	123,002	7.3	8.2	7.5	0.682	626	9,088,392	6.9
Liver and Bile Duct	Male	7	63,020	11.1 3.3	12.7 3.7	5.0 2.5	0.477	416	4,564,677	9.1 4.6
Liver and Bile Duct Lung and Bronchus	Female Total	2 17	59,982 123,002	3.3 13.8	3.7 15.4	2.5	1.000 0.001 <<	210 2,920	4,523,715 9,088,392	4.0 32.1
Lung and Bronchus	Male	12	63,020	19.0	21.8	18.5	0.001 <<	1,529	4,564,677	33.5
Lung and Bronchus	Female	5	59,982	8.3	9.0	17.0	0.001 <<	1,391	4,523,715	30.7
Melanoma of the Skin	Total	7	123,002	5.7	6.3	3.6	0.150	294	9,088,392	3.2
Melanoma of the Skin	Male	3	63,020	4.8	5.4	2.4	0.867	197	4,564,677	4.3
Melanoma of the Skin	Female	4	59,982	6.7	7.1	1.2	0.068	97	4,523,715	2.1
Myeloma	Total	9	123,002	7.3	8.0	3.9	0.037 >>	316	9,088,392	3.5
Myeloma	Male	5	63,020	7.9	9.0	2.2	0.151	183	4,564,677	4.0
Myeloma	Female	4	59,982	6.7	7.1	1.6	0.172	133	4,523,715	2.9
Non-Hodgkin Lymphoma	Total	7	123,002	5.7	6.2	7.0	1.000	561	9,088,392	6.2
Non-Hodgkin Lymphoma	Male	6	63,020	9.5	10.8	3.7	0.344	304	4,564,677	6.7
Non-Hodgkin Lymphoma Oral Cavity and Pharynx	Female	1	59,982 123,002	1.7 3.3	1.7 3.6	3.2 3.3	0.330	257 271	4,523,715 9,088,392	5.7 3.0
Oral Cavity and Pharynx Oral Cavity and Pharynx	Total Male	4	63,020	3.3 4.8	3.6 5.4	3.3 2.3	0.825 0.798	189	9,088,392 4,564,677	3.0 4.1
Oral Cavity and Pharynx	Female	3 1	59,982	4.0	5.4 1.8	2.3	1.000	82	4,523,715	4.1
Ovary	Female	2	59,982	3.3	3.7	4.3	0.384	359	4,523,715	7.9
Pancreas	Total	13	123,002	10.6	11.8	14.3	0.871	1,177	9,088,392	13.0
Pancreas	Male	6	63,020	9.5	10.9	7.8	0.682	644	4,564,677	14.1
Pancreas	Female	7	59,982	11.7	12.7	6.5	0.949	533	4,523,715	11.8
Prostate	Male	15	63,020	23.8	26.7	12.1	0.468	982	4,564,677	21.5
Stomach	Total	2	123,002	1.6	1.8	2.4	1.000	192	9,088,392	2.1
	Male	2	63,020	3.2	3.6	1.4	0.835	117	4,564,677	2.6
Stomach	Female	-	59,982	-	-	0.9	0.790	75	4,523,715	1.7

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Cassia County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	88.8% 11.2%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	53.7%
Current Tobacco User (2020–2022) <u>Other Cancer-Related</u>	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	19.3%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	29.0% 70.7% 14.1% 8.7%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





CLARK COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 16 cases of invasive cancer were diagnosed among Clark County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,

 Lung and Bronchus, and Colorectal Cancers in Clark County

 and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Clark County	State of Idaho
All Sites/Types	16	47,333
Female Breast	2	6,943
Prostate	1	6,766
Lung & Bronchus	1	4,959
Colorectal	0	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Clark County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Clark County. The table also shows the number of observed cases, person-

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 6 Clark County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Clark County and the State of Idaho, 2018–2022

Mortality 2018–2022	Clark County	State of Idaho
All Deaths	30	80,538
Cancer Deaths	6	15,233
% of All Deaths	20.0%	18.9%
Lung & Bronchus	0	2,937
Colorectal	0	1,332
Pancreas	1	1,190
Female Breast	0	1,111
Prostate	0	997

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Clark County was 380.4 cases per 100,000 personyears per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (526.5) gives an estimate of the relative burden of disease in Clark County.

The age- and sex-adjusted incidence rate of invasive cancer in Clark County, all sites combined, was 349.9 cases per 100,000 persons per year during 2017–2021. There were fewer cases of cancer in Clark County (16) than expected (24.1) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Clark County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Clark County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Clark County, all sites combined, was 123.1 deaths per 100,000 persons per year during 2018–2022, compared with 165.4 for the remainder of the state. There were fewer cancer deaths in Clark County (6) than expected (8.1) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN CLARK COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Cl	ark County				Rem	nainder of Ida	aho
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	16	4,206	380.4	349.9	24.1	0.109	47,317	8,987,900	526.5
All Sites Combined	Male	7	2,173	322.1	270.9	14.5	0.049 <<	25,263	4,510,100	560.1
All Sites Combined	Female	9	2,033	442.7	440.5	10.1	0.900	22,054	4,477,800	492.5
Bladder	Total	-	4,206	-	-	1.2	0.613	2,220	8,987,900	24.7
Bladder	Male	-	2,173	-	-	1.1	0.679	1,773	4,510,100	39.3
Bladder	Female	-	2,033	-	-	0.2	1.000	447	4,477,800	10.0
Brain - malignant	Total	-	4,206	-	-	0.3	1.000	657	8,987,900	7.3
Brain - malignant	Male	-	2,173	-	-	0.2	1.000	382	4,510,100	8.5
Brain - malignant Brain and other CNS - non-malignant	Female Total	-	2,033 4,206	-	-	0.1 0.8	1.000 0.911	275 1,547	4,477,800 8,987,900	6.1 17.2
	Male	-	2,173	-	-	0.8	1.000	500	4,510,100	11.1
Brain and other CNS - non-malignant	Female	-	2,033	-	-	0.5	1.000	1,047	4,477,800	23.4
Breast	Total	2	4,206	47.6	44.7	3.5	0.646	7,006	8,987,900	77.9
Breast	Male	-	2,173	-	-	0.0	1.000	65	4,510,100	1.4
Breast	Female	2	2,033	98.4	99.1	3.1	0.790	6,941	4,477,800	155.0
Breast - in situ	Total	-	4,206	-	-	0.7	1.000	1,369	8,987,900	15.2
Breast - in situ	Male	-	2,173	-	-	0.0	1.000	4	4,510,100	0.1
Breast - in situ	Female	-	2,033	-	-	0.6	1.000	1,365	4,477,800	30.5
Cervix	Female	-	2,033	-	-	0.1	1.000	294	4,477,800	6.6
Colorectal Colorectal	Total Male	-	4,206 2,173	-	-	1.9 1.1	0.306 0.642	3,632 1,977	8,987,900 4,510,100	40.4 43.8
Colorectal	Female	-	2,173	-		0.8	0.642	1,977	4,510,100	43.8 37.0
Corpus Uteri	Female	- 2	2,033	- 98.4	- 100.9	0.6	0.243	1,352	4,477,800	30.2
Esophagus	Total	-	4,206	- 30.4	-	0.0	1.000	507	8,987,900	5.6
Esophagus	Male	-	2,173	-	-	0.3	1.000	429	4,510,100	9.5
Esophagus	Female	-	2,033	-	-	0.0	1.000	78	4,477,800	1.7
Hodgkin Lymphoma	Total	-	4,206	-	-	0.1	1.000	222	8,987,900	2.5
Hodgkin Lymphoma	Male	-	2,173	-	-	0.1	1.000	129	4,510,100	2.9
Hodgkin Lymphoma	Female	-	2,033	-	-	0.0	1.000	93	4,477,800	2.1
Kidney and Renal Pelvis	Total	-	4,206	-	-	1.0	0.746	1,951	8,987,900	21.7
Kidney and Renal Pelvis	Male	-	2,173	-	-	0.7	0.959	1,310	4,510,100	29.0
Kidney and Renal Pelvis	Female Total	-	2,033 4,206	-	-	0.3 0.1	1.000 1.000	641 220	4,477,800	14.3 2.4
Larynx Larynx	Male	-	2,173	-	-	0.1	1.000	167	8,987,900 4,510,100	2.4
Larynx	Female	-	2,033	-	-	0.0	1.000	53	4,477,800	1.2
Leukemia	Total	1	4,206	23.8	21.5	0.9	1.000	1,726	8,987,900	19.2
Leukemia	Male	-	2,173	-	-	0.6	1.000	1,036	4,510,100	23.0
Leukemia	Female	1	2,033	49.2	47.8	0.3	0.551	690	4,477,800	15.4
Liver and Bile Duct	Total	-	4,206	-	-	0.4	1.000	843	8,987,900	9.4
Liver and Bile Duct	Male	-	2,173	-	-	0.3	1.000	594	4,510,100	13.2
Liver and Bile Duct	Female	-	2,033	-	-	0.1	1.000	249	4,477,800	5.6
Lung and Bronchus	Total	1	4,206	23.8	21.3	2.6	0.539	4,958	8,987,900	55.2
Lung and Bronchus Lung and Bronchus	Male Female	- 1	2,173 2,033	46.0	37.7	1.5 1.1	1.000 0.638	2,494 2,464	4,510,100 4,477,800	55.3 55.0
Melanoma of the Skin	Total	- 2	4,206	47.6	43.8	1.1	0.947	3,142	8,987,900	35.0
Melanoma of the Skin	Male	2	2,173	92.0	76.5	1.0	0.600	1,893	4,510,100	42.0
Melanoma of the Skin	Female	-	2,033	-	-	0.6	1.000	1,249	4,477,800	27.9
Myeloma	Total	1	4,206	23.8	21.4	0.4	0.630	727	8,987,900	8.1
Myeloma	Male	1	2,173	46.0	37.4	0.3	0.464	446	4,510,100	9.9
Myeloma	Female		2,033	-	-	0.1	1.000	281	4,477,800	6.3
Non-Hodgkin Lymphoma	Total	2	4,206	47.6	43.6	1.0	0.540	1,990	8,987,900	22.1
Non-Hodgkin Lymphoma	Male	1	2,173	46.0	39.5	0.6	0.948	1,145	4,510,100	25.4
Non-Hodgkin Lymphoma	Female		2,033	49.2	48.4	0.4	0.645	845	4,477,800	18.9
Oral Cavity and Pharynx Oral Cavity and Pharynx	Total Male	-	4,206 2,173	-	-	0.7	1.000 1.000	1,315	8,987,900 4,510,100	14.6 20.8
Oral Cavity and Pharynx	Female	-	2,173	-	-	0.5 0.2	1.000	940 375	4,477,800	20.8
Ovary	Female	-	2,033	-		0.2	1.000	553	4,477,800	12.3
Pancreas	Total	- 1	4,206	23.8	21.2	0.2	1.000	1,487	8,987,900	12.5
Pancreas	Male	-	2,173	-		0.5	1.000	826	4,510,100	18.3
Pancreas	Female	1	2,033	49.2	48.0	0.3	0.529	661	4,477,800	14.8
Prostate	Male	1	2,173	46.0	39.7	3.8	0.219	6,765	4,510,100	150.0
Stomach	Total	1	4,206	23.8	21.3	0.2	0.439	473	8,987,900	5.3
Stomach	Male	-	2,173	-	-	0.2	1.000	307	4,510,100	6.8
Stomach	Female	1	2,033	49.2	47.3	0.1	0.151	166	4,477,800	3.7
Testis	Male	-	2,173	-	-	0.1	1.000	274	4,510,100	6.1
Thyroid	Total	1	4,206	23.8	23.4	0.6	0.861	1,184	8,987,900	13.2
Thyroid	Male	- ,	2,173	-	-	0.2	1.000	372	4,510,100	8.2
Thyroid	Female	1	2,033	49.2	50.2	0.4	0.607	812	4,477,800	18.1
Pediatric Age 0 to 19	Total	-	1,123	-	-	0.2	1.000	425	2,498,201	17.0
									4	
Pediatric Age 0 to 19 Pediatric Age 0 to 19 Pediatric Age 0 to 19	Male Female	-	538 585	-	-	0.1 0.1	1.000 1.000	214 211	1,273,783 1,224,418	16.8 17.2

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN CLARK COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Cl	ark County				Re	mainder of Idah	10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	30	4,134	725.7	583.9	44.9	0.024 <<	80,505	9,207,260	874.4
All Causes of Death	Male	30 14	2,144	653.0	480.1	27.0	0.024 <<		4,625,553	924.7
All Causes of Death	Female	14	1,990	804.0	707.2	18.6	0.642	37,733	4,581,707	823.6
All Malignant Cancers	Total	6	4,134	145.1	123.1	8.1	0.642	15,227	9,207,260	165.4
All Malignant Cancers	Male	1	2,144	46.6	35.6	5.0	0.012	8,234	4,625,553	178.0
All Malignant Cancers	Female	5	1,990	251.3	234.1	3.3	0.460	6,993	4,581,707	152.6
Bladder	Total	5	4,134	201.0	204.1	0.3	1.000	485	9,207,260	5.3
Bladder	Male	-	2,144	-	_	0.3	1.000	375	4,625,553	8.1
Bladder	Female	-	1,990	-	_	0.1	1.000	110	4,581,707	2.4
Brain and Other Nervous System	Total	-	4,134	-	-	0.3	1.000	518	9,207,260	5.6
Brain and Other Nervous System	Male	-	2,144	-	-	0.2	1.000	289	4,625,553	6.2
Brain and Other Nervous System	Female	-	1,990	-	-	0.1	1.000	229	4,581,707	5.0
Breast	Total	-	4,134	-	-	0.6	1.000	1,124	9,207,260	12.2
Breast	Male	-	2,144	-	-	0.0	1.000	13	4,625,553	0.3
Breast	Female	-	1,990	-	-	0.5	1.000	1,111	4,581,707	24.2
Cervix	Female	-	1,990	-	-	0.0	1.000	88	4,581,707	1.9
Colorectal	Total	-	4,134	-	-	0.7	0.988	1,332	9,207,260	14.5
Colorectal	Male	-	2,144	-	-	0.4	1.000	732	4,625,553	15.8
Colorectal	Female	-	1,990	-	-	0.3	1.000	600	4,581,707	13.1
Corpus Uteri	Female	-	1,990	-	-	0.1	1.000	169	4,581,707	3.7
Esophagus	Total	-	4,134	-	-	0.2	1.000	461	9,207,260	5.0
Esophagus	Male	-	2,144	-	-	0.2	1.000	391	4,625,553	8.5
Esophagus	Female	-	1,990	-	-	0.0	1.000	70	4,581,707	1.5
Hodgkin Lymphoma	Total	-	4,134 2,144	-	-	0.0	1.000 1.000	25	9,207,260	0.3
Hodgkin Lymphoma	Male	-		-	-	0.0 0.0	1.000	14	4,625,553 4,581,707	0.3
Hodgkin Lymphoma	Female Total	- 1	1,990 4,134	- 24.2	- 20.5	0.0	0.369	11 385		0.2
Kidney Kidney	Male	1	2,144	24.2 46.6	36.3	0.2	0.309	245	9,207,260 4,625,553	4.2 5.3
Kidney	Female	- '	1,990	40.0	- 30.3	0.1	1.000	140	4,025,555	3.1
Larynx	Total	-	4,134	-	-	0.0	1.000	76	9,207,260	0.8
Larynx	Male	-	2,144	-	-	0.0	1.000	65	4,625,553	1.4
Larynx	Female	-	1,990	-	_	0.0	1.000	11	4,581,707	0.2
Leukemia	Total	-	4,134	-	-	0.4	1.000	665	9,207,260	7.2
Leukemia	Male	-	2,144	-	-	0.2	1.000	397	4,625,553	8.6
Leukemia	Female	-	1,990	-	-	0.1	1.000	268	4,581,707	5.8
Liver and Bile Duct	Total	-	4,134	-	-	0.3	1.000	635	9,207,260	6.9
Liver and Bile Duct	Male	-	2,144	-	-	0.2	1.000	423	4,625,553	9.1
Liver and Bile Duct	Female	-	1,990	-	-	0.1	1.000	212	4,581,707	4.6
Lung and Bronchus	Total	-	4,134	-	-	1.5	0.431	2,937	9,207,260	31.9
Lung and Bronchus	Male	-	2,144	-	-	0.9	0.807	1,541	4,625,553	33.3
Lung and Bronchus	Female	-	1,990	-	-	0.6	1.000	1,396	4,581,707	30.5
Melanoma of the Skin	Total	-	4,134	-	-	0.2	1.000	301	9,207,260	3.3
Melanoma of the Skin	Male	-	2,144	-	-	0.1	1.000	200	4,625,553	4.3
Melanoma of the Skin	Female	-	1,990	-	-	0.0	1.000	101	4,581,707	2.2
Myeloma	Total	-	4,134	-	-	0.2	1.000	325	9,207,260	3.5
Myeloma	Male	-	2,144	-	-	0.1	1.000	188	4,625,553	4.1
Myeloma	Female	-	1,990 4,134	-	-	0.1	1.000	137	4,581,707	3.0
Non-Hodgkin Lymphoma	Total Male	-	4,134	-	-	0.3	1.000 1.000	568 310	9,207,260	6.2 6.7
Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma	Female	-	2,144 1,990	-	-	0.2 0.1	1.000	258	4,625,553 4,581,707	6.7 5.6
Oral Cavity and Pharynx	Total	-	4,134	-	-	0.1	1.000	200	9,207,260	3.0
Oral Cavity and Pharynx	Male	-	2,144	-	-	0.1	1.000	192	4,625,553	4.2
Oral Cavity and Pharynx	Female	-	1,990	-	-	0.0	1.000	83	4,581,707	1.8
Ovary	Female	-	1,990	-	-	0.0	1.000	361	4,581,707	7.9
Pancreas	Total	1	4,134	24.2	21.1	0.2	0.915	1,189	9,207,260	12.9
Pancreas	Male	- '	2,144	-	-	0.0	1.000	650	4,625,553	14.1
Pancreas	Female	1	1,990	50.3	47.4	0.4	0.440	539	4,581,707	11.8
Prostate	Male		2,144	-	-	0.2	1.000	997	4,625,553	21.6
Stomach	Total	1	4,134	24.2	20.4	0.1	0.195	193	9,207,260	2.1
Stomach	Male	- '	2,144		-	0.1	1.000	119	4,625,553	2.6
Stomach	Female	1	1,990	50.3	46.7	0.0	0.068	74	4,581,707	1.6

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Clark County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	· ·
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	- - -
Current Tobacco User (2020–2022) <u>Other Cancer-Related</u>	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	•
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	30.0% 79.1% 22.0%	30.0% 79.0% 22.8%	30.1% 78.0% 19.2%	26.5% 75.4% 20.0%	33.7% 82.7% 25.2%	27.5% 75.2% 19.5%	26.7% 76.7% 20.4%	30.2% 81.0% 20.3%	•
Home Ever Tested for Radon (2016, 2018, 2020)	22.9%	30.8%	18.3%	16.9%	25.2%	20.1%	23.0%	21.0%	

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





CLEARWATER COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 364 cases of invasive cancer were diagnosed among Clearwater County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,

 Lung and Bronchus, and Colorectal Cancers in Clearwater

 County and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Clearwater County	State of Idaho
All Sites/Types	364	47,333
Female Breast	39	6,943
Prostate	56	6,766
Lung & Bronchus	60	4,959
Colorectal	36	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Clearwater County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Clearwater County. The table also shows the number of observed cases,

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 140 Clearwater County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Clearwater County and the State of Idaho, 2018–2022

Mortality 2018–2022	Clearwater County	State of Idaho
All Deaths	598	80,538
Cancer Deaths	140	15,233
% of All Deaths	23.4%	18.9%
Lung & Bronchus	40	2,937
Colorectal	16	1,332
Pancreas	6	1,190
Female Breast	5	1,111
Prostate	6	997

person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, nonmalignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Clearwater County was 828.5 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (524.9) gives an estimate of the relative burden of disease in Clearwater County.

The age- and sex-adjusted incidence rate of invasive cancer in Clearwater County, all sites combined, was 539.4 cases per 100,000 persons per year during 2017–2021. There were more cases of cancer in Clearwater County (364) than expected (354.2) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Clearwater County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Clearwater County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Clearwater County, all sites combined, was 188.9 deaths per 100,000 persons per year during 2018–2022, compared with 164.6 for the remainder of the state. There were more cancer deaths in Clearwater County (140) than expected (122.0) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021 COMPARISON BETWEEN CLEARWATER COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Clear	Remainder of Idaho						
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)		P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	364	43,934	828.5	539.4	354.2	0.617	46,969	8,948,172	524.9
All Sites Combined	Male	206	24,286	848.2	545.7	210.8	0.773	25,064	4,487,987	558.5
All Sites Combined	Female	158	19.648	804.2	526.6	147.4	0.401	21,905	4,460,185	491.1
Bladder	Total	22	43,934	50.1	29.8	18.1	0.417	2,198	8,948,172	24.6
Bladder	Male	19	24,286	78.2	46.7	15.9	0.498	1,754	4,487,987	39.1
Bladder	Female	3	19,648	15.3	9.1	3.3	1.000	444	4,460,185	10.0
Brain - malignant	Total	2	43,934	4.6	3.4	4.4	0.378	655	8,948,172	7.3
Brain - malignant	Male	2	24,286	8.2	6.2	2.7	0.964	380	4,487,987	8.5
Brain - malignant	Female	-	19,648	-	-	1.7	0.363	275	4,460,185	6.2
Brain and other CNS - non-malignant	Total	12	43,934	27.3	18.7	11.0	0.839	1,535	8,948,172	17.2
	Male	4	24,286	16.5	11.7	3.8	1.000	496	4,487,987	11.1
Brain and other CNS - non-malignant Breast	Female Total	8 39	19,648 43,934	40.7 88.8	27.2 60.4	6.9 50.3	0.759 0.118	1,039 6,969	4,460,185	23.3 77.9
Breast	Male	39	43,934 24,286	00.0	00.4	0.6	1.000	0,909	8,948,172 4,487,987	1.4
Breast	Female	- 39	19,648	- 198.5	132.7	45.5	0.377	6,904	4,460,185	154.8
Breast - in situ	Total	5	43,934	11.4	7.9	9.6	0.169	1,364	8,948,172	15.2
Breast - in situ	Male	-	24,286	-	-	0.0	1.000	4	4,487,987	0.1
Breast - in situ	Female	5	19,648	25.4	17.5	8.7	0.266	1,360	4,460,185	30.5
Cervix	Female	-	19,648	-	-	1.5	0.459	294	4,460,185	6.6
Colorectal	Total	36	43,934	81.9	53.6	27.0	0.111	3,596	8,948,172	40.2
Colorectal	Male	23	24,286	94.7	63.0	15.9	0.110	1,954	4,487,987	43.5
Colorectal	Female	13	19,648	66.2	42.2	11.3	0.697	1,642	4,460,185	36.8
Corpus Uteri	Female	7	19,648	35.6	23.5	9.0	0.648	1,347	4,460,185	30.2
Esophagus	Total	10	43,934	22.8	14.2	3.9	0.014 >>	497	8,948,172	5.6
Esophagus	Male	9	24,286	37.1	23.4	3.6	0.023 >>	420	4,487,987	9.4
Esophagus	Female	1	19,648	5.1	3.0	0.6	0.867	77	4,460,185	1.7
Hodgkin Lymphoma	Total	-	43,934	-	-	1.2	0.600	222	8,948,172	2.5
Hodgkin Lymphoma	Male Female	-	24,286	-	-	0.8 0.4	0.890 1.000	129	4,487,987 4.460.185	2.9 2.1
Hodgkin Lymphoma Kidney and Renal Pelvis	Total	- 14	19,648 43,934	- 31.9	- 21.0	14.4	1.000	93 1,937	4,460,165 8,948,172	2.1
Kidney and Renal Pelvis	Male	14	24,286	41.2	27.5	14.4	1.000	1,300	4,487,987	21.0
Kidney and Renal Pelvis	Female	4	19,648	20.4	13.2	4.3	1.000	637	4,460,185	14.3
Larynx	Total	4	43,934	9.1	5.7	1.7	0.182	216	8,948,172	2.4
Larynx	Male	2	24,286	8.2	5.2	1.4	0.820	165	4,487,987	3.7
Larynx	Female	2	19,648	10.2	6.4	0.4	0.102	51	4,460,185	1.1
Leukemia	Total	16	43,934	36.4	23.9	12.8	0.438	1,711	8,948,172	19.1
Leukemia	Male	10	24,286	41.2	27.3	8.4	0.664	1,026	4,487,987	22.9
Leukemia	Female	6	19,648	30.5	19.6	4.7	0.660	685	4,460,185	15.4
Liver and Bile Duct	Total	6	43,934	13.7	8.7	6.4	1.000	837	8,948,172	9.4
Liver and Bile Duct	Male	6	24,286	24.7	16.0	4.9	0.738	588	4,487,987	13.1
Liver and Bile Duct	Female	-	19,648	-	-	1.8	0.343	249	4,460,185	5.6
Lung and Bronchus	Total	60	43,934	136.6	82.2	40.0	0.004 >>	4,899	8,948,172	54.7
Lung and Bronchus	Male	22	24,286	90.6	54.6	22.2	1.000	2,473	4,487,987	55.1
Lung and Bronchus Melanoma of the Skin	Female Total	38 17	19,648 43,934	193.4 38.7	114.5 26.1	18.0 22.8	0.000 >> 0.263	2,426 3,127	4,460,185	54.4 34.9
Melanoma of the Skin	Male	9	43,934 24,286	30.7	20.1	15.6	0.203	1,886	8,948,172 4,487,987	42.0
Melanoma of the Skin	Female	9 8	24,200 19,648	40.7	24.3	7.7	1.000	1,000	4,460,185	42.0 27.8
Myeloma	Total	1	43,934	2.3	1.4	5.8	0.042 <<	727	8,948,172	8.1
Myeloma	Male	- '	24,286	-	-	3.9	0.041 <<		4,487,987	10.0
Myeloma	Female	1	19,648	5.1	3.1	2.0	0.802	280	4,460,185	6.3
Non-Hodgkin Lymphoma	Total	15	43,934	34.1	22.3	14.8	1.000	1,977	8,948,172	22.1
Non-Hodgkin Lymphoma	Male	8	24,286	32.9	21.9	9.3	0.845	1,138	4,487,987	25.4
Non-Hodgkin Lymphoma	Female	7	19,648	35.6	22.4	5.9	0.745	839	4,460,185	18.8
Oral Cavity and Pharynx	Total	17	43,934	38.7	25.3	9.7	0.043 >>	1,298	8,948,172	14.5
Oral Cavity and Pharynx	Male	9	24,286	37.1	24.8	7.5	0.685	931	4,487,987	20.7
Oral Cavity and Pharynx	Female	8	19,648	40.7	25.8	2.5	0.009 >>	367	4,460,185	8.2
Ovary	Female	2	19,648	10.2	6.8	3.6	0.601	551	4,460,185	12.4
Pancreas	Total	11	43,934	25.0	15.4	11.8	0.969	1,477	8,948,172	16.5
Pancreas	Male	6	24,286	24.7	15.3	7.2	0.854	820	4,487,987	18.3
Pancreas Brostato	Female	5	19,648	25.4	15.3	4.8	1.000	657 6 710	4,460,185	14.7
Prostate Stomach	Male Total	56	24,286 43,934	230.6 11.4	145.5	57.5	0.907 0.601	6,710	4,487,987 8,948,172	149.5
Stomach	Male	5 2	43,934 24,286	8.2	7.2 5.2	3.6 2.6	1.000	469 305	0,940,172 4,487,987	5.2 6.8
Stomach	Female	23	24,200 19,648	0.2 15.3	9.7	2.0	0.214	305 164	4,460,185	3.7
Testis	Male	-	24,286	-	5.7	1.1	0.214	274	4,487,987	6.1
Thyroid	Total	- 2	43,934	4.6	3.8	6.9	0.466	1,183	8,948,172	13.2
Thyroid	Male	2	43,934 24,286	4.0 8.2	6.3	2.6	1.000	370	4,487,987	8.2
Thyroid	Female	2	24,200 19,648	0.2	0.3	2.0 4.0	0.036 <<	813	4,460,185	0.2 18.2
Pediatric Age 0 to 19	Total	- 1	7,491	- 13.3	- 13.2	4.0	1.000	424	2,491,833	10.2
		1		13.3	13.2				2,491,633	
Pediatric Age 0 to 19 Pediatric Age 0 to 19	Male Female	- 1	4,226 3,265	- 30.6	- 30.6	0.7 0.6	0.980 0.859	214 210	1,270,095	16.8 17.2
	I CITICILE	I	5,205	30.0	50.0	0.0	0.003	210	1,221,100	17.2

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN CLEARWATER COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Clear	Re	Remainder of Idaho					
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	598	44,298	1,349.9	804.0	648.5	0.047 <<	79,937	9,167,096	872.0
All Causes of Death	Male	340	24,507	1,387.4	848.2	369.6	0.127	42,446	4.603.190	922.1
All Causes of Death	Female	258	19,791	1,303.6	737.6	287.3	0.085	37,491	4,563,906	821.5
All Malignant Cancers	Total	140	44,298	316.0	188.9	122.0	0.119	15,093	9,167,096	164.6
All Malignant Cancers	Male	75	24,507	306.0	182.8	72.7	0.823	8,160	4,603,190	177.3
All Malignant Cancers	Female	65	19,791	328.4	193.2	51.1	0.068	6,933	4,563,906	151.9
Bladder	Total	2	44,298	4.5	2.5	4.2	0.426	483	9,167,096	5.3
Bladder	Male	2	24,507	8.2	4.6	3.5	0.624	373	4,603,190	8.1
Bladder	Female	-	19,791	-	-	0.9	0.834	110	4,563,906	2.4
Brain and Other Nervous System	Total	2	44,298	4.5	3.0	3.7	0.564	516	9,167,096	5.6
Brain and Other Nervous System	Male	2	24,507	8.2	5.6	2.2	1.000	287	4,603,190	6.2
Brain and Other Nervous System	Female	-	19,791	-	-	1.5	0.432	229	4,563,906	5.0
Breast	Total	6	44,298	13.5	8.3	8.8	0.453	1,118	9,167,096	12.2
Breast	Male Female	1 5	24,507 19,791	4.1 25.3	2.4 15.2	0.1 8.0	0.203 0.388	12 1,106	4,603,190 4,563,906	0.3 24.2
Breast Cervix	Female	- 5	19,791	- 25.5	-	0.0	1.000	88	4,563,906	1.9
Colorectal	Total	- 16	44,298	- 36.1	- 22.3	10.5	0.122	00 1,316	9,167,096	14.4
Colorectal	Male	7	24,507	28.6	18.1	6.1	0.122	725	4,603,190	14.4
Colorectal	Female	9	19,791	45.5	26.7	4.4	0.068	591	4,563,906	12.9
Corpus Uteri	Female	2	19,791	10.1	6.0	1.2	0.686	167	4,563,906	3.7
Esophagus	Total	9	44,298	20.3	12.3	3.6	0.024 >>	452	9,167,096	4.9
Esophagus	Male	9	24,507	36.7	22.5	3.3	0.014 >>	382	4,603,190	8.3
Esophagus	Female	-	19,791	-	-	0.5	1.000	70	4,563,906	1.5
Hodgkin Lymphoma	Total	-	44,298	-	-	0.2	1.000	25	9,167,096	0.3
Hodgkin Lymphoma	Male	-	24,507	-	-	0.1	1.000	14	4,603,190	0.3
Hodgkin Lymphoma	Female	-	19,791	-	-	0.1	1.000	11	4,563,906	0.2
Kidney	Total	6	44,298	13.5	7.9	3.1	0.195	380	9,167,096	4.1
Kidney	Male	3	24,507	12.2	7.3	2.2	0.737	243	4,603,190	5.3
Kidney	Female	3	19,791	15.2	8.5	1.1	0.181	137	4,563,906	3.0 0.8
Larynx	Total Male	-	44,298 24,507	-	-	0.6 0.6	1.000 1.000	76 65	9,167,096 4,603,190	0.0
Larynx Larynx	Female	-	19,791	-	-	0.0	1.000	11	4,563,906	0.2
Leukemia	Total	3	44,298	6.8	4.0	5.4	0.421	662	9,167,096	7.2
Leukemia	Male	2	24,507	8.2	4.8	3.6	0.622	395	4,603,190	8.6
Leukemia	Female	1	19,791	5.1	2.9	2.0	0.813	267	4,563,906	5.9
Liver and Bile Duct	Total	5	44,298	11.3	6.9	5.0	1.000	630	9,167,096	6.9
Liver and Bile Duct	Male	5	24,507	20.4	12.7	3.6	0.582	418	4,603,190	9.1
Liver and Bile Duct	Female	-	19,791	-	-	1.5	0.427	212	4,563,906	4.6
Lung and Bronchus	Total	40	44,298	90.3	52.9	23.9	0.003 >>	2,897	9,167,096	31.6
Lung and Bronchus	Male	15	24,507	61.2	36.0	13.8	0.817	1,526	4,603,190	33.2
Lung and Bronchus	Female	25	19,791	126.3	72.4	10.4	0.000 >>	1,371	4,563,906	30.0
Melanoma of the Skin	Total	1	44,298	2.3	1.4	2.3	0.641	300	9,167,096	3.3
Melanoma of the Skin	Male	1	24,507	4.1	2.5	1.7	0.975	199	4,603,190	4.3
Melanoma of the Skin	Female	- 1	19,791	-	-	0.7	0.981	101 324	4,563,906	2.2 3.5
Myeloma Myeloma	Total Male	1	44,298 24,507	2.3	1.3	2.7	0.489 0.351	324 188	9,167,096 4,603,190	3.5 4.1
Myeloma	Female	- 1	19,791	- 5.1	- 2.9	1.7	1.000	136	4,563,906	3.0
Non-Hodgkin Lymphoma	Total	6	44,298	13.5	7.9	4.6	0.644	562	9,167,096	6.1
Non-Hodgkin Lymphoma	Male	4	24,507	16.3	9.8	2.7	0.583	306	4,603,190	6.6
Non-Hodgkin Lymphoma	Female	2	19,791	10.0	5.6	2.0	1.000	256	4,563,906	5.6
Oral Cavity and Pharynx	Total	6	44,298	13.5	8.3	2.1	0.043 >>	269	9,167,096	2.9
Oral Cavity and Pharynx	Male	5	24,507	20.4	12.5	1.6	0.050 >>	187	4,603,190	4.1
Oral Cavity and Pharynx	Female	1	19,791	5.1	3.0	0.6	0.900	82	4,563,906	1.8
Ovary	Female	3	19,791	15.2	9.0	2.6	0.967	358	4,563,906	7.8
Pancreas	Total	6	44,298	13.5	8.1	9.6	0.320	1,184	9,167,096	12.9
Pancreas	Male	3	24,507	12.2	7.4	5.7	0.355	647	4,603,190	14.1
Pancreas	Female	3	19,791	15.2	8.9	4.0	0.877	537	4,563,906	11.8
Prostate	Male	6	24,507	24.5	13.6	9.5	0.332	991	4,603,190	21.5
Stomach	Total	3	44,298	6.8	4.3	1.5	0.367	191	9,167,096	2.1
Stomach	Male	1	24,507	4.1	2.5	1.0	1.000	118	4,603,190	2.6
Stomach	Female	2	19,791	10.1	6.5	0.5	0.176	73	4,563,906	1.6

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Clearwater County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	82.7% 18.0%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	53.6%
Current Tobacco User (2020–2022) Other Cancer-Related	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	18.1%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	29.9% 71.1% 16.4% 20.0%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





CUSTER COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 158 cases of invasive cancer were diagnosed among Custer County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in CusterCounty and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Custer County	State of Idaho
All Sites/Types	158	47,333
Female Breast	16	6,943
Prostate	30	6,766
Lung & Bronchus	17	4,959
Colorectal	16	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Custer County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Custer County. The table also shows the number of observed cases, person-

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 64 Custer County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Custer County and the State of Idaho, 2018–2022

Mortality 2018–2022	Custer County	State of Idaho
All Deaths	276	80,538
Cancer Deaths	64	15,233
% of All Deaths	23.2%	18.9%
Lung & Bronchus	13	2,937
Colorectal	7	1,332
Pancreas	6	1,190
Female Breast	7	1,111
Prostate	4	997

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Custer County was 741.4 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (525.9) gives an estimate of the relative burden of disease in Custer County.

The age- and sex-adjusted incidence rate of invasive cancer in Custer County, all sites combined, was 465.2 cases per 100,000 persons per year during 2017–2021. There were fewer cases of cancer in Custer County (158) than expected (178.6) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Custer County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Custer County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Custer County, all sites combined, was 178.2 deaths per 100,000 persons per year during 2018–2022, compared with 165.1 for the remainder of the state. There were more cancer deaths in Custer County (64) than expected (59.3) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN CUSTER COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Cu	ster County	/			Ren	nainder of Ida	aho
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)		P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	158	21,310	741.4	465.2	178.6	0.128	47,175	8,970,796	525.9
All Sites Combined	Male	103	11,106	927.4	536.1	107.4	0.715	25,167	4,501,167	559.1
All Sites Combined	Female	55	10,204	539.0	365.9	74.0	0.026 <<	22,008	4,469,629	492.4
Bladder	Total	12	21,310	56.3	32.7	9.0	0.398	2,208	8,970,796	24.6
Bladder	Male	9 3	11,106	81.0	44.2	8.0	0.807	1,764	4,501,167	39.2
Bladder Brain - malignant	Female Total	2	10,204 21,310	29.4 9.4	18.3 6.7	1.6 2.2	0.449	444 655	4,469,629 8,970,796	9.9 7.3
Brain - malignant	Male	2	11,106	9.4 18.0	12.5	1.3	0.780	380	4,501,167	8.4
Brain - malignant	Female		10,204	-	-	0.9	0.853	275	4,469,629	6.2
Brain and other CNS - non-malignant	Total	5	21,310	23.5	15.8	5.4	1.000	1,542	8,970,796	17.2
Brain and other CNS - non-malignant	Male	3	11,106	27.0	17.9	1.8	0.564	497	4,501,167	11.0
Brain and other CNS - non-malignant	Female	2	10,204	19.6	13.6	3.4	0.669	1,045	4,469,629	23.4
Breast	Total	16	21,310	75.1	49.1	25.4	0.064	6,992	8,970,796	77.9
Breast Breast	Male Female	- 16	11,106 10,204	- 156.8	- 107.7	0.3 23.0	1.000 0.162	65 6,927	4,501,167 4,469,629	1.4 155.0
Breast - in situ	Total	4	21,310	130.0	107.7	4.9	0.162	0,927	4,469,629	155.0
Breast - in situ	Male	-	11,106	-	-	0.0	1.000	1,000	4,501,167	0.1
Breast - in situ	Female	4	10,204	39.2	27.2	4.5	1.000	1,361	4,469,629	30.4
Cervix	Female	-	10,204	-	-	0.7	0.949	294	4,469,629	6.6
Colorectal	Total	16	21,310	75.1	48.3	13.3	0.536	3,616	8,970,796	40.3
Colorectal	Male	10	11,106	90.0	55.4	7.9	0.538	1,967	4,501,167	43.7
Colorectal	Female	6	10,204	58.8	39.5	5.6	0.976	1,649	4,469,629	36.9
Corpus Uteri	Female	5	10,204	49.0	32.9	4.6	0.969	1,349	4,469,629	30.2
Esophagus	Total Male	2 2	21,310 11,106	9.4 18.0	5.7 10.3	2.0 1.8	1.000 1.000	505 427	8,970,796 4,501,167	5.6 9.5
Esophagus Esophagus	Female	2	10,204	16.0	10.5	0.3	1.000	427 78	4,501,167	9.5
Hodgkin Lymphoma	Total		21,310	-	-	0.5	1.000	222	8,970,796	2.5
Hodgkin Lymphoma	Male	-	11,106	_	-	0.0	1.000	129	4,501,167	2.9
Hodgkin Lymphoma	Female	-	10,204	-	-	0.2	1.000	93	4,469,629	2.1
Kidney and Renal Pelvis	Total	7	21,310	32.8	20.9	7.2	1.000	1,944	8,970,796	21.7
Kidney and Renal Pelvis	Male	5	11,106	45.0	27.4	5.3	1.000	1,305	4,501,167	29.0
Kidney and Renal Pelvis	Female	2	10,204	19.6	13.1	2.2	1.000	639	4,469,629	14.3
Larynx	Total	-	21,310	-	-	0.9	0.848	220	8,970,796	2.5
Larynx	Male	-	11,106	-	-	0.7	0.983	167	4,501,167	3.7
Larynx	Female		10,204	- 9.4	- 6.0	0.2 6.4	1.000	53	4,469,629	1.2
Leukemia Leukemia	Total Male	2 1	21,310 11,106	9.4 9.0	6.0 5.5	6.4 4.2	0.094 0.157	1,725 1,035	8,970,796 4,501,167	19.2 23.0
Leukemia	Female	1	10,204	9.0 9.8	5.5 6.6	2.3	0.646	690	4,469,629	15.4
Liver and Bile Duct	Total	2	21,310	9.4	5.6	3.3	0.700	841	8,970,796	9.4
Liver and Bile Duct	Male	1	11,106	9.0	5.0	2.6	0.530	593	4,501,167	13.2
Liver and Bile Duct	Female	1	10,204	9.8	6.3	0.9	1.000	248	4,469,629	5.5
Lung and Bronchus	Total	17	21,310	79.8	46.2	20.3	0.554	4,942	8,970,796	55.1
Lung and Bronchus	Male	9	11,106	81.0	43.7	11.4	0.602	2,486	4,501,167	55.2
Lung and Bronchus	Female	8	10,204	78.4	48.6	9.1	0.897	2,456	4,469,629	54.9
Melanoma of the Skin Melanoma of the Skin	Total Male	8 8	21,310	37.5	24.7 43.4	11.3 7.7	0.409 1.000	3,136 1,887	8,970,796	35.0 41.9
Melanoma of the Skin	Female	0	11,106 10,204	72.0	43.4	3.9	0.040 <<	1,007	4,501,167 4,469,629	27.9
Myeloma	Total	- 3	21,310	- 14.1	- 8.4	2.9	1.000	725	8,970,796	8.1
Myeloma	Male	2	11,106	18.0	10.3	1.9	1.000	445	4,501,167	9.9
Myeloma	Female	1	10,204	9.8	6.2	1.0	1.000	280	4,469,629	6.3
Non-Hodgkin Lymphoma	Total	2	21,310	9.4	5.9	7.5	0.041 <<	1,990	8,970,796	22.2
Non-Hodgkin Lymphoma	Male	2	11,106	18.0	10.8	4.7	0.305	1,144	4,501,167	25.4
Non-Hodgkin Lymphoma	Female		10,204	-	-	2.9	0.107	846	4,469,629	18.9
Oral Cavity and Pharynx	Total	7	21,310	32.8	20.5	5.0	0.472	1,308	8,970,796	14.6
Oral Cavity and Pharynx	Male Female	6 1	11,106 10,204	54.0	32.0	3.9 1 3	0.394 1.000	934 374	4,501,167	20.8
Oral Cavity and Pharynx Ovary	Female	1	10,204	9.8 9.8	6.4 6.8	1.3 1.8	0.914	374 552	4,469,629 4,469,629	8.4 12.4
Pancreas	Total	6	21,310	28.2	16.8	5.9	1.000	1,482	8,970,796	12.4
Pancreas	Male	4	11,106	36.0	20.3	3.6	0.968	822	4,501,167	18.3
Pancreas	Female	2	10,204	19.6	12.4	2.4	1.000	660	4,469,629	14.8
Prostate	Male	30	11,106	270.1	146.8	30.6	1.000	6,736	4,501,167	149.7
Stomach	Total	2	21,310	9.4	5.9	1.8	1.000	472	8,970,796	5.3
Stomach	Male	1	11,106	9.0	5.2	1.3	1.000	306	4,501,167	6.8
Stomach	Female	1	10,204	9.8	6.6	0.6	0.858	166	4,469,629	3.7
Testis	Male	-	11,106	-	-	0.6	1.000	274	4,501,167	6.1
Thyroid	Total	3	21,310	14.1	11.8	3.4	1.000	1,182	8,970,796	13.2
	Male	1	11,106	9.0	6.4	1.3	1.000	371	4,501,167	8.2
Thyroid							4 000	044		18.1
Thyroid	Female	2	10,204	19.6	17.8	2.0	1.000	811	4,469,629	
Thyroid Pediatric Age 0 to 19	Female Total	2 1	3,960	19.6 25.3	17.8 25.1	0.7	0.983	424	2,495,364	17.0
Thyroid	Female									

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN CUSTER COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

Cause of Death Cancer Site/Type Sex Deaths Deskerved Vears Rate (1) Rate (1) Repreted Rate (1) P-Value (4) Observed Deaths Years All Causes of Death All Causes of Death Male Total 216.75 1.273.2 801.9 300.6 0.162 80.259 9.189.716 All Causes of Death All Causes of Death Female 121 0.305 237. 42.631 4.616.324 All Malignant Cancers Total 64 21.675 255.2 178.2 59.3 0.574 65.84 9.189.716 All Malignant Cancers Total 4 21.675 164.2 2.83 0.344 66.66 1.979.733.82 Brain and Other Nervous System Male 1 11.373 8.8 5.5 1 1.000 288 4.616.324 Breast Female 7 10.305 9.7 5.9 0.4 0.661 109 4.573.392 Grancer System Male 1 11.373	Crude Rate (1) 873.4 923.5 822.8 165.1 177.7 152.4 5.2 8.1 2.4 5.6 6.2 5.0
Cancer Site/Type Sex Deaths Years Rate (1) Rate (12) Deaths (3) P-Value (4) Deaths Years All Causes of Death India 256 11,772 13,822 801.9 30.05 0.162 40,253 4,616,324 All Causes of Death Female 12 12,677 177.2 743.7 13,629 30.354 17,618 4,616,324 All Malignant Cancers Female 30 10,305 291.1 1184.2 24.8 0.344 6,968 4,573.392 Bladder India 3 12,1678 13.7 85.5 1.1 0.255 4,816.324 Bladder Female 1 0.305 9.7 0.4 0.661 100 4,467.3322 Brain and Other Nervous System Total 3 21,678 13.8 9.0 1.9 0.570 515 9,189,716 Brain and Other Nervous System Total 7 21,678 32.3 20.3 4.2 2.2.8,3392 2.27	Rate (1) 873.4 923.5 822.8 165.1 177.7 152.4 5.2 8.1 2.4 5.6 6.2 5.0
All Causes of Death Total 276 21,678 1,273.2 801 9 300.6 0.162 80,259 9.189,716 All Causes of Death Female 121 10,305 1,74.2 746.7 133.3 0.305 37,628 4,673,392 All Malignant Cancers Male 34 11,373 299.0 171.3 53.3 0.921 82.01 4,616,324 All Malignant Cancers Female 30 10,305 291.1 184.2 24.8 0.344 6,968 4,673,392 Bladder Male 3 21,878 18.5 10.9 1.9 0.285 1.66,324 Bladder Male 3 11,373 8.8 1.5 1.6 0.430 372 4,616,324 Brain and Other Nervous System Male 1 11,373 8.8 5.5 1.000 288 4,616,324 Brain and Other Nervous System Female 1 11,373 8.8 5.5 1.000 288 4,616,324 Breast Male - 11,373 8.8 5.5 1.000 1	873.4 923.5 822.8 165.1 177.7 152.4 5.2 8.1 2.4 5.6 6.2 5.0
All Causes of Death Male 155 11,373 13,62.9 837.7 170.9 0.237 42,631 4,616,324 All Causes of Death Female 121 10,305 1174.2 59.3 0.574 15,169 9,189,716 All Malignant Cancers Male 34 11,373 299.0 171.3 35.3 0.921 8,201 4,616,324 All Malignant Cancers Female 30 10,305 291.1 184.2 24.8 0.344 6,968 4,573,392 Bladder Total 4 21,678 18.5 1.0 0.255 481 9,189,716 Brain and Other Nervous System Total 3 21,778 13.8 9.0 1.9 0.257 515 9,189,716 Brain and Other Nervous System Male 1 11,373 8.8 5.5 1.1 1.000 288 4,616,324 Breast Female 7 0,305 19.4 13.1 0.8 0.189 1,014 4,573,392 Group Catal Total 7 21,678 3.2 2.0	923.5 822.8 165.1 177.7 152.4 5.2 8.1 2.4 5.6 6.2 5.0
All Causes of Death Female 121 10,305 1,174.2 74.7 133.3 0.305 37,628 4,573.392 All Malignant Cancers Male 34 11,373 299.0 171.3 353 0.921 8,201 4,616,324 All Malignant Cancers Female 30 10,305 291.1 184.2 24.8 0.344 6,696 4,573.392 Bladder Male 3 11,373 26.4 15.2 1.6 0.430 372 4,616,324 Bladder Male 3 11,373 26.4 15.2 1.6 0.430 372 4,616,324 Brain and Other Nervous System Female 1 11,373 8.8 5.5 1.1 1.000 288 4,616,324 Brain and Other Nervous System Male 7 21,678 32.3 20.3 4.2 0.285 1,117 9,189,716 Breast Female 7 10,305 6.7.9 4.40 3.8 0.189 1,000 1.3 4,616,324 Colorectal Male 6 11,373	822.8 165.1 177.7 152.4 5.2 8.1 2.4 5.6 6.2 5.0
All Malignant Cancers Total 64 21/678 295.2 178.2 59.3 0.574 15.169 9.189.716 All Malignant Cancers Female 30 10.305 291.1 184.2 24.8 0.344 6,968 4,573.392 Bladder Itolal 4 216.78 18.5 10.9 19 0.255 481 9,189.716 Bladder Male 3 11.373 28.4 15.2 1.6 0.430 372 4,616.324 Bladder Female 1 10.305 9.7 5.9 0.4 0.661 109 4,573.392 Brain and Other Nervous System Male 1 11.373 8.8 5.5 1.1 1.000 13 4,616.324 Breast Male 1 13.37 - - 1.1 1.000 13 4,616.324 Breast Male 7 21.678 32.3 20.3 4.2 0.285 1.117 9,189.716 Gorectal Total 7 21.6778 32.3 20.2 5.0 0.477	165.1 177.7 152.4 5.2 8.1 2.4 5.6 6.2 5.0
All Malignant Cancers Male 34 11,373 299.0 171.3 35.3 0.921 8.201 4.616,324 Bladder Total 4 21,678 18.5 10.9 1.9 0.285 481 9.189,716 Bladder Male 3 11.373 22.4 15.2 1.6 0.430 372 4.616,324 Bladder Female 1 10.305 9.7 5.9 0.4 0.661 10.9 4.573,392 Brain and Other Nervous System Total 3 21,678 13.8 9.0 1.9 0.570 515 9,189,716 Brain and Other Nervous System Female 2 10.305 19.4 13.1 0.8 0.333 227 4,573,392 Breast Total 7 21,678 32.3 20.2 2.9 0.177 726 4,616,324 Breast Female 7 10.305 - - 0.3 1.000 13 4,616,324 <td< td=""><td>177.7 152.4 5.2 8.1 2.4 5.6 6.2 5.0</td></td<>	177.7 152.4 5.2 8.1 2.4 5.6 6.2 5.0
All Maigmant Cancers Female 30 10.305 291.1 184.2 24.8 0.344 6.968 4.573.392 Bladder Male 3 11.373 26.4 15.2 1.6 0.430 372 4.616.324 Bladder Female 1 0.050 9.7 5.9 0.4 0.661 109 4.673.392 Brain and Other Nervous System Total 3 21.678 13.8 9.0 1.9 0.570 515 4.818,716 Brain and Other Nervous System Female 2 10.305 19.4 13.1 0.8 0.353 227 4.573.392 Breast Male - 11.373 8.2 5.5 1.1 1.000 13 4.616.324 Breast Female 7 10.305 - - 0.1 1.000 183 4.573.392 Colorectal Male 6 11.373 52.8 32.0 2.9 0.157 726 4.616.324	152.4 5.2 8.1 2.4 5.6 6.2 5.0
Bladder Total 4 21,678 18.5 10.9 1.9 0.255 481 9,189,716 Bladder Female 1 10,305 9.7 5.9 0.4 0.661 109 4,573,392 Brain and Other Nervous System Total 3 21,678 13.8 9.0 1.9 0,570 515 31.89,716 Brain and Other Nervous System Female 2 10,305 19.4 13.1 0.8 0.353 227 4,573,392 Breast Total 7 21,678 32.3 20.3 4.2 0.285 1,117 9,189,716 Breast Female 7 10,305 67.9 44.0 3.8 0.189 1,004 4,573,392 Coriorectal Total 7 21,678 32.3 20.2 5.0 0.472 1,325 9,189,716 Colorectal Temale 1 0.305 -7 6.2 2.1 0.757 726 4,616,324 C	5.2 8.1 2.4 5.6 6.2 5.0
Bladder Male 3 11,373 26.4 15.2 1.6 0.430 372 4,616,324 Brain and Other Nervous System Total 3 21,678 13.8 9.0 1.9 0.570 515 9,189,716 Brain and Other Nervous System Male 1 11,373 8.8 5.5 1.1 1.000 288 4.616,324 Breast Total 7 21,678 32.3 20.3 4.2 0.265 1,117 9,189,716 Breast Total 7 21,678 32.3 20.3 4.2 0.265 1,117 9,189,716 Breast Female 7 10,305 6.7.9 4.4.0 3.8 0.189 1,104 4,573,392 Colorectal Male 6 11,373 52.8 32.0 2.9 0.477 7,359 4,616,324 Colorectal Male 1 10,305 9.7 6.2 2.1 0.757 599 4,573,392 Coro	8.1 2.4 5.6 6.2 5.0
Bladder Female 1 10,305 9.7 5.9 0.4 0.661 109 4,573,392 Brain and Other Nervous System Male 1 11,373 8.8 5.5 1.1 1.000 286 4,616,324 Brain and Other Nervous System Female 2 10,305 19.4 13.1 0.8 0.353 227 4,573,392 Breast Male - 11,373 - - 0.1 1000 13 4,616,324 Breast Male - 10,305 6-7.9 44.0 3.8 0.189 1,104 4,573,392 Colorectal Total 7 21678 32.3 20.2 5.0 0.477 1,325 9.189,716 Colorectal Male 6 11,373 52.8 32.0 2.9 0.157 726 4,616,324 Colorectal Male 1 10,305 - - 0.6 1.000 45.9 9,189,716 Colorectal	2.4 5.6 6.2 5.0
Brain and Other Nervous System Total 3 21,678 13.8 9.0 1.9 0.570 515 9.189,716 Brain and Other Nervous System Female 2 10,305 19.4 13.1 0.8 0.353 227 4,573,392 Breast Ital 7 21,678 32.3 20.3 4.2 0.285 1,117 9,199,716 Breast Male - 10,305 - - 0.1 1.000 13 4,616,324 Colorectal Female 7 10,305 - - 0.3 1000 88 4,573,392 Colorectal Male 6 11,373 52.8 32.0 2.9 0.157 726 4,616,324 Colorectal Male 1 10,305 - - 0.6 1.000 149 4,573,392 Corpus Uteri Female 1 10,305 - - 0.6 1.000 148 4,616,324 Corpus Uteri	5.6 6.2 5.0
Brain and Other Nervous System Male 1 11,373 8.8 5.5 1.1 1.000 288 4,616,324 Breast Total 7 21,678 32.3 20.3 4.2 0.265 1,117 9,189,716 Breast Male - 11,373 - - 0.1 1.000 13 4,616,324 Breast Female 7 10,305 - - 0.3 1.000 88 4,573,392 Colorectal Total 7 21,678 32.3 20.2 5.0 0.472 1,325 9,189,716 Colorectal Total 7 21,678 32.3 20.0 5.0 0.472 1,325 9,189,716 Colorectal Female 1 10,305 - - 0.6 1.000 169 4,573.392 Corpus Uteri Female 1 10,305 - - 0.6 1.000 169 4,573.392 Esophagus Male	6.2 5.0
Brain and Other Nervous System Female 2 10,305 19.4 13.1 0.8 0.353 227 4,573,392 Breast Male - 11,373 - - 0.1 1,000 13 4,616,324 Breast Female 7 10,305 67.9 - 0.3 1,000 188 4,573,392 Colorectal Total 7 21,678 32.3 20.2 5.0 0.472 1,325 9,189,716 Colorectal Male 6 11,373 52.8 32.0 2.9 0.157 726 4,616,324 Colorectal Female 1 10,305 9.7 6.2 2.1 0.757 599 4,573,392 Copus Uteri Female 1 11,373 8.8 5.0 1.7 0.988 390 4,616,324 Esophagus Male 1 11,373 8.8 5.0 1.7 0.988 390 4,616,324 Hodgkin Lymphoma <t< td=""><td>5.0</td></t<>	5.0
Breast Total 7 21,678 32.3 20.3 4.2 0.265 1,117 9189,716 Breast Female - 11,373 - - 0.1 1.000 13 4,616,324 Breast Female - 10,305 - - 0.3 1.000 88 4,573,392 Colorectal Total 7 21,678 32.3 20.2 5.0 0.472 1,325 9,189,716 Colorectal Male 6 11,373 52.8 32.0 2.9 0.157 726 4,616,324 Colorectal Female 1 0,305 - - 0.6 1.000 459 9,189,716 Esophagus Total 2 21,678 9,2 5.5 1.8 1.000 459 9,189,716 Esophagus Total 2 21,678 9,2 5.5 1.8 1.000 1.4 4,616,324 Hodgkin Lymphoma Male 1	
Breast Male - 11,373 - - 0.1 1.000 13 4.616,324 Breast Female 7 10,305 67.9 44.0 3.8 0.189 1,104 4,573,392 Colorectal Total 7 21,678 32.3 20.2 5.0 0.472 1,325 9,189,716 Colorectal Male 6 11,373 52.8 32.0 2.9 0.157 726 4,616,324 Colorectal Female 1 10,305 9.7 6.2 2.1 0.757 599 4,573,392 Corpus Uferi Female 1 11,373 8.8 5.0 1.7 0.988 390 4,616,324 Esophagus Female 1 11,373 8.8 5.0 1.7 0.988 390 4,616,324 Hodgkin Lymphoma Total 2 21,678 9.2 5.4 1.5 0.911 384 9,189,716 Hodgkin Lymphoma Total </td <td>12.2</td>	12.2
Breast Female 7 10,305 67.9 44.0 3.8 0.189 1,104 4,573,392 Cervix Female - 10,305 - - 0.3 1.000 88 4,573,392 Colorectal Male 6 11,373 52.8 32.0 2.9 0.157 726 4,616,324 Colorectal Female 1 10,305 - - 0.6 1.000 169 4,573,392 Corpus Uteri Female 1 10,305 - - 0.6 1.000 459 9,189,716 Esophagus Male 1 11,373 8.8 5.0 1.7 0.988 39.0 4,616,324 Esophagus Female 1 10,305 9.7 6.1 0.2 0.436 69 4,573,392 Hodgkin Lymphoma Male - 11,373 8.8 5.0 1.7 1.000 14 4,616,324 Hodgkin Lymphoma Female <	0.3
Cervix Female - 10,305 - - 0.3 1.000 88 4,573,392 Colorectal Male 6 11,373 52.8 32.0 2.0 0.472 1,325 9,189,716 Colorectal Female 1 10,305 9.7 6.2 2.1 0.757 599 4,573,392 Corpus Uteri Female - 10,305 9.7 6.2 2.1 0.757 599 4,573,392 Esophagus Total 2 21,678 9.2 5.5 1.8 1.000 459 9,189,716 Esophagus Female 1 11,373 8.8 5.0 1.7 0.988 390 4,616,324 Hodgkin Lymphoma Total - 21,678 9.2 5.4 1.0 0.2 0.436 69 4,573,392 Hodgkin Lymphoma Total - 21,678 9.2 5.4 1.5 0.911 384 9,189,716 Hodgkin Lymphoma<	24.1
Colorectal Total 7 21,678 32.3 20.2 5.0 0.472 1,325 9,189,716 Colorectal Female 6 11,373 52.8 32.0 2.9 0.157 726 4,616,324 Colorectal Female 1 10,305 9.7 6.2 2.1 0.757 599 4,573,392 Esophagus Total 2 21,678 9.2 5.5 1.8 1.000 459 9,189,716 Esophagus Male 1 11,373 8.8 5.0 1.7 0.988 390 4,616,324 Hodgkin Lymphoma Total - 10,305 9.7 - 0.1 1.000 14 4,616,324 Hodgkin Lymphoma Male - 11,373 - - 0.1 1.000 14 4,616,324 Kidney Male - 11,373 - - 0.1 1.000 14 4,673,392 Kidney Male - </td <td>1.9</td>	1.9
Colorectal Male 6 11,373 52.8 32.0 2.9 0.157 726 4,616,324 Colorectal Female 1 10,305 9.7 6.2 2.1 0.757 599 4,573,392 Esophagus Total 2 21,678 9.2 5.5 1.8 1.000 459 9,189,716 Esophagus Female 1 10,305 9.7 6.1 0.2 0.436 69 4,573,392 Hodgkin Lymphoma Total - 21,678 - - 0.1 1.000 14 4,616,324 Hodgkin Lymphoma Total - 21,678 - - 0.1 1.000 14 4,616,324 Kidney Total 2 21,678 9.2 5.4 1.5 0.911 384 9,189,716 Kidney Male 1 11,373 8.8 5.0 1.1 1.000 14 4,673,392 Kidney Male 1	14.4
Colorectal Female 1 10,305 9.7 6.2 2.1 0.757 599 4,573,392 Corpus Uteri Female - 10,305 - - 0.6 1.000 169 4,573,392 Esophagus Total 2 21,678 9.2 5.5 1.8 1.000 459 9,189,716 Esophagus Female 1 11,373 8.8 5.0 1.7 0.988 390 4,616,324 Hodgkin Lymphoma Total - 21,678 - - 0.1 1.000 25 9,189,716 Hodgkin Lymphoma Female - 11,373 - - 0.1 1.000 14 4,616,324 Hodgkin Lymphoma Female - 11,373 - - 0.0 1.000 11 4,573,392 Kidney Male 1 11,373 8.8 5.0 1.1 1.000 245 4,616,324 Kidney Female	15.7
Corpus Uteri Female - 10,305 - - 0.6 1.000 169 4,573,392 Esophagus Total 2 21,678 9.2 5.5 1.8 1.000 459 9,189,776 Esophagus Male 1 11,373 8.8 5.0 1.7 0.988 390 4,616,324 Esophagus Female 1 10,305 9.7 6.1 0.2 0.436 69 4,573,392 Hodgkin Lymphoma Male - 21,678 - - 0.1 1.000 14 4,616,324 Hodgkin Lymphoma Female - 10,305 - - 0.0 1.000 11 4,573,392 Kidney Total 2 21,678 9.2 5.4 1.5 0.911 384 9,189,716 Kidney Male 1 10,305 9.7 5.9 0.5 0.806 139 4,573,392 Larynx Total -	13.1
Esophagus Total 2 21,678 9.2 5.5 1.8 1.000 459 9,189,716 Esophagus Male 1 11,373 8.8 5.0 1.7 0.988 390 4,616,324 Hodgkin Lymphoma Total - 21,678 - 0.1 1.000 25 9,189,716 Hodgkin Lymphoma Male - 11,373 - - 0.1 1.000 14 4,616,324 Hodgkin Lymphoma Female - 10,305 - - 0.1 1.000 14 4,616,324 Hodgkin Lymphoma Female 1 11,373 8.8 5.0 1.1 1.000 245 4,616,324 Kidney Male 1 10,305 9.7 5.9 0.5 0.806 139 4,573,392 Larynx Male 1 11,373 8.8 5.0 1.1 1.000 245 4,616,324 Larynx Male 1 11,3	3.7
Esophagus EsophagusMale Female111,3738.85.01.70.9883904,616,324Hodgkin LymphomaTotal-21,6780.11.000259,78,7392Hodgkin LymphomaMale-11,3730.11.000144,616,324Hodgkin LymphomaFemale-10,3050.11.000144,616,324Hodgkin LymphomaFemale-10,3050.01.000114,573,392KidneyTotal221,6789.25.41.50.9113849,189,716KidneyMale111,3738.85.01.11.0002454,616,324KidneyFemale110,3059.75.90.50.8061394,573,392LarynxTotal-21,6780.31.000769,189,716LarynxMale-11,3730.01.000114,573,392LeukemiaTotal121,6784.62.82.60.5456649,189,716LeukemiaMale-11,3731.70.3723974,616,324LeukemiaMale-11,37326.414.81.80.5604204,616,324Liver and Bile DuctTotal421,67818.511.02.50.4876319	5.0
EsophagusFemale110,3059.76.10.20.436694,573,392Hodgkin LymphomaMale-21,6780.11.000259,189,716Hodgkin LymphomaMale-11,3730.011.000114,573,392Hodgkin LymphomaFemale-10,3050.01.000114,573,392KidneyTotal221,6789.25.41.50.9113849,189,716KidneyMale111,3738.85.01.11.0002454,616,324KidneyMale110,3059.75.90.50.8061394,573,392LarynxTotal-21,6780.31.000769,189,716LarynxMale-11,3730.31.000654,616,324LarynxMale-11,3730.31.000114,573,392LeukemiaTotal121,6784.62.82.60.5456649,189,716LeukemiaMale-11,3731.70.3723974,616,324LeukemiaMale-11,3732.6.414.81.80.5604204,616,324LeukemiaFemale110,3059.76.20.91.0002674,573,392Liver and Bile Duct <td>8.4</td>	8.4
Hodgkin LymphomaTotal-21,6780.11.000259,189,716Hodgkin LymphomaMale-11,3730.11.000144,616,324Hodgkin LymphomaFemale-10,3050.01.000114,573,392KidneyTotal221,6789.25.41.50.9113849,189,716KidneyMale111,3738.85.01.11.0002454,616,324KidneyFemale10.3059.75.90.50.8061394,573,392LarynxTotal-21,6780.31.000769,189,716LarynxMale-11,3730.31.000769,189,716LarynxFemale-10,3050.31.000769,189,716LeukemiaTotal121,6784.62.82.60.5456649,189,716LeukemiaMale-11,3730.31.000114,573,392LeukemiaMale-11,3730.31.0002674,616,324LeukemiaFemale110,3059.76.20.91.0002674,573,392Liver and Bile DuctTotal421,67818.511.02.50.4876319,189,716Liver and Bile D	1.5
Hodğkin LýmphomaMale-11,3730.11.000144,616,324Hodgkin LymphomaFemale-10,3050.01.000114,573,392KidneyTotal221,6789.25.41.50.9113849,189,716KidneyMale111,3738.85.01.11.0002454,616,324KidneyFemale110,3059.75.90.50.8061394,573,392LarynxTotal-21,6780.31.000769,189,716LarynxMale-11,3730.31.000654,616,324LarynxFemale-11,3730.31.000769,189,716LarynxFemale-11,3730.01.000114,573,392LeukemiaTotal121,6784.62.82.60.5456649,189,716LeukemiaMale-11,3731.70.3723974,616,324LeukemiaMale-11,3731.70.3723974,616,324LeukemiaFemale110,3059.76.20.91.0002674,573,392Liver and Bile DuctTotal421,67818.511.02.50.4876319,189,716Liver and Bile Duct <td>0.3</td>	0.3
Hodgkin LýmphomaFemale-10,3050.01.000114,573,392KidneyTotal221,6789.25.41.50.9113849,189,716KidneyMale111,3738.85.01.11.0002454,616,324KidneyFemale110,3059.75.90.50.8061394,573,392LarynxTotal-21,6780.31.000769,189,716LarynxMale-11,3730.31.000654,616,324LarynxFemale-10,3050.01.000114,573,392LeukemiaTotal121,6784.62.82.60.5456649,189,716LeukemiaMale-11,3731.70.3723974,616,324LeukemiaMale-11,3731.70.3723974,616,324LeukemiaMale-11,3731.70.3723974,616,324LeukemiaMale-11,3732.6.414.81.80.5604204,616,324Liver and Bile DuctTotal421,67818.511.02.50.4876319,189,716Liver and Bile DuctFemale110,3059.76.10.81.0002114,573,392Liver and B	0.3
KidneyTotal221,6789.25.41.50.9113849,189,716KidneyMale111,3738.85.01.11.0002454,616,324KidneyFemale110,3059.75.90.50.8061394,573,392LarynxTotal-21,6780.31.000769,189,716LarynxMale-11,3730.31.000654,616,324LarynxFemale-10,3050.01.000114,573,392LeukemiaTotal121,6784.62.82.60.5456649,189,716LeukemiaMale-11,3731.70.3723974,616,324LeukemiaMale-11,3731.70.3723974,616,324LeukemiaMale-11,3731.70.3723974,616,324Liver and Bile DuctTotal421,67818.511.02.50.4876319,189,716Liver and Bile DuctMale311,37326.414.81.80.5604204,616,324Liver and Bile DuctFemale110,3059.76.10.81.0002114,573,392Lung and BronchusTotal1321,67860.035.011.80.8102,9249,189,716 <td>0.2</td>	0.2
KidneyMale111,3738.85.01.11.0002454,616,324KidneyFemale110,3059.75.90.50.8061394,573,392LarynxTotal-21,6780.31.000769,189,716LarynxMale-11,3730.31.000654,616,324LarynxFemale-10,3050.01.000114,573,392LeukemiaTotal121,6784.62.82.60.5456649,189,716LeukemiaMale-11,3731.70.3723974,616,324LeukemiaMale-11,3731.70.3723974,616,324LeukemiaMale-11,3731.70.3723974,616,324LeukemiaMale-11,3731.70.3723974,616,324Liver and Bile DuctTotal421,67818.511.02.50.4876319,189,716Liver and Bile DuctMale311,37326.414.81.80.5604204,616,324Liver and Bile DuctFemale110,3059.76.10.81.0002114,573,392Lung and BronchusTotal1321,67860.035.011.80.8102,9249,189,716<	4.2
KidneyFemale110,3059.75.90.50.8061394,573,392LarynxTotal-21,6780.31.000769,189,716LarynxMale-11,3730.31.000654,616,324LarynxFemale-10,3050.01.000114,573,392LeukemiaTotal121,6784.62.82.60.5456649,189,716LeukemiaMale-11,3731.70.3723974,616,324LeukemiaMale-11,3731.70.3723974,616,324LeukemiaMale-11,3731.70.3723974,616,324LeukemiaMale-11,3731.70.3723974,616,324Liver and Bile DuctTotal421,67818.511.02.50.4876319,189,716Liver and Bile DuctMale311,37326.414.81.80.5604204,616,324Lurg and BronchusTotal1321,67860.035.011.80.8102.9249,189,716Lung and BronchusMale611,37352.829.06.90.9361,5354,616,324Lung and BronchusFemale710,30567.941.75.10.5041,3894,5	5.3
LarynxTotal-21,6780.31.000769,189,716LarynxMale-11,3730.31.000654,616,324LarynxFemale-10,3050.01.000114,573,392LeukemiaTotal121,6784.62.82.60.5456649,189,716LeukemiaMale-11,3731.70.3723974,616,324LeukemiaFemale110,3059.76.20.91.0002674,573,392Liver and Bile DuctTotal421,67818.511.02.50.4876319,189,716Liver and Bile DuctTotal421,67818.511.02.50.4876319,189,716Liver and Bile DuctTotal110,3059.76.10.81.0002114,573,392Lurg and BronchusTotal1321,67860.035.011.80.8102,9249,189,716Lung and BronchusMale611,37352.829.06.90.9361,5354,616,324Lung and BronchusFemale710,30567.941.75.10.5041,3894,573,392Lung and BronchusFemale710,30567.941.75.10.5041,3894,573,392Melanoma of the SkinTotal221,6789.2 <t< td=""><td>3.0</td></t<>	3.0
LarynxMale-11,3730.31.000654,616,324LarynxFemale-10,3050.01.000114,573,392LeukemiaTotal121,6784.62.82.60.5456649,189,716LeukemiaMale-11,3731.70.3723974,616,324LeukemiaFemale110,3059.76.20.91.0002674,573,392Liver and Bile DuctTotal421,67818.511.02.50.4876319,189,716Liver and Bile DuctMale311,37326.414.81.80.5604204,616,324Liver and Bile DuctFemale110,3059.76.10.81.0002114,573,392Lung and BronchusTotal1321,67860.035.011.80.8102,9249,189,716Lung and BronchusMale611,37352.829.06.90.9361,5354,616,324Lung and BronchusFemale710,30567.941.75.10.5041,3894,573,392Lung and BronchusFemale710,30567.941.75.10.5041,3894,573,392Lung and BronchusFemale710,30567.941.75.10.5041,3894,573,392Melanoma of the SkinTotal221,6	0.8
LarynxFemale-10,3050.01.000114,573,392LeukemiaTotal121,6784.62.82.60.5456649,189,716LeukemiaMale-11,3731.70.3723974,616,324LeukemiaFemale110,3059.76.20.91.0002674,573,392Liver and Bile DuctTotal421,67818.511.02.50.4876319,189,716Liver and Bile DuctMale311,37326.414.81.80.5604204,616,324Liver and Bile DuctFemale110,3059.76.10.81.0002114,573,392Lung and BronchusTotal1321,67860.035.011.80.8102,9249,189,716Lung and BronchusMale611,37352.829.06.90.9361,5354,616,324Lung and BronchusFemale710,30567.941.75.10.5041,3894,573,392Lung and BronchusFemale721,6789.25.81.10.6182999,189,716Melanoma of the SkinTotal221,6789.25.81.10.6182999,189,716Melanoma of the SkinMale211,37317.610.50.80.3941984,616,324	1.4
LeukemiaTotal121,6784.62.82.60.5456649,189,716LeukemiaMale-11,3731.70.3723974,616,324LeukemiaFemale110,3059.76.20.91.0002674,573,392Liver and Bile DuctTotal421,67818.511.02.50.4876319,189,716Liver and Bile DuctMale311,37326.414.81.80.5604204,616,324Liver and Bile DuctFemale110,3059.76.10.81.0002114,573,392Lung and BronchusTotal1321,67860.035.011.80.8102,9249,189,716Lung and BronchusMale611,37352.829.06.90.9361,5354,616,324Lung and BronchusFemale710,30567.941.75.10.5041,3894,573,392Lung and BronchusFemale710,30567.941.75.10.5041,3894,573,392Melanoma of the SkinTotal221,6789.25.81.10.6182999,189,716Melanoma of the SkinMale211,37317.610.50.80.3941984,616,324	0.2
LeukemiaMale-11,3731.70.3723974,616,324LeukemiaFemale110,3059.76.20.91.0002674,573,392Liver and Bile DuctTotal421,67818.511.02.50.4876319,189,716Liver and Bile DuctMale311,37326.414.81.80.5604204,616,324Liver and Bile DuctFemale110,3059.76.10.81.0002114,573,392Lung and BronchusTotal1321,67860.035.011.80.8102,9249,189,716Lung and BronchusMale611,37352.829.06.90.9361,5354,616,324Lung and BronchusFemale710,30567.941.75.10.5041,3894,573,392Melanoma of the SkinTotal221,6789.25.81.10.6182999,189,716Melanoma of the SkinMale211,37317.610.50.80.3941984,616,324	7.2
Liver and Bile DuctTotal421,67818.511.02.50.4876319,189,716Liver and Bile DuctMale311,37326.414.81.80.5604204,616,324Liver and Bile DuctFemale110,3059.76.10.81.0002114,573,392Lung and BronchusTotal1321,67860.035.011.80.8102,9249,189,716Lung and BronchusMale611,37352.829.06.90.9361,5354,616,324Lung and BronchusFemale710,30567.941.75.10.5041,3894,573,392Melanoma of the SkinTotal221,6789.25.81.10.6182999,189,716Melanoma of the SkinMale211,37317.610.50.80.3941984,616,324	8.6
Liver and Bile DuctTotal421,67818.511.02.50.4876319,189,716Liver and Bile DuctMale311,37326.414.81.80.5604204,616,324Liver and Bile DuctFemale110,3059.76.10.81.0002114,573,392Lung and BronchusTotal1321,67860.035.011.80.8102,9249,189,716Lung and BronchusMale611,37352.829.06.90.9361,5354,616,324Lung and BronchusFemale710,30567.941.75.10.5041,3894,573,392Melanoma of the SkinTotal221,6789.25.81.10.6182999,189,716Melanoma of the SkinMale211,37317.610.50.80.3941984,616,324	5.8
Liver and Bile DuctFemale110,3059.76.10.81.0002114,573,392Lung and BronchusTotal1321,67860.035.011.80.8102,9249,189,716Lung and BronchusMale611,37352.829.06.90.9361,5354,616,324Lung and BronchusFemale710,30567.941.75.10.5041,3894,573,392Melanoma of the SkinTotal221,6789.25.81.10.6182999,189,716Melanoma of the SkinMale211,37317.610.50.80.3941984,616,324	6.9
Lung and BronchusTotal1321,67860.035.011.80.8102,9249,189,716Lung and BronchusMale611,37352.829.06.90.9361,5354,616,324Lung and BronchusFemale710,30567.941.75.10.5041,3894,573,392Melanoma of the SkinTotal221,6789.25.81.10.6182999,189,716Melanoma of the SkinMale211,37317.610.50.80.3941984,616,324	9.1
Lung and BronchusTotal1321,67860.035.011.80.8102,9249,189,716Lung and BronchusMale611,37352.829.06.90.9361,5354,616,324Lung and BronchusFemale710,30567.941.75.10.5041,3894,573,392Melanoma of the SkinTotal221,6789.25.81.10.6182999,189,716Melanoma of the SkinMale211,37317.610.50.80.3941984,616,324	4.6
Lung and BronchusFemale710,30567.941.75.10.5041,3894,573,392Melanoma of the SkinTotal221,6789.25.81.10.6182999,189,716Melanoma of the SkinMale211,37317.610.50.80.3941984,616,324	31.8
Melanoma of the Skin Total 2 21,678 9.2 5.8 1.1 0.618 299 9,189,716 Melanoma of the Skin Male 2 11,373 17.6 10.5 0.8 0.394 198 4,616,324	33.3
Melanoma of the Skin Total 2 21,678 9.2 5.8 1.1 0.618 299 9,189,716 Melanoma of the Skin Male 2 11,373 17.6 10.5 0.8 0.394 198 4,616,324	30.4
	3.3
	4.3
Melanoma of the Skin Female - 10,305 0.3 1.000 101 4,573,392	2.2
Myeloma Total 1 21,678 4.6 2.7 1.3 1.000 324 9,189,716	3.5
Myeloma Male - 11,373 0.8 0.872 188 4,616,324	4.1
Myeloma Female 1 10,305 9.7 6.0 0.5 0.786 136 4,573,392	3.0
Non-Hodgkin Lymphoma Total 1 21,678 4.6 2.8 2.2 0.705 567 9,189,716	6.2
Non-Hodğkin Lýmphoma Male 1 11,373 8.8 5.1 1.3 1.000 309 4,616,324	6.7
Non-Hodgkin Lymphoma Female - 10,305 0.9 0.781 258 4,573,392	5.6
Oral Cavity and Pharynx Total 2 21,678 9.2 5.5 1.1 0.584 273 9,189,716	3.0
Oral Cavity and Pharynx Male 1 11,373 8.8 4.9 0.8 1.000 191 4,616,324	4.1
Oral Cavity and Pharynx Female 1 10,305 9.7 6.2 0.3 0.505 82 4,573,392	1.8
Ovary Female 1 10,305 9.7 6.1 1.3 1.000 360 4,573,392	7.9
Pancreas Total 6 21,678 27.7 16.3 4.7 0.676 1,184 9,189,716	12.9
Pancreas Male 3 11,373 26.4 14.7 2.9 1.000 647 4,616,324	14.0
Pancreas Female 3 10,305 29.1 18.1 1.9 0.618 537 4,573,392	11.7
Prostate Male 4 11,373 35.2 20.0 4.3 1.000 993 4,616,324	21.5
Stomach Total - 21,678 0.7 0.987 194 9,189,716	0.1
Stomach Male - 11,373 0.5 1.000 119 4,616,324	2.1
Stomach Female - 10,305 0.2 1.000 75 4,573,392	2.1 2.6 1.6

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Custer County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	7.8%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	76.0%
Current Tobacco User (2020–2022) <u>Other Cancer-Related</u>	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	20.0%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	33.5% 75.8% 27.4% 43.3%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





ELMORE COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 719 cases of invasive cancer were diagnosed among Elmore County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in ElmoreCounty and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Elmore County	State of Idaho
All Sites/Types	719	47,333
Female Breast	80	6,943
Prostate	83	6,766
Lung & Bronchus	114	4,959
Colorectal	69	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Elmore County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Elmore County. The table also shows the number of observed cases, person-

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 234 Elmore County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Elmore County and the State of Idaho, 2018–2022

Mortality 2018–2022	Elmore County	State of Idaho
All Deaths	1,169	80,538
Cancer Deaths	234	15,233
% of All Deaths	20.0%	18.9%
Lung & Bronchus	66	2,937
Colorectal	24	1,332
Pancreas	20	1,190
Female Breast	5	1,111
Prostate	12	997

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Elmore County was 521.1 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (526.5) gives an estimate of the relative burden of disease in Elmore County.

The age- and sex-adjusted incidence rate of invasive cancer in Elmore County, all sites combined, was 592.8 cases per 100,000 persons per year during 2017–2021. There were statistically significantly more cases of cancer in Elmore County (719) than expected (638.5) based upon rates in the remainder of the state (p=.002).

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Elmore County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Elmore County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Elmore County, all sites combined, was 192.1 deaths per 100,000 persons per year during 2018–2022, compared with 165.4 for the remainder of the state. There were statistically significantly more cancer deaths in Elmore County (234) than expected (201.4) based upon rates in the remainder of the state (p=.027).

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN ELMORE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Elm	nore County	/			Ren	nainder of Ida	aho
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	719	137,978	521.1	592.8	638.5	0.002 >>	46,614	8,854,128	526.5
All Sites Combined	Male	375	72,389	518.0	613.2	342.9	0.091	24,895	4,439,884	560.7
All Sites Combined	Female	344	65,589	524.5	574.2	294.7	0.006 >>	21,719	4,414,244	492.0
Bladder	Total	43	137,978	31.2	36.2	29.2	0.020 >>	2,177	8,854,128	24.6
Bladder	Male	36	72,389	49.7	60.5	23.3	0.017 >>	1,737	4,439,884	39.1
Bladder Brein melignent	Female	7 11	65,589 137,978	10.7	11.8 8.7	5.9 9.2	0.755 0.645	440 646	4,414,244	10.0
Brain - malignant Brain - malignant	Total Male	7	72,389	8.0 9.7	0.7 10.8	9.2 5.5	0.626	375	8,854,128 4,439,884	7.3 8.4
Brain - malignant	Female	4	65,589	6.1	6.5	3.8	1.000	271	4,414,244	6.1
Brain and other CNS - non-malignant	Total	25	137,978	18.1	20.4	21.1	0.450	1,522	8,854,128	17.2
Brain and other CNS - non-malignant	Male	8	72,389	11.1	12.7	7.0	0.795	492	4,439,884	11.1
	Female	17	65,589	25.9	28.3	14.0	0.495	1,030	4,414,244	23.3
Breast	Total	81	137,978	58.7	67.1	94.5	0.176	6,927	8,854,128	78.2
Breast	Male	1 80	72,389	1.4	1.6	0.9 92.4	1.000 0.212	64	4,439,884 4,414,244	1.4
Breast Breast - in situ	Female Total	80 24	65,589 137,978	122.0 17.4	134.6 19.9	92.4	0.212	6,863 1,345	4,414,244 8,854,128	155.5 15.2
Breast - in situ	Male	- 24	72,389	-	-	0.1	1.000	1,545	4,439,884	0.1
Breast - in situ	Female	- 24	65,589	36.6	40.6	18.0	0.200	1,341	4,414,244	30.4
Cervix	Female	4	65,589	6.1	6.5	4.1	1.000	290	4,414,244	6.6
Colorectal	Total	69	137,978	50.0	57.1	48.7	0.007 >>	3,563	8,854,128	40.2
Colorectal	Male	41	72,389	56.6	66.9	26.7	0.012 >>	1,936	4,439,884	43.6
Colorectal	Female	28	65,589	42.7	47.0	22.0	0.243	1,627	4,414,244	36.9
Corpus Uteri	Female	18	65,589	27.4	30.1	18.1	1.000	1,336	4,414,244	30.3
Esophagus	Total	8	137,978	5.8	6.6	6.8 5.8	0.739 0.712	499	8,854,128	5.6 9.5
Esophagus Esophagus	Male Female	7 1	72,389 65,589	9.7 1.5	11.5 1.7	5.8 1.0	1.000	422 77	4,439,884 4,414,244	9.5
Hodgkin Lymphoma	Total	2	137,978	1.3	1.7	3.5	0.643	220	8,854,128	2.5
Hodgkin Lymphoma	Male	- 2	72,389	-	-	2.1	0.243	129	4,439,884	2.9
Hodgkin Lymphoma	Female	2	65,589	3.0	3.0	1.4	0.807	91	4,414,244	2.1
Kidney and Renal Pelvis	Total	36	137,978	26.1	29.7	26.3	0.081	1,915	8,854,128	21.6
Kidney and Renal Pelvis	Male	26	72,389	35.9	42.3	17.8	0.079	1,284	4,439,884	28.9
Kidney and Renal Pelvis	Female	10	65,589	15.2	16.7	8.6	0.713	631	4,414,244	14.3
Larynx	Total	1	137,978	0.7	0.8	3.0	0.396	219	8,854,128	2.5
Larynx	Male	1	72,389	1.4	1.6	2.3	0.672	166	4,439,884	3.7
Larynx	Female	-	65,589	-	-	0.7	0.969	53	4,414,244	1.2
Leukemia Leukemia	Total Male	23 16	137,978 72,389	16.7 22.1	18.8 25.9	23.6 14.2	1.000 0.702	1,704 1,020	8,854,128 4,439,884	19.2 23.0
Leukemia	Female	7	65,589	10.7	11.6	9.4	0.566	684	4,414,244	15.5
Liver and Bile Duct	Total	13	137,978	9.4	10.8	11.3	0.684	830	8,854,128	9.4
Liver and Bile Duct	Male	9	72,389	12.4	14.8	8.0	0.825	585	4,439,884	13.2
Liver and Bile Duct	Female	4	65,589	6.1	6.7	3.3	0.840	245	4,414,244	5.6
Lung and Bronchus	Total	114	137,978	82.6	95.7	65.2	0.000 >>	4,845	8,854,128	54.7
Lung and Bronchus	Male	51	72,389	70.5	85.4	32.9	0.004 >>	2,444	4,439,884	55.0
Lung and Bronchus	Female	63	65,589	96.1	106.0	32.3	0.000 >>	2,401	4,414,244	54.4
Melanoma of the Skin	Total	34	137,978	24.6	27.8	43.0	0.190	3,110	8,854,128	35.1
Melanoma of the Skin Melanoma of the Skin	Male Female	16 18	72,389 65,589	22.1 27.4	26.1 29.7	25.9 16.9	0.051 0.851	1,879 1,231	4,439,884 4,414,244	42.3 27.9
Myeloma	Total	8	137,978	5.8	29.7	9.7	0.651	720	8,854,128	8.1
Myeloma	Male	4	72,389	5.5	6.7	6.0	0.730	443	4,439,884	10.0
Myeloma	Female	4	65,589	6.1	6.8	3.7	1.000	277	4,414,244	6.3
Non-Hodgkin Lymphoma	Total	30	137,978	21.7	24.6	27.0	0.618	1,962	8,854,128	22.2
Non-Hodgkin Lymphoma	Male	18	72,389	24.9	29.0	15.8	0.636	1,128	4,439,884	25.4
Non-Hodgkin Lymphoma	Female	12	65,589	18.3	20.0	11.4	0.926	834	4,414,244	18.9
Oral Cavity and Pharynx	Total	17	137,978	12.3	14.1	17.7	0.988	1,298	8,854,128	14.7
Oral Cavity and Pharynx	Male	8	72,389	11.1	13.0	12.9	0.211	932	4,439,884	21.0
Oral Cavity and Pharynx	Female Female	9 11	65,589 65,589	13.7 16.8	15.1 18.4	4.9	0.128 0.252	366	4,414,244 4,414,244	8.3 12.3
Ovary Pancreas	Total	28	137,978	20.3	23.4	7.4 19.7	0.252	542 1,460	4,414,244 8,854,128	12.3
Pancreas	Male	16	72,389	20.3	26.6	19.7	0.181	810	4.439.884	18.2
Pancreas	Female	10	65,589	18.3	20.0	8.7	0.343	650	4,414,244	14.7
Prostate	Male	83	72,389	114.7	137.2	91.1	0.430	6,683	4,439,884	150.5
Stomach	Total	8	137,978	5.8	6.6	6.3	0.609	466	8,854,128	5.3
Stomach	Male	5	72,389	6.9	8.2	4.1	0.796	302	4,439,884	6.8
Stomach	Female	3	65,589	4.6	5.0	2.2	0.760	164	4,414,244	3.7
Testis	Male	6	72,389	8.3	7.4	4.9	0.733	268	4,439,884	6.0
Thyroid	Total	23	137,978	16.7	17.4	17.4	0.224	1,162	8,854,128	13.1
Thyroid	Male	4	72,389	5.5	6.1	5.4	0.749	368	4,439,884	8.3
Thyroid	Female	19	65,589	29.0	29.6	11.5	0.054	794	4,414,244	18.0
Pediatric Age 0 to 19	Total	10	37,933	26.4	26.2	6.4	0.235	415	2,461,391	16.9
Pediatric Age 0 to 19	Male	5	19,645	25.5	25.2	3.3	0.478	209	1,254,676	16.7
Pediatric Age 0 to 19	Female	5	18,288	27.3	27.4	3.1	0.411	206	1,206,715	17.1

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN ELMORE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Eln	nore County	/			Re	mainder of Idah	10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	1,169	140,474	832.2	955.1	1,070.9	0.003 >>	79,366	9,070,920	874.9
All Causes of Death	Male	640	73,916	865.8	1,020.2	580.6	0.016 >>	42,146	4,553,781	925.5
All Causes of Death	Female	529	66,558	794.8	883.2	493.5	0.118	37,220	4,517,139	824.0
All Malignant Cancers	Total	234	140,474	166.6	192.1	201.4	0.027 >>	14,999	9,070,920	165.4
All Malignant Cancers	Male	141	73,916	190.8	229.1	109.4	0.004 >>	8,094	4,553,781	177.7
All Malignant Cancers	Female	93	66,558	139.7	154.5	92.0	0.945	6,905	4,517,139	152.9
Bladder	Total	5	140,474	3.6	4.2	6.3	0.788	480	9,070,920	5.3
Bladder	Male	4	73,916	5.4	6.6	4.9	0.915	371	4,553,781	8.1
Bladder	Female	1	66,558	1.5	1.7	1.4	1.000	109	4,517,139	2.4
Brain and Other Nervous System	Total	7	140,474	5.0	5.6	7.1	1.000	511	9,070,920	5.6
Brain and Other Nervous System	Male	5	73,916	6.8	7.7	4.0	0.754	284	4,553,781	6.2
Brain and Other Nervous System	Female	2	66,558	3.0	3.3	3.1	0.811	227	4,517,139	5.0
Breast	Total	5	140,474	3.6	4.1	15.0	0.005 <<	1,119	9,070,920	12.3
Breast	Male	-	73,916	-	-	0.2	1.000	13	4,553,781	0.3
Breast	Female	5	66,558	7.5	8.3	14.7	0.007 <<	1,106	4,517,139	24.5
Cervix	Female	2	66,558	3.0	3.2	1.2	0.659	86	4,517,139	1.9
Colorectal	Total	24	140,474	17.1	19.6	17.6	0.170	1,308	9,070,920	14.4
Colorectal	Male	16	73,916	21.6	25.7	9.8	0.083	716	4,553,781	15.7
Colorectal	Female	8	66,558	12.0	13.3	7.9	1.000	592	4,517,139	13.1
Corpus Uteri	Female	1	66,558	1.5 6.4	1.7	2.2	0.701 0.326	168	4,517,139	3.7
Esophagus Esophagus	Total Male	9 7	140,474 73,916	0.4 9.5	11.3	6.1 5.2	0.526	452 384	9,070,920 4,553,781	5.0 8.4
Esophagus	Female	2	66,558	9.5 3.0	3.3	0.9	0.342	504 68	4,553,781	0.4 1.5
Hodgkin Lymphoma	Total		140,474	0.7	0.8	0.3	0.551	24	9,070,920	0.3
Hodgkin Lymphoma	Male	1	73,916	1.4	1.6	0.3	0.324	13	4,553,781	0.3
Hodgkin Lymphoma	Female	- '	66,558	-	-	0.2	1.000	11	4,517,139	0.2
Kidney	Total	2	140,474	1.4	1.7	5.1	0.230	384	9,070,920	4.2
Kidney	Male	2	73,916	2.7	3.3	3.3	0.721	244	4,553,781	5.4
Kidney	Female	-	66,558	-	-	1.8	0.315	140	4,517,139	3.1
Larynx	Total	1	140,474	0.7	0.8	1.0	1.000	75	9,070,920	0.8
Larynx	Male	1	73,916	1.4	1.6	0.9	1.000	64	4,553,781	1.4
Larynx	Female	-	66,558	-	-	0.1	1.000	11	4,517,139	0.2
Leukemia	Total	6	140,474	4.3	4.9	8.8	0.445	659	9,070,920	7.3
Leukemia	Male	4	73,916	5.4	6.5	5.3	0.772	393	4,553,781	8.6
Leukemia	Female	2	66,558	3.0	3.3	3.5	0.632	266	4,517,139	5.9
Liver and Bile Duct	Total	10	140,474	7.1	8.2	8.4	0.674	625	9,070,920	6.9
Liver and Bile Duct	Male	6	73,916	8.1	9.6	5.7	1.000	417	4,553,781	9.2
Liver and Bile Duct	Female	4	66,558	6.0	6.6	2.8	0.606	208	4,517,139	4.6
Lung and Bronchus	Total	66	140,474	47.0	54.3	38.5	0.000 >>	2,871	9,070,920	31.7
Lung and Bronchus	Male	39	73,916	52.8	63.7	20.2	0.000 >>	1,502	4,553,781	33.0
Lung and Bronchus Molanoma of the Skin	Female Total	27 2	66,558 140,474	40.6 1.4	44.8	18.3 4.1	0.066 0.458	1,369 299	4,517,139 9,070,920	30.3 3.3
Melanoma of the Skin Melanoma of the Skin	Male	2 1	73,916	1.4	1.0	4.1 2.7	0.458	299 199	9,070,920 4,553,781	3.3 4.4
Melanoma of the Skin	Female	1	66,558	1.4	1.6	2.7	1.000	199	4,553,781	4.4
Myeloma	Total	5	140,474	3.6	4.1	4.3	0.847	320	9,070,920	3.5
Myeloma	Male	3	73,916	4.1	4.1	2.5	0.897	185	4,553,781	4.1
Myeloma	Female	2	66,558	3.0	3.3	1.8	1.000	135	4,517,139	3.0
Non-Hodgkin Lymphoma	Total	10	140,474	7.1	8.2	7.5	0.453	558	9,070,920	6.2
	Male	9	73,916	12.2	14.5	4.1	0.049 >>	301	4,553,781	6.6
Non-Hodgkin Lymphoma	Female	1	66,558	1.5	1.7	3.4	0.285	257	4,517,139	5.7
Oral Cavity and Pharynx	Total	1	140,474	0.7	0.8	3.7	0.232	274	9,070,920	3.0
	Male	-	73,916	-	-	2.6	0.145	192	4,553,781	4.2
Oral Cavity and Pharynx	Female	1	66,558	1.5	1.7	1.1	1.000	82	4,517,139	1.8
Ovary	Female	7	66,558	10.5	11.6	4.7	0.394	354	4,517,139	7.8
Pancreas	Total	20	140,474	14.2	16.5	15.7	0.331	1,170	9,070,920	12.9
Pancreas	Male	15	73,916	20.3	24.4	8.6	0.058	635	4,553,781	13.9
Pancreas	Female	5	66,558	7.5	8.3	7.1	0.572	535	4,517,139	11.8
Prostate	Male	12	73,916	16.2	19.9	13.0	0.921	985	4,553,781	21.6
Stomach	Total	3	140,474	2.1	2.4	2.6	0.959	191	9,070,920	2.1
	Male	3	73,916	4.1	4.8	1.6	0.424	116	4,553,781	2.5
Stomach	Female	-	66,558	-	-	1.0	0.735	75	4,517,139	1.7

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Elmore County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	89.0% 10.7%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	71.7%
Current Tobacco User (2020–2022) <u>Other Cancer-Related</u>	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	33.5%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	21.5% 71.6% 21.4% 12.5%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





FRANKLIN COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 303 cases of invasive cancer were diagnosed among Franklin County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in FranklinCounty and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Franklin County	State of Idaho
All Sites/Types	303	47,333
Female Breast	49	6,943
Prostate	46	6,766
Lung & Bronchus	8	4,959
Colorectal	33	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Franklin County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Franklin County. The table also shows the number of observed cases, person-

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 93 Franklin County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Franklin County and the State of Idaho, 2018–2022

Mortality 2018–2022	Franklin County	State of Idaho
All Deaths	592	80,538
Cancer Deaths	93	15,233
% of All Deaths	15.7%	18.9%
Lung & Bronchus	8	2,937
Colorectal	12	1,332
Pancreas	9	1,190
Female Breast	10	1,111
Prostate	6	997

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Franklin County was 432.8 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (527.1) gives an estimate of the relative burden of disease in Franklin County.

The age- and sex-adjusted incidence rate of invasive cancer in Franklin County, all sites combined, was 475.8 cases per 100,000 persons per year during 2017–2021. There were fewer cases of cancer in Franklin County (303) than expected (335.7) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Franklin County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Franklin County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Franklin County, all sites combined, was 141.3 deaths per 100,000 persons per year during 2018–2022, compared with 165.7 for the remainder of the state. There were fewer cancer deaths in Franklin County (93) than expected (109.0) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN FRANKLIN COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Fra	nklin Count	у			Ren	nainder of Ida	ho
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)		P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	303	70,008	432.8	475.8	335.7	0.076	47,030	8,922,098	527.1
All Sites Combined	Male	157	35,891	437.4	478.4	184.1	0.046 <<	25,113	4,476,382	561.0
All Sites Combined	Female	146	34,117	427.9	469.6	153.3	0.591	21,917	4,445,716	493.0
Bladder	Total	19	70,008	27.1	29.7	15.8	0.476	2,201	8,922,098	24.7
Bladder	Male	17	35,891	47.4	51.1	13.1	0.336	1,756	4,476,382	39.2
Bladder Brein melianent	Female	2 11	34,117 70,008	5.9	6.5 16.7	3.1 4.8	0.806	445 646	4,445,716 8,922,098	10.0
Brain - malignant Brain - malignant	Total Male	6	35,891	15.7 16.7	17.9	4.0 2.8	0.020 >> 0.134	376	4,476,382	7.2 8.4
Brain - malignant	Female	5	34,117	14.7	15.6	2.0	0.097	270	4.445.716	6.1
Brain and other CNS - non-malignant	Total	10	70,008	14.3	15.5	11.1	0.885	1,537	8,922,098	17.2
	Male	3	35,891	8.4	8.9	3.7	0.976	497	4,476,382	11.1
Brain and other CNS - non-malignant	Female	7	34,117	20.5	22.3	7.3	1.000	1,040	4,445,716	23.4
Breast	Total	51	70,008	72.8	80.1	49.6	0.883	6,957	8,922,098	78.0
Breast Breast	Male Female	2 49	35,891 34,117	5.6 143.6	6.0 158.1	0.5 48.1	0.161 0.931	63 6,894	4,476,382 4,445,716	1.4 155.1
Breast - in situ	Total	49	70,008	4.3	4.7	9.7	0.026 <<	1,366	8,922,098	155.1
Breast - in situ	Male		35,891	-	-	0.0	1.000	1,000	4,476,382	0.1
Breast - in situ	Female	3	34,117	8.8	9.7	9.5	0.030 <<	1,362	4,445,716	30.6
Cervix	Female	1	34,117	2.9	3.1	2.1	0.754	293	4,445,716	6.6
Colorectal	Total	33	70,008	47.1	51.3	26.0	0.205	3,599	8,922,098	40.3
Colorectal	Male	19	35,891	52.9	57.4	14.5	0.292	1,958	4,476,382	43.7
Colorectal	Female	14	34,117	41.0	44.7	11.6	0.548	1,641	4,445,716	36.9
Corpus Uteri	Female	9	34,117	26.4	29.3	9.3	1.000	1,345	4,445,716	30.3
Esophagus	Total	2	70,008	2.9	3.1	3.6	0.604 0.782	505	8,922,098	5.7 9.5
Esophagus Esophagus	Male Female	2	35,891 34,117	5.6	6.1	3.1 0.5	1.000	427 78	4,476,382 4,445,716	9.5 1.8
Hodgkin Lymphoma	Total	- 1	70,008	- 1.4	- 1.5	1.6	1.000	221	8,922,098	2.5
Hodgkin Lymphoma	Male	_ '	35,891	-	-	1.0	0.766	129	4,476,382	2.9
Hodgkin Lymphoma	Female	1	34,117	2.9	3.1	0.7	0.973	92	4.445.716	2.1
Kidney and Renal Pelvis	Total	10	70,008	14.3	15.7	13.9	0.370	1,941	8,922,098	21.8
Kidney and Renal Pelvis	Male	7	35,891	19.5	21.3	9.6	0.524	1,303	4,476,382	29.1
Kidney and Renal Pelvis	Female	3	34,117	8.8	9.6	4.5	0.695	638	4,445,716	14.4
Larynx	Total	1	70,008	1.4	1.6	1.6	1.000	219	8,922,098	2.5
Larynx	Male	-	35,891	-	-	1.2	0.575	167	4,476,382	3.7
Larynx	Female	1 12	34,117 70,008	2.9 17.1	3.3 18.4	0.4 12.5	0.604 1.000	52	4,445,716	1.2 19.2
Leukemia Leukemia	Total Male	12	35,891	27.9	29.7	7.7	0.500	1,715 1,026	8,922,098 4,476,382	22.9
Leukemia	Female	2	34,117	5.9	6.3	4.9	0.267	689	4,445,716	15.5
Liver and Bile Duct	Total	3	70,008	4.3	4.8	5.9	0.318	840	8,922,098	9.4
Liver and Bile Duct	Male	-	35,891	-	-	4.3	0.027 <<	594	4,476,382	13.3
Liver and Bile Duct	Female	3	34,117	8.8	9.8	1.7	0.486	246	4,445,716	5.5
Lung and Bronchus	Total	8	70,008	11.4	12.6	35.1	>> 000.0	4,951	8,922,098	55.5
Lung and Bronchus	Male	4	35,891	11.1	12.2	18.2	0.000 <<	2,491	4,476,382	55.6
Lung and Bronchus	Female	4	34,117	11.7	13.1	17.0	0.000 <<	2,460	4,445,716	55.3
Melanoma of the Skin Melanoma of the Skin	Total Male	21	70,008 35,891	30.0 36.2	32.8 39.3	22.4 13.9	0.878 0.947	3,123 1,882	8,922,098	35.0 42.0
Melanoma of the Skin	Female	13 8	35,891	23.4	25.6	8.7	0.947	1,002	4,476,382 4,445,716	42.0 27.9
Myeloma	Total	5	70,008	7.1	7.9	5.1	1.000	723	8,922,098	8.1
Myeloma	Male	4	35,891	11.1	12.1	3.3	0.828	443	4,476,382	9.9
Myeloma	Female	1	34,117	2.9	3.3	1.9	0.856	280	4,445,716	6.3
Non-Hodgkin Lymphoma	Total	9	70,008	12.9	14.0	14.2	0.197	1,983	8,922,098	22.2
Non-Hodgkin Lymphoma	Male	4	35,891	11.1	12.1	8.4	0.155	1,142	4,476,382	25.5
Non-Hodgkin Lymphoma	Female	5	34,117	14.7	16.1	5.9	0.936	841	4,445,716	18.9
Oral Cavity and Pharynx	Total	3	70,008	4.3	4.7	9.3	0.034 <<	1,312	8,922,098	14.7
Oral Cavity and Pharynx Oral Cavity and Pharynx	Male Female	2 1	35,891 34,117	5.6 2.9	6.1 3.2	6.8 2.6	0.067 0.536	938 374	4,476,382 4,445,716	21.0 8.4
Ovary	Female	6	34,117	2.9	3.z 19.2	3.8	0.381	547	4,445,716	12.3
Pancreas	Total	9	70,008	17.0	19.2	10.6	0.381	1,479	8,922,098	12.3
Pancreas	Male	5	35,891	13.9	15.1	6.1	0.865	821	4,476,382	18.3
Pancreas	Female	4	34,117	11.7	12.9	4.6	1.000	658	4,445,716	14.8
Prostate	Male	46	35,891	128.2	143.3	48.2	0.827	6,720	4,476,382	150.1
Stomach	Total	3	70,008	4.3	4.7	3.4	1.000	471	8,922,098	5.3
Stomach	Male	1	35,891	2.8	3.0	2.3	0.682	306	4,476,382	6.8
Stomach	Female	2	34,117	5.9	6.4	1.2	0.646	165	4,445,716	3.7
Testis	Male	-	35,891	-	-	2.0	0.281	274	4,476,382	6.1
Thyroid	Total	14	70,008	20.0	21.8	8.4	0.097	1,171	8,922,098	13.1
Thyroid	Male	3	35,891	8.4	9.1	2.7	1.000	369	4,476,382	8.2
Thyroid	Female	11	34,117	32.2	34.7	5.7	0.064	802	4,445,716	18.0
Pediatric Age 0 to 19	Total	6	24,086	24.9	25.0	4.1	0.451	419	2,475,238	16.9
Pediatric Age 0 to 19	Male	3 3	12,746	23.5 26.5	23.6 26.7	2.1	0.715	211 208	1,261,575 1,213,663	16.7
Pediatric Age 0 to 19	Female	3	11,340	20.5	20.7	1.9	0.608	208	1,213,003	17.1

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN FRANKLIN COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Frai	nklin County	/			Re	mainder of Idah	10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years		Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	592	71,696	825.7	875.3	591.6	0.998	79.943	9.139.698	874.7
All Causes of Death	Male	314	36,884	851.3	893.8	325.0	0.564	42,472	4,590,813	925.2
All Causes of Death	Female	278	34,812	798.6	850.2	269.4	0.615	37,471	4,548,885	823.7
All Malignant Cancers	Total	93	71,696	129.7	141.3	109.0	0.132	15,140	9.139.698	165.7
All Malignant Cancers	Male	51	36,884	138.3	141.5	61.2	0.132	8,184	4,590,813	178.3
All Malignant Cancers	Female	42	34,812	120.6	132.2	48.6	0.386	6,956	4,548,885	152.9
Bladder	Total	1	71,696	1.4	1.5	3.6	0.256	484	9,139,698	5.3
Bladder	Male	1	36,884	2.7	2.8	2.9	0.424	374	4,590,813	8.1
Bladder	Female	- '	34,812	-	-	0.8	0.914	110	4,548,885	2.4
Brain and Other Nervous System	Total	4	71,696	5.6	6.1	3.7	1.000	514	9,139,698	5.6
Brain and Other Nervous System	Male	3	36,884	8.1	8.9	2.1	0.706	286	4,590,813	6.2
Brain and Other Nervous System	Female	1	34,812	2.9	3.1	1.6	1.000	228	4,548,885	5.0
Breast	Total	10	71,696	13.9	15.1	8.1	0.585	1,114	9,139,698	12.2
Breast	Male	-	36,884	-	-	0.1	1.000	13	4,590,813	0.3
Breast	Female	10	34,812	28.7	31.3	7.7	0.502	1,101	4,548,885	24.2
Cervix	Female	1	34,812	2.9	3.1	0.6	0.925	87	4,548,885	1.9
Colorectal	Total	12	71,696	16.7	18.1	9.6	0.509	1,320	9,139,698	14.4
Colorectal	Male	8	36,884	21.7	23.3	5.4	0.358	724	4,590,813	15.8
Colorectal	Female	4	34,812	11.5	12.5	4.2	1.000	596	4,548,885	13.1
Corpus Uteri	Female	-	34,812	-	-	1.2	0.628	169	4,548,885	3.7
Esophagus	Total	-	71,696	-	-	3.3	0.076	461	9,139,698	5.0
Esophagus	Male	-	36,884	-	-	2.9	0.114	391	4,590,813	8.5
Esophagus	Female	-	34,812	-	-	0.5	1.000	70	4,548,885	1.5
Hodgkin Lymphoma	Total	-	71,696	-	-	0.2	1.000	25	9,139,698	0.3
Hodgkin Lymphoma	Male Female	-	36,884	-	-	0.1	1.000	14	4,590,813	0.3
Hodgkin Lymphoma			34,812 71,696	- 2.8	- 3.0	0.1	1.000 0.960	11 384	4,548,885 9,139,698	0.2
Kidney Kidney	Total Male	2 1	36,884	2.0	3.0 2.9	2.0	0.900	245	4,590,813	4.2 5.3
Kidney	Female	1	34,812	2.7	2.9	1.0	1.000	139	4,548,885	3.1
Larynx	Total	- '	71,696	-	-	0.5	1.000	76	9,139,698	0.8
Larynx	Male	_	36,884	-	_	0.5	1.000	65	4,590,813	1.4
Larynx	Female	-	34,812	-	-	0.1	1.000	11	4,548,885	0.2
Leukemia	Total	8	71,696	11.2	12.0	4.8	0.225	657	9,139,698	7.2
Leukemia	Male	3	36,884	8.1	8.6	3.0	1.000	394	4,590,813	8.6
Leukemia	Female	5	34,812	14.4	15.5	1.9	0.083	263	4,548,885	5.8
Liver and Bile Duct	Total	2	71,696	2.8	3.1	4.5	0.356	633	9,139,698	6.9
Liver and Bile Duct	Male	-	36,884	-	-	3.1	0.093	423	4,590,813	9.2
Liver and Bile Duct	Female	2	34,812	5.7	6.4	1.5	0.851	210	4,548,885	4.6
Lung and Bronchus	Total	8	71,696	11.2	12.3	20.8	0.002 <<	2,929	9,139,698	32.0
Lung and Bronchus	Male	6	36,884	16.3	17.8	11.3	0.136	1,535	4,590,813	33.4
Lung and Bronchus	Female	2	34,812	5.7	6.4	9.6	0.008 <<	1,394	4,548,885	30.6
Melanoma of the Skin	Total	2	71,696	2.8	3.0	2.2	1.000	299	9,139,698	3.3
Melanoma of the Skin	Male	2	36,884	5.4	5.8	1.5	0.874	198	4,590,813	4.3
Melanoma of the Skin	Female	-	34,812	-	-	0.7	0.982	101	4,548,885	2.2
Myeloma	Total	2	71,696	2.8	3.0	2.3	1.000	323	9,139,698	3.5
Myeloma	Male	2	36,884	5.4	5.8	1.4	0.814	186	4,590,813	4.1
Myeloma	Female	- 2	34,812	- 2.8	- 3.0	0.9	0.776 0.447	137	4,548,885 9,139,698	3.0 6.2
Non-Hodgkin Lymphoma	Total Male	2	71,696 36,884	∠.8	3.0		0.447 0.195	566 310		6.8
Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma	Female	- 2	36,004 34,812	- 5.7	- 6.3	2.3 1.8	1.000	310 256	4,590,813 4,548,885	0.0 5.6
Oral Cavity and Pharynx	Total	- 2	71,696	5.7 -	0.3	1.0	0.287	256	9,139,698	5.0 3.0
Oral Cavity and Pharynx	Male	-	36,884	-	-	1.9	0.287	192	4,590,813	4.2
Oral Cavity and Pharynx	Female	-	34,812	-	-	0.6	1.000	83	4,548,885	4.2
Ovary	Female	- 4	34,812	- 11.5	- 12.8	2.5	0.467	357	4,548,885	7.8
Pancreas	Total	9	71,696	12.6	13.9	8.4	0.921	1,181	9,139,698	12.9
Pancreas	Male	7	36,884	19.0	20.8	4.7	0.393	643	4,590,813	14.0
Pancreas	Female	2	34,812	5.7	6.3	3.7	0.562	538	4,548,885	11.8
Prostate	Male	6	36,884	16.3	16.9	7.7	0.708	991	4,590,813	21.6
Stomach	Total	4	71,696	5.6	6.0	1.4	0.103	190	9,139,698	2.1
Stomach	Male	2	36,884	5.4	5.8	0.9	0.444	117	4,590,813	2.5
Stomach	Female	2	34,812	5.7	6.2	0.5	0.191	73	4,548,885	1.6

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Franklin County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	88.8% 6.6%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	59.5%
Current Tobacco User (2020–2022) <u>Other Cancer-Related</u>	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	23.2%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	36.7% 74.7% 9.5% 10.7%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





FREMONT COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 319 cases of invasive cancer were diagnosed among Fremont County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in FremontCounty and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Fremont County	State of Idaho
All Sites/Types	319	47,333
Female Breast	49	6,943
Prostate	51	6,766
Lung & Bronchus	29	4,959
Colorectal	23	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Fremont County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Fremont County. The table also shows the number of observed cases, person-

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 110 Fremont County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Fremont County and the State of Idaho, 2018–2022

Mortality 2018–2022	Fremont County	State of Idaho
All Deaths	633	80,538
Cancer Deaths	110	15,233
% of All Deaths	17.4%	18.9%
Lung & Bronchus	20	2,937
Colorectal	11	1,332
Pancreas	14	1,190
Female Breast	8	1,111
Prostate	10	997

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Fremont County was 481.6 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (526.7) gives an estimate of the relative burden of disease in Fremont County.

The age- and sex-adjusted incidence rate of invasive cancer in Fremont County, all sites combined, was 452.7 cases per 100,000 persons per year during 2017–2021. There were statistically significantly fewer cases of cancer in Fremont County (319) than expected (371.1) based upon rates in the remainder of the state (p=.006).

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Fremont County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Fremont County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Fremont County, all sites combined, was 154.2 deaths per 100,000 persons per year during 2018–2022, compared with 165.4 for the remainder of the state. There were fewer cancer deaths in Fremont County (110) than expected (118.0) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN FREMONT COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Frer	mont Count	y			Ren	nainder of Ida	aho
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)		P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	319	66,231	481.6	452.7	371.1	0.006 <<	47,014	8,925,875	526.7
All Sites Combined	Male	172	34,685	495.9	452.1	213.3	0.004 <<	25,098	4,477,588	560.5
All Sites Combined	Female	147	31,546	466.0	449.3	161.2	0.280	21,916	4,448,287	492.7
Bladder	Total	13	66,231	19.6	18.2	17.6	0.325	2,207	8,925,875	24.7
Bladder	Male	10	34,685	28.8	25.8	15.3	0.213	1,763	4,477,588	39.4
Bladder	Female	3	31,546	9.5	9.1	3.3	1.000	444	4,448,287	10.0
Brain - malignant	Total	3	66,231	4.5	4.3	5.1	0.511	654	8,925,875	7.3
Brain - malignant	Male	1	34,685	2.9	2.7	3.1	0.357	381	4,477,588	8.5
Brain - malignant	Female	2	31,546	6.3	6.2	2.0	1.000	273	4,448,287	6.1
Brain and other CNS - non-malignant	Total	14	66,231	21.1	20.1	12.0	0.627	1,533	8,925,875	17.2
- 5	Male Female	3 11	34,685 31,546	8.6 34.9	8.1 33.8	4.1 7.6	0.818 0.288	497 1,036	4,477,588 4.448.287	11.1 23.3
Brain and other CNS - non-malignant Breast	Total	49	66,231	74.0	69.9	54.6	0.288	6,959	8,925,875	78.0
Breast	Male	43	34,685	74.0	03.3	0.6	1.000	65	4,477,588	1.5
Breast	Female	49	31,546	155.3	149.3	50.9	0.866	6,894	4,448,287	155.0
Breast - in situ	Total	5	66,231	7.5	7.1	10.7	0.089	1,364	8,925,875	15.3
Breast - in situ	Male	-	34,685	-	-	0.0	1.000	4	4,477,588	0.1
Breast - in situ	Female	5	31,546	15.8	15.2	10.1	0.127	1,360	4,448,287	30.6
Cervix	Female	-	31,546	-	-	2.1	0.255	294	4,448,287	6.6
Colorectal	Total	23	66,231	34.7	32.7	28.5	0.355	3,609	8,925,875	40.4
Colorectal	Male	12	34,685	34.6	31.6	16.7	0.303	1,965	4,477,588	43.9
Colorectal	Female	11	31,546	34.9	33.8	12.0	0.917	1,644	4,448,287	37.0
Corpus Uteri	Female	13	31,546	41.2	39.5	9.9	0.401	1,341	4,448,287	30.1
Esophagus	Total	-	66,231	-	-	4.1	0.035 <<	507	8,925,875	5.7
Esophagus	Male	-	34,685	-	-	3.7	0.049 <<	429	4,477,588	9.6
Esophagus	Female	-	31,546	-	-	0.6	1.000	78	4,448,287	1.8
Hodgkin Lymphoma	Total Male	2	66,231	3.0	3.0	1.7	0.988 1.000	220	8,925,875 4,477,588	2.5
Hodgkin Lymphoma	Female	1	34,685 31,546	2.9 3.2	2.8 3.1	1.0 0.7	0.964	128 92	4,477,588	2.9 2.1
Hodgkin Lymphoma Kidney and Renal Pelvis	Total	8	66,231	12.1	11.4	15.3	0.063	1,943	8,925,875	2.1
Kidney and Renal Pelvis	Male	5	34,685	14.4	13.2	11.0	0.075	1,305	4,477,588	21.0
Kidney and Renal Pelvis	Female	3	31,546	9.5	9.1	4.7	0.614	638	4,448,287	14.3
Larynx	Total	2	66,231	3.0	2.8	1.7	1.000	218	8,925,875	2.4
Larynx	Male	2	34,685	5.8	5.2	1.4	0.834	165	4,477,588	3.7
Larynx	Female	-	31,546	-	-	0.4	1.000	53	4,448,287	1.2
Leukemia	Total	16	66,231	24.2	22.8	13.5	0.559	1,711	8,925,875	19.2
Leukemia	Male	9	34,685	25.9	23.8	8.7	1.000	1,027	4,477,588	22.9
Leukemia	Female	7	31,546	22.2	21.4	5.0	0.487	684	4,448,287	15.4
Liver and Bile Duct	Total	8	66,231	12.1	11.3	6.6	0.695	835	8,925,875	9.4
Liver and Bile Duct	Male	7	34,685	20.2	18.4	5.0	0.468	587	4,477,588	13.1
Liver and Bile Duct	Female	1	31,546	3.2	3.0	1.8	0.899	248	4,448,287	5.6
Lung and Bronchus	Total	29	66,231	43.8	40.5	39.5	0.101	4,930	8,925,875	55.2
Lung and Bronchus	Male	13	34,685	37.5	33.7	21.4	0.074	2,482	4,477,588	55.4
Lung and Bronchus	Female	16	31,546	50.7	48.0 28.7	18.3	0.693	2,448	4,448,287	55.0
Melanoma of the Skin Melanoma of the Skin	Total Male	20 16	66,231 34,685	30.2 46.1	42.2	24.4 15.9	0.435 1.000	3,124 1,879	8,925,875 4,477,588	35.0 42.0
Melanoma of the Skin	Female	4	34,005	40.1	42.2	9.0	0.108	1,079	4,477,588	42.0 28.0
Myeloma	Total	4	66,231	6.0	5.6	5.8	0.631	724	8,925,875	8.1
Myeloma	Male	3	34,685	8.6	7.8	3.8	0.938	444	4,477,588	9.9
Myeloma	Female	1	31,546	3.2	3.0	2.1	0.765	280	4,448,287	6.3
Non-Hodgkin Lymphoma	Total	13	66,231	19.6	18.4	15.6	0.612	1,979	8,925,875	22.2
Non-Hodgkin Lymphoma	Male	4	34,685	11.5	10.6	9.6	0.075	1,142	4,477,588	25.5
Non-Hodgkin Lýmphoma	Female	9	31,546	28.5	27.5	6.2	0.340	837	4,448,287	18.8
Oral Cavity and Pharynx	Total	15	66,231	22.6	21.2	10.3	0.200	1,300	8,925,875	14.6
Oral Cavity and Pharynx	Male	13	34,685	37.5	34.2	7.9	0.115	927	4,477,588	20.7
Oral Cavity and Pharynx	Female	2	31,546	6.3	6.1	2.7	0.964	373	4,448,287	8.4
Ovary	Female	2	31,546	6.3	6.1	4.0	0.463	551	4,448,287	12.4
Pancreas	Total	14	66,231	21.1	19.7	11.7	0.578	1,474	8,925,875	16.5
Pancreas	Male Female	6 8	34,685 31,546	17.3 25.4	15.6 24.3	7.0 4.8	0.888 0.235	820 654	4,477,588 4,448,287	18.3 14.7
Pancreas Prostate	Female Male	8 51	31,546 34,685	25.4 147.0	24.3	4.8 57.1	0.235	6,715	4,448,287	14.7
Stomach	Total	51 1	54,005 66,231	147.0	1.4	3.7	0.469	473	4,477,566	5.3
Stomach	Male	- '	34,685	-	- 1.4	2.6	0.227	307	4,477,588	5.3 6.9
Stomach	Female	- 1	34,005	- 3.2	- 3.1	1.2	1.000	166	4,448,287	3.7
Testis	Male	3	34,685	8.6	9.0	2.0	0.655	271	4,440,207	6.1
Thyroid	Total	7	66,231	10.6	10.4	8.9	0.678	1,178	8,925,875	13.2
Thyroid	Male	2	34,685	5.8	5.5	3.0	0.841	370	4,477,588	8.3
Thyroid	Female	2 5	34,685 31,546	5.8 15.8	5.5 15.9	3.0 5.7	0.841 0.987	370 808	4,477,588 4,448,287	8.3 18.2
Pediatric Age 0 to 19	Total	5	18,272	32.8	32.5	5.7 3.1	0.987	419	4,448,287	18.2
Pediatric Age 0 to 19	Male Female	5 1	9,508 8 764	52.6	52.4 11.3	1.6	0.045 >> 1.000	209	1,264,813	16.5 17.3
Pediatric Age 0 to 19	Female	1	8,764	11.4	11.3	1.5	1.000	210	1,216,239	17.3

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN FREMONT COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Frer	nont Count	у			Re	mainder of Idal	10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	633	67,069	943.8	905.4	610.9	0.381	79,902	9,144,325	873.8
All Causes of Death	Male	348	35,244	987.4	894.7	359.4	0.568	42,438	4,592,453	924.1
All Causes of Death	Female	285	31,825	895.5	908.4	258.2	0.105	37,464	4,551,872	823.0
All Malignant Cancers	Total	110	67,069	164.0	154.2	118.0	0.497	15,123	9,144,325	165.4
All Malignant Cancers	Male	59	35,244	167.4	150.7	69.7	0.218	8,176	4,592,453	178.0
All Malignant Cancers	Female	51	31,825	160.3	155.8	50.0	0.921	6,947	4,551,872	152.6
Bladder	Total	6	67,069	8.9	8.5	3.7	0.336	479	9,144,325	5.2
Bladder	Male	5	35,244	14.2	12.6	3.2	0.439	370	4,592,453	8.1
Bladder	Female	1	31,825	3.1	3.1	0.8	1.000	109	4,551,872	2.4
Brain and Other Nervous System	Total	4	67,069	6.0	5.6	4.0	1.000	514	9,144,325	5.6
	Male	2	35,244	5.7	5.2	2.4	1.000	287	4,592,453	6.2
	Female	2	31,825	6.3	6.1	1.6	0.977	227	4,551,872	5.0
Breast	Total	8	67,069	11.9	11.3	8.6	1.000	1,116	9,144,325	12.2
Breast	Male	- 0	35,244	-	-	0.1 7.9	1.000	13	4,592,453	0.3
Breast	Female	8	31,825 31,825	25.1 3.1	24.7 3.1	0.6	1.000 0.921	1,103 87	4,551,872 4,551,872	24.2
Cervix Colorectal	Female Total	11	67,069	16.4	3.1	10.8	0.921	1,321	4,551,872	1.9
Colorectal	Male	7	35,244	19.9	17.9	6.2	0.904	725	4,592,453	14.4
Colorectal	Female	4	31,825	12.6	12.4	4.2	1.000	596	4,551,872	13.0
Corpus Uteri	Female	-	31,825	-	-	4.2	0.581	169	4,551,872	3.7
Esophagus	Total	1	67,069	1.5	1.4	3.6	0.247	460	9,144,325	5.0
Esophagus	Male	1	35,244	2.8	2.6	3.3	0.312	390	4,592,453	8.5
Esophagus	Female	-	31,825	-	-	0.5	1.000	70	4,551,872	1.5
Hodgkin Lymphoma	Total	-	67,069	-	-	0.2	1.000	25	9,144,325	0.3
Hodgkin Lymphoma	Male	-	35,244	-	-	0.1	1.000	14	4,592,453	0.3
Hodgkin Lymphoma	Female	-	31,825	-	-	0.1	1.000	11	4,551,872	0.2
Kidney	Total	2	67,069	3.0	2.8	3.0	0.850	384	9,144,325	4.2
Kidney	Male	2	35,244	5.7	5.1	2.1	1.000	244	4,592,453	5.3
Kidney	Female	-	31,825	-	-	1.0	0.733	140	4,551,872	3.1
Larynx	Total	1	67,069	1.5	1.4	0.6	0.893	75	9,144,325	0.8
Larynx	Male	1	35,244	2.8	2.5	0.6	0.850	64	4,592,453	1.4
Larynx	Female		31,825	-	-	0.1	1.000	11	4,551,872	0.2
Leukemia	Total	5	67,069	7.5	7.0	5.1	1.000	660	9,144,325	7.2
Leukemia	Male	3 2	35,244 31,825	8.5 6.3	7.7 6.1	3.4 1.9	1.000 1.000	394 266	4,592,453 4,551,872	8.6 5.8
Leukemia Liver and Bile Duct	Female Total	5	67,069	7.5	7.0	4.9	1.000	630	9,144,325	6.9
Liver and Bile Duct	Male	3	35,244	8.5	7.0	3.5	1.000	420	4,592,453	9.1
Liver and Bile Duct	Female	2	31,825	6.3	6.0	1.5	0.909	210	4,551,872	4.6
Lung and Bronchus	Total	20	67,069	29.8	27.8	23.0	0.625	2,917	9,144,325	31.9
Lung and Bronchus	Male	7	35,244	19.9	17.9	13.1	0.105	1,534	4,592,453	33.4
Lung and Bronchus	Female	13	31,825	40.8	39.1	10.1	0.435	1,383	4,551,872	30.4
Melanoma of the Skin	Total	2	67,069	3.0	2.8	2.3	1.000	299	9,144,325	3.3
Melanoma of the Skin	Male	1	35,244	2.8	2.6	1.7	0.990	199	4,592,453	4.3
Melanoma of the Skin	Female	1	31,825	3.1	3.1	0.7	1.000	100	4,551,872	2.2
Myeloma	Total	2	67,069	3.0	2.8	2.5	1.000	323	9,144,325	3.5
Mýeloma	Male	1	35,244	2.8	2.5	1.6	1.000	187	4,592,453	4.1
Myeloma	Female	1	31,825	3.1	3.0	1.0	1.000	136	4,551,872	3.0
Non-Hodgkin Lymphoma	Total	7	67,069	10.4	9.8	4.4	0.311	561	9,144,325	6.1
	Male	2	35,244	5.7	5.1	2.6	1.000	308	4,592,453	6.7
Non-Hodgkin Lymphoma	Female	5	31,825	15.7	15.5	1.8	0.072	253	4,551,872	5.6
Oral Cavity and Pharynx	Total	1	67,069	1.5	1.4	2.1	0.735	274	9,144,325	3.0
	Male	1	35,244	2.8	2.6	1.6	1.000	191	4,592,453	4.2
Oral Cavity and Pharynx	Female	-	31,825	-	-	0.6	1.000	83	4,551,872	1.8
Ovary	Female	3	31,825	9.4	9.1	2.6	0.965	358	4,551,872	7.9
Pancreas	Total	14	67,069	20.9	19.5	9.2	0.171	1,176	9,144,325	12.9
Pancreas	Male	8	35,244	22.7	20.6	5.4	0.365	642 534	4,592,453	14.0
	Female	6	31,825	18.9	18.1	3.9	0.393	534	4,551,872	11.7
Prostate	Male	10	35,244	28.4	25.2	8.5 1.5	0.702 0.444	987	4,592,453	21.5
Stomach Stomach	Total Male	-	67,069 35,244	-	-	1.5	0.444	194 110	9,144,325	2.1
		-		-	-	1.0		119	4,592,453	2.6
Stomach	Female	-	31,825	-	-	0.5	1.000	75	4,551,872	1.6

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Fremont County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	83.5% 12.0%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	44.4%
Current Tobacco User (2020–2022) Other Cancer-Related	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	24.9%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	31.9% 80.3% 14.2% 14.6%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





GEM COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 647 cases of invasive cancer were diagnosed among Gem County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,

 Lung and Bronchus, and Colorectal Cancers in Gem County

 and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Gem County	State of Idaho
All Sites/Types	647	47,333
Female Breast	76	6,943
Prostate	99	6,766
Lung & Bronchus	70	4,959
Colorectal	68	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Gem County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Gem County. The table also shows the number of observed cases, person-years, and

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 214 Gem County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Gem County and the State of Idaho, 2018–2022

Mortality 2018–2022	Gem County	State of Idaho
All Deaths	1,237	80,538
Cancer Deaths	214	15,233
% of All Deaths	17.3%	18.9%
Lung & Bronchus	50	2,937
Colorectal	19	1,332
Pancreas	20	1,190
Female Breast	15	1,111
Prostate	13	997

crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Gem County was 705.7 cases per 100,000 personyears per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (524.5) gives an estimate of the relative burden of disease in Gem County.

The age- and sex-adjusted incidence rate of invasive cancer in Gem County, all sites combined, was 549.9 cases per 100,000 persons per year during 2017–2021. There were more cases of cancer in Gem County (647) than expected (617.2) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Gem County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Gem County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Gem County, all sites combined, was 169.1 deaths per 100,000 persons per year during 2018–2022, compared with 164.7 for the remainder of the state. There were more cancer deaths in Gem County (214) than expected (208.5) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN GEM COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Ge	em County				Ren	nainder of Ida	aho
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	647	91,682	705.7	549.9	617.2	0.239	46,686	8,900,424	524.5
All Sites Combined	Male	354	46,104	767.8	572.3	345.1	0.646	24,916	4,466,169	557.9
All Sites Combined	Female	293	45,578	642.9	519.9	276.7	0.341	21,770	4,434,255	491.0
Bladder	Total	35	91,682	38.2	28.1	30.6	0.468	2,185	8,900,424	24.5
Bladder Bladder	Male Female	29 6	46,104 45,578	62.9 13.2	44.2 10.1	25.6 5.9	0.557 1.000	1,744 441	4,466,169 4,434,255	39.0 9.9
Brain - malignant	Total	9	91,682	9.8	8.3	7.9	0.797	648	8,900,424	9.9 7.3
Brain - malignant	Male	6	46,104	13.0	10.9	4.6	0.643	376	4,466,169	8.4
Brain - malignant	Female	3	45,578	6.6	5.6	3.3	1.000	272	4,434,255	6.1
Brain and other CNS - non-malignant	Total	20	91,682	21.8	17.7	19.4	0.958	1,527	8,900,424	17.2
- 5	Male	4	46,104	8.7	6.9	6.4	0.472	496	4,466,169	11.1
	Female	16	45,578	35.1	28.8	12.9	0.457	1,031	4,434,255	23.3
Breast Breast	Total Male	77 1	91,682 46,104	84.0 2.2	67.5 1.6	88.9 0.9	0.224 1.000	6,931 64	8,900,424 4,466,169	77.9 1.4
Breast	Female	76	40,104 45,578	166.7	135.6	0.9 86.8	0.266	6,867	4,400,109	1.4
Breast - in situ	Total	11	91,682	12.0	9.8	17.2	0.158	1,358	8,900,424	15.3
Breast - in situ	Male	-	46,104	-	-	0.0	1.000	4	4,466,169	0.1
Breast - in situ	Female	11	45,578	24.1	19.7	17.0	0.168	1,354	4,434,255	30.5
Cervix	Female	3	45,578	6.6	6.2	3.2	1.000	291	4,434,255	6.6
Colorectal	Total	68 26	91,682	74.2	58.2	46.8	0.004 >>	3,564	8,900,424	40.0
Colorectal Colorectal	Male Female	36 32	46,104 45,578	78.1 70.2	59.6 56.5	26.3 20.7	0.081 0.026 >>	1,941 1,623	4,466,169 4,434,255	43.5 36.6
Colorectal Corpus Uteri	Female	32 15	45,578	32.9	26.5	20.7	0.026 >>	1,623	4,434,255	30.0
Esophagus	Total	8	91,682	8.7	6.6	6.8	0.746	499	8,900,424	5.6
Esophagus	Male	5	46,104	10.8	7.9	6.0	0.891	424	4,466,169	9.5
Esophagus	Female	3	45,578	6.6	5.2	1.0	0.155	75	4,434,255	1.7
Hodgkin Lymphoma	Total	1	91,682	1.1	1.1	2.4	0.634	221	8,900,424	2.5
Hodgkin Lymphoma	Male	-	46,104	-	-	1.4	0.485	129	4,466,169	2.9
Hodgkin Lymphoma	Female	1 28	45,578	2.2	2.2 24.0	0.9	1.000 0.633	92	4,434,255 8,900,424	2.1
Kidney and Renal Pelvis Kidney and Renal Pelvis	Total Male	20 16	91,682 46,104	30.5 34.7	24.0	25.2 17.4	0.861	1,923 1,294	4,466,169	21.6 29.0
Kidney and Renal Pelvis	Female	10	45,578	26.3	20.7	8.1	0.235	629	4,434,255	14.2
Larynx	Total	1	91,682	1.1	0.8	3.0	0.406	219	8,900,424	2.5
Larynx	Male	1	46,104	2.2	1.6	2.4	0.639	166	4,466,169	3.7
Larynx	Female	-	45,578	-	-	0.7	0.998	53	4,434,255	1.2
Leukemia	Total	17	91,682	18.5	14.5	22.6	0.284	1,710	8,900,424	19.2
Leukemia	Male	9 8	46,104	19.5	14.7 14.1	14.1	0.214 0.982	1,027	4,466,169	23.0
Leukemia Liver and Bile Duct	Female Total	0 19	45,578 91,682	17.6 20.7	14.1	8.7 11.1	0.982	683 824	4,434,255 8,900,424	15.4 9.3
Liver and Bile Duct	Male	16	46,104	34.7	26.0	8.0	0.016 >>	578	4,466,169	12.9
Liver and Bile Duct	Female	3	45,578	6.6	5.1	3.2	1.000	246	4,434,255	5.5
Lung and Bronchus	Total	70	91,682	76.4	56.3	68.3	0.868	4,889	8,900,424	54.9
Lung and Bronchus	Male	33	46,104	71.6	50.7	35.9	0.711	2,462	4,466,169	55.1
Lung and Bronchus	Female	37	45,578	81.2	62.0	32.7	0.494	2,427	4,434,255	54.7
Melanoma of the Skin	Total	44	91,682	48.0	38.5	39.8	0.550	3,100	8,900,424	34.8
Melanoma of the Skin Melanoma of the Skin	Male Female	23 21	46,104 45,578	49.9 46.1	37.8 38.9	25.5 15.0	0.717 0.162	1,872 1,228	4,466,169 4,434,255	41.9 27.7
Myeloma	Total	6	45,578 91,682	6.5	30.9 4.9	9.9	0.162	722	4,434,255	8.1
Myeloma	Male	5	46,104	10.8	7.9	6.3	0.798	442	4,466,169	9.9
Myeloma	Female	1	45,578	2.2	1.7	3.7	0.232	280	4,434,255	6.3
Non-Hodgkin Lymphoma	Total	21	91,682	22.9	17.9	26.0	0.384	1,971	8,900,424	22.1
Non-Hodgkin Lymphoma	Male	13	46,104	28.2	21.6	15.2	0.680	1,133	4,466,169	25.4
Non-Hodgkin Lymphoma	Female	8	45,578	17.6	14.0	10.8	0.497	838	4,434,255	18.9
Oral Cavity and Pharynx Oral Cavity and Pharynx	Total Male	18 14	91,682 46,104	19.6 30.4	15.3 23.2	17.2 12.5	0.906 0.750	1,297 926	8,900,424 4,466,169	14.6 20.7
Oral Cavity and Pharynx	Female	4	40,104 45,578	30.4 8.8	7.0	4.8	0.951	920 371	4,400,109	8.4
Ovary	Female	9	45,578	19.7	16.2	6.8	0.498	544	4,434,255	12.3
Pancreas	Total	24	91,682	26.2	19.6	20.1	0.439	1,464	8,900,424	16.4
Pancreas	Male	12	46,104	26.0	18.8	11.6	0.993	814	4,466,169	18.2
Pancreas	Female	12	45,578	26.3	20.4	8.6	0.324	650	4,434,255	14.7
Prostate	Male	99	46,104	214.7	158.0	93.5	0.600	6,667	4,466,169	149.3
Stomach Stomach	Total Male	9 5	91,682 46,104	9.8 10.8	7.6 8.0	6.2 4.2	0.354 0.835	465 302	8,900,424 4,466,169	5.2 6.8
Stomach	iviale Female	5 4	46,104 45,578	8.8	8.0 7.1	4.2	0.835	302 163	4,466,169	6.8 3.7
Testis	Male	4	45,578	6.5	7.1	2.1	0.312	271	4,434,235	6.1
Thyroid	Total	15	91,682	16.4	15.2	13.0	0.642	1,170	8,900,424	13.1
Thyroid	Male	6	46,104	13.0	11.2	4.4	0.555	366	4,466,169	8.2
Thyroid	Female	9	45,578	19.7	18.9	8.7	0.997	804	4,434,255	18.1
Pediatric Age 0 to 19	Total	2	22,713	8.8	8.8	3.9	0.537	423	2,476,611	17.1
Pediatric Age 0 to 19	Male	2	12,003	16.7	16.7	2.0	1.000	212	1,262,318	16.8
Pediatric Age 0 to 19	Female		10,710	-	-	1.8	0.317	211	1,214,293	17.4

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN GEM COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Ge	em County				Re	mainder of Idah	10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	1,237	94,749	1,305.6	989.0	1,087.9	0.000 >>	79,298	9,116,645	869.8
All Causes of Death	Male	663	47,797	1,387.1	1,007.0	605.5	0.022 >>	42,123	4,579,900	919.7
All Causes of Death	Female	574	46,952	1,222.5	963.6	488.1	0.000 >>	37,175	4,536,745	819.4
All Malignant Cancers	Total	214	94,749	225.9	169.1	208.5	0.720	15,019	9,116,645	164.7
All Malignant Cancers	Male	117	47,797	244.8	174.2	119.1	0.898	8,118	4,579,900	177.3
All Malignant Cancers	Female	97	46,952	206.6	161.2	91.5	0.593	6,901	4,536,745	152.1
Bladder	Total	7	94,749	7.4	5.4	6.8	1.000	478	9,116,645	5.2
Bladder	Male	5	47,797	10.5	7.1	5.7	0.993	370	4,579,900	8.1
Bladder	Female	2	46,952	4.3	3.3	1.5	0.855	108	4,536,745	2.4
Brain and Other Nervous System	Total	9	94,749	9.5	7.6	6.6	0.447	509	9,116,645	5.6
	Male	5	47,797	10.5	8.2	3.8	0.654	284	4,579,900	6.2
Brain and Other Nervous System	Female	4	46,952	8.5	6.9	2.9	0.651	225	4,536,745	5.0
Breast	Total	15	94,749	15.8	12.1	15.1	1.000	1,109	9,116,645	12.2
Breast	Male	-	47,797	-	-	0.2	1.000	13	4,579,900	0.3
Breast	Female	15	46,952	31.9	25.3	14.3	0.929	1,096	4,536,745	24.2
Cervix	Female	1	46,952	2.1	1.9	1.0	1.000	87	4,536,745	1.9
Colorectal	Total	19	94,749	20.1	15.3	17.9	0.848	1,313	9,116,645	14.4
Colorectal	Male	11	47,797	23.0	17.1	10.2	0.872	721	4,579,900	15.7
Colorectal	Female	8	46,952	17.0	13.4	7.8	1.000	592	4,536,745	13.0
Corpus Uteri	Female	2	46,952	4.3	3.3	2.2	1.000	167	4,536,745	3.7
Esophagus	Total	7	94,749	7.4	5.5	6.3	0.881	454	9,116,645	5.0
Esophagus	Male	4	47,797	8.4	6.1	5.6	0.690	387	4,579,900	8.4
Esophagus	Female	3	46,952	6.4	5.0	0.9	0.122	67	4,536,745	1.5
Hodgkin Lymphoma	Total	-	94,749	-	-	0.3	1.000	25	9,116,645	0.3
Hodgkin Lymphoma	Male	-	47,797	-	-	0.2	1.000	14	4,579,900	0.3
Hodgkin Lymphoma	Female	-	46,952	-	-	0.1	1.000	11	4,536,745	0.2
Kidney	Total	1	94,749	1.1	0.8	5.4	0.057	385	9,116,645	4.2
Kidney	Male	1	47,797	2.1	1.5	3.6	0.254	245	4,579,900	5.3
Kidney	Female	-	46,952	-	-	1.9	0.300	140	4,536,745	3.1
Larynx	Total	-	94,749	-	-	1.1	0.698	76	9,116,645	0.8
Larynx	Male	-	47,797	-	-	1.0	0.767 1.000	65	4,579,900	1.4 0.2
Larynx	Female Total	- 6	46,952 94,749	- 6.3	- 4.7	0.1	0.383	11	4,536,745	7.2
Leukemia Leukemia	Male	o 4	94,749 47,797	0.3 8.4	4.7 5.9	9.2 5.8	0.363	659 393	9,116,645 4,579,900	7.2 8.6
Leukemia	Female	2	46,952	4.3	3.3	3.5	0.633	266	4,536,745	5.9
Liver and Bile Duct	Total	9	94,749	9.5	7.2	8.6	0.033	626	9,116,645	6.9
Liver and Bile Duct	Male	6	47,797	12.6	9.2	5.9	1.000	417	4,579,900	9.1
Liver and Bile Duct	Female	3	46,952	6.4	4.9	2.8	1.000	209	4,536,745	4.6
Lung and Bronchus	Total	50	94,749	52.8	38.8	40.8	0.179	2,887	9,116,645	31.7
Lung and Bronchus	Male	27	47,797	56.5	39.8	22.4	0.384	1,514	4,579,900	33.1
Lung and Bronchus	Female	23	46,952	49.0	37.4	18.6	0.360	1,373	4,536,745	30.3
Melanoma of the Skin	Total	5	94,749	5.3	4.0	4.0	0.750	296	9,116,645	3.2
Melanoma of the Skin	Male	2	47,797	4.2	3.0	2.8	0.918	198	4,579,900	4.3
Melanoma of the Skin	Female	3	46,952	6.4	5.1	1.3	0.267	98	4,536,745	2.2
Myeloma	Total	1	94,749	1.1	0.8	4.6	0.113	324	9,116,645	3.6
Myeloma	Male	1	47,797	2.1	1.5	2.8	0.458	187	4,579,900	4.1
Myeloma	Female	-	46,952	-	-	1.9	0.314	137	4,536,745	3.0
Non-Hodgkin Lymphoma	Total	9	94,749	9.5	7.0	7.8	0.767	559	9,116,645	6.1
Non-Hodgkin Lymphoma	Male	6	47,797	12.6	8.9	4.5	0.580	304	4,579,900	6.6
Non-Hodgkin Lymphoma	Female	3	46,952	6.4	4.9	3.4	1.000	255	4,536,745	5.6
Oral Cavity and Pharynx	Total	5	94,749	5.3	4.0	3.7	0.634	270	9,116,645	3.0
Oral Cavity and Pharynx	Male	4	47,797	8.4	6.1	2.7	0.569	188	4,579,900	4.1
Oral Cavity and Pharynx	Female	1	46,952	2.1	1.7	1.1	1.000	82	4,536,745	1.8
Ovary	Female	4	46,952	8.5	6.6	4.7	0.974	357	4,536,745	7.9
Pancreas	Total	20	94,749	21.1	15.7	16.3	0.421	1,170	9,116,645	12.8
Pancreas	Male	10	47,797	20.9	15.0	9.3	0.906	640	4,579,900	14.0
Pancreas	Female	10	46,952	21.3	16.4	7.1	0.362	530	4,536,745	11.7
Prostate	Male	13	47,797	27.2	18.3	15.2	0.683	984	4,579,900	21.5
Stomach	Total	4	94,749	4.2	3.3	2.5	0.504	190	9,116,645	2.1
Stomach	Male	3	47,797	6.3	4.6	1.7	0.469	116	4,579,900	2.5
Stomach	Female	1	46,952	2.1	1.8	0.9	1.000	74	4,536,745	1.6

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Gem County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	90.6% 14.7%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	45.5%
Current Tobacco User (2020–2022) <u>Other Cancer-Related</u>	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	29.0%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	30.6% 77.5% 16.4% 18.4%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





GOODING COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 409 cases of invasive cancer were diagnosed among Gooding County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in GoodingCounty and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Gooding County	State of Idaho
All Sites/Types	409	47,333
Female Breast	56	6,943
Prostate	50	6,766
Lung & Bronchus	45	4,959
Colorectal	38	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Gooding County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Gooding County. The table also shows the number of observed cases, person-

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 139 Gooding County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Gooding County and the State of Idaho, 2018–2022

Mortality 2018–2022	Gooding County	State of Idaho				
All Deaths	813	80,538				
Cancer Deaths	139	15,233				
% of All Deaths	17.1%	18.9%				
Lung & Bronchus	31	2,937				
Colorectal	8	1,332				
Pancreas	9	1,190				
Female Breast	9	1,111				
Prostate	13	997				

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Gooding County was 531.3 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (526.3) gives an estimate of the relative burden of disease in Gooding County.

The age- and sex-adjusted incidence rate of invasive cancer in Gooding County, all sites combined, was 497.8 cases per 100,000 persons per year during 2017–2021. There were fewer cases of cancer in Gooding County (409) than expected (432.5) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Gooding County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Gooding County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Gooding County, all sites combined, was 162.3 deaths per 100,000 persons per year during 2018–2022, compared with 165.3 for the remainder of the state. There were fewer cancer deaths in Gooding County (139) than expected (141.5) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN GOODING COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Gooding County							Remainder of Idaho				
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude			
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)			
All Sites Combined	Total	409	76,975	531.3	497.8	432.5	0.269	46,924	8,915,131	526.3			
All Sites Combined	Male	211	39,289	537.0	489.9	241.3	0.051	25,059	4,472,984	560.2			
All Sites Combined	Female	198	37,686	525.4	503.7	193.5	0.764	21,865	4,442,147	492.2			
Bladder	Total	14	76,975	18.2	16.4	21.2	0.134	2,206	8,915,131	24.7			
Bladder Bladder	Male Female	12 2	39,289 37,686	30.5 5.3	26.6 4.9	17.7 4.1	0.203 0.454	1,761 445	4,472,984 4,442,147	39.4 10.0			
Brain - malignant	Total	7	76,975	9.1	4.9	5.8	0.434	650	8,915,131	7.3			
Brain - malignant	Male	5	39,289	12.7	12.2	3.5	0.533	377	4,472,984	8.4			
Brain - malignant	Female	2	37,686	5.3	5.1	2.4	1.000	273	4,442,147	6.1			
Brain and other CNS - non-malignant	Total	21	76,975	27.3	25.7	14.0	0.094	1,526	8,915,131	17.1			
	Male	8	39,289	20.4	18.9	4.7	0.201	492	4,472,984	11.0			
	Female	13	37,686	34.5	33.1	9.2	0.272	1,034	4,442,147	23.3			
Breast Breast	Total Male	57 1	76,975 39,289	74.1 2.5	70.8 2.3	62.8 0.6	0.512 0.933	6,951 64	8,915,131 4,472,984	78.0 1.4			
Breast	Female	56	39,289	2.5 148.6	2.3 144.4	60.1	0.652	6,887	4,472,904 4,442,147	155.0			
Breast - in situ	Total	8	76,975	10.4	10.1	12.1	0.297	1,361	8,915,131	15.3			
Breast - in situ	Male	-	39,289	-	-	0.0	1.000	4	4,472,984	0.1			
Breast - in situ	Female	8	37,686	21.2	20.9	11.7	0.353	1,357	4,442,147	30.5			
Cervix	Female	5	37,686	13.3	13.8	2.4	0.180	289	4,442,147	6.5			
Colorectal	Total	38	76,975	49.4	46.0	33.3	0.461	3,594	8,915,131	40.3			
Colorectal	Male Fomalo	17	39,289 37,686	43.3	39.6 52.6	18.8	0.790	1,960	4,472,984	43.8			
Colorectal Corpus Uteri	Female Female	21 8	37,686	55.7 21.2	52.6 20.7	14.7 11.7	0.141 0.353	1,634 1,346	4,442,147 4,442,147	36.8 30.3			
Esophagus	Total	12	76,975	15.6	14.4	4.6	0.006 >>	495	8,915,131	5.6			
Esophagus	Male	10	39,289	25.5	22.9	4.1	0.019 >>	419	4,472,984	9.4			
Esophagus	Female	2	37,686	5.3	5.0	0.7	0.302	76	4,442,147	1.7			
Hodgkin Lymphoma	Total	1	76,975	1.3	1.3	1.9	0.881	221	8,915,131	2.5			
Hodgkin Lymphoma	Male	-	39,289	-	-	1.1	0.650	129	4,472,984	2.9			
Hodgkin Lymphoma	Female	1	37,686	2.7	2.7 28.1	0.8	1.000	92	4,442,147	2.1 21.6			
Kidney and Renal Pelvis Kidney and Renal Pelvis	Total Male	23 14	76,975 39,289	29.9 35.6	20.1 33.0	17.7 12.3	0.255 0.697	1,928 1,296	8,915,131 4,472,984	21.0			
Kidney and Renal Pelvis	Female	9	37,686	23.9	22.7	5.6	0.235	632	4,442,147	14.2			
Larynx	Total	4	76,975	5.2	4.8	2.0	0.286	216	8,915,131	2.4			
Larynx	Male	3	39,289	7.6	6.9	1.6	0.425	164	4,472,984	3.7			
Larynx	Female	1	37,686	2.7	2.6	0.5	0.732	52	4,442,147	1.2			
Leukemia	Total	9	76,975	11.7	10.8	16.1	0.083	1,718	8,915,131	19.3			
Leukemia	Male	4	39,289	10.2	9.2	10.0	0.057	1,032	4,472,984	23.1			
Leukemia Liver and Bile Duct	Female Total	5 5	37,686 76,975	13.3 6.5	12.4 6.1	6.2 7.7	0.827 0.442	686 838	4,442,147 8,915,131	15.4 9.4			
Liver and Bile Duct	Male	5	39,289	10.2	9.4	5.6	0.688	590	4,472,984	9.4 13.2			
Liver and Bile Duct	Female	1	37,686	2.7	2.5	2.2	0.697	248	4,442,147	5.6			
Lung and Bronchus	Total	45	76,975	58.5	53.2	46.6	0.890	4,914	8,915,131	55.1			
Lung and Bronchus	Male	19	39,289	48.4	43.0	24.5	0.315	2,476	4,472,984	55.4			
Lung and Bronchus	Female	26	37,686	69.0	63.9	22.3	0.492	2,438	4,442,147	54.9			
Melanoma of the Skin	Total	19	76,975	24.7	23.3	28.6	0.077	3,125	8,915,131	35.1			
Melanoma of the Skin	Male	10	39,289	25.5	23.1 23.4	18.2	0.055	1,885	4,472,984	42.1			
Melanoma of the Skin Myeloma	Female Total	9 6	37,686 76,975	23.9 7.8	7.2	10.7 6.8	0.743 0.963	1,240 722	4,442,147 8,915,131	27.9 8.1			
Myeloma	Male	5	39,289	12.7	11.4	4.3	0.874	442	4,472,984	9.9			
Myeloma	Female	1	37,686	2.7	2.5	2.5	0.561	280	4,442,147	6.3			
Non-Hodgkin Lymphoma	Total	18	76,975	23.4	21.8	18.2	1.000	1,974	8,915,131	22.1			
Non-Hodgkin Lymphoma	Male	9	39,289	22.9	21.1	10.8	0.721	1,137	4,472,984	25.4			
Non-Hodgkin Lymphoma	Female	9	37,686	23.9	22.5	7.5	0.683	837	4,442,147	18.8			
Oral Cavity and Pharynx Oral Cavity and Pharynx	Total Male	18 13	76,975 39,289	23.4 33.1	22.1	11.8 8.7	0.114 0.212	1,297 927	8,915,131 4,472,984	14.5 20.7			
Oral Cavity and Pharynx Oral Cavity and Pharynx	iviale Female	13 5	39,289 37,686	33.1 13.3	30.8 12.7	8.7 3.3	0.212	927 370	4,472,984 4,442,147	20.7			
Ovary	Female	3	37,686	8.0	7.7	4.8	0.580	550	4,442,147	12.4			
Pancreas	Total	12	76,975	15.6	14.2	14.0	0.723	1,476	8,915,131	16.6			
Pancreas	Male	8	39,289	20.4	18.1	8.1	1.000	818	4,472,984	18.3			
Pancreas	Female	4	37,686	10.6	9.9	6.0	0.569	658	4,442,147	14.8			
Prostate	Male	50	39,289	127.3	117.5	63.9	0.086	6,716	4,472,984	150.1			
Stomach	Total Malo	6	76,975	7.8	7.2	4.4	0.556	468	8,915,131	5.2			
Stomach Stomach	Male Female	4 2	39,289 37,686	10.2 5.3	9.1 5.0	3.0 1.5	0.691 0.873	303 165	4,472,984 4,442,147	6.8 3.7			
Testis	Male	2	39,289	5.3	5.0 5.5	2.2	1.000	272	4,442,147	<u> </u>			
Thyroid	Total	5	76,975	6.5	6.6	10.0	0.131	1,180	8,915,131	13.2			
Thyroid	Male	1	39,289	2.5	2.5	3.3	0.305	371	4,472,984	8.3			
Thyroid	Female	4	37,686	10.6	11.0	6.6	0.423	809	4,442,147	18.2			
Pediatric Age 0 to 19	Total	1	22,696	4.4	4.4	3.9	0.206	424	2,476,628	17.1			
Pediatric Age 0 to 19	Male	1	11,528	8.7	8.7	1.9	0.844	213	1,262,793	16.9			

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN GOODING COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Goo	Re	Remainder of Idaho					
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	813	77,535	1,048.6	934.4	759.5	0.056	79,722	9,133,859	872.8
All Causes of Death	Male	452	39,598	1,141.5	982.7	424.4	0.190	42,334	4,588,099	922.7
All Causes of Death	Female	361	37,937	951.6	874.5	339.5	0.256	37,388	4,545,760	822.5
All Malignant Cancers	Total	139	77,535	179.3	162.3	141.5	0.876	15,094	9,133,859	165.3
All Malignant Cancers	Male	83	39,598	209.6	182.4	80.9	0.842	8,152	4,588,099	177.7
All Malignant Cancers	Female	56	37,937	147.6	137.8	62.0	0.488	6,942	4,545,760	152.7
Bladder Bladder	Total Male	5 3	77,535 39,598	6.4 7.6	5.6 6.2	4.7 3.9	1.000 0.895	480 372	9,133,859 4,588,099	5.3 8.1
Bladder	Female	2	37,937	5.3	4.8	1.0	0.521	108	4,545,760	2.4
Brain and Other Nervous System	Total	4	77,535	5.2	4.9	4.6	1.000	514	9,133,859	5.6
Brain and Other Nervous System	Male	2	39,598	5.1	4.7	2.7	1.000	287	4,588,099	6.3
Brain and Other Nervous System	Female	2	37,937	5.3	5.1	2.0	1.000	227	4,545,760	5.0
Breast	Total	9	77,535	11.6	10.6	10.4	0.825	1,115	9,133,859	12.2
Breast	Male	-	39,598	-	-	0.1	1.000	13	4,588,099	0.3
Breast	Female	9	37,937	23.7	22.3	9.8	0.975	1,102	4,545,760	24.2
Cervix	Female	1	37,937	2.6	2.7	0.7	1.000	87	4,545,760	1.9
Colorectal Colorectal	Total Male	8 6	77,535 39,598	10.3 15.2	9.4 13.5	12.3 7.0	0.271 0.891	1,324 726	9,133,859 4,588,099	14.5 15.8
Colorectal	Female	2	39,598	5.3	4.9	7.0 5.4	0.196	598	4,588,099	13.8
Corpus Uteri	Female	1	37,937	2.6	2.5	1.5	1.000	168	4,545,760	3.7
Esophagus	Total	9	77,535	11.6	10.7	4.2	0.054	452	9,133,859	4.9
Esophagus	Male	8	39,598	20.2	18.0	3.7	0.071	383	4,588,099	8.3
Esophagus	Female	1	37,937	2.6	2.5	0.6	0.917	69	4,545,760	1.5
Hodgkin Lymphoma	Total	-	77,535	-	-	0.2	1.000	25	9,133,859	0.3
Hodgkin Lymphoma	Male	-	39,598	-	-	0.1	1.000	14	4,588,099	0.3
Hodgkin Lymphoma	Female	-	37,937	-	-	0.1	1.000	11	4,545,760	0.2
Kidney Kidney	Total Male	1	77,535 39,598	1.3 2.5	1.2 2.2	3.6 2.4	0.246 0.609	385 245	9,133,859 4,588,099	4.2 5.3
Kidney	Female	- '	39,598	2.5	2.2	2.4	0.560	140	4,545,760	3.1
Larynx	Total	1	77,535	1.3	1.2	0.7	1.000	75	9,133,859	0.1
Larynx	Male	1	39,598	2.5	2.2	0.6	0.937	64	4,588,099	1.4
Larýnx	Female	-	37,937	-	-	0.1	1.000	11	4,545,760	0.2
Leukemia	Total	6	77,535	7.7	6.9	6.3	1.000	659	9,133,859	7.2
Leukemia	Male	2	39,598	5.1	4.3	4.0	0.484	395	4,588,099	8.6
Leukemia	Female	4	37,937	10.5	9.7	2.4	0.438	264	4,545,760	5.8
Liver and Bile Duct Liver and Bile Duct	Total Male	1	77,535 39,598	1.3 2.5	1.2 2.3	5.8 4.0	0.040 << 0.179	634 422	9,133,859 4,588,099	6.9 9.2
Liver and Bile Duct	Female	- '	37,937	2.5	2.5	4.0	0.303	212	4,545,760	9.2 4.7
Lung and Bronchus	Total	31	77,535	40.0	36.1	27.3	0.526	2,906	9,133,859	31.8
Lung and Bronchus	Male	15	39,598	37.9	33.2	15.0	1.000	1,526	4,588,099	33.3
Lung and Bronchus	Female	16	37,937	42.2	39.0	12.4	0.379	1,380	4,545,760	30.4
Melanoma of the Skin	Total	5	77,535	6.4	5.9	2.7	0.288	296	9,133,859	3.2
Melanoma of the Skin	Male	4	39,598	10.1	8.9	1.9	0.258	196	4,588,099	4.3
Melanoma of the Skin	Female	1	37,937	2.6	2.5	0.9	1.000	100	4,545,760	2.2
Myeloma	Total	2	77,535	2.6	2.3	3.1	0.814	323	9,133,859	3.5
Myeloma Myeloma	Male Female	2	39,598 37,937	5.1 -	4.3	1.9 1.2	1.000 0.575	186 137	4,588,099 4,545,760	4.1 3.0
Non-Hodgkin Lymphoma	Total	- 6	77,535	- 7.7	- 6.9	5.3	0.575	562	9,133,859	6.2
Non-Hodgkin Lymphoma	Male	3	39,598	7.6	6.6	3.1	1.000	302	4,588,099	6.7
Non-Hodgkin Lymphoma	Female	3	37,937	7.9	7.2	2.3	0.819	255	4,545,760	5.6
Oral Cavity and Pharynx	Total	4	77,535	5.2	4.8	2.5	0.482	271	9,133,859	3.0
Oral Cavity and Pharynx	Male	4	39,598	10.1	9.1	1.8	0.219	188	4,588,099	4.1
Oral Cavity and Pharynx	Female	-	37,937	-	-	0.7	0.960	83	4,545,760	1.8
Ovary	Female	1	37,937	2.6	2.5	3.2	0.345	360	4,545,760	7.9
Pancreas	Total	9	77,535	11.6	10.6	11.0	0.687	1,181	9,133,859	12.9
Pancreas	Male Female	5 4	39,598 37,937	12.6 10.5	11.2 9.9	6.3 4.8	0.808 0.958	645 536	4,588,099 4,545,760	14.1
Pancreas Prostate	Female Male	4 13	37,937 39,598	32.8	9.9 26.9	4.8	0.958	984	4,545,760	11.8 21.4
Stomach	Total	2	77,535	2.6	20.9	10.4	1.000	904 192	9,133,859	21.4
Stomach	Male	- 2	39,598	-	-	1.0	0.616	119	4,588,099	2.6
Stomach	Female	2	37,937	5.3	5.1	0.6	0.266	73	4,545,760	1.6

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Gooding County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	79.6% 9.3%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	51.4%
Current Tobacco User (2020–2022) <u>Other Cancer-Related</u>	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	24.5%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	25.6% 68.1% 16.8% 12.4%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





IDAHO COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 651 cases of invasive cancer were diagnosed among Idaho County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,

 Lung and Bronchus, and Colorectal Cancers in Idaho County

 and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021					
All Sites/Types	651	47,333			
Female Breast	81	6,943			
Prostate	116	6,766			
Lung & Bronchus	77	4,959			
Colorectal	57	3,632			

Table 3 (*Cancer Incidence 2017–2021, Comparison between Idaho County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Idaho County. The table also shows the number of observed cases, person-

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 245 Idaho County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Idaho County and the State of Idaho, 2018–2022

Mortality 2018–2022	Idaho County	State of Idaho
All Deaths	1,088	80,538
Cancer Deaths	245	15,233
% of All Deaths	22.5%	18.9%
Lung & Bronchus	41	2,937
Colorectal	26	1,332
Pancreas	24	1,190
Female Breast	14	1,111
Prostate	19	997

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Idaho County was 781.0 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (524.0) gives an estimate of the relative burden of disease in Idaho County.

The age- and sex-adjusted incidence rate of invasive cancer in Idaho County, all sites combined, was 513.0 cases per 100,000 persons per year during 2017–2021. There were fewer cases of cancer in Idaho County (651) than expected (665.0) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Idaho County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Idaho County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Idaho County, all sites combined, was 177.0 deaths per 100,000 persons per year during 2018–2022, compared with 164.2 for the remainder of the state. There were more cancer deaths in Idaho County (245) than expected (227.3) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN IDAHO COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			lda	aho County				Ren	nainder of Ida	aho
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	651	83,360	781.0	513.0	665.0	0.605	46,682	8,908,746	524.0
All Sites Combined	Male	385	43,837	878.3	543.4	394.5	0.654	24,885	4,468,436	556.9
All Sites Combined	Female	266	39,523	673.0	466.1	280.2	0.416	21,797	4,440,310	490.9
Bladder	Total	32	83,360	38.4	22.9	34.3	0.782	2,188	8,908,746	24.6
Bladder	Male	26	43,837	59.3	33.5	30.3	0.499	1,747	4,468,436	39.1
Bladder	Female	6	39,523	15.2	9.6	6.2	1.000	441	4,440,310	9.9
Brain - malignant	Total	7	83,360	8.4	6.2	8.2	0.857	650	8,908,746	7.3
Brain - malignant	Male	6	43,837	13.7	10.1	5.0	0.767	376	4,468,436	8.4
Brain - malignant	Female	1	39,523	2.5	1.9	3.3	0.320	274	4,440,310	6.2
Brain and other CNS - non-malignant	Total	22	83,360	26.4	18.5	20.4	0.781	1,525	8,908,746	17.1
	Male	8	43,837	18.2	12.7	6.9	0.777	492	4,468,436	11.0
Brain and other CNS - non-malignant Breast	Female Total	14 83	39,523 83,360	35.4 99.6	25.1 69.0	13.0 93.5	0.847 0.301	1,033 6,925	4,440,310 8,908,746	23.3 77.7
Breast	Male	2	43,837	4.6	2.8	1.0	0.531	63	4,468,436	1.4
Breast	Female	81 81	39,523	204.9	144.4	86.7	0.587	6,862	4,440,310	154.5
Breast - in situ	Total	3	83,360	3.6	2.6	17.9	0.000 <<	1,366	8,908,746	15.3
Breast - in situ	Male	-	43,837	-	-	0.1	1.000	4	4,468,436	0.1
Breast - in situ	Female	3	39,523	7.6	5.5	16.9	>> 000.0	1,362	4,440,310	30.7
Cervix	Female	3	39,523	7.6	7.1	2.8	1.000	291	4,440,310	6.6
Colorectal	Total	57	83,360	68.4	45.6	50.2	0.367	3,575	8,908,746	40.1
Colorectal	Male	25	43,837	57.0	37.1	29.4	0.478	1,952	4,468,436	43.7
Colorectal	Female	32	39,523	81.0	55.3	21.2	0.033 >>	1,623	4,440,310	36.6
Corpus Uteri	Female	21	39,523	53.1	36.8	17.1	0.410	1,333	4,440,310	30.0
Esophagus	Total	9	83,360	10.8	6.8	7.4	0.657	498	8,908,746	5.6
Esophagus	Male	8	43,837	18.2	11.0	6.8	0.751	421	4,468,436	9.4
Esophagus	Female	1	39,523	2.5	1.6	1.1	1.000	77	4,440,310	1.7
Hodgkin Lymphoma	Total Male	3	83,360 43,837	3.6 6.8	3.3 6.0	2.2 1.4	0.771 0.343	219 126	8,908,746 4,468,436	2.5 2.8
Hodgkin Lymphoma Hodgkin Lymphoma	Female	-	43,837 39,523	0.0	0.0	1.4 0.8	0.343	93	4,400,430	2.0
Kidney and Renal Pelvis	Total	- 25	83,360	- 30.0	- 20.1	26.9	0.806	1,926	8,908,746	2.1
Kidney and Renal Pelvis	Male	16	43,837	36.5	23.9	19.4	0.521	1,294	4,468,436	29.0
Kidney and Renal Pelvis	Female	9	39,523	22.8	15.6	8.2	0.880	632	4,440,310	14.2
Larynx	Total	- ĭ	83,360	1.2	0.8	3.2	0.334	219	8,908,746	2.5
Larynx	Male	1	43,837	2.3	1.4	2.7	0.505	166	4.468.436	3.7
Larynx	Female	-	39,523	-	-	0.7	0.981	53	4,440,310	1.2
Leukemia	Total	22	83,360	26.4	17.4	24.2	0.757	1,705	8,908,746	19.1
Leukemia	Male	16	43,837	36.5	23.2	15.8	1.000	1,020	4,468,436	22.8
Leukemia	Female	6	39,523	15.2	10.3	9.0	0.422	685	4,440,310	15.4
Liver and Bile Duct	Total	13	83,360	15.6	9.9	12.2	0.903	830	8,908,746	9.3
Liver and Bile Duct	Male	9	43,837	20.5	12.7	9.3	1.000	585	4,468,436	13.1
Liver and Bile Duct	Female	4	39,523	10.1	6.6	3.4	0.864	245	4,440,310	5.5
Lung and Bronchus Lung and Bronchus	Total Male	77 45	83,360 43,837	92.4 102.7	55.5 58.8	76.0 42.0	0.938 0.683	4,882 2,450	8,908,746 4,468,436	54.8 54.8
Lung and Bronchus	Female	43 32	39,523	81.0	50.7	34.6	0.741	2,430	4,400,430	54.8
Melanoma of the Skin	Total	39	83,360	46.8	32.1	42.3	0.677	3,105	8,908,746	34.9
Melanoma of the Skin	Male	26	43,837	59.3	37.8	28.8	0.687	1,869	4,468,436	41.8
Melanoma of the Skin	Female	13	39,523	32.9	24.5	14.8	0.770	1,236	4,440,310	27.8
Myeloma	Total	5	83,360	6.0	3.7	10.9	0.081	723	8,908,746	8.1
Myeloma	Male	2	43,837	4.6	2.7	7.3	0.047 <<	445	4,468,436	10.0
Myeloma	Female	3	39,523	7.6	4.9	3.8	0.928	278	4,440,310	6.3
Non-Hodgkin Lymphoma	Total	24	83,360	28.8	19.0	27.9	0.527	1,968	8,908,746	22.1
Non-Hodgkin Lymphoma	Male	14	43,837	31.9	20.6	17.3	0.522	1,132	4,468,436	25.3
Non-Hodgkin Lymphoma	Female	10	39,523	25.3	16.9	11.1	0.893	836	4,440,310	18.8
Oral Cavity and Pharynx	Total	20	83,360	24.0	15.9	18.3	0.758	1,295	8,908,746	14.5
Oral Cavity and Pharynx	Male	15	43,837	34.2	22.3	13.9	0.846	925	4,468,436	20.7
Oral Cavity and Pharynx	Female	5	39,523	12.7	8.5	4.9	1.000	370	4,440,310	8.3
Ovary Pancreas	Female Total	2 25	39,523 83,360	5.1 30.0	3.6 18.5	6.9 22.1	0.063 0.598	551 1,463	4,440,310 8,908,746	12.4 16.4
Pancreas	Male	25 18	43,837	41.1	24.4	13.4	0.398	808	4,468,436	18.1
Pancreas	Female	7	39,523	17.7	11.3	9.1	0.621	655	4,440,310	14.8
Prostate	Male	116	43,837	264.6	159.2	108.4	0.492	6,650	4,468,436	148.8
Stomach	Total	6	83,360	7.2	4.6	6.8	0.959	468	8,908,746	5.3
Stomach	Male	5	43,837	11.4	7.0	4.9	1.000	302	4,468,436	6.8
Stomach	Female	1	39,523	2.5	1.7	2.2	0.727	166	4,440,310	3.7
Testis	Male	2	43,837	4.6	5.4	2.2	1.000	272	4,468,436	6.1
Thyroid	Total	14	83,360	16.8	14.8	12.4	0.726	1,171	8,908,746	13.1
,		5	43,837	11.4	8.8	4.7	0.998	367	4,468,436	8.2
	Male	5							, , •	
Thyroid Thyroid	Male Female	5 9		22.8	21.4	7.6	0.704	804	4,440,310	18.1
Thyroid Thyroid			39,523		21.4	7.6 3.0	0.704 0.389	804 424		18.1 17.1
Thyroid	Female	9		22.8					4,440,310 2,481,491 1,264,896	

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN IDAHO COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			lda	aho County				Re	mainder of Idah	0
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	1,088	84,561	1,286.6	794.0	1,192.9	0.002 <<	79,447	9,126,833	870.5
All Causes of Death	Male	614	44,508	1,379.5	818.3	690.5	0.003 <<	42.172	4,583,189	920.1
All Causes of Death	Female	474	40,053	1,183.4	752.3	516.9	0.060	37,275	4,543,644	820.4
All Malignant Cancers	Total	245	84,561	289.7	177.0	227.3	0.255	14,988	9,126,833	164.2
All Malignant Cancers	Male	140	44,508	314.6	181.2	136.5	0.785	8,095	4,583,189	176.6
All Malignant Cancers	Female	105	40,053	262.2	167.8	94.9	0.326	6,893	4,543,644	151.7
Bladder	Total	13	84,561	15.4	8.9	7.6	0.091	472	9,126,833	5.2
Bladder	Male	8	44,508	18.0	9.6	6.7	0.702	367	4,583,189	8.0
Bladder	Female	5	40,053	12.5	7.6	1.5	0.039 >>	105	4,543,644	2.3
Brain and Other Nervous System	Total	3	84,561	3.5	2.4	7.0	0.163	515	9,126,833	5.6
Brain and Other Nervous System	Male	3	44,508	6.7	4.5	4.2	0.808	286	4,583,189	6.2
Brain and Other Nervous System	Female	-	40,053	-	-	2.9	0.107	229	4,543,644	5.0
Breast	Total	14	84,561	16.6	10.5	16.2	0.701	1,110	9,126,833	12.2
Breast Breast	Male Female	- 14	44,508 40,053	- 35.0	- 23.0	0.2 14.7	1.000 0.993	13 1,097	4,583,189 4,543,644	0.3 24.1
Cervix	Female	- 14	40,053	- 35.0	- 23.0	14.7	0.993	1,097	4,543,644	1.9
Colorectal	Total	- 26	40,053 84,561	- 30.7	- 19.5	1.0	0.765	00 1,306	9,126,833	14.3
Colorectal	Male	10	44,508	22.5	13.9	11.3	0.130	722	4,583,189	14.3
Colorectal	Female	16	40,053	39.9	25.9	7.9	0.015 >>	584	4,543,644	12.9
Corpus Uteri	Female	3	40,053	7.5	4.7	2.3	0.818	166	4,543,644	3.7
Esophagus	Total	9	84,561	10.6	6.6	6.8	0.491	452	9,126,833	5.0
Esophagus	Male	8	44,508	18.0	10.6	6.3	0.594	383	4,583,189	8.4
Esophagus	Female	1	40,053	2.5	1.6	0.9	1.000	69	4,543,644	1.5
Hodgkin Lymphoma	Total	-	84,561	-	-	0.4	1.000	25	9,126,833	0.3
Hodgkin Lymphoma	Male	-	44,508	-	-	0.2	1.000	14	4,583,189	0.3
Hodgkin Lymphoma	Female	-	40,053	-	-	0.1	1.000	11	4,543,644	0.2
Kidney	Total	4	84,561	4.7	2.8	5.9	0.589	382	9,126,833	4.2
Kidney	Male	1	44,508	2.2	1.3	4.1	0.164	245	4,583,189	5.3
Kidney	Female	3	40,053	7.5	4.6	2.0	0.633	137	4,543,644	3.0
Larynx	Total	-	84,561	-	-	1.1	0.637	76	9,126,833	0.8
Larynx	Male Female	-	44,508 40,053	-	-	1.1 0.1	0.667 1.000	65 11	4,583,189 4,543,644	1.4 0.2
Larynx Leukemia	Total	- 10	84,561	- 11.8	- 7.2	10.0	1.000	655	9,126,833	7.2
Leukemia	Male	8	44,508	18.0	10.2	6.6	0.695	389	4,583,189	8.5
Leukemia	Female	2	40,053	5.0	3.2	3.7	0.575	266	4,543,644	5.9
Liver and Bile Duct	Total	11	84,561	13.0	8.0	9.4	0.674	624	9,126,833	6.8
Liver and Bile Duct	Male	6	44,508	13.5	8.0	6.8	0.964	417	4,583,189	9.1
Liver and Bile Duct	Female	5	40,053	12.5	8.0	2.9	0.325	207	4,543,644	4.6
Lung and Bronchus	Total	41	84,561	48.5	28.8	45.1	0.600	2,896	9,126,833	31.7
Lung and Bronchus	Male	23	44,508	51.7	29.2	26.1	0.635	1,518	4,583,189	33.1
Lung and Bronchus	Female	18	40,053	44.9	27.8	19.6	0.830	1,378	4,543,644	30.3
Melanoma of the Skin	Total	6	84,561	7.1	4.5	4.3	0.526	295	9,126,833	3.2
Melanoma of the Skin	Male	6	44,508	13.5	8.1	3.1	0.196	194	4,583,189	4.2
Melanoma of the Skin	Female		40,053	-	-	1.3	0.531	101	4,543,644	2.2
Myeloma	Total	7	84,561	8.3	4.9	5.0	0.481	318	9,126,833	3.5
Myeloma	Male	2 5	44,508	4.5	2.5	3.3	0.728	186	4,583,189	4.1
Myeloma Non-Hodgkin Lymphoma	Female Total	5 4	40,053 84,561	12.5 4.7	7.7 2.8	1.9 8.7	0.085 0.131	132 564	4,543,644 9,126,833	2.9 6.2
Non-Hodgkin Lymphoma	Male	4 1	64,501 44,508	4.7	2.0 1.3	o.7 5.2	0.131	309	9,120,033 4,583,189	6.2 6.7
Non-Hodgkin Lymphoma	Female	3	40,053	7.5	4.7	3.6	1.000	255	4,543,644	5.6
Oral Cavity and Pharynx	Total	6	84,561	7.1	4.4	4.0	0.432	269	9,126,833	2.9
Oral Cavity and Pharynx	Male	5	44,508	11.2	6.7	3.1	0.387	187	4,583,189	4.1
Oral Cavity and Pharynx	Female	1	40,053	2.5	1.6	1.1	1.000	82	4,543,644	1.8
Ovary	Female	4	40,053	10.0	6.4	4.9	0.912	357	4,543,644	7.9
Pancreas	Total	24	84,561	28.4	17.2	17.8	0.185	1,166	9,126,833	12.8
Pancreas	Male	18	44,508	40.4	23.5	10.6	0.046 >>	632	4,583,189	13.8
Pancreas	Female	6	40,053	15.0	9.4	7.5	0.765	534	4,543,644	11.8
Prostate	Male	19	44,508	42.7	22.7	17.9	0.851	978	4,583,189	21.3
Stomach	Total	2	84,561	2.4	1.5	2.7	0.972	192	9,126,833	2.1
Stomach	Male	2	44,508	4.5	2.7	1.9	1.000	117	4,583,189	2.6
Stomach	Female	-	40,053	-	-	0.9	0.782	75	4,543,644	1.7

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Idaho County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	64.8% 13.6%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	65.0% 64.3% 42.7%
Current Tobacco User (2020–2022) <u>Other Cancer-Related</u>	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	21.1%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	32.1% 69.2% 14.2% 9.6%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





JEFFERSON COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 610 cases of invasive cancer were diagnosed among Jefferson County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in JeffersonCounty and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021						
All Sites/Types	610	47,333				
Female Breast	83	6,943				
Prostate	83	6,766				
Lung & Bronchus	50	4,959				
Colorectal	53	3,632				

Table 3 (*Cancer Incidence 2017–2021, Comparison between Jefferson County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Jefferson County. The table also shows the number of observed cases, person-

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 167 Jefferson County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Jefferson County and the State of Idaho, 2018–2022

Mortality 2018–2022	Jefferson County	State of Idaho
All Deaths	1,030	80,538
Cancer Deaths	167	15,233
% of All Deaths	16.2%	18.9%
Lung & Bronchus	26	2,937
Colorectal	12	1,332
Pancreas	17	1,190
Female Breast	18	1,111
Prostate	9	997

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Jefferson County was 405.0 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (528.5) gives an estimate of the relative burden of disease in Jefferson County.

The age- and sex-adjusted incidence rate of invasive cancer in Jefferson County, all sites combined, was 511.6 cases per 100,000 persons per year during 2017–2021. There were fewer cases of cancer in Jefferson County (610) than expected (630.1) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Jefferson County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Jefferson County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Jefferson County, all sites combined, was 144.7 deaths per 100,000 persons per year during 2018–2022, compared with 166.4 for the remainder of the state. There were fewer cancer deaths in Jefferson County (167) than expected (192.0) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN JEFFERSON COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Jefferson County						Remainder of Idaho				
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude			
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)		P-Value (4)	Cases	Years	Rate (1)			
All Sites Combined	Total	610	150,618	405.0	511.6	630.1	0.437	46,723	8,841,488	528.5			
All Sites Combined	Male	328	76,791	427.1	537.1	343.4	0.423	24,942	4,435,482	562.3			
All Sites Combined	Female	282	73,827	382.0	482.7	288.8	0.717	21,781	4,406,006	494.3			
Bladder	Total	33	150,618	21.9	29.5	27.7	0.358	2,187	8,841,488	24.7			
Bladder	Male	25	76,791	32.6	43.2	22.8	0.700	1,748	4,435,482	39.4			
Bladder	Female	8	73,827	10.8	14.6	5.4	0.367	439	4,406,006	10.0			
Brain - malignant	Total	11	150,618	7.3	8.5	9.5	0.709	646	8,841,488	7.3			
Brain - malignant	Male	6	76,791	7.8	8.9	5.7	1.000	376	4,435,482	8.5			
Brain - malignant	Female	5	73,827	6.8	7.9 17.8	3.9	0.686	270	4,406,006 8,841,488	6.1			
Brain and other CNS - non-malignant Brain and other CNS - non-malignant	Total Male	22 8	150,618 76,791	14.6 10.4	17.0	21.3 7.2	0.930 0.855	1,525 492	4,435,482	17.2 11.1			
Brain and other CNS - non-malignant	Female	14	73,827	19.0	23.7	13.9	1.000	1,033	4,406,006	23.4			
Breast	Total	83	150,618	55.1	67.7	96.1	0.196	6,925	8,841,488	78.3			
Breast	Male	-	76,791	-	-	0.9	0.829	65	4,435,482	1.5			
Breast	Female	83	73,827	112.4	140.2	92.1	0.369	6,860	4,406,006	155.7			
Breast - in situ	Total	14	150,618	9.3	11.2	19.1	0.287	1,355	8,841,488	15.3			
Breast - in situ	Male	-	76,791	-	-	0.1	1.000	4	4,435,482	0.1			
Breast - in situ	Female	14	73,827	19.0	23.3	18.4	0.365	1,351	4,406,006	30.7			
Cervix	Female	5	73,827	6.8	7.4	4.4	0.902	289	4,406,006	6.6			
Colorectal	Total	53	150,618	35.2	44.4	48.3	0.535	3,579	8,841,488	40.5			
Colorectal	Male	35	76,791	45.6	56.3 31.4	27.2 21.3	0.171	1,942 1,637	4,435,482	43.8 37.2			
Colorectal Corpus Uteri	Female Female	18 17	73,827 73,827	24.4 23.0	28.8	17.9	0.559 0.956	1,637	4,406,006	37.2			
Esophagus	Total	7	150,618	4.6	6.0	6.6	0.967	500	8,841,488	5.7			
Esophagus	Male	6	76,791	7.8	9.9	5.8	1.000	423	4,435,482	9.5			
Esophagus	Female	1	73,827	1.4	1.8	1.0	1.000	77	4,406,006	1.7			
Hodgkin Lymphoma	Total	4	150,618	2.7	2.9	3.4	0.871	218	8,841,488	2.5			
Hodgkin Lýmphoma	Male	2	76,791	2.6	2.9	2.0	1.000	127	4,435,482	2.9			
Hodgkin Lymphoma	Female	2	73,827	2.7	2.9	1.4	0.820	91	4,406,006	2.1			
Kidney and Renal Pelvis	Total	15	150,618	10.0	12.4	26.4	0.024 <<	1,936	8,841,488	21.9			
Kidney and Renal Pelvis	Male	12	76,791	15.6	19.2	18.3	0.163	1,298	4,435,482	29.3			
Kidney and Renal Pelvis	Female	3	73,827	4.1	5.2	8.4	0.064	638	4,406,006	14.5			
Larynx	Total Male	1	150,618 76,791	0.7	0.9	2.9	0.427 0.205	219	8,841,488	2.5 3.8			
Larynx Larynx	Female	- 1	73,827	- 1.4	- 1.7	2.3 0.7	0.205	167 52	4,435,482 4,406,006	3.0 1.2			
Leukemia	Total	17	150,618	11.3	14.1	23.4	0.217	1,710	8,841,488	19.3			
Leukemia	Male	16	76,791	20.8	25.6	14.4	0.737	1,020	4,435,482	23.0			
Leukemia	Female	1	73,827	1.4	1.7	9.1	0.002 <<	690	4,406,006	15.7			
Liver and Bile Duct	Total	11	150,618	7.3	9.3	11.1	1.000	832	8,841,488	9.4			
Liver and Bile Duct	Male	8	76,791	10.4	13.0	8.2	1.000	586	4,435,482	13.2			
Liver and Bile Duct	Female	3	73,827	4.1	5.3	3.2	1.000	246	4,406,006	5.6			
Lung and Bronchus	Total	50	150,618	33.2	44.2	62.7	0.114	4,909	8,841,488	55.5			
Lung and Bronchus	Male	29	76,791	37.8	49.6	32.5	0.611	2,466	4,435,482	55.6			
Lung and Bronchus	Female	21	73,827	28.4	38.4	30.3	0.097	2,443	4,406,006	55.4			
Melanoma of the Skin Melanoma of the Skin	Total Male	47 26	150,618 76,791	31.2 33.9	38.7 42.2	42.5 25.9	0.529 1.000	3,097 1,869	8,841,488 4,435,482	35.0 42.1			
Melanoma of the Skin	Female	20	73,827	28.4	42.2 34.6	16.9	0.374	1,009	4,435,482	27.9			
Myeloma	Total	6	150,618	4.0	5.2	9.4	0.344	722	8,841,488	8.2			
Myeloma	Male	2	76,791	2.6	3.3	6.0	0.124	445	4,435,482	10.0			
Myeloma	Female	4	73,827	5.4	7.2	3.5	0.930	277	4,406,006	6.3			
Non-Hodgkin Lymphoma	Total	34	150,618	22.6	28.4	26.5	0.182	1,958	8,841,488	22.1			
Non-Hodgkin Lymphoma	Male	17	76,791	22.1	27.1	15.9	0.857	1,129	4,435,482	25.5			
Non-Hodgkin Lymphoma	Female		73,827	23.0	29.8	10.7	0.093	829	4,406,006	18.8			
Oral Cavity and Pharynx	Total	15	150,618	10.0	12.5	17.6	0.633	1,300	8,841,488	14.7			
Oral Cavity and Pharynx	Male	9 6	76,791	11.7	14.3	13.2	0.310	931	4,435,482	21.0			
Oral Cavity and Pharynx Ovary	Female Female	6	73,827 73,827	8.1 8.1	10.5 10.1	4.8	0.696 0.797	369 547	4,406,006	8.4 12.4			
Pancreas	Total	20	150,618	13.3	10.1	19.0	0.797	1,468	4,406,006	12.4			
Pancreas	Male	11	76,791	14.3	18.5	10.9	1.000	815	4,435,482	18.4			
Pancreas	Female	9	73,827	12.2	16.3	8.2	0.866	653	4,406,006	14.8			
Prostate	Male	83	76,791	108.1	137.0	91.3	0.420	6,683	4,435,482	150.7			
Stomach	Total	11	150,618	7.3	9.4	6.1	0.095	463	8,841,488	5.2			
Stomach	Male	6	76,791	7.8	10.0	4.1	0.452	301	4,435,482	6.8			
Stomach	Female	5	73,827	6.8	8.7	2.1	0.127	162	4,406,006	3.7			
Testis	Male	1	76,791	1.3	1.4	4.4	0.130	273	4,435,482	6.2			
Thyroid	Total	30	150,618	19.9	22.4	17.5	0.008 >>	1,155	8,841,488	13.1			
Thyroid	Male	12	76,791	15.6	18.0	5.4	0.019 >>	360	4,435,482	8.1			
Thyroid	Female	18	73,827	24.4	27.1	12.0	0.124	795	4,406,006	18.0			
Pediatric Age 0 to 19	Total	6	54,536	11.0	11.2	9.2	0.376	419	2,444,788	17.1			
Pediatric Age 0 to 19	Male	4	27,795	14.4	14.5	4.7	1.000	210	1,246,526	16.8			
Pediatric Age 0 to 19	Female	2	26,741	7.5	7.7	4.5	0.337	209	1,198,262	17.4			

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN JEFFERSON COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Jeffe	erson Count	y			Re	mainder of Idah	10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	1,030	155,598	662.0	901.8	1,002.7	0.397	79,505	9,055,796	877.9
All Causes of Death	Male	572	79,546	719.1	947.7	560.2	0.630	42,214	4,548,151	928.2
All Causes of Death	Female	458	76,052	602.2	847.8	446.9	0.613	37,291	4,507,645	827.3
All Malignant Cancers	Total	167	155,598	107.3	144.7	192.0	0.073	15,066	9,055,796	166.4
All Malignant Cancers	Male	87	79,546	109.4	145.7	107.0	0.054	8,148	4,548,151	179.1
All Malignant Cancers	Female	80	76,052	105.2	143.1	85.8	0.578	6,918	4,507,645	153.5
Bladder	Total	6	155,598	3.9	5.5	5.7	1.000	479	9,055,796	5.3
Bladder	Male	5	79,546	6.3	8.9	4.6	0.961	370	4,548,151	8.1
Bladder	Female	1	76,052	1.3	1.9	1.3	1.000	109	4,507,645	2.4
Brain and Other Nervous System	Total	7	155,598	4.5	5.6	7.1	1.000	511	9,055,796	5.6
Brain and Other Nervous System	Male	3	79,546	3.8	4.6	4.1	0.812	286	4,548,151	6.3
Brain and Other Nervous System	Female	4	76,052	5.3	6.7	3.0	0.706	225	4,507,645	5.0
Breast	Total	18	155,598	11.6	15.3	14.4	0.399	1,106	9,055,796	12.2
Breast	Male	- 10	79,546	- 23.7	- 31.7	0.2	1.000	13	4,548,151	0.3
Breast	Female	18	76,052 76,052			13.8 1.3	0.313 1.000	1,093 87	4,507,645 4,507,645	24.2 1.9
Cervix Colorectal	Female Total	1 12	155,598	1.3 7.7	1.5 10.2	1.3	0.252	1,320	9,055,796	1.9
Colorectal	Male	8	79,546	10.1	10.2	9.9	0.252	724	4,548,151	14.0
Colorectal	Female	4	76,052	5.3	7.2	7.4	0.282	596	4,507,645	13.2
Corpus Uteri	Female	2	76,052	2.6	3.6	2.1	1.000	167	4,507,645	3.7
Esophagus	Total	3	155,598	1.9	2.6	5.9	0.314	458	9,055,796	5.1
Esophagus	Male	3	79,546	3.8	4.9	5.2	0.471	388	4,548,151	8.5
Esophagus	Female	-	76,052	-	-	0.9	0.838	70	4,507,645	1.6
Hodgkin Lymphoma	Total	1	155,598	0.6	0.9	0.3	0.532	24	9,055,796	0.3
Hodgkin Lymphoma	Male	-	79,546	-	-	0.2	1.000	14	4,548,151	0.3
Hodgkin Lymphoma	Female	1	76,052	1.3	1.8	0.1	0.233	10	4,507,645	0.2
Kidney	Total	3	155,598	1.9	2.6	4.8	0.585	383	9,055,796	4.2
Kidney	Male	-	79,546	-	-	3.2	0.079	246	4,548,151	5.4
Kidney	Female	3	76,052	3.9	5.6	1.6	0.448	137	4,507,645	3.0
Larynx	Total	-	155,598	-	-	1.0	0.744	76	9,055,796	0.8
Larynx	Male	-	79,546	-	-	0.9	0.847	65	4,548,151	1.4
Larynx	Female	-	76,052	-	-	0.1	1.000	11	4,507,645	0.2
Leukemia	Total	4	155,598	2.6	3.5	8.3	0.163	661	9,055,796	7.3
Leukemia	Male	3	79,546	3.8	5.1	5.1	0.494	394	4,548,151	8.7
Leukemia	Female	1	76,052	1.3	1.8	3.3	0.325	267	4,507,645	5.9
Liver and Bile Duct Liver and Bile Duct	Total Male	10 7	155,598 79,546	6.4 8.8	8.5 11.4	8.1 5.6	0.600 0.671	625 416	9,055,796 4,548,151	6.9 9.1
Liver and Bile Duct	Female	3	79,540	0.0 3.9	5.3	2.6	0.966	209	4,507,645	4.6
Lung and Bronchus	Total	26	155,598	3.9 16.7	22.8	36.6	0.986	2,911	9,055,796	32.1
Lung and Bronchus	Male	13	79,546	16.3	21.9	19.9	0.137	1,528	4,548,151	33.6
Lung and Bronchus	Female	13	76,052	17.1	23.7	16.8	0.427	1,383	4,507,645	30.7
Melanoma of the Skin	Total	6	155,598	3.9	5.0	3.9	0.392	295	9,055,796	3.3
Melanoma of the Skin	Male	5	79,546	6.3	8.1	2.6	0.254	195	4,548,151	4.3
Melanoma of the Skin	Female	1	76,052	1.3	1.7	1.3	1.000	100	4,507,645	2.2
Myeloma	Total	3	155,598	1.9	2.7	4.0	0.872	322	9,055,796	3.6
Myeloma	Male	2	79,546	2.5	3.4	2.4	1.000	186	4,548,151	4.1
Myeloma	Female	1	76,052	1.3	1.8	1.6	1.000	136	4,507,645	3.0
Non-Hodgkin Lymphoma	Total	4	155,598	2.6	3.5	7.1	0.336	564	9,055,796	6.2
Non-Hodgkin Lymphoma	Male	2	79,546	2.5	3.4	4.0	0.465	308	4,548,151	6.8
Non-Hodgkin Lymphoma	Female	2	76,052	2.6	3.7	3.1	0.822	256	4,507,645	5.7
Oral Cavity and Pharynx	Total	3	155,598	1.9	2.6	3.5	1.000	272	9,055,796	3.0
Oral Cavity and Pharynx	Male	2	79,546	2.5	3.3	2.5	1.000	190	4,548,151	4.2
Oral Cavity and Pharynx	Female	1	76,052	1.3	1.8	1.0	1.000	82	4,507,645	1.8
Ovary	Female	2	76,052	2.6	3.5	4.5	0.346	359	4,507,645	8.0
Pancreas	Total	17	155,598	10.9	14.7	15.0	0.671	1,173	9,055,796	13.0
Pancreas	Male	9	79,546	11.3	14.9	8.5	0.950	641	4,548,151	14.1
Pancreas	Female	8	76,052	10.5	14.4	6.6	0.675	532	4,507,645	11.8
Prostate	Male	9	79,546	11.3	16.1	12.2	0.457	988	4,548,151	21.7
Stomach	Total	-	155,598	-	-	2.6	0.153	194	9,055,796	2.1
Stomach	Male	-	79,546	-	-	1.6	0.408	119	4,548,151	2.6
Stomach	Female	-	76,052	-	-	1.0	0.732	75	4,507,645	1.7

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Jefferson County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	87.2% 7.9%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	65.8% 55.3%
Current Tobacco User (2020–2022) Other Cancer-Related	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	20.0%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	25.4% 79.1% 16.7% 20.5%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





JEROME COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 522 cases of invasive cancer were diagnosed among Jerome County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in JeromeCounty and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Jerome County	State of Idaho
All Sites/Types	522	47,333
Female Breast	65	6,943
Prostate	64	6,766
Lung & Bronchus	54	4,959
Colorectal	48	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Jerome County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Jerome County. The table also shows the number of observed cases, person-

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 172 Jerome County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Jerome County and the State of Idaho, 2018–2022

Mortality 2018–2022	Jerome County	State of Idaho
All Deaths	976	80,538
Cancer Deaths	172	15,233
% of All Deaths	17.6%	18.9%
Lung & Bronchus	29	2,937
Colorectal	20	1,332
Pancreas	9	1,190
Female Breast	13	1,111
Prostate	14	997

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Jerome County was 429.0 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (527.7) gives an estimate of the relative burden of disease in Jerome County.

The age- and sex-adjusted incidence rate of invasive cancer in Jerome County, all sites combined, was 497.4 cases per 100,000 persons per year during 2017–2021. There were fewer cases of cancer in Jerome County (522) than expected (553.8) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Jerome County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Jerome County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Jerome County, all sites combined, was 168.1 deaths per 100,000 persons per year during 2018–2022, compared with 165.7 for the remainder of the state. There were more cancer deaths in Jerome County (172) than expected (169.6) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021 COMPARISON BETWEEN JEROME COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Jer	ome Count	y			Ren	nainder of Ida	aho
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	522	121,678	429.0	497.4	553.8	0.182	46,811	8,870,428	527.7
All Sites Combined	Male	262	62,556	418.8	489.0	301.1	0.024 <<	25,008	4,449,717	562.0
All Sites Combined	Female	260	59,122	439.8	507.0	252.9	0.672	21,803	4,420,711	493.2
Bladder	Total	22	121,678	18.1	21.7	25.1	0.625	2,198	8,870,428	24.8
Bladder	Male	16	62,556	25.6	31.0	20.4	0.395	1,757	4,449,717	39.5
Bladder Brein melignent	Female	6 6	59,122 121,678	10.1	12.1	5.0	0.755	441 651	4,420,711	10.0 7.3
Brain - malignant Brain - malignant	Total Male	0	62,556	4.9 1.6	5.4 1.8	8.1 4.9	0.598 0.088	381	8,870,428 4,449,717	8.6
Brain - malignant	Female	5	59,122	8.5	9.3	3.3	0.469	270	4,420,711	6.1
Brain and other CNS - non-malignant	Total	6	121,678	4.9	5.6	18.6	0.001 <<	1,541	8,870,428	17.4
	Male	4	62,556	6.4	7.2	6.2	0.511	496	4,449,717	11.1
Brain and other CNS - non-malignant	Female	2	59,122	3.4	3.9	12.2	0.001 <<	1,045	4,420,711	23.6
Breast	Total	65	121,678	53.4	61.1	83.3	0.045 <<	6,943	8,870,428	78.3
Breast	Male	-	62,556	-	-	0.8	0.910	65	4,449,717	1.5
Breast	Female	65	59,122	109.9	126.4	80.0	0.098	6,878	4,420,711	155.6
Breast - in situ Breast - in situ	Total	15	121,678	12.3	14.0	16.4	0.859	1,354	8,870,428	15.3
Breast - in situ Breast - in situ	Male Female	- 15	62,556 59,122	- 25.4	- 29.0	0.1 15.8	1.000 0.976	4 1,350	4,449,717 4,420,711	0.1 30.5
Cervix	Female	7	59,122	25.4 11.8	29.0	3.6	0.976	287	4,420,711	30.5 6.5
Colorectal	Total	48	121,678	39.4	45.5	42.6	0.448	3,584	8,870,428	40.4
Colorectal	Male	23	62,556	36.8	42.1	24.0	0.944	1,954	4,449,717	43.9
Colorectal	Female	25	59,122	42.3	49.0	18.8	0.196	1,630	4,420,711	36.9
Corpus Uteri	Female	22	59,122	37.2	42.8	15.5	0.138	1,332	4,420,711	30.1
Esophagus	Total	8	121,678	6.6	7.7	5.8	0.469	499	8,870,428	5.6
Esophagus	Male	7	62,556	11.2	13.1	5.1	0.498	422	4,449,717	9.5
Esophagus	Female	1	59,122	1.7	2.0	0.9	1.000	77	4,420,711	1.7
Hodgkin Lymphoma	Total	2	121,678	1.6	1.7	2.8	0.919	220	8,870,428	2.5
Hodgkin Lymphoma	Male Female	1 1	62,556 59,122	1.6 1.7	1.7 1.8	1.7 1.2	0.995 1.000	128 92	4,449,717 4.420.711	2.9 2.1
Hodgkin Lymphoma Kidney and Renal Pelvis	Total	18	121,678	1.7	1.0	23.1	0.343	1,933	8,870,428	2.1
Kidney and Renal Pelvis	Male	15	62,556	24.0	27.4	15.9	0.951	1,333	4,449,717	21.0
Kidney and Renal Pelvis	Female	3	59,122	5.1	5.9	7.4	0.127	638	4,420,711	14.4
Larynx	Total	5	121,678	4.1	4.8	2.5	0.224	215	8,870,428	2.4
Larynx	Male	4	62,556	6.4	7.5	2.0	0.271	163	4,449,717	3.7
Larynx	Female	1	59,122	1.7	2.0	0.6	0.898	52	4,420,711	1.2
Leukemia	Total	20	121,678	16.4	18.8	20.4	1.000	1,707	8,870,428	19.2
Leukemia	Male	10	62,556	16.0	18.3	12.6	0.577	1,026	4,449,717	23.1
Leukemia Liver and Bile Duct	Female Total	10	59,122	16.9 6.6	19.4	8.0 9.8	0.555 0.716	681	4,420,711	15.4
Liver and Bile Duct	Male	8 7	121,678 62,556	0.0 11.2	7.7 13.1	9.0 7.1	1.000	835 587	8,870,428 4,449,717	9.4 13.2
Liver and Bile Duct	Female	1	59,122	1.7	2.0	2.8	0.451	248	4,420,711	5.6
Lung and Bronchus	Total	54	121,678	44.4	53.1	56.2	0.836	4,905	8,870,428	55.3
Lung and Bronchus	Male	25	62,556	40.0	48.2	28.8	0.554	2,470	4,449,717	55.5
Lung and Bronchus	Female	29	59,122	49.1	58.2	27.4	0.817	2,435	4,420,711	55.1
Melanoma of the Skin	Total	45	121,678	37.0	42.4	37.0	0.225	3,099	8,870,428	34.9
Melanoma of the Skin	Male	28	62,556	44.8	51.9	22.6	0.307	1,867	4,449,717	42.0
Melanoma of the Skin	Female	17	59,122	28.8	32.6	14.5	0.581	1,232	4,420,711	27.9
Myeloma	Total	5	121,678	4.1	4.8	8.4	0.314	723	8,870,428	8.2
Myeloma Myeloma	Male Female	4 1	62,556 59,122	6.4 1.7	7.5 2.0	5.3 3.2	0.785 0.348	443 280	4,449,717 4,420,711	10.0 6.3
Non-Hodgkin Lymphoma	Total	23	121,678	1.7	2.0	23.4	1.000	1,969	8,870,428	22.2
Non-Hodgkin Lymphoma	Male	16	62,556	25.6	29.5	13.8	0.621	1,130	4,449,717	25.4
Non-Hodgkin Lymphoma	Female	7	59,122	11.8	13.8	9.7	0.505	839	4,420,711	19.0
Oral Cavity and Pharynx	Total	9	121,678	7.4	8.5	15.5	0.108	1,306	8,870,428	14.7
Oral Cavity and Pharynx	Male	3	62,556	4.8	5.5	11.6	0.006 <<		4,449,717	21.1
Oral Cavity and Pharynx	Female	6	59,122	10.1	11.8	4.2	0.506	369	4,420,711	8.3
Ovary	Female	11	59,122	18.6	21.3	6.3	0.116	542	4,420,711	12.3
Pancreas Pancreas	Total Male	18	121,678	14.8	17.6	17.0	0.868	1,470	8,870,428	16.6
Pancreas Pancreas	Female	8 10	62,556 59,122	12.8 16.9	15.2 20.0	9.7 7.4	0.747 0.417	818 652	4,449,717 4,420,711	18.4 14.7
Prostate	Male	64	62,556	102.3	120.0	79.8	0.080	6,702	4,449,717	150.6
Stomach	Total	5	121,678	4.1	4.8	5.5	1.000	469	8,870,428	5.3
Stomach	Male	3	62,556	4.8	5.6	3.7	1.000	304	4,449,717	6.8
Stomach	Female	2	59,122	3.4	4.0	1.9	1.000	165	4,420,711	3.7
Testis	Male	5	62,556	8.0	8.1	3.7	0.641	269	4,449,717	6.0
Thyroid	Total	9	121,678	7.4	8.0	15.0	0.141	1,176	8,870,428	13.3
Thyroid	Male	3	62,556	4.8	5.3	4.7	0.609	369	4,449,717	8.3
Thyroid	Female	6	59,122	10.1	10.9	10.0	0.260	807	4,420,711	18.3
Pediatric Age 0 to 19	Total	5	39,939	12.5	12.6	6.8	0.665	420	2,459,385	17.1
Pediatric Age 0 to 19	Male	-	20,251	-	-	3.5	0.063	214	1,254,070	17.1
Pediatric Age 0 to 19	Female	5	19,688	25.4	26.0	3.3	0.470	206	1,205,315	17.1

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN JEROME COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Jer	ome County	/			Re	mainder of Idah	10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	976	123,198	792.2	956.9	892.8	0.006 >>	79,559	9,088,196	875.4
-	Male	538	63,505	847.2	1,012.8	491.7	0.041 >>	42,248	4.564.192	925.6
All Causes of Death	Female	438	59,693	733.8	892.8	404.6	0.105	37,311	4,524,004	824.7
All Malignant Cancers	Total	172	123,198	139.6	168.1	169.6	0.873	15,061	9,088,196	165.7
All Malignant Cancers	Male	84	63,505	132.3	160.1	93.7	0.342	8,151	4,564,192	178.6
All Malignant Cancers	Female	88	59,693	147.4	176.3	76.2	0.201	6,910	4,524,004	152.7
Bladder	Total	4	123,198	3.2	4.1	5.2	0.804	481	9,088,196	5.3
Bladder	Male	4	63,505	6.3	7.9	4.1	1.000	371	4,564,192	8.1
Bladder	Female	- 4	59,693	- 3.2	- 3.7	1.2	0.620	110	4,524,004	2.4
Brain and Other Nervous System Brain and Other Nervous System	Total Male	- 4	123,198 63,505	3.2	3.7	6.1 3.5	0.544 0.058	514 289	9,088,196 4,564,192	5.7 6.3
	Female	- 4	59,693	- 6.7	- 7.7	2.6	0.058	209	4,524,004	5.0
Breast	Total	13	123,198	10.6	12.5	12.7	1.000	1,111	9,088,196	12.2
Breast	Male	-	63,505	-	-	0.2	1.000	13	4,564,192	0.3
Breast	Female	13	59,693	21.8	25.9	12.2	0.892	1,098	4,524,004	24.3
Cervix	Female	1	59,693	1.7	1.9	1.0	1.000	87	4,524,004	1.9
Colorectal	Total	20	123,198	16.2	19.2	15.0	0.252	1,312	9,088,196	14.4
Colorectal	Male	9	63,505	14.2	16.6	8.6	0.984	723	4,564,192	15.8
Colorectal	Female	11	59,693	18.4	22.0	6.5	0.134	589	4,524,004	13.0
Corpus Uteri	Female	6	59,693	10.1	12.1	1.8	0.020 >>	163	4,524,004	3.6
Esophagus	Total	6	123,198	4.9	5.8	5.2	0.826	455	9,088,196	5.0
Esophagus Esophagus	Male Female	6	63,505 59,693	9.4	11.3	4.5 0.8	0.589 0.923	385 70	4,564,192 4,524,004	8.4 1.5
Hodgkin Lymphoma	Total	- 1	123,198	- 0.8	- 1.0	0.3	0.923	24	9,088,196	0.3
Hodgkin Lymphoma	Male	- '	63,505	-	-	0.3	1.000	14	4,564,192	0.3
Hodgkin Lymphoma	Female	1	59,693	1.7	1.9	0.1	0.215	10	4,524,004	0.2
Kidney	Total	3	123,198	2.4	3.0	4.3	0.768	383	9,088,196	4.2
Kidney	Male	3	63,505	4.7	5.7	2.8	1.000	243	4,564,192	5.3
Kidney	Female	-	59,693	-	-	1.5	0.441	140	4,524,004	3.1
Larynx	Total	1	123,198	0.8	1.0	0.9	1.000	75	9,088,196	0.8
Larynx	Male	1	63,505	1.6	1.9	0.7	1.000	64	4,564,192	1.4
Larynx	Female	-	59,693	-	-	0.1	1.000	11	4,524,004	0.2
Leukemia	Total	4	123,198	3.2	3.9	7.4	0.279	661	9,088,196	7.3
Leukemia Leukemia	Male Female	3 1	63,505 59,693	4.7 1.7	5.7 2.0	4.5 2.9	0.683 0.419	394 267	4,564,192 4,524,004	8.6 5.9
Liver and Bile Duct	Total	3	123,198	2.4	2.0	7.2	0.146	632	9,088,196	7.0
Liver and Bile Duct	Male	2	63,505	3.1	3.8	4.9	0.264	421	4,564,192	9.2
Liver and Bile Duct	Female	1	59,693	1.7	2.0	2.3	0.645	211	4,524,004	4.7
Lung and Bronchus	Total	29	123,198	23.5	28.6	32.5	0.619	2,908	9,088,196	32.0
Lung and Bronchus	Male	14	63,505	22.0	26.9	17.4	0.501	1,527	4,564,192	33.5
Lung and Bronchus	Female	15	59,693	25.1	30.3	15.1	1.000	1,381	4,524,004	30.5
Melanoma of the Skin	Total	4	123,198	3.2	3.8	3.4	0.887	297	9,088,196	3.3
Melanoma of the Skin	Male	3	63,505	4.7	5.6	2.3	0.813	197	4,564,192	4.3
Melanoma of the Skin	Female	1	59,693	1.7	2.0 1.0	1.1	1.000	100	4,524,004	2.2 3.6
Myeloma Myeloma	Total Male	1	123,198 63,505	0.8 1.6	1.0 2.0	3.6 2.1	0.255 0.759	324 187	9,088,196 4,564,192	3.6 4.1
Myeloma	Female	- '	59,693	-	2.0 -	1.5	0.759	137	4,504,192	3.0
Non-Hodgkin Lymphoma	Total	9	123,198	7.3	8.8	6.3	0.361	559	9,088,196	6.2
	Male	4	63,505	6.3	7.6	3.5	0.937	306	4,564,192	6.7
Non-Hodgkin Lymphoma	Female	5	59,693	8.4	10.2	2.8	0.291	253	4,524,004	5.6
Oral Cavity and Pharynx	Total	2	123,198	1.6	1.9	3.1	0.799	273	9,088,196	3.0
	Male	1	63,505	1.6	1.9	2.2	0.695	191	4,564,192	4.2
Oral Cavity and Pharynx	Female	1	59,693	1.7	2.0	0.9	1.000	82	4,524,004	1.8
Ovary	Female	6	59,693	10.1	12.0	3.9	0.409	355	4,524,004	7.8
Pancreas	Total	9	123,198	7.3	8.8	13.3	0.299 0.043 <<	1,181	9,088,196	13.0
Pancreas Pancreas	Male Female	2 7	63,505 59,693	3.1 11.7	3.8 14.1	7.4 5.9	0.043 << 0.741	648 533	4,564,192 4,524,004	14.2 11.8
Prostate	Male	14	63,505	22.0	27.8	10.9	0.741	983	4,524,004	21.5
Stomach	Total	2	123,198	1.6	1.9	2.2	1.000	192	9,088,196	21.3
	Male	- 2	63,505	-	-	1.4	0.491	119	4,564,192	2.6
	Female	2	59,693	3.4	3.9	0.8	0.402	73	4,524,004	1.6
		Z a avprossed as th	,				0.402	15	7,027,004	1.0

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Jerome County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	72.0% 9.9%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	56.1%
Current Tobacco User (2020–2022) Other Cancer-Related	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	19.7%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	21.5% 71.1% 14.4% 13.3%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





KOOTENAI COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 5,199 cases of invasive cancer were diagnosed among Kootenai County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in KootenaiCounty and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Kootenai County	State of Idaho
All Sites/Types	5,199	47,333
Female Breast	744	6,943
Prostate	704	6,766
Lung & Bronchus	636	4,959
Colorectal	398	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Kootenai County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Kootenai County. The table also shows the number of observed cases, person-

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 1,788 Kootenai County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Kootenai County and the State of Idaho, 2018–2022

Mortality 2018–2022	Kootenai County	State of Idaho
All Deaths	8,689	80,538
Cancer Deaths	1,788	15,233
% of All Deaths	20.6%	18.9%
Lung & Bronchus	382	2,937
Colorectal	145	1,332
Pancreas	140	1,190
Female Breast	125	1,111
Prostate	118	997

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Kootenai County was 622.4 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (516.6) gives an estimate of the relative burden of disease in Kootenai County.

The age- and sex-adjusted incidence rate of invasive cancer in Kootenai County, all sites combined, was 537.5 cases per 100,000 persons per year during 2017–2021. There were statistically significantly more cases of cancer in Kootenai County (5,199) than expected (4,996.4) based upon rates in the remainder of the state (p=.004).

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Kootenai County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Kootenai County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Kootenai County, all sites combined, was 176.9 deaths per 100,000 persons per year during 2018–2022, compared with 161.0 for the remainder of the state. There were statistically significantly more cancer deaths in Kootenai County (1,788) than expected (1,627.4) based upon rates in the remainder of the state (p<.001).

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN KOOTENAI COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

All Sites Combined Mais 2,757 41,984 1,2857 0,222 >> 22,613 4,168,833 5,616 All Sites Combined Parallel 2,442 42,1240 5,725 5,22,8 2,443,00,056 9,827 4,083,369 5,444 43,345 Bladder Mais 2,442 42,1240 5,725 5,22,8 2,443,00,056 9,725 1,737 0,408,359 5,454 43,358 Bladder Mais 2,444 2,423 42,1240 4,459 3,456 1,452 4,453,444 45,9 3,566 1,76 0,072 1,377 4,068,359 5,454 443,358 Bladder Family Total 1,458 4,459 3,456 4,45 2,452 4,47 0,072 1,377 0,408,359 5,454 4,459 4,449 6,459 4,45				Koo	tenai Coun	ty			Ren	nainder of Ida	aho
Site Crype Sex Cases Years Rate (1) Rate (1) Rate (1) Rate (1) All Sites Combined Male 2,757 413,194 662.4 537.4 1,263.7 413,194 662.4 537.4 1,263.7 413,194 666.1 1,273.7 413,194 666.1 1,273.7 413,194 666.1 1,273.7 413,194 666.2 223.0 0,022 2,213.4 4,083.86 34.8 Bidder Male 1,44 413,014 46.9 39.6 168.8 0,725 1,279 4,083.86 38.8 33.8 Bidder Male 421,138.9 7.9 8.8 30.0 0.786 324.2 408.8 39.8 1.658.8 32.4 408.8 1.658.8 1.75 1.858.9 1.658.8 1.75 1.858.9 1.758.8 1.758.8 1.758.8 1.758.8 1.758.8 1.758.8 1.758.8 1.758.8 1.758.8 1.758.8 1.758.8 1.758.8 1.758.8 1.758.8 1.758.8 1.758.8	Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
All Sites Combined Iotal 5199 853.305 622.4 537.5 4.994.4 0.004 > 22,513 4.108.106 916. All Sites Combined Famale 2.4.02 421.134 672.6 622.7 2.4.33 0.026 1022 > 22,513 408.395 443.34 Baddor Male 2.4.02 421.349 1.6.2 2.2.4.33 0.026 917.3 63.6 108.8 0.026 397 4.068.44 443.344 Baddor Male 44.1.349 1.4.2 12.0 47.7 0.022 397 4.068.44 93.85 73.85 68.6 0.75 0.022 1.387 4.069.356 93.85 73.85 12.0 0.77 0.022 1.387 0.022 1.386 0.02 13.85 0.01 13.85 0.01 13.85 0.01 0.022 1.386 0.02 13.85 0.01 0.022 1.386 0.022 1.386 0.022 1.386 0.022 1.386 0.01 0.022 1.386 0.022 1.386 0.018 0.022 0.018 0.022 </td <td></td> <td>Sex</td> <td>Cases</td> <td></td> <td></td> <td></td> <td></td> <td>P-Value (4)</td> <td></td> <td></td> <td>Rate (1)</td>		Sex	Cases					P-Value (4)			Rate (1)
All Sites Combined Mele 2.767 413.014 (Bob S) 574.1 2.837.9 0.025 22.513 4.098.809 424 Bladder Freinale 244 453.037 30.05 20.58 2.943.9 0.056 19.27 3.098.09 23.8 Bladder Freinale 0.473.89 14.2 47.56 0.988 0.078.8 3.07.8 3.08.9 2.85.8 3.08.9 2.85.8 3.08.9 2.85.8 3.08.9 2.85.8 3.08.9 2.85.8 3.08.9 2.85.8 3.08.9 4.085.308 8.8 4.058.44 4.088.308 8.8 4.058.108 8.8 4.058.108 8.8 4.058.308 7.8 5.8 0.078.8 3.08.7 1.08.8 8.9 4.058.408 8.8 8.9 7.6 7.8 1.58 162.1 0.30.8 8.9 7.6 7.8 1.8 2.9 1.22 0.12.2 1.12.8 0.40.6 4.098.309 7.0 7.1 2.80 1.000 6.55.8 1.000 6.55.9 1.05.80 7.0 7.1 2.80 7.0 7.1 2.80 7.0	, , , , , , , , , , , , , , , , , , ,				()	. ,	. ,	. ,			516.6
ALSIBES Combined Formale 2.4.42 427.380 670.28 2.3.48.3 0.056 19.621 4.05.8444 433.34 Bladder Male 100 421.380 400.43 35.0 0.348 1.307 4.058.344 38.4 Bladder Male 400 433.31 30.7 7.8 66 67.6 0.426 53.44 4.083.344 6.0 Brain - malignant Male 40 413.314 0.7 8.8 38.0 0.768 34.4 4.083.444 4.6 Brain - malignant Female 142 2.18.9 5.0 4.5 2.24 0.138 1.26 4.01.44 4.083.444 4.08 4											549.3
Bladder Male (* 143,914) 49,9 38,6 188,8 0,725, 1,779 4,098,359 38,79 39,79 39											483.5
Biader Frank Frank (1997) Biader (1	Bladder	Total		835,303	30.4	25.6		0.348		8,156,803	24.1
Srain - mailgrant Tolal 61 835, 333 7.3 6.6 67.6 0.486 598 51.65, 803 7.3 Brain - mailgrant Male 0 413, 414 9.7 8.8 3.00 0.786 3.24 4.098, 345 8.8 3.00 2.02 0.0786 3.24 4.098, 350 8.5 8.0 7.86 3.00 7.87 4.48 4.098, 350 1.0 8.0 7.87 4.48 4.098, 350 1.0 8.0 0.786 7.33 8.0 0.787 1.44 4.098, 350 1.0 5.0 6.0 0.677 1.44 4.098, 350 1.0 5.0 6.0 0.677 1.44 4.098, 350 1.0 5.0 6.8 1.000 6.6 0.877 1.44 4.098, 350 1.1 5.0 6.8 1.000 6.6 0.827 1.658 1.000 5.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0											38.5
Brain - malignamt Male 40 413,914 9.7 6.8 33.0 0.766 3.42 4.008,359 6.8 37 4.408,359 6.8 37 4.408,359 6.8 37 4.408,359 6.8 37 4.408,359 6.8 37 4.408,359 6.8 37 4.408,359 6.8 37 4.408,359 6.408,444 6.6 37 4.308 5.003 7.12 5.15 7.340 7.136 5.503 7.1 5.15 7.100 7.101 7.15 7.10 7.101 7.15 7.10 7.10 7.10 7.10 7.10 7.10 7.10 7.15 7.10 7.10 7.10 7.15 7.10 7.10 7.10 7.15 7.10 7.10 7.10 7.15 7.10 7.10 7.10 7.15 7.10 7.10 7.15 7.15 7.10 7.10 7.10 7.15 7.10 7.10 7.15 7.15 7.10 7.10 7.15 7.10 7.10 7.10 7.15 7.15 7.10 7.10 7.15 7.10 7.10 7.10 7.15 7.10 7.10 7.10 7.15 7.10 7.10 7.10 7.15 7.10 7.10 7.10 7.10 7.10 7.10 7.15 7.10 7.10 7.10 7.10 7.10 7.10 7.10 7.10	Bladder	Female			14.2	12.0	-			4,058,444	9.5
Brain and Obst. Female 21 421,389 5.0 4.5 22.4 0.058 22.54 0.058 0.052 0.052 0.058 0.057 0.058 0.057 0.058 0.057 0.058 0.057 0.058 0.057 0.058 0.057 0.058 0.057 0.058 0.057 0.058 0.057 0.058 0.057 0.058 0.057 0.058 0.057 0.058 0.057 0.058 0.058 0.057 0.058 0.058 0.057 0.058 0.058 0.057 0.058 0.050 0.058											7.3
Brain and other CNS -non-malgnant Total 149 835.303 17.8 15.8 162.1 0.322 1.388 1.55.803 17.7 Brain and other CNS - non-malgnant Female 97 41.314 12.6 0.6 0.777 4.84 4.089.350 10.0 Brain and other CNS - non-malgnant Female 97 41.314 1.7 15 16.8 10.00 0.65 4.099.350 11.1 Breast Imale 7 41.314 0.2 2.7 14.8 0.0892 1.224 8.156.803 157. Breast - In situ Male 1 413.914 0.2 0.2 1.3 0.0616 1.224 8.156.803 136. Breast - In situ Male 1 413.914 0.2 0.2 1.2 0.616 1.224 8.156.803 9.37. Colorectal Male 143.938 32.033 47.6 4.42 0.247 1.467 4.089.444 36. Colorectal Male 38 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>8.3</td></td<>											8.3
Brain and other CNSnon-malignant Male 52 413.914 12.6 11.2 50.6 0.877 44.8 4.098.359 101 Breast Total 757 335.303 86.9 78.5 734.0 0.538 62.57 81.55 0.67 0.498 44.44 23.8 Breast Total 757 34.53 89.9 76.5 734.0 0.538 62.57 81.55 0.67 44.44 123.8 Breast - in situ Female 144 421.389 76.6 0.57 14.48 0.945 6.199 4.058.444 152. Breast - in situ Female 144 21.389 76 74.7 4.221 4.058.349 0.6 10.59 4.058.359 0.6 0.671 1.221 4.058.444 30.5 0.50 4.42 200.7 1.072 1.058.359 0.6 0.671 1.221 4.055.444 30.6 0.671 1.221 0.651 1.221 0.651 1.221 0.651 1.212											
Brain and Other CNS - non-malignant Female 97 421,389 23.0 20.2 112.6 0.149 9600 4,058,444 23.3 Breast Male 74 413,914 17 15.5 7.40 0.539 6.257 8.166,003 7.6 Breast main Totalia 7.1 413,914 17.7 15.5 7.40 0.586 1.224 4.157,803 15.5 Breast - in situ Female 141,3914 0.2 0.2 0.30 0.566 1.221 4.068,444 0.6 Caivrectal Female 32 421,389 7.6 7.7 1.28.5 0.471 1.0574 1.0574 1.0574 1.0574 1.058,444 0.6 0.0574 1.0574 1.058,444 9.6 0.0574 1.0574 1.058,444 9.6 0.0574 1.0574 1.058,444 9.6 0.0574 1.058,444 9.6 0.0574 1.058,444 9.6 0.0574 1.058,444 9.6 0.0574 1.058,444 1.16	Brain and other CNS - non-malignant Brain and other CNS - non-malignant									8,150,803	
Breast Total 751 835.303 89.9 78.5 734 (d) 0.539 6.257 8.168.039 76. Breast in situ Fermine 744 421,389 176.6 153.2 741.8 0.945 6.199 4,088.359 1.1 Breast in situ Fermine 744 421,389 176.6 153.2 741.8 0.924 1.227 E.185.000 155.000 176.000 155.000 155.000 155.000 155.000 156.000 155.000 156.000 156.000 156.000 166.000 176.000 176.000 156.000 176.000 166.000 176.000 166.000<	0										
											76.7
Breast Fennale 744 421,389 176.6 153.2 741.8 0.945 6,199 4,088,444 152. Breast in situ Male 1 413,914 0.2 0.2 0.3 0.856 .3 4,088,556 0.0 Breast in situ Fernale 42 427,1389 42 237 14.8 0.9456 .3 4,088,559 40.0 Colorectal Fernale 120 413,914 50.7 44.2 0.374 1.168,803 937 Colorectal Fernale 156 427,389 37.0 31.9 14.4 55.8 0.374 1.468,444 26.3 Esophagus Total 43 835,303 2.4 2.2 2.1 1.442 0.347 1.168,403,403 1.2 1.4 4.4 55.8 0.374 1.468,404 3.1 1.468,404 1.1 1.168,403,403 1.1 1.406,404 1.1 1.4 8.9 0.243 3.1 1.56,503											1.4
Breast in situ Total Vala Vala Vala Vala Vala Vala Vala V											152.7
Breast: initu Female 144 421,389 34.2 29.7 145.8 0.924 1.221 4,058,444 36. Colorectal Total 398 835,303 47.6 41.4 381.5 0.816 2264 4,058,444 36. Colorectal Female 188 421,389 70.7 44.2 0.874 1,467 4,088,444 36. Colorectal Female 188 421,389 30.7 114.5 0.374 1,467 4,088,444 38. Colorectal Female 15 421,389 1.4 1.4 2.0 0.374 1,467 4,088,439 5. Esophagus Female 5 421,389 1.4 1.4 8.9 0.226 391 4,058,444 1.1 Hodgkin Lymphona Female 6 421,389 1.4 1.4 8.9 0.426 87 4,058,444 1.2 Kidney and Kenai Petvis Male 163 413.914 3.4											15.0
Cervix Female 32 421,389 7.6 7.1 28.9 0.616 2022 4,058,444 65. Colorectal Male 210 413,914 50.7 44.2 204.7 7.76 4,058,444 38.5 0.339 Colorectal Female 186 421,389 44.6 38.7 175.8 0.374 1,467 4,058,444 36.5 Corpus Uleri Female 185 421,389 44.6 35.8 0.031 44.4 55.8 0.034 44.058,444 36.5 Esophagus Malei 43 833,303 5.1 4.4 65.8 0.031 44.98 4.088,444 32.5 22.2 0.974 202 8.176.600.5 5.6 5.6 0.531 4.048,453 2.2 7.1 4.058,444 2.4 1.4 4.99 0.426 87 4.058,444 2.2 1.6 4.058,444 2.4 1.319.01 33.4 3.0.01 5.5 5.2 1.002.7 1.002 <td< td=""><td>Breast - in situ</td><td>Male</td><td>1</td><td></td><td>0.2</td><td>0.2</td><td>0.3</td><td></td><td>3</td><td>4,098,359</td><td>0.1</td></td<>	Breast - in situ	Male	1		0.2	0.2	0.3		3	4,098,359	0.1
Colorectal Total 398 855,303 47.6 41.4 38.15 0.411 3.234 8.156,803 399 43. Colorectal Female 188 421,399 44.6 38.7 17.58 0.374 1.467 4.058,444 250 Colorectal Female 168 421,389 37.0 31.9 144.2 0.374 1.147 4.058,444 250 Esophagus Male 35.3 5.1 4.4 455.8 0.091 4404 8.156,803 55 4.058,303 51 4.44 55.8 0.091 4.058,303 2.0 4.058,303 2.0 4.058,303 2.0 4.058,303 2.0 4.058,303 2.0 4.058,303 2.0 4.058,303 2.0 4.058,303 2.0 1.058 1.157,803 2.0 4.058,444 2.0 4.058,444 2.0 4.058,444 2.0 4.058,444 2.0 4.058,444 2.0 1.0 1.0 3.03,13,1 1.147 4.098,550 2.2											30.1
											6.5
Colorectal Female 188 421389 37.0 31.9 144.2 0.374 1.467 4.058,444 289 Esophagus Total 43 847,389 37.0 31.9 144.2 0.374 1.187 4.098,359 99 9 Esophagus Female 5 421.389 1.2 1.0 8.9 0.243 7.3 4.058,444 1.0 Hodgin Lymphoma Total 20 885,303 2.4 2.3 2.12 0.858 116 4.098,359 2.2 Hodgin Lymphoma Female 6 421,389 1.4 4.8 9.0 0.243 7.7 4.056,444 2.2 7.94 4.056,444 2.4											39.6
	-										43.1
Esophagus Total 43 835,303 5.1 4.4 4.5 5.8 0.091 4464 9.15,803 5. Esophagus Female 5 421,399 1.2 1.0 8.9 0.243 73 4,058,444 1.1 Hodgkin Lymphoma Male 14 433,914 3.4 3.2 2.1 0.668 115 4,098,359 9.2 Hodgkin Lymphoma Female 6 421,389 1.4 1.4 8.9 0.243 71 4,088 1.4 1.4 8.9 0.425 × 1,715 81,558,03 2.1 Kidney and Renal Petvis Total 6 31,138 1.7 1.7 81,558,03 2.1 1.7 81,558,03 2.1 Uarynx Female 6 421,391 4.8 1.7 1.7 81,558,03 1.8 1.8 1.7 1.00 47 4,058,444 1.1 Lavynx Female 6 421,391 4.8 1.1											36.1
Esophagus Male 38 413,914 9.2 7.9 46.2 0.243 391 4,096,359 9.9 Hodgkin Lymphoma Total 20 835,303 2.4 2.3 2.12 0.914 202 8155,803 2.2 Hodgkin Lymphoma Female 6 421,389 1.4 1.4 1.8 9 0.426 87 4,058,444 1.2 Kidney and Renal Pelvis Male 6 421,389 1.4 1.4 1.4 8.9 0.424 87 4,058,444 1.2 Kidney and Renal Pelvis Hale 26 835,303 3.1 2.7 2.3 0.602 568 4.054,444 1.1 Larynx Female 7 4.13,914 4.4 1.7 7.6 0.588 4.17 4.058,444 1.2 Larynx Female 7 4.13,914 4.2 1.7 4.058,454 1.6 1.000 4.4 4.058,464 1.2 Larynx Male										, ,	
EsophagusFemale5421,3891.21.08.90.2437.34,058,4444.1Hodgkin LymphomaMale14413,9143.43.221.20.9142028,156,80322Hodgkin LymphomaFemale6421,3891.41.48.90.426874,058,4442.2Kidney and Renal PelvisTotal236835,30328.324.5202.70.024 >>1.1171.658,4342.2Kidney and Renal PelvisFemale73421,38917.315.066.30.6025684,068,4441.2LaynxTotal26835,3033.12.723.30.6281.941.658,4032.2LaynxTotal20413,9144.84.11.74.058,9441.11.058,4441.1LaynxFemale6421,3891.41.25.71.000474,068,4393.3LaynxFemale66421,3891.41.25.71.00474,068,4441.5LeukemiaTotal101835,30312.110.389.20.2247421.658,30318.1LeukemiaMale167413,91416.21.398.20.25477224.068,44415.5LeukemiaMale167413,91416.21.398.20.1682.168,4039.31.147LeukemiaInde164421,389 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>5.7 9.5</td></td<>											5.7 9.5
											9.5
Hodgin Lymphoma Female 6									-	, ,	2.5
Hodgkin Lýmphoma Female 6 421,389 1.4 1.4 8.9 0.426 87 4,058,444 22. Kidney and Renal Pelvis Male 163 433,914 39.4 34.3 133.0 0.013 >> 1.147 4,098,359 281. Kidney and Renal Pelvis Total 26 355,303 3.1 2.7 23.3 0.628 194 8,165,803 22. Larynx Total 26 435,314 4.8 4.1 17.4 0.589 147 4,098,359 33. Larynx Female 6 421,389 1.4 1.2 5.7 1.000 47 4,058,434 15. Leukemia Total 163 855,303 21.7 10.63 0.321 919 4,098,359 22. Leukemia Female 64 421,389 15.7 13.6 74.6 0.348 62.5 4,058,444 15. Leukemia Total 103 852,03 0.57 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>2.8</td></t<>											2.8
$ Kidney and Renal Pelvis Male 163 413,914 39.4 34.3 13.0 0.012 \Rightarrow 1,715 8,156,803 21.1Kidney and Renal Pelvis Female 73 421,389 17.3 15.0 663.0 0.062 \Rightarrow 147 4,098,359 28.0Kidney and Renal Pelvis Female 73 421,389 17.3 15.0 663.0 0.062 \Rightarrow 568 4,058,444 14.0Larynx Total 26 835,303 3.1 2.7 23.0 0528 194 4,098,359 33.Larynx Male 20 413,914 4.8 4.1 17.4 0.589 147 4,098,359 33.Larynx Female 6 421,389 1.4 1.2 5.7 1.000 47 4,0588,444 1.1Leukemia Total 183 835,303 2.19 19.1 181.5 0.934 1.544 8,156,803 184Leukemia Male 17 41,3914 28.3 24.7 1063.0 .321 919 4,098,359 22.Leukemia Female 66 421,389 15.7 13.6 74.6 0.348 625 4,058,444 15.Liver and Bile Duct Total 101 835,303 12.1 10.3 882 0.234 742 8,156,803 9.2Liver and Bile Duct Total 101 835,303 12.1 10.3 882 0.234 742 8,156,803 9.2Liver and Bile Duct Female 34 421,389 8.1 6.9 26.3 0.168 215 4,058,444 5.5Lung and Bronchus Total 636 835,303 76.1 640 528.7 0.000 \Rightarrow 4,323 8,156,803 533Lung and Bronchus Male 312 413,914 75.4 63.5 26.1 0.0003 \Rightarrow 2.148 4,088,449 55Lung and Bronchus Male 187 413,914 75.4 63.5 26.1 0.0003 \Rightarrow 2.140 4,058,444 52Lung and Bronchus Male 187 413,914 75.4 63.5 26.1 0.0003 \Rightarrow 2.140 4,058,444 52Lung and Bronchus Female 324 421,389 76.9 64.6 264.5 0.000 \Rightarrow 2.140 4,058,444 52Lung and Bronchus Male 187 413,914 45.2 39.3 198.2 0.450 1.708 4,098,359 43.1Melanoma of the Skin Male 187 413,914 45.2 39.3 198.2 0.450 1.708 4,088,359 43.1Melanoma of the Skin Female 19 421,389 77.6 9 64.6 30.4 0.0689 \Rightarrow 2.140 4,058,444 65.Male 604 413,914 45.2 39.3 198.2 0.450 1.708 4,088,359 43.1Melanoma of the Skin Female 187 413,914 45.2 39.3 198.2 0.450 1.708 4,088,359 43.1Melanoma of the Skin Male 187 413,914 45.2 3.913 198.2 0.450 1.708 4,088,359 43.1$											2.1
Kidney and Renal PelvisFemale73421,38917.315.068.30.6025684,058,44414.1LarynxMale20413,9144.84.117.40.5891474,098,35933.1LarynxFemale6421,3891.41.25.71.000474,058,40323.1LeukemiaMaleTotal183835,30321.919.1181.50.9341.5448,156,60318.1LeukemiaMale17413,91428.324.7106.30.3219194,098,35922.2LeukemiaFemale66421,38915.713.674.60.3486254,058,44415.1Liver and Bile DuctTotal101835,30312.1100.389.20.2547428,156,6039.9Liver and Bile DuctFemale636835,30376.164.0526.70.000 >>4.3238,156,80353.3Lung and BronchusTotal636835,30376.164.0526.70.000 >>2.1404,058,44452.3Melanoma of the SkinMale187413,91445.239.3198.20.4501.7084,098,35953.3Lung and BronchusFemale324413,891445.239.3198.20.4501.7084,068,44452.3Melanoma of the SkinMale187413,91445.22.500.0731.6562.258 <t< td=""><td></td><td>Total</td><td>236</td><td></td><td>28.3</td><td>24.5</td><td></td><td>0.024 >></td><td>1,715</td><td>8,156,803</td><td>21.0</td></t<>		Total	236		28.3	24.5		0.024 >>	1,715	8,156,803	21.0
	Kidney and Renal Pelvis		163	413,914							28.0
Larýnx Male 20 413,914 4.8 4.1 17.4 0.589 147 4.098,359 33. Larynx Female 6 421,389 14 1.2 5.7 1.000 47 4.098,359 32. Leukemia Male 117 413,914 2.83 24.7 106.3 0.321 199 4.098,359 22. Leukemia Female 64 421,389 15.7 13.6 74.6 0.324 62.9 4.098,359 22. Leukemia Female 67 413,914 61.6 13.9 62.0 0.557 52.7 4.098,359 12. Lurg and Bronchus Total 636 835,303 76.1 64.0 526.7 0.000 >> 2.188 4.098,359 53. Lung and Bronchus Male 312 413,914 45.2 39.3 198.2 0.450 1.708 4.098,359 53. Lung and Bronchus Female 324 421,389 76.9 64.6 264.5 0.000 >> 2.140 4.058,444 52.											14.0
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $											2.4
											3.6
Leukemia Male 117 413,914 28.3 24.7 106.3 0.321 919 4,098,359 22. Leukemia Female 66 421,389 15.7 13.6 74.6 0.348 625 4,058,444 15.7 Liver and Bile Duct Male 67 413,914 16.2 13.9 62.0 0.557 527 4,098,359 12.2 Liver and Bile Duct Female 34 421,389 8.1 6.9 26.3 0.168 215 4,058,444 5.2 Lung and Bronchus Male 132 413,914 45.2 39.3 198.2 0.450 1,708 4,098,359 33.3 Lung and Bronchus Female 324 421,389 76.9 64.6 264.5 0.000 >> 2,183 4,098,359 33.3 Melanoma of the Skin Male 187 413,914 45.2 25.0 132.7 0.251 1,130 4,058,444 27.7 Myeloma Female 194 </td <td></td>											
LeukemiaFemale66421,38915.713.674.60.3486254.058,44415.Liver and Bile DuctTotal101855,30312.1103.89.20.2347428.156.8039.Liver and Bile DuctFemale34421,3898.16.926.30.1682154.058,4445.Lung and BronchusTotal638835,30376.164.0526.70.000 >>4.3238.156.80353.Lung and BronchusFemale324413,91475.463.5261.50.000 >>2.1834.098,35953.Lung and BronchusFemale324413,91445.239.3198.20.4501.7084.088,44452.Melanoma of the SkinTotal306835,30336.632.1332.20.1562.8388.156,80334.4Melanoma of the SkinFemale119421,38928.225.0132.70.2511,1304.068,44427.1MyelomaMale60413,9144.5239.3198.20.450>.8774.098,3599.MyelomaMale60413,9147.57.650.0746358.156.8037.1MyelomaFemale33421,3897.86.630.40.6892484.058,4446.Non-Hodgkin LymphomaTotal213835,30317.414.519.010.007554.058,4446. <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>											
Liver and Bile DuctMale67413,91416.213.962.00.5575274,098,35912.1Liver and Bile DuctFemale34421,3898.16.926.30.1682154,058,44455.1Lung and BronchusMale312413,91475.463.5261.50.003 >>2,1834,098,35953.1Lung and BronchusFemale324421,38976.964.6264.50.000 >>2,1834,098,35953.1Melanoma of the SkinTotal306835,30336.632.1332.20.1562.8388,156,80334.1Melanoma of the SkinMale107413,91445.239.3198.20.4501,7084,098,35941.1Melanoma of the SkinFemale119421,38928.225.0132.70.2511,1304,058,44427.7MyelomaMale60413,91414.512.445.80.050>3874,098,3599.9MyelomaFemale33421,3897.86.630.40.6892484,058,4446.Non-Hodgkin LymphomaTotal145835,30317.414.9139.31,0264,998,35925.1Non-Hodgkin LymphomaMale120413,91425.622.997.20.3888344,098,35925.1Non-Hodgkin LymphomaMale120413,91425.622.997.20.388											9.1
Liver and Bile Duct Female 34 421,389 8.1 6.9 26.3 0.168 215 4.058,444 55. Lung and Bronchus Male 312 413,914 75.4 64.0 526.7 0.000 >> 4,323 8.156,803 533. Lung and Bronchus Female 324 421,389 76.9 64.6 264.5 0.000 >> 2,143 4,098,359 533. Melanoma of the Skin Total 306 835,303 36.6 321.1 332.2 0.156 2,838 8,156,803 34.4 Melanoma of the Skin Female 119 421,389 28.2 25.0 132.7 0.251 1,130.4 0,98,359 9.4 Myeloma Male 60 413,914 14.5 12.4 45.8 0.050 387 4,098,359 9.7 Myeloma Female 33 421,389 7.8 6.6 30.4 0.689 248 4,058,444 6.6 Non-Hodgkin Lymphoma Total											12.9
Lung and BronchusTotal6366353,30376.164.0 5267 $0.000 >>$ 4.323 $8.156,803$ 53.3Lung and BronchusFemale312413,91475.4 63.5 261.5 $0.003 >>$ 2.183 $4,098,359$ 53.3 Lung and BronchusFemale324421,38976.9 64.6 264.5 $0.000 >>$ 2.140 $4,058,444$ $52.$ Melanoma of the SkinMale187 $413,914$ 45.2 39.3 138.2 0.450 1.708 $4,098,359$ 34.1 Melanoma of the SkinFemale119 $421,389$ 28.2 25.0 132.7 0.251 $1,130$ $4,058,444$ 27.1 MyelomaTotal93 $835,303$ 11.1 9.5 76.5 0.074 633 $8,156,803$ 7.1 MyelomaMale60 $413,914$ 14.5 12.4 $4.68.6$ 0.069 248 $4,098,359$ 25.1 Non-Hodgkin LymphomaTotal211 $435,303$ 27.8 6.6 30.4 0.689 248 $4,058,444$ 6.6 Non-Hodgkin LymphomaMale120 $413,914$ 29.0 25.4 118.5 0.913 1.026 $4,098,359$ 25.1 Non-Hodgkin LymphomaFemale91 $421,389$ 21.6 18.6 91.0 1.000 755 $4,058,444$ 6.6 Oral Cavity and PharynxTotal146 $435,303$ 17.4 14.99 139.3 7.9 $40.$											5.3
Lung and BronchusMale312413,91475.463.5261.50.003 >>2,1834,098,35953.3Lung and BronchusFemale324421,38976.964.6264.50.000 >>2,1404,058,44452.3Melanoma of the SkinMale187413,91445.239.3198.20.4501,7084,098,35941.4Melanoma of the SkinFemale119421,38928.225.0132.70.2511,1304,058,44427.4MyelomaTotal93835,30311.19.576.50.0746358,156,8037.7MyelomaMale60413,91414.512.445.80.050>3874,098,3599.9MyelomaFemale33421,3897.86.630.40.6892484,058,4446.6Non-Hodgkin LymphomaTotal211835,30317.418.69.101.0007554,098,35925.1Non-Hodgkin LymphomaFemale91421,38921.618.691.01.0007554,098,35925.1Non-Hodgkin LymphomaFemale91421,3897.622.297.20.3988344,098,35920.2Oral Cavity and PharynxTotal145835,30317.414.913.930.6541.1708.156,80314.1Oral Cavity and PharynxMale106413,91425.622.297.20.398<			636							, ,	53.0
Melanoma of the Skin Total 306 835,303 36.6 32.1 332.2 0.156 2.838 8,156,803 34.4 Melanoma of the Skin Male 187 413,914 45.2 39.3 198.2 0.450 1,708 4,098,359 41.1 Myeloma Total 93 835,303 11.1 9.5 76.5 0.074 635 8,156,803 7.7 Myeloma Male 60 413,914 14.5 12.4 45.8 0.050 >> 387 4,098,359 9.7 Myeloma Female 33 421,389 7.8 6.6 30.4 0.689 248 4,058,444 6. Non-Hodgkin Lymphoma Total 211 835,303 25.3 21.9 210.2 0.973 1,781 8,156,803 21.6 Non-Hodgkin Lymphoma Female 91 421,389 21.6 18.6 91.0 1.000 755 4,058,444 18.1 Oral Cavity and Pharynx Total 1	Lung and Bronchus	Male	312	413,914						4,098,359	53.3
Melanoma of the Skin Male 187 413,914 45.2 39.3 198.2 0.450 1,708 4,098,359 411 Melanoma of the Skin Female 119 421,389 28.2 25.0 132.7 0.251 1,130 4,058,454 27.4 Myeloma Male 60 413,914 14.5 12.4 45.8 0.050 >> 387 4,098,359 9.9 Myeloma Female 33 421,389 7.8 6.6 30.4 0.689 248 4,058,444 6. Non-Hodgkin Lymphoma Total 211 835,303 25.3 21.9 210.2 0.973 1,781 8,156,803 21.5 Non-Hodgkin Lymphoma Male 120 413,914 29.0 25.4 118.5 0.913 1,026 4,098,359 25.5 Non-Hodgkin Lymphoma Female 91 421,389 21.6 18.6 91.0 1.000 755 4,058,444 14.1 Oral Cavity and Pharynx Male <td></td> <td>Female</td> <td></td> <td>421,389</td> <td></td> <td></td> <td></td> <td></td> <td>2,140</td> <td>4,058,444</td> <td>52.7</td>		Female		421,389					2,140	4,058,444	52.7
Melanoma of the Skin Female 119 421,389 28.2 25.0 132.7 0.251 1,130 4,058,444 27.4 Myeloma Male 60 413,914 14.5 12.4 45.8 0.074 635 8,156,803 7.4 Myeloma Female 33 421,389 7.8 6.6 30.4 0.689 248 4,058,444 6.6 Non-Hodgkin Lymphoma Total 211 835,303 25.3 21.9 210.2 0.973 1,781 8,156,803 21.0 Non-Hodgkin Lymphoma Male 120 413,914 29.0 25.4 118.5 0.913 1,026 4,098,359 25.1 Non-Hodgkin Lymphoma Female 91 421,389 21.6 18.6 91.0 1.000 755 4,058,444 18.1 Oral Cavity and Pharynx Male 106 413,914 25.6 22.2 97.2 0.398 834 4,058,359 20.0 Oral Cavity and Pharynx Female </td <td></td> <td>34.8</td>											34.8
MyelomaTotal93835,30311.19.576.5 0.074 635 $8,156,803$ 7.1MyelomaMale60413,91414.512.445.8 0.050 >>387 $4,098,359$ 9.MyelomaFemale33421,3897.86.630.4 0.689 248 $4,058,444$ 6.Non-Hodgkin LymphomaTotal211835,30325.321.9210.2 0.973 $1,781$ $8,156,803$ 21.3Non-Hodgkin LymphomaFemale91421,38921.618.691.0 1.000 755 $4,058,444$ 18.3Oral Cavity and PharynxTotal145835,30317.414.9139.3 0.654 $1,170$ $8,156,803$ 14.3Oral Cavity and PharynxMale106413,91425.622.297.2 0.398 834 $4,098,359$ 20.3OvaryFemale39421,3899.37.940.7 0.870 336 $4,058,444$ 12.3OvaryFemale58421,38913.812.058.7 0.993 495 $4,058,444$ 12.3PancreasTotal174835,30320.817.7158.4 0.2322 $1,314$ $8,156,803$ 16.3PancreasMale94413,91422.719.486.7 0.458 732 $4,098,359$ 17.4PancreasFemale80421,38919.016.171.3 0.328 582 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>41.7</td></td<>											41.7
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $											27.8
MyelomaFemale33421,3897.86.630.40.6892484,058,4446.Non-Hodgkin LymphomaTotal211835,30325.321.9210.20.9731,7818,156,80321.1Non-Hodgkin LymphomaFemale91421,38921.618.691.01.0007554,058,44418.1Oral Cavity and PharynxTotal145835,30317.414.9139.30.6541,1708,156,80314.2Oral Cavity and PharynxMale106413,91425.622.297.20.3988344,058,4448.3Oral Cavity and PharynxFemale39421,3899.37.940.70.8703364,058,4448.3OvaryFemale39421,38913.812.058.70.9934954,058,4448.3PancreasTotal174835,30320.817.7158.40.2321,3148,156,80316.7PancreasMale94413,91422.719.486.70.4587324,098,35917.7PancreasMale704413,914170.1144.7719.70.3002694,098,359147.3PancreasFemale80421,38919.016.171.30.3285824,058,459147.3StomachTotal156835,3036.75.849.80.4144188,156,803157.3 <t< td=""><td></td><td></td><td></td><td>835,303</td><td></td><td></td><td></td><td>0.050</td><td></td><td></td><td>7.8</td></t<>				835,303				0.050			7.8
Non-Hodgkin LymphomaTotal211835,30325.321.9210.20.9731,7818,156,80321.1Non-Hodgkin LymphomaFemale91421,38921.618.691.01.0007554,058,45418.1Oral Cavity and PharynxTotal145835,30317.414.9139.30.6541,1708,156,80314.2Oral Cavity and PharynxMale106413,91425.622.297.20.3988344,098,35920.2Oral Cavity and PharynxFemale39421,3899.37.940.70.8703364,058,44418.2Oral Cavity and PharynxFemale58421,38913.812.058.70.9934954,058,44412.2OvaryFemale58421,38913.812.058.70.9934954,058,44412.2PancreasTotal174835,30320.817.7158.40.2321,3148,156,80316.7PancreasMale94413,91422.719.486.70.4587324,098,35917.7PancreasMale704413,914170.1144.7719.70.5756,0624,098,35914.7ProstateMale704413,9149.27.931.70.3002694,098,3596.5StomachMale38413,9149.27.931.70.3002694,098,3596.5<	Myeloma			413,914						4,090,359	
Non-Hodgkin LýmphomaMale120413,91429.025.4118.50.9131,0264,098,35925.1Non-Hodgkin LymphomaFemale91421,38921.618.691.01.0007554,058,44418.1Oral Cavity and PharynxTotal145835,30317.414.9139.30.6541,1708,156,80314.1Oral Cavity and PharynxMale106413,91425.622.297.20.3988344,098,35920.1Oral Cavity and PharynxFemale39421,3899.37.940.70.8703364,058,44412.1Oral Cavity and PharynxFemale58421,38913.812.058.70.9934954,058,44412.1PancreasTotal174835,30320.817.7158.40.2321,3148,156,80316.1PancreasMale94413,91422.719.486.70.4587324,098,35917.9PancreasMale94413,914170.1144.7719.70.5756,0624,098,359147.3PancreasFemale80421,38919.016.171.30.3002694,098,359147.3StomachTotal56835,3036.75.849.80.4144188,156,8035.5StomachMale38413,9149.27.931.70.3002694,098,3596.											21.8
Non-Hodğkin LýmphomaFemale91421,38921.618.691.01.0007554,058,44418.1Oral Cavity and PharynxTotal14.5835,30317.414.9139.30.6541,1708,156,80314.2Oral Cavity and PharynxMale106413,91425.622.297.20.3988344,098,35920.2Oral Cavity and PharynxFemale39421,3899.37.940.70.8703364,058,4448.3OvaryFemale58421,38913.812.058.70.9934954,058,44412.2PancreasTotal17.4835,30320.817.7158.40.2321,3148,156,80316.7PancreasMale94413,91422.719.486.70.4587324,098,35917.7PancreasFemale80421,38919.016.171.30.3285824,058,44414.2ProstateMale704413,914170.1144.7719.70.5756,0624,098,359147.3StomachTotal56835,3036.75.849.80.4144188,156,8035.5StomachMale38413,9149.27.931.70.3002694,098,3596.7ThyroidTotal102835,30312.211.5118.30.1421,0838,156,80313.3Testis <td></td> <td>25.0</td>											25.0
Oral Cavity and PharynxTotal145835,30317.414.9139.30.6541,1708,156,80314.1Oral Cavity and PharynxMale106413,91425.622.297.20.3988344,098,35920.1Oral Cavity and PharynxFemale39421,3899.37.940.70.8703364,058,4448.1OvaryFemale58421,38913.812.058.70.9934954,058,44412.1PancreasTotal174835,30320.817.7158.40.2321,3148,156,80316.1PancreasMale94413,91422.719.486.70.4587324,098,35917.1PancreasFemale80421,38919.016.171.30.3285824,058,44414.1ProstateMale704413,914170.1144.7719.70.5756,0624,098,359147.1StomachTotal56835,3036.75.849.80.4144188,156,8035.1StomachMale38413,9149.27.931.70.3002694,098,3596.1StomachMale26413,9146.36.524.30.7812484,098,3596.1TestisMale26413,9146.36.524.30.7812484,098,3596.1ThyroidTotal102<											18.6
Oral Cavity and PharynxMale106413,91425.622.297.20.3988344,098,35920.3Oral Cavity and PharynxFemale39421,3899.37.940.70.8703364,058,4448.3OvaryFemale58421,38913.812.058.70.9934954,058,44412.3PancreasTotal174835,30320.817.7158.40.2321,3148,156,40316.6PancreasMale94413,91422.719.486.70.4587324,098,35917.3PancreasFemale80421,38919.016.171.30.3285824,058,44414.3ProstateMale704413,914170.1144.7719.70.5756,0624,098,359147.3StomachTotal56835,3036.75.849.80.4144188,156,8035.4StomachMale38413,9149.27.931.70.3002694,098,3596.4StomachFemale18421,3894.33.717.81.0001494,058,4443.3TestisMale26413,9146.36.524.30.7812484,098,3596.4ThyroidTotal102835,30312.211.5118.30.1421,0838,156,80313.3ThyroidFemale69421,389 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>8,156,803</td> <td>14.3</td>										8,156,803	14.3
Oral Cavity and PharynxFemale39421,3899.37.940.70.8703364,058,4448.1OvaryFemale58421,38913.812.058.70.9934954,058,44412.1PancreasTotal174835,30320.817.7158.40.2321,3148,156,80316.1PancreasMale94413,91422.719.486.70.4587324,098,35917.1PancreasFemale80421,38919.016.171.30.3285824,058,44414.1ProstateMale704413,914170.1144.7719.70.5756,0624,098,359147.1StomachTotal56835,3036.75.849.80.4144188,156,8035.5StomachMale38413,9149.27.931.70.3002694,098,3596.1StomachFemale18421,3894.33.717.81.0001494,058,4443.3TestisMale26413,9146.36.524.30.7812484,098,3596.1ThyroidTotal102835,30312.211.5118.30.1421,0838,156,80313.3ThyroidMale33413,9148.07.337.50.5223394,098,3596.1ThyroidFemale69421,38916.415	Oral Cavity and Pharynx	Male	106	413,914	25.6	22.2	97.2	0.398	834	4,098,359	20.3
PancreasTotal174835,30320.817.7158.40.2321,3148,156,80316.PancreasMale94413,91422.719.486.70.4587324,098,35917.9PancreasFemale80421,38919.016.171.30.3285824,058,44414.1ProstateMale704413,914170.1144.7719.70.5756,0624,098,359147.9StomachTotal56835,3036.75.849.80.4144188,156,8035.5StomachMale38413,9149.27.931.70.3002694,098,3596.1StomachFemale18421,3894.33.717.81.0001494,058,4443.1TestisMale26413,9146.36.524.30.7812484,098,3596.ThyroidTotal102835,30312.211.5118.30.1421,0838,156,80313.1ThyroidMale33413,9148.07.337.50.5223394,098,3598.1ThyroidFemale69421,38916.415.581.60.1767444,058,44418.1Pediatric Age 0 to 19Total29206,78614.014.135.60.3073962,292,53817.4Pediatric Age 0 to 19Male15106,94114.										4,058,444	8.3
PancreasMale94413,91422.719.486.70.4587324,098,35917.3PancreasFemale80421,38919.016.171.30.3285824,058,44414.3ProstateMale704413,914170.1144.7719.70.5756,0624,098,359147.3StomachTotal56835,3036.75.849.80.4144188,156,8035.5StomachMale38413,9149.27.931.70.3002694,098,3596.1StomachFemale18421,3894.33.717.81.0001494,058,4443.3TestisMale26413,9146.36.524.30.7812484,098,3596.ThyroidTotal102835,30312.211.5118.30.1421,0838,156,80313.3ThyroidMale33413,9148.07.337.50.5223394,098,3598.3ThyroidFemale69421,38916.415.581.60.1767444,058,44418.3Pediatric Age 0 to 19Total29206,78614.014.135.60.3073962,292,53817.3Pediatric Age 0 to 19Male15106,94114.014.018.20.5361991,167,38017.3											12.2
PancreasFemale80421,38919.016.171.30.3285824,058,44414.1ProstateMale704413,914170.1144.7719.70.5756,0624,098,359147.3StomachTotal56835,3036.75.849.80.4144188,156,8035.StomachMale38413,9149.27.931.70.3002694,098,3596.1StomachFemale18421,3894.33.717.81.0001494,058,4443.TestisMale26413,9146.36.524.30.7812484,098,3596.ThyroidTotal102835,30312.211.5118.30.1421,0838,156,80313.3ThyroidMale33413,9148.07.337.50.5223394,098,3598.3ThyroidFemale69421,38916.415.581.60.3077444,058,44418.3Pediatric Age 0 to 19Total29206,78614.014.135.60.3073962,292,53817.3Pediatric Age 0 to 19Male15106,94114.014.014.20.5361991,167,38017.3											16.1
ProstateMale704413,914170.1144.7719.70.5756,0624,098,359147.3StomachTotal56835,3036.75.849.80.4144188,156,8035.StomachMale38413,9149.27.931.70.3002694,098,3596.1StomachFemale18421,3894.33.717.81.0001494,058,4443.TestisMale26413,9146.36.524.30.7812484,098,3596.ThyroidTotal102835,30312.211.5118.30.1421,0838,156,80313.3ThyroidMale33413,9148.07.337.50.5223394,098,3598.3ThyroidFemale69421,38916.415.581.60.1767444,058,44418.3Pediatric Age 0 to 19Total29206,78614.014.135.60.3073962,292,53817.3Pediatric Age 0 to 19Male15106,94114.014.018.20.5361991,167,38017.3		Male									17.9
StomachTotal56835,3036.75.849.80.4144188,156,8035.StomachMale38413,9149.27.931.70.3002694,098,3596.1StomachFemale18421,3894.33.717.81.0001494,058,4443.TestisMale26413,9146.36.524.30.7812484,098,3596.ThyroidTotal102835,30312.211.5118.30.1421,0838,156,80313.ThyroidMale33413,9148.07.337.50.5223394,098,3598.ThyroidFemale69421,38916.415.581.60.1767444,058,44418.Pediatric Age 0 to 19Total29206,78614.014.135.60.3073962,292,53817.4Pediatric Age 0 to 19Male15106,94114.014.018.20.5361991,167,38017.4											
Stomach StomachMale38413,9149.27.931.70.3002694,098,3596.1StomachFemale18421,3894.33.717.81.0001494,058,4443.1TestisMale26413,9146.36.524.30.7812484,098,3596.1ThyroidTotal102835,30312.211.5118.30.1421,0838,156,80313.1ThyroidMale33413,9148.07.337.50.5223394,098,3598.1ThyroidFemale69421,38916.415.581.60.1767444,058,44418.1Pediatric Age 0 to 19Total29206,78614.014.135.60.3073962,292,53817.2Pediatric Age 0 to 19Male15106,94114.014.018.20.5361991,167,38017.2											5.1
StomachFemale18421,3894.33.717.81.0001494,058,4443.7TestisMale26413,9146.36.524.30.7812484,098,3596.7ThyroidTotal102835,30312.211.5118.30.1421,0838,156,80313.3ThyroidMale33413,9148.07.337.50.5223394,098,3598.3ThyroidFemale69421,38916.415.581.60.1767444,058,44418.3Pediatric Age 0 to 19Total29206,78614.014.135.60.3073962,292,53817.3Pediatric Age 0 to 19Male15106,94114.014.018.20.5361991,167,38017.3											6.6
TestisMale26413,9146.36.524.30.7812484,098,3596.ThyroidTotal102835,30312.211.5118.30.1421,0838,156,80313.3ThyroidMale33413,9148.07.337.50.5223394,098,3598.3ThyroidFemale69421,38916.415.581.60.1767444,058,44418.3Pediatric Age 0 to 19Total29206,78614.014.135.60.3073962,292,53817.3Pediatric Age 0 to 19Male15106,94114.014.018.20.5361991,167,38017.3								1 000			3.7
ThyroidTotal102835,30312.211.5118.30.1421,0838,156,80313.3ThyroidMale33413,9148.07.337.50.5223394,098,3598.3ThyroidFemale69421,38916.415.581.60.1767444,058,44418.3Pediatric Age 0 to 19Total29206,78614.014.135.60.3073962,292,53817.3Pediatric Age 0 to 19Male15106,94114.014.018.20.5361991,167,38017.3				,							6.1
Thyroid Male 33 413,914 8.0 7.3 37.5 0.522 339 4,098,359 8.3 Thyroid Female 69 421,389 16.4 15.5 81.6 0.176 744 4,058,444 18.3 Pediatric Age 0 to 19 Total 29 206,786 14.0 14.1 35.6 0.307 396 2,292,538 17.3 Pediatric Age 0 to 19 Male 15 106.941 14.0 14.0 18.2 0.536 199 1.167.380 17.4											13.3
Thyroid Female 69 421,389 16.4 15.5 81.6 0.176 744 4,058,444 18.3 Pediatric Age 0 to 19 Total 29 206,786 14.0 14.1 35.6 0.307 396 2,292,538 17.3 Pediatric Age 0 to 19 Male 15 106.941 14.0 14.0 18.2 0.536 199 1.167.380 17.3											8.3
Pediatric Age 0 to 19 Total 29 206,786 14.0 14.1 35.6 0.307 396 2,292,538 17.3 Pediatric Age 0 to 19 Male 15 106,941 14.0 14.0 18.2 0.536 199 1.167.380 17.3											18.3
Pediatric Age 0 to 19 Male 15 106.941 14.0 14.0 18.2 0.536 199 1.167.380 17.0											17.3
יין דעמובין דער איין דער אי											
Pediatric Age 0 to 19 Female 14 99,845 14.0 14.2 17.3 0.515 197 1,125,158 17.4										1 125 158	17.0

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN KOOTENAI COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Koo	tenai Count	у			Re	mainder of Idah	10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	8,689	861,287	1,008.8	874.9	8,545.7	0.123	71,846	8,350,107	860.4
All Causes of Death	Male	4,551	427,856	1,063.7	930.9	4,450.6	0.135	38,235	4,199,841	910.4
All Causes of Death	Female	4,138	433,431	954.7	822.4	4,074.7	0.325	33,611	4,150,266	809.9
All Malignant Cancers	Total	1,788	861,287	207.6	176.9	1,627.4	0.000 >>	13,445	8,350,107	161.0
All Malignant Cancers	Male	966	427,856	225.8	193.3	864.7	0.001 >>	7,269	4,199,841	173.1
All Malignant Cancers	Female	822	433,431	189.6	161.3	758.4	0.023 >>	6,176	4,150,266	148.8
Bladder	Total	52	861,287	6.0	5.1	52.5	1.000	433	8,350,107	5.2
Bladder	Male	41	427,856	9.6	8.2	39.7	0.872	334	4,199,841	8.0
Bladder	Female	11	433,431	2.5	2.1	12.2	0.875	99	4,150,266	2.4
Brain and Other Nervous System	Total	55	861,287	6.4	5.6	54.7	1.000	463	8,350,107	5.5
Brain and Other Nervous System	Male	37	427,856	8.6	7.6	29.1	0.179	252	4,199,841	6.0
Brain and Other Nervous System Breast	Female Total	18 126	433,431 861,287	4.2 14.6	3.6 12.6	25.5 119.3	0.155 0.565	211 998	4,150,266 8,350,107	5.1 12.0
Breast	Male	120	427,856	0.2	0.2	1.4	1.000	12	4,199,841	0.3
Breast	Female	125	433,431	28.8	24.7	120.1	0.680	986	4,150,266	23.8
Cervix	Female	6	433,431	1.4	1.3	9.5	0.336	82	4,150,266	2.0
Colorectal	Total	145	861,287	16.8	14.5	142.2	0.833	1,187	8,350,107	14.2
Colorectal	Male	82	427,856	19.2	16.6	76.3	0.543	650	4,199,841	15.5
Colorectal	Female	63	433,431	14.5	12.5	65.4	0.828	537	4,150,266	12.9
Corpus Uteri	Female	22	433,431	5.1	4.3	18.2	0.434	147	4,150,266	3.5
Esophagus	Total	47	861,287	5.5	4.6	50.4	0.700	414	8,350,107	5.0
Esophagus	Male	41	427,856	9.6	8.2	41.8	0.988	350	4,199,841	8.3
Esophagus	Female	6	433,431	1.4	1.2	7.9	0.656	64	4,150,266	1.5
Hodgkin Lymphoma	Total	-	861,287	-	-	3.0	0.103	25	8,350,107	0.3
Hodgkin Lymphoma	Male	-	427,856 433.431	-	-	1.6	0.385 0.539	14	4,199,841	0.3 0.3
Hodgkin Lymphoma Kidney	Female Total	- 51	433,431 861,287	- 5.9	- 5.0	1.3 40.8	0.539	11 335	4,150,266 8,350,107	4.0
Kidney	Male	32	427,856	7.5	6.4	25.4	0.133	214	4.199.841	4.0 5.1
Kidney	Female	19	433,431	4.4	3.7	15.0	0.365	121	4,150,266	2.9
Larynx	Total	6	861,287	0.7	0.6	8.5	0.514	70	8,350,107	0.8
Larynx	Male	5	427,856	1.2	1.0	7.2	0.558	60	4,199,841	1.4
Larýnx	Female	1	433,431	0.2	0.2	1.2	1.000	10	4,150,266	0.2
Leukemia	Total	67	861,287	7.8	6.6	72.2	0.588	598	8,350,107	7.2
Leukemia	Male	39	427,856	9.1	7.8	42.5	0.655	358	4,199,841	8.5
Leukemia	Female	28	433,431	6.5	5.5	29.4	0.898	240	4,150,266	5.8
Liver and Bile Duct	Total	70	861,287	8.1	6.9	68.7	0.904	565	8,350,107	6.8
Liver and Bile Duct	Male	54	427,856	12.6	10.8	43.9	0.154	369	4,199,841	8.8
Liver and Bile Duct Lung and Bronchus	Female Total	16 382	433,431 861,287	3.7 44.4	3.1 37.3	24.2 313.1	0.103 0.000 >>	196 2,555	4,150,266 8,350,107	4.7 30.6
Lung and Bronchus	Male	190	427,856	44.4	37.6	162.4	0.037 >>	1,351	4,199,841	32.2
Lung and Bronchus	Female	192	433,431	44.3	37.2	149.8	0.001 >>	1,204	4,150,266	29.0
Melanoma of the Skin	Total	43	861,287	5.0	4.3	30.8	0.044 >>	258	8,350,107	3.1
Melanoma of the Skin	Male	29	427,856	6.8	5.8	20.2	0.077	171	4,199,841	4.1
Melanoma of the Skin	Female	14	433,431	3.2	2.8	10.4	0.339	87	4,150,266	2.1
Myeloma	Total	34	861,287	3.9	3.3	35.7	0.863	291	8,350,107	3.5
Myeloma	Male	23	427,856	5.4	4.6	19.8	0.533	165	4,199,841	3.9
Myeloma	Female	11	433,431	2.5	2.1	15.7	0.287	126	4,150,266	3.0
Non-Hodgkin Lymphoma	Total	59 25	861,287	6.9	5.8	61.7	0.791	509 275	8,350,107	6.1
Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma	Male Female	35 24	427,856 433,431	8.2 5.5	7.0 4.7	32.8 28.9	0.741 0.422	275 234	4,199,841 4,150,266	6.5 5.6
Oral Cavity and Pharvnx	Total	34	433,431 861,287	5.5 3.9	4.7	20.9	0.422	234 241	4,150,266	2.9
Oral Cavity and Pharynx	Male	23	427,856	5.4	4.6	20.1	0.424	169	4,199,841	4.0
Oral Cavity and Pharynx	Female	11	433,431	2.5	2.2	8.8	0.552	72	4,150,266	1.7
Ovary	Female	38	433,431	8.8	7.4	39.9	0.848	323	4,150,266	7.8
Pancreas	Total	140	861,287	16.3	13.8	128.0	0.308	1,050	8,350,107	12.6
Pancreas	Male	77	427,856	18.0	15.3	68.5	0.336	573	4,199,841	13.6
Pancreas	Female	63	433,431	14.5	12.3	59.1	0.643	477	4,150,266	11.5
Prostate	Male	118	427,856	27.6	23.5	105.0	0.225	879	4,199,841	20.9
Stomach	Total	17	861,287	2.0	1.7	21.1	0.444	177	8,350,107	2.1
Stomach	Male	9	427,856	2.1	1.8	13.0	0.332	110	4,199,841	2.6
Stomach	Female	8	433,431	1.8	1.6	8.0	1.000	67	4,150,266	1.6

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Kootenai County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	89.5% 9.3%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	62.9% 75.8% 63.4%
Current Tobacco User (2020–2022) <u>Other Cancer-Related</u>	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	23.8%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	28.6% 80.0% 23.3% 34.7%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





LATAH COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 855 cases of invasive cancer were diagnosed among Latah County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,

 Lung and Bronchus, and Colorectal Cancers in Latah County

 and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Latah County	State of Idaho
All Sites/Types	855	47,333
Female Breast	133	6,943
Prostate	153	6,766
Lung & Bronchus	93	4,959
Colorectal	48	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Latah County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Latah County. The table also shows the number of observed cases, person-

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 285 Latah County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Latah County and the State of Idaho, 2018–2022

Mortality 2018–2022	Latah County	State of Idaho
All Deaths	1,273	80,538
Cancer Deaths	285	15,233
% of All Deaths	22.4%	18.9%
Lung & Bronchus	47	2,937
Colorectal	18	1,332
Pancreas	26	1,190
Female Breast	22	1,111
Prostate	20	997

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Latah County was 424.3 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (528.7) gives an estimate of the relative burden of disease in Latah County.

The age- and sex-adjusted incidence rate of invasive cancer in Latah County, all sites combined, was 491.6 cases per 100,000 persons per year during 2017–2021. There were statistically significantly fewer cases of cancer in Latah County (855) than expected (919.5) based upon rates in the remainder of the state (p=.033).

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Latah County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Latah County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Latah County, all sites combined, was 161.0 deaths per 100,000 persons per year during 2018–2022, compared with 165.9 for the remainder of the state. There were fewer cancer deaths in Latah County (285) than expected (293.7) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN LATAH COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			La	tah County				Ren	nainder of Ida	aho
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	855	201,498	424.3	491.6	919.5	0.033 <<	46,478	8,790,608	528.7
All Sites Combined	Male	462	102,780	449.5	524.2	495.9	0.131	24,808	4,409,493	562.6
All Sites Combined	Female	393	98,718	398.1	457.3	425.1	0.123	21,670	4,381,115	494.6
Bladder	Total	36	201,498	17.9	20.8	43.0	0.323	2,184	8,790,608	24.8
Bladder	Male	28	102,780	27.2	31.9	34.7	0.289	1,745	4,409,493	39.6
Bladder Brain malignant	Female Total	8 17	98,718 201,498	8.1 8.4	9.3 9.4	8.6 13.2	1.000 0.352	439 640	4,381,115 8,790,608	10.0
Brain - malignant Brain - malignant	Male	11	102,780	0.4 10.7	9.4 12.0	7.7	0.312	371	4,409,493	8.4
Brain - malignant	Female	6	98,718	6.1	6.7	5.5	0.942	269	4,381,115	6.1
Brain and other CNS - non-malignant	Total	33	201,498	16.4	18.8	30.2	0.659	1,514	8,790,608	17.2
Brain and other CNS - non-malignant	Male	9	102,780	8.8	10.1	9.9	0.931	491	4,409,493	11.1
	Female	24	98,718	24.3	27.8	20.2	0.446	1,023	4,381,115	23.4
Breast	Total	133	201,498	66.0	77.9	133.5	1.000	6,875	8,790,608	78.2
Breast Breast	Male Female	- 133	102,780 98,718	- 134.7	- 158.0	1.3 130.8	0.553 0.871	65 6,810	4,409,493 4,381,115	1.5 155.4
Breast - in situ	Total	37	201,498	18.4	21.9	25.6	0.040 >>	1,332	8,790,608	15.2
Breast - in situ	Male	1	102,780	1.0	1.2	0.1	0.112	3	4,409,493	0.1
Breast - in situ	Female	36	98,718	36.5	43.2	25.3	0.051	1,329	4,381,115	30.3
Cervix	Female	5	98,718	5.1	5.8	5.7	0.991	289	4,381,115	6.6
Colorectal	Total	48	201,498	23.8	27.7	70.6	0.006 <<	3,584	8,790,608	40.8
Colorectal	Male	28	102,780	27.2	32.1	38.5	0.097	1,949	4,409,493	44.2
Colorectal Corpus Uteri	Female Female	20 25	98,718 98,718	20.3 25.3	23.2 29.6	32.1 25.6	0.030 << 1.000	1,635 1,329	4,381,115 4,381,115	37.3 30.3
Esophagus	Total	14	201,498	6.9	29.0	9.6	0.221	493	8,790,608	5.6
Esophagus	Male	14	102,780	11.7	13.8	8.2	0.221	493	4,409,493	9.5
Esophagus	Female	2	98,718	2.0	2.3	1.5	0.869	76	4,381,115	1.7
Hodgkin Lymphoma	Total	2	201,498	1.0	0.9	5.8	0.138	220	8,790,608	2.5
Hodgkin Lymphoma	Male	1	102,780	1.0	0.9	3.3	0.324	128	4,409,493	2.9
Hodgkin Lymphoma	Female	1	98,718	1.0	0.8	2.6	0.542	92	4,381,115	2.1
Kidney and Renal Pelvis	Total Male	30	201,498	14.9	17.5	37.4	0.255	1,921	8,790,608	21.9
Kidney and Renal Pelvis Kidney and Renal Pelvis	Female	22 8	102,780 98,718	21.4 8.1	25.4 9.5	25.3 12.2	0.590 0.281	1,288 633	4,409,493 4,381,115	29.2 14.4
Larynx	Total	2	201,498	1.0	1.2	4.3	0.398	218	8,790,608	2.5
Larynx	Male	1	102,780	1.0	1.2	3.3	0.324	166	4,409,493	3.8
Larýnx	Female	1	98,718	1.0	1.1	1.0	1.000	52	4,381,115	1.2
Leukemia	Total	25	201,498	12.4	14.3	33.8	0.144	1,702	8,790,608	19.4
Leukemia	Male	11	102,780	10.7	12.5	20.5	0.034 <<	1,025	4,409,493	23.2
Leukemia Liver and Bile Duct	Female Total	14	98,718	14.2	16.1	13.4	0.941 0.351	677	4,381,115	15.5 9.5
Liver and Bile Duct	Male	12 11	201,498 102,780	6.0 10.7	7.0 12.6	16.3 11.5	1.000	831 583	8,790,608 4,409,493	9.5 13.2
Liver and Bile Duct	Female	1	98,718	1.0	1.2	4.8	0.092	248	4,381,115	5.7
Lung and Bronchus	Total	93	201,498	46.2	54.0	95.3	0.870	4,866	8,790,608	55.4
Lung and Bronchus	Male	43	102,780	41.8	49.1	48.7	0.464	2,452	4,409,493	55.6
Lung and Bronchus	Female	50	98,718	50.6	59.1	46.6	0.661	2,414	4,381,115	55.1
Melanoma of the Skin	Total	46	201,498	22.8	26.3	61.7	0.045 <<	3,098	8,790,608	35.2
Melanoma of the Skin	Male	25	102,780	24.3	28.4	37.4	0.042 <<	1,870	4,409,493	42.4
Melanoma of the Skin Myeloma	Female Total	21 13	98,718 201,498	21.3 6.5	24.1 7.6	24.5 14.0	0.565 0.937	1,228 715	4,381,115 8,790,608	28.0 8.1
Myeloma	Male	10	102,780	9.7	7.0 11.5	8.6	0.937	437	4,409,493	9.9
Myeloma	Female	3	98,718	3.0	3.5	5.4	0.435	278	4,381,115	6.3
Non-Hodgkin Lymphoma	Total	40	201,498	19.9	22.7	39.1	0.931	1,952	8,790,608	22.2
Non-Hodgkin Lymphoma	Male	25	102,780	24.3	28.0	22.7	0.685	1,121	4,409,493	25.4
Non-Hodgkin Lymphoma	Female	15	98,718	15.2	17.2	16.5	0.832	831	4,381,115	19.0
Oral Cavity and Pharynx	Total	29 24	201,498	14.4	16.9 27.7	25.1	0.487	1,286	8,790,608	14.6
Oral Cavity and Pharynx Oral Cavity and Pharynx	Male Female	24 5	102,780 98,718	23.4 5.1	27.7 5.9	18.0 7.2	0.201 0.549	916 370	4,409,493 4,381,115	20.8 8.4
Ovary	Female	7	98,718	7.1	8.1	10.8	0.310	546	4,381,115	12.5
Pancreas	Total	29	201,498	14.4	16.8	28.7	1.000	1,459	8,790,608	16.6
Pancreas	Male	13	102,780	12.6	14.8	16.1	0.526	813	4,409,493	18.4
Pancreas	Female	16	98,718	16.2	18.7	12.6	0.409	646	4,381,115	14.7
Prostate	Male	153	102,780	148.9	175.3	130.9	0.063	6,613	4,409,493	
Stomach	Total	7	201,498	3.5	4.0	9.2	0.601	467	8,790,608	5.3
Stomach Stomach	Male Female	6 1	102,780 98,718	5.8 1.0	6.9 1.2	5.9 3.3	1.000 0.321	301 166	4,409,493 4,381,115	6.8 3.8
Stomach Testis	Female Male	1	98,718	3.9	3.4	3.3 7.2	0.321	270	4,381,115	<u> </u>
Thyroid	Total	4 19	201,498	9.4	9.9	25.5	0.300	1,166	8,790,608	13.3
Thyroid	Male	4	102,780	9.4 3.9	9.9 4.4	7.5	0.258	368	4,409,493	8.3
Thyroid	Female	15	98,718	15.2	4.4 15.4	17.7	0.238	798	4,381,115	18.2
Pediatric Age 0 to 19	Total	5	49,735	10.1	9.6	8.9	0.018	420	2,449,589	17.1
Pediatric Age 0 to 19	Male	4	25,061	16.0	15.8	4.3	1.000	210	1,249,260	16.8
Pediatric Age 0 to 19	Female	4	24,674	4.1	3.8	4.3	0.107	210	1,200,329	17.5

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN LATAH COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			La	tah County				Re	mainder of Idah	10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	1,273	202,573	628.4	693.2	1,615.8	0.000 <<	79,262	9,008,821	879.8
All Causes of Death	Male	667	103,314	645.6	721.0	861.3	0.000 <<	42,119	4,524,383	930.9
All Causes of Death	Female	606	99,259	610.5	662.4	757.8	>> 000.0	37,143	4,484,438	828.3
All Malignant Cancers	Total	285	202,573	140.7	161.0	293.7	0.636	14,948	9,008,821	165.9
All Malignant Cancers	Male	153	103,314	148.1	170.7	160.1	0.607	8,082	4,524,383	178.6
All Malignant Cancers	Female	132	99,259	133.0	150.9	133.9	0.915	6,866	4,484,438	153.1
Bladder	Total	9	202,573	4.4	5.0	9.6	1.000	476	9,008,821	5.3
Bladder	Male	8	103,314	7.7	8.8	7.4	0.920	367	4,524,383	8.1
Bladder	Female	1	99,259	1.0	1.1	2.2	0.717	109	4,484,438	2.4
Brain and Other Nervous System	Total Male	13 6	202,573	6.4 5.8	7.3 6.5	10.0	0.413 1.000	505 283	9,008,821 4,524,383	5.6 6.3
Brain and Other Nervous System Brain and Other Nervous System	Female	0 7	103,314 99,259	5.0 7.1	6.5 8.1	5.7 4.3	0.285	203	4,524,363 4,484,438	6.3 5.0
Breast	Total	22	202,573	10.9	12.4	21.6	0.205	1,102	9,008,821	12.2
Breast	Male	-	103,314	-	-	0.3	1.000	13	4,524,383	0.3
Breast	Female	22	99,259	22.2	25.1	21.3	0.931	1,089	4,484,438	24.3
Cervix	Female	-	99,259	-	-	1.7	0.357	88	4,484,438	2.0
Colorectal	Total	18	202,573	8.9	10.2	25.7	0.145	1,314	9,008,821	14.6
Colorectal	Male	8	103,314	7.7	9.1	14.1	0.116	724	4,524,383	16.0
Colorectal	Female	10	99,259	10.1	11.4	11.6	0.783	590	4,484,438	13.2
Corpus Uteri	Female	6	99,259	6.0	6.9	3.1	0.197	163	4,484,438	3.6
Esophagus	Total	14	202,573	6.9	8.0	8.6	0.115	447	9,008,821	5.0
Esophagus	Male	12	103,314	11.6	13.6	7.4	0.149	379	4,524,383	8.4
Esophagus	Female	2	99,259	2.0	2.3	1.3	0.753	68	4,484,438 9.008.821	1.5
Hodgkin Lymphoma Hodgkin Lymphoma	Total Male	-	202,573 103,314	-	-	0.5 0.3	1.000 1.000	25 14	4,524,383	0.3 0.3
Hodgkin Lymphoma	Female	-	99,259	-	-	0.3	1.000	14	4,484,438	0.3
Kidney	Total	- 5	202,573	- 2.5	- 2.8	7.5	0.483	381	9,008,821	4.2
Kidney	Male	4	103,314	3.9	4.5	4.8	0.960	242	4,524,383	5.3
Kidney	Female	1	99,259	1.0	1.1	2.7	0.483	139	4,484,438	3.1
Larynx	Total	-	202,573	-	-	1.5	0.460	76	9,008,821	0.8
Larynx	Male	-	103,314	-	-	1.3	0.557	65	4,524,383	1.4
Larynx	Female	-	99,259	-	-	0.2	1.000	11	4,484,438	0.2
Leukemia	Total	16	202,573	7.9	9.0	12.8	0.442	649	9,008,821	7.2
Leukemia	Male	8	103,314	7.7	8.9	7.8	1.000	389	4,524,383	8.6
Leukemia	Female	8 16	99,259 202,573	8.1	9.1 9.2	5.1	0.290 0.313	260	4,484,438 9,008,821	5.8 6.9
Liver and Bile Duct Liver and Bile Duct	Total Male	10	202,573	7.9 11.6	9.2 13.5	12.0 8.1	0.313	619 411	4,524,383	0.9 9.1
Liver and Bile Duct	Female	4	99,259	4.0	4.7	4.0	1.000	208	4,484,438	4.6
Lung and Bronchus	Total	47	202,573	23.2	26.8	56.3	0.235	2,890	9,008,821	32.1
Lung and Bronchus	Male	23	103,314	22.3	25.8	29.9	0.236	1,518	4,524,383	33.6
Lung and Bronchus	Female	24	99,259	24.2	27.7	26.5	0.720	1,372	4,484,438	30.6
Melanoma of the Skin	Total	9	202,573	4.4	5.1	5.7	0.252	292	9,008,821	3.2
Melanoma of the Skin	Male	4	103,314	3.9	4.5	3.8	1.000	196	4,524,383	4.3
Melanoma of the Skin	Female	5	99,259	5.0	5.6	1.9	0.089	96	4,484,438	2.1
Myeloma	Total	4	202,573	2.0	2.3	6.3	0.495	321	9,008,821	3.6
Myeloma	Male	1	103,314	1.0	1.1	3.7	0.230	187	4,524,383	4.1
Myeloma Non-Hodgkin Lymphoma	Female	3 12	99,259 202,573	3.0 5.9	3.5	2.6 11.0	0.956	134	4,484,438	3.0 6.2
	Total Male	12			6.8 7.8		0.834 0.796	556	9,008,821	6.2 6.7
Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma	Female	7 5	103,314 99,259	6.8 5.0	7.8 5.7	6.0 5.0	1.000	303 253	4,524,383 4,484,438	5.6
Oral Cavity and Pharynx	Total	4	202,573	2.0	2.3	5.3	0.789	233	9,008,821	3.0
Oral Cavity and Pharynx	Male	4	103,314	3.9	4.5	3.7	1.000	188	4,524,383	4.2
Oral Cavity and Pharynx	Female	- '	99,259	-	-	1.6	0.404	83	4.484.438	1.9
Ovary	Female	5	99,259	5.0	5.8	6.8	0.641	356	4,484,438	7.9
Pancreas	Total	26	202,573	12.8	14.8	22.6	0.534	1,164	9,008,821	12.9
Pancreas	Male	13	103,314	12.6	14.6	12.5	0.963	637	4,524,383	14.1
Pancreas	Female	13	99,259	13.1	15.0	10.2	0.456	527	4,484,438	11.8
Prostate	Male	20	103,314	19.4	22.0	19.6	0.996	977	4,524,383	21.6
Stomach	Total	4	202,573	2.0	2.3	3.7	1.000	190	9,008,821	2.1
Stomach	Male	3	103,314	2.9	3.4	2.3	0.794	116	4,524,383	2.6
Stomach	Female	1	99,259	1.0	1.2	1.4	1.000	74	4,484,438	1.7

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Latah County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	91.9% 9.8%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	70.8% 76.2% 59.5%
Current Tobacco User (2020–2022) <u>Other Cancer-Related</u>	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	21.1%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	35.1% 85.2% 23.3% 21.0%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





LEMHI COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 328 cases of invasive cancer were diagnosed among Lemhi County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in LemhiCounty and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Lemhi County	State of Idaho
All Sites/Types	328	47,333
Female Breast	37	6,943
Prostate	75	6,766
Lung & Bronchus	39	4,959
Colorectal	20	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Lemhi County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Lemhi County. The table also shows the number of observed cases, person-

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 125 Lemhi County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Lemhi County and the State of Idaho, 2018–2022

Mortality 2018–2022	Lemhi County	State of Idaho
All Deaths	630	80,538
Cancer Deaths	125	15,233
% of All Deaths	19.8%	18.9%
Lung & Bronchus	29	2,937
Colorectal	13	1,332
Pancreas	10	1,190
Female Breast	8	1,111
Prostate	10	997

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Lemhi County was 818.6 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (525.1) gives an estimate of the relative burden of disease in Lemhi County.

The age- and sex-adjusted incidence rate of invasive cancer in Lemhi County, all sites combined, was 505.4 cases per 100,000 persons per year during 2017–2021. There were fewer cases of cancer in Lemhi County (328) than expected (340.8) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Lemhi County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Lemhi County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Lemhi County, all sites combined, was 175.6 deaths per 100,000 persons per year during 2018–2022, compared with 164.7 for the remainder of the state. There were more cancer deaths in Lemhi County (125) than expected (117.3) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN LEMHI COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Lemhi County							Remainder of Idaho				
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude			
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)		P-Value (4)	Cases	Years	Rate (1)			
All Sites Combined	Total	328	40,068	818.6	505.4	340.8	0.510	47,005	8,952,038	525.1			
All Sites Combined	Male	199	20,301	980.2	557.4	199.3	1.000	25,071	4,491,972	558.1			
All Sites Combined	Female	129	19,767	652.6	435.0	145.8	0.172	21,934	4,460,066	491.8			
Bladder	Total	17	40,068	42.4	23.5	17.8	0.969	2,203	8,952,038	24.6			
Bladder	Male	14	20,301	69.0	35.3	15.5	0.826	1,759	4,491,972	39.2			
Bladder Brein melignent	Female Total	3	19,767 40,068	15.2 2.5	9.1 1.8	3.3 4.1	1.000 0.166	444 656	4,460,066 8,952,038	10.0 7.3			
Brain - malignant Brain - malignant	Male	- '	20,301	2.5	1.0	2.5	0.168	382	4,491,972	8.5			
Brain - malignant	Female	- 1	19,767	5.1	3.7	1.7	1.000	274	4,460,066	6.1			
Brain and other CNS - non-malignant	Total	10	40,068	25.0	16.5	10.4	1.000	1,537	8,952,038	17.2			
Brain and other CNS - non-malignant		2	20,301	9.9	6.4	3.5	0.653	498	4,491,972	11.1			
	Female	8	19,767	40.5	27.6	6.7	0.728	1,039	4,460,066	23.3			
Breast	Total	37	40,068	92.3	60.7	47.4	0.141	6,971	8,952,038	77.9			
Breast Breast	Male Female	- 37	20,301 19,767	- 187.2	- 127.8	0.5 44.8	1.000 0.270	65 6,906	4,491,972 4,460,066	1.4 154.8			
Breast - in situ	Total	5	40,068	107.2	8.5	8.9	0.270	1,364	8,952,038	154.0			
Breast - in situ	Male	-	20,301	-	-	0.0	1.000	4	4,491,972	0.1			
Breast - in situ	Female	5	19,767	25.3	17.8	8.6	0.288	1,360	4,460,066	30.5			
Cervix	Female	1	19,767	5.1	4.7	1.4	1.000	293	4,460,066	6.6			
Colorectal	Total	20	40,068	49.9	31.4	25.7	0.302	3,612	8,952,038	40.3			
Colorectal	Male	14	20,301	69.0	41.6	14.7	0.990	1,963	4,491,972	43.7			
Colorectal Corpus Uteri	Female Female	6 7	19,767 19,767	30.4 35.4	19.9 23.7	11.2 8.9	0.145 0.668	1,649 1,347	4,460,066	37.0 30.2			
Esophagus	Total	6	40,068	35.4 15.0	8.8	3.8	0.000	501	8,952,038	5.6			
Esophagus	Male	6	20,301	29.6	16.4	3.4	0.271	423	4,491,972	9.4			
Esophagus	Female	-	19,767	-	-	0.6	1.000	78	4,460,066	1.7			
Hodgkin Lymphoma	Total	-	40,068	-	-	1.1	0.670	222	8,952,038	2.5			
Hodgkin Lymphoma	Male	-	20,301	-	-	0.7	1.000	129	4,491,972	2.9			
Hodgkin Lymphoma	Female	-	19,767	-	-	0.4	1.000	93	4,460,066	2.1			
Kidney and Renal Pelvis	Total Male	12	40,068	29.9	18.9	13.8	0.766	1,939	8,952,038	21.7			
Kidney and Renal Pelvis Kidney and Renal Pelvis	Female	8 4	20,301 19,767	39.4 20.2	23.8 13.3	9.7 4.3	0.728 1.000	1,302 637	4,491,972 4,460,066	29.0 14.3			
Larynx	Total		40,068	- 20.2	-	1.6	0.386	220	8,952,038	2.5			
Larynx	Male	-	20,301	-	-	1.3	0.520	167	4,491,972	3.7			
Larynx	Female	-	19,767	-	-	0.4	1.000	53	4,460,066	1.2			
Leukemia	Total	5	40,068	12.5	7.7	12.5	0.030 <<	1,722	8,952,038	19.2			
Leukemia	Male	2	20,301	9.9	5.7	8.0	0.027 <<	1,034	4,491,972	23.0			
Leukemia Liver and Bile Duct	Female Total	3	19,767	15.2	9.9 10.4	4.7	0.629 0.877	688	4,460,066	15.4 9.3			
Liver and Bile Duct	Male	4	40,068 20,301	17.5 19.7	10.4	6.3 4.7	1.000	836 590	8,952,038 4,491,972	9.3			
Liver and Bile Duct	Female	3	19,767	15.2	9.4	1.8	0.514	246	4,460,066	5.5			
Lung and Bronchus	Total	39	40,068	97.3	54.3	39.5	1.000	4,920	8,952,038	55.0			
Lung and Bronchus	Male	24	20,301	118.2	61.4	21.5	0.647	2,471	4,491,972	55.0			
Lung and Bronchus	Female	15	19,767	75.9	45.2	18.2	0.536	2,449	4,460,066	54.9			
Melanoma of the Skin	Total	18	40,068	44.9	29.1	21.6	0.514	3,126	8,952,038	34.9			
Melanoma of the Skin	Male	10	20,301	49.3	28.8	14.6	0.284	1,885	4,491,972	42.0			
Melanoma of the Skin Myeloma	Female Total	8 5	19,767 40,068	40.5 12.5	29.1 7.2	7.6 5.6	0.994	1,241 723	4,460,066 8,952,038	27.8 8.1			
Myeloma	Male	3	20,301	12.5	8.1	3.7	0.997	444	4,491,972	9.9			
Myeloma	Female	2	19,767	10.1	6.2	2.0	1.000	279	4,460,066	6.3			
Non-Hodgkin Lymphoma	Total	11	40,068	27.5	17.0	14.3	0.470	1,981	8,952,038	22.1			
Non-Hodgkin Lymphoma	Male	8	20,301	39.4	23.4	8.7	1.000	1,138	4,491,972	25.3			
Non-Hodgkin Lymphoma	Female	3	19,767	15.2	9.8	5.8	0.338	843	4,460,066	18.9			
Oral Cavity and Pharynx	Total	10	40,068	25.0	15.6	9.4	0.922	1,305	8,952,038	14.6			
Oral Cavity and Pharynx Oral Cavity and Pharynx	Male Female	8 2	20,301 19,767	39.4 10.1	23.8 6.5	7.0 2.6	0.799 1.000	932 373	4,491,972 4,460,066	20.7 8.4			
Ovary	Female	6	19,767	30.4	20.9	3.5	0.292	547	4,460,066	12.3			
Pancreas	Total	13	40,068	32.4	18.7	11.5	0.729	1,475	8,952,038	16.5			
Pancreas	Male	7	20,301	34.5	18.7	6.8	1.000	819	4,491,972	18.2			
Pancreas	Female	6	19,767	30.4	18.4	4.8	0.693	656	4,460,066	14.7			
Prostate	Male	75	20,301	369.4	204.3	54.7	0.011 >>	6,691	4,491,972	149.0			
Stomach	Total	2	40,068	5.0	3.0	3.5	0.639	472	8,952,038	5.3			
Stomach Stomach	Male Female	2	20,301 19,767	9.9	5.5 -	2.5 1.1	1.000 0.645	305 167	4,491,972 4,460,066	6.8 3.7			
Testis	Female Male	- 1	20,301	- 4.9	- 6.2	1.1	1.000	273	4,460,066	<u> </u>			
Thyroid	Total	5	40,068	12.5	10.2	6.2	0.843	1,180	8,952,038	13.2			
Thyroid	Male		20,301	-	-	2.3	0.843	372	4,491,972	8.3			
Thyroid	Female	- 5	19,767	25.3	23.3	3.9	0.699	808	4,460,066	18.1			
Pediatric Age 0 to 19	Total	1	8,021	12.5	12.5	1.4	1.000	424	2,491,303	17.0			
Pediatric Age 0 to 19	Male	_ '	4,228	-	-	0.7	0.980	214	1,270,093	16.8			
		1	3,793	26.4	26.4	0.7	0.956	210	1,221,210	17.2			

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN LEMHI COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Lei	Re	Remainder of Idaho					
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Crude	
Cancer Site/Type	Sex	Deaths	Years		Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Person Years	Rate (1)
All Causes of Death	Total	630	40,471	1,556.7	895.8	612.7	0.496	79,905	9,170,923	871.3
All Causes of Death	Male	367	20,539	1,786.8	972.8	347.3	0.304	42,419	4,607,158	920.7
All Causes of Death	Female	263	19,932	1,319.5	797.8	270.8	0.665	37,486	4,563,765	821.4
All Malignant Cancers	Total	125	40,471	308.9	175.6	117.3	0.500	15,108	9,170,923	164.7
All Malignant Cancers	Male	77	20,539	374.9	197.1	69.2	0.376	8,158	4,607,158	177.1
All Malignant Cancers	Female	48	19,932	240.8	146.6	49.9	0.864	6,950	4,563,765	152.3
Bladder	Total	5	40,471	12.4	6.6	4.0	0.730	480	9,170,923	5.2
Bladder	Male	5	20,539	24.3	11.8	3.4	0.509	370	4,607,158	8.0
Bladder	Female	-	19,932	-	-	0.8	0.866	110	4,563,765	2.4
Brain and Other Nervous System	Total	1	40,471	2.5	1.6	3.5	0.263	517	9,170,923	5.6
Brain and Other Nervous System	Male	-	20,539	-	-	2.1	0.253	289	4,607,158	6.3
Brain and Other Nervous System	Female	1	19,932	5.0	3.3	1.5	1.000	228	4,563,765	5.0
Breast	Total	8	40,471	19.8	11.8	8.3	1.000	1,116	9,170,923	12.2
Breast	Male	-	20,539	-	-	0.1	1.000	13	4,607,158	0.3
Breast	Female	8	19,932	40.1	25.3	7.7	0.995	1,103	4,563,765	24.2
Cervix	Female	- 13	19,932	-	- 19.1	0.5	1.000	88	4,563,765	1.9
Colorectal	Total Male		40,471 20,539	32.1 48.7	19.1 27.9	9.8 5.6	0.376 0.121	1,319 722	9,170,923 4,607,158	14.4 15.7
Colorectal Colorectal	Male Female	10 3	20,539	48.7 15.1	27.9 9.3	5.6 4.2	0.121	722 597	4,607,158 4,563,765	15.7
Colorectal Corpus Uteri	Female	-	19,932	10.1 -	9.3	4.2	0.786	169	4,563,765	3.7
Esophagus	Total	- 2	40,471	- 4.9	- 2.8	3.5	0.632	459	9,170,923	5.0
Esophagus	Male	2	20,539	9.7	5.3	3.2	0.759	389	4,607,158	8.4
Esophagus	Female	-	19,932	-	-	0.5	1.000	70	4,563,765	1.5
Hodgkin Lymphoma	Total	-	40,471	-	-	0.0	1.000	25	9,170,923	0.3
Hodgkin Lymphoma	Male	-	20,539	-	-	0.1	1.000	14	4,607,158	0.3
Hodgkin Lymphoma	Female	-	19,932	-	_	0.1	1.000	11	4,563,765	0.2
Kidney	Total	4	40,471	9.9	5.5	3.0	0.726	382	9,170,923	4.2
Kidney	Male	2	20,539	9.7	5.1	2.1	1.000	244	4,607,158	5.3
Kidney	Female	2	19,932	10.0	5.8	1.0	0.561	138	4,563,765	3.0
Larynx	Total	-	40,471	-	-	0.6	1.000	76	9,170,923	0.8
Larynx	Male	-	20,539	-	-	0.5	1.000	65	4,607,158	1.4
Larynx	Female	-	19,932	-	-	0.1	1.000	11	4,563,765	0.2
Leukemia	Total	3	40,471	7.4	4.2	5.2	0.473	662	9,170,923	7.2
Leukemia	Male	1	20,539	4.9	2.5	3.4	0.291	396	4,607,158	8.6
Leukemia	Female	2	19,932	10.0	6.0	1.9	1.000	266	4,563,765	5.8
Liver and Bile Duct	Total	(40,471	17.3	10.0	4.8	0.419	628	9,170,923	6.8
Liver and Bile Duct	Male	4	20,539	19.5	10.7	3.4	0.881	419	4,607,158	9.1
Liver and Bile Duct	Female	3	19,932	15.1	9.1	1.5	0.388	209	4,563,765	4.6
Lung and Bronchus	Total Male	29 19	40,471 20,539	71.7 92.5	39.4 47.6	23.3	0.285 0.156	2,908	9,170,923	31.7 33.0
Lung and Bronchus Lung and Bronchus	Female	19	20,539	92.5 50.2	47.6 29.4	13.2 10.3	1.000	1,522 1,386	4,607,158 4,563,765	33.0 30.4
Melanoma of the Skin	Total	3	40,471	50.2 7.4	29.4	2.2	0.760	298	9,170,923	30.4
Melanoma of the Skin	Male	3	20,539	14.6	4.4 8.0	1.6	0.433	197	4,607,158	4.3
Melanoma of the Skin	Female	-	19,932	-	-	0.7	1.000	101	4,563,765	2.2
Myeloma	Total	2	40,471	4.9	2.7	2.6	1.000	323	9,170,923	3.5
Myeloma	Male	1	20,539	4.9	2.4	1.7	1.000	187	4,607,158	4.1
Myeloma	Female	1	19,932	5.0	2.9	1.0	1.000	136	4,563,765	3.0
Non-Hodgkin Lymphoma	Total	5	40,471	12.4	6.9	4.4	0.917	563	9,170,923	6.1
Non-Hodgkin Lýmphoma	Male	4	20,539	19.5	10.3	2.6	0.522	306	4,607,158	6.6
Non-Hodgkin Lymphoma	Female	1	19,932	5.0	3.0	1.9	0.863	257	4,563,765	5.6
Oral Cavity and Pharynx	Total	2	40,471	4.9	2.9	2.1	1.000	273	9,170,923	3.0
Oral Cavity and Pharynx	Male	1	20,539	4.9	2.6	1.6	1.000	191	4,607,158	4.1
Oral Cavity and Pharynx	Female	1	19,932	5.0	3.1	0.6	0.879	82	4,563,765	1.8
Ovary	Female	4	19,932	20.1	12.3	2.6	0.508	357	4,563,765	7.8
Pancreas	Total	10	40,471	24.7	13.9	9.2	0.888	1,180	9,170,923	12.9
Pancreas	Male	5	20,539	24.3	12.9	5.4	1.000	645	4,607,158	14.0
Pancreas	Female	5	19,932	25.1	15.0	3.9	0.708	535	4,563,765	11.7
Prostate	Male	10	20,539	48.7	23.5	9.1	0.859	987	4,607,158	21.4
Stomach	Total	3	40,471	7.4	4.6	1.4	0.318	191	9,170,923	2.1
Stomach	Male	2	20,539	9.7	5.5	0.9	0.478	117	4,607,158	2.5
Stomach	Female	1	19,932	5.0	3.4	0.5	0.760	74	4,563,765	1.6

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Lemhi County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	6.1%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	53.2%
Current Tobacco User (2020–2022) <u>Other Cancer-Related</u>	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	27.2%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	34.7% 74.3% 18.9% 24.1%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





LEWIS COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 153 cases of invasive cancer were diagnosed among Lewis County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in LewisCounty and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Lewis County	State of Idaho
All Sites/Types	153	47,333
Female Breast	23	6,943
Prostate	24	6,766
Lung & Bronchus	26	4,959
Colorectal	12	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Lewis County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Lewis County. The table also shows the number of observed cases, person-

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 55 Lewis County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Lewis County and the State of Idaho, 2018–2022

Mortality 2018–2022	Lewis County	State of Idaho
All Deaths	280	80,538
Cancer Deaths	55	15,233
% of All Deaths	19.6%	18.9%
Lung & Bronchus	12	2,937
Colorectal	3	1,332
Pancreas	3	1,190
Female Breast	0	1,111
Prostate	4	997

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Lewis County was 800.6 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (525.8) gives an estimate of the relative burden of disease in Lewis County.

The age- and sex-adjusted incidence rate of invasive cancer in Lewis County, all sites combined, was 544.8 cases per 100,000 persons per year during 2017–2021. There were more cases of cancer in Lewis County (153) than expected (147.7) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Lewis County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Lewis County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Lewis County, all sites combined, was 180.7 deaths per 100,000 persons per year during 2018–2022, compared with 165.1 for the remainder of the state. There were more cancer deaths in Lewis County (55) than expected (50.3) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN LEWIS COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Le	wis County				Remainder of Idaho			
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude	
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)		P-Value (4)	Cases	Years	Rate (1)	
All Sites Combined	Total	153	19,110	800.6	544.8	147.7	0.682	47,180	8,972,996	525.8	
All Sites Combined	Male	90	9,693	928.5	586.2	85.9	0.683	25,180	4,502,580	559.2	
All Sites Combined	Female	63	9,417	669.0	487.2	63.6	1.000	22,000	4,470,416	492.1	
Bladder	Total	9	19,110	47.1	29.0	7.7	0.720	2,211	8,972,996	24.6	
Bladder	Male	6	9,693	61.9	35.6	6.6	1.000	1,767	4,502,580	39.2	
Bladder Brain molignent	Female Total	3	9,417 19,110	31.9	21.0	1.4 1.8	0.341 0.319	444 657	4,470,416 8,972,996	9.9 7.3	
Brain - malignant Brain - malignant	Male	-	9,693	-	-	1.0	0.667	382	4,502,580	8.5	
Brain - malignant	Female	_	9,417	-	_	0.7	0.946	275	4,470,416	6.2	
Brain and other CNS - non-malignant	Total	5	19,110	26.2	18.9	4.6	0.956	1,542	8,972,996	17.2	
	Male	3	9,693	31.0	21.9	1.5	0.388	497	4,502,580	11.0	
	Female	2	9,417	21.2	15.7	3.0	0.859	1,045	4,470,416	23.4	
Breast	Total	23	19,110	120.4	86.9	20.6	0.655	6,985	8,972,996	77.8	
Breast	Male Female	- 23	9,693 9,417	- 244.2	- 182.1	0.2 19.5	1.000 0.491	65	4,502,580 4,470,416	1.4	
Breast Breast - in situ	Female Total	23	9,417 19,110	244.2	7.8	3.9	0.491 0.511	6,920 1,367	4,470,416 8,972,996	154.8 15.2	
Breast - in situ	Male		9,693	10.5	7.0	0.0	1.000	1,507	4,502,580	0.1	
Breast - in situ	Female	- 2	9,417	21.2	16.3	3.7	0.557	1,363	4,470,416	30.5	
Cervix	Female	-	9,417	-	-	0.6	1.000	294	4,470,416	6.6	
Colorectal	Total	12	19,110	62.8	43.2	11.2	0.891	3,620	8,972,996	40.3	
Colorectal	Male	10	9,693	103.2	68.3	6.4	0.228	1,967	4,502,580	43.7	
Colorectal	Female	2	9,417	21.2	15.1	4.9	0.269	1,653	4,470,416	37.0	
Corpus Uteri	Female	4	9,417	42.5	31.5	3.8	1.000	1,350	4,470,416	30.2	
Esophagus	Total	2 1	19,110	10.5	6.8	1.7 1.5	0.990 1.000	505	8,972,996	5.6 9.5	
Esophagus	Male Female	1	9,693 9,417	10.3 10.6	6.3 7.2	1.5 0.2	0.424	428 77	4,502,580 4.470.416	9.5 1.7	
Esophagus Hodgkin Lymphoma	Total		9,417	-	1.Z	0.2	1.000	222	8,972,996	2.5	
Hodgkin Lymphoma	Male	-	9,693	-	_	0.3	1.000	129	4,502,580	2.9	
Hodgkin Lymphoma	Female	-	9,417	-	_	0.2	1.000	93	4,470,416	2.1	
Kidney and Renal Pelvis	Total	6	19,110	31.4	21.7	6.0	1.000	1,945	8,972,996	21.7	
Kidney and Renal Pelvis	Male	3	9,693	31.0	20.6	4.2	0.779	1,307	4,502,580	29.0	
Kidney and Renal Pelvis	Female	3	9,417	31.9	22.9	1.9	0.578	638	4,470,416	14.3	
Larynx	Total	1	19,110	5.2	3.4	0.7	1.000	219	8,972,996	2.4	
Larynx	Male	1	9,693	10.3	6.3	0.6	0.886	166	4,502,580	3.7	
Larynx Leukemia	Female Total	- 3	9,417 19,110	- 15.7	- 10.6	0.2 5.4	1.000 0.421	53	4,470,416	1.2 19.2	
Leukemia	Male	3	9,693	31.0	10.0	3.5	1.000	1,724 1,033	8,972,996 4,502,580	22.9	
Leukemia	Female		9,417	-	-	2.1	0.257	691	4,470,416	15.5	
Liver and Bile Duct	Total	2	19,110	10.5	6.9	2.7	0.988	841	8,972,996	9.4	
Liver and Bile Duct	Male	2	9,693	20.6	13.1	2.0	1.000	592	4,502,580	13.1	
Liver and Bile Duct	Female	-	9,417	-	-	0.8	0.936	249	4,470,416	5.6	
Lung and Bronchus	Total	26	19,110	136.1	84.4	16.9	0.048 >>	4,933	8,972,996	55.0	
Lung and Bronchus	Male	15	9,693	154.8	90.3	9.1	0.093	2,480	4,502,580	55.1	
Lung and Bronchus	Female	11	9,417	116.8	76.6	7.9	0.346	2,453	4,470,416	54.9	
Melanoma of the Skin Melanoma of the Skin	Total Male	7 5	19,110 9,693	36.6 51.6	26.0 33.5	9.4 6.3	0.555 0.806	3,137 1,890	8,972,996 4,502,580	35.0 42.0	
Melanoma of the Skin Melanoma of the Skin	Female	5 2	9,693 9,417	21.2	33.5 16.6	0.3 3.4	0.606	1,090	4,502,580	42.0 27.9	
Myeloma	Total	4	19,110	21.2	13.4	2.4	0.092	724	8,972,996	8.1	
Myeloma	Male	3	9,693	31.0	18.8	1.6	0.420	444	4,502,580	9.9	
Myeloma	Female	1	9,417	10.6	7.2	0.9	1.000	280	4,470,416	6.3	
Non-Hodgkin Lymphoma	Total	4	19,110	20.9	14.3	6.2	0.514	1,988	8,972,996	22.2	
Non-Hodgkin Lymphoma	Male	4	9,693	41.3	27.1	3.7	1.000	1,142	4,502,580	25.4	
Non-Hodgkin Lymphoma	Female	-	9,417	-	-	2.5	0.158	846	4,470,416	18.9	
Oral Cavity and Pharynx Oral Cavity and Pharynx	Total Malo	4 3	19,110	20.9	14.4	4.1	1.000	1,311	8,972,996	14.6	
Oral Cavity and Pharynx Oral Cavity and Pharynx	Male Female	3 1	9,693 9,417	31.0 10.6	20.5 7.6	3.0 1.1	1.000 1.000	937 374	4,502,580 4,470,416	20.8 8.4	
Oral Cavity and Fharynx Ovary	Female	-	9,417	-	-	1.1	0.421	553	4,470,416	12.4	
Pancreas	Total	- 7	19,110	- 36.6	- 23.3	5.0	0.421	1,481	8,972,996	12.4	
Pancreas	Male	2	9,693	20.6	12.4	2.9	0.870	824	4,502,580	18.3	
Pancreas	Female	5	9,417	53.1	35.6	2.1	0.117	657	4,470,416	14.7	
Prostate	Male	24	9,693	247.6	153.1	23.5	0.967	6,742	4,502,580	149.7	
Stomach	Total	3	19,110	15.7	10.4	1.5	0.388	471	8,972,996	5.2	
Stomach	Male	1	9,693	10.3	6.4	1.1	1.000	306	4,502,580	6.8	
Stomach	Female	2	9,417	21.2	15.2	0.5	0.173	165	4,470,416	3.7	
Testis	Male	-	9,693	-	-	0.5	1.000	274	4,502,580	6.1	
Thyroid	Total	5	19,110	26.2	23.9	2.8	0.290	1,180	8,972,996	13.2	
Thyroid	Male	3	9,693	31.0	24.6	1.0	0.160	369	4,502,580	8.2	
Thyroid	Female	2	9,417	21.2	20.5	1.8	1.000	811	4,470,416	18.1	
Pediatric Age 0 to 19	Total	2	4,695	42.6	43.0	0.8	0.374	423	2,494,629	17.0	
Pediatric Age 0 to 19	Male	2	2,503	79.9	80.4	0.4	0.131 1.000	212	1,271,818 1,222,811	16.7 17.3	
Pediatric Age 0 to 19	Female	-	2,192	-	-	0.4	1.000	211	1,222,011	17.3	

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN LEWIS COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Le	wis County				Re	mainder of Idah	0
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	280	18,990	1,474.5	924.8	264.3	0.350	80,255	9,192,404	873.1
All Causes of Death	Male	179	9,669	1,851.3	1,109.5	148.9	0.018 >>	42,607	4,618,028	922.6
All Causes of Death	Female	101	9,321	1,083.6	707.1	117.6	0.133	37,648	4,574,376	823.0
All Malignant Cancers	Total	55	18,990	289.6	180.7	50.3	0.540	15,178	9,192,404	165.1
All Malignant Cancers	Male	41	9,669	424.0	247.2	29.4	0.050	8.194	4,618,028	177.4
All Malignant Cancers	Female	14	9,321	150.2	99.4	21.5	0.117	6,984	4,574,376	152.7
Bladder	Total	4	18,990	21.1	12.3	1.7	0.186	481	9,192,404	5.2
Bladder	Male	3	9,669	31.0	16.7	1.4	0.354	372	4,618,028	8.1
Bladder	Female	1	9,321	10.7	6.7	0.4	0.600	109	4,574,376	2.4
Brain and Other Nervous System	Total	3	18,990	15.8	11.1	1.5	0.392	515	9,192,404	5.6
Brain and Other Nervous System	Male	3	9,669	31.0	21.0	0.9	0.120	286	4,618,028	6.2
Brain and Other Nervous System	Female	-	9,321 18,990	-	-	0.6	1.000	229	4,574,376	5.0 12.2
Breast Breast	Total Male	-	9,669	-	-	3.6 0.0	0.056 1.000	1,124 13	9,192,404 4,618,028	0.3
Breast	Female	-	9,321	-	-	3.3	0.073	1,111	4,574,376	24.3
Cervix	Female	-	9,321	-	_	0.2	1.000	88	4,574,376	1.9
Colorectal	Total	- 3	18,990	15.8	10.2	4.2	0.777	1,329	9,192,404	14.5
Colorectal	Male	2	9,669	20.7	12.9	2.4	1.000	730	4,618,028	15.8
Colorectal	Female	1	9,321	10.7	7.2	1.8	0.911	599	4,574,376	13.1
Corpus Uteri	Female	1	9,321	10.7	7.1	0.5	0.807	168	4,574,376	3.7
Esophagus	Total	2	18,990	10.5	6.6	1.5	0.886	459	9,192,404	5.0
Esophagus	Male	1	9,669	10.3	6.2	1.4	1.000	390	4,618,028	8.4
Esophagus	Female	1	9,321	10.7	7.0	0.2	0.385	69	4,574,376	1.5
Hodgkin Lymphoma	Total	-	18,990	-	-	0.1	1.000	25	9,192,404	0.3
Hodgkin Lymphoma	Male	-	9,669	-	-	0.0	1.000	14	4,618,028	0.3
Hodgkin Lymphoma	Female	-	9,321	-		0.0	1.000	11	4,574,376	0.2
Kidney Kidney	Total Male	3 2	18,990	15.8	9.7	1.3	0.283 0.437	383	9,192,404	4.2
Kidney	Female	2 1	9,669 9,321	20.7 10.7	12.1 6.8	0.9 0.4	0.437	244 139	4,618,028 4,574,376	5.3 3.0
Larynx	Total	2	18,990	10.7	6.5	0.4	0.052	74	9,192,404	0.8
Larynx	Male	1	9,669	10.3	5.9	0.2	0.418	64	4,618,028	1.4
Larynx	Female	1	9,321	10.7	7.8	0.0	0.056	10	4,574,376	0.2
Leukemia	Total	1	18,990	5.3	3.2	2.2	0.692	664	9,192,404	7.2
Leukemia	Male	1	9,669	10.3	5.9	1.4	1.000	396	4,618,028	8.6
Leukemia	Female	-	9,321	-	-	0.8	0.862	268	4,574,376	5.9
Liver and Bile Duct	Total	2	18,990	10.5	6.7	2.0	1.000	633	9,192,404	6.9
Liver and Bile Duct	Male	2	9,669	20.7	12.6	1.4	0.846	421	4,618,028	9.1
Liver and Bile Duct	Female	-	9,321	-	-	0.7	1.000	212	4,574,376	4.6
Lung and Bronchus	Total	12	18,990	63.2	38.4	9.9	0.593	2,925	9,192,404	31.8
Lung and Bronchus	Male	8	9,669	82.7	47.6	5.6	0.401	1,533	4,618,028	33.2
Lung and Bronchus Melanoma of the Skin	Female Total	4	9,321 18,990	42.9	27.4	4.4	1.000 0.763	1,392 301	4,574,376 9,192,404	30.4 3.3
Melanoma of the Skin	Male	-	9,669	-	-	0.7	0.703	200	4,618,028	3.3 4.3
Melanoma of the Skin	Female	-	9,321	-	-	0.7	1.000	101	4,574,376	2.2
Myeloma	Total	- 2	18,990	- 10.5	6.3	1.1	0.618	323	9,192,404	3.5
Myeloma	Male	2	9,669	20.7	11.5	0.7	0.311	186	4,618,028	4.0
Myeloma	Female		9,321	-	-	0.4	1.000	137	4,574,376	3.0
Non-Hodgkin Lymphoma	Total	3	18,990	15.8	9.6	1.9	0.604	565	9,192,404	6.1
Non-Hodgkin Lymphoma	Male	2	9,669	20.7	12.0	1.1	0.608	308	4,618,028	6.7
Non-Hodgkin Lymphoma	Female	1	9,321	10.7	6.8	0.8	1.000	257	4,574,376	5.6
Oral Cavity and Pharynx	Total	2	18,990	10.5	6.7	0.9	0.441	273	9,192,404	3.0
Oral Cavity and Pharynx	Male	2	9,669	20.7	12.6	0.7	0.281	190	4,618,028	4.1
Oral Cavity and Pharynx	Female	- ,	9,321	-	-	0.3	1.000	83	4,574,376	1.8
Ovary	Female	1	9,321	10.7	7.1	1.1	1.000	360	4,574,376	7.9
Pancreas	Total	3	18,990	15.8	9.8 12.2	3.9	0.890	1,187	9,192,404	12.9
Pancreas Pancreas	Male Female	2 1	9,669 9,321	20.7 10.7	12.2 7.0	2.3 1.7	1.000 1.000	648 539	4,618,028 4,574,376	14.0 11.8
Prostate	Male	4	9,321	41.4	22.1	3.9	1.000	993	4,574,376	21.5
Stomach	Total	4	18,990	5.3	3.5	0.6	0.904	193	9,192,404	21.5
Stomach	Male	_ '	9,669	-		0.0	1.000	119	4,618,028	2.6
Stomach	Female	1	9,321	10.7	7.8	0.4	0.376	74	4,574,376	1.6
	i cillale	1	3,J∠ I	10.7	1.0	0.2	0.070	/4	4,514,510	1.0

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Lewis County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	10.7%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	64.9%
Current Tobacco User (2020–2022) <u>Other Cancer-Related</u>	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	20.1%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	20.9% 68.8% 15.3% 17.6%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





LINCOLN COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 117 cases of invasive cancer were diagnosed among Lincoln County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in LincolnCounty and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Lincoln County	State of Idaho
All Sites/Types	117	47,333
Female Breast	14	6,943
Prostate	17	6,766
Lung & Bronchus	21	4,959
Colorectal	6	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Lincoln County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Lincoln County. The table also shows the number of observed cases, person-

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 45 Lincoln County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Lincoln County and the State of Idaho, 2018–2022

Mortality 2018–2022	Lincoln County	State of Idaho
All Deaths	228	80,538
Cancer Deaths	45	15,233
% of All Deaths	19.7%	18.9%
Lung & Bronchus	12	2,937
Colorectal	6	1,332
Pancreas	1	1,190
Female Breast	1	1,111
Prostate	3	997

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Lincoln County was 438.8 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (526.6) gives an estimate of the relative burden of disease in Lincoln County.

The age- and sex-adjusted incidence rate of invasive cancer in Lincoln County, all sites combined, was 474.8 cases per 100,000 persons per year during 2017–2021. There were fewer cases of cancer in Lincoln County (117) than expected (129.8) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Lincoln County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Lincoln County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Lincoln County, all sites combined, was 187.6 deaths per 100,000 persons per year during 2018–2022, compared with 165.4 for the remainder of the state. There were more cancer deaths in Lincoln County (45) than expected (39.7) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN LINCOLN COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Line	coln County	/			Ren	nainder of Ida	aho
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	117	26,664	438.8	474.8	129.8	0.280	47,216	8,965,442	526.6
All Sites Combined	Male	62	13,822	448.6	472.9	73.5	0.196	25,208	4,498,451	560.4
All Sites Combined	Female	55	12,842	428.3	473.7	57.2	0.838	22,008	4,466,991	492.7
Bladder	Total	7	26,664	26.3	29.3	5.9	0.755	2,213	8,965,442	24.7
Bladder	Male	5	13,822	36.2	38.6	5.1	1.000	1,768	4,498,451	39.3
Bladder	Female	2	12,842	15.6	17.8	1.1	0.614	445	4,466,991	10.0
Brain - malignant	Total	1	26,664	3.8	3.9	1.9	0.890	656	8,965,442	7.3
Brain - malignant	Male	- 1	13,822 12,842	- 7.8	- 8.3	1.1	0.637 1.000	382	4,498,451 4,466,991	8.5
Brain - malignant Brain and other CNS - non-malignant	Female Total	1	26,664	7.8	0.3 4.0	0.7 4.3	0.143	274 1,546	8,965,442	6.1 17.2
	Male	1	13,822	7.2	7.4	4.5	1.000	499	4,498,451	11.2
Brain and other CNS - non-malignant	Female	- '	12,842	-	-	2.7	0.131	1,047	4.466.991	23.4
Breast	Total	15	26,664	56.3	59.8	19.6	0.361	6,993	8,965,442	78.0
Breast	Male	1	13,822	7.2	7.6	0.2	0.343	64	4,498,451	1.4
Breast	Female	14	12,842	109.0	119.5	18.2	0.394	6,929	4,466,991	155.1
Breast - in situ	Total	1	26,664	3.8	3.9	3.9	0.203	1,368	8,965,442	15.3
Breast - in situ	Male	-	13,822	-	-	0.0	1.000	4	4,498,451	0.1
Breast - in situ	Female	1	12,842	7.8	8.4	3.6	0.248	1,364	4,466,991	30.5
Cervix Colorectal	Female Total	1 6	12,842 26,664	7.8 22.5	8.1 24.2	0.8 10.0	1.000 0.259	293 3,626	4,466,991 8,965,442	6.6 40.4
Colorectal	Male	6 6	20,004 13,822	22.5 43.4	24.2 44.9	10.0 5.9	0.259	3,626 1,971	8,965,442 4,498,451	40.4 43.8
Colorectal	Female	-	12,842			4.3	0.029 <<	1,655	4,466,991	37.0
Corpus Uteri	Female	- 3	12,842	23.4	25.4	3.6	1.000	1,351	4,466,991	30.2
Esophagus	Total	1	26,664	3.8	4.1	1.4	1.000	506	8,965,442	5.6
Esophagus	Male	-	13,822	-	-	1.2	0.575	429	4,498,451	9.5
Esophagus	Female	1	12,842	7.8	8.8	0.2	0.357	77	4,466,991	1.7
Hodgkin Lymphoma	Total	-	26,664	-	-	0.6	1.000	222	8,965,442	2.5
Hodgkin Lymphoma	Male	-	13,822	-	-	0.4	1.000	129	4,498,451	2.9
Hodgkin Lymphoma	Female	-	12,842	-	-	0.3	1.000	93	4,466,991	2.1
Kidney and Renal Pelvis Kidney and Renal Pelvis	Total Male	6 5	26,664 13,822	22.5 36.2	24.2 37.6	5.4 3.9	0.898 0.685	1,945 1,305	8,965,442 4,498,451	21.7 29.0
Kidney and Renal Pelvis	Female	5	12,842	7.8	8.7	3.9 1.6	1.000	640	4,496,451	14.3
Larynx	Total	- '	26,664	-	-	0.6	1.000	220	8,965,442	2.5
Larynx	Male	-	13,822	-	-	0.5	1.000	167	4,498,451	3.7
Larynx	Female	-	12,842	-	-	0.1	1.000	53	4,466,991	1.2
Leukemia	Total	3	26,664	11.3	12.2	4.7	0.610	1,724	8,965,442	19.2
Leukemia	Male	2	13,822	14.5	15.1	3.0	0.829	1,034	4,498,451	23.0
Leukemia	Female	1	12,842	7.8	8.7	1.8	0.943	690	4,466,991	15.4
Liver and Bile Duct	Total	2	26,664	7.5	8.1	2.3	1.000	841	8,965,442	9.4
Liver and Bile Duct	Male	1	13,822	7.2	7.7	1.7	0.972	593	4,498,451	13.2
Liver and Bile Duct Lung and Bronchus	Female Total	21	12,842 26,664	7.8 78.8	8.7 87.7	0.6 13.2	0.941 0.057	248 4,938	4,466,991 8,965,442	5.6 55.1
Lung and Bronchus	Male	11	13,822	79.6	85.5	7.1	0.212	2,484	4,498,451	55.2
Lung and Bronchus	Female	10	12,842	77.9	89.1	6.2	0.191	2,454	4,466,991	54.9
Melanoma of the Skin	Total	5	26,664	18.8	20.1	8.7	0.271	3,139	8,965,442	35.0
Melanoma of the Skin	Male	2	13,822	14.5	15.1	5.6	0.167	1,893	4,498,451	42.1
Melanoma of the Skin	Female	3	12,842	23.4	25.4	3.3	1.000	1,246	4,466,991	27.9
Myeloma	Total	2	26,664	7.5	8.3	2.0	1.000	726	8,965,442	8.1
Myeloma	Male	1	13,822	7.2	7.7	1.3	1.000	446	4,498,451	9.9
Nyeloma	Female	1	12,842	7.8	8.8	0.7	1.000	280	4,466,991	6.3
Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma	Total Male	4 1	26,664 13,822	15.0	16.2	5.5 3.4	0.725 0.304	1,988	8,965,442	22.2 25.5
Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma	iviale Female	3	13,822	7.2 23.4	7.6 26.1	3.4 2.2	0.304 0.736	1,145 843	4,498,451 4,466,991	25.5 18.9
Oral Cavity and Pharynx	Total	2	26,664	7.5	8.0	3.6	0.591	1,313	8,965,442	14.6
Oral Cavity and Pharynx	Male	2	13,822	14.5	15.1	2.8	0.956	938	4,498,451	20.9
Oral Cavity and Pharynx	Female	-	12,842	-	-	1.0	0.760	375	4,466,991	8.4
Ovary	Female	2	12,842	15.6	17.0	1.5	0.853	551	4,466,991	12.3
Pancreas	Total	3	26,664	11.3	12.4	4.0	0.862	1,485	8,965,442	16.6
Pancreas	Male	1	13,822	7.2	7.6	2.4	0.614	825	4,498,451	18.3
Pancreas Broatato	Female	2	12,842	15.6	17.8	1.7	0.991	660	4,466,991	14.8
Prostate	Male Total	17	13,822	123.0	131.2	19.4	0.681	6,749	4,498,451	150.0
Stomach Stomach	Male	2 1	26,664 13,822	7.5 7.2	8.2 7.6	1.3 0.9	0.738 1.000	472 306	8,965,442 4,498,451	5.3 6.8
Stomach	Female	1	12,842	7.2	8.8	0.9	0.690	166	4,466,991	3.7
Testis	Male	- 1	13,822	-	-	0.4	0.886	274	4,400,991	6.1
Thyroid	Total	- 3	26,664	- 11.3	- 11.6	3.4	1.000	1,182	8,965,442	13.2
Thyroid	Male		13,822	-		1.1	0.655	372	4,498,451	8.3
Thyroid	Female	- 3	12,842	- 23.4	- 24.3	2.2	0.035	810	4,466,991	18.1
	Total	1	8,189	12.2	12.3	1.4	1.000	424	2,491,135	17.0
Pediatric Ade U to 19			5,105		12.0			74		
Pediatric Age 0 to 19 Pediatric Age 0 to 19	Male	1	4,222	23.7	23.8	0.7	1.000	213	1,270,099	16.8

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN LINCOLN COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Lin	coln County	,			Re	mainder of Idah	0
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years		Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death			26,632	856.1	952.0	209.4	0.213	80,307	9,184,762	874.4
-	Total	228								
All Causes of Death	Male	121	13,821	875.5	909.0	123.1	0.897	42,665	4,613,876	924.7
All Causes of Death	Female	107	12,811	835.2	998.5	88.2	0.058	37,642	4,570,886	823.5
All Malignant Cancers	Total	45	26,632	169.0	187.6	39.7	0.436	15,188	9,184,762	165.4
All Malignant Cancers	Male	21	13,821	151.9	160.4	23.3	0.732 0.121	8,214	4,613,876	178.0
All Malignant Cancers	Female	24	12,811	187.3	216.5	16.9 1.2	-	6,974	4,570,886	152.6
Bladder Bladder	Total	-	26,632 13,821	-	-		0.581 0.679	485 375	9,184,762 4,613,876	5.3 8.1
Bladder	Male Female	-		-	-	1.1 0.3	1.000		4,613,876	
Brain and Other Nervous System	Total	- 2	12,811 26,632	- 7.5	- 8.0	0.3	0.816	110 516	, ,	2.4 5.6
Brain and Other Nervous System	Male		13,821	7.5	0.0	0.8	0.870	289	9,184,762 4.613.876	5.0 6.3
Brain and Other Nervous System	Female	- 2	12,811	- 15.6	- 17.2	0.6	0.870	209	4,570,886	0.3 5.0
Breast	Total	<u> </u>	26,632	3.8	4.1	3.0	0.229	1,123	9,184,762	12.2
Breast	Male	1	13,821	5.0	4.1	0.0	1.000	1,123	4,613,876	0.3
Breast	Female	- 1	12,811	- 7.8	- 8.9	2.7	0.490	1,110	4,570,886	24.3
Cervix	Female	1	12,811	7.8	8.2	0.2	0.490	87	4,570,886	24.3
Colorectal	Total	6	26,632	22.5	24.6	3.5	0.414	1,326	9,184,762	1.9
Colorectal	Male	4	13,821	22.3	30.1	2.1	0.323	728	4,613,876	14.4
Colorectal	Female	2	12,811	15.6	18.1	1.4	0.323	598	4,570,886	13.1
Colorectal Corpus Uteri	Female	-	12,811	-	-	0.4	1.000	169	4,570,886	3.7
Esophagus	Total	-	26,632	-	-	1.2	0.592	461	9,184,762	5.0
Esophagus	Male	-	13,821	-	-	1.2	0.660	391	4,613,876	3.0 8.5
Esophagus	Female	_	12,811	_	_	0.2	1.000	70	4,570,886	1.5
Hodgkin Lymphoma	Total	-	26.632	-	_	0.2	1.000	25	9,184,762	0.3
Hodgkin Lymphoma	Male	_	13,821	-		0.0	1.000	14	4,613,876	0.3
Hodgkin Lymphoma	Female	-	12,811	_	_	0.0	1.000	11	4,570,886	0.0
Kidney	Total	3	26,632	11.3	12.6	1.0	0.158	383	9.184.762	4.2
Kidney	Male	2	13,821	14.5	15.2	0.7	0.308	244	4,613,876	5.3
Kidney	Female	1	12,811	7.8	9.2	0.3	0.561	139	4,570,886	3.0
Larynx	Total	-	26,632	-	-	0.2	1.000	76	9,184,762	0.8
Larynx	Male	-	13,821	-	-	0.2	1.000	65	4,613,876	1.4
Larynx	Female	-	12,811	-	-	0.0	1.000	11	4,570,886	0.2
Leukemia	Total	-	26,632	-	-	1.7	0.359	665	9,184,762	7.2
Leukemia	Male	-	13,821	-	-	1.1	0.647	397	4,613,876	8.6
Leukemia	Female	-	12,811	-	-	0.6	1.000	268	4,570,886	5.9
Liver and Bile Duct	Total	1	26,632	3.8	4.1	1.7	1.000	634	9,184,762	6.9
Liver and Bile Duct	Male	-	13,821	-	-	1.2	0.602	423	4,613,876	9.2
Liver and Bile Duct	Female	1	12,811	7.8	9.0	0.5	0.805	211	4,570,886	4.6
Lung and Bronchus	Total	12	26,632	45.1	50.6	7.5	0.164	2,925	9,184,762	31.8
Lung and Bronchus	Male	7	13,821	50.6	54.5	4.3	0.282	1,534	4,613,876	33.2
Lung and Bronchus	Female	5	12,811	39.0	45.5	3.3	0.491	1,391	4,570,886	30.4
Melanoma of the Skin	Total	-	26,632	-	-	0.8	0.899	301	9,184,762	3.3
Melanoma of the Skin	Male	-	13,821	-	-	0.6	1.000	200	4,613,876	4.3
Melanoma of the Skin	Female	-	12,811	-	-	0.3	1.000	101	4,570,886	2.2
Myeloma	Total	-	26,632	-	-	0.8	0.871	325	9,184,762	3.5
Myeloma	Male	-	13,821	-	-	0.5	1.000	188	4,613,876	4.1
Myeloma	Female	-	12,811	-	-	0.3	1.000	137	4,570,886	3.0
Non-Hodgkin Lymphoma	Total	3	26,632	11.3	12.6	1.5	0.363	565	9,184,762	6.2
Non-Hodgkin Lymphoma	Male	2	13,821	14.5	15.4	0.9	0.431	308	4,613,876	6.7
Non-Hodgkin Lymphoma	Female	1	12,811	7.8	9.3	0.6	0.905	257	4,570,886	5.6
Oral Cavity and Pharynx	Total	1	26,632	3.8	4.1	0.7	1.000	274	9,184,762	3.0
Oral Cavity and Pharynx	Male	-	13,821	-	-	0.5	1.000	192	4,613,876	4.2
Oral Cavity and Pharynx	Female	1	12,811	7.8	8.9	0.2	0.366	82	4,570,886	1.8
Ovary	Female	2	12,811	15.6	17.8	0.9	0.441	359	4,570,886	7.9
Pancreas	Total	1	26,632	3.8	4.2	3.1	0.367	1,189	9,184,762	12.9
Pancreas	Male	-	13,821	-	-	1.8	0.320	650	4,613,876	14.1
Pancreas	Female	1	12,811	7.8	9.0	1.3	1.000	539	4,570,886	11.8
Prostate	Male	3	13,821	21.7	22.7	2.8	1.000	994	4,613,876	21.5
Stomach	Total	1	26,632	3.8	4.1	0.5	0.804	193	9,184,762	2.1
Stomach	Male	-	13,821	-	-	0.3	1.000	119	4,613,876	2.6
Stomach	Female	1	12,811	7.8	8.8	0.2	0.336	74	4,570,886	1.6

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Lincoln County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	4.7%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	
Current Tobacco User (2020–2022) <u>Other Cancer-Related</u>	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	25.1%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	21.8% 70.5% 18.2% 13.7%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





MADISON COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 485 cases of invasive cancer were diagnosed among Madison County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in MadisonCounty and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Madison County	State of Idaho		
All Sites/Types	485	47,333		
Female Breast	75	6,943		
Prostate	74	6,766		
Lung & Bronchus	17	4,959		
Colorectal	39	3,632		

Table 3 (*Cancer Incidence 2017–2021, Comparison between Madison County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Madison County. The table also shows the number of observed cases, person-

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 112 Madison County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Madison County

 and the State of Idaho, 2018–2022

Mortality 2018–2022	Madison County	State of Idaho		
All Deaths	983	80,538		
Cancer Deaths	112	15,233		
% of All Deaths	11.4%	18.9%		
Lung & Bronchus	9	2,937		
Colorectal	14	1,332		
Pancreas	9	1,190		
Female Breast	11	1,111		
Prostate	9	997		

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Madison County was 227.0 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (533.7) gives an estimate of the relative burden of disease in Madison County.

The age- and sex-adjusted incidence rate of invasive cancer in Madison County, all sites combined, was 480.0 cases per 100,000 persons per year during 2017–2021. There were statistically significantly fewer cases of cancer in Madison County (485) than expected (539.2) based upon rates in the remainder of the state (p=.019).

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Madison County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Madison County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Madison County, all sites combined, was 115.5 deaths per 100,000 persons per year during 2018–2022, compared with 168.3 for the remainder of the state. There were statistically significantly fewer cancer deaths in Madison County (112) than expected (163.3) based upon rates in the remainder of the state (p<.001).

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN MADISON COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Mad	lison Count	Y			Ren	nainder of Ida	iho
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)		P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	485	213,628	227.0	480.0	539.2	0.019 <<	46,848	8,778,478	533.7
All Sites Combined	Male	240	105,405	227.0	480.0	278.7	0.020 <<	25,030	4,406,868	568.0
All Sites Combined	Female	240	108,223	226.4	471.0	259.6	0.383	21,818	4,371,610	499.1
Bladder	Total	13	213,628	6.1	14.1	23.2	0.032 <<	2,207	8,778,478	25.1
Bladder	Male	10	105,405	9.5	22.1	18.1	0.057	1,763	4,406,868	40.0
Bladder	Female	3	108,223	2.8	6.3	4.8	0.576	444	4,371,610	10.2
Brain - malignant	Total	8	213,628	3.7	6.0	9.8	0.711	649	8,778,478	7.4
Brain - malignant Brain - malignant	Male Female	5 3	105,405 108,223	4.7 2.8	7.6 4.4	5.6 4.2	1.000 0.787	377 272	4,406,868 4.371.610	8.6 6.2
Brain and other CNS - non-malignant	Total	23	213,628	10.8	20.8	19.2	0.442	1,524	8,778,478	17.4
Brain and other CNS - non-malignant	Male	9	105,405	8.5	15.5	6.5	0.406	491	4,406,868	11.1
Brain and other CNS - non-malignant	Female	14	108,223	12.9	25.7	12.8	0.821	1,033	4,371,610	23.6
Breast	Total	77	213,628	36.0	79.2	76.8	1.000	6,931	8,778,478	79.0
Breast	Male	_2	105,405	1.9	4.3	0.7	0.290	63	4,406,868	1.4
Breast	Female	75	108,223	69.3	153.8	76.6	0.915	6,868	4,371,610	157.1
Breast - in situ Breast - in situ	Total Male	- 11	213,628 105,405	5.1 -	11.5	14.8 0.0	0.391 1.000	1,358 4	8,778,478 4,406,868	15.5 0.1
Breast - in situ	Female	- 11	108,223	- 10.2	22.8	14.9	0.379	1,354	4,371,610	31.0
Cervix	Female	4	108,223	3.7	6.8	3.9	1.000	290	4,371,610	6.6
Colorectal	Total	39	213,628	18.3	39.1	40.8	0.859	3,593	8,778,478	40.9
Colorectal	Male	19	105,405	18.0	39.1	21.6	0.676	1,958	4,406,868	44.4
Colorectal	Female	20	108,223	18.5	38.9	19.2	0.917	1,635	4,371,610	37.4
Corpus Uteri	Female	22	108,223	20.3	45.9	14.6	0.085	1,332	4,371,610	30.5
Esophagus Esophagus	Total Male	2 1	213,628 105,405	0.9 0.9	2.1 2.2	5.4 4.5	0.189 0.123	505 428	8,778,478 4,406,868	5.8 9.7
Esophagus	Female	1	105,405	0.9	2.2	4.5 0.9	1.000	420 77	4,400,000 4,371,610	9.7
Hodgkin Lymphoma	Total	1	213,628	0.5	0.4	6.3	0.028 <<	221	8,778,478	2.5
Hodgkin Lymphoma	Male	1	105,405	0.9	0.9	3.1	0.365	128	4,406,868	2.9
Hodgkin Lymphoma	Female	-	108,223	-	-	3.2	0.078	93	4,371,610	2.1
Kidney and Renal Pelvis	Total	17	213,628	8.0	17.3	21.6	0.381	1,934	8,778,478	22.0
Kidney and Renal Pelvis	Male	12	105,405	11.4	24.7	14.3	0.660	1,298	4,406,868	29.5
Kidney and Renal Pelvis Larynx	Female Total	5 2	108,223 213,628	4.6	10.0 2.1	7.2 2.4	0.542	636 218	4,371,610 8,778,478	14.5 2.5
Larynx	Male	2	105,405	1.9	4.3	2.4 1.7	1.000	165	4,406,868	2.5
Larynx	Female		108,223	-		0.6	1.000	53	4,371,610	1.2
Leukemia	Total	20	213,628	9.4	18.3	21.3	0.893	1,707	8,778,478	19.4
Leukemia	Male	11	105,405	10.4	20.6	12.4	0.823	1,025	4,406,868	23.3
Leukemia	Female	9	108,223	8.3	15.8	8.9	1.000	682	4,371,610	15.6
Liver and Bile Duct	Total	8	213,628	3.7	8.5	9.0	0.921	835	8,778,478	9.5
Liver and Bile Duct Liver and Bile Duct	Male Female	4 4	105,405 108,223	3.8 3.7	8.6 8.2	6.2 2.7	0.520 0.588	590 245	4,406,868 4,371,610	13.4 5.6
Lung and Bronchus	Total	4	213,628	8.0	0.2 18.6	51.6	0.000 <<	4,942	8,778,478	56.3
Lung and Bronchus	Male	6	105,405	5.7	13.3	25.5	0.000 <<	2,489	4,406,868	56.5
Lung and Bronchus	Female	11	108,223	10.2	23.7	26.1	0.001 <<	2,453	4,371,610	56.1
Melanoma of the Skin	Total	31	213,628	14.5	29.5	37.3	0.341	3,113	8,778,478	35.5
Melanoma of the Skin	Male	19	105,405	18.0	38.2	21.2	0.743	1,876	4,406,868	42.6
Melanoma of the Skin	Female	12	108,223	11.1	21.3	16.0	0.391	1,237	4,371,610	28.3
Myeloma	Total	5	213,628	2.3	5.4	7.7	0.450	723	8,778,478	8.2
Myeloma Myeloma	Male Female	1 4	105,405 108,223	0.9 3.7	2.2 8.5	4.6 3.0	0.109 0.693	446 277	4,406,868 4,371,610	10.1 6.3
Non-Hodgkin Lymphoma	Total	24	213,628	11.2	22.4	24.0	1.000	1,968	8,778,478	22.4
Non-Hodgkin Lymphoma	Male	15	105,405	14.2	27.8	13.8	0.825	1,131	4,406,868	25.7
Non-Hodgkin Lymphoma	Female	9	108,223	8.3	17.1	10.1	0.903	837	4,371,610	19.1
Oral Cavity and Pharynx	Total	7	213,628	3.3	7.3	14.2	0.057	1,308	8,778,478	14.9
Oral Cavity and Pharynx	Male	5	105,405	4.7	10.7	9.9	0.139	935	4,406,868	21.2
Oral Cavity and Pharynx	Female	2	108,223	1.8	4.1 10.9	4.1	0.436	373	4,371,610	8.5
Ovary Pancreas	Female Total	6 15	108,223 213,628	5.5 7.0	10.9	6.9 15.7	0.942 0.992	547 1,473	4,371,610 8,778,478	12.5 16.8
Pancreas	Male	10	105,405	9.5	21.7	8.5	0.704	816	4,406,868	18.5
Pancreas	Female	5	108,223	4.6	10.5	7.1	0.564	657	4,371,610	15.0
Prostate	Male	74	105,405	70.2	164.4	68.3	0.524	6,692	4,406,868	151.9
Stomach	Total	5	213,628	2.3	5.2	5.1	1.000	469	8,778,478	5.3
Stomach	Male	3	105,405	2.8	6.4	3.2	1.000	304	4,406,868	6.9
Stomach	Female	2	108,223	1.8	4.0	1.9	1.000	165	4,371,610	3.8
Testis	Male	8	105,405	7.6	6.3	7.7	1.000	266	4,406,868	6.0
Thyroid	Total	37	213,628	17.3	23.9	20.2	0.001 >>	1,148	8,778,478	13.1
Thyroid	Male	8	105,405	7.6	12.9	5.1	0.293	364	4,406,868	8.3
Thyroid	Female	29 11	108,223	26.8 13.9	34.7 12.6	15.0	0.002 >> 0.377	784	4,371,610	17.9 17.1
Pediatric Age 0 to 19 Pediatric Age 0 to 19	Total		79,164			14.9		414	2,420,160 1,239,941	
Pediatric Age 0 to 19 Pediatric Age 0 to 19	Male Female	4 7	34,380 44,784	11.6 15.6	11.2 12.7	6.0 9.5	0.564 0.534	210 204	1,239,941 1,180,219	16.9 17.3
I CUIDING AYE VIO 18	i cillale	1	++,/04	13.0	12.1	9.0	0.004	204	1,100,219	17.5

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN MADISON COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Mac	lison Count	у			Re	emainder of Idah	10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	983	229,064	429.1	907.5	959.4	0.454	79,552	8,982,330	885.6
All Causes of Death	Male	495	110,233	449.0	893.3	518.7	0.308	42,291	4,517,464	936.2
All Causes of Death	Female	488	118,831	410.7	931.9	437.0	0.017 >>	37,261	4,464,866	834.5
All Malignant Cancers	Total	112	229,064	48.9	115.5	163.3	0.000 <<	15,121	8,982,330	168.3
All Malignant Cancers	Male	61	110,233	55.3	127.5	86.6	0.000 <<	8,174	4,517,464	180.9
All Malignant Cancers	Female	51	118,831	42.9	104.0	76.3	0.003 <<	6,947	4,464,866	155.6
Bladder	Total	6	229,064	2.6	6.3	5.0	0.000 44	479	8,982,330	5.3
Bladder	Male	6	110,233	2.0 5.4	12.9	3.8	0.371	369	4,517,464	8.2
Bladder	Female	-	118,831		12.5	1.2	0.616	110	4,464,866	2.5
Brain and Other Nervous System	Total	- 5	229,064	- 2.2	- 4.4	6.5	0.010	513	8,982,330	5.7
Brain and Other Nervous System	Male	4	110,233	3.6	6.7	3.8	1.000	285	4,517,464	6.3
Brain and Other Nervous System	Female	1	118,831	0.8	1.9	2.7	0.515	228	4.464.866	5.1
Breast	Total	12	229,064	5.2	12.5	11.9	1.000	1,112	8,982,330	12.4
Breast	Male	1	110,233	0.9	2.1	0.1	0.234	12	4,517,464	0.3
Breast	Female	11	118,831	9.3	22.8	11.9	0.947	1,100	4,464,866	24.6
Cervix	Female	-	118,831	-	-	1.1	0.654	88	4,464,866	2.0
Colorectal	Total	14	229,064	6.1	14.5	14.1	1.000	1,318	8,982,330	14.7
Colorectal	Male	7	110,233	6.4	14.6	7.7	1.000	725	4,517,464	16.0
Colorectal	Female	7	118,831	5.9	14.4	6.4	0.927	593	4,464,866	13.3
Corpus Uteri	Female	-	118,831	-	-	1.8	0.337	169	4,464,866	3.8
Esophagus	Total	3	229,064	1.3	3.2	4.8	0.589	458	8,982,330	5.1
Esophagus	Male	3	110,233	2.7	6.5	4.0	0.871	388	4,517,464	8.6
Esophagus	Female	-	118,831	-	-	0.8	0.940	70	4,464,866	1.6
Hodgkin Lymphoma	Total	-	229,064	-	-	0.4	1.000	25	8,982,330	0.3
Hodgkin Lýmphoma	Male	-	110,233	-	-	0.2	1.000	14	4,517,464	0.3
Hodgkin Lymphoma	Female	-	118,831	-	-	0.2	1.000	11	4,464,866	0.2
Kidney	Total	2	229,064	0.9	2.1	4.0	0.467	384	8,982,330	4.3
Kidney	Male	1	110,233	0.9	2.1	2.5	0.560	245	4,517,464	5.4
Kidney	Female	1	118,831	0.8	2.1	1.5	1.000	139	4,464,866	3.1
Larynx	Total	-	229,064	-	-	0.8	0.895	76	8,982,330	0.8
Larynx	Male	-	110,233	-	-	0.7	1.000	65	4,517,464	1.4
Larynx	Female	-	118,831	-	-	0.1	1.000	11	4,464,866	0.2
Leukemia	Total	10	229,064	4.4	9.6	7.6	0.461	655	8,982,330	7.3
Leukemia	Male	7	110,233	6.4	14.0	4.3	0.295	390	4,517,464	8.6
Leukemia	Female	3	118,831	2.5	5.5	3.3	1.000	265	4,464,866	5.9
Liver and Bile Duct	Total	5	229,064	2.2	5.3	6.6	0.707	630	8,982,330	7.0
Liver and Bile Duct	Male	3	110,233	2.7	6.4	4.3	0.737	420	4,517,464	9.3
Liver and Bile Duct	Female	2	118,831	1.7	4.2	2.2	1.000	210	4,464,866	4.7
Lung and Bronchus	Total	9	229,064	3.9	9.6	30.6	>> 000.0	2,928	8,982,330	32.6
Lung and Bronchus	Male	3	110,233	2.7	6.5	15.7	0.000 <<	1,538	4,517,464	34.0
Lung and Bronchus	Female	6	118,831	5.0	12.6	14.8	0.018 <<	1,390	4,464,866	31.1
Melanoma of the Skin	Total	1	229,064	0.4	1.0	3.4	0.300	300	8,982,330	3.3
Melanoma of the Skin	Male	-	110,233	-	-	2.1	0.244	200	4,517,464	4.4
Melanoma of the Skin	Female	1	118,831	0.8	1.8	1.3	1.000	100	4,464,866	2.2
Myeloma	Total	4	229,064	1.7	4.2	3.4	0.872	321	8,982,330	3.6
Myeloma	Male	2	110,233	1.8	4.3	1.9	1.000	186	4,517,464	4.1
Myeloma	Female	2	118,831	1.7	4.2	1.4	0.850	135	4,464,866	3.0
Non-Hodgkin Lymphoma	Total	4	229,064	1.7	4.1	6.2	0.522	564	8,982,330	6.3
Non-Hodgkin Lymphoma	Male	3	110,233	2.7	6.0	3.4	1.000	307	4,517,464	6.8
Non-Hodgkin Lymphoma	Female	1	118,831	0.8	2.1	2.8	0.465	257	4,464,866	5.8
Oral Cavity and Pharynx	Total	-	229,064	-	-	2.9	0.108	275	8,982,330	3.1
Oral Cavity and Pharynx	Male	-	110,233	-	-	2.0	0.263	192	4,517,464	4.3
Oral Cavity and Pharynx	Female	-	118,831	-	-	0.9	0.825	83	4,464,866	1.9
Ovary	Female	4	118,831	3.4	8.4	3.8	1.000	357	4,464,866	8.0
Pancreas	Total	9	229,064	3.9	9.6	12.3	0.428	1,181	8,982,330	13.1
Pancreas	Male	4	110,233	3.6	8.7 10 5	6.6	0.424	646 535	4,517,464	14.3
Pancreas	Female	5	118,831	4.2	10.5	5.7	0.994		4,464,866	12.0
Prostate	Male	9	110,233	8.2	19.4	10.2	0.876	988	4,517,464	21.9
Stomach	Total	1	229,064	0.4	1.0	2.1	0.767	193	8,982,330	2.1
Stomach	Male	1	110,233	0.9	2.1	1.2	1.000	118	4,517,464	2.6
Stomach	Female	-	118,831	-	-	0.8	0.870	75	4,464,866	1.7

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Madison County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	95.5% 12.4%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	61.9% 65.8%
Current Tobacco User (2020–2022) <u>Other Cancer-Related</u>	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	6.1%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	33.9% 86.2% 21.7% 13.6%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





MINIDOKA COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 524 cases of invasive cancer were diagnosed among Minidoka County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in MinidokaCounty and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Minidoka County	State of Idaho
All Sites/Types	524	47,333
Female Breast	73	6,943
Prostate	63	6,766
Lung & Bronchus	47	4,959
Colorectal	52	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Minidoka County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Minidoka County. The table also shows the number of observed cases, person-

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 177 Minidoka County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Minidoka County and the State of Idaho, 2018–2022

Mortality 2018–2022	Minidoka County	State of Idaho
All Deaths	1,078	80,538
Cancer Deaths	177	15,233
% of All Deaths	16.4%	18.9%
Lung & Bronchus	19	2,937
Colorectal	16	1,332
Pancreas	17	1,190
Female Breast	13	1,111
Prostate	14	997

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Minidoka County was 497.1 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (526.7) gives an estimate of the relative burden of disease in Minidoka County.

The age- and sex-adjusted incidence rate of invasive cancer in Minidoka County, all sites combined, was 499.5 cases per 100,000 persons per year during 2017–2021. There were fewer cases of cancer in Minidoka County (524) than expected (552.5) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Minidoka County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Minidoka County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Minidoka County, all sites combined, was 161.8 deaths per 100,000 persons per year during 2018–2022, compared with 165.4 for the remainder of the state. There were fewer cancer deaths in Minidoka County (177) than expected (180.9) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN MINIDOKA COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Mini	doka Coun	ty			Rem	nainder of Ida	aho
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)		P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	524	105,421	497.1	499.5	552.5	0.232	46,809	8,886,685	526.7
All Sites Combined	Male	290	52.807	549.2	551.2	294.7	0.813	24,980	4.459.466	560.2
All Sites Combined	Female	234	52,614	444.7	449.1	256.9	0.159	21,829	4,427,219	493.1
Bladder	Total	29	105,421	27.5	26.8	26.7	0.707	2,191	8,886,685	24.7
Bladder	Male	22	52,807	41.7	40.8	21.2	0.916	1,751	4,459,466	39.3
Bladder	Female	7	52,614	13.3	13.0	5.4	0.583	440	4,427,219	9.9
Brain - malignant	Total	10	105,421	9.5	9.5	7.6	0.481	647	8,886,685	7.3
Brain - malignant	Male	10	52,807	18.9	19.2	4.3	0.027 >>	372	4,459,466	8.3
Brain - malignant Brain and other CNS - non-malignant	Female Total	- 23	52,614 105,421	- 21.8	- 21.9	3.3 18.0	0.072 0.294	275 1,524	4,427,219 8,886,685	6.2 17.1
	Male	23 5	52,807	9.5	9.5	5.9	0.938	495	4,459,466	11.1
Brain and other CNS - non-malignant	Female	18	52,614	34.2	34.4	12.2	0.139	1,029	4,427,219	23.2
Breast	Total	74	105,421	70.2	72.0	80.2	0.531	6,934	8,886,685	78.0
Breast	Male	1	52,807	1.9	1.9	0.8	1.000	64	4,459,466	1.4
Breast	Female	73	52,614	138.7	143.3	79.1	0.540	6,870	4,427,219	155.2
Breast - in situ	Total	14	105,421	13.3	13.9	15.4	0.856	1,355	8,886,685	15.2
Breast - in situ Breast - in situ	Male	-	52,807	-	-	0.0	1.000	4	4,459,466	0.1
Breast - in situ Cervix	Female Female	14 5	52,614 52,614	26.6 9.5	28.1 10.2	15.2 3.2	0.892 0.435	1,351 289	4,427,219 4,427,219	30.5 6.5
Colorectal	Total	52	105,421	9.5 49.3	49.1	42.6	0.435	209 3,580	8,886,685	40.3
Colorectal	Male	33	52,807	49.3 62.5	62.6	23.0	0.057	1,944	4,459,466	40.3
Colorectal	Female	19	52,607	36.1	35.7	19.7	0.999	1,636	4,427,219	37.0
Corpus Uteri	Female	21	52,614	39.9	41.4	15.3	0.191	1,333	4,427,219	30.1
Esophagus	Total	6	105,421	5.7	5.7	6.0	1.000	501	8,886,685	5.6
Esophagus	Male	6	52,807	11.4	11.3	5.0	0.774	423	4,459,466	9.5
Esophagus	Female	-	52,614	-	-	0.9	0.775	78	4,427,219	1.8
Hodgkin Lymphoma	Total	4	105,421	3.8	3.9	2.5	0.481	218	8,886,685	2.5
Hodgkin Lymphoma	Male	1	52,807 52,614	1.9 5.7	2.0 5.9	1.5	1.000 0.175	128	4,459,466 4,427,219	2.9 2.0
Hodgkin Lymphoma Kidney and Renal Pelvis	Female Total	3 29	105,421	27.5	5.9 27.8	1.0 22.6	0.175	90 1,922	8,886,685	2.0
Kidney and Renal Pelvis	Male	20	52,807	37.9	38.3	15.1	0.263	1,290	4,459,466	28.9
Kidney and Renal Pelvis	Female	9	52,614	17.1	17.2	7.5	0.669	632	4,427,219	14.3
Larynx	Total	8	105,421	7.6	7.5	2.5	0.009 >>	212	8,886,685	2.4
Larynx	Male	3	52,807	5.7	5.6	2.0	0.624	164	4,459,466	3.7
Larynx	Female	5	52,614	9.5	9.6	0.6	0.001 >>	48	4,427,219	1.1
Leukemia	Total	17	105,421	16.1	15.8	20.7	0.498	1,710	8,886,685	19.2
Leukemia	Male	13	52,807	24.6	24.3	12.3	0.913	1,023	4,459,466	22.9
Leukemia Liver and Bile Duct	Female Total	4	52,614 105,421	7.6 6.6	7.4 6.7	8.3 9.8	0.163 0.482	687 836	4,427,219 8,886,685	15.5 9.4
Liver and Bile Duct	Male	6	52,807	11.4	11.5	9.8 6.8	0.945	588	4,459,466	9.4 13.2
Liver and Bile Duct	Female	1	52,614	1.9	1.9	2.9	0.416	248	4,427,219	5.6
Lung and Bronchus	Total	47	105,421	44.6	44.0	59.0	0.125	4,912	8,886,685	55.3
Lung and Bronchus	Male	27	52,807	51.1	50.8	29.4	0.744	2,468	4,459,466	55.3
Lung and Bronchus	Female	20	52,614	38.0	37.3	29.6	0.083	2,444	4,427,219	55.2
Melanoma of the Skin	Total	25	105,421	23.7	23.9	36.7	0.054	3,119	8,886,685	35.1
Melanoma of the Skin	Male	14	52,807	26.5	26.5	22.3	0.085	1,881	4,459,466	42.2
Melanoma of the Skin	Female	11	52,614	20.9	21.5	14.3	0.467	1,238	4,427,219	28.0
Myeloma Myeloma	Total Male	8 4	105,421 52,807	7.6 7.6	7.5 7.5	8.6 5 3	1.000	720 443	8,886,685	8.1 g g
Myeloma Myeloma	Female	4 4	52,807 52,614	7.6 7.6	7.5 7.6	5.3 3.3	0.785 0.838	443 277	4,459,466 4,427,219	9.9 6.3
Non-Hodgkin Lymphoma	Total	20	105,421	19.0	19.0	23.4	0.566	1,972	8,886,685	22.2
Non-Hodgkin Lymphoma	Male	10	52,807	18.9	19.1	13.3	0.446	1,136	4,459,466	25.5
Non-Hodgkin Lýmphoma	Female	10	52,614	19.0	18.8	10.0	1.000	836	4,427,219	18.9
Oral Cavity and Pharynx	Total	13	105,421	12.3	12.5	15.2	0.686	1,302	8,886,685	14.7
Oral Cavity and Pharynx	Male	7	52,807	13.3	13.5	10.9	0.303	933	4,459,466	20.9
Oral Cavity and Pharynx	Female	6	52,614	11.4	11.5	4.4	0.548	369	4,427,219 4,427,219	8.3
Ovary Pancreas	Female Total	5 21	52,614 105,421	9.5 19.9	9.7 19.6	6.4 17.7	0.768 0.493	548 1,467	4,427,219	12.4 16.5
Pancreas	Male	17	52,807	32.2	31.8	9.7	0.0493	809	4,459,466	18.1
Pancreas	Female	4	52,614	7.6	7.4	8.0	0.201	658	4,427,219	14.9
Prostate	Male	63	52,807	119.3	121.5	77.9	0.095	6,703	4,459,466	150.3
Stomach	Total	7	105,421	6.6	6.6	5.6	0.663	467	8,886,685	5.3
Stomach	Male	4	52,807	7.6	7.5	3.6	0.973	303	4,459,466	6.8
Stomach	Female	3	52,614	5.7	5.6	2.0	0.642	164	4,427,219	3.7
Testis	Male	2	52,807	3.8	4.0	3.0	0.832	272	4,459,466	6.1
Thyroid	Total	13	105,421	12.3	13.0	13.2	1.000	1,172	8,886,685	13.2
Thyroid	Male	7	52,807	13.3	13.7	4.2	0.263	365	4,459,466	8.2
Thyroid	Female	6	52,614	11.4	12.1	9.0	0.413	807	4,427,219	18.2
Pediatric Age 0 to 19	Total	5	32,751	15.3	15.4	5.5	1.000	420	2,466,573	17.0
Pediatric Age 0 to 19	Male	1	16,600	6.0	6.0	2.8	0.459	213	1,257,721	16.9
Pediatric Age 0 to 19	Female	4	16,151	24.8	25.4	2.7	0.570	207	1,208,852	17.1

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN MINIDOKA COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

Cancer Sile/Type Sex Deaths Years Rate (1) Rate (1) Bate (1) Bate (1) Deaths (3) Vears (4) Vears Rate All Causes of Death Male 601 53,709 1,119.0 1,099.6 604.1 0,000 >> 42,185 4,573,988 92 All Causes of Death Female 77 108,832 119.5 119.1 848.0 0,774 37,272 43,504,474 25 All Malignant Cancers Total 777 108,832 175.1 64.0 0,810 15,056 8,132.4 45,73,489 175 163.4 10.4 53,730.7 11.8 10.4 53,704 11.4 50,552 6.47 51,04,462 175 10.4 10.4 10.4 10.4 10.4 10.4 10.4 10.4 11.4 11.4 11.4 11.4 10.4 10.4 10.4 10.4 10.4 10.4 10.4 10.4 10.4 10.4 10.4 10.4 10.4 10.4 10.4				Mini	doka Count	У			Re	emainder of Idah	10
Cancer Sile/Type Sex Deaths Years Rate (1) Rate (1) Deaths (3) P-Value (4) Deaths Years Rate All Causes of Death Male 601 53,709 1,119.0 1,099.6 604.1 0.000 >> 42,185 4,573,988 92 All Malgipant Cancers Total 177 108,832 185.5 181.8 180.9 0.810 15,056 9,114,462 16 All Malgipant Cancers Total 7 108,332 175.1 6.60 0.521 6.47 9,104,462 175 164,60 9,114,462 165 11.1 1.1 1.1 1.1 1.4 1.0 1.4 1.0 1.4 1.0 1.4 1.0 1.4 1.0 1.4 1.0 1.4 1.0 1.4 1.0 1.4 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 </td <td>Cause of Death</td> <td></td> <td>Observed</td> <td>Person</td> <td>Crude</td> <td>A.A.M.</td> <td>Expected</td> <td></td> <td>Observed</td> <td>Person</td> <td>Crude</td>	Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$		Sex	-					P-Value (4)	-		Rate (1)
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $. ,	· · · ·				872.7
All Causes of Death Female 477 55.223 896.2 810.8 484.0 0.774 37.272 4.530.474 62.2 All Maignant Cancers Male 103 53.709 191.8 191.1 95.0 0.431 81.02 4.57.3986 17 All Maignant Cancers Male 6 53.709 191.8 191.1 95.0 0.431 8.132 4.57.3986 17 Bladder Male 6 53.709 11.2 0.07 4.0 0.568 369 4.57.3986 Brain and Other Nervous System Total 8 105.922 7.5 7.6 5.9 0.488 510 9.104.462 Brain and Other Nervous System Female 2 53.223 3.8 3.8 2.1 1.000 1.7 3.9 9.07.4450 9.07.4450 Brain and Other Nervous System Female 1 53.223 1.4 1.000 1.00 1.01 1.000 1.01 1.00 1.04 4.530.474 2.02 0.021 1.00 1.01 1.000 1.01 1.01 0.04 4.	-										922.3
All Maignant Cancers Total 177 106.832 165.5 161.8 180.0 0.810 15.066 9.104.462 6 All Maignant Cancers Female 74 53.223 139.0 134.1 84.3 0.282 6.924 4.573.986 17 All Maignant Cancers Female 2 53.223 132 6.3 0.282 6.924 4.530.474 15 Bladder Female 2 53.223 3.8 3.4 4.4 0.816 9.104.462 16 Brain and Other Nervous System Total 6 653.709 11.2 11.4 3.2 0.221 4.530.474 Breast Total 13 105.932 7.5 7.6 5.9 0.248 5.100 1.000 1.34 4.530.474 Breast Total 13 105.932 1.22 1.30 1.000 1.38 4.573.986 2 Breast Total 13 105.932 1.4 7.4 1.000 1.34 4.530.474 1 Colorectal Female 10.53.709				53 223		810.8					822.7
All Maignant Cancers Male 103 53,709 191.8 191.1 95.8 0.491 8.132 4.430,474 15 Bladder Total 8 106,932 7.5 6.9 6.0 0.521 4.77 9,104,462 Bladder Intra 6 105,932 7.5 6.9 6.0 0.521 4.77 9,104,462 Bladder Intra 6 105,709 112 114 4.3 0.818 100 4.530,474 Brain and Other Nervous System Female 2 53,223 3.8 3.8 2.7 10.00 111 9,104,462 1 Brain and Other Nervous System Female 2 53,223 3.8 3.8 2.7 1.000 1.11 9,104,462 1 Breast Male - 53,709 - - 0.20 1.000 1.31 4,530,474 2 Colorectal Male - 53,709 1.6 1.47 1.84 1.000 8.4 4,530,474 2 Colorectal Male 1.65,223								-			165.4
All Mailgrant Cancers Female 74 53,223 139.0 134.1 84.3 0.282 6,524 4,75,948 Bladder Male 6 55,709 11.2 10.7 4.5 0.598 366 4,573,988 Bladder Male 6 55,709 11.2 10.7 4.5 0.598 366 4,573,986 Brain and Other Nervous System Total 8 1008,932 7.5 7.6 5.9 0.2488 510 9,104,462 Breast Male 2 53,709 - - 0.2 1000 13 4,573,986 Breast Female 13 53,223 1.9 2.0 1.00 1.08 4,530,474 Colorectal Male 105,322 1.5 1.4.7 15.8 1.000 1.3 4,530,474 Colorectal Female 6 53,223 - - 2.0 0.272 163 4,530,474 Colorectal Female 6											177.8
Bladder Total 8 106,932 7,5 6.9 6.0 0.521 4.77 9,104,462 Bladder Female 2 53,223 3.8 3.4 1.4 0.816 108 4,530,474 Brain and Other Nervous System Male 2 53,223 3.8 3.4 1.4 0.816 108 4,530,474 Brain and Other Nervous System Total 8 105,932 1.2 11.7 9,704,462 1 Breast Total - 53,709 - - 0.22 1.000 1.11 9,704,462 1 Breast Male - 53,223 1.9 2.0 1.000 1.87 8,430,474 2 Colorectal Male 10 53,709 18.6 18.7 8.4 0.675 7.22 4,453,947 1 Colorectal Male 10 53,709 18.6 18.7 8.4 0.675 7.22 4,453,947 1 Colo											152.8
Bladder Male 6 33,709 11.2 10.7 4.5 0.598 369 4,573,988 374 4 573,988 374 4 573,988 374 4 573,988 374 4 573,989 374 4 573,989 374 573,980 374 573,974 574,974,974 574,974 574,974 574,974 574,974 574,974 574,974		Total				6.9	6.0	0.521	477		5.2
Brain and Other Nervous System Total 8 106.932 7.5 7.6 5.9 0.488 510 9.104.462 Brain and Other Nervous System Female 2 53.273 3.8 3.8 2.7 1.000 227 4.530.474 Breast Male - 53.709 - - 0.2 1.000 1.11 9.104.462 Breast Male - 53.223 2.4 2.36 1.3 1.000 1.84 4.530.474 Colorectal Total 16 53.223 1.9 2.0 1.0 1.000 87 4.530.474 Colorectal Total 16 53.709 1.0 7.5 9.0437 7.58 1.000 1.76 9.104.462 1.000 2.00 1.000 1.63.303.471 1.000 1.001 8.73 9.8 1.004.62 1.000 1.004.453 1.05.302.77 1.000 1.04.573.988 1.004.62 1.000 1.04.573.988 1.004.62 1.000 1.04.573.988 <td< td=""><td>Bladder</td><td>Male</td><td></td><td></td><td>11.2</td><td>10.7</td><td>4.5</td><td>0.598</td><td>369</td><td>4,573,988</td><td>8.1</td></td<>	Bladder	Male			11.2	10.7	4.5	0.598	369	4,573,988	8.1
Brain and Other Nervous System Male 6 53,709 11.2 11.4 32.2 0.221 4533,988 Brain and Other Nervous System Total 13 106,932 12.2 11.9 13.4 1.000 1.111 9,104,462 1 Breast Female 13 53,223 2.4 23.6 13.3 1.000 1.98 4,573,988 Cervix Female 1 53,223 1.9 2.0 1.0 1.000 1.98 4,530,474 2 Colorectal Total 16 106,322 1.9 2.0 1.0 1.000 87 4,530,474 1 Colorectal Female 6 53,223 1.3 1.7 7.3 0.601 1.54 4.503,474 1 Colorectal Female 6 53,223 - - 0.9 0.852 70 4.530,474 Colorectal Female - 53,223 - - 0.9 0.852 70		Female			3.8			0.816	108		2.4
Brain and Other Nervous System Female 2 53,223 3.8 3.8 2.7 1.000 227 4,530,474 Breast Male - 53,709 - - 0.02 1.000 1.111 9,104,462 Breast Female 1 53,223 2.4 2.36 1.3 1.000 1.84 4,530,474 Colroctal Total 16 105,322 1.9 2.0 1.0 1.000 .87 4,530,474 Colroctal Male 10 53,229 1.5.0 1.47 1.5.8 1.000 .87 4,530,474 Colroctal Male 10 53,229 1.8 1.6.7 7.3 0.031 56 5.7 4.5 0.685 388 4.573,988 Esophagus Female - 53,223 - - 0.1 1.000 1.4 4.530,474 Hodgkin Lymphoma Male - 53,223 - - 0.1 1.000 1.4											5.6
Breast Total 13 106.932 12.2 11.9 13.4 1.000 1,111 9,104.462 1.3 Breast Female 13 53.223 24.4 23.6 13.3 1.000 1.98 4.530.474 2 Colorectal Total 16 106.932 1.5 2.0 1.0 1.000 87 4.530.474 2 Colorectal Male 10 53.223 1.8 1.0.7 7.3 0.801 594 4.530.474 1 Colorectal Female 6 53.223 - - 2.0 0.272 169 4.530.474 1 5.6 5.7 4.5 0.431 458 9,104.462 1 5.6 5.7 4.5 0.852 70 4.530.474 1 5.6 5.7 4.5 0.431 458 9,104.462 1 5.7 4.5 0.852 70 4.530.474 1 1.000 14 4.573.984 1 1.000 14 </td <td></td> <td></td> <td></td> <td>53,709</td> <td></td> <td></td> <td>3.2</td> <td></td> <td></td> <td></td> <td>6.2</td>				53,709			3.2				6.2
$\begin{array}{c c c c c c c c c c c c c c c c c c c $				53,223							5.0
Breast Female 13 53,223 24.4 23.6 13.3 1.000 1,098 4,530,474 2 Colorectal Total 16 106,932 1.5 2.0 1.0 1.000 87 4,530,474 2 Colorectal Male 10 53,279 18.6 18.7 8.4 0.675 722 4,530,474 1 Colorectal Female 6 53,223 - - 2.0 0.272 168 4,530,474 1 Esophagus Total 3 106,932 2.8 2.8 5.4 0.431 458 9,104,462 Esophagus Female - 53,223 - - 0.3 1.000 14 4,573,984 Esophagus Female - 63,703 - - 0.1 1.000 14 4,573,984 Hodgkin Lymphoma Male 1 69,52 7 4.6 1.000 14 4,530,474 <t< td=""><td></td><td></td><td>13</td><td></td><td>12.2</td><td>11.9</td><td></td><td></td><td></td><td></td><td>12.2</td></t<>			13		12.2	11.9					12.2
Cervix Female 1 53,223 1.9 2.0 1.0 1.000 67 4,530,474 Colorectal Male 10 53,709 18.6 18.7 15.8 1.000 1.316 9.104,462 1 Colorectal Female 6 53,223 - - 2.0 0.675 722 4,530,474 1 Corpus Uleri Female - 53,223 - - 2.0 0.272 169 4,530,474 1 Esophagus Male 3 53,709 5.6 5.7 4.5 0.685 388 4,573,988 Esophagus Male - 53,223 - - 0.3 11000 25 9.104,462 Hodgkin Lymphoma Female - 53,223 - - 0.1 1.000 11 4,553,473,988 Hodgkin Lymphoma Female - 53,223 - - 0.1 1.000 114 4,550,474			-		-	-					0.3
											24.2
Colorectal Male 10 53,709 18.6 18.7 8.4 0.675 722 4,573,988 11 Colorectal Female - 53,223 - - 2.0 0.272 169 4,530,474 1 Scophagus Total 3 106,932 2.8 5.4 0.431 458 9.104,462 Esophagus Female - 53,223 - - 0.9 0.852 70 4,530,474 Hodgkin Lymphoma Female - 53,223 - - 0.3 11000 11 4,530,474 Hodgkin Lymphoma Female - 53,223 - - 0.1 1000 11 4,530,474 Kidney Male 1 63,709 1.9 1.9 2.9 0.437 245 4,573,988 Larynx Female 2 53,223 - - 0.1 1000 13 4,530,474 Larynx Female <											1.9 14.5
Colorectal Female 6 53,223 11.3 10.7 7.3 0.801 594 4,530,474 1 Esophagus Total 3 106,932 2.8 2.8 5.4 0.431 458 9,104,462 Esophagus Male 3 53,709 5.6 5.7 4.5 0.865 388 4,573,988 Esophagus Female - 53,223 - - 0.3 1.000 14 4,573,988 Hodgkin Lymphoma Male - 53,729 - - 0.1 1.000 14 4,573,988 Hodgkin Lymphoma Female - 53,729 - - 0.1 1.000 14 4,530,474 Kidney Male 1 53,709 1.9 1.9 2.9 0.437 245 4,573,988 Kidney Female 2 53,223 3.5 1.7 1.000 13 4,530,474 Larynx Female 1											14.5
Corpus Uteri Female - 53,223 - - 2.0 0.272 169 4,530,474 Esophagus Total 3 106,932 2.8 2.8 2.8 5.4 0.431 458 9,104,462 Esophagus Female - 53,223 - - 0.9 0.852 7.0 4,530,474 Hodgkin Lymphoma Male - 53,223 - - 0.1 1.000 12 4,530,474 Hodgkin Lymphoma Female - 53,223 - - 0.1 1.000 14 4,573,988 Hodgkin Lymphoma Female - 53,223 - - 0.1 1.000 11 4,530,474 Kidney Male 1 53,709 1.9 1.9 2.9 0.437 245 4,573,988 Laynx Female - 53,223 - - 0.1 1.000 14 4,530,474 Laynx Male											13.0
Esophagus Total 3 106,932 2.8 5.4 0.431 458 9,104,462 Esophagus Female - 53,223 - - 0.9 0.852 70 4,530,474 Hodgkin Lymphoma Total - 106,832 - - 0.3 1.000 125 9,104,462 Hodgkin Lymphoma Female - 53,223 - - 0.1 1.000 14 4,530,474 Kidney Male 1 53,709 2.8 2.7 4.6 0.647 383 9,104,462 Kidney Female 2 53,223 3.8 3.5 1.7 1.000 138 4,573,988 Larynx Female 1 53,709 1.9 1.8 0.8 1.000 75 9,104,462 Larynx Female - 53,223 - 0.1 1.000 11 4,530,474 Learynx Female 3 53,709											3.7
Esophagus Male 3 53,709 5.6 5.7 4.5 0.685 388 4,573,988 Hodgkin Lymphoma Total - 106,932 - - 0.9 0.852 70 4,530,474 Hodgkin Lymphoma Male - 53,223 - - 0.1 1.000 11 4,573,988 Hodgkin Lymphoma Female - 53,223 - - 0.1 1.000 11 4,573,988 Kidney Male 1 53,709 1.9 1.9 2.9 0.437 245 4,573,988 Larynx Total 1 106,932 0.9 0.9 0.9 1.000 75 9,104,462 Larynx Female - 53,223 - - 0.1 1.000 11 4,530,474 Learynx Female - 53,223 - - 0.1 1.000 11 4,530,474 Learynx Female 53,223											5.0
Esophagus Female - 53.223 - - 0.9 0.852 70 4.530.474 Hodgkin Lymphoma Male - 1069.932 - - 0.3 1.000 14 4573.988 Hodgkin Lymphoma Female - 53.709 - - 0.1 1.000 14 4573.988 Kidney Male 1 53.709 1.9 1.9 2.9 0.437 245 4573.988 Kidney Female 2 53.223 3.8 3.5 1.7 1.000 138 4.530.474 Larynx Total 1 106.932 0.9 0.9 1.000 138 4.530.474 Larynx Female 53.709 1.9 1.8 0.8 0.9 1.000 14 4.53.0474 Larynx Female 7 106.932 6.5 6.3 8.0 0.894 685 9.104.462 Leukemia Male 7 5.709 <				53,709							8.5
Hodgkin Lymphoma Total - 106,932 - - 0.3 1.000 25 9.104,462 Hodgkin Lymphoma Female - 53.223 - - 0.1 1.000 14 4.53.0474 Kidney Total 3 106.932 2.8 2.7 4.6 0.647 383 9.104,462 Kidney Female 2 53.223 3.8 3.5 1.7 1.000 13 4.53.0474 Larynx Total 1 106.932 0.9 0.9 0.9 0.9 0.9 0.9 1.000 13 4.53.0474 Larynx Female - 53.223 - - 0.1 0.00 64 4.573.988 Larynx Female - 53.709 7.4 7.3 4.7 0.8 0.00 64 4.573.988 Leukemia Male 4 53.709 7.4 7.3 4.7 0.99 939 34.57 3.08 627 9.104,462 Liver and Bile Duct Male 7 53.709	Esophagus			53.223							1.5
Hodgkin Lymphoma Male - 53.709 - 0.2 1.000 14 4,573.988 Kidney Total 3 106.932 - - 0.1 1.000 14 4,573.988 Kidney Male 1 53.709 1.9 2.9 0.437 245 4,573.988 Kidney Female 2 53.223 3.8 3.5 1.7 1.000 138 4,550.474 Larynx Total 1 106.932 0.9 0.9 1.9 1.8 0.8 1.000 64 4,573.988 Larynx Female - 53.223 - - 0.1 1.000 11 4,530.474 Leukemia Total 7 106.932 6.5 6.3 3.0 0.0895 393 4,573.988 Leukemia Female 3 53.223 7.5 7.6 7.3 0.890 627 9.104.462 Liver and Bile Duct Total 8			-		-	-					0.3
Hodgkin Lymphoma Female - 53,223 - - 0.1 1.000 11 4,530,474 Kidney Male 1 3 106,932 2.8 2.7 4.6 0.647 383 9.104,462 Kidney Female 2 53,223 3.8 3.5 1.7 1.000 138 4,530,474 Larynx Total 1 105,932 0.9 0.9 0.9 1.000 64 4,573,988 Larynx Female - 53,223 - - 0.1 1.000 14 4,530,474 Leukemia Total 7 106,932 6.5 6.3 8.0 0.894 658 9,104,462 Leukemia Female 3 53,223 5.6 5.3 3.3 1.000 265 4,530,474 Liver and Bile Duct Total 8 106,932 7.5 7.6 7.3 0.890 627 9,104,462 Lung and Bronchus T		Male	-		-	-		1.000			0.3
Kidney Male 1 53,709 1.9 1.9 2.9 0.437 245 4.573,988 Kidney Female 2 53,223 3.8 3.5 1.7 1.000 138 4.530,474 Larynx Total 1 106,932 0.9 0.9 0.9 1.000 75 9,104,462 Larynx Female - 53,223 - - 0.1 1.000 64 4,573,988 Larynx Female 7 106,932 6.5 6.3 8.0 0.894 658 9,104,462 Leukemia Male 4 53,709 7.4 7.3 4.7 0.995 393 4,573,988 Leukemia Female 3 53,223 7.6 7.3 0.880 627 9,104,462 Liver and Bile Duct Male 7 53,709 13.0 13.3 4.8 0.413 416 4,573,988 Liver and Bile Duct Female 1 53,223 1.9 1.9 2.5 0.571 211 4,530,474	Hodgkin Lymphoma	Female	-	53,223	-	-		1.000	11	4,530,474	0.2
Kidney Female 2 53,223 3.8 3.5 1.7 1.000 138 4,530,474 Larynx Total 1 106,932 0.9 0.9 0.9 1.000 75 9,104,462 Larynx Female - 53,223 - - 0.1 1.000 64 4,573,988 Leukemia Total 7 106,932 6.5 6.3 8.0 0.894 658 9,104,462 Leukemia Male 4 53,709 7.4 7.3 4.7 0.995 393 4,573,988 Liver and Bile Duct Total 8 106,932 7.5 7.6 7.3 0.890 627 9,104,462 Liver and Bile Duct Female 1 53,223 1.9 1.9 2.5 0.571 211 4,530,474 Lung and Bronchus Total 19 106,932 1.7.8 17.5 34.8 0.0056 1,531 4,530,474 3 Lung and Br		Total	3		2.8	2.7	4.6	0.647	383		4.2
Larynx Total 1 106,932 0.9 0.9 1.000 75 9,104,462 Larynx Female - 53,203 - - 0.1 1.000 64 4,573,988 Larynx Female - 53,223 - - 0.1 1.000 14 4,530,474 Leukemia Male 4 53,709 7,4 7,3 4,77 0.995 393 4,573,988 Leukemia Female 3 53,223 5.6 5.3 3.3 1.000 265 4,530,474 Liver and Bile Duct Male 7 53,709 13.0 13.3 4.8 0.413 416 4,573,988 Liver and Bile Duct Female 1 53,223 1.9 1.9 2.5 0.571 211 4,530,474 Lung and Bronchus Male 10 53,709 18.6 18.7 7.9 0.065 1,531 4,573,988 3 Lung and Bronchus Femal				53,709							5.4
Larjnx Male 1 53,709 1.9 1.8 0.8 1.000 64 4,573,988 Larynx Female - 53,223 - - 0.1 1.000 11 4,530,474 Leukemia Male 4 53,709 7.4 7.3 4.7 0.995 393 4,573,988 Leukemia Female 3 53,223 5.6 5.3 3.3 1.000 265 4,530,474 Liver and Bile Duct Total 8 106,932 7.5 7.6 7.3 0.890 627 9,104,462 Liver and Bile Duct Female 1 53,223 1.9 1.9 2.5 0.571 211 4,530,474 Lung and Bronchus Total 19 106,932 1.78 17.5 34.8 0.0056 1,531 4,573,988 3 Lung and Bronchus Female 9 53,223 1.69 1.6.3 16.9 0.651 1,531 4,573,988 3											3.0
Larjnx Female - 53,223 - - 0.1 1.000 11 4,530,474 Leukemia Male 7 106,932 6.5 6.3 8.0 0.894 658 9,104,462 Leukemia Female 3 53,223 5.6 5.3 3.3 1.000 265 4,530,474 Liver and Bile Duct Total 8 106,932 7.5 7.6 7.3 0.890 627 9,104,462 Liver and Bile Duct Male 7 53,709 13.0 13.3 4.8 0.413 416 4,573,988 Lurg and Bronchus Total 19 106,932 17.8 17.5 34.8 0.005 <			-								0.8
Leukemia Total 7 106,932 6.5 6.3 8.0 0.894 658 9,104,462 Leukemia Female 3 53,709 7.4 7.3 4.7 0.995 393 4,573,988 Liver and Bile Duct Total 8 106,932 7.5 7.6 7.3 0.890 627 9,104,462 Liver and Bile Duct Male 7 53,709 13.0 13.3 4.8 0.413 416 4,573,988 Liver and Bile Duct Female 1 53,709 17.8 17.5 34.8 0.005 1,531 4,573,988 Lung and Bronchus Total 19 106,932 17.8 17.5 34.8 0.0056 1,531 4,573,988 33 Lung and Bronchus Female 9 53,223 16.9 16.3 16.9 0.056 1,387 4,530,474 3 Melanoma of the Skin Total 2 106,932 1.9 1.8 3.6 0.617 299			1	53,709	1.9				-		1.4
Leukemia Male 4 53,709 7.4 7.3 4.7 0.995 393 4.573,988 Leukemia Female 3 53,223 5.6 5.3 3.3 1.000 265 4,530,474 Liver and Bile Duct Male 7 53,709 13.0 13.3 4.8 0.413 416 4,573,988 Liver and Bile Duct Male 7 53,709 13.0 13.3 4.8 0.413 416 4,573,988 Lung and Binochus Total 19 106,932 17.8 17.5 34.8 0.005 <				53,223	-						0.2
Leukemia Female 3 53,223 5.6 5.3 3.3 1.000 265 4,530,474 Liver and Bile Duct Total 8 106,932 7.5 7.6 7.3 0.890 627 9,104,462 Liver and Bile Duct Female 1 53,223 1.9 1.9 2.5 0.571 211 4,530,474 Lung and Bronchus Total 19 106,932 17.8 17.5 34.8 0.005 <			1								7.2 8.6
Liver and Bile Duct Total 8 106,932 7.5 7.6 7.3 0.890 627 9,104,462 Liver and Bile Duct Male 7 53,709 13.0 13.3 4.8 0.413 416 4,573,988 Liver and Bile Duct Female 1 53,223 1.9 1.9 2.5 0.571 211 4,530,474 Lung and Bronchus Male 10 53,709 17.8 17.5 34.8 0.005 2.918 9,104,462 3 Lung and Bronchus Male 10 53,709 18.6 18.7 17.9 0.065 1,331 4,573,988 3 Melanoma of the Skin Total 2 106,932 1.9 1.8 3.6 0.617 299 9,104,462 3 Melanoma of the Skin Male - 53,709 - - 2.4 0.190 200 4,573,988 Myeloma Male 4 53,709 7.4 7.4 2.2 0.354											0.0 5.8
Liver and Bile Duct Male 7 53,709 13.0 13.3 4.8 0.413 416 4,573,988 Liver and Bile Duct Female 1 53,223 1.9 1.9 2.5 0.571 211 4,530,474 Lung and Bronchus Total 19 106,932 17.8 17.5 34.8 0.005 <			3								6.9
Liver and Bile Duct Female 1 53,223 1.9 1.9 2.5 0.571 211 4,530,474 Lung and Bronchus Total 19 106,932 17.8 17.5 34.8 0.005 <			7								9.1
Lung and Bronchus Total 19 106,932 17.8 17.5 34.8 0.005 2,918 9,104,462 33 Lung and Bronchus Hale 10 53,709 18.6 18.7 17.9 0.065 1,531 4,573,988 33 Lung and Bronchus Female 9 53,223 16.9 16.3 16.9 0.056 1,387 4,530,474 33 Melanoma of the Skin Male - 53,709 - - 2.4 0.190 200 4,573,988 Melanoma of the Skin Female 2 53,223 3.8 3.7 1.2 0.669 99 4,530,474 Myeloma Total 6 106,932 5.6 5.4 3.9 0.388 319 9,104,462 Myeloma Male 4 53,709 7.4 7.4 2.2 0.354 184 4,573,988 Myeloma Female 2 53,223 3.8 3.6 1.7 0.989 135											4.7
Lung and Bronchus Male 10 53,709 18.6 18.7 17.9 0.065 1,531 4,573,988 33 Lung and Bronchus Female 9 53,223 16.9 16.3 16.9 0.056 1,387 4,573,988 33 Melanoma of the Skin Total 2 106,932 1.9 1.8 3.6 0.617 299 9,104,462 Melanoma of the Skin Female 2 53,223 3.8 3.7 1.2 0.669 99 4,530,474 Myeloma Total 6 106,932 5.6 5.4 3.9 0.388 319 9,104,462 Myeloma Male 4 53,709 7.4 7.4 2.2 0.354 184 4,573,988 Myeloma Female 2 53,223 3.8 3.6 1.7 0.989 135 4,530,474 Non-Hodgkin Lymphoma Female 3 53,223 3.8 3.6 1.7 0.989 135 4,53											32.1
Lung and BronchusFemale953,22316.916.316.90.0561,3874,530,4743Melanoma of the SkinTotal2106,9321.91.83.60.6172999,104,462Melanoma of the SkinMale-53,7092.40.1902004,573,988Melanoma of the SkinFemale253,2233.83.71.20.6699094,530,474MyelomaTotal6106,9325.65.43.90.3883199,104,462MyelomaMale453,7097.47.42.20.3541844,573,988MyelomaFemale253,2233.83.61.70.9891354,530,474Non-Hodgkin LymphomaTotal7106,9326.56.36.81.0005619,104,462Non-Hodgkin LymphomaMale453,7097.47.43.21.0002554,530,474Non-Hodgkin LymphomaFemale353,2235.65.23.21.0002554,530,474Oral Cavity and PharynxTotal3106,9322.82.83.21.0002729,104,462Oral Cavity and PharynxTotal3106,9322.83.21.0002729,104,462Oral Cavity and PharynxFemale153,2237.57.44.21.0003574,530,474Oral Cavity and											33.5
Melanoma of the Skin Total 2 106,932 1.9 1.8 3.6 0.617 299 9,104,462 Melanoma of the Skin Male - 53,709 - - 2.4 0.190 200 4,573,988 Melanoma of the Skin Female 2 53,223 3.8 3.7 1.2 0.669 99 4,530,474 Myeloma Total 6 106,932 5.6 5.4 3.9 0.388 319 9,104,462 Myeloma Male 4 53,709 7.4 7.4 2.2 0.354 184 4,573,988 Myeloma Female 2 53,223 3.8 3.6 1.7 0.989 135 4,530,474 Non-Hodgkin Lymphoma Male 4 53,709 7.4 7.4 3.6 0.972 306 4,573,988 Non-Hodgkin Lymphoma Female 3 53,223 5.6 5.2 3.2 1.000 255 4,530,474 Oral Cavi										4,530,474	30.6
Melanoma of the SkinFemale253,2233.83.71.20.669994,530,474MyelomaTotal6106,9325.65.43.90.3883199,104,462MyelomaMale453,7097.47.42.20.3541844,573,988MyelomaFemale253,2233.83.61.70.9891354,530,474Non-Hodgkin LymphomaTotal7106,9326.56.36.81.0005619,104,462Non-Hodgkin LymphomaMale453,7097.47.43.60.9723064,573,988Non-Hodgkin LymphomaFemale353,2235.65.23.21.0002554,530,474Oral Cavity and PharynxTotal3106,9322.82.83.21.0002729,104,462Oral Cavity and PharynxMale253,7093.73.82.21.0001904,573,988Oral Cavity and PharynxFemale153,2237.57.44.21.0003574,530,474OvaryFemale453,2237.57.44.21.0003574,530,474PancreasTotal17106,93215.915.813.90.4641,1739,104,462PancreasMale1153,70920.520.77.44.221.0003574,530,474PancreasMale11		Total	2		1.9	1.8	3.6	0.617		9,104,462	3.3
Myeloma Total 6 106,932 5.6 5.4 3.9 0.388 319 9,104,462 Myeloma Male 4 53,709 7.4 7.4 2.2 0.354 184 4,573,988 Myeloma Female 2 53,223 3.8 3.6 1.7 0.989 135 4,530,474 Non-Hodgkin Lymphoma Total 7 106,932 6.5 6.3 6.8 1.000 561 9,104,462 Non-Hodgkin Lymphoma Male 4 53,709 7.4 7.4 3.6 0.972 306 4,573,988 Non-Hodgkin Lymphoma Female 3 53,223 5.6 5.2 3.2 1.000 255 4,530,474 Oral Cavity and Pharynx Total 3 106,932 2.8 2.8 3.2 1.000 272 9,104,462 Oral Cavity and Pharynx Male 2 53,709 3.7 3.8 2.2 1.000 190 4,573,988 <t< td=""><td>Melanoma of the Skin</td><td>Male</td><td>-</td><td></td><td>-</td><td>-</td><td>2.4</td><td>0.190</td><td>200</td><td></td><td>4.4</td></t<>	Melanoma of the Skin	Male	-		-	-	2.4	0.190	200		4.4
MýelomaMale453,7097.47.42.20.3541844,573,988MyelomaFemale253,2233.83.61.70.9891354,530,474Non-Hodgkin LymphomaTotal7106,9326.56.36.81.0005619,104,462Non-Hodgkin LymphomaMale453,7097.47.43.60.9723064,573,988Non-Hodgkin LymphomaFemale353,2235.65.23.21.0002554,530,474Oral Cavity and PharynxTotal3106,9322.82.83.21.0002729,104,462Oral Cavity and PharynxMale253,7093.73.82.21.0002729,104,462Oral Cavity and PharynxFemale153,2237.57.44.21.000824,530,474OvaryFemale453,7093.73.82.21.0003574,530,474OvaryFemale453,2237.57.44.21.0003574,530,474PancreasTotal17106,93215.915.813.90.4641,1739,104,4621PancreasMale1153,70920.520.77.40.2636394,573,9881PancreasFemale653,22311.311.06.41.0005344,530,4741PancreasFemale <td>Melanoma of the Skin</td> <td>Female</td> <td></td> <td></td> <td></td> <td>3.7</td> <td>1.2</td> <td>0.669</td> <td>99</td> <td>4,530,474</td> <td>2.2</td>	Melanoma of the Skin	Female				3.7	1.2	0.669	99	4,530,474	2.2
Myeloma Female 2 53,223 3.8 3.6 1.7 0.989 135 4,530,474 Non-Hodgkin Lymphoma Total 7 106,932 6.5 6.3 6.8 1.000 561 9,104,462 Non-Hodgkin Lymphoma Male 4 53,709 7.4 7.4 3.6 0.972 306 4,573,988 Non-Hodgkin Lymphoma Female 3 53,223 5.6 5.2 3.2 1.000 255 4,530,474 Oral Cavity and Pharynx Total 3 106,932 2.8 2.2 1.000 272 9,104,462 Oral Cavity and Pharynx Male 2 53,709 3.7 3.8 2.2 1.000 272 9,104,462 Oral Cavity and Pharynx Male 2 53,709 3.7 3.8 2.2 1.000 82 4,530,474 Ovary Female 1 53,223 7.5 7.4 4.2 1.000 357 4,530,474 Pancre											3.5
Non-Hodgkin LymphomaTotal7106,9326.56.36.81.0005619,104,462Non-Hodgkin LymphomaMale453,7097.47.43.60.9723064,573,988Non-Hodgkin LymphomaFemale353,2235.65.23.21.0002554,530,474Oral Cavity and PharynxTotal3106,9322.82.83.21.0002729,104,462Oral Cavity and PharynxMale253,7093.73.82.21.0001904,573,988Oral Cavity and PharynxMale153,2231.91.81.01.000824,530,474OvaryFemale453,2237.57.44.21.0003574,530,474PancreasTotal17106,93215.915.813.90.4641,1739,104,4621PancreasMale1153,70920.520.77.44.21.0005344,573,9881PancreasFemale653,22311.311.06.41.0005344,573,9881PancreasFemale653,22311.311.06.41.0005344,573,9881PancreasFemale653,22311.311.06.41.0005344,573,9881PancreasFemale653,22311.311.00.6349834,573,9882 <td></td> <td></td> <td></td> <td>53,709</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>4.0</td>				53,709							4.0
Non-Hodgkin Lymphoma Male 4 53,709 7.4 7.4 3.6 0.972 306 4,573,988 Non-Hodgkin Lymphoma Female 3 53,223 5.6 5.2 3.2 1.000 255 4,530,474 Oral Cavity and Pharynx Total 3 106,932 2.8 2.8 3.2 1.000 272 9,104,462 Oral Cavity and Pharynx Male 2 53,709 3.7 3.8 2.2 1.000 190 4,573,988 Oral Cavity and Pharynx Male 2 53,709 3.7 3.8 2.2 1.000 190 4,573,988 Oral Cavity and Pharynx Female 1 53,223 1.9 1.8 1.0 1.000 82 4,530,474 Ovary Female 4 53,223 7.5 7.4 4.2 1.000 357 4,530,474 Pancreas Total 17 106,932 15.9 15.8 13.9 0.464 1,173 9,104,462										4,530,474	3.0
Non-Hodgkin Lymphoma Female 3 53,223 5.6 5.2 3.2 1.000 255 4,530,474 Oral Cavity and Pharynx Total 3 106,932 2.8 2.8 3.2 1.000 272 9,104,462 Oral Cavity and Pharynx Male 2 53,709 3.7 3.8 2.2 1.000 190 4,573,988 Oral Cavity and Pharynx Female 1 53,223 1.9 1.8 1.0 1.000 82 4,530,474 Ovary Female 4 53,223 7.5 7.4 4.2 1.000 357 4,530,474 Pancreas Total 17 106,932 15.9 15.8 13.9 0.464 1,173 9,104,462 1 Pancreas Total 17 106,932 15.9 15.8 13.9 0.464 1,173 9,104,462 1 Pancreas Male 11 53,709 20.5 20.7 7 4 0.263 639	Non-Hodgkin Lymphoma		7	106,932						9,104,462	6.2
Oral Cavity and Pharynx Total 3 106,932 2.8 2.8 3.2 1.000 272 9,104,462 Oral Cavity and Pharynx Male 2 53,709 3.7 3.8 2.2 1.000 190 4,573,988 Oral Cavity and Pharynx Female 1 53,223 1.9 1.8 1.0 1.000 82 4,530,474 Ovary Female 4 53,223 7.5 7.4 4.2 1.000 357 4,530,474 Pancreas Total 17 106,932 15.9 15.8 13.9 0.464 1,173 9,104,462 1 Pancreas Male 11 53,709 20.5 20.7 7.4 0.263 639 4,573,988 1 Pancreas Male 11 53,223 11.3 11.0 6.4 1.000 534 4,530,474 Pancreas Female 6 53,223 11.3 11.0 6.4 1.000 534 4,530,474			4			7.4					6.7
Oral Cavity and Pharynx Male 2 53,709 3.7 3.8 2.2 1.000 190 4,573,988 Oral Cavity and Pharynx Female 1 53,223 1.9 1.8 1.0 1.000 82 4,530,474 Ovary Female 4 53,223 7.5 7.4 4.2 1.000 357 4,530,474 Pancreas Total 17 106,932 15.9 15.8 13.9 0.464 1,173 9,104,462 1 Pancreas Male 11 53,709 20.5 20.7 7.4 0.263 639 4,573,988 1 Pancreas Male 11 53,709 20.5 20.7 7.4 0.263 639 4,573,988 1 Pancreas Female 6 53,223 11.3 11.0 6.4 1.000 534 4,530,474 1 Prostate Male 14 53,709 26.1 25.1 12.0 0.634 983											5.6
Oral Cavity and PharynxFemale153,2231.91.81.01.000824,530,474OvaryFemale453,2237.57.44.21.0003574,530,474PancreasTotal17106,93215.915.813.90.4641,1739,104,4621PancreasMale1153,70920.520.77.40.2636394,573,9881PancreasFemale653,22311.311.06.41.0005344,530,4741ProstateMale1453,70926.125.112.00.6349834,573,9882											3.0
Ovary Female 4 53,223 7.5 7.4 4.2 1.000 357 4,530,474 Pancreas Total 17 106,932 15.9 15.8 13.9 0.464 1,173 9,104,462 1 Pancreas Male 11 53,709 20.5 20.7 7.4 0.263 639 4,573,988 1 Pancreas Female 6 53,223 11.3 11.0 6.4 1.000 534 4,530,474 1 Prostate Male 14 53,709 26.1 25.1 12.0 0.634 983 4,573,988 2											4.2
PancreasTotal17106,93215.915.813.90.4641,1739,104,4621PancreasMale1153,70920.520.77.40.2636394,573,9881PancreasFemale653,22311.311.06.41.0005344,530,4741ProstateMale1453,70926.125.112.00.6349834,573,9882										4,530,474	1.8 7.9
Pancreas Male 11 53,709 20.5 20.7 7.4 0.263 639 4,573,988 1 Pancreas Female 6 53,223 11.3 11.0 6.4 1.000 534 4,530,474 1 Prostate Male 14 53,709 26.1 25.1 12.0 0.634 983 4,573,988 2	,										12.9
Pancreas Female 6 53,223 11.3 11.0 6.4 1.000 534 4,530,474 1 Prostate Male 14 53,709 26.1 25.1 12.0 0.634 983 4,573,988 2											12.9
Prostate Male 14 53,709 26.1 25.1 12.0 0.634 983 4,573,988 2											14.0
				53 700							21.5
ioiuiada – Etulari 4 Etulo 932 Et 37 Et 23 EU 307 Et 190 E 9 104 467 E	Stomach	Total	4	106,932	3.7	3.7	2.3	0.387	190	9,104,462	21.3
											2.5
											1.6

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Minidoka County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	93.8% 10.5%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	59.2%
Current Tobacco User (2020–2022) Other Cancer-Related	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	22.4%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	21.2% 75.1% 13.9% 18.3%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





NEZ PERCE COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 1,262 cases of invasive cancer were diagnosed among Nez Perce County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in Nez PerceCounty and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Nez Perce County	State of Idaho
All Sites/Types	1,262	47,333
Female Breast	181	6,943
Prostate	187	6,766
Lung & Bronchus	180	4,959
Colorectal	97	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Nez Perce County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Nez Perce County. The table also shows the number of observed cases,

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 483 Nez Perce County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Nez Perce County and the State of Idaho, 2018–2022

Mortality 2018–2022	Nez Perce County	State of Idaho
All Deaths	2,788	80,538
Cancer Deaths	483	15,233
% of All Deaths	17.3%	18.9%
Lung & Bronchus	105	2,937
Colorectal	45	1,332
Pancreas	39	1,190
Female Breast	22	1,111
Prostate	33	997

person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, nonmalignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Nez Perce County was 616.7 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (524.3) gives an estimate of the relative burden of disease in Nez Perce County.

The age- and sex-adjusted incidence rate of invasive cancer in Nez Perce County, all sites combined, was 516.4 cases per 100,000 persons per year during 2017–2021. There were fewer cases of cancer in Nez Perce County (1,262) than expected (1,281.3) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Nez Perce County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Nez Perce County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Nez Perce County, all sites combined, was 180.6 deaths per 100,000 persons per year during 2018–2022, compared with 163.8 for the remainder of the state. There were statistically significantly more cancer deaths in Nez Perce County (483) than expected (438.2) based upon rates in the remainder of the state (p=.037).

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN NEZ PERCE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Nez	Perce Cour	nty			Ren	nainder of Ida	aho
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	1,262	204,649	616.7	516.4	1,281.3	0.601	46,071	8,787,457	524.3
All Sites Combined	Male	670	204,049	662.7	552.2	676.6	0.819	24,600	4,411,172	557.7
All Sites Combined	Female	592	103,548	571.7	482.9	601.5	0.718	24,000	4,376,285	490.6
Bladder	Total	61	204.649	29.8	23.4	63.9	0.776	2,159	8,787,457	24.6
Bladder	Male	47	101,101	46.5	36.8	50.0	0.738	1,726	4,411,172	39.1
Bladder	Female	14	103,548	13.5	10.7	13.0	0.843	433	4,376,285	9.9
Brain - malignant	Total	19	204,649	9.3	8.2	16.8	0.652	638	8,787,457	7.3
Brain - malignant	Male	12	101,101	11.9	10.6	9.5	0.491	370	4,411,172	8.4
Brain - malignant	Female	7	103,548	6.8	5.9	7.3	1.000	268	4,376,285	6.1
Brain and other CNS - non-malignant	Total	28	204,649	13.7	11.6	41.7	0.033 <<	1,519	8,787,457	17.3
	Male	8	101,101	7.9	6.8	13.1	0.193	492	4,411,172	11.2
Brain and other CNS - non-malignant Breast	Female Total	20 181	103,548 204,649	19.3 88.4	16.3 76.5	28.8 183.7	0.109 0.878	1,027 6,827	4,376,285 8,787,457	23.5 77.7
Breast	Male	-	101,101	- 00.4	70.5	1.8	0.315	65	4,411,172	1.5
Breast	Female	181	103,548	174.8	151.5	184.6	0.828	6,762	4,376,285	154.5
Breast - in situ	Total	32	204,649	15.6	13.9	34.9	0.701	1,337	8,787,457	15.2
Breast - in situ	Male	-	101,101	-	-	0.1	1.000	4	4,411,172	0.1
Breast - in situ	Female	32	103,548	30.9	27.6	35.3	0.653	1,333	4,376,285	30.5
Cervix	Female	5	103,548	4.8	4.7	7.1	0.582	289	4,376,285	6.6
Colorectal	Total	97	204,649	47.4	39.3	99.3	0.868	3,535	8,787,457	40.2
Colorectal	Male	52	101,101	51.4	43.2	52.6	1.000	1,925	4,411,172	43.6
Colorectal	Female	45 31	103,548	43.5 29.9	35.6	46.6	0.896	1,610	4,376,285	36.8
Corpus Uteri	Female		103,548 204.649		26.1	35.9	0.466 0.873	1,323	4,376,285	30.2
Esophagus Esophagus	Total Male	15 12	204,649	7.3 11.9	6.0 9.7	14.1 11.7	1.000	492 417	8,787,457 4.411.172	5.6 9.5
Esophagus	Female	3	103,548	2.9	2.3	2.2	0.761	75	4,376,285	1.7
Hodgkin Lymphoma	Total	4	204.649	2.0	1.9	5.2	0.796	218	8.787.457	2.5
Hodgkin Lymphoma	Male	2	101,101	2.0	1.9	3.0	0.826	127	4,411,172	2.9
Hodgkin Lymphoma	Female	2	103,548	1.9	1.9	2.2	1.000	91	4,376,285	2.1
Kidney and Renal Pelvis	Total	47	204,649	23.0	19.5	52.3	0.511	1,904	8,787,457	21.7
Kidney and Renal Pelvis	Male	33	101,101	32.6	27.8	34.4	0.902	1,277	4,411,172	28.9
Kidney and Renal Pelvis	Female	14	103,548	13.5	11.4	17.7	0.464	627	4,376,285	14.3
Larynx	Total	10	204,649	4.9	4.0	5.9	0.161	210	8,787,457	2.4
Larynx	Male Female	8 2	101,101 103,548	7.9 1.9	6.5 1.6	4.5 1.4	0.168 0.833	159 51	4,411,172 4,376,285	3.6 1.2
Larynx Leukemia	Total	39	204,649	1.9	15.8	47.4	0.835	1,688	8,787,457	19.2
Leukemia	Male	24	101,101	23.7	19.8	27.8	0.542	1,000	4,411,172	22.9
Leukemia	Female	15	103,548	14.5	11.9	19.4	0.378	676	4,376,285	15.4
Liver and Bile Duct	Total	20	204,649	9.8	8.2	22.8	0.649	823	8,787,457	9.4
Liver and Bile Duct	Male	12	101,101	11.9	10.0	15.8	0.413	582	4,411,172	13.2
Liver and Bile Duct	Female	8	103,548	7.7	6.4	6.9	0.769	241	4,376,285	5.5
Lung and Bronchus	Total	180	204,649	88.0	70.5	138.8	0.001 >>	4,779	8,787,457	54.4
Lung and Bronchus	Male	82	101,101	81.1	65.6	68.4	0.119	2,413	4,411,172	54.7
Lung and Bronchus	Female	98 65	103,548	94.6	75.5	70.2	0.002 >>	2,366	4,376,285	54.1
Melanoma of the Skin Melanoma of the Skin	Total Male	65 34	204,649 101,101	31.8 33.6	26.9 28.0	84.6 51.2	0.032 << 0.014 <<	3,079 1,861	8,787,457 4,411,172	35.0 42.2
Melanoma of the Skin	Female	34 31	101,101	29.9	26.0	32.9	0.824	1,001	4,411,172	27.8
Myeloma	Total	11	204.649	5.4	4.4	20.6	0.032 <<	717	8,787,457	8.2
Myeloma	Male	8	101,101	7.9	6.4	12.4	0.265	439	4,411,172	10.0
Myeloma	Female	3	103,548	2.9	2.4	8.1	0.081	278	4,376,285	6.4
Non-Hodgkin Lymphoma	Total	55	204,649	26.9	22.5	53.9	0.919	1,937	8,787,457	22.0
Non-Hodgkin Lymphoma	Male	33	101,101	32.6	27.8	30.0	0.628	1,113	4,411,172	25.2
Non-Hodgkin Lymphoma	Female	22	103,548	21.2	17.4	23.8	0.818	824	4,376,285	18.8
Oral Cavity and Pharynx	Total	37	204,649	18.1	15.3	35.2	0.805	1,278	8,787,457	14.5
Oral Cavity and Pharynx Oral Cavity and Pharynx	Male Female	30 7	101,101 103,548	29.7 6.8	25.2 5.6	24.6 10.5	0.317 0.364	910 368	4,411,172 4,376,285	20.6 8.4
Ovary	Female	14	103,548	13.5	11.6	10.5	0.364	539	4,376,285	12.3
Pancreas	Total	44	204,649	21.5	17.2	42.0	0.796	1,444	8,787,457	12.3
Pancreas	Male	27	101,101	26.7	21.6	22.7	0.415	799	4,411,172	18.1
Pancreas	Female	17	103,548	16.4	13.1	19.2	0.730	645	4,376,285	14.7
Prostate	Male	187	101,101	185.0	155.3	179.5	0.597	6,579	4,411,172	149.1
Stomach	Total	12	204,649	5.9	4.8	13.2	0.877	462		5.3
Stomach	Male	8	101,101	7.9	6.5	8.3	1.000	299	4,411,172	6.8
Stomach	Female	4	103,548	3.9	3.1	4.8	0.961	163	4,376,285	3.7
Testis	Male	3	101,101	3.0	3.0	6.1	0.281	271	4,411,172	6.1
Thyroid	Total	28	204,649	13.7	12.9	28.5	1.000	1,157	8,787,457	13.2
Thyroid	Male	7	101,101	6.9	6.3	9.2	0.598	365	4,411,172	8.3
Thyroid	Female	21	103,548	20.3	19.6	19.4	0.778	792	4,376,285	18.1
Pediatric Age 0 to 19	Total	6	48,403	12.4	12.3	8.3	0.553	419	2,450,921	17.1
Pediatric Age 0 to 19	Male	2	24,561	8.1	8.1	4.2	0.426	212	1,249,760	17.0
Pediatric Age 0 to 19	Female	4	23,842	16.8	16.7	4.1	1.000	207	1,201,161	17.2

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN NEZ PERCE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Nez	Perce Coun	ity			Re	mainder of Idah	10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	2,788	207,277	1,345.1	998.3	2,411.5	0.000 >>	77,747	9,004,117	863.5
All Causes of Death	Male	1,418	102,513	1,383.2	1,062.6	1,220.0	0.000 >>	41,368	4,525,184	914.2
All Causes of Death	Female	1,370	104,764	1,307.7	938.6	1,185.5	0.000 >>	36,379	4,478,933	812.2
All Malignant Cancers	Total	483	207,277	233.0	180.6	438.2	0.037 >>	14,750	9,004,117	163.8
All Malignant Cancers	Male	263	102,513	256.6	200.1	231.6	0.046 >>	7,972	4,525,184	176.2
All Malignant Cancers	Female	220	104,764	210.0	162.1	205.3	0.322	6,778	4,478,933	151.3
Bladder	Total	20	207,277	9.6	6.9	15.1	0.257	465	9,004,117	5.2
Bladder	Male	15	102,513	14.6	10.5	11.4	0.355	360	4,525,184	8.0
Bladder	Female	5	104,764	4.8	3.4	3.5	0.546	105	4,478,933	2.3
Brain and Other Nervous System	Total	17	207,277	8.2	7.0	13.6	0.419	501	9,004,117	5.6
	Male	11	102,513	10.7	9.3	7.3	0.242	278	4,525,184	6.1
Brain and Other Nervous System	Female	6 22	104,764	5.7	4.8 8.3	6.2 32.6	1.000	223	4,478,933	5.0
Breast Breast	Total Male	22	207,277 102,513	10.6	0.3	0.4	0.066 1.000	1,102 13	9,004,117 4,525,184	12.2 0.3
Breast	Female	- 22	102,513	- 21.0	- 16.4	32.7	0.064	1,089	4,525,164	24.3
Cervix	Female	22	104,764	1.9	10.4	2.2	1.000	1,089	4,478,933	24.3
Colorectal	Total	45	207,277	21.7	17.1	37.7	0.272	1,287	9,004,117	14.3
Colorectal	Male	18	102,513	17.6	14.1	20.1	0.750	714	4,525,184	15.8
Colorectal	Female	27	104,764	25.8	19.7	17.6	0.043 >>	573	4,478,933	12.8
Corpus Uteri	Female	3	104,764	2.9	2.3	4.9	0.569	166	4,478,933	3.7
Esophagus	Total	12	207,277	5.8	4.6	12.9	0.942	449	9,004,117	5.0
Esophagus	Male	9	102,513	8.8	7.1	10.7	0.744	382	4,525,184	8.4
Esophagus	Female	3	104,764	2.9	2.2	2.1	0.676	67	4,478,933	1.5
Hodgkin Lymphoma	Total	-	207,277	-	-	0.7	0.978	25	9,004,117	0.3
Hodgkin Lymphoma	Male	-	102,513	-	-	0.4	1.000	14	4,525,184	0.3
Hodgkin Lymphoma	Female	-	104,764	-	-	0.3	1.000	11	4,478,933	0.2
Kidney	Total	12	207,277	5.8	4.4	11.2	0.895 0.504	374	9,004,117	4.2 5.2
Kidney Kidney	Male Female	9 3	102,513 104,764	8.8 2.9	6.9 2.1	6.9 4.3	0.504	237 137	4,525,184 4,478,933	5.2 3.1
Larynx	Total	1	207,277	0.5	0.4	2.2	0.709	75	9,004,117	0.8
Larynx	Male	1	102,513	1.0	0.4	1.9	0.885	64	4,525,184	1.4
Larynx	Female	-	104,764	-	-	0.3	1.000	11	4,478,933	0.2
Leukemia	Total	20	207,277	9.6	7.3	19.5	0.977	645	9,004,117	7.2
Leukemia	Male	13	102,513	12.7	9.8	11.3	0.689	384	4,525,184	8.5
Leukemia	Female	7	104,764	6.7	5.0	8.1	0.866	261	4,478,933	5.8
Liver and Bile Duct	Total	17	207,277	8.2	6.6	17.6	1.000	618	9,004,117	6.9
Liver and Bile Duct	Male	9	102,513	8.8	7.2	11.5	0.585	414	4,525,184	9.1
Liver and Bile Duct	Female	8	104,764	7.6	6.1	6.0	0.517	204	4,478,933	4.6
Lung and Bronchus	Total	105	207,277	50.7	39.4	83.8	0.028 >>	2,832	9,004,117	31.5
Lung and Bronchus	Male	50 55	102,513	48.8 52.5	38.5 40.3	42.8 40.9	0.303 0.040 >>	1,491	4,525,184	32.9 29.9
Lung and Bronchus Melanoma of the Skin	Female Total	5 5	104,764 207,277	52.5 2.4	40.3	40.9	0.040 >>	1,341 296	4,478,933 9,004,117	29.9
	Male	5	102,513	2.4	3.1	6.0 5.6	0.281	290 196	4,525,184	4.3
Melanoma of the Skin	Female	1	102,515	1.0	0.8	3.0	0.410	100	4,478,933	2.2
Myeloma	Total	9	207,277	4.3	3.3	9.6	1.000	316	9,004,117	3.5
Myeloma	Male	7	102,513	6.8	5.2	5.4	0.593	181	4,525,184	4.0
Myeloma	Female	2	104,764	1.9	1.4	4.2	0.421	135	4,478,933	3.0
Non-Hodgkin Lymphoma	Total	25	207,277	12.1	9.1	16.5	0.062	543	9,004,117	6.0
	Male	13	102,513	12.7	9.9	8.6	0.192	297	4,525,184	6.6
	Female	12	104,764	11.5	8.3	7.9	0.210	246	4,478,933	5.5
Oral Cavity and Pharynx	Total	11	207,277	5.3	4.3	7.6	0.288	264	9,004,117	2.9
	Male	7	102,513	6.8	5.5	5.2	0.528	185	4,525,184	4.1
, ,	Female	4	104,764	3.8	3.0	2.3	0.416	79	4,478,933	1.8
Ovary	Female	6	104,764	5.7	4.5	10.5	0.207	355	4,478,933	7.9
Pancreas	Total Male	39 19	207,277	18.8 18.5	14.9 14.9	33.5 17.8	0.387 0.844	1,151	9,004,117 4,525,184	12.8
Pancreas Pancreas	iviale Female	19 20	102,513 104,764	18.5	14.9 14.9	17.8	0.844 0.321	631 520	4,525,184 4,478,933	13.9 11.6
	Male	33	104,704	32.2	23.1	30.4	0.686	964	4,525,184	21.3
Stomach	Total	7	207,277	3.4	23.1	5.4	0.603	187	9,004,117	21.3
	Male	6	102,513	5.9	4.6	3.3	0.223	113	4,525,184	2.5
	Female	1	102,010	1.0	0.8	2.1	0.742	74	4,478,933	1.7
otomaon	i ciliale	1	104,704	1.0	0.0	۷.۱	0.742	74	4,410,933	1.7

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Nez Perce County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	92.2% 9.5%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	76.1% 72.5% 74.9%
Current Tobacco User (2020–2022) Other Cancer-Related	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	19.9%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	25.3% 77.0% 18.2% 18.8%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





ONEIDA COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 129 cases of invasive cancer were diagnosed among Oneida County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in OneidaCounty and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Oneida County	State of Idaho
All Sites/Types	129	47,333
Female Breast	11	6,943
Prostate	17	6,766
Lung & Bronchus	14	4,959
Colorectal	10	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Oneida County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Oneida County. The table also shows the number of observed cases, person-

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 38 Oneida County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Oneida County and the State of Idaho, 2018–2022

Mortality 2018–2022	Oneida County	State of Idaho
All Deaths	255	80,538
Cancer Deaths	38	15,233
% of All Deaths	14.9%	18.9%
Lung & Bronchus	5	2,937
Colorectal	1	1,332
Pancreas	2	1,190
Female Breast	3	1,111
Prostate	9	997

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Oneida County was 575.1 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (526.3) gives an estimate of the relative burden of disease in Oneida County.

The age- and sex-adjusted incidence rate of invasive cancer in Oneida County, all sites combined, was 489.0 cases per 100,000 persons per year during 2017–2021. There were fewer cases of cancer in Oneida County (129) than expected (138.8) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Oneida County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Oneida County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Oneida County, all sites combined, was 132.9 deaths per 100,000 persons per year during 2018–2022, compared with 165.4 for the remainder of the state. There were fewer cancer deaths in Oneida County (38) than expected (47.3) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN ONEIDA COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Oneida County						Remainder of Idaho				
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude		
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)		
All Sites Combined	Total	129	22,430	575.1	489.0	138.8	0.432	47,204	8,969,676	526.3		
All Sites Combined	Male	85	11,279	753.6	614.4	77.4	0.416	25,185	4,500,994	559.5		
All Sites Combined	Female	44	11,151	394.6	348.0	62.3	0.018 <<	22,019	4,468,682	492.7		
Bladder	Total	13	22,430	58.0	46.1	6.9	0.051	2,207	8,969,676	24.6		
Bladder Bladder	Male Female	13	11,279 11,151	115.3	88.8	5.7 1.3	0.012 >> 0.519	1,760 447	4,500,994 4,468,682	39.1 10.0		
Brain - malignant	Total	- 1	22,430	- 4.5	- 4.0	1.3	0.904	656	8,969,676	7.3		
Brain - malignant	Male	1	11,279	8.9	7.9	1.0	1.000	381	4,500,994	8.5		
Brain - malignant	Female	- '	11,151	-	-	0.8	0.924	275	4,468,682	6.2		
Brain and other CNS - non-malignant	Total	1	22,430	4.5	3.9	4.4	0.128	1,546	8,969,676	17.2		
0	Male	1	11,279	8.9	7.6	1.5	1.000	499	4,500,994	11.1		
	Female	-	11,151	-	-	3.0	0.104	1,047	4,468,682	23.4		
Breast	Total	11	22,430	49.0	43.3	19.8	0.046 <<	6,997	8,969,676	78.0		
Breast Breast	Male Female	- 11	11,279 11,151	- 98.6	- 89.1	0.2 19.1	1.000 0.065	65 6,932	4,500,994 4,468,682	1.4 155.1		
Breast - in situ	Total	4	22,430	17.8	16.2	3.8	1.000	1,365	8,969,676	15.2		
Breast - in situ	Male	-	11,279	-	-	0.0	1.000	4	4,500,994	0.1		
Breast - in situ	Female	4	11,151	35.9	33.4	3.6	0.990	1,361	4,468,682	30.5		
Cervix	Female	-	11,151	-	-	0.7	0.974	294	4,468,682	6.6		
Colorectal	Total	10	22,430	44.6	37.8	10.7	0.995	3,622	8,969,676	40.4		
Colorectal	Male	7	11,279	62.1	51.8	5.9	0.760	1,970	4,500,994	43.8		
Colorectal	Female	3	11,151	26.9	23.1	4.8	0.585	1,652	4,468,682	37.0		
Corpus Uteri	Female	3	11,151	26.9	24.4	3.7	0.980	1,351	4,468,682	30.2		
Esophagus Esophagus	Total Male	1	22,430 11,279	4.5 8.9	3.7 7.1	1.5 1.3	1.000 1.000	506 428	8,969,676 4,500,994	5.6 9.5		
Esophagus	Female	_ '	11,151	0.9	-	0.2	1.000	420	4,468,682	1.7		
Hodgkin Lymphoma	Total	-	22,430	-	-	0.2	1.000	222	8,969,676	2.5		
Hodgkin Lymphoma	Male	-	11,279	-	-	0.3	1.000	129	4.500.994	2.9		
Hodgkin Lymphoma	Female	-	11,151	-	-	0.2	1.000	93	4,468,682	2.1		
Kidney and Renal Pelvis	Total	7	22,430	31.2	26.9	5.6	0.675	1,944	8,969,676	21.7		
Kidney and Renal Pelvis	Male	6	11,279	53.2	44.7	3.9	0.396	1,304	4,500,994	29.0		
Kidney and Renal Pelvis	Female	1	11,151	9.0	7.8	1.8	0.910	640	4,468,682	14.3		
Larynx	Total	-	22,430	-	-	0.7	1.000	220	8,969,676	2.5		
Larynx	Male Female	-	11,279	-	-	0.5	1.000 1.000	167	4,500,994	3.7 1.2		
Larynx Leukemia	Total	- 7	11,151 22,430	- 31.2	- 26.1	0.2 5.1	0.518	53 1,720	4,468,682 8,969,676	1.2		
Leukemia	Male	, 5	11,279	44.3	36.2	3.2	0.425	1,031	4,500,994	22.9		
Leukemia	Female	ž	11,151	17.9	15.3	2.0	1.000	689	4,468,682	15.4		
Liver and Bile Duct	Total	2	22,430	8.9	7.5	2.5	1.000	841	8,969,676	9.4		
Liver and Bile Duct	Male	2	11,279	17.7	14.5	1.8	1.000	592	4,500,994	13.2		
Liver and Bile Duct	Female	-	11,151	-	-	0.7	0.972	249	4,468,682	5.6		
Lung and Bronchus	Total	14	22,430	62.4	50.4	15.3	0.868	4,945	8,969,676	55.1		
Lung and Bronchus	Male	10	11,279	88.7	69.3	8.0	0.559	2,485	4,500,994	55.2		
Lung and Bronchus Melanoma of the Skin	Female Total	4	11,151	35.9	29.9	7.4	0.284	2,460	4,468,682	55.0		
Melanoma of the Skin Melanoma of the Skin	Male	9 6	22,430 11,279	40.1 53.2	34.8 43.9	9.0 5.7	1.000 1.000	3,135 1,889	8,969,676 4,500,994	35.0 42.0		
Melanoma of the Skin	Female	3	11,151	26.9	24.7	3.4	1.000	1,009	4,468,682	27.9		
Myeloma	Total	1	22,430	4.5	3.7	2.2	0.706	727	8,969,676	8.1		
Myeloma	Male	1	11,279	8.9	7.1	1.4	1.000	446	4,500,994	9.9		
Myeloma	Female	-	11,151	-	-	0.8	0.882	281	4,468,682	6.3		
Non-Hodgkin Lymphoma	Total	2	22,430	8.9	7.6	5.9	0.137	1,990	8,969,676	22.2		
Non-Hodgkin Lymphoma	Male	2	11,279	17.7	14.7	3.4	0.662	1,144	4,500,994	25.4		
Non-Hodgkin Lymphoma	Female	-	11,151	-	-	2.5	0.171	846	4,468,682	18.9		
Oral Cavity and Pharynx Oral Cavity and Pharynx	Total Male	-	22,430 11,279	-	-	3.8 2.8	0.043 << 0.119	1,315	8,969,676 4,500,994	14.7 20.9		
Oral Cavity and Pharynx Oral Cavity and Pharynx	Female	-	11,279	-	-	2.8	0.119 0.681	940 375	4,500,994 4,468,682	20.9		
Ovary	Female	- 5	11,151	44.8	40.2	1.1	0.040 >>	548	4,468,682	12.3		
Pancreas	Total	4	22,430	17.8	14.5	4.6	1.000	1,484	8,969,676	12.5		
Pancreas	Male	2	11,279	17.7	14.0	2.6	1.000	824	4,500,994	18.3		
Pancreas	Female	2	11,151	17.9	14.9	2.0	1.000	660	4,468,682	14.8		
Prostate	Male	17	11,279	150.7	122.1	20.9	0.470	6,749	4,500,994	149.9		
Stomach	Total	1	22,430	4.5	3.7	1.4	1.000	473	8,969,676	5.3		
Stomach	Male	1	11,279	8.9	7.2	0.9	1.000	306	4,500,994	6.8		
Stomach	Female	-	11,151	-	-	0.5	1.000	167	4,468,682	3.7		
Testis	Male	1	11,279	8.9	10.6	0.6	0.870	273	4,500,994	6.1		
Thyroid	Total	3	22,430	13.4	13.4	2.9	1.000	1,182	8,969,676	13.2		
Thyroid	Male	-	11,279	-	-	1.0	0.728	372	4,500,994	8.3		
Thyroid	Female	3	11,151	26.9	28.1	1.9	0.613	810	4,468,682	18.1		
Pediatric Age 0 to 19	Total	4	6,792	58.9	59.6	1.1	0.056	421	2,492,532	16.9		
									4 070 041			
Pediatric Age 0 to 19 Pediatric Age 0 to 19	Male Female	- 4	3,480 3,312	- 120.8	- 123.5	0.6 0.5	1.000 0.005 >>	214 207	1,270,841 1,221,691	16.8 16.9		

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN ONEIDA COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			On	Re	Remainder of Idaho					
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	255	22,749	1,120.9	865.9	257.3	0.920	80,280	9,188,645	873.7
All Causes of Death	Male	145	11,458	1,265.5	982.7	136.3	0.478	42,641	4,616,239	923.7
All Causes of Death	Female	110	11,291	974.2	741.5	122.1	0.292	37,639	4,572,406	823.2
All Malignant Cancers	Total	38	22,749	167.0	132.9	47.3	0.196	15,195	9,188,645	165.4
All Malignant Cancers	Male	28	11,458	244.4	188.5	26.4	0.807	8,207	4,616,239	177.8
All Malignant Cancers	Female	10	11,291	88.6	72.4	21.1	0.012 <<	6,988	4,572,406	152.8
Bladder Bladder	Total Male	1	22,749 11,458	4.4 8.7	3.3 6.3	1.6 1.3	1.000 1.000	484 374	9,188,645 4,616,239	5.3 8.1
Bladder	Female	- '	11,430	0.7	0.5	0.4	1.000	110	4,572,406	2.4
Brain and Other Nervous System	Total	2	22,749	8.8	7.6	1.5	0.869	516	9,188,645	5.6
Brain and Other Nervous System	Male	2	11,458	17.5	14.8	0.8	0.411	287	4,616,239	6.2
Brain and Other Nervous System	Female	-	11,291	-	-	0.6	1.000	229	4,572,406	5.0
Breast	Total	3	22,749	13.2	10.6	3.4	1.000	1,121	9,188,645	12.2
Breast	Male	-	11,458	-	-	0.0	1.000	13	4,616,239	0.3
Breast	Female	3	11,291	26.6	21.9	3.3	1.000	1,108	4,572,406	24.2
Cervix	Female	- 1	11,291 22,749	- 4.4	-	0.2	1.000	88	4,572,406	1.9
Colorectal Colorectal	Total Male	1 1	22,749 11,458	4.4 8.7	3.6 7.0	4.1 2.3	0.173 0.679	1,331 731	9,188,645 4,616,239	14.5 15.8
Colorectal	Female	- '	11,456	0.7 -	-	2.3	0.320	600	4,010,239	13.0
Corpus Uteri	Female	-	11,291	-	-	0.5	1.000	169	4,572,400	3.7
Esophagus	Total	2	22,749	8.8	7.2	1.4	0.812	459	9,188,645	5.0
Esophagus	Male	2	11,458	17.5	13.8	1.2	0.691	389	4,616,239	8.4
Esophagus	Female	-	11,291	-	-	0.2	1.000	70	4,572,406	1.5
Hodgkin Lymphoma	Total	-	22,749	-	-	0.1	1.000	25	9,188,645	0.3
Hodgkin Lymphoma	Male	-	11,458	-	-	0.0	1.000	14	4,616,239	0.3
Hodgkin Lymphoma	Female	-	11,291	-	-	0.0	1.000	11	4,572,406	0.2
Kidney Kidney	Total Male	1 1	22,749 11,458	4.4 8.7	3.5 6.8	1.2 0.8	1.000 1.000	385 245	9,188,645 4,616,239	4.2 5.3
Kidney	Female	- '	11,456	0.7	0.0	0.8	1.000	245 140	4,572,406	3.1
Larynx	Total	1	22,749	4.4	3.5	0.2	0.413	75	9,188,645	0.8
Larýnx	Male	1	11,458	8.7	6.6	0.2	0.377	64	4,616,239	1.4
Larýnx	Female	-	11,291	-	-	0.0	1.000	11	4,572,406	0.2
Leukemia	Total	1	22,749	4.4	3.4	2.1	0.757	664	9,188,645	7.2
Leukemia	Male	1	11,458	8.7	6.7	1.3	1.000	396	4,616,239	8.6
Leukemia	Female	-	11,291	-	- 3.6	0.8	0.868	268	4,572,406	5.9
Liver and Bile Duct Liver and Bile Duct	Total Male	1	22,749 11,458	4.4 8.7	3.6 7.0	1.9 1.3	0.867 1.000	634 422	9,188,645 4,616,239	6.9 9.1
Liver and Bile Duct	Female	- '	11,291	0.7	7.0	0.6	1.000	212	4,572,406	4.6
Lung and Bronchus	Total	5	22,749	22.0	17.4	9.1	0.215	2,932	9,188,645	31.9
Lung and Bronchus	Male	4	11,458	34.9	26.9	4.9	0.900	1,537	4,616,239	33.3
Lung and Bronchus	Female	1	11,291	8.9	7.2	4.2	0.152	1,395	4,572,406	30.5
Melanoma of the Skin	Total	-	22,749	-	-	0.9	0.799	301	9,188,645	3.3
Melanoma of the Skin	Male	-	11,458	-	-	0.6	1.000	200	4,616,239	4.3
Melanoma of the Skin	Female	-	11,291	-	-	0.3	1.000	101	4,572,406	2.2
Myeloma	Total	1	22,749	4.4	3.4	1.0	1.000	324	9,188,645	3.5
Myeloma Myeloma	Male Female	- 1	11,458 11,291	8.7	6.6	0.6 0.4	0.919 1.000	187 137	4,616,239 4,572,406	4.1 3.0
Non-Hodgkin Lymphoma	Total	- 1	22,749	- 4.4	- 3.4	0.4	0.929	567	9,188,645	6.2
Non-Hodgkin Lymphoma	Male	- '	11,458	- +.+	-	1.0	0.739	310	4,616,239	6.7
Non-Hodgkin Lymphoma	Female	1	11,291	8.9	6.9	0.8	1.000	257	4,572,406	5.6
Oral Cavity and Pharynx	Total	-	22,749	-	-	0.8	0.874	275	9,188,645	3.0
Oral Cavity and Pharynx	Male	-	11,458	-	-	0.6	1.000	192	4,616,239	4.2
Oral Cavity and Pharynx	Female	-	11,291	-	-	0.2	1.000	83	4,572,406	1.8
Ovary	Female	1	11,291	8.9	7.4	1.1	1.000	360	4,572,406	7.9
Pancreas	Total	2	22,749	8.8	7.1	3.6	0.588	1,188	9,188,645	12.9
Pancreas	Male Female	- 2	11,458 11,291	- 17.7	- 14.6	2.1 1.6	0.256 0.960	650 538	4,616,239 4,572,406	14.1
Pancreas Prostate	Female Male	2	11,291	78.5	14.6 56.8	3.4	0.960	538 988	4,616,239	11.8 21.4
Stomach	Total	-	22,749	-		0.6	1.000	900 194	9,188,645	21.4
Stomach	Male	-	11,458	-	_	0.0	1.000	119	4,616,239	2.6
Stomach	Female	-	11,291	_	_	0.2	1.000	75	4,572,406	1.6

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Oneida County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	6.1%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	51.6%
Current Tobacco User (2020–2022) <u>Other Cancer-Related</u>	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	18.9%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	32.2% 66.9% 11.2% 12.6%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





OWYHEE COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 333 cases of invasive cancer were diagnosed among Owyhee County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in OwyheeCounty and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Owyhee County	State of Idaho
All Sites/Types	333	47,333
Female Breast	55	6,943
Prostate	43	6,766
Lung & Bronchus	39	4,959
Colorectal	23	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Owyhee County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Owyhee County. The table also shows the number of observed cases, person-

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 118 Owyhee County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Owyhee County

 and the State of Idaho, 2018–2022

Mortality 2018–2022	Owyhee County	State of Idaho
All Deaths	624	80,538
Cancer Deaths	118	15,233
% of All Deaths	18.9%	18.9%
Lung & Bronchus	19	2,937
Colorectal	17	1,332
Pancreas	17	1,190
Female Breast	8	1,111
Prostate	10	997

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Owyhee County was 558.7 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (526.2) gives an estimate of the relative burden of disease in Owyhee County.

The age- and sex-adjusted incidence rate of invasive cancer in Owyhee County, all sites combined, was 513.2 cases per 100,000 persons per year during 2017–2021. There were fewer cases of cancer in Owyhee County (333) than expected (341.4) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Owyhee County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Owyhee County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Owyhee County, all sites combined, was 178.0 deaths per 100,000 persons per year during 2018–2022, compared with 165.2 for the remainder of the state. There were more cancer deaths in Owyhee County (118) than expected (109.5) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN OWYHEE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Ow	hee Count	у			Ren	nainder of Ida	aho
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	333	59.600	558.7	513.2	341.4	0.674	47,000	8,932,506	526.2
All Sites Combined	Male	176	30,398	579.0	506.6	194.5	0.193	25,094	4,481,875	559.9
All Sites Combined	Female	157	29,202	537.6	513.4	150.5	0.618	21,906	4,450,631	492.2
Bladder	Total	9	59,600	15.1	13.6	16.4	0.073	2,211	8,932,506	24.8
Bladder	Male	9	30,398	29.6	25.3	14.0	0.216	1,764	4,481,875	39.4
Bladder	Female	-	29,202	-	-	3.1	0.090	447	4,450,631	10.0
Brain - malignant	Total	2	59,600	3.4	3.2	4.6	0.318	655	8,932,506	7.3
Brain - malignant	Male	1	30,398	3.3	3.0	2.8	0.461	381	4,481,875	8.5
Brain - malignant	Female Total	1	29,202	3.4	3.3 9.4	1.9	0.890	274	4,450,631	6.2 17.3
Brain and other CNS - non-malignant Brain and other CNS - non-malignant	Male	6 1	59,600 30,398	10.1 3.3	9.4 3.0	11.0 3.7	0.155 0.225	1,541 499	8,932,506 4,481,875	11.3
	Female	5	29,202	17.1	16.4	7.1	0.568	1,042	4.450.631	23.4
Breast	Total	55	59,600	92.3	85.6	50.0	0.519	6,953	8,932,506	77.8
Breast	Male	-	30,398	-	-	0.5	1.000	65	4,481,875	1.5
Breast	Female	55	29,202	188.3	179.3	47.5	0.307	6,888	4,450,631	154.8
Breast - in situ	Total	10	59,600	16.8	15.6	9.8	1.000	1,359	8,932,506	15.2
Breast - in situ	Male	-	30,398	-	-	0.0	1.000	4	4,481,875	0.1
Breast - in situ	Female	10	29,202	34.2	32.4	9.4	0.928	1,355	4,450,631	30.4
Cervix	Female	2	29,202	6.8	6.9	1.9	1.000	292	4,450,631	6.6
Colorectal	Total	23	59,600	38.6	35.4	26.2	0.611	3,609	8,932,506	40.4
Colorectal	Male Female	12	30,398 29.202	39.5	34.8 35.9	15.1	0.515 1.000	1,965	4,481,875	43.8
Colorectal Corpus Uteri	Female	11 10	29,202	37.7 34.2	35.9	11.3 9.3	0.898	1,644 1,344	4,450,631 4,450,631	36.9 30.2
Esophagus	Total	10	59,600	34.2 1.7	1.5	9.3 3.7	0.898	506	8.932.506	5.7
Esophagus	Male	1	30,398	3.3	2.8	3.4	0.302	428	4,481,875	9.5
Esophagus	Female	- '	29,202	-	-	0.5	1.000	78	4,450,631	1.8
Hodgkin Lymphoma	Total	2	59,600	3.4	3.3	1.5	0.865	220	8,932,506	2.5
Hodgkin Lýmphoma	Male	2	30,398	6.6	6.5	0.9	0.439	127	4,481,875	2.8
Hodgkin Lymphoma	Female	-	29,202	-	-	0.6	1.000	93	4,450,631	2.1
Kidney and Renal Pelvis	Total	20	59,600	33.6	30.9	14.0	0.154	1,931	8,932,506	21.6
Kidney and Renal Pelvis	Male	15	30,398	49.3	43.7	9.9	0.158	1,295	4,481,875	28.9
Kidney and Renal Pelvis	Female	5	29,202	17.1	16.2	4.4	0.897	636	4,450,631	14.3
Larynx	Total Male	3	59,600 30,398	5.0 9.9	4.5 8.4	1.6	0.436 0.286	217 164	8,932,506	2.4 3.7
Larynx Larynx	Female	3	29,202	9.9	0.4	1.3 0.4	1.000	53	4,481,875 4,450,631	1.2
Leukemia	Total	- 11	59,600	- 18.5	17.0	12.5	0.822	1,716	8,932,506	19.2
Leukemia	Male	8	30,398	26.3	23.2	7.9	1.000	1,028	4,481,875	22.9
Leukemia	Female	3	29,202	10.3	9.8	4.7	0.606	688	4,450,631	15.5
Liver and Bile Duct	Total	8	59,600	13.4	12.2	6.1	0.545	835	8,932,506	9.3
Liver and Bile Duct	Male	7	30,398	23.0	20.1	4.6	0.353	587	4,481,875	13.1
Liver and Bile Duct	Female	1	29,202	3.4	3.2	1.7	0.975	248	4,450,631	5.6
Lung and Bronchus	Total	39	59,600	65.4	59.0	36.4	0.711	4,920	8,932,506	55.1
Lung and Bronchus	Male	21	30,398	69.1	59.4	19.5	0.799	2,474	4,481,875	55.2
Lung and Bronchus	Female	18	29,202	61.6	57.9 26.6	17.1 22.4	0.886	2,446	4,450,631	55.0
Melanoma of the Skin Melanoma of the Skin	Total Male	17 9	59,600 30,398	28.5 29.6	26.6 26.1	22.4 14.5	0.298 0.176	3,127 1,886	8,932,506 4,481,875	35.0 42.1
Melanoma of the Skin	Female	8	29,202	29.0	26.6	8.4	1.000	1,000	4,450,631	27.9
Myeloma	Total	4	59,600	6.7	6.1	5.3	0.768	724	8,932,506	8.1
Myeloma	Male	3	30,398	9.9	8.5	3.5	1.000	444	4,481,875	9.9
Myeloma	Female	1	29,202	3.4	3.2	1.9	0.843	280	4,450,631	6.3
Non-Hodgkin Lymphoma	Total	19	59,600	31.9	29.3	14.3	0.273	1,973	8,932,506	22.1
Non-Hodgkin Lymphoma	Male	7	30,398	23.0	20.5	8.7	0.721	1,139	4,481,875	25.4
Non-Hodgkin Lymphoma	Female	12	29,202	41.1	39.1	5.8	0.030 >>	834	4,450,631	18.7
Oral Cavity and Pharynx	Total	11	59,600	18.5	16.8	9.5	0.718	1,304	8,932,506	14.6
Oral Cavity and Pharynx	Male	8 3	30,398	26.3	23.1	7.2	0.864	932	4,481,875	20.8
Oral Cavity and Pharynx Ovary	Female Female	3	29,202 29,202	10.3 30.8	9.8 29.5	2.6 3.7	0.945	372 544	4,450,631 4,450,631	8.4 12.2
Pancreas	Total	9 20	29,202	30.8	29.5	10.8	0.029 >>	1,468	8,932,506	12.2
Pancreas	Male	12	30,398	39.5	34.0	6.4	0.062	814	4,481,875	18.2
Pancreas	Female	8	29,202	27.4	26.0	4.5	0.177	654	4,450,631	14.7
Prostate	Male	43	30,398	141.5	122.8	52.5	0.209	6,723	4,481,875	
Stomach	Total	4	59,600	6.7	6.1	3.4	0.896	470	8,932,506	5.3
Stomach	Male	4	30,398	13.2	11.4	2.4	0.430	303	4,481,875	6.8
Stomach	Female	-	29,202	-	-	1.1	0.645	167	4,450,631	3.8
Testis	Male	1	30,398	3.3	3.6	1.7	0.982	273	4,481,875	6.1
Thyroid	Total	5	59,600	8.4	8.3	8.0	0.388	1,180	8,932,506	13.2
Thyroid	Male	3	30,398	9.9	9.3	2.7	0.991	369	4,481,875	8.2
Thyroid	Female	2	29,202	6.8	6.9	5.3	0.204	811	4,450,631	18.2
Pediatric Age 0 to 19	Total	4	16,741	23.9	23.9	2.8	0.633	421	2,482,583	17.0
Pediatric Age 0 to 19	Male	3	8,520	35.2	35.3	1.4	0.341	211	1,265,801	16.7
Pediatric Age 0 to 19	Female	1	8,221	12.2	12.1	1.4	1.000	210	1,216,782	17.3

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN OWYHEE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Ow	yhee County	/			Re	mainder of Idah	10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	624	60,581	1,030.0	949.6	573.9	0.040 >>	79,911	9,150,813	873.3
All Causes of Death	Male	378	30,960	1,220.9	1,052.4	331.4	0.013 >>	42,408	4,596,737	922.6
All Causes of Death	Female	246	29,621	830.5	820.6	246.9	0.989	37,503	4,554,076	823.5
All Malignant Cancers	Total	118	60,581	194.8	178.0	109.5	0.441	15,115	9,150,813	165.2
All Malignant Cancers	Male	72	30,960	232.6	200.0	63.9	0.342	8,163	4,596,737	177.6
All Malignant Cancers	Female	46	29,621	155.3	149.1	47.1	0.949	6,952	4,554,076	152.7
Bladder Bladder	Total Male	3 2	60,581 30,960	5.0 6.5	4.5 5.3	3.5 3.0	1.000 0.831	482 373	9,150,813 4,596,737	5.3 8.1
Bladder	Female	2 1	29,621	3.4	3.3	0.7	1.000	109	4,554,076	2.4
Brain and Other Nervous System	Total	-	60,581	-	-	3.7	0.050 <<	518	9,150,813	5.7
	Male	-	30,960	-	-	2.2	0.231	289	4,596,737	6.3
Brain and Other Nervous System	Female	-	29,621	-	-	1.5	0.425	229	4,554,076	5.0
Breast	Total	8	60,581	13.2	12.1	8.0	1.000	1,116	9,150,813	12.2
Breast	Male	-	30,960	-	-	0.1	1.000	13	4,596,737	0.3
Breast	Female	8	29,621	27.0	26.1	7.4	0.931	1,103	4,554,076	24.2
Cervix	Female	- 17	29,621	-	- 25.7	0.6	1.000	88	4,554,076	1.9 14.4
Colorectal Colorectal	Total Male	17	60,581 30,960	28.1 38.8	25.7 33.8	9.5 5.6	0.035 >> 0.024 >>	1,315 720	9,150,813 4,596,737	14.4
Colorectal	Female	5	29,621	36.6 16.9	33.8 16.3	4.0	0.024	595	4,590,737	13.1
Corpus Uteri	Female	2	29,621	6.8	6.4	1.1	0.630	167	4,554,076	3.7
Esophagus	Total	2	60,581	3.3	3.0	3.3	0.703	459	9,150,813	5.0
Esophagus	Male	2	30,960	6.5	5.6	3.0	0.837	389	4,596,737	8.5
Esophagus	Female	-	29,621	-	-	0.5	1.000	70	4,554,076	1.5
Hodgkin Lymphoma	Total	-	60,581	-	-	0.2	1.000	25	9,150,813	0.3
Hodgkin Lymphoma	Male	-	30,960	-	-	0.1	1.000	14	4,596,737	0.3
Hodgkin Lymphoma	Female		29,621	-	-	0.1	1.000	11	4,554,076	0.2
Kidney Kidney	Total Male	5 2	60,581 30,960	8.3 6.5	7.5 5.6	2.8 1.9	0.294 1.000	381 244	9,150,813 4,596,737	4.2 5.3
Kidney	Female	23	29,621	10.1	9.7	0.9	0.134	137	4,554,076	3.0
Larynx	Total	1	60,581	1.7	1.5	0.6	0.847	75	9,150,813	0.0
Larýnx	Male	1	30,960	3.2	2.7	0.5	0.798	64	4,596,737	1.4
Larýnx	Female	-	29,621	-	-	0.1	1.000	11	4,554,076	0.2
Leukemia	Total	2	60,581	3.3	3.0	4.8	0.287	663	9,150,813	7.2
Leukemia	Male	1	30,960	3.2	2.8	3.1	0.368	396	4,596,737	8.6
Leukemia	Female	1	29,621	3.4	3.3	1.8	0.925	267	4,554,076	5.9
Liver and Bile Duct Liver and Bile Duct	Total	6 5	60,581 30,960	9.9 16.1	9.1 14.1	4.6 3.2	0.613 0.449	629 418	9,150,813 4,596,737	6.9 9.1
Liver and Bile Duct	Male Female	5 1	29,621	3.4	3.2	3.2 1.4	1.000	211	4,590,737	4.6
Lung and Bronchus	Total	19	60,581	31.4	28.5	21.3	0.726	2,918	9,150,813	31.9
Lung and Bronchus	Male	9	30,960	29.1	25.1	11.9	0.495	1,532	4,596,737	33.3
Lung and Bronchus	Female	10	29,621	33.8	32.0	9.5	0.957	1,386	4,554,076	30.4
Melanoma of the Skin	Total	2	60,581	3.3	3.0	2.2	1.000	299	9,150,813	3.3
Melanoma of the Skin	Male	1	30,960	3.2	2.8	1.5	1.000	199	4,596,737	4.3
Melanoma of the Skin	Female	1	29,621	3.4	3.3	0.7	0.982	100	4,554,076	2.2
Myeloma	Total	4	60,581	6.6	6.0	2.3	0.417	321	9,150,813	3.5
Myeloma	Male	3	30,960	9.7	8.3	1.5	0.363	185	4,596,737	4.0 3.0
Myeloma Non-Hodgkin Lymphoma	Female Total	1	29,621 60,581	3.4 5.0	3.2 4.5	0.9	1.000 0.823	136 565	4,554,076 9,150,813	6.2
Non-Hodgkin Lymphoma	Male	2	30,960	5.0 6.5	4.5 5.6	2.4	1.000	308	4,596,737	6.7
Non-Hodgkin Lymphoma	Female	2 1	29,621	3.4	3.2	1.7	0.961	257	4,554,076	5.6
Oral Cavity and Pharynx	Total	1	60,581	1.7	1.5	2.0	0.820	274	9,150,813	3.0
Oral Cavity and Pharynx	Male	1	30,960	3.2	2.8	1.5	1.000	191	4,596,737	4.2
Oral Cavity and Pharynx	Female	-	29,621	-	-	0.6	1.000	83	4,554,076	1.8
Ovary	Female	1	29,621	3.4	3.2	2.5	0.593	360	4,554,076	7.9
Pancreas	Total	17	60,581	28.1	25.6	8.5	0.013 >>	1,173	9,150,813	12.8
Pancreas	Male	10	30,960	32.3	28.0	5.0	0.061	640	4,596,737	13.9
Pancreas Prostato	Female	7 10	29,621 30,960	23.6	22.6	3.6	0.151	533	4,554,076 4,596,737	11.7
Prostate Stomach	Male Total	10	30,960 60,581	32.3 1.7	26.8 1.5	8.0 1.4	0.569 1.000	987 193	4,596,737 9,150,813	21.5 2.1
Stomach	Male	1	30,960	3.2	2.8	0.9	1.000	193	4,596,737	2.1
Stomach	Female	- '	29,621		2.0	0.5	1.000	75	4,554,076	1.6
otomacii	remale	-	29,021	-	-	0.5	1.000	10	4,004,070	1.0

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Owyhee County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	74.3% 12.4%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	41.6%
Current Tobacco User (2020–2022) Other Cancer-Related	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	26.6%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	30.4% 71.0% 25.9% 16.7%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





PAYETTE COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 783 cases of invasive cancer were diagnosed among Payette County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in PayetteCounty and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Payette County	State of Idaho
All Sites/Types	783	47,333
Female Breast	110	6,943
Prostate	102	6,766
Lung & Bronchus	122	4,959
Colorectal	65	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Payette County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Payette County. The table also shows the number of observed cases, person-

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 283 Payette County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Payette County and the State of Idaho, 2018–2022

Mortality 2018–2022	Payette County	State of Idaho
All Deaths	1,407	80,538
Cancer Deaths	283	15,233
% of All Deaths	20.1%	18.9%
Lung & Bronchus	74	2,937
Colorectal	30	1,332
Pancreas	11	1,190
Female Breast	27	1,111
Prostate	21	997

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Payette County was 641.9 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (524.8) gives an estimate of the relative burden of disease in Payette County.

The age- and sex-adjusted incidence rate of invasive cancer in Payette County, all sites combined, was 576.9 cases per 100,000 persons per year during 2017–2021. There were statistically significantly more cases of cancer in Payette County (783) than expected (712.3) based upon rates in the remainder of the state (p=.009).

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Payette County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Payette County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Payette County, all sites combined, was 196.3 deaths per 100,000 persons per year during 2018–2022, compared with 164.5 for the remainder of the state. There were statistically significantly more cancer deaths in Payette County (283) than expected (237.2) based upon rates in the remainder of the state (p=.004).

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021 COMPARISON BETWEEN PAYETTE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Pav	ette Count	v			Ren	nainder of Ida	aho
Cancer		Observed	Person	Crude	, A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)		P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	783	121,977	641.9	576.9	712.3	0.009 >>	46,550	8,870,129	524.8
All Sites Combined	Male	410	61,046	671.6	590.0	388.1	0.278	24,860	4,451,227	558.5
All Sites Combined	Female	373	60,931	612.2	559.9	327.0	0.013 >>	21,690	4,418,902	490.8
Bladder	Total	26	121,977	21.3	18.4	35.0	0.141	2,194	8,870,129	24.7
Bladder	Male	18	61,046	29.5	24.7	28.7	0.044 <<	1,755	4,451,227	39.4
Bladder	Female	8	60,931	13.1	11.7	6.8	0.749	439	4,418,902	9.9
Brain - malignant Brain - malignant	Total Male	9 5	121,977 61,046	7.4 8.2	6.9 7.6	9.6 5.6	1.000 1.000	648 377	8,870,129 4.451.227	7.3 8.5
Brain - malignant	Female	4	60,931	6.6	6.1	4.0	1.000	271	4,418,902	6.1
Brain and other CNS - non-malignant	Total	22	121,977	18.0	16.4	23.0	0.939	1,525	8,870,129	17.2
	Male	8	61,046	13.1	11.9	7.5	0.939	492	4,451,227	11.1
	Female	14	60,931	23.0	21.1	15.5	0.824	1,033	4,418,902	23.4
Breast	Total	110	121,977	90.2	82.5	103.8	0.565	6,898	8,870,129	77.8
Breast	Male	-	61,046	- 180.5	- 165.7	1.0	0.706	65	4,451,227	1.5
Breast Breast - in situ	Female Total	110 19	60,931 121,977	180.5	165.7	102.6 20.1	0.492 0.927	6,833 1,350	4,418,902 8,870,129	154.6 15.2
Breast - in situ	Male	- 10	61,046	-	-	0.1	1.000	1,000	4,451,227	0.1
Breast - in situ	Female	19	60,931	31.2	28.8	20.1	0.922	1,346	4,418,902	30.5
Cervix	Female	8	60,931	13.1	13.0	4.0	0.101	286	4,418,902	6.5
Colorectal	Total	65	121,977	53.3	47.8	54.7	0.191	3,567	8,870,129	40.2
Colorectal	Male	41	61,046	67.2	59.4	30.0	0.066	1,936	4,451,227	43.5
Colorectal	Female	24 13	60,931 60,931	39.4 21.3	35.8 19.7	24.7 20.0	0.990 0.133	1,631 1,341	4,418,902 4,418,902	36.9 30.3
Corpus Uteri Esophagus	Female Total	5	121,977	4.1	3.6	20.0	0.133	1,341	4,418,902 8,870,129	30.3
Esophagus	Male	5	61,046	6.6	5.0 5.7	7.0 6.7	0.398	425	4,451,227	9.5
Esophagus	Female	1	60,931	1.6	1.5	1.2	1.000	77	4,418,902	1.7
Hodgkin Lymphoma	Total	2	121,977	1.6	1.6	3.0	0.843	220	8,870,129	2.5
Hodgkin Lymphoma	Male	1	61,046	1.6	1.6	1.8	0.952	128	4,451,227	2.9
Hodgkin Lymphoma	Female	1	60,931	1.6	1.7	1.2	1.000	92	4,418,902	2.1
Kidney and Renal Pelvis	Total	39	121,977	32.0	28.7	29.3	0.097	1,912	8,870,129	21.6
Kidney and Renal Pelvis Kidney and Renal Pelvis	Male Female	29 10	61,046 60,931	47.5 16.4	42.4 14.8	19.7 9.6	0.059 0.989	1,281 631	4,451,227 4,418,902	28.8 14.3
Larynx	Total	5	121,977	4.1	3.6	3.3	0.484	215	8,870,129	2.4
Larynx	Male	5	61,046	8.2	7.1	2.6	0.235	162	4,451,227	3.6
Larynx	Female	-	60,931	-	-	0.8	0.901	53	4,418,902	1.2
Leukemia	Total	28	121,977	23.0	20.4	26.3	0.790	1,699	8,870,129	19.2
Leukemia	Male	16	61,046	26.2	22.8	16.1	1.000	1,020	4,451,227	22.9
Leukemia	Female	12	60,931	19.7	17.8	10.4	0.692	679	4,418,902	15.4
Liver and Bile Duct Liver and Bile Duct	Total Male	18 15	121,977 61,046	14.8 24.6	13.3 22.0	12.6 8.9	0.177 0.075	825 579	8,870,129 4,451,227	9.3 13.0
Liver and Bile Duct	Female	3	60,931	4.9	4.5	3.7	0.970	246	4,418,902	5.6
Lung and Bronchus	Total	122	121.977	100.0	86.7	76.7	0.000 >>	4,837	8,870,129	54.5
Lung and Bronchus	Male	59	61,046	96.6	82.1	39.3	0.004 >>	2,436	4,451,227	54.7
Lung and Bronchus	Female	63	60,931	103.4	91.1	37.6	0.000 >>	2,401	4,418,902	54.3
Melanoma of the Skin	Total	27	121,977	22.1	20.2	47.1	0.002 <<	3,117	8,870,129	35.1
Melanoma of the Skin	Male	15	61,046	24.6	21.6	29.3	0.006 <<	1,880	4,451,227	42.2
Melanoma of the Skin Myeloma	Female Total	12 14	60,931 121,977	19.7 11.5	18.5 10.0	18.2 11.2	0.170 0.478	1,237 714	4,418,902 8,870,129	28.0 8.0
Myeloma	Male	9	61,046	11.5	10.0	7.0	0.478	438	4,451,227	0.0 9.8
Myeloma	Female	5	60,931	8.2	7.3	4.3	0.846	276	4,418,902	6.2
Non-Hodgkin Lymphoma	Total	40	121,977	32.8	29.4	29.9	0.089	1,952	8,870,129	22.0
Non-Hodgkin Lymphoma	Male	15	61,046	24.6	21.9	17.4	0.670	1,131	4,451,227	25.4
Non-Hodgkin Lymphoma	Female	25	60,931	41.0	37.2	12.5	0.002 >>	821	4,418,902	18.6
Oral Cavity and Pharynx Oral Cavity and Pharynx	Total Malo	15 10	121,977	12.3	11.2	19.7	0.345	1,300	8,870,129 4,451,227	14.7
Oral Cavity and Pharynx Oral Cavity and Pharynx	Male Female	10 5	61,046 60,931	16.4 8.2	14.8 7.5	14.2 5.6	0.331 1.000	930 370	4,451,227 4,418,902	20.9 8.4
Ovary	Female	10	60,931	16.4	15.2	8.1	0.590	543	4,418,902	12.3
Pancreas	Total	22	121,977	18.0	15.8	23.0	0.944	1,466	8,870,129	16.5
Pancreas	Male	12	61,046	19.7	16.8	13.0	0.916	814	4,451,227	18.3
Pancreas	Female	10	60,931	16.4	14.7	10.1	1.000	652	4,418,902	14.8
Prostate	Male	102	61,046	167.1	148.2	103.0	0.970	6,664	4,451,227	149.7
Stomach	Total	6	121,977	4.9	4.4	7.3	0.821	468	8,870,129	5.3
Stomach Stomach	Male Female	4 2	61,046 60,931	6.6 3.3	5.7 3.0	4.8 2.5	0.946 1.000	303 165	4,451,227	6.8 3.7
Testis	Female Male	2	61,046	3.3	3.0	2.5	0.686	165 272	4,418,902 4,451,227	<u> </u>
Thyroid	Total	24	121,977	19.7	19.4	16.2	0.080	1,161	8,870,129	13.1
Thyroid	Male	11	61,046	18.0	19.4	5.2	0.035 >>	361	4,451,227	8.1
Thyroid	Female	13	60,931	21.3	21.3	11.1	0.638	800	4,418,902	18.1
Pediatric Age 0 to 19	Total	9	34,505	21.3	21.3	5.8	0.264	416	2,464,819	16.9
Pediatric Age 0 to 19	Male	4	17.921	22.3	22.4	3.0	0.700	210	1,256,400	16.7
Pediatric Age 0 to 19	Female	5	16,584	30.1	30.4	2.8	0.305	206	1,208,419	17.0

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN PAYETTE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Pay	ette Count	y			Re	mainder of Idah	10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	1,407	125,715	1,119.2	982.7	1,246.9	0.000 >>	79,128	9,085,679	870.9
All Causes of Death	Male	780	63,112	1,235.9	1,050.2	683.5	0.000 >>	42,006	4,564,585	920.3
All Causes of Death	Female	627	62,603	1.001.5	910.1	565.7	0.012 >>	37,122	4,521,094	821.1
All Malignant Cancers	Total	283	125,715	225.1	196.3	237.2	0.004 >>	14,950	9,085,679	164.5
All Malignant Cancers	Male	153	63,112	242.4	205.2	132.0	0.080	8,082	4,564,585	177.1
All Malignant Cancers	Female	130	62,603	207.7	185.3	106.6	0.030 >>	6,868	4,521,094	151.9
Bladder	Total	9	125,715	7.2	6.1	7.7	0.732	476	9,085,679	5.2
Bladder	Male	8	63,112	12.7	10.3	6.3	0.583	367	4,564,585	8.0
Bladder	Female	1	62,603	1.6	1.4	1.7	0.983	109	4,521,094	2.4
Brain and Other Nervous System	Total	9	125,715	7.2	6.5	7.7	0.742	509	9,085,679	5.6
Brain and Other Nervous System	Male	4	63,112	6.3	5.7	4.4	1.000	285	4,564,585	6.2
Brain and Other Nervous System	Female	5 27	62,603	8.0	7.3	3.4	0.502	224	4,521,094	5.0
Breast Breast	Total Male	21	125,715 63,112	21.5	19.1	17.1 0.2	1.000	1,097 13	9,085,679 4,564,585	12.1 0.3
Breast	Female	- 27	62,603	- 43.1	- 39.1	16.6	0.023 >>	1,084	4,504,585	24.0
Cervix	Female	- 21	62,603	43.1	- 39.1	1.3	0.023	1,004	4,521,094	1.9
Colorectal	Total	- 30	125,715	- 23.9	21.1	20.4	0.055	1,302	9,085,679	14.3
Colorectal	Male	16	63,112	25.4	22.0	11.4	0.230	716	4,564,585	15.7
Colorectal	Female	14	62,603	22.4	20.1	9.0	0.149	586	4,521,094	13.0
Corpus Uteri	Female	2	62,603	3.2	2.9	2.6	1.000	167	4,521,094	3.7
Esophagus	Total	8	125,715	6.4	5.6	7.2	0.849	453	9,085,679	5.0
Esophagus	Male	8	63,112	12.7	11.0	6.1	0.547	383	4,564,585	8.4
Esophagus	Female	-	62,603	-	-	1.1	0.664	70	4,521,094	1.5
Hodgkin Lymphoma	Total	-	125,715	-	-	0.4	1.000	25	9,085,679	0.3
Hodgkin Lymphoma	Male	-	63,112	-	-	0.2	1.000	14	4,564,585	0.3
Hodgkin Lymphoma	Female	-	62,603	-	-	0.2	1.000	11	4,521,094	0.2
Kidney Kidney	Total	4	125,715	3.2	2.8	6.1	0.551	382	9,085,679	4.2 5.3
Kidney	Male Female	- 4	63,112 62,603	6.3	5.4	3.9 2.2	1.000 0.225	242 140	4,564,585 4,521,094	3.1
Larynx	Total	- 1	125,715	- 0.8	0.7	1.2	1.000	75	9,085,679	0.8
Larynx	Male	1	63,112	1.6	1.3	1.0	1.000	64	4,564,585	1.4
Larynx	Female	-	62,603	-	-	0.2	1.000	11	4,521,094	0.2
Leukemia	Total	10	125,715	8.0	6.8	10.5	1.000	655	9,085,679	7.2
Leukemia	Male	9	63,112	14.3	11.9	6.4	0.401	388	4,564,585	8.5
Leukemia	Female	1	62,603	1.6	1.4	4.2	0.156	267	4,521,094	5.9
Liver and Bile Duct	Total	10	125,715	8.0	7.0	9.8	1.000	625	9,085,679	6.9
Liver and Bile Duct	Male	8	63,112	12.7	11.1	6.5	0.665	415	4,564,585	9.1
Liver and Bile Duct	Female	2	62,603	3.2	2.8	3.3	0.728	210	4,521,094	4.6
Lung and Bronchus	Total Male	74 35	125,715 63,112	58.9 55.5	50.7 46.9	46.0 24.6	0.000 >> 0.056	2,863	9,085,679	31.5 33.0
Lung and Bronchus Lung and Bronchus	Female	35 39	62,603	62.3	40.9 54.5	24.0	0.000	1,506 1,357	4,564,585 4,521,094	30.0
Melanoma of the Skin	Total	4	125,715	3.2	2.8	4.7	1.000	297	9,085,679	3.3
Melanoma of the Skin	Male	2	63,112	3.2	2.7	3.2	0.760	198	4,564,585	4.3
Melanoma of the Skin	Female	2	62,603	3.2	2.9	1.5	0.895	99	4,521,094	2.2
Myeloma	Total	6	125,715	4.8	4.1	5.2	0.830	319	9,085,679	3.5
Myeloma	Male	4	63,112	6.3	5.3	3.1	0.734	184	4,564,585	4.0
Myeloma	Female	2	62,603	3.2	2.8	2.2	1.000	135	4,521,094	3.0
Non-Hodgkin Lymphoma	Total	9	125,715	7.2	6.1	9.0	1.000	559	9,085,679	6.2
Non-Hodgkin Lymphoma	Male	3	63,112	4.8	4.0	5.1	0.512	307	4,564,585	6.7
Non-Hodgkin Lymphoma	Female	6	62,603	9.6	8.4	4.0	0.427	252	4,521,094	5.6
Oral Cavity and Pharynx	Total	6	125,715	4.8	4.2	4.2	0.500	269	9,085,679	3.0
Oral Cavity and Pharynx	Male	5	63,112	7.9	6.9	3.0	0.363	187	4,564,585	4.1
Oral Cavity and Pharynx Ovary	Female Female	1	62,603 62,603	1.6 12.8	1.4 11.4	1.3 5.5	1.000 0.375	82 353	4,521,094 4,521,094	1.8 7.8
Pancreas	Total	0 11	125,715	8.7	7.6	18.7	0.080	1,179	9,085,679	13.0
Pancreas	Male	6	63,112	9.5	8.1	10.4	0.000	644	4,564,585	13.0
Pancreas	Female	5	62,603	8.0	7.1	8.3	0.324	535	4,521,094	11.8
Prostate	Male	21	63,112	33.3	26.9	16.7	0.349	976	4,564,585	21.4
Stomach	Total	2	125,715	1.6	1.4	3.0	0.843	192	9,085,679	2.1
Stomach	Male	1	63,112	1.6	1.3	1.9	0.854	118	4,564,585	2.6
Stomach	Female	1	62,603	1.6	1.5	1.1	1.000	74	4,521,094	1.6

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Payette County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	90.1% 11.9%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	68.9% 72.3%
Current Tobacco User (2020–2022) Other Cancer-Related	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	27.5%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	18.7% 76.4% 14.1% 14.7%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





POWER COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 179 cases of invasive cancer were diagnosed among Power County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in PowerCounty and the State of Idaho. 2017–2021

Cancer Incidence 2017–2021	Power County	State of Idaho
All Sites/Types	179	47,333
Female Breast	23	6,943
Prostate	27	6,766
Lung & Bronchus	21	4,959
Colorectal	22	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Power County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Power County. The table also shows the number of observed cases, person-

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 62 Power County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Power County and the State of Idaho, 2018–2022

Mortality 2018–2022	Power County	State of Idaho
All Deaths	348	80,538
Cancer Deaths	62	15,233
% of All Deaths	17.8%	18.9%
Lung & Bronchus	11	2,937
Colorectal	7	1,332
Pancreas	4	1,190
Female Breast	5	1,111
Prostate	4	997

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Power County was 465.2 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (526.6) gives an estimate of the relative burden of disease in Power County.

The age- and sex-adjusted incidence rate of invasive cancer in Power County, all sites combined, was 475.7 cases per 100,000 persons per year during 2017–2021. There were fewer cases of cancer in Power County (179) than expected (198.2) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Power County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Power County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Power County, all sites combined, was 159.8 deaths per 100,000 persons per year during 2018–2022, compared with 165.4 for the remainder of the state. There were fewer cancer deaths in Power County (62) than expected (64.2) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN POWER COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

All Sites Combined Male 96 19.613 49.02 448.07 109.8 0.159 25.174 4.402,670 480.07 Bidder Total 5 33.479 13.5 13.1 97.8 0.150 2,213 0.850,277 420. Bidder Fennie 1 38.479 2.6 2.6 2.8 0.489 4400,867 100. Brain - mailgnant Total 1 1.89.479 2.6 2.6 2.8 0.473 656 8.953,267 7.0 6.83 Brain - mailgnant Male 1 1.94,173 -1 1.03.8 3.82,77 7.0 6.63 8.953,267 7.0 6.0 8.83,827 7.7 4.492,700 6.0 11.1 1.93 1.93,15 5.4 5.6 2.1 0.71 4.492,700 10.1 1.93 8.93,827 7.7 1.83 8.93,827 7.7 1.00 1.00 4.402,700 10.1 1.93 8.93,827 7.6 1.00 1.00 4.402,700 10.1 1.93 8.93,827 7.5 1.00 1.00 1.00 <th></th> <th></th> <th></th> <th>Po</th> <th>wer County</th> <th></th> <th></th> <th></th> <th>Ren</th> <th>nainder of Ida</th> <th>aho</th>				Po	wer County				Ren	nainder of Ida	aho	
Site Crype Sex Cases Years Rate (1) Class (2) P-value (4) Cases Years Rate (1) All Sites Combined Male 66 1931 462.0 449.7 1982 0.1982 7.178 4.492.760 660.3 Budder Toilai 3 38.775 22.16 7.830.827 52.00 39.4 7.93 2.216 7.830.827 39.4 Budder Male 4 19.613 20.5 2.0 1.78 0.220 1.760 4.422.760 39.4 Budder Male - 19.913 7.5 2.2 1.6 0.386 39.2 4.402.760 1.6 39.2 4.402.760 1.7 39.75 39.2 2.4 2.76 4.2 0.334 1.002 7.44 4.402.760 1.7 39.75 39.2 2.4 2.76 4.2 0.34 1.042 4.402.760 1.7 39.75 39.2 2.4 2.76 4.20 0.314 0.427.76 4.4	Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude	
All Siles Combined Nate 179 38.479 485.2 475.7 198.2 0.182 0.1182 <td></td> <td>Sex</td> <td>-</td> <td></td> <td>-</td> <td></td> <td></td> <td>P-Value (4)</td> <td></td> <td></td> <td></td>		Sex	-		-			P-Value (4)				
All Sites Combined Male 96 19.613 49.02 448.07 109.8 0.159 25.174 4.402,670 480.07 Bidder Total 5 33.479 13.5 13.1 97.8 0.150 2,213 0.850,277 420. Bidder Fennie 1 38.479 2.6 2.6 2.8 0.489 4400,867 100. Brain - mailgnant Total 1 1.89.479 2.6 2.6 2.8 0.473 656 8.953,267 7.0 6.83 Brain - mailgnant Male 1 1.94,173 -1 1.03.8 3.82,77 7.0 6.63 8.953,267 7.0 6.0 8.83,827 7.7 4.492,700 6.0 11.1 1.93 1.93,15 5.4 5.6 2.1 0.71 4.492,700 10.1 1.93 8.93,827 7.7 1.83 8.93,827 7.7 1.00 1.00 4.402,700 10.1 1.93 8.93,827 7.6 1.00 1.00 4.402,700 10.1 1.93 8.93,827 7.5 1.00 1.00 1.00 <td></td> <td>Total</td> <td>179</td> <td>38,479</td> <td>()</td> <td>. ,</td> <td>. ,</td> <td>. ,</td> <td>47.154</td> <td>8.953.627</td> <td>526.6</td>		Total	179	38,479	()	. ,	. ,	. ,	47.154	8.953.627	526.6	
Bladder Total 5 38479 13.0 13.1 9.5 0.179 2215 8.95327 24.1 8492.700 38.4 422.700 38.4 422.700 38.4 422.700 38.4 422.700 38.4 422.700 38.4 422.700 38.6 12.0 12.0 12.0 12.0 12.0 12.0 12.0 12.0	All Sites Combined	Male				489.7		0.199			560.3	
Bladder Meie 4 19,513 20.5 20.1 7.8 0.220 1,768 4,440,877 100 Brain - malignant Total 1 19,665 5.3 5.4 1.8 0.289 4.44 0.400 100 Brain And Other CNS - non-malignant Total 8 39,479 20.8 2.1 6.4 0.898 4.440,807 6.5 Brain And Other CNS - non-malignant Total 8 19,813 15.4 1.6 6.4 0.898 4.492,760 1.1 Breast Total 8 19,813 15.4 1.5 6.22 2.8 0.319 4.640,807 0.6 1.430 1.442,760 1.42 1.800 6.53 5.3 1.1 1.000 6.53 4.532,8027 1.760 4.492,760 1.6 1.253,8027 1.253 1.253 1.26 1.000 6.53 6.53 1.1 1.000 2.440,807 3.00 1.66 4.492,760 1.25 1.253,173 1.30 1.300											492.7	
Bladder Female 1 18,866 5.3 5.4 1.8 0.899 446 4,40,807 107 Brain - malignant Brain - malignant Brain and other CNS - non-malignant Brain and other CNS - non-malignant Brain and other CNS - non-malignant Female 18,513 5.4 1.6 0.834 1,442 7.7 7.7 Brain and other CNS - non-malignant Brain and other CNS - non-malignant Brain and other CNS - non-malignant Female Total 3 3.8,79 20.8 C.2 2.4 0.74 4.492 7.60 1.2 Breast Total 2.3 18,866 2.4 2.4 2.7.8 0.421 0.423 4.402 7.60 1.1 Breast Total 5 3.8,476 13.0 13.6 5.6 1.000 1.4 4.422 7.60 1.1 Breast in situ Female 1 9.896 5.2 2.6 0.40 1.4 4.422 7.60 0.00 4.44 4.422 7.60 0.00 4.44 4.422 7.60 0.00 2.4 4.422 7.7									2,215		24.7	
Grain - malignant Total T 38,479 2.6 2.6 2.8 0.473 0.66 6,883,527 P.7. Brain - malignant Total 18,966 5.3 5.4 1.1 1.000 2214 4,400,667 65 Brain and other CNS - non-malignant Male 3 19,513 15.4 11.6 62.2 2.8 0.319 66,985 62.5 77.6 64.2 0.86 68.6 68.55,27 77.6 64.2 0.86 68.6 68.55,27 77.6 64.2 0.8 0.319 66.985 65.6 68.55,27 77.6 67.6 62.2 2.86 0.31 0.00 65.4 44.92,760 75.7 75.5 77.6 75.7 75.5 75.6 10.00 1.36.4 43.0 63.0 63.4 63.0 63.4 63.0 63.6 63.5 75.7 75.5 75.6 75.7 75.5 75.6 75.7 75.7 75.5 75.7 75.7 75.7 75.7 75.7<												
Brain - malgrant Male - 1 15, 13 - - 1.6 0.380 332 4, 492, 760 65. Brain - malgrant Total 8 38, 479 20.8 21.4 6.4 10.300 72.4 4.460, 667 6.1 Brain and Other CNS - non-mallgrant Total 8 38, 479 50.8 27.6 4.2 0.334 1.042 4.460, 667 23.3 Breast Male - 10.5 55.6 1.000 6.4 4.92, 760 1.6 Breast Male - 13.6 55.6 1.000 1.46, 667 13.0 Breast nslu Fernale 5 18.966 5.3 5.8 1.1 1.000 1.36 5.6 1.500 1.360 4.460, 667 30.2 4.400, 667 30.2 4.400, 667 30.2 4.400, 667 30.2 4.400, 667 30.2 4.400, 667 30.2 4.400, 667 30.2 4.400, 667 30.2 4.400, 667 30.2						-			-	, ,		
			_ '		2.0					0,955,027 4 492 760		
Grain and other CNS - non-malignant Note in the second seco			- 1		53					4 460 867		
Brain and other (NSnon-maignant) Herale 3 19,513 15,4 15,6 27,6 42,2 0,814 1,402 4460,267 224 Breast Tolin Z2 38,479 59,8 62,2 28,8 0,310 6,955 69,83,927 78,7 Breast In situ Fermale 2 15,16 12,4 22,4 0,421 6,956 44,60,267 156,15 Breast-In situ Fermale 10,16 5 38,479 13,0 13,6 5,6 10,000 1,44 44,92,760 0,0 Breast-In situ Fermale 7 18,966 26,4 28,1 5,4 10,000 1,360 4,460,677 0,07 Geniza Fermale 7 18,966 36,9 38,5 6,7 1,000 1,364 4,460,867 36,5 6,7 1,000 1,464 4,460,867 36,5 1,000 1,364 4,460,867 36,5 1,000 1,364 4,460,867 36,55 6,7			8							8,953,627	17.2	
Breast Total 23 38,479 59.8 62.2 28.8 0.319 6.885 8,953,627 78.0 Breast Female 2 18,966 12.3 12.4 27.8 0.31 0.00 65 4.492,660 15.5 Breast Institu Total 5 38,9479 13.0 13.6 5.5 11.000 1.368 5.53,8270 15.3 Breast In situ Female 5 18,966 2.8 4.8 4.1000 1.368 35.8 11 1.000 1.364 35.95,827 73.0 Colorectal Male 15 15.13 76.0 77.1 6.86 15.1 1.000 1.36 3.490,867 3.6.0 Colorectal Female 7 18.966 7.7 7.86 15.1 1.000 3.7 4.492,760 4.490,867 3.6.0 Colorectal Female 18.366 7.7 7.0.5 1.000 7.4422,760 2.4.100,24 1.000	Brain and other CNS - non-malignant			19,513		15.6	2.1	0.719			11.1	
Breast Male - 19,513 - - 0.3 1000 665 4,492,760 11 Breast in situ Total 5 38,479 13.0 13.6 6.6 1.000 1.384 8,953,827 15.2 Breast in situ Female 5 18,966 2.4 2.8 1.000 1.384 8,953,827 15.2 Colorectal Total 22 38,479 5.7 5.8 1.1 1.000 1.28 4,400,867 0.0 Colorectal Male 15 19,513 7.6 9.7.1 8.5 0.055 1.962 4,400,867 30.5 Colorectal Female 7 18,966 32.5 5.7 1.000 1.648 4,400,867 30.5 Esophagus Total 2 18,966 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 <											23.4	
Breast Female 23 18,966 121.3 122.4 27.8 0.421 6,920 4,409,867 155.5 Breast - in situ Male - 19,513 - - 0.0 1.000 4 4,492,760 0.0 Breast - in situ Fermale 5 18,060 28.8 1.000 4 4,492,760 0.0 Colorectal Total 2 38,479 57.2 55.8 1.6 1.000 6 4.400,867 40.0 Colorectal Female 7 18,966 33.5 6.7 1.000 1.648 4.400,867 35.0 Esophagus Total 2 38,479 5.2 2.2 2.000 50.5 8.953,827 2.7 1.000 5.6 1.800,867 1.0 1.000 4.460,867 1.0 1.000 4.42,760 2.2 1.000 4.42,760 2.2 1.000 4.42,760 2.2 1.000 1.000 4.42,760 2.2 1.000 1.0			23		59.8	62.2						
Breast In situ Total 5 38,479 13.0 13.6 5.6 1.000 1,364 8,955,227 15.7 Breast In situ Fernale 5 18,966 26.4 28.1 5.4 1.000 1,440,867 30.0 Breast In situ Fernale 1 18,966 30.5 5.8 1.1 1.000 1,364 4,460,867 30.0 Colorectal Male 2 30.513 7.6.9 37.1 18.5 0.055 3462 4,460,867 33.6 Colorectal Fernale 6 18.966 31.6 33.2 5.5 0.927 1,348 4,460,867 33.6 Esophagus Total 2 98,479 2.5 2.2 2.00 50.6 3,853,627 2.7 2.8 5.556,7 2.2 1.000 4.440,867 30.2 1.000 1.000 4.440,867 30.2 1.000 1.444,440,867 30.2 1.000 1.440,867 30.2 1.00			-		-	-						
Breast - in situ Male - 19,513 - - 0.00 1,4 4,492,760 0.00 Cervix Female 1 18,966 2.6 2.8 1.1 1000 1,380 4,460,867 6.6 Calorectal Male 15 19,518 0.15 0.155 1,152 4,460,867 6.6 Colorectal Male 15 19,518 0.055 1,862 4,482,760 4.3 Colorectal Male 16 18,986 31.5 3.5 1000 7.7 4.460,867 3.0 Esophagus Female - 18,986 - - 0.3 1,000 7.7 4.460,867 1.7 4.460,867 1.7 1.000 7.8 4.460,867 1.7 1.000 7.8 4.460,867 1.7 1.000 7.8 4.460,867 1.7 1.000 7.8 4.460,867 1.7 1.000 1.300 5.8 1.858,527 2.2 1.000 1.30 5.4 </td <td></td>												
Breast- Female 5 16,966 28.1 5.4 1.000 1,360 4,460,867 30.1 Colorectal Total 22 38,479 57.2 58.6 15.1 1.000 1.284 440,867 66.6 Colorectal Female 7 16.896 36.5 0.55 1.000 1.644 4.460,867 36.5 Colorectal Female 7 16.896 36.5 0.57 0.500 1.644 4.460,867 36.5 Colorectal Female 6 16.997 30.2 1.000 1.244 4.460,867 36.5 Esophagus Hale 2 19.513 5.1 5.3 1.000 78 4.460,867 21.5 Hodgkin Lymphoma Male 1 19.513 5.1 5.3 0.5 0.828 1.24 4.482,760 22.7 1.000 19.844,408,867 22.1 1.000 19.844,808,872 22.1 1.000 19.844,808,872 21.1 1.000 19.846,8					-	-						
Cervix Female 1 18,966 5.3 1.7 1.000 223 3,4,460,867 6.6 Colorectal Male 15 19,513 76,9 77.1 8.5 0.055 1,962 4,492,760 43.5 Colorectal Female 6 18,966 33.2 5.5 0.927 1,348 4,460,867 36.5 Carpus Uleri Female 6 18,966 31.6 33.2 5.5 0.927 1,348 4,460,867 36.5 Esophagus Male 2 19,518 10.2 10.1 1.1 10.000 47.4 4,482,760 22.7 Hodgkin Lymphoma Male 1 19,513 5.1 5.3 0.5 0.428 128 4,460,867 22.2 Kidney and Renal Petvis Total 138,479 2.6 0.8 0.828 128 4,460,867 42.2 Kidney and Renal Petvis Female 18,966 - - 0.4 10.00 168			5		26.4	28.1					30.5	
Colorectal Total 122 38,479 57.2 58.6 151 0.115 3.610 8.953,627 4492,764 Colorectal Female 7 18.966 36.9 38.6 6.7 1.000 1.648 4460,867 38.5 Colorectal Female 6 18.966 38.6 6.7 1.000 1.648 4460,867 39.7 Esophagus Total 2 38.479 5.2 2.2 1.000 505 8.953,827 62.7 Esophagus Male 2 18.516 0.2 1.0.1 1.1 1.3 1.000 47.4486,070 1.1 Hodgkin Lymphoma Temale - 1.8966 - - 0.5 0.828 1.28 4.922.760 22.1 1.300 9.34.469,867 2.21.1 Kidney and Renal Petvis Male 8 19.513 4.1.0 4.1.4 5.6 0.407 1.302 4.492.760 22.1 2.37 0.79 1.000 63.4426,703						5.8	-	1.000		4,460,867	6.6	
		Total	22	38,479	57.2	58.6	15.1	0.115	3,610	8,953,627	40.3	
Corpus Uleri Female 6 18,966 31.6 33.2 5.5 9.22 1,348 4,460,867 33.2 Esophagus Female - 18,966 - - 0.3 1000 427 4,482,760 55 55,2 2.2 1000 427 4,482,760 55 55,2 2.2 1000 427 4,482,760 52 55 0.55 0.55 0.55 0.528 128 4,492,760 2.2 140dgkn Lymphoma Female - 18,966 - - 0.4 1.000 93 4,460,867 1.2 Kidney and Renal Pelvis Male 8 19,513 4.10 41.4 4.5 0.972 638 4,600,867 14.2 Larynx Total 1 38,479 2.2 2.6 0.9 1.000 18 4,82,760 2.2 1.2 1.44 4.42,760 2.2 1.2 1.44 4.42,760 2.2 1.2 1.000 1.45 1.42,760	-									4,492,760	43.7	
Esophagus EsophagusTotal Tesophagus238.479 Pernale5.25.25.22.21.0005058.953.6275.5EsophagusFemale-18.9660.31.000784.460.8671.7Hodgkin LymphomaMale119.5135.15.30.002218.953.6272.2Hodgkin LymphomaFemale-18.9660.41.000784.460.8672.1Kidney and Renal PelvisTotal138.4792.82.98.10.3941.9408.953.6272.2Kidney and Renal PelvisMale138.4792.82.98.10.3941.9408.953.6272.1Kidney and Renal PelvisMale33.9792.82.60.9076.064.492.7602.2LaypyMale138.4793.516.70.0005.64.492.7602.2LaypyFemale-18.9660.0015.84.492.7602.3LeukemiaMale119.5131.0.210.14.60.3361.0344.492.7602.3LeukemiaFemale10.896652.75.92.80.0015.84.492.7603.2LeukemiaMale19.5132.60.1505.44.492.7605.5Luyr and Bile DuctMale19.5132.60.1505.	-										36.9	
Esophagus EsophagusMale Female219,513 18,96610.210.11.91.000427 4.492,7604.492,760 4.8,9879.5 4.5 4.9,87Hodgkin Lymphoma Hodgkin LymphomaMale Female138,479 19,5132.62.70.91.000221 8.935,8272.7Hodgkin Lymphoma Kinhey and Renal PelvisTotal Total1138,479 19,5132.62.70.91.0009.84.460,867 4.9302.1Kinhey and Renal Pelvis Kinhey and Renal PelvisMale Female318,966 10.51.61.64.20.09726.38 												
ExophagusFemale-18,9660.31.000784.460.86717.7Hodgkin LymphomaMale119,5135.15.30.50.5281284.492.7602.2Hodgkin LymphomaFemale-18,9660.41.000934.460.8672.1Kidney and Renal PelvisTotal1138,47928.629.38.10.3941.9408.933.62722.1Kidney and Renal PelvisFemale318,96615.816.42.60.9726.384.460.86714.2LarynxTotal138,47923.62.60.9726.384.460.86714.2LarynxFemale-18,9660.21.0001664.492.76023.0LarynxFemale-18,9665.15.10.71.0001684.460.86715.2LeukemiaTotal1238,47931.231.47.30.1391.7158.953.62713.2LeukemiaMale219,5131.21.14.60.0578438.93.62713.2Liver and Bile DuctTotal-38,4795.65.01.011.464.02.6615.5Liver and Bile DuctTotal-18,9665.61.011.0004.83.75,755.2Liver and Bile DuctTotal-18,9665.61.011.0004.												
Hodgin Lymphoma Total 1 38/479 2.6 2.7 0.9 1.000 221 8/93.827 22.2 Hodgin Lymphoma Female - 18.966 - - 0.4 1.000 93 4.480.260 2.2 Kidney and Renal Pelvis Total 1 38.479 28.6 29.3 8.1 0.394 1.940 8.953.627 22.1 Kidney and Renal Pelvis Male 8 19.513 41.0 41.4 5.6 0.407 1.302 4.492.760 23.1 Larynx Total 1 38.479 2.6 2.6 0.9 1.000 218 8.933.627 2.2 Larynx Total 1 38.479 3.1.2 1.0.1 4.60.867 1.1 2.1000 5.3 4.460.867 1.3. Leukemia Total 7 38.479 3.1.2 1.0.1 4.6 0.336 1.034 4.492.760 2.3. Leukemia Total 7 38.479 </td <td></td> <td></td> <td>2</td> <td></td> <td>10.2</td> <td>10.1</td> <td></td> <td></td> <td></td> <td></td> <td></td>			2		10.2	10.1						
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$			- 1		26	27						
Hodgkin Lymphoma Female - 13,966 - - - 0.4 1.000 93 4,460,867 22.1 Kidney and Renal Pelvis Male 8 19,513 41.0 41.4 5.6 0.407 1.302 4,460,867 22.1.7 Kidney and Renal Pelvis Total 1 38,479 2.6 2.6 0.97 6.38 4,460,867 14.3 Larynx Total 1 19,513 5.1 0.7 1.000 158 4,460,867 14.3 Larynx Female - 18,966 - - 0.2 1.000 53 4,460,867 14.3 Leukemia Total 12 38,479 31.2 31.4 7.3 0.139 1.715 8353,627 93.2 Leukemia Female 10 18,966 - - 3.6 0.057 843 8,953,827 94.46 Leukemia Female 18,966 - - - 0.01										4.492.760	2.8	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $			-		-	-				4.460.867	2.1	
Kidney and Renal Pelvis Female 3 13,866 15.8 16.4 2.6 0.972 638 4,460,867 14.5 Larynx Male 1 13,879 2.6 2.6 0.9 1.000 129 8,953,527 2.2 Larynx Male 1 13,879 2.6 2.6 0.9 1.000 166 4,492,760 3.7 Leukemia Total 12 38,479 31.2 31.4 7.3 0.139 1.715 8,953,827 19.2 Leukemia Male 2 19,513 10.2 10.1 4.6 0.336 10.34 4.492,760 23.5 Liver and Bile Duct Total - 38,479 - - 3.6 0.057 643 8,953,827 9.4 Liver and Bile Duct Male - 19,513 - - 2.6 0.150 534 4,460,867 55.5 Lung and Bronchus Male 13 19,513 - - <td></td> <td>Total</td> <td>11</td> <td></td> <td>28.6</td> <td>29.3</td> <td>8.1</td> <td>0.394</td> <td>1,940</td> <td>8,953,627</td> <td>21.7</td>		Total	11		28.6	29.3	8.1	0.394	1,940	8,953,627	21.7	
	Kidney and Renal Pelvis				-						29.0	
											14.3	
Larýmx Female - 18,966 - - 0.2 1.000 53 4,460,867 11 Leukemia Male 2 19,513 10.2 10.1 4.6 0.336 1.034 4,492,760 233 Leukemia Male 2 19,513 10.2 10.1 4.6 0.336 1.034 4,492,760 233 Lever and Bile Duct Total - 18,966 - - 2.6 0.057 843 8,953,627 55.2 Lurer and Bile Duct Female 18,966 - - 1.0 0.717 249 4,400,867 55.5 Lung and Bronchus Male 13 19,513 66.6 65.6 10.9 0.611 2,422 760.55.7 55.0 Lung and Bronchus Female 8 18,966 4.2 4.33 10.02 0.630 2,456 4,400,867 55.6 Melanoma of the Skin Male 19,513 10.2 10.3 8.2 </td <td></td> <td>2.4</td>											2.4	
Leukemia LeukemiaTotal1238,47931.231.47.30.1391.7158.953,627192.LeukemiaFemale1018,96652.753.92.80.001 >>6814.492,76023.3LeukemiaTotal-38,4793.60.0575438.953,62792.4Liver and Bile DuctMale-19,5132.60.1505944.492,76013.2Liver and Bile DuctFemale-18,9661.00.7172494.460,86755.5Lung and BronchusTotal2138,47954.655.021.11.0004.9388.953,82755.2Lung and BronchusFemale818,96642.243.310.20.6302.4664.460,86755.5Melanoma of the SkinMale119,51310.210.38.20.0244.342,76055.2Melanoma of the SkinFemale218,96610.511.25.00.2511.2474.460,86722.6MyelomaTotal438,47910.410.813.00.007 <			-		5.1	5.1						
LeukemiaMale219,51310.210.14.60.3361.0344.492,760233Liver and Bile DuctTotal-38,47952.753.92.80.001 >>6814.490,8715.3Liver and Bile DuctMale-19,5132.60.1505944,492,76013.2Liver and Bile DuctFemale-19,5132.60.01505944,492,76013.2Lung and BronchusTotal21138,47954.655.021.11.0004,9388,935,82755.2Lung and BronchusFemale818,96642.243.310.20.6302,4564,460,86755.5Lung and BronchusFemale818,96642.243.310.20.6302,4564,460,86755.5Melanoma of the SkinMale219,51310.210.38.20.024 <					-	-						
LeukemiaFemale1018,96652.753.92.8 $0.001 \gg$ 6814,460,86715.7Liver and Bile DuctMale-38,4793.60.0578438,953,62794Liver and Bile DuctFemale-18,9661.00.7172494,460,8675.5Lung and BronchusTotal2138,47954.655.021.11.0004,9388,953,62755.2Lung and BronchusMale1319,51366.665.610.90.6112,4824,492,76055.2Lung and BronchusFemale818,96642.243.310.20.6302,456450.655.7Melanoma of the SkinTotal438,47910.410.813.00.007 <						-			,			
Liver and Bile Duct Total - 38.479 - - 3.6 0.057 843 8.953,627 9.9 Liver and Bile Duct Male - 19.513 - - 2.6 0.150 594 4.402,760 13.2 Liver and Bile Duct Female - 18.966 - - 1.0 0.717 249 4.460,867 55.0 Lung and Bronchus Female 8 18.966 42.2 43.3 10.2 0.630 2.456 4.460,867 55.1 Melanoma of the Skin Total 4 38.479 10.4 10.8 13.0 0.007 <											15.3	
Liver and Bile Duct Female - 18,966 - - 1.0 0.717 249 4,460,867 55.6 Lung and Bronchus Male 13 38,479 54.6 55.0 21.1 1.000 4,938 8,953,627 55.2 Lung and Bronchus Female 8 18,966 42.2 43.3 10.2 0.630 2,456 4,460,867 55.1 Melanoma of the Skin Male 2 19,513 10.2 10.3 8.2 0.024 4,492,760 42.1 Melanoma of the Skin Male 2 19,513 10.2 10.3 8.2 0.024 1,893,627 35.1 Melanoma of the Skin Female 2 19,513 5.1 5.1 2.0 0.251 1,247 4,460,867 6.5 Myeloma Male 1 19,513 5.1 5.1 2.0 0.835 444 4,492,760 9.5 Non-Hodgkin Lymphoma Total 4 38,479 10.4	Liver and Bile Duct	Total	-	38,479	-	-	3.6		843	8,953,627	9.4	
Lung and Bronchus Total 21 38,479 54.6 55.0 21.1 1.000 4.938 8.953,627 55.2 Lung and Bronchus Fermale 8 19,513 66.6 65.6 10.9 0.611 2,482 4,492,760 55.2 Lung and Bronchus Fermale 8 18,966 42.2 43.3 10.2 0.630 2,456 4,460,867 55.7 Melanoma of the Skin Male 2 19,513 10.2 10.3 8.2 0.024 < <td>3,8479 2.6 2.6 3.1 0.375 727 8,953,627 8.7 Myeloma Total 1 19,513 5.1 5.1 2.0 0.251 1.247 4,460,867 28.6 Myeloma Total 1 19,513 5.1 5.1 2.0 0.835 446 4,92,760 22.2 0.061 1988 8953,627 4.60,867 6.3 0.063 1,145 4,92,760 22.5 0.061,919 0.083 1,44.</td> <td></td> <td></td> <td>-</td> <td></td> <td>-</td> <td>-</td> <td></td> <td></td> <td></td> <td></td> <td>13.2</td>	3,8479 2.6 2.6 3.1 0.375 727 8,953,627 8.7 Myeloma Total 1 19,513 5.1 5.1 2.0 0.251 1.247 4,460,867 28.6 Myeloma Total 1 19,513 5.1 5.1 2.0 0.835 446 4,92,760 22.2 0.061 1988 8953,627 4.60,867 6.3 0.063 1,145 4,92,760 22.5 0.061,919 0.083 1,44.			-		-	-					13.2
Lung and Bronchus Male 13 19,513 66.6 65.6 10.9 0.611 2.482 4.492,760 55.2 Lung and Bronchus Female 8 18,966 42.2 43.3 10.2 0.630 2.456 4.460,867 55.1 Melanoma of the Skin Male 2 19,513 10.2 10.3 8.2 0.024 <<			-		-	-		-			5.6	
Lung and Bronchus Female 8 18,966 42.2 43.3 10.2 0.630 2.456 4,460,867 55.1 Melanoma of the Skin Male 2 19,513 10.2 10.3 8.2 0.007 <											55.2	
Melänoma of the Skin Total 4 38,479 10.4 10.8 13.0 0.007 < 31.40 8,953,627 35.1 Melanoma of the Skin Female 2 19,513 10.2 10.3 8.2 0.024 <												
Melanoma of the Skin Male 2 19,513 10.2 10.3 8.2 0.024 4.893 4.492,760 42.1 Melanoma of the Skin Female 2 18,966 10.5 11.2 5.0 0.251 1,247 4,460,867 28.5 Myeloma Male 1 138,479 2.6 C.6 3.1 0.375 727 8,953,627 853,627 Ms.1 Myeloma Female - 18,966 - - 1.1 0.633 281 4,460,867 62.5 Non-Hodgkin Lymphoma Total 4 38,479 10.4 10.6 8.4 0.160 1,988 8,953,627 22.2 Non-Hodgkin Lymphoma Female 3 18,966 15.8 16.4 3.5 1.000 843 4,460,867 18.5 Non-Hodgkin Lymphoma Female 3 18,966 15.8 16.7 2.2 0.766 550 4,460,867 842 Oral Cavity and Pharynx Male						43.3						
Melanoma of the Skin Female 2 18,966 10.5 11.2 5.0 0.251 1.247 4,460,867 28.0 Myeloma Total 1 38,479 2.6 2.6 3.1 0.375 727 8,953,627 8.1 Myeloma Female - 18,966 - - 1.1 0.633 281 4,460,867 6.5 Non-Hodgkin Lymphoma Total 4 38,479 10.4 10.6 8.4 0.160 1,988 8,953,627 22.2 Non-Hodgkin Lymphoma Male 1 19,513 5.1 5.0 0.083 1,145 4,492,760 25.5 Non-Hodgkin Lymphoma Female 3 18,966 15.8 16.4 3.5 1.000 843 4,460,867 18.9 Oral Cavity and Pharynx Total 3 38,479 7.8 8.0 5.5 0.399 1,312 8,953,627 14.7 Oral Cavity and Pharynx Female 2 18,966												
Myeloma Total 1 38,479 2.6 2.6 3.1 0.375 727 8,953,627 8.1 Myeloma Male 1 19,513 5.1 5.1 2.0 0.835 446 4,492,760 9.5 Non-Hodgkin Lymphoma Total 4 38,479 10.4 10.6 8.4 0.160 1.988 8,953,627 22.2 Non-Hodgkin Lymphoma Male 1 19,513 5.1 5.0 0.083 1,145 4,492,760 25.5 Non-Hodgkin Lymphoma Female 3 18,966 15.8 16.4 3.5 1.000 843 4,460,867 14.7 Oral Cavity and Pharynx Total 3 38,479 7.8 8.0 5.5 0.399 1,312 8,953,627 14.7 Oral Cavity and Pharynx Male 1 19,513 5.1 5.1 4.1 0.170 939 4,460,867 12.3 Oral Cavity and Pharynx Female 3 18,966 <											28.0	
Myeloma Male 1 19,513 5.1 5.1 2.0 0.835 446 4,492,760 9.5 Myeloma Female - 18,966 - - 1.1 0.633 281 4,460,867 63.3 Non-Hodgkin Lymphoma Male 1 19,513 5.1 5.0 0.083 1,145 4,492,760 222.7 Non-Hodgkin Lymphoma Male 1 19,513 5.1 5.0 0.083 1,145 4,492,760 22.7 Non-Hodgkin Lymphoma Female 3 18,966 15.8 16.4 3.5 1.000 843 4,460,867 18.2 Oral Cavity and Pharynx Total 3 38,479 7.8 8.0 5.5 0.399 1,312 8,953,627 14.7 Oral Cavity and Pharynx Female 2 18,966 10.5 11.0 1.5 0.899 373 4,460,867 8.4 Ovary Female 3 18,966 10.5 11.0	Myeloma										8.1	
Myeloma Female - 18,966 - - 1.1 0.633 281 4,460,867 6.3 Non-Hodgkin Lymphoma Male 1 9,879 10.4 10.6 8.4 0.160 1,988 8,953,627 22.2 Non-Hodgkin Lymphoma Male 1 19,513 5.1 5.0 0.083 1,145 4,492,760 25.5 Non-Hodgkin Lymphoma Female 3 18,966 15.8 16.4 3.5 1.000 843 4,460,867 18.5 Oral Cavity and Pharynx Total 3 38,479 7.8 8.0 5.5 0.399 1,312 8,953,627 14.7 Oral Cavity and Pharynx Male 1 19,513 5.1 5.1 4.1 0.170 939 4,460,867 8.4 Ovary Female 3 18,966 10.5 11.0 1.5 0.899 3.73 4,460,867 14.5 Pancreas Total 7 38,479 18.2	Myeloma	Male	1	19,513				0.835	446	4,492,760	9.9	
Non-Hodgkin Lymphoma Male 1 19,513 5.1 5.1 5.0 0.083 1,145 4,492,760 25.5 Non-Hodgkin Lymphoma Female 3 18,966 15.8 16.4 3.5 1.000 843 4,460,867 18.5 Oral Cavity and Pharynx Total 3 38,479 7.8 8.0 5.5 0.399 1,312 8,953,627 14.7 Oral Cavity and Pharynx Male 1 19,513 5.1 5.1 4.1 0.170 939 4,492,760 20.5 Oral Cavity and Pharynx Female 2 18,966 10.5 11.0 1.5 0.899 373 4,460,867 82.5 Oral Cavity and Pharynx Female 3 18,966 10.5 11.0 1.5 0.899 373 4,460,867 12.5 Pancreas Total 7 88,479 18.2 18.4 6.3 0.880 1,413 8,95,627 16.5 Pancreas Male 5	Myeloma					-	1.1			4,460,867	6.3	
Non-Hodğkin Lýmphoma Female 3 18,966 15.8 16.4 3.5 1.000 843 4,460,867 18.5 Oral Cavity and Pharynx Total 3 38,479 7.8 8.0 5.5 0.399 1,312 8,953,627 14.7 Oral Cavity and Pharynx Male 1 19,513 5.1 5.1 4.1 0.170 939 4,460,867 8.4 Oral Cavity and Pharynx Female 2 18,966 10.5 11.0 1.5 0.170 939 4,460,867 12.3 Ovary Female 3 18,966 15.8 16.7 2.2 0.766 550 4,460,867 12.3 Pancreas Total 7 38,479 18.2 18.4 6.3 0.880 1.481 8,953,627 16.5 Pancreas Male 5 19,513 25.6 25.4 3.6 0.586 821 4,492,760 18.5 Prostate Male 1 19,513											22.2	
Oral Cavity and Pharynx Total 3 38,479 7.8 8.0 5.5 0.399 1,312 8,953,627 14.7 Oral Cavity and Pharynx Male 1 19,513 5.1 5.1 4.1 0.170 939 4,492,760 20.5 Oral Cavity and Pharynx Female 2 18,966 10.5 11.0 1.5 0.899 373 4,460,867 82.5 Ovary Female 3 18,966 15.8 16.7 2.2 0.766 550 4,460,867 12.5 Pancreas Total 7 38,479 18.2 18.4 6.3 0.880 1,481 8,953,627 16.5 Pancreas Male 5 19,513 25.6 25.4 3.6 0.586 821 4,492,760 18.5 Pancreas Female 2 18,966 10.5 10.9 2.7 0.975 66.00 4,460,867 14.6 Prostate Male 1 19,513 5.1<											25.5	
Oral Cavity and Pharynx Male 1 19,513 5.1 5.1 4.1 0.170 939 4,492,760 20.5 Oral Cavity and Pharynx Female 2 18,966 10.5 11.0 1.5 0.899 373 4,460,867 8.4 Ovary Female 3 18,966 15.8 16.7 2.2 0.766 550 4,460,867 8.4 Pancreas Total 7 38,479 18.2 18.4 6.3 0.880 1.41 8,953,627 16.5 Pancreas Male 5 19,513 25.6 25.4 3.6 0.586 821 4,492,760 18.3 Pancreas Female 2 18,966 10.5 10.9 2.7 0.975 660 4,460,867 14.8 Prostate Male 2 38,479 5.2 5.3 2.0 1.000 306 4,492,760 6.5.3 Stomach Male 1 19,513 5.1 5.1 <td></td>												
Oral Cavity and Pharynx Female 2 18,966 10.5 11.0 1.5 0.899 373 4,460,867 8.4 Ovary Female 3 18,966 15.8 16.7 2.2 0.766 550 4,460,867 12.3 Pancreas Total 7 38,479 18.2 18.4 6.3 0.880 1,481 8,953,627 16.5 Pancreas Male 5 19,513 25.6 25.4 3.6 0.586 821 4,492,760 18.3 Pancreas Male 2 18,966 10.5 10.9 2.7 0.975 6.604 4,492,760 18.3 Prostate Male 2 38,479 5.2 5.3 2.0 1.000 472 8,953,627 5.3 5.3 Stomach Male 1 19,513 5.1 5.1 1.3 1.000 306 4,492,760 6.8 Stomach Male 1 19,513 5.1 5.									030			
Ovary Female 3 18,966 15.8 16.7 2.2 0.766 550 4,460,867 12.3 Pancreas Total 7 38,479 18.2 18.4 6.3 0.880 1,481 8,953,627 16.5 Pancreas Male 5 19,513 25.6 25.4 3.6 0.586 821 4,492,760 18.3 Pancreas Female 2 18,966 10.5 10.9 2.7 0.975 660 4,460,867 14.8 Prostate Male 27 19,513 138.4 137.1 29.5 0.729 6,739 4,492,760 150.0 Stomach Total 2 38,479 5.2 5.3 2.0 1.000 306 4,492,760 65.8 Stomach Male 1 19,513 5.1 5.1 1.3 1.000 306 4,492,760 6.5 Stomach Male 1 19,513 - - 1.1											8.4	
Pancreas Total 7 38,479 18.2 18.4 6.3 0.880 1,481 8,953,627 16.5 Pancreas Male 5 19,513 25.6 25.4 3.6 0.586 821 4,492,760 18.3 Pancreas Female 2 18,966 10.5 10.9 2.7 0.975 660 4,460,867 14.5 Prostate Male 27 19,513 138.4 137.1 29.5 0.729 6,739 4,492,760 150.0 Stomach Total 2 38,479 5.2 5.3 2.0 1.000 306 4,492,760 66.5 Stomach Male 1 19,513 5.1 5.1 1.3 1.000 306 4,492,760 66.5 Stomach Female 1 18,966 5.3 5.5 0.7 0.981 166 4,460,867 3.7 Testis Male - 19,513 - - 1.1											12.3	
Pancreas Male 5 19,513 25.6 25.4 3.6 0.586 821 4,492,760 18.5 Pancreas Female 2 18,966 10.5 10.9 2.7 0.975 660 4,460,867 14.5 Prostate Male 27 19,513 138.4 137.1 29.5 0.729 6,739 4,492,760 150.0 Stomach Total 2 38,479 5.2 5.3 2.0 1.000 472 8,953,627 5.3 Stomach Male 1 19,513 5.1 5.1 1.3 1.000 472 8,953,627 5.3 Stomach Female 1 18,966 5.3 5.5 0.7 0.981 166 4,460,867 3.7 Testis Male - 19,513 - - 1.1 0.683 274 4,492,760 6.1 Thyroid Total 4 38,479 10.4 11.2 4.7	Pancreas		7				6.3		1,481	8,953,627	16.5	
Prostate Male 27 19,513 138.4 137.1 29.5 0.729 6,739 4,492,760 150.0 Stomach Total 2 38,479 5.2 5.3 2.0 1.000 472 8,953,627 5.3 Stomach Male 1 19,513 5.1 5.1 1.3 1.000 306 4,492,760 6.5 Stomach Male 1 19,513 5.1 5.1 1.3 1.000 306 4,492,760 6.5 Stomach Female 1 19,513 5.1 5.5 0.7 0.981 166 4,460,867 3.7 Testis Male - 19,513 - - 1.1 0.683 274 4,492,760 6.1 Thyroid Total 4 38,479 10.4 11.2 4.7 0.980 1,181 8,953,627 13.2 Thyroid Total 4 38,479 10.4 11.2 4.7 0.98	Pancreas	Male			25.6	25.4	3.6	0.586	821	4,492,760	18.3	
Stomach Total 2 38,479 5.2 5.3 2.0 1.000 472 8,953,627 5.3 Stomach Male 1 19,513 5.1 5.1 1.3 1.000 306 4,492,760 6.8 Stomach Female 1 18,966 5.3 5.5 0.7 0.981 166 4,460,867 3.7 Testis Male - 19,513 - - 1.1 0.683 274 4,492,760 6.1 Thyroid Total 4 38,479 10.4 11.2 4.7 0.980 1,181 8,953,627 13.2 Thyroid Total 4 38,479 10.4 11.2 4.7 0.980 1,181 8,953,627 13.2 Thyroid Male 1 19,513 5.1 5.4 1.5 1.000 371 4,492,760 8.3 Thyroid Female 3 18,966 15.8 17.3 3.2 1.000 <td></td> <td>14.8</td>											14.8	
Stomach Male 1 19,513 5.1 5.1 1.3 1.000 306 4,492,760 6.8 Stomach Female 1 18,966 5.3 5.5 0.7 0.981 166 4,460,867 3.7 Testis Male - 19,513 - - 1.1 0.683 274 4,492,760 6.1 Thyroid Total 4 38,479 10.4 11.2 4.7 0.980 1,181 8,953,627 13.2 Thyroid Male 1 19,513 5.1 5.4 1.5 1.000 371 4,492,760 8.3 Thyroid Male 1 19,513 5.1 5.4 1.5 1.000 371 4,492,760 8.3 Thyroid Male 1 19,513 5.1 5.4 1.5 1.000 371 4,492,760 8.3 Thyroid Female 3 18,966 15.8 17.3 3.2 1.000											150.0	
Stomach Female 1 18,966 5.3 5.5 0.7 0.981 166 4,460,867 3.7 Testis Male - 19,513 - - 1.1 0.683 274 4,492,760 6.1 Thyroid Total 4 38,479 10.4 11.2 4.7 0.980 1,181 8,953,627 13.2 Thyroid Male 1 19,513 5.1 5.4 1.5 1.000 371 4,492,760 8.3 Thyroid Male 1 19,513 5.1 5.4 1.5 1.000 371 4,492,760 8.3 Thyroid Female 3 18,966 15.8 17.3 3.2 1.000 810 4,460,867 18.2 Pediatric Age 0 to 19 Total 2 12,841 15.6 15.7 2.2 1.000 423 2,486,483 17.0 Pediatric Age 0 to 19 Male - 6,512 - - 1.1 <td></td> <td>5.3</td>											5.3	
TestisMale-19,5131.10.6832744,492,7606.1ThyroidTotal438,47910.411.24.70.9801,1818,953,62713.2ThyroidMale119,5135.15.41.51.0003714,492,7608.3ThyroidFemale318,96615.817.33.21.0008104,460,86718.2Pediatric Age 0 to 19Total212,84115.615.72.21.0004232,486,48317.0Pediatric Age 0 to 19Male-6,5121.10.6692141,267,80916.5												
ThyroidTotal438,47910.411.24.70.9801,1818,953,62713.2ThyroidMale119,5135.15.41.51.0003714,492,7608.3ThyroidFemale318,96615.817.33.21.0008104,460,86718.2Pediatric Age 0 to 19Total212,84115.615.72.21.0004232,486,48317.0Pediatric Age 0 to 19Male-6,5121.10.6692141,267,80916.5												
Thyroid Male 1 19,513 5.1 5.4 1.5 1.000 371 4,492,760 8.3 Thyroid Female 3 18,966 15.8 17.3 3.2 1.000 810 4,460,867 18.2 Pediatric Age 0 to 19 Total 2 12,841 15.6 15.7 2.2 1.000 423 2,486,483 17.0 Pediatric Age 0 to 19 Male - 6,512 - - 1.1 0.669 214 1.267,809 16.5												
Thyroid Female 3 18,966 15.8 17.3 3.2 1.000 810 4,460,867 18.2 Pediatric Age 0 to 19 Total 2 12,841 15.6 15.7 2.2 1.000 423 2,486,483 17.0 Pediatric Age 0 to 19 Male - 6,512 - - 1.1 0.669 214 1.267,809 16.9												
Pediatric Age 0 to 19 Total 2 12,841 15.6 15.7 2.2 1.000 423 2,486,483 17.0 Pediatric Age 0 to 19 Male - 6,512 - - 1.1 0.669 214 1.267,809 16.5												
Pediatric Age 0 to 19 Male - 6,512 1.1 0.669 214 1.267.809 16.9												
					-	-						
Pediatric Age 0 to 19 [Female] 2 6,329 31.6 32.3 1.1 0.573 209 1,218,674 17.1			- 2	6,329	- 31.6	32.3			209	1,218,674	17.1	

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN POWER COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Po	wer County				Re	mainder of Idah	0
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years		Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	348	38,960	893.2	888.4	342.4	0.778	80.187	9.172.434	874.2
All Causes of Death	Male	178	19,748	901.4	882.9	186.4	0.567	42,608	4,607,949	924.7
All Causes of Death	Female	170	19,212	884.9	889.2	157.4	0.334	37,579	4,564,485	823.3
All Malignant Cancers	Total	62	38,960	159.1	159.8	64.2	0.851	15,171	9,172,434	165.4
All Malignant Cancers	Male	33	19,748	167.1	164.1	35.8	0.720	8,202	4,607,949	178.0
All Malignant Cancers	Female	29	19,212	150.9	154.3	28.7	1.000	6,969	4,564,485	152.7
Bladder	Total	-	38,960	-	-	2.1	0.246	485	9,172,434	5.3
Bladder	Male	-	19,748	-	-	1.7	0.372	375	4,607,949	8.1
Bladder	Female	-	19,212	-	-	0.5	1.000	110	4,564,485	2.4
Brain and Other Nervous System	Total	1	38,960	2.6	2.6	2.2	0.733	517	9,172,434	5.6
Brain and Other Nervous System	Male	-	19,748	-	-	1.2	0.582	289	4,607,949	6.3
Brain and Other Nervous System	Female	1	19,212	5.2	5.4	0.9	1.000	228	4,564,485	5.0
Breast	Total	5	38,960	12.8	13.0	4.7	1.000	1,119	9,172,434	12.2
Breast	Male	-	19,748	-	-	0.1	1.000	13	4,607,949	0.3
Breast	Female	5	19,212	26.0	26.8	4.5	0.943	1,106	4,564,485	24.2
Cervix	Female	1	19,212	5.2	5.6	0.3	0.578	87	4,564,485	1.9
Colorectal	Total	7	38,960	18.0	18.2	5.6	0.648	1,325	9,172,434	14.4
Colorectal	Male	5	19,748	25.3	25.1	3.1	0.416	727	4,607,949	15.8
Colorectal	Female	2	19,212	10.4	10.7	2.5	1.000	598	4,564,485	13.1
Corpus Uteri	Female	-	19,212	-	-	0.7	1.000	169	4,564,485	3.7
Esophagus	Total	1	38,960	2.6	2.6	1.9	0.848	460	9,172,434	5.0
Esophagus	Male	1	19,748	5.1	5.0	1.7	0.996	390	4,607,949	8.5
Esophagus	Female	-	19,212	-	-	0.3	1.000	70	4,564,485	1.5
Hodgkin Lymphoma	Total	-	38,960	-	-	0.1	1.000	25	9,172,434	0.3
Hodgkin Lymphoma Hodgkin Lymphoma	Male Female	-	19,748	-	-	0.1 0.0	1.000 1.000	14	4,607,949	0.3 0.2
Kidney	Total	-	19,212 38,960	- 2.6	- 2.6	1.6	1.000	11 385	4,564,485 9,172,434	4.2
Kidney	Male	1	19,748	2.0 5.1	2.0 5.0	1.0	1.000	245	4,607,949	4.2 5.3
Kidney	Female	- '	19,740	5.1	5.0	0.6	1.000	140	4,564,485	3.1
Larynx	Total	_	38,960	-	-	0.0	1.000	76	9,172,434	0.8
Larynx	Male	-	19,748	-	-	0.3	1.000	65	4,607,949	1.4
Larynx	Female	-	19,212	-	-	0.0	1.000	11	4,564,485	0.2
Leukemia	Total	5	38,960	12.8	12.8	2.8	0.310	660	9,172,434	7.2
Leukemia	Male	1	19,748	5.1	4.9	1.7	0.961	396	4,607,949	8.6
Leukemia	Female	4	19,212	20.8	21.0	1.1	0.051	264	4,564,485	5.8
Liver and Bile Duct	Total	1	38,960	2.6	2.6	2.7	0.514	634	9,172,434	6.9
Liver and Bile Duct	Male	1	19,748	5.1	5.0	1.8	0.917	422	4,607,949	9.2
Liver and Bile Duct	Female	-	19,212	-	-	0.9	0.838	212	4,564,485	4.6
Lung and Bronchus	Total	11	38,960	28.2	28.3	12.4	0.833	2,926	9,172,434	31.9
Lung and Bronchus	Male	7	19,748	35.4	34.9	6.7	1.000	1,534	4,607,949	33.3
Lung and Bronchus	Female	4	19,212	20.8	21.2	5.8	0.636	1,392	4,564,485	30.5
Melanoma of the Skin	Total	2	38,960	5.1	5.2	1.3	0.716	299	9,172,434	3.3
Melanoma of the Skin	Male	-	19,748	-	-	0.9	0.842	200	4,607,949	4.3
Melanoma of the Skin	Female	2	19,212	10.4	10.7	0.4	0.126	99	4,564,485	2.2
Myeloma	Total	1	38,960	2.6	2.6	1.4	1.000	324	9,172,434	3.5
Myeloma	Male	1	19,748	5.1	4.9	0.8	1.000 1.000	187	4,607,949	4.1
Myeloma Non-Hodgkin Lymphoma	Female Total	- 2	19,212 38,960	- 5.1	- 5.1	0.6	1.000	137 566	4,564,485 9,172,434	3.0 6.2
Non-Hodgkin Lymphoma	Male		38,960 19,748	5. I	5.1	2.4 1.4	0.514	566 310	9,172,434 4,607,949	6.2 6.7
Non-Hodgkin Lymphoma	Female	- 2	19,748	- 10.4	- 10.5	1.4	0.514	256	4,564,485	5.6
Oral Cavity and Pharynx	Total	<u> </u>	38,960	2.6	2.6	1.1	1.000	230	9,172,434	3.0 3.0
Oral Cavity and Pharynx	Male	1	19,748	5.1	2.0 5.0	0.8	1.000	191	4,607,949	4.1
Oral Cavity and Pharynx	Female	- '	19,212	-	-	0.3	1.000	83	4,564,485	1.8
Ovary	Female	5	19,212	26.0	26.9	1.5	0.033 >>	356	4,564,485	7.8
Pancreas	Total	4	38,960	10.3	10.4	5.0	0.885	1,186	9,172,434	12.9
Pancreas	Male	3	19,748	15.2	15.1	2.8	1.000	647	4,607,949	14.0
Pancreas	Female	1	19,212	5.2	5.3	2.2	0.698	539	4,564,485	11.8
Prostate	Male	4	19,748	20.3	19.4	4.4	1.000	993	4,607,949	21.5
Stomach	Total	1	38,960	2.6	2.6	0.8	1.000	193	9,172,434	2.1
Stomach	Male	-	19,748	-	-	0.5	1.000	119	4,607,949	2.6
Stomach	Female	1	19,212	5.2	5.4	0.3	0.516	74	4,564,485	1.6

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Power County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	8.7%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	71.4%
Current Tobacco User (2020–2022) <u>Other Cancer-Related</u>	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	24.3%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	11.7% 71.6% 16.5% 20.7%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





SHOSHONE COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 496 cases of invasive cancer were diagnosed among Shoshone County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in ShoshoneCounty and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Shoshone County	State of Idaho
All Sites/Types	496	47,333
Female Breast	44	6,943
Prostate	69	6,766
Lung & Bronchus	90	4,959
Colorectal	58	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Shoshone County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Shoshone County. The table also shows the number of observed cases,

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 166 Shoshone County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Shoshone County and the State of Idaho, 2018–2022

Mortality 2018–2022	Shoshone County	State of Idaho
All Deaths	1,009	80,538
Cancer Deaths	166	15,233
% of All Deaths	16.5%	18.9%
Lung & Bronchus	42	2,937
Colorectal	21	1,332
Pancreas	13	1,190
Female Breast	9	1,111
Prostate	15	997

person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, nonmalignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Shoshone County was 766.3 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (524.6) gives an estimate of the relative burden of disease in Shoshone County.

The age- and sex-adjusted incidence rate of invasive cancer in Shoshone County, all sites combined, was 572.1 cases per 100,000 persons per year during 2017–2021. There were more cases of cancer in Shoshone County (496) than expected (454.8) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Shoshone County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Shoshone County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Shoshone County, all sites combined, was 181.7 deaths per 100,000 persons per year during 2018–2022, compared with 164.8 for the remainder of the state. There were more cancer deaths in Shoshone County (166) than expected (150.5) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN SHOSHONE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Person Years 3,927,376 4,479,620 4,47,756 9,927,376 4,479,620 4,477,756 4,479,620 4,477,756 5,927,376	Crude Rate (1) 524.6 557.2 491.8 24.7 39.3 10.0 7.3 8.5
Site/Type Sex Cases Years Rate (1) Rate (1,2) Cases (3) P-Value (4) Cases All Sites Combined Total 496 64,730 766.3 572.1 454.8 0.059 46,837 8 All Sites Combined Male 308 32,653 943.3 689.5 248.9 0.000 >> 24,962 4 All Sites Combined Female 188 32,077 586.1 448.5 206.2 0.216 21,875 4 Bladder Total 17 64,730 26.3 18.6 22.5 0.285 2,203 8 Bladder Male 14 32,653 42.9 30.5 18.0 0.417 1,759 4 Bladder Female 3 32,077 9.4 6.7 4.5 0.692 444 4 Brain - malignant Total 4 64,730 6.2 5.0 5.8 0.620 653 8 Brain - malignant <td< td=""><td>Years 9,927,376 4,479,620 4,447,756 9,927,376 4,479,620 4,479,620 4,477,56 9,927,376 1,927,376 1,927,376</td><td>Rate (1) 524.6 557.2 491.8 24.7 39.3 10.0 7.3 8.5</td></td<>	Years 9,927,376 4,479,620 4,447,756 9,927,376 4,479,620 4,479,620 4,477,56 9,927,376 1,927,376 1,927,376	Rate (1) 524.6 557.2 491.8 24.7 39.3 10.0 7.3 8.5
All Sites Combined Total 496 64,730 766.3 572.1 454.8 0.059 46,837 8 All Sites Combined Male 308 32,653 943.3 689.5 248.9 0.000 >> 24,962 4 All Sites Combined Female 188 32,077 586.1 448.5 206.2 0.216 21,875 4 Bladder Total 17 64,730 26.3 18.6 22.5 0.285 2,203 8 Bladder Male 14 32,653 42.9 30.5 18.0 0.417 1,759 4 Bladder Female 3 32,077 9.4 6.7 4.5 0.692 444 4 Brain - malignant Total 4 64,730 6.2 5.0 5.8 0.620 653 8 Brain - malignant Male 3 32,077 3.1 2.5 2.5 0.592 274 4 Brain and other CNS - non-malignant	8,927,376 4,479,620 4,47,756 6,927,376 4,479,620 4,447,756 5,927,376 4,479,620 4,447,756 5,927,376	524.6 557.2 491.8 24.7 39.3 10.0 7.3 8.5
All Sites CombinedMale308 $32,653$ 943.3 689.5 248.9 $0.000 >>$ $24,962$ 4All Sites CombinedFemale188 $32,077$ 586.1 448.5 206.2 0.216 $21,875$ 4BladderTotal17 $64,730$ 26.3 18.6 22.5 0.285 $2,203$ 8BladderMale14 $32,653$ 42.9 30.5 18.0 0.417 $1,759$ 4BladderFemale3 $32,077$ 9.4 6.7 4.5 0.692 444 4Brain - malignantTotal4 $64,730$ 6.2 5.0 5.8 0.620 653 8Brain - malignantMale3 $32,653$ 9.2 7.5 3.4 1.000 379 4Brain - malignantFemale1 $32,077$ 3.1 2.5 2.5 0.592 274 4Brain and other CNS - non-malignantTotal10 $64,730$ 15.4 12.1 14.3 0.318 $1,537$ 8Brain and other CNS - non-malignantMale1 $32,653$ 3.1 2.4 4.6 0.115 499 4	479,620 447,756 5927,376 447,756 447,756 5927,376 447,756 5927,376 447,756 5927,376	557.2 491.8 24.7 39.3 10.0 7.3 8.5
All Sites CombinedFemale18832,077586.1448.5206.20.21621,8754BladderTotal1764,73026.318.622.50.2852,2038BladderMale1432,65342.930.518.00.4171,7594BladderFemale332,0779.46.74.50.6924444Brain - malignantTotal464,7306.25.05.80.6206538Brain - malignantMale332,6539.27.53.41.0003794Brain - malignantFemale132,0773.12.52.50.5922744Brain and other CNS - non-malignantTotal1064,73015.412.114.30.3181,5378Brain and other CNS - non-malignantMale132,6533.12.44.60.1154994	447,756 9927,376 479,620 447,756 9927,376 479,620 447,756 9927,376 9927,376	24.7 39.3 10.0 7.3 8.5
Bladder Male 14 32,653 42.9 30.5 18.0 0.417 1,759 4 Bladder Female 3 32,077 9.4 6.7 4.5 0.692 444 4 Brain - malignant Total 4 64,730 6.2 5.0 5.8 0.620 653 8 Brain - malignant Male 3 32,653 9.2 7.5 3.4 1.000 379 4 Brain - malignant Female 1 32,077 3.1 2.5 2.5 0.592 274 4 Brain and other CNS - non-malignant Total 10 64,730 15.4 12.1 14.3 0.318 1,537 8 Brain and other CNS - non-malignant Male 1 32,653 3.1 2.4 4.6 0.115 499 4	4,479,620 4,447,756 5,927,376 4,479,620 4,447,756 5,927,376	39.3 10.0 7.3 8.5
Bladder Female 3 32,077 9.4 6.7 4.5 0.692 444 4 Brain - malignant Total 4 64,730 6.2 5.0 5.8 0.620 653 8 Brain - malignant Male 3 32,653 9.2 7.5 3.4 1.000 379 4 Brain - malignant Female 1 32,077 3.1 2.5 2.5 0.592 274 4 Brain and other CNS - non-malignant Total 10 64,730 15.4 12.1 14.3 0.318 1,537 8 Brain and other CNS - non-malignant Male 1 32,653 3.1 2.4 4.6 0.115 499 4	447,756 3,927,376 4,479,620 4,447,756 3,927,376	10.0 7.3 8.5
Brain - malignant Total 4 64,730 6.2 5.0 5.8 0.620 653 8 Brain - malignant Male 3 32,653 9.2 7.5 3.4 1.000 379 4 Brain - malignant Female 1 32,077 3.1 2.5 2.5 0.592 274 4 Brain and other CNS - non-malignant Total 10 64,730 15.4 12.1 14.3 0.318 1,537 8 Brain and other CNS - non-malignant Male 1 32,653 3.1 2.4 4.6 0.115 499 4	8,927,376 ,479,620 ,447,756 8,927,376	7.3 8.5
Brain - malignant Male 3 32,653 9.2 7.5 3.4 1.000 379 4 Brain - malignant Female 1 32,077 3.1 2.5 2.5 0.592 274 4 Brain and other CNS - non-malignant Total 10 64,730 15.4 12.1 14.3 0.318 1,537 8 Brain and other CNS - non-malignant Male 1 32,653 3.1 2.4 4.6 0.115 499 4	,479,620 ,447,756 3,927,376	8.5
Brain - malignant Female 1 32,077 3.1 2.5 2.5 0.592 274 4 Brain and other CNS - non-malignant Total 10 64,730 15.4 12.1 14.3 0.318 1,537 8 Brain and other CNS - non-malignant Male 1 32,653 3.1 2.4 4.6 0.115 499 4	,447,756 3,927,376	
Brain and other CNS - non-malignant Total 10 64,730 15.4 12.1 14.3 0.318 1,537 8 Brain and other CNS - non-malignant Male 1 32,653 3.1 2.4 4.6 0.115 499 4	3,927,376	6.2
Brain and other CNS - non-malignant Male 1 32,653 3.1 2.4 4.6 0.115 499 4		17.2
	,479,620	11.1
	,447,756	23.3
	3,927,376	78.0
	,479,620	1.4
	,447,756	155.1
	3,927,376	15.2
	,479,620	0.1
	,447,756	30.5 6.5
	3.927.376	40.0
	,479,620	43.2
Colorectal Female 18 32,077 56.1 42.2 15.7 0.627 1,637 4	,447,756	36.8
Corpus Uteri Female 14 32,077 43.6 33.5 12.6 0.766 1.340 4	,447,756	30.1
	3,927,376	5.6
	,479,620	9.5
	,447,756	1.8
	3,927,376 ,479,620	2.5 2.9
	,479,020	2.9
	3,927,376	21.7
Kidney and Renal Pelvis Male 10 32,653 30.6 22.9 12.7 0.561 1,300 4	,479,620	29.0
	,447,756	14.3
	3,927,376	2.4
	,479,620	3.6
	,447,756	1.2
	3,927,376 479,620	19.2 22.9
	,479,620	22.9 15.4
	3,927,376	9.3
	,479,620	13.0
	,447,756	5.5
	3,927,376	54.5
	,479,620	54.5
	,447,756	54.5
	3,927,376	35.0
	,479,620 ,447,756	41.9 28.0
	,447,756 3,927,376	20.0
	,479,620	10.0
Myeloma Female 3 32,077 9.4 6.8 2.8 1.000 278 4	,447,756	6.3
Non-Hodgkin Lymphoma Total 15 64,730 23.2 17.4 19.1 0.415 1,977 8	3,927,376	22.1
	,479,620	25.4
	,447,756	18.8
	3,927,376	14.5
	,479,620 ,447,756	20.6 8.4
Oral Cavity and Final yinx Female 5 52,077 9.4 7.0 5.0 1.000 572 4 Ovary Female 4 32,077 12.5 9.7 5.1 0.848 549 4	,447,756	12.3
	3,927,376	16.5
Pancreas Male 8 32,653 24.5 17.7 8.3 1.000 818 4	,479,620	18.3
Pancreas Female 9 32,077 28.1 20.3 6.5 0.420 653 4	,447,756	14.7
	,479,620	149.5
	3,927,376	5.3
	,479,620	6.8
	,447,756	3.8 6.0
	,479,620 3,927,376	13.2
	,479,620	8.2
	,479,620	0.2 18.2
	2,484,924	17.1
	.,464,924	16.8
Pediatric Age 0 to 19 Female - 6,983 1.2 0.595 211 1	,200,904 ,218,020	17.3

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN SHOSHONE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Shos	hone Coun	ty			Re	mainder of Idah	10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	1,009	66,231	1,523.5	1,125.7	779.5	0.000 >>	79,526	9,145,163	869.6
All Causes of Death	Male	561	33,464	1,676.4	1,305.9	394.8	0.000 >>	42,225	4,594,233	919.1
All Causes of Death	Female	448	32,767	1,367.2	953.8	385.0	0.002 >>	37,301	4,550,930	819.6
All Malignant Cancers	Total	166	66,231	250.6	181.7	150.5	0.224	15,067	9,145,163	164.8
All Malignant Cancers	Male	97	33,464	289.9	214.1	80.3	0.224	8,138	4,594,233	177.1
All Malignant Cancers	Female	69	32,767	203.5	151.2	69.5	1.000	6,929	4,550,930	152.3
Bladder	Total	3	66,231	4.5	3.2	4.9	0.551	482	9,145,163	5.3
Bladder	Male	3	33,464	9.0	6.8	3.6	1.000	372	4,594,233	8.1
Bladder	Female	- 5	32.767	-	0.0	1.2	0.627	110	4,550,930	2.4
Brain and Other Nervous System	Total	2	66,231	3.0	2.3	4.9	0.274	516	9,145,163	5.6
	Male	1	33,464	3.0	2.3	2.7	0.484	288	4,594,233	6.3
Brain and Other Nervous System	Female	1	32,767	3.1	2.3	2.1	0.735	228	4,550,930	5.0
Breast	Total	10	66,231	15.1	11.2	10.9	0.952	1,114	9,145,163	12.2
Breast	Male	1	33,464	3.0	2.3	0.1	0.218	12	4,594,233	0.3
Breast	Female	9	32,767	27.5	20.0	10.9	0.707	1,102	4,550,930	24.2
Cervix	Female	-	32,767	-	-	0.7	0.950	88	4,550,930	1.9
Colorectal	Total	21	66,231	31.7	23.4	12.8	0.045 >>	1,311	9,145,163	14.3
Colorectal	Male	13	33,464	38.8	29.4	6.9	0.050	719	4,594,233	15.7
Colorectal	Female	8	32,767	24.4	17.5	5.9	0.498	592	4.550.930	13.0
Corpus Uteri	Female	1	32,767	3.1	2.2	1.7	1.000	168	4,550,930	3.7
Esophagus	Total	7	66,231	10.6	7.6	4.6	0.353	454	9,145,163	5.0
Esophagus	Male	7	33,464	20.9	15.1	3.9	0.196	384	4,594,233	8.4
Esophagus	Female		32,767	-	-	0.7	0.986	70	4,550,930	1.5
Hodgkin Lymphoma	Total	-	66,231	-	-	0.2	1.000	25	9,145,163	0.3
Hodgkin Lymphoma	Male	-	33,464	-	-	0.1	1.000	14	4,594,233	0.3
Hodgkin Lymphoma	Female	-	32,767	-	-	0.1	1.000	11	4,550,930	0.2
Kidney	Total	6	66,231	9.1	6.5	3.8	0.381	380	9,145,163	4.2
Kidney	Male	3	33,464	9.0	6.6	2.4	0.866	243	4,594,233	5.3
Kidney	Female	3	32,767	9.2	6.4	1.4	0.343	137	4,550,930	3.0
Larynx	Total	-	66,231	-	-	0.8	0.924	76	9,145,163	0.8
Larynx	Male	-	33,464	-	-	0.7	1.000	65	4,594,233	1.4
Larynx	Female	-	32,767	-	-	0.1	1.000	11	4,550,930	0.2
Leukemia	Total	4	66,231	6.0	4.4	6.6	0.428	661	9,145,163	7.2
Leukemia	Male	4	33,464	12.0	8.9	3.8	1.000	393	4,594,233	8.6
Leukemia	Female	-	32,767	-	-	2.7	0.134	268	4,550,930	5.9
Liver and Bile Duct	Total	6	66,231	9.1	6.6	6.3	1.000	629	9,145,163	6.9
Liver and Bile Duct	Male	4	33,464	12.0	8.6	4.2	1.000	419	4,594,233	9.1
Liver and Bile Duct	Female	2	32,767	6.1	4.4	2.1	1.000	210	4,550,930	4.6
Lung and Bronchus	Total	42	66,231	63.4	45.1	29.5	0.034 >>	2,895	9,145,163	31.7
Lung and Bronchus	Male	22	33,464	65.7	47.3	15.4	0.132	1,519	4,594,233	33.1
Lung and Bronchus	Female	20	32,767	61.0	43.1	14.0	0.156	1,376	4,550,930	30.2
Melanoma of the Skin	Total	5	66,231	7.5	5.6	2.9	0.335	296	9,145,163	3.2
Melanoma of the Skin	Male	2	33,464	6.0	4.5	1.9	1.000	198	4,594,233	4.3
Melanoma of the Skin	Female	3	32,767	9.2	6.8	1.0	0.144	98	4,550,930	2.2
Myeloma	Total	2	66,231	3.0	2.1	3.3	0.719	323	9,145,163	3.5
Myeloma	Male	-	33,464	-	-	1.9	0.306	188	4,594,233	4.1
Myeloma	Female	2	32,767	6.1	4.3	1.4	0.809	135	4,550,930	3.0
Non-Hodgkin Lymphoma	Total	4	66,231	6.0	4.3	5.7	0.656	564	9,145,163	6.2
Non-Hodgkin Lymphoma	Male	1	33,464	3.0	2.2	3.1	0.383	309	4,594,233	6.7
Non-Hodgkin Lymphoma	Female	3	32,767	9.2	6.3	2.7	0.991	255	4,550,930	5.6
Oral Cavity and Pharynx	Total	4	66,231	6.0	4.4	2.7	0.571	271	9,145,163	3.0
Oral Cavity and Pharynx	Male	4	33,464	12.0	8.7	1.9	0.244	188	4,594,233	4.1
	Female	-	32,767	-	-	0.8	0.876	83	4,550,930	1.8
Ovary	Female	2	32,767	6.1	4.4	3.6	0.613	359	4,550,930	7.9
Pancreas	Total	13	66,231	19.6	14.1	11.8	0.812	1,177	9,145,163	12.9
Pancreas	Male	6	33,464	17.9	12.9	6.5	1.000	644	4,594,233	14.0
Pancreas	Female	7	32,767	21.4	15.3	5.4	0.581	533	4,550,930	11.7
Prostate	Male	15	33,464	44.8	33.6	9.5	0.122	982	4,594,233	21.4
Stomach	Total	1	66,231	1.5	1.1	1.9	0.890	193	9,145,163	2.1
Stomach	Male	1	33,464	3.0	2.2	1.1	1.000	118	4,594,233	2.6
Stomach	Female	-	32,767	-	-	0.7	0.989	75	4,550,930	1.6

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Shoshone County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	95.9% 9.8%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	55.9%
Current Tobacco User (2020–2022) Other Cancer-Related	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	24.0%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	33.2% 68.7% 19.7% 29.3%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





TETON COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 261 cases of invasive cancer were diagnosed among Teton County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in TetonCounty and the State of Idaho. 2017–2021

Cancer Incidence 2017–2021	Teton County	State of Idaho
All Sites/Types	261	47,333
Female Breast	40	6,943
Prostate	35	6,766
Lung & Bronchus	18	4,959
Colorectal	15	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Teton County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Teton County. The table also shows the number of observed cases, person-

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 73 Teton County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Teton County and the State of Idaho, 2018–2022

Mortality 2018–2022	Teton County	State of Idaho
All Deaths	280	80,538
Cancer Deaths	73	15,233
% of All Deaths	26.1%	18.9%
Lung & Bronchus	13	2,937
Colorectal	7	1,332
Pancreas	8	1,190
Female Breast	6	1,111
Prostate	2	997

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Teton County was 435.0 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (527.0) gives an estimate of the relative burden of disease in Teton County.

The age- and sex-adjusted incidence rate of invasive cancer in Teton County, all sites combined, was 487.9 cases per 100,000 persons per year during 2017–2021. There were fewer cases of cancer in Teton County (261) than expected (281.9) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Teton County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Teton County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Teton County, all sites combined, was 149.1 deaths per 100,000 persons per year during 2018–2022, compared with 165.7 for the remainder of the state. There were fewer cancer deaths in Teton County (73) than expected (81.1) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN TETON COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

Site/TypeSexCasesYearsRate (1)Rate (1,2)Cases (3)P-Value (4)CasesYearsAll Sites CombinedTotal26159,994435.0487.9281.90.22247,0728,5All Sites CombinedMale14931,360475.1526.0158.80.46425,1214,4All Sites CombinedFemale11228,634391.1439.5125.70.23821,9514,4BladderTotal1059,99416.721.211.70.7622,2108,5BladderMale1031,36031.938.910.11.0001,7634,4BladderFemale-28,6342.20.2124474,4Brain - malignantTotal459,9946.77.14.11.0006538,5Brain - malignantMale431,36012.813.12.60.5213784,4Brain - malignantMale431,3609.610.03.31.0004974,4Brain and other CNS - non-malignantFemale-28,6341.60.4062754,4Brain and other CNS - non-malignantMale331,3609.610.03.31.0004974,4Brain and other CNS - non-malignantFemale228,6347.07.86.00.1241,0454,4BreastT	verson Years 332,112 480,913 451,199 332,112 480,913 451,199 332,112 480,913 451,199 332,112 480,913 451,199 332,112 480,913	Crude Rate (1) 527.0 560.6 493.1 24.7 39.3 10.0 7.3 8.4 6.2 17.3 11.1 23.5
Site/TypeSexCasesYearsRate (1)Rate (1,2)Cases (3)P-Value (4)CasesNAll Sites CombinedTotal26159,994435.0487.9281.90.22247,0728,5All Sites CombinedMale14931,360475.1526.0158.80.46425,1214,4All Sites CombinedFemale11228,634391.1439.5125.70.23821,9514,4BladderTotal1059,99416.721.211.70.7622,2108,5BladderMale1031,36031.938.910.11.0001,7634,4Brain - malignantTotal459,9946.77.14.11.0001,7634,4Brain - malignantMale431,36012.813.12.60.5213784,4Brain - malignantMale431,36012.813.12.60.5213784,4Brain and other CNS - non-malignantFemale-28,6341.60.4062754,4Brain and other CNS - non-malignantFemale228,6341.60.1751,5428,5Brain and other CNS - non-malignantFemale228,6347.07.86.00.1241,0454,4BreastTotal4159,99468.371.244.90.6216,9678,5Breast <td>Years 32,112 480,913 451,199 32,112 480,913 451,199 32,112 480,913 451,199 32,112 480,913 451,199 32,112 480,913 451,199 32,112 480,913</td> <td>Rate (1) 527.0 560.6 493.1 24.7 39.3 10.0 7.3 8.4 6.2 17.3 11.1</td>	Years 32,112 480,913 451,199 32,112 480,913 451,199 32,112 480,913 451,199 32,112 480,913 451,199 32,112 480,913 451,199 32,112 480,913	Rate (1) 527.0 560.6 493.1 24.7 39.3 10.0 7.3 8.4 6.2 17.3 11.1
All Sites Combined Total 261 59,994 435.0 487.9 281.9 0.222 47,072 8,5 All Sites Combined Male 149 31,360 475.1 526.0 158.8 0.464 25,121 4,4 All Sites Combined Female 112 28,634 391.1 439.5 125.7 0.238 21,951 4,4 Bladder Total 10 59,994 16.7 21.2 11.7 0.762 2,210 8,5 Bladder Male 10 31,360 31.9 38.9 10.1 1.000 1,763 4,4 Brain - malignant Total 4 59,994 6.7 7.1 4.1 1.000 453 8,5 Brain - malignant Male 4 31,360 12.8 13.1 2.6 0.521 378 4,4 Brain - malignant Female - 28,634 - - 1.6 0.406 275 4,4 Brain and othe	932,112 480,913 451,199 932,112 480,913 451,199 932,112 480,913 451,199 932,112 480,913 451,199 932,112 480,913 450,913	527.0 560.6 493.1 24.7 39.3 10.0 7.3 8.4 6.2 17.3 11.1
All Sites Combined Male 149 31,360 475.1 526.0 158.8 0.464 25,121 4,4 All Sites Combined Female 112 28,634 391.1 439.5 125.7 0.238 21,951 4,4 Bladder Total 10 59,994 16.7 21.2 11.7 0.762 2,210 8,5 Bladder Male 10 31,360 31.9 38.9 10.1 1.000 1,763 4,4 Brain - malignant Total 4 59,994 6.7 7.1 4.1 1.000 1,763 4,4 Brain - malignant Male 4 59,994 6.7 7.1 4.1 1.000 653 8,5 Brain - malignant Male 4 59,994 6.7 7.1 4.1 1.000 653 8,5 Brain and other CNS - non-malignant Female - 28,634 - - 1.6 0.406 275 4,4 Breast <td>480,913 451,199 932,112 480,913 451,199 932,112 480,913 451,199 932,112 480,913 451,199 932,112 480,913</td> <td>560.6 493.1 24.7 39.3 10.0 7.3 8.4 6.2 17.3 11.1</td>	480,913 451,199 932,112 480,913 451,199 932,112 480,913 451,199 932,112 480,913 451,199 932,112 480,913	560.6 493.1 24.7 39.3 10.0 7.3 8.4 6.2 17.3 11.1
All Sites CombinedFemale11228,634391.1439.5125.70.23821,9514,4BladderTotal1059,99416.721.211.70.7622,2108,5BladderMale1031,36031.938.910.11.0001,7634,4BladderFemale-28,6342.20.2124474,4Brain - malignantTotal459,9946.77.14.11.0006538,5Brain - malignantMale431,36012.813.12.60.5213784,4Brain - malignantFemale-28,6341.60.4062754,4Brain and other CNS - non-malignantFemale-28,6341.60.4062754,4Brain and other CNS - non-malignantTotal559,9948.39.19.50.1751,5428,5Brain and other CNS - non-malignantFemale228,6347.07.86.00.1241,0454,4BreastTotal4159,99468.371.244.90.6216,9678,5BreastMale131,3603.23.70.40.643644,4BreastMale131,3603.23.70.40.6436,44,4BreastFemale4028,634139.7148.841.7 <td>451,199 32,112 480,913 451,199 32,112 480,913 451,199 32,112 480,913 451,199 32,112 480,913 451,199 32,112 480,913</td> <td>493.1 24.7 39.3 10.0 7.3 8.4 6.2 17.3 11.1</td>	451,199 32,112 480,913 451,199 32,112 480,913 451,199 32,112 480,913 451,199 32,112 480,913 451,199 32,112 480,913	493.1 24.7 39.3 10.0 7.3 8.4 6.2 17.3 11.1
Bladder Total 10 59,994 16.7 21.2 11.7 0.762 2,210 8,5 Bladder Male 10 31,360 31.9 38.9 10.1 1.000 1,763 4,4 Bladder Female - 28,634 - - 2.2 0.212 447 4,4 Brain - malignant Total 4 59,994 6.7 7.1 4.1 1.000 653 8,5 Brain - malignant Male 4 31,360 12.8 13.1 2.6 0.521 378 4,4 Brain - malignant Female - 28,634 - - 1.6 0.406 275 4,4 Brain and other CNS - non-malignant Total 5 59,994 8.3 9.1 9.5 0.175 1,542 8,5 Brain and other CNS - non-malignant Male 3 31,360 9.6 10.0 3.3 1.000 4,4 Breast Total <td< td=""><td>932,112 480,913 451,199 932,112 480,913 451,199 932,112 480,913 451,199 932,112 480,913 451,199 932,112 480,913</td><td>24.7 39.3 10.0 7.3 8.4 6.2 17.3 11.1</td></td<>	932,112 480,913 451,199 932,112 480,913 451,199 932,112 480,913 451,199 932,112 480,913 451,199 932,112 480,913	24.7 39.3 10.0 7.3 8.4 6.2 17.3 11.1
Bladder Male 10 31,360 31.9 38.9 10.1 1.000 1,763 4,7 Bladder Female - 28,634 - - 2.2 0.212 447 4,4 Brain - malignant Total 4 59,994 6.7 7.1 4.1 1.000 653 8,5 Brain - malignant Male 4 31,360 12.8 13.1 2.6 0.521 378 4,4 Brain - malignant Female - 28,634 - - 1.6 0.406 275 4,4 Brain and other CNS - non-malignant Total 5 59,994 8.3 9.1 9.5 0.175 1,542 8,5 Brain and other CNS - non-malignant Male 3 31,360 9.6 10.0 3.3 1.000 497 4,4 Breast Total 41 59,994 68.3 71.2 44.9 0.621 6,967 8,5 Breast Ma	451,199 332,112 480,913 451,199 332,112 480,913 451,199 332,112 480,913	10.0 7.3 8.4 6.2 17.3 11.1
Brain - malignant Total 4 59,994 6.7 7.1 4.1 1.000 653 8,5 Brain - malignant Male 4 31,360 12.8 13.1 2.6 0.521 378 4,4 Brain - malignant Female - 28,634 - - 1.6 0.406 275 4,4 Brain and other CNS - non-malignant Total 5 59,994 8.3 9.1 9.5 0.175 1,542 8,5 Brain and other CNS - non-malignant Male 3 31,360 9.6 10.0 3.3 1.000 497 4,4 Brain and other CNS - non-malignant Female 2 28,634 7.0 7.8 6.0 0.124 1,045 4,4 Breast Total 41 59,994 68.3 71.2 44.9 0.621 6,967 8,5 Breast Male 1 31,360 3.2 3.7 0.4 0.643 64 4,4	932,112 480,913 451,199 932,112 480,913 451,199 932,112 480,913 450,913	7.3 8.4 6.2 17.3 11.1
Brain - malignant Male 4 31,360 12.8 13.1 2.6 0.521 378 4,4 Brain - malignant Female - 28,634 - - 1.6 0.406 275 4,4 Brain and other CNS - non-malignant Total 5 59,994 8.3 9.1 9.5 0.175 1,542 8,5 Brain and other CNS - non-malignant Male 3 31,360 9.6 10.0 3.3 1.000 497 4,4 Brain and other CNS - non-malignant Female 2 28,634 7.0 7.8 6.0 0.124 1,045 4,4 Breast Total 41 59,994 68.3 71.2 44.9 0.621 6,967 8,5 Breast Male 1 31,360 3.2 3.7 0.4 0.643 64 4,4 Breast Female 40 28,634 139.7 148.8 41.7 0.875 6,903 4,4 Br	480,913 451,199 932,112 480,913 451,199 932,112 480,913	8.4 6.2 17.3 11.1
Brain - malignant Female - 28,634 - - 1.6 0.406 275 4,4 Brain and other CNS - non-malignant Total 5 59,994 8.3 9.1 9.5 0.175 1,542 8,5 Brain and other CNS - non-malignant Male 3 31,360 9.6 10.0 3.3 1.000 497 4,4 Brain and other CNS - non-malignant Female 2 28,634 7.0 7.8 6.0 0.124 1,045 4,4 Breast Total 41 59,994 68.3 71.2 44.9 0.621 6,967 8,5 Breast Male 1 31,360 3.2 3.7 0.4 0.643 64 4,4 Breast Female 40 28,634 139.7 148.8 41.7 0.875 6,903 4,4 Breast - in situ Total 10 59,994 16.7 16.5 9.2 0.881 1,359 8,5	451,199 932,112 480,913 451,199 932,112 480,913	6.2 17.3 11.1
Brain and other CNS - non-malignant Brain and other CNS - non-malignant Brain and other CNS - non-malignant MaleTotal559,9948.39.19.50.1751,5428,5Brain and other CNS - non-malignant BreastMale331,3609.610.03.31.0004974,4BreastTotal228,6347.07.86.00.1241,0454,4BreastTotal4159,99468.371.244.90.6216,9678,5BreastMale131,3603.23.70.40.643644,4BreastFemale4028,634139.7148.841.70.8756,9034,4Breast - in situTotal1059,99416.716.59.20.8811,3598,5	932,112 180,913 151,199 932,112 180,913	17.3 11.1
Brain and other CNS - non-malignant Brain and other CNS - non-malignant FemaleMale331,3609.610.03.31.0004974,7Brain and other CNS - non-malignant BreastFemale228,6347.07.86.00.1241,0454,7BreastTotal4159,99468.371.244.90.6216,9678,5BreastMale131,3603.23.70.40.643644,7BreastFemale4028,634139,7148.841.70.8756,9034,7Breast - in situTotal1059,99416.716.59.20.8811,3598,5	480,913 451,199 932,112 480,913	11.1
Brain and other CNS - non-malignantFemale228,6347.07.86.00.1241,0454,4BreastTotal4159,99468.371.244.90.6216,9678,5BreastMale131,3603.23.70.40.643644,4BreastFemale4028,634139.7148.841.70.8756,9034,4Breast - in situTotal1059,99416.716.59.20.8811,3598,5	451,199 932,112 480,913	
Breast Total 41 59,994 68.3 71.2 44.9 0.621 6,967 8,5 Breast Male 1 31,360 3.2 3.7 0.4 0.643 64 4,4 Breast Female 40 28,634 139.7 148.8 41.7 0.875 6,903 4,4 Breast - in situ Total 10 59,994 16.7 16.5 9.2 0.881 1,359 8,5	932,112 180,913	
Breast Male 1 31,360 3.2 3.7 0.4 0.643 64 4,4 Breast Female 40 28,634 139.7 148.8 41.7 0.875 6,903 4,4 Breast - in situ Total 10 59,994 16.7 16.5 9.2 0.881 1,359 8,5	480,913	78.0
Breast Female 40 28,634 139.7 148.8 41.7 0.875 6,903 4,2 Breast - in situ Total 10 59,994 16.7 16.5 9.2 0.881 1,359 8,5		1.4
Breast - in situ Total 10 59,994 16.7 16.5 9.2 0.881 1,359 8,9	151,199	155.1
	932,112	15.2
	480,913	0.1
	151,199	30.4
Cervix Female - 28,634 2.1 0.235 294 4,4	151,199	6.6
	932,112	40.5
Colorectal Male 11 31,360 35.1 37.4 12.9 0.724 1,966 4,4	480,913	43.9
	151,199	37.1
	451,199	30.3
	932,112	5.6
	480,913	9.5
	151,199	1.8
	932,112	2.5
	480,913 451,199	2.9 2.1
57	32,112	2.1
	480,913	21.0
	451,199	14.4
Larynx Total 2 59,994 3.3 3.8 1.3 0.727 218 8,	932,112	2.4
Larvnx Male 2 31,360 6.4 7.2 1.0 0.549 165 4.4	180.913	3.7
Larynx Female - 28,634 0.3 1.000 53 4,4	451,199	1.2
Leukemia Total 13 59,994 21.7 25.3 9.9 0.393 1,714 8,9	932,112	19.2
	480,913	22.9
	451,199	15.5
	932,112	9.4
	480,913	13.2
	151,199	5.5
	932,112	55.3
	480,913 451,199	55.5 55.2
	32,112	34.8
	480,913	41.9
	451,199	27.7
	932,112	8.1
Myeloma Male 1 31,360 3.2 3.7 2.7 0.489 446 4.4	480,913	10.0
Myeloma Female 3 28,634 10.5 12.8 1.5 0.364 278 4,4	151,199	6.2
Non-Hodgkin Lymphoma Total 9 59,994 15.0 17.0 11.8 0.526 1,983 8,9	932,112	22.2
	480,913	25.5
	451,199	18.9
	932,112	14.7
	480,913	20.9
	151,199	8.4
	451,199 932,112	12.3 16.5
	480,913	16.5
	460,913 451,199	14.8
	480,913	150.2
	932,112	5.3
	480,913	6.9
	451,199	3.7
	480,913	6.1
	932,112	13.2
	480,913	8.3
	451,199	18.2
	183,793	17.0
	266,329	16.8
Pediatric Age 0 to 19 Female 2 7,539 26.5 27.5 1.3 0.711 209 1,2	217,464	17.2

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN TETON COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Те	ton County				Re	mainder of Idah	10
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	280	61,075	458.5	601.2	408.5	0.000 <<	80,255	9,150,319	877.1
All Causes of Death	Male	159	31,945	497.7	597.6	246.8	0.000 <<	42,627	4.595.752	927.5
All Causes of Death	Female	121	29,130	415.4	599.4	166.8	0.000 <<	37,628	4,554,567	826.2
All Malignant Cancers	Total	73	61,075	119.5	149.1	81.1	0.400	15,160	9,150,319	165.7
All Malignant Cancers	Male	42	31,945	131.5	156.6	47.8	0.448	8,193	4,595,752	178.3
All Malignant Cancers	Female	31	29,130	106.4	137.7	34.4	0.632	6,967	4,554,567	153.0
Bladder	Total	3	61,075	4.9	7.0	2.2	0.780	482	9,150,319	5.3
Bladder	Male	3	31,945	9.4	12.4	2.0	0.622	372	4,595,752	8.1
Bladder	Female	-	29,130	-	-	0.5	1.000	110	4,554,567	2.4
Brain and Other Nervous System	Total	1	61,075	1.6	1.8	3.2	0.350	517	9,150,319	5.7
Brain and Other Nervous System	Male	1	31,945	3.1	3.3	1.9	0.865	288	4,595,752	6.3
Brain and Other Nervous System	Female	-	29,130	-	-	1.3	0.547	229	4,554,567	5.0
Breast	Total	7	61,075	11.5	13.6	6.3	0.881	1,117	9,150,319	12.2
Breast	Male	1	31,945	3.1	3.6	0.1	0.140	12	4,595,752	0.3
Breast	Female	6	29,130	20.6	25.3	5.8	1.000	1,105	4,554,567	24.3
Cervix	Female	1	29,130	3.4	3.3	0.6	0.885	87	4,554,567	1.9
Colorectal	Total	7	61,075	11.5	13.6	7.5	1.000	1,325	9,150,319	14.5
Colorectal	Male	3	31,945	9.4	10.3	4.6	0.649	729	4,595,752	15.9
Colorectal	Female	4	29,130	13.7	17.7	2.9	0.683	596	4,554,567	13.1
Corpus Uteri	Female	-	29,130	-	-	0.9	0.827	169	4,554,567	3.7
Esophagus	Total	2	61,075	3.3	3.9	2.6	1.000	459	9,150,319	5.0
Esophagus	Male Female	2	31,945 29,130	6.3	7.1	2.4 0.3	1.000 1.000	389 70	4,595,752 4,554,567	8.5 1.5
Esophagus Hodgkin Lymphoma	Total		61,075	-	-	0.3	1.000	25	9.150.319	0.3
Hodgkin Lymphoma	Male	-	31,945	-	-	0.1	1.000	14	4,595,752	0.3
Hodgkin Lymphoma	Female	-	29,130	-	_	0.1	1.000	14	4,554,567	0.3
Kidney	Total	- 1	61,075	- 1.6	2.1	2.0	0.801	385	9,150,319	4.2
Kidney	Male	- '	31,945	-	-	1.4	0.469	246	4,595,752	5.4
Kidney	Female	1	29,130	3.4	4.9	0.6	0.934	139	4,554,567	3.1
Larynx	Total	-	61,075	-	-	0.4	1.000	76	9,150,319	0.8
Larynx	Male	-	31,945	-	-	0.4	1.000	65	4,595,752	1.4
Larýnx	Female	-	29,130	-	-	0.1	1.000	11	4,554,567	0.2
Leukemia	Total	4	61,075	6.5	8.7	3.3	0.852	661	9,150,319	7.2
Leukemia	Male	4	31,945	12.5	15.6	2.2	0.356	393	4,595,752	8.6
Leukemia	Female	-	29,130	-	-	1.2	0.590	268	4,554,567	5.9
Liver and Bile Duct	Total	2	61,075	3.3	3.8	3.6	0.597	633	9,150,319	6.9
Liver and Bile Duct	Male	1	31,945	3.1	3.5	2.7	0.512	422	4,595,752	9.2
Liver and Bile Duct	Female	1	29,130	3.4	4.3	1.1	1.000	211	4,554,567	4.6
Lung and Bronchus	Total	13	61,075	21.3	27.1	15.3	0.669	2,924	9,150,319	32.0
Lung and Bronchus	Male	8	31,945	25.0	30.0	8.9	0.939	1,533	4,595,752	33.4
Lung and Bronchus	Female	5	29,130	17.2	23.2	6.6	0.716	1,391	4,554,567	30.5
Melanoma of the Skin	Total	4	61,075	6.5	7.8	1.7	0.174	297	9,150,319 4,595,752	3.2
Melanoma of the Skin Melanoma of the Skin	Male Female	2 2	31,945 29,130	6.3 6.9	7.2 8.4	1.2 0.5	0.669 0.192	198 99	4,595,752 4,554,567	4.3 2.2
Myeloma	Total	3	61,075	4.9	6.6	0.5	0.192	322	4,554,567	3.5
Myeloma	Male	-	31,945	4.9	0.0	1.0	0.436	322 188	4,595,752	3.5 4.1
Myeloma	Female	- 3	29,130	- 10.3	- 14.7	0.6	0.047 >>	134	4,554,567	2.9
Non-Hodgkin Lymphoma	Total	2	61,075	3.3	4.3	2.9	0.909	566	9,150,319	6.2
	Male	2	31,945	6.3	7.6	1.8	1.000	308	4,595,752	6.7
Non-Hodgkin Lymphoma	Female	-	29,130	-	-	1.0	0.639	258	4,554,567	5.7
Oral Cavity and Pharynx	Total	3	61,075	4.9	5.8	1.5	0.405	272	9,150,319	3.0
Oral Cavity and Pharynx	Male	2	31,945	6.3	7.0	1.2	0.657	190	4,595,752	4.1
Oral Cavity and Pharynx	Female	1	29,130	3.4	4.2	0.4	0.697	82	4,554,567	1.8
Ovary	Female	1	29,130	3.4	4.2	1.9	0.885	360	4,554,567	7.9
Pancreas	Total	8	61,075	13.1	16.0	6.4	0.637	1,182	9,150,319	12.9
Pancreas	Male	6	31,945	18.8	21.8	3.9	0.387	644	4,595,752	14.0
Pancreas	Female	2	29,130	6.9	8.9	2.7	1.000	538	4,554,567	11.8
Prostate	Male	2	31,945	6.3	8.4	5.2	0.224	995	4,595,752	21.7
Stomach	Total	-	61,075	-	-	1.1	0.655	194	9,150,319	2.1
	Male	-	31,945	-	-	0.7	0.971	119	4,595,752	2.6
Stomach	Female	-	29,130	-	-	0.4	1.000	75	4,554,567	1.6

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Teton County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	90.0% 10.4%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	72.0%
Current Tobacco User (2020–2022) <u>Other Cancer-Related</u>	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	18.4%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	39.4% 88.3% 20.4% 40.9%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





TWIN FALLS COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 2,192 cases of invasive cancer were diagnosed among Twin Falls County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in Twin FallsCounty and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021						
All Sites/Types	2,192	47,333				
Female Breast	278	6,943				
Prostate	238	6,766				
Lung & Bronchus	247	4,959				
Colorectal	168	3,632				

Table 3 (*Cancer Incidence 2017–2021, Comparison between Twin Falls County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Twin Falls County. The table also shows the number of observed cases,

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 776 Twin Falls County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Twin Falls County and the State of Idaho, 2018–2022

Mortality 2018–2022	Twin Falls County	State of Idaho
All Deaths	4,527	80,538
Cancer Deaths	776	15,233
% of All Deaths	17.1%	18.9%
Lung & Bronchus	144	2,937
Colorectal	62	1,332
Pancreas	52	1,190
Female Breast	41	1,111
Prostate	63	997

person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, nonmalignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Twin Falls County was 498.7 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (527.8) gives an estimate of the relative burden of disease in Twin Falls County.

The age- and sex-adjusted incidence rate of invasive cancer in Twin Falls County, all sites combined, was 515.6 cases per 100,000 persons per year during 2017–2021. There were fewer cases of cancer in Twin Falls County (2,192) than expected (2,244.1) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Twin Falls County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Twin Falls County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Twin Falls County, all sites combined, was 174.3 deaths per 100,000 persons per year during 2018–2022, compared with 165.0 for the remainder of the state. There were more cancer deaths in Twin Falls County (776) than expected (734.3) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN TWIN FALLS COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Twin Falls County							Remainder of Idaho				
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude			
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)			
All Sites Combined	Total	2,192	439,500	498.7	515.6	2,244.1	0.276	45,141	8,552,606	527.8			
All Sites Combined	Male	1,160	217,016	534.5	559.5	1,163.9	0.926	24,110	4,295,257	561.3			
All Sites Combined	Female	1,032	222,484	463.9	476.9	1,069.1	0.263	21,031	4,257,349	494.0			
Bladder	Total	120	439,500	27.3	27.7	106.2	0.200	2,100	8,552,606	24.6			
Bladder	Male	105	217,016	48.4	50.2	81.3	0.013 >>	1,668	4,295,257	38.8			
Bladder	Female	15	222,484	6.7	6.8	22.4	0.134	432	4,257,349	10.1			
Brain - malignant	Total	29	439,500	6.6	6.7	31.6	0.732	628	8,552,606	7.3			
Brain - malignant	Male	17	217,016	7.8	8.1	17.9	0.960	365	4,295,257	8.5			
Brain - malignant	Female	12	222,484	5.4	5.5	13.6	0.801	263	4,257,349	6.2			
Brain and other CNS - non-malignant Brain and other CNS - non-malignant	Total Male	65 20	439,500 217,016	14.8 9.2	15.2 9.5	74.3 23.5	0.304 0.554	1,482 480	8,552,606 4,295,257	17.3 11.2			
	Female	20 45	222,484	20.2	20.6	23.3 51.4	0.415	1,002	4,257,349	23.5			
Breast	Total	280	439,500	63.7	66.6	330.9	0.005 <<	6,728	8,552,606	78.7			
Breast	Male	2	217,016	0.9	1.0	3.1	0.808	63	4,295,257	1.5			
Breast	Female	278	222,484	125.0	130.6	333.3	0.002 <<	6,665	4,257,349	156.6			
Breast - in situ	Total	35	439,500	8.0	8.5	64.6	>> 000.0	1,334	8,552,606	15.6			
Breast - in situ	Male	-	217,016	-	-	0.2	1.000	4	4,295,257	0.1			
Breast - in situ	Female	35	222,484	15.7	16.8	65.2	0.000 <<	1,330	4,257,349	31.2			
Cervix	Female	8	222,484	3.6	3.7	14.5	0.099	286	4,257,349	6.7			
Colorectal	Total	168	439,500	38.2	39.3	173.0	0.739	3,464	8,552,606	40.5			
Colorectal	Male	95	217,016	43.8	45.7	91.1	0.713	1,882	4,295,257	43.8			
Colorectal	Female	73 86	222,484 222,484	32.8 38.7	33.3	81.5	0.377	1,582	4,257,349 4,257,349	37.2 29.8			
Corpus Uteri	Female				40.7	62.9	0.006 >>	1,268					
Esophagus Esophagus	Total Male	27 21	439,500 217,016	6.1 9.7	6.3 10.1	23.9 19.7	0.584 0.830	480 408	8,552,606 4,295,257	5.6 9.5			
Esophagus	Female	21 6	217,010	9.7 2.7	2.7	3.7	0.343	408	4,295,257	9.5			
Hodgkin Lymphoma	Total	14	439.500	3.2	3.3	10.4	0.336	208	8,552,606	2.4			
Hodgkin Lymphoma	Male	12	217,016	5.5	5.7	5.7	0.029 >>	117	4,295,257	2.7			
Hodgkin Lymphoma	Female	2	222,484	0.9	0.9	4.7	0.309	91	4,257,349	2.1			
Kidney and Renal Pelvis	Total	75	439,500	17.1	17.7	93.0	0.063	1,876	8,552,606	21.9			
Kidney and Renal Pelvis	Male	50	217,016	23.0	24.1	60.8	0.179	1,260	4,295,257	29.3			
Kidney and Renal Pelvis	Female	25	222,484	11.2	11.5	31.4	0.291	616	4,257,349	14.5			
Larynx	Total	10	439,500	2.3	2.4	10.4	1.000	210	8,552,606	2.5			
Larynx	Male	5	217,016	2.3	2.4	7.8	0.413	162	4,295,257	3.8			
Larynx	Female	5	222,484	2.2	2.3	2.4	0.193	48	4,257,349	1.1			
Leukemia	Total	105	439,500	23.9	24.3	82.1	0.017 >>	1,622	8,552,606	19.0			
Leukemia Leukemia	Male Female	57 48	217,016 222,484	26.3 21.6	27.0 21.7	48.1 33.4	0.228 0.020 >>	979 643	4,295,257 4,257,349	22.8 15.1			
Liver and Bile Duct	Total	29	439,500	6.6	6.9	40.0	0.020	814	8,552,606	9.5			
Liver and Bile Duct	Male	20	217,016	9.2	9.8	27.4	0.179	574	4,295,257	13.4			
Liver and Bile Duct	Female	-0	222,484	4.0	4.2	12.2	0.449	240	4,257,349	5.6			
Lung and Bronchus	Total	247	439,500	56.2	57.6	236.2	0.498	4,712	8,552,606	55.1			
Lung and Bronchus	Male	138	217,016	63.6	66.4	114.0	0.032 >>	2,357	4,295,257	54.9			
Lung and Bronchus	Female	109	222,484	49.0	49.6	121.5	0.274	2,355	4,257,349	55.3			
Melanoma of the Skin	Total	152	439,500	34.6	35.5	149.6	0.868	2,992	8,552,606	35.0			
Melanoma of the Skin	Male	89	217,016	41.0	42.6	87.9	0.935	1,806	4,295,257	42.0			
Melanoma of the Skin	Female	63	222,484	28.3	29.1	60.3	0.759	1,186	4,257,349	27.9			
Myeloma	Total	35	439,500	8.0	8.2	34.6	0.994	693 495	8,552,606	8.1			
Myeloma	Male	22 13	217,016	10.1	10.6	20.6	0.817	425	4,295,257	9.9 6.3			
Myeloma Non-Hodgkin Lymphoma	Female Total	13	222,484 439,500	5.8 25.9	6.0 26.7	13.7 93.6	0.994 0.045 >>	268 1,878	4,257,349 8,552,606	6.3 22.0			
Non-Hodgkin Lymphoma	Male	59	217,016	25.9	20.7	93.0 52.6	0.045	1,070	4,295,257	22.0			
Non-Hodgkin Lymphoma	Female	55	222,484	24.7	25.2	40.6	0.036 >>	791	4,257,349	18.6			
Oral Cavity and Pharynx	Total	68	439,500	15.5	16.2	61.1	0.411	1,247	8,552,606	14.6			
Oral Cavity and Pharynx	Male	45	217,016	20.7	21.9	42.8	0.773	895	4,295,257	20.8			
Oral Cavity and Pharynx	Female	23	222,484	10.3	10.7	17.8	0.273	352	4,257,349	8.3			
Ovary	Female	36	222,484	16.2	16.8	26.0	0.074	517	4,257,349	12.1			
Pancreas	Total	72	439,500	16.4	16.8	71.1	0.948	1,416	8,552,606	16.6			
Pancreas	Male	48	217,016	22.1	23.0	37.7	0.120	778	4,295,257	18.1			
Pancreas	Female	24	222,484	10.8	10.9	33.0	0.128	638	4,257,349	15.0			
Prostate	Male	238	217,016	109.7	116.5	310.4	0.000 <<	6,528	4,295,257	152.0			
Stomach	Total	16	439,500	3.6	3.7	23.0	0.162	458	8,552,606	5.4			
Stomach	Male	6 10	217,016	2.8	2.9	14.6	0.020 <<	301	4,295,257	7.0			
Stomach	Female	10	222,484	4.5	4.5	8.2	0.612	157	4,257,349	3.7			
Testis	Male	21	217,016	9.7	9.8	12.7	0.040 >>	253	4,295,257	5.9			
Thyroid	Total	50	439,500	11.4	11.7	56.5	0.428	1,135	8,552,606	13.3			
Thyroid	Male	17	217,016	7.8	8.1	17.3	1.000	355	4,295,257	8.3			
Thyroid	Female	33	222,484	14.8	15.3	39.5	0.342	780	4,257,349	18.3			
Pediatric Age 0 to 19	Total	29	130,236	22.3	22.5	21.6	0.145	396	2,369,088	16.7			
			00.01						4 000 00-				
Pediatric Age 0 to 19 Pediatric Age 0 to 19	Male Female	18 11	66,041 64,195	27.3 17.1	27.3 17.5	10.7 10.8	0.051 1.000	196 200	1,208,280 1,160,808	16.2 17.2			

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN TWIN FALLS COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Twin	Falls Coun	ty			Re	Remainder of Idaho				
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude			
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)			
All Causes of Death	Total	4,527	447,757	1,011.0	990.6	3,963.5	0.000 >>	76,008	8,763,637	867.3			
All Causes of Death	Male	2,378	221,372	1,074.2	1,097.4	1,987.3	0.000 >>	40,408	4.406.325	917.0			
All Causes of Death	Female	2,149	226,385	949.3	895.9	1,959.7	0.000 >>	35,600	4,357,312	817.0			
All Malignant Cancers	Total	776	447,757	173.3	174.3	734.3	0.131	14,457	8,763,637	165.0			
All Malignant Cancers	Male	432	221,372	195.1	201.6	379.5	0.009 >>	7,803	4,406,325	177.1			
All Malignant Cancers	Female	344	226,385	152.0	150.3	349.6	0.793	6,654	4,357,312	152.7			
Bladder	Total	26	447,757	5.8	5.6	24.1	0.759	459	8,763,637	5.2			
Bladder	Male	20	221,372	9.0	9.2	17.6	0.624	355	4,406,325	8.1			
Bladder	Female	6	226,385	2.7	2.5	5.7	1.000	104	4,357,312	2.4			
Brain and Other Nervous System	Total	19	447,757	4.2	4.4	24.8	0.288	499	8,763,637	5.7			
Brain and Other Nervous System	Male	7	221,372	3.2	3.3	13.6	0.079	282	4,406,325	6.4			
Brain and Other Nervous System	Female	12	226,385	5.3	5.4	11.1	0.867	217	4,357,312	5.0			
Breast	Total	41	447,757	9.2	9.2	55.0	0.060	1,083	8,763,637	12.4			
Breast	Male	-	221,372	-	-	0.6	1.000	13	4,406,325	0.3			
Breast	Female	41	226,385	18.1	18.0	56.0	0.045 <<	1,070	4,357,312	24.6			
Cervix Colorectal	Female	4 62	226,385 447,757	1.8 13.8	1.8 14.0	4.2 64.3	1.000 0.836	84 1,270	4,357,312 8,763,637	1.9 14.5			
Colorectal Colorectal	Total Male	62 39	447,757 221,372	13.8	14.0	64.3 33.6	0.836	693	4,406,325	14.5 15.7			
Colorectal	Female	23	226,385	17.0	10.3	30.6	0.390	577	4,400,325	13.2			
Corpus Uteri	Female	10	226,385	4.4	4.5	8.1	0.191	159	4,357,312	3.6			
Esophagus	Total	20	447,757	4.5	4.6	22.0	0.772	441	8.763.637	5.0			
Esophagus	Male	13	221,372	5.9	6.1	18.2	0.266	378	4,406,325	8.6			
Esophagus	Female	.0	226,385	3.1	3.1	3.3	0.102	63	4,357,312	1.4			
Hodgkin Lymphoma	Total	-	447,757	-	-	1.2	0.574	25	8,763,637	0.3			
Hodgkin Lýmphoma	Male	-	221,372	-	-	0.7	1.000	14	4,406,325	0.3			
Hodgkin Lymphoma	Female	-	226,385	-	-	0.6	1.000	11	4,357,312	0.3			
Kidney	Total	25	447,757	5.6	5.6	18.3	0.159	361	8,763,637	4.1			
Kidney	Male	18	221,372	8.1	8.4	11.0	0.066	228	4,406,325	5.2			
Kidney	Female	7	226,385	3.1	3.0	7.1	1.000	133	4,357,312	3.1			
Larynx	Total	3	447,757	0.7	0.7	3.7	1.000	73	8,763,637	0.8			
Larynx	Male	3	221,372	1.4	1.4	3.0	1.000	62	4,406,325	1.4			
Larynx	Female	-	226,385	-	-	0.5	1.000	11	4,357,312	0.3			
Leukemia	Total	40 28	447,757	8.9	8.8	32.2	0.207	625	8,763,637	7.1			
Leukemia Leukemia	Male Female	20 12	221,372 226,385	12.6 5.3	12.9 5.1	18.1 13.7	0.038 >> 0.769	369 256	4,406,325 4,357,312	8.4 5.9			
Liver and Bile Duct	Total	30	447,757	6.7	6.9	30.1	1.000	605	8,763,637	6.9			
Liver and Bile Duct	Male	21	221,372	9.5	9.9	19.3	0.752	402	4,406,325	9.1			
Liver and Bile Duct	Female	9	226,385	4.0	4.0	10.5	0.797	203	4,357,312	4.7			
Lung and Bronchus	Total	144	447,757	32.2	32.5	141.1	0.829	2,793	8,763,637	31.9			
Lung and Bronchus	Male	80	221,372	36.1	37.6	70.6	0.292	1,461	4,406,325	33.2			
Lung and Bronchus	Female	64	226,385	28.3	28.0	69.9	0.527	1,332	4,357,312	30.6			
Melanoma of the Skin	Total	13	447,757	2.9	2.9	14.6	0.798	288	8,763,637	3.3			
Melanoma of the Skin	Male	7	221,372	3.2	3.3	9.4	0.553	193	4,406,325	4.4			
Melanoma of the Skin	Female	6	226,385	2.7	2.6	5.0	0.762	95	4,357,312	2.2			
Myeloma	Total	20	447,757	4.5	4.5	15.6	0.326	305	8,763,637	3.5			
Myeloma	Male	10	221,372	4.5	4.6	8.7	0.745	178	4,406,325	4.0			
Myeloma	Female	10	226,385	4.4	4.3	6.8	0.291	127	4,357,312	2.9			
Non-Hodgkin Lymphoma	Total	36	447,757	8.0	8.0	27.3	0.126	532	8,763,637	6.1			
	Male	20	221,372	9.0	9.3	14.1	0.165	290	4,406,325	6.6			
Non-Hodgkin Lymphoma	Female	16	226,385	7.1	6.8	13.1	0.484	242	4,357,312	5.6			
Oral Cavity and Pharynx Oral Cavity and Pharynx	Total	18	447,757	4.0	4.1	12.8	0.197	257	8,763,637	2.9			
Oral Cavity and Pharynx Oral Cavity and Pharynx	Male Female	11 7	221,372 226,385	5.0 3.1	5.2 3.1	8.7 3.9	0.516 0.204	181	4,406,325 4,357,312	4.1 1.7			
Orar Cavity and Pharynx Ovary	Female	24	226,385	10.6	3.1 10.7	3.9 17.3	0.204	76 337	4,357,312	7.7			
Pancreas	Total	52	447,757	10.6	11.8	57.1	0.148	1,138	8,763,637	13.0			
Pancreas	Male	32	221,372	14.5	15.1	29.8	0.550	618	4,406,325	13.0			
Pancreas	Female	20	226,385	8.8	8.8	23.0	0.198	520	4,357,312	11.9			
Prostate	Male	63	221,372	28.5	28.9	46.2	0.022 >>	934	4,406,325	21.2			
Stomach	Total	7	447,757	1.6	1.6	9.5	0.543	187	8,763,637	2.1			
	Male	4	221,372	1.8	1.9	5.6	0.685	115	4,406,325	2.6			
Stomach	Female	3	226,385	1.3	1.3	3.7	0.971	72	4,357,312	1.7			
	- onaic	5	220,000	1.5	1.5	5.1	0.071	12	4,007,012	1.7			

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Twin Falls County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	89.7% 11.2%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	58.1% 66.3% 67.8%
Current Tobacco User (2020–2022) <u>Other Cancer-Related</u>	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	24.9%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	26.2% 76.1% 20.8% 16.9%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





VALLEY COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 410 cases of invasive cancer were diagnosed among Valley County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in ValleyCounty and the State of Idaho. 2017–2021

Cancer Incidence 2017–2021	Valley County	State of Idaho
All Sites/Types	410	47,333
Female Breast	58	6,943
Prostate	94	6,766
Lung & Bronchus	29	4,959
Colorectal	27	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Valley County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Valley County. The table also shows the number of observed cases, person-

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 113 Valley County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Valley County and the State of Idaho, 2018–2022

Mortality 2018–2022	Valley County	State of Idaho
All Deaths	434	80,538
Cancer Deaths	113	15,233
% of All Deaths	26.0%	18.9%
Lung & Bronchus	18	2,937
Colorectal	8	1,332
Pancreas	9	1,190
Female Breast	7	1,111
Prostate	10	997

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Valley County was 716.1 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (525.2) gives an estimate of the relative burden of disease in Valley County.

The age- and sex-adjusted incidence rate of invasive cancer in Valley County, all sites combined, was 500.5 cases per 100,000 persons per year during 2017–2021. There were fewer cases of cancer in Valley County (410) than expected (430.2) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Valley County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Valley County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Valley County, all sites combined, was 134.7 deaths per 100,000 persons per year during 2018–2022, compared with 165.2 for the remainder of the state. There were statistically significantly fewer cancer deaths in Valley County (113) than expected (138.6) based upon rates in the remainder of the state (p=.029).

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN VALLEY COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Va	Rem	Remainder of Idaho					
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	410	57,253	716.1	500.5	430.2	0.342	46,923	8,934,853	525.2
All Sites Combined	Male	252	29,534	853.3	548.2	256.5	0.809	25,018	4,482,739	558.1
All Sites Combined	Female	158	27,719	570.0	429.9	180.8	0.092	21,905	4,452,114	492.0
Bladder	Total	20	57,253	34.9	23.7	20.8	0.979	2,200	8,934,853	24.6
Bladder	Male	16	29,534	54.2	33.7	18.6	0.646	1,757	4,482,739	39.2
Bladder	Female	4	27,719	14.4	10.6	3.8	1.000	443	4,452,114	10.0
Brain - malignant	Total	4	57,253	7.0	5.4	5.4	0.752	653	8,934,853	7.3
Brain - malignant	Male	2	29,534	6.8	5.0	3.4	0.695	380	4,482,739	8.5
Brain - malignant Brain and other CNS - non-malignant	Female Total	2	27,719 57,253	7.2 10.5	5.9 7.8	2.1 13.3	1.000 0.045 <<	273 1,541	4,452,114 8,934,853	6.1 17.2
	Male	2	29,534	6.8	4.9	4.6	0.335	498	4,482,739	11.1
Brain and other CNS - non-malignant	Female	4	27,719	14.4	11.2	8.3	0.163	1,043	4,452,114	23.4
Breast	Total	58	57,253	101.3	71.9	62.8	0.599	6,950	8,934,853	77.8
Breast	Male	-	29,534	-	-	0.6	1.000	65	4,482,739	1.5
Breast	Female	58	27,719	209.2	155.2	57.8	1.000	6,885	4,452,114	154.6
Breast - in situ	Total	8	57,253	14.0	9.8	12.4	0.260	1,361	8,934,853	15.2
Breast - in situ	Male	-	29,534	-	-	0.0	1.000	4	4,482,739	0.1
Breast - in situ	Female	8	27,719	28.9	21.0	11.6	0.365	1,357	4,452,114	30.5
Cervix	Female	4	27,719	14.4	12.6	2.1	0.308	290	4,452,114	6.5
Colorectal	Total Malo	27 10	57,253	47.2	33.9	32.1	0.423 1.000	3,605	8,934,853	40.3
Colorectal Colorectal	Male Female	19 8	29,534 27,719	64.3 28.9	43.4 22.2	19.1 13.3	0.173	1,958 1,647	4,482,739 4,452,114	43.7 37.0
Colorectal Corpus Uteri	Female	~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	27,719	20.9	18.2	13.3	0.173	1,647	4,452,114	37.0
Esophagus	Total	5	57,253	8.7	6.0	4.7	1.000	502	8,934,853	5.6
Esophagus	Male	4	29,534	13.5	8.6	4.4	1.000	425	4,482,739	9.5
Esophagus	Female	1	27,719	3.6	2.7	0.6	0.942	77	4,452,114	1.7
Hodgkin Lymphoma	Total	3	57,253	5.2	4.9	1.5	0.387	219	8,934,853	2.5
Hodgkin Lymphoma	Male	3	29,534	10.2	8.8	1.0	0.147	126	4,482,739	2.8
Hodgkin Lymphoma	Female	-	27,719	-	-	0.6	1.000	93	4,452,114	2.1
Kidney and Renal Pelvis	Total	16	57,253	27.9	19.7	17.6	0.829	1,935	8,934,853	21.7
Kidney and Renal Pelvis	Male	11	29,534	37.2	24.9	12.8	0.742	1,299	4,482,739	29.0
Kidney and Renal Pelvis	Female	5	27,719	18.0	13.5	5.3	1.000	636	4,452,114	14.3
Larynx	Total Male	1	57,253 29,534	1.7 3.4	1.2 2.2	2.0 1.7	0.790 0.991	219 166	8,934,853 4,482,739	2.5 3.7
Larynx Larynx	Female	- '	29,534	- 5.4	2.2	0.5	1.000	53	4,462,739	1.2
Leukemia	Total	- 13	57,253	22.7	16.5	15.1	0.706	1,714	8,934,853	19.2
Leukemia	Male	8	29,534	27.1	18.4	10.0	0.669	1,028	4,482,739	22.9
Leukemia	Female	5	27,719	18.0	14.0	5.5	1.000	686	4,452,114	15.4
Liver and Bile Duct	Total	5	57,253	8.7	5.8	8.1	0.361	838	8,934,853	9.4
Liver and Bile Duct	Male	4	29,534	13.5	8.4	6.3	0.503	590	4,482,739	13.2
Liver and Bile Duct	Female	1	27,719	3.6	2.6	2.2	0.730	248	4,452,114	5.6
Lung and Bronchus	Total	29	57,253	50.7	33.7	47.4	0.006 <<	4,930	8,934,853	55.2
Lung and Bronchus	Male	10	29,534	33.9	20.7	26.8	0.000 <<	2,485	4,482,739	55.4
Lung and Bronchus	Female	19	27,719	68.5	49.4	21.1	0.750	2,445	4,452,114	54.9
Melanoma of the Skin Melanoma of the Skin	Total Male	38 22	57,253 29,534	66.4 74.5	48.2 49.7	27.4 18.5	0.063 0.472	3,106 1,873	8,934,853 4,482,739	34.8 41.8
Melanoma of the Skin	Female	16	29,534	57.7	49.7	9.8	0.084	1,073	4,462,739	27.7
Myeloma	Total	8	57,253	14.0	9.5	6.8	0.734	720	8,934,853	8.1
Myeloma	Male	6	29,534	20.3	13.0	4.5	0.606	441	4,482,739	9.8
Myeloma	Female		27,719	7.2	5.2	2.4	1.000	279	4,452,114	6.3
Non-Hodgkin Lymphoma	Total	16	57,253	27.9	19.8	17.9	0.767	1,976	8,934,853	22.1
Non-Hodgkin Lymphoma	Male	12	29,534	40.6	27.0	11.3	0.902	1,134	4,482,739	25.3
Non-Hodgkin Lymphoma	Female		27,719	14.4	10.9	7.0	0.355	842	4,452,114	18.9
Oral Cavity and Pharynx	Total	18	57,253	31.4	21.5	12.1	0.137	1,297	8,934,853	14.5
Oral Cavity and Pharynx	Male	15	29,534	50.8	33.0	9.4	0.109	925	4,482,739	20.6
Oral Cavity and Pharynx	Female	3	27,719	10.8	7.9	3.2	1.000	372	4,452,114	8.4
Ovary Pancreas	Female Total	3	27,719 57,253	10.8 15.7	8.2 10.8	4.5 13.8	0.679 0.237	550 1,479	4,452,114 8,934,853	12.4 16.6
Pancreas	Male	9	29,534	13.7	8.6	8.5	0.237	822	4,482,739	18.3
Pancreas	Female	5	27,719	18.0	13.3	5.5	1.000	657	4,452,114	14.8
Prostate	Male	94	29,534	318.3	192.2	72.8	0.019 >>	6,672	4,482,739	148.8
Stomach	Total	1	57,253	1.7	1.2	4.3	0.147	473	8,934,853	5.3
Stomach	Male	1	29,534	3.4	2.2	3.1	0.369	306	4,482,739	6.8
Stomach	Female	-	27,719	-	-	1.3	0.532	167	4,452,114	3.8
Testis	Male	2	29,534	6.8	7.6	1.6	0.942	272	4,482,739	6.1
Thyroid	Total	2	57,253	3.5	3.0	8.9	0.013 <<	1,183	8,934,853	13.2
Thyroid	Male	-	29,534	-	-	3.3	0.077	372	4,482,739	8.3
Thyroid	Female	2	27,719	7.2	6.4	5.7	0.159	811	4,452,114	18.2
Dedictric Are 0 to 10	Total	1	11,117	9.0	9.1	1.9	0.882	424	2,488,207	17.0
Pediatric Age 0 to 19										
Pediatric Age 0 to 19 Pediatric Age 0 to 19 Pediatric Age 0 to 19	Male	1	5,694 5,423	17.6	17.6	1.0	1.000 0.799	213	1,268,627 1,219,580	16.8 17.3

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN VALLEY COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Va	lley County				Re	mainder of Idah	0
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	434	59,017	735.4	556.4	682.6	0.000 <<	80,101	9,152,377	875.2
All Causes of Death	Male	256	30,464	840.3	573.5	413.0	0.000 <<	42,530	4,597,233	925.1
All Causes of Death	Female	178	28,553	623.4	526.2	279.0	>> 000.0	37,571	4,555,144	824.8
All Malignant Cancers	Total	113	59,017	191.5	134.7	138.6	0.029 <<	15,120	9,152,377	165.2
All Malignant Cancers	Male	62	30,464	203.5	130.4	84.5	0.013 <<	8,173	4,597,233	177.8
All Malignant Cancers	Female	51	28,553	178.6	136.9	56.8	0.489	6,947	4,555,144	152.5
Bladder Bladder	Total Male	5 3	59,017 30,464	8.5 9.8	6.2 6.4	4.2 3.8	0.830 0.949	480 372	9,152,377 4,597,233	5.2 8.1
Bladder	Female	2	28,553	9.0 7.0	5.8	0.8	0.949	108	4,555,144	2.4
Brain and Other Nervous System	Total	6	59,017	10.2	7.3	4.6	0.624	512	9,152,377	5.6
	Male	5	30,464	16.4	11.2	2.8	0.291	284	4,597,233	6.2
Brain and Other Nervous System	Female	1	28,553	3.5	2.7	1.9	0.879	228	4,555,144	5.0
Breast	Total	7	59,017	11.9	8.6	9.9	0.454	1,117	9,152,377	12.2
Breast	Male		30,464	-	-	0.1	1.000	13	4,597,233	0.3
Breast	Female	7	28,553	24.5	19.1	8.9	0.675	1,104	4,555,144	24.2
Cervix	Female	1	28,553 59,017	3.5 13.6	2.8 9.8	0.7	0.982 0.332	87 1,324	4,555,144	1.9 14.5
Colorectal Colorectal	Total Male	8	59,017 30,464	13.6 9.8	9.8 6.6	11.8 7.3	0.332	729	9,152,377 4,597,233	14.5 15.9
Colorectal	Female	5	28,553	9.0 17.5	13.8	4.7	1.000	595	4,555,144	13.1
Corpus Uteri	Female	1	28,553	3.5	2.5	1.5	1.000	168	4,555,144	3.7
Esophagus	Total	-	59,017	-	-	4.4	0.025 <<	461	9,152,377	5.0
Esophagus	Male	-	30,464	-	-	4.1	0.032 <<	391	4,597,233	8.5
Esophagus	Female	-	28,553	-	-	0.6	1.000	70	4,555,144	1.5
Hodgkin Lymphoma	Total	-	59,017	-	-	0.2	1.000	25	9,152,377	0.3
Hodgkin Lymphoma	Male	-	30,464	-	-	0.1	1.000	14	4,597,233	0.3
Hodgkin Lymphoma	Female	-	28,553	-	-	0.1	1.000	11	4,555,144	0.2
Kidney Kidney	Total Male	-	59,017 30,464	-	-	3.6 2.6	0.054 0.150	386 246	9,152,377 4,597,233	4.2 5.4
Kidney	Female	-	28,553	-	-	1.2	0.629	140	4,555,144	3.4
Larynx	Total	2	59,017	3.4	2.4	0.7	0.299	74	9,152,377	0.8
Larynx	Male	1	30,464	3.3	2.1	0.6	0.956	64	4,597,233	1.4
Larynx	Female	1	28,553	3.5	2.4	0.1	0.175	10	4,555,144	0.2
Leukemia	Total	6	59,017	10.2	7.4	5.9	1.000	659	9,152,377	7.2
Leukemia	Male	4	30,464	13.1	8.6	4.0	1.000	393	4,597,233	8.5
Leukemia	Female	2	28,553 59,017	7.0 6.8	5.6 4.5	2.1	1.000	266	4,555,144 9,152,377	5.8 6.9
Liver and Bile Duct Liver and Bile Duct	Total Male	4	30,464	0.0 9.8	4.5 6.1	6.1 4.5	0.550 0.686	631 420	4,597,233	0.9 9.1
Liver and Bile Duct	Female	5 1	28,553	3.5	2.6	1.8	0.925	211	4,555,144	4.6
Lung and Bronchus	Total	18	59,017	30.5	20.7	27.7	0.068	2,919	9,152,377	31.9
Lung and Bronchus	Male	7	30,464	23.0	14.2	16.4	0.015 <<	1,534	4,597,233	33.4
Lung and Bronchus	Female	11	28,553	38.5	28.7	11.7	1.000	1,385	4,555,144	30.4
Melanoma of the Skin	Total	3	59,017	5.1	3.7	2.6	0.988	298	9,152,377	3.3
Melanoma of the Skin	Male	1	30,464	3.3	2.2	2.0	0.821	199	4,597,233	4.3
Melanoma of the Skin	Female	2	28,553	7.0	5.5	0.8	0.373	99	4,555,144	2.2
Myeloma Myeloma	Total Male	4 2	59,017 30,464	6.8 6.6	4.7	3.0 2.0	0.695 1.000	321	9,152,377 4,597,233	3.5 4.0
Myeloma Myeloma	Female	2	30,464 28,553	6.6 7.0	4.1 5.4	2.0	0.608	186 135	4,597,233 4,555,144	4.0 3.0
Non-Hodgkin Lymphoma	Total	7	59,017	11.9	8.5	5.0	0.008	561	9,152,377	6.1
Non-Hodgkin Lymphoma	Male	5	30,464	16.4	10.7	3.1	0.403	305	4,597,233	6.6
Non-Hodgkin Lymphoma	Female	2	28,553	7.0	5.6	2.0	1.000	256	4,555,144	5.6
Oral Cavity and Pharynx	Total	2	59,017	3.4	2.3	2.6	1.000	273	9.152.377	3.0
Oral Cavity and Pharynx	Male	2	30,464	6.6	4.1	2.0	1.000	190	4,597,233	4.1
Oral Cavity and Pharynx	Female	-	28,553	-	-	0.7	0.996	83	4,555,144	1.8
Ovary	Female	-	28,553	-	-	3.1	0.093	361	4,555,144	7.9
Pancreas	Total	9	59,017	15.2	10.4	11.2	0.639	1,181	9,152,377	12.9
Pancreas Pancreas	Male Female	4 5	30,464 28,553	13.1 17.5	8.2 13.0	6.9 4.5	0.369 0.941	646 535	4,597,233 4,555,144	14.1 11.7
Prostate	Male	10	30,464	32.8	21.2	4.5	1.000	987	4,597,233	21.5
Stomach	Total	10	59,017	1.7	1.3	1.7	1.000	193	9,152,377	21.3
	Male	1	30,464	3.3	2.2	1.2	1.000	118	4,597,233	2.6
Stomach	Female	-	28,553	-	-	0.6	1.000	75	4,555,144	1.6

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Valley County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	10.0%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	60.5%
Current Tobacco User (2020–2022) <u>Other Cancer-Related</u>	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	23.2%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	44.0% 80.7% 26.3% 29.9%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.





WASHINGTON COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/ jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see <u>https://www.dietaryguidelines.gov</u>

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute Cancer Information Services 1-800-4CANCER https://www.cancer.gov/contact American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 416 cases of invasive cancer were diagnosed among Washington County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate,Lung and Bronchus, and Colorectal Cancers in WashingtonCounty and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Washington County	State of Idaho
All Sites/Types	416	47,333
Female Breast	59	6,943
Prostate	57	6,766
Lung & Bronchus	45	4,959
Colorectal	48	3,632

Table 3 (*Cancer Incidence 2017–2021, Comparison between Washington County and the Remainder of the State of Idaho*) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Washington County. The table also shows the number of observed cases,

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 134 Washington County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Washington
County and the State of Idaho, 2018–2022

Mortality 2018–2022	Washington County	State of Idaho
All Deaths	749	80,538
Cancer Deaths	134	15,233
% of All Deaths	17.9%	18.9%
Lung & Bronchus	28	2,937
Colorectal	12	1,332
Pancreas	15	1,190
Female Breast	6	1,111
Prostate	5	997

person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, nonmalignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Washington County was 807.8 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (524.8) gives an estimate of the relative burden of disease in Washington County.

The age- and sex-adjusted incidence rate of invasive cancer in Washington County, all sites combined, was 581.5 cases per 100,000 persons per year during 2017–2021. There were statistically significantly more cases of cancer in Washington County (416) than expected (375.4) based upon rates in the remainder of the state (p=.041).

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

Table 4 (*Cancer Mortality 2018–2022, Comparison between Washington County and the Remainder of the State of Idaho*) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Washington County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Washington County, all sites combined, was 171.2 deaths per 100,000 persons per year during 2018–2022, compared with 164.9 for the remainder of the state. There were more cancer deaths in Washington County (134) than expected (129.1) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021COMPARISON BETWEEN WASHINGTON COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Wash	Ren	nainder of Ida	aho				
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)		P-Value (4)	Cases	Years	Rate (1)
All Sites Combined	Total	416	51,498	807.8	581.5	375.4	0.041 >>	46,917	8,940,608	524.8
All Sites Combined	Male	220	25,645	857.9	580.6	211.6	0.580	25,050	4,486,628	558.3
All Sites Combined	Female	196	25,853	758.1	577.7	166.6	0.028 >>	21,867	4,453,980	491.0
Bladder	Total	17	51,498	33.0	21.7	19.3	0.698	2,203	8,940,608	24.6
Bladder	Male	14	25,645	54.6	33.8	16.2	0.695	1,759	4,486,628	39.2
Bladder	Female	3	25,853	11.6	8.1	3.7	0.992	444	4,453,980	10.0
Brain - malignant	Total	2	51,498	3.9	3.1	4.7	0.297	655	8,940,608	7.3
Brain - malignant	Male	-	25,645		-	2.8	0.123	382	4,486,628	8.5
Brain - malignant Brain and other CNS - non-malignant	Female Total	2 13	25,853 51,498	7.7 25.2	6.2 19.1	2.0 11.7	1.000 0.778	273 1,534	4,453,980 8,940,608	6.1 17.2
	Male	5	25,645	19.5	14.5	3.8	0.662	495	4,486,628	11.0
Brain and other CNS - non-malignant	Female	8	25,853	30.9	23.9	7.8	1.000	1,039	4,453,980	23.3
Breast	Total	59	51,498	114.6	86.6	52.9	0.439	6,949	8,940,608	77.7
Breast	Male	-	25,645	-	-	0.6	1.000	65	4,486,628	1.4
Breast	Female	59	25,853	228.2	177.6	51.4	0.318	6,884	4,453,980	154.6
Breast - in situ	Total	8	51,498	15.5	12.1	10.1	0.653	1,361	8,940,608	15.2
Breast - in situ	Male	-	25,645	-	-	0.0	1.000	4	4,486,628	0.1
Breast - in situ	Female Female	8	25,853	30.9	24.7	9.9	0.693	1,357	4,453,980	30.5
Cervix		2	25,853 51,498	7.7	7.6	1.7	1.000 0.001 >>	292	4,453,980	6.6
Colorectal Colorectal	Total Male	48 25	51,498 25,645	93.2 97.5	67.6 68.8	28.4 15.8	0.001 >>	3,584 1,952	8,940,608 4,486,628	40.1 43.5
Colorectal	Female	23	25,853	97.3 89.0	66.3	12.7	0.012 >>	1,932	4,453,980	36.6
Corpus Uteri	Female	8	25,853	30.9	24.1	10.0	0.655	1,346	4,453,980	30.0
Esophagus	Total	8	51,498	15.5	10.7	4.2	0.123	499	8,940,608	5.6
Esophagus	Male	6	25,645	23.4	15.5	3.6	0.325	423	4,486,628	9.4
Esophagus	Female	2	25,853	7.7	5.5	0.6	0.255	76	4,453,980	1.7
Hodgkin Lymphoma	Total	1	51,498	1.9	1.8	1.3	1.000	221	8,940,608	2.5
Hodgkin Lymphoma	Male	1	25,645	3.9	3.5	0.8	1.000	128	4,486,628	2.9
Hodgkin Lymphoma	Female	-	25,853	-	-	0.5	1.000	93	4,453,980	2.1
Kidney and Renal Pelvis Kidney and Renal Pelvis	Total Male	16 12	51,498 25,645	31.1 46.8	22.7 33.1	15.3 10.5	0.917 0.719	1,935 1,298	8,940,608 4,486,628	21.6 28.9
Kidney and Renal Pelvis	Female	4	25,853	40.8	11.6	4.9	0.909	637	4,453,980	14.3
Larynx	Total	4	51,498	7.8	5.4	1.8	0.211	216	8,940,608	2.4
Larynx	Male	3	25,645	11.7	7.7	1.0	0.342	164	4,486,628	3.7
Larynx	Female	1	25,853	3.9	2.9	0.4	0.661	52	4,453,980	1.2
Leukemia	Total	20	51,498	38.8	27.7	13.8	0.135	1,707	8,940,608	19.1
Leukemia	Male	10	25,645	39.0	26.7	8.6	0.711	1,026	4,486,628	22.9
Leukemia	Female	10	25,853	38.7	28.7	5.3	0.091	681	4,453,980	15.3
Liver and Bile Duct	Total	12	51,498	23.3	16.5	6.8	0.086	831	8,940,608	9.3
Liver and Bile Duct Liver and Bile Duct	Male Female	6 6	25,645 25,853	23.4 23.2	16.1 16.9	4.9 1.9	0.728 0.029 >>	588 243	4,486,628 4,453,980	13.1 5.5
Lung and Bronchus	Total	45	25,855	87.4	57.9	42.7	0.029	4,914	8,940,608	55.0
Lung and Bronchus	Male	43 19	25,645	74.1	46.6	22.5	0.542	2,476	4,486,628	55.2
Lung and Bronchus	Female	26	25,853	100.6	69.9	20.4	0.257	2,438	4,453,980	54.7
Melanoma of the Skin	Total	15	51,498	29.1	21.7	24.2	0.064	3,129	8,940,608	35.0
Melanoma of the Skin	Male	10	25,645	39.0	26.9	15.6	0.184	1,885	4,486,628	42.0
Melanoma of the Skin	Female	5	25,853	19.3	15.7	8.9	0.243	1,244	4,453,980	27.9
Myeloma	Total	8	51,498	15.5	10.6	6.1	0.533	720	8,940,608	8.1
Myeloma	Male	6	25,645	23.4	15.3	3.9	0.387	441	4,486,628	9.8
Myeloma Non-Hodgkin Lymphoma	Female Total	2 21	25,853	7.7 40.8	5.5 29.3	2.3 15.8	1.000 0.240	279 1,971	4,453,980 8,940,608	6.3 22.0
Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma	Male	21 14	51,498 25,645	40.8 54.6	29.3 38.1	9.3	0.240 0.176	1,971	8,940,608 4,486,628	22.0
Non-Hodgkin Lymphoma	Female	7	25,853	27.1	20.0	9.3 6.6	0.176	839	4,460,028	18.8
Oral Cavity and Pharynx	Total	6	51,498	11.7	8.5	10.3	0.224	1,309	8,940,608	14.6
Oral Cavity and Pharynx	Male	3	25,645	11.7	8.3	7.5	0.118	937	4,486,628	20.9
Oral Cavity and Pharynx	Female	3	25,853	11.6	8.7	2.9	1.000	372	4,453,980	8.4
Ovary	Female	1	25,853	3.9	3.0	4.1	0.168	552	4,453,980	12.4
Pancreas	Total	14	51,498	27.2	18.4	12.5	0.748	1,474	8,940,608	16.5
Pancreas	Male	11	25,645	42.9	27.8	7.2	0.227	815	4,486,628	18.2
Pancreas Broatato	Female	3 57	25,853	11.6	8.2	5.4	0.425	659	4,453,980 4,486,628	14.8
Prostate Stomach	Male Total	57	25,645 51,498	222.3 5.8	148.3 4.1	57.5 3.9	1.000 0.922	6,709 471	4,486,628	149.5 5.3
Stomach	Male	3	25,645	11.7	7.8	2.6	0.922	304	4,486,628	6.8
Stomach	Female	- 1	25,853	-		1.3	0.541	167	4,453,980	3.7
Testis	Male	2	25,645	7.8	9.4	1.3	0.738	272	4,486,628	6.1
Thyroid	Total	5	51,498	9.7	9.0	7.3	0.520	1,180	8,940,608	13.2
Thyroid	Male	2	25,645	7.8	6.4	2.6	1.000	370	4,486,628	8.2
			25,853	11.6	11.4	4.8	0.591	810	4,453,980	18.2
	Female		20,000							
Thyroid	Female Total	3								
	Female Total Male	3 2 1	12,875 6,461	15.5 15.5	15.5	2.2	1.000	423 213	2,486,449	17.0 16.8

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2018-2022 COMPARISON BETWEEN WASHINGTON COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

			Wash	ington Cou	nty			Re	mainder of Idah	0
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)
All Causes of Death	Total	749	52,530	1,425.9	958.8	680.5	0.010 >>	79,786	9,158,864	871.1
All Causes of Death	Male	389	26,206	1,484.4	961.2	372.9	0.417	42,397	4,601,491	921.4
All Causes of Death	Female	360	26,324	1,367.6	948.8	311.3	0.007 >>	37,389	4,557,373	820.4
All Malignant Cancers	Total	134	52,530	255.1	171.2	129.1	0.686	15,099	9.158.864	164.9
All Malignant Cancers	Male	67	26,206	255.7	161.4	73.7	0.477	8,168	4,601,491	177.5
All Malignant Cancers	Female	67	26,324	254.5	180.2	56.6	0.191	6,931	4,557,373	152.1
Bladder	Total	4	52,530	7.6	4.8	4.4	1.000	481	9,158,864	5.3
Bladder	Male	2	26,206	7.6	4.5	3.6	0.603	373	4,601,491	8.1
Bladder	Female	2	26,324	7.6	5.1	0.9	0.479	108	4,557,373	2.4
Brain and Other Nervous System	Total	1	52,530	1.9	1.4	4.0	0.187	517	9,158,864	5.6
Brain and Other Nervous System	Male	1	26,206	3.8	2.8	2.3	0.676	288	4,601,491	6.3
Brain and Other Nervous System	Female	-	26,324	-	-	1.7	0.355	229	4,557,373	5.0
Breast	Total	6	52,530	11.4	8.0	9.2	0.378	1,118	9,158,864	12.2
Breast	Male Female	- 6	26,206 26,324	- 22.8	- 16.6	0.1 8.8	1.000 0.455	13 1,105	4,601,491	0.3 24.2
Breast Cervix		-	26,324	-	-	0.0	1.000	1,105	4,557,373 4,557,373	24.2
Colorectal	Female Total	- 12	20,324 52,530	- 22.8	- 15.9	10.0	0.819	00 1,320	9,158,864	1.9
Colorectal	Male	5	26,206	19.1	12.9	6.1	0.819	727	4,601,491	14.4
Colorectal	Female	7	26,324	26.6	12.0	4.8	0.420	593	4.557.373	13.0
Corpus Uteri	Female	2	26,324	7.6	5.4	1.4	0.787	167	4,557,373	3.7
Esophagus	Total	4	52,530	7.6	5.2	3.9	1.000	457	9.158.864	5.0
Esophagus	Male	3	26,206	11.4	7.4	3.4	1.000	388	4,601,491	8.4
Esophagus	Female	1	26,324	3.8	2.7	0.6	0.865	69	4,557,373	1.5
Hodgkin Lymphoma	Total	-	52,530	-	-	0.2	1.000	25	9,158,864	0.3
Hodgkin Lymphoma	Male	-	26,206	-	-	0.1	1.000	14	4,601,491	0.3
Hodgkin Lymphoma	Female	-	26,324	-	-	0.1	1.000	11	4,557,373	0.2
Kidney	Total	1	52,530	1.9	1.3	3.3	0.306	385	9,158,864	4.2
Kidney	Male	1	26,206	3.8	2.4	2.2	0.710	245	4,601,491	5.3
Kidney	Female		26,324	- 3.8	- 2.6	1.2	0.608	140	4,557,373	3.1
Larynx	Total Mala	2 2	52,530 26,206	3.0 7.6		0.6 0.6	0.265 0.231	74 63	9,158,864 4,601,491	0.8 1.4
Larynx Larynx	Male Female	- 2	26,200	7.0	4.7	0.0	1.000	11	4,557,373	0.2
Leukemia	Total	- 4	52,530	- 7.6	- 5.0	5.8	0.638	661	9,158,864	7.2
Leukemia	Male	1	26,206	3.8	2.4	3.6	0.243	396	4,601,491	8.6
Leukemia	Female	3	26,324	11.4	7.9	2.2	0.757	265	4,557,373	5.8
Liver and Bile Duct	Total	11	52,530	20.9	14.4	5.2	0.036 >>	624	9,158,864	6.8
Liver and Bile Duct	Male	6	26,206	22.9	15.1	3.6	0.311	417	4,601,491	9.1
Liver and Bile Duct	Female	5	26,324	19.0	13.5	1.7	0.057	207	4,557,373	4.5
Lung and Bronchus	Total	28	52,530	53.3	35.0	25.4	0.661	2,909	9,158,864	31.8
Lung and Bronchus	Male	12	26,206	45.8	28.5	14.0	0.720	1,529	4,601,491	33.2
Lung and Bronchus	Female	16	26,324	60.8	41.9	11.6	0.253	1,380	4,557,373	30.3
Melanoma of the Skin	Total	1	52,530	1.9	1.3	2.5	0.581	300	9,158,864	3.3
Melanoma of the Skin	Male	1	26,206	3.8	2.5	1.7	0.961	199	4,601,491	4.3
Melanoma of the Skin	Female	-	26,324	-	-	0.8	0.905	101	4,557,373	2.2
Myeloma	Total Malo	5 4	52,530 26,206	9.5 15.3	6.1 9.2	2.9	0.323 0.197	320	9,158,864 4,601,491	3.5 4.0
Myeloma Myeloma	Male Female	4	26,206 26,324	15.3 3.8	9.2 2.6	1.7 1.2	1.000	184 136	4,557,373	4.0 3.0
Non-Hodgkin Lymphoma	Total	9	52,530	17.1	11.2	4.9	0.124	559	9,158,864	6.1
Non-Hodgkin Lymphoma	Male	4	26,206	15.3	9.6	2.8	0.608	306	4,601,491	6.7
Non-Hodgkin Lymphoma	Female	5	26,324	19.0	12.9	2.0	0.134	253	4,557,373	5.6
Oral Cavity and Pharynx	Total	1 1	52,530	1.9	1.3	2.3	0.670	274	9,158,864	3.0
Oral Cavity and Pharynx	Male	-	26,206	-	-	1.7	0.379	192	4,601,491	4.2
Oral Cavity and Pharynx	Female	1	26,324	3.8	2.7	0.7	0.964	82	4,557,373	1.8
Ovary	Female	2	26,324	7.6	5.4	2.9	0.889	359	4,557,373	7.9
Pancreas	Total	15	52,530	28.6	19.1	10.1	0.173	1,175	9,158,864	12.8
Pancreas	Male	11	26,206	42.0	26.7	5.7	0.065	639	4,601,491	13.9
Pancreas	Female	4	26,324	15.2	10.7	4.4	1.000	536	4,557,373	11.8
Prostate	Male	5	26,206	19.1	11.2	9.7	0.163	992	4,601,491	21.6
Stomach	Total	2	52,530	3.8	2.7	1.6	0.923	192	9,158,864	2.1
Stomach	Male	1	26,206	3.8	2.5	1.0	1.000	118	4,601,491	2.6
Stomach	Female	1	26,324	3.8	2.9	0.6	0.854	74	4,557,373	1.6

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution. "<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

Measure	State of Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	Washington County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022) Cancer Screening	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	11.6%
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) <u>Tobacco Use</u>	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	66.2%
Current Tobacco User (2020–2022) <u>Other Cancer-Related</u>	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	27.6%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022) Any Physical Activity Besides Job Past 30 Days (2018–2022) Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) Home Ever Tested for Radon (2016, 2018, 2020)	30.0% 79.1% 22.0% 22.9%	30.0% 79.0% 22.8% 30.8%	30.1% 78.0% 19.2% 18.3%	26.5% 75.4% 20.0% 16.9%	33.7% 82.7% 25.2% 25.2%	27.5% 75.2% 19.5% 20.1%	26.7% 76.7% 20.4% 23.0%	30.2% 81.0% 20.3% 21.0%	28.5% 68.7% 23.5% 14.1%

Access to Care

Have Health Insurance - 2021-2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

<u>Pap Test</u> – 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21– 65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

<u>Physical Activity Guidelines</u> – 2011, 2013, 2015, 2017, 2019

Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention and Prevention or the National Cancer Institute.



